<SEC-DOCUMENT>0001144204-15-063377.txt : 20151110
<SEC-HEADER>0001144204-15-063377.hdr.sgml : 20151110
<ACCEPTANCE-DATETIME>20151106163055
ACCESSION NUMBER:		0001144204-15-063377
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		11
CONFORMED PERIOD OF REPORT:	20150930
FILED AS OF DATE:		20151106
DATE AS OF CHANGE:		20151106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PHARMATHENE, INC
		CENTRAL INDEX KEY:			0001326190
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				202726770
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32587
		FILM NUMBER:		151212076

	BUSINESS ADDRESS:	
		STREET 1:		ONE PARK PLACE, SUITE 450
		CITY:			ANNAPOLIS
		STATE:			MD
		ZIP:			21401
		BUSINESS PHONE:		410 269 2600

	MAIL ADDRESS:	
		STREET 1:		ONE PARK PLACE, SUITE 450
		CITY:			ANNAPOLIS
		STATE:			MD
		ZIP:			21401

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HEALTHCARE ACQUISITION CORP
		DATE OF NAME CHANGE:	20050505
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>v422632_10q.htm
<DESCRIPTION>10-Q
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
Washington, D.C. 20549</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">FORM 10-Q</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Mark One)</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings"><B>x</B></FONT></TD><TD STYLE="text-align: justify"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934</B></TD>
</TR></TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the quarterly period ended September
30, 2015</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">or</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings"><B>&uml;</B></FONT></TD><TD STYLE="text-align: justify"><B>TRANSITION
                                         REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></TD>
</TR></TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission File Number: 001-32587</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">PHARMATHENE, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <TD STYLE="width: 45%; text-align: center"><b>Delaware</b></td>
    <TD STYLE="width: 10%; text-align: center">&nbsp;</td>
    <TD STYLE="width: 45%; text-align: center"><b>20-2726770</b></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center">(State or other jurisdiction of incorporation or organization)</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">(I.R.S. Employer Identification No.)</td></tr>
<tr style="vertical-align: top">
    <TD>&nbsp;</td>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center"><b>One Park Place, Suite 450, Annapolis, Maryland</b></td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center"><b>21401</b></td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center">(Address of principal executive offices)</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">(Zip Code)</td></tr>
<tr style="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td>
    <TD STYLE="text-align: center">&nbsp;</td></tr>
</table>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(410) 269-2600<BR>
<FONT STYLE="font-weight: normal">(Registrant&rsquo;s telephone number, including area code)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes <FONT STYLE="font-family: Wingdings">x</FONT> No <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Indicate by check mark whether the registrant
has submitted electronically and posted on its corporate Web site, if any, every Interactive Data file required to be submitted
and posted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the preceding 12 months (or for such shorter
period that the registrant was required to submit and post such files). Yes <FONT STYLE="font-family: Wingdings">x</FONT> No <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2
of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 46%; text-align: center">Large Accelerated Filer <font style="font-family: Wingdings">&uml;</font></td>
    <td style="width: 9%; text-align: center">&nbsp;</td>
    <td style="width: 45%; text-align: center">Accelerated Filer <font style="font-family: Wingdings">x</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">Non-Accelerated Filer <font style="font-family: Wingdings">&uml;</font></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">Smaller Reporting Company <font style="font-family: Wingdings">&uml;</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">(Do not check if a smaller reporting company)</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Act). Yes <FONT STYLE="font-family: Wingdings">&uml;</FONT> No&nbsp;<FONT STYLE="font-family: Wingdings">x</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Indicate the number of shares outstanding
of each of the issuer&rsquo;s classes of common stock, as of the latest practicable date: The number of shares of the registrant&rsquo;s
Common Stock, par value $0.0001 per share, outstanding as of November 4, 2015 was 64,451,334.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">PHARMATHENE, INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 92%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 7%; border-bottom: black 1pt solid; text-align: center"><b>Page</b></td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td>PART&nbsp;I &mdash; FINANCIAL INFORMATION</td>
    <td>&nbsp;</td>
    <td style="text-align: center">1&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#a_001">Item 1.&nbsp;&nbsp;<u>Unaudited Condensed Consolidated Financial Statements</u></A></td>
    <td>&nbsp;</td>
    <td style="text-align: center">1</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#a_002">Item 2.&nbsp;&nbsp;<u>Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</u></A></td>
    <td>&nbsp;</td>
    <td style="text-align: center">17</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#a_003">Item 3.&nbsp;&nbsp;<u>Quantitative and Qualitative Disclosures about Market Risk</u></A></td>
    <td>&nbsp;</td>
    <td style="text-align: center">27</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#a_004">Item 4.&nbsp;&nbsp;<u>Controls and Procedures</u></A></td>
    <td>&nbsp;</td>
    <td style="text-align: center">27</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#a_005">PART&nbsp;II &mdash; OTHER INFORMATION</A></td>
    <td>&nbsp;</td>
    <td style="text-align: center">28</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#a_006">Item 1.&nbsp;&nbsp;<u>Legal Proceedings</u></A></td>
    <td>&nbsp;</td>
    <td style="text-align: center">28</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#a_007">Item 1A.&nbsp;&nbsp;<u>Risk Factors</u></A></td>
    <td>&nbsp;</td>
    <td style="text-align: center">29</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#a_008">Item 2.&nbsp;&nbsp;<u>Unregistered Sales of Equity Securities and Use of Proceeds</u></A></td>
    <td>&nbsp;</td>
    <td style="text-align: center">29</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#a_009">Item 3.&nbsp;&nbsp;<u>Defaults Upon Senior Securities</u></A></td>
    <td>&nbsp;</td>
    <td style="text-align: center">29</td></tr>
<TR STYLE="vertical-align: top; background-color: White">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#a_010">Item 4. <u>Mine Safety Disclosures</u></A></td>
    <td>&nbsp;</td>
    <td style="text-align: center">29</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td nowrap>&nbsp;</td>
    <td nowrap>&nbsp;</td>
    <td nowrap>&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#a_011">Item 5.&nbsp;&nbsp;<u>Other Information</u></A></td>
    <td>&nbsp;</td>
    <td style="text-align: center">29</td></tr>
<TR STYLE="vertical-align: bottom; background-color: White">
    <td nowrap>&nbsp;</td>
    <td nowrap>&nbsp;</td>
    <td nowrap>&nbsp;</td></tr>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <td><A HREF="#a_012">Item 6.&nbsp;&nbsp;<u>Exhibits</u></A></td>
    <td>&nbsp;</td>
    <td style="text-align: center">29</td></tr>
</table>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_001"></A>Item 1. Financial Statements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">PHARMATHENE, INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNAUDITED CONDENSED
CONSOLIDATED BALANCE SHEETS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">December 31,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-decoration: underline; text-align: center">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Current assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; font-size: 10pt; text-align: left; padding-left: 10pt">Cash and cash equivalents</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">17,389,409</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">18,643,351</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Billed accounts receivable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">110,656</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Unbilled accounts receivable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">659,663</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">297,431</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Prepaid expenses and other current assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">196,478</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">199,194</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Total current assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">18,245,550</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">19,250,632</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Property and equipment, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">248,270</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">325,772</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Other long-term assets and deferred costs</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">53,384</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">53,384</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt">Goodwill</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,348,453</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,348,453</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total assets</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">20,895,657</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">21,978,241</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-decoration: underline; text-align: center">LIABILITIES AND STOCKHOLDERS' EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Current liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Accounts payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">306,172</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">391,396</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Accrued expenses and other liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,453,123</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,195,412</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Accrued restructuring expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">619,119</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 10pt">Short-term debt</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">746,146</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Other short-term liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">70,326</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Current portion of derivative instruments</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,355</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">178,509</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Total current liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,380,769</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,581,789</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Accrued restructuring expenses - long term</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">184,018</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Other long-term liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">431,015</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">493,137</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Derivative instruments, less current portion</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">227,898</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">629,170</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Total liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,223,700</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,704,096</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Stockholders' equity:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Common stock, $0.0001 par value; 100,000,000 shares authorized; 64,358,834 and 63,603,303 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,436</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">6,360</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 10pt">Additional paid-in-capital</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">240,151,146</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">238,780,633</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Accumulated other comprehensive loss</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(229,528</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Accumulated deficit</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(222,485,625</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(220,283,320</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total stockholders' equity</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">17,671,957</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">18,274,145</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total liabilities and stockholders' equity</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">20,895,657</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">21,978,241</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying notes are an integral part
of the unaudited condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">PHARMATHENE, INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF OPERATIONS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three months ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine months ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; font-size: 10pt; text-align: left">Contract revenue</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">1,155,839</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">962,451</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">9,374,155</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">8,363,909</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Operating expenses:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Research and development</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,125,865</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,728,929</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,962,019</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">7,528,616</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">General and administrative</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,231,035</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">3,192,427</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,246,396</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">8,289,788</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Restructuring expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">422,482</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,519,273</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Depreciation</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">35,005</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">37,125</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">108,798</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">113,272</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total operating expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,814,387</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">4,958,481</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11,836,486</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">15,931,676</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Loss from operations</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(1,658,548</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(3,996,030</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(2,462,331</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(7,567,767</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Other income (expense):</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Interest expense, net</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(9,888</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(46,930</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(48,492</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(173,356</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Realization of cumulative translation adjustment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(229,192</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Change in fair value of derivative instruments</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">359,796</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(560,487</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">577,426</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">464,703</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Other income (expense)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(691</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">80</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,594</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(1,470</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total other income (expense)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">349,217</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(607,337</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">306,336</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">289,877</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Net loss before income taxes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,309,331</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4,603,367</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(2,155,995</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(7,277,890</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 10pt">Income tax provision</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(15,437</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(25,068</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(46,310</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(48,105</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Net loss</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,324,768</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(4,628,435</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(2,202,305</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(7,325,995</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Basic and diluted net loss per share</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(0.02</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(0.08</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(0.03</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(0.13</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Weighted average shares used in calculation of basic and diluted net loss per share</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">64,187,618</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">58,952,731</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">63,858,500</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">55,577,550</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying notes are an integral part
of the unaudited condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">PHARMATHENE, INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF COMPREHENSIVE LOSS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three months ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine months ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; font-size: 10pt; text-align: left">Net loss</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">(1,324,768</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">(4,628,435</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">(2,202,305</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">(7,325,995</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Other comprehensive income (loss):</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Foreign currency translation adjustments</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(5,869</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">336</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(7,162</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Realization of cumulative translation adjustment included in net loss</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">229,192</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Comprehensive loss</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,324,768</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(4,634,304</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,972,777</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(7,333,157</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD></TR>
</TABLE>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of the unaudited condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PHARMATHENE, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNAUDITED CONDENSED CONSOLIDATED STATEMENTS
OF CASH FLOWS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD COLSPAN="5" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine months ended September 30,</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Operating activities</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 68%; font-size: 10pt; text-align: left">Net loss</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">(2,202,305</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">(7,325,995</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Realization of cumulative translation adjustment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">229,192</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Share-based compensation expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">426,988</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,172,703</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Change in fair value of derivative instruments</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(577,426</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(464,703</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Depreciation expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">108,798</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">113,272</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Deferred income taxes</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">46,310</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">48,105</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Non-cash interest expense</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(51,820</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">68,130</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Impairment of property and equipment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">36,981</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Gain on the disposal of property and equipment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(7,600</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(5,393</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 10pt">Changes in operating assets and liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Billed accounts receivable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">110,656</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,427,113</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Unbilled accounts receivable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(362,232</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,895,858</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Prepaid expenses and other current assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(9,602</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">23,869</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Accounts payable</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(85,175</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(846,090</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Accrued restructuring expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">800,769</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-left: 20pt">Accrued expenses and other liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">149,438</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(773,517</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 20pt">Deferred revenue</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(284,937</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Net cash used in operating activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,387,028</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(4,951,585</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Investing activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Purchases of property and equipment</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(68,277</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(92,269</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Proceeds from the sale of property and equipment</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">7,600</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">8,000</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Net cash used in investing activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(60,677</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(84,269</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Financing activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Repayment of debt</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(750,007</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(749,997</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Net repayment of revolving credit agreement</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,091,740</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Net proceeds from exercise of warrants</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">683,325</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Proceeds from issuance of common stock, including exercise of</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">stock options, net of offering costs</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">943,601</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">15,341,264</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Net cash provided by financing activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">193,594</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">14,182,852</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Effects of exchange rates on cash</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">169</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(7,585</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">(Decrease) increase in cash and cash equivalents</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1,253,942</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">9,139,413</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Cash and cash equivalents, at beginning of period</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">18,643,351</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,480,979</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Cash and cash equivalents, at end of period</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">17,389,409</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">19,620,392</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; text-align: left">Supplemental disclosure of cash flow information</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Cash paid for interest</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">108,134</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">105,916</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The accompanying notes are an integral part
of the unaudited condensed consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">PHARMATHENE, INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Notes to Unaudited Condensed Consolidated
Financial Statements<BR>
September 30, 2015</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 1 &ndash; Business, Liquidity and Organization</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since 2001, PharmAthene, Inc. (&quot;we&quot;,
the &quot;Company&quot;) has been a biodefense company engaged in the development of next generation medical counter measures against
biological and chemical threats. During this time, we have devoted substantial effort and resources to the development of the prevention
and treatment of anthrax infection and nerve agent poisoning.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 9, 2015, our Board of
Directors approved our realignment plan (the &ldquo;Realignment Plan&rdquo;) with the goal of preserving and maximizing, for
the benefit of our stockholders, the value of any proceeds from our litigation with SIGA Technologies, Inc.
(&ldquo;SIGA&rdquo;) and our existing biodefense assets. The plan eliminated approximately two-thirds of our workforce and
aimed to preserve sufficient cash and cash equivalents to finance our continued operations through a period of time that is
expected to extend beyond the adjudication of SIGA&rsquo;s appeal. We intend to maintain sufficient resources and personnel
so that we can seek partners, co-developers or acquirers for our biodefense programs and continue to execute under our
government contract with the National Institutes of Allergy and Infectious Diseases (&ldquo;NIAID&rdquo;). The Company
estimates total severance payments to executives and non-executives in connection with the Realignment Plan to amount to
approximately $2 million (all of which was expensed as of September 30, 2015), with substantially all such severance expenses
expected to be paid in 2015. Historically, the Company has performed under government contracts and grants and raised funds
from investors (including additional debt and equity issued in 2015 and 2014) to sustain our operations. The Company has
spent substantial funds in the research, development, clinical and preclinical testing in excess of revenues, to support the
Company&rsquo;s product candidates and to market and sell its products. We have incurred losses in each year since inception,
and have an accumulated deficit of $222.5 million. If we continue to incur losses and are not able to raise adequate funds to
cover those losses, we may be required to cease operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2015, our cash balance
was $17.4 million, our unbilled accounts receivable balance was $0.7 million, and our current liabilities were $2.4 million. As
of September 30, 2015, we had approximately $3.0 million of remaining availability under our controlled equity offering arrangement,
although we did not sell any shares of common stock under such facility during the three and nine months ended September 30, 2015
(see Note 6 &ndash; <I>Financing Transactions</I> &ndash;<I> Controlled Equity Offering</I>). We believe, based on the operating
cash requirements and capital expenditures expected for 2015, the Company&rsquo;s cash on hand at September 30, 2015 is adequate
to fund operations through at least the end of 2016. On September 3, 2015, following a payment of $81,347, representing a $75,000 final payment fee pursuant to
the March 30, 2012 Loan Agreement, $10 outstanding principal balance, $208 accrued interest, and $6,129 legal fees of the lender,
we satisfied in full our remaining obligation under our March 2012 Loan Agreement with General Electric Capital Corporation (&ldquo;GE
Capital&rdquo;), as discussed further in Note 6- <I>Financing Transactions</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2015, PharmAthene signed
a license agreement with ImmunoVaccine for the exclusive use of the DepoVax<SUP>TM </SUP>vaccine platform, to develop
an anthrax vaccine utilizing PharmAthene&rsquo;s recombinant protective antigen (&ldquo;rPA&rdquo;). ImmunoVaccine is
a clinical-stage vaccine development company located in Halifax, Nova Scotia. PharmAthene will reimburse up to $210,000 to
ImmunoVaccine for their efforts in developing this vaccine. In addition, ImmunoVaccine will receive
annual payments of $200,000, and additional payments for the achievement of certain milestones relating to contracting with
the U.S. Government as well as achieving certain clinical/regulatory and commercial milestones, and achievement of sales
targets. Additionally, ImmunoVaccine will receive a royalty on sales related to the use of DepoVax<SUP>TM</SUP>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 2, 2015, the Company entered into a sublease agreement with a third party with respect to a portion
of its leased office space in Annapolis, Maryland. See Note 4 - <I>Commitments and Contingencies</I> -<I> Leases.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 10, 2015, NIAID exercised
the first option under our September 2014 contract for the development of a next generation lyophilized anthrax vaccine. The option
provides additional funding of approximately $2.3 million and an extension of the period of performance through September 30, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We can offer no assurances that we have
correctly estimated the resources or personnel necessary to seek partners, co-developers or acquirers for our biodefense programs
or execute under our NIAID contract. If a larger workforce or one with a different skillset is ultimately required to implement
our Realignment Plan successfully, we may be unable to maximize the value of the SIGA litigation and our existing biodefense assets.
In addition, in connection with the Realignment Plan, executive officers who have served the Company for many years have been terminated,
and, with the exception of Mr. Richman&rsquo;s continued service on the Board, will no longer be available to guide the Company.
We also cannot assure you that we have accurately estimated the cash and cash equivalents necessary to finance our operations until
SIGA&rsquo;s appeal has been adjudicated and we have received SIGA&rsquo;s payment, if any. If revenues from our NIAID contract
are less than we anticipate, if operating expenses exceed our expectations or cannot be adjusted accordingly, or if we have underestimated
the time it will take for us to prevail in SIGA&rsquo;s appeal, or enforce payment of or collect any damages award from SIGA, or
if we do not prevail on appeal, then our business, results of operations, financial condition and cash flows will be materially
and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we may raise additional capital
to strengthen our financial position. There can be no assurances that we would be successful in raising additional funds on acceptable
terms or at all. Additional sales of common stock may be made at prices that are dilutive to existing stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 2 - Summary of Significant Accounting Policies</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Basis of Presentation</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our unaudited condensed consolidated financial
statements include the accounts of PharmAthene, Inc. and its wholly-owned subsidiary. All significant intercompany transactions
and balances have been eliminated in consolidation. Our unaudited condensed consolidated financial statements have been prepared
in accordance with generally accepted accounting principles in the United States (&ldquo;U.S. GAAP&rdquo;). In the opinion of management,
the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring
adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The condensed
consolidated balance sheet at December 31, 2014 has been derived from audited consolidated financial statements at that date. The
interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information
and footnote disclosure normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed
or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission (&ldquo;SEC&rdquo;).
We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited
condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included
in our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC. We currently operate in one business
segment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Use of Estimates</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements
in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and
liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts
of revenues and expenses during the reporting period. Our unaudited condensed consolidated financial statements include significant
estimates for our share-based compensation and the value of our financial instruments, among other things. Because of the use of
estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Foreign Currency Translation</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The functional currency of our wholly-owned
foreign subsidiary, PharmAthene UK Limited, is its local currency. Assets and liabilities of our foreign subsidiary are translated
into United States dollars based on the exchange rate at the end of the reporting period. Income and expense items are translated
at the weighted average exchange rates prevailing during the reporting period. Translation adjustments for subsidiaries that have
not been sold, substantially liquidated or otherwise disposed of, are accumulated in other comprehensive loss, a component of stockholders&rsquo;
equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive loss at December 31,
2014. Transaction gains or losses are included in the determination of net income (loss).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2015, we substantially completed
the liquidation of PharmAthene UK Limited, which we had acquired in 2008. Prior to substantially liquidating the UK subsidiary,
currency fluctuations were recorded as foreign currency translation adjustments, a component of other comprehensive income. As
a result of the substantially completed liquidation, we realized an approximate loss of $0.2 million in our condensed consolidated
statements of operations, which represents the amount of previously recorded foreign currency translation adjustments related to
our UK subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cash and Cash Equivalents</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash and cash equivalents are stated at
cost which approximates market value and include investments in money market funds with financial institutions which are stated
at market value. The Company maintains cash balances with financial institutions in excess of insured limits. The Company does
not anticipate any losses on such cash balances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Significant Customers and Accounts Receivable</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our primary customers are NIAID, and the
Biomedical Advanced Research and Development Authority (&ldquo;BARDA&rdquo;). As of September 30, 2015, the Company&rsquo;s unbilled
accounts receivable balance was comprised of receivables from NIAID. The Company&rsquo;s receivable balances (both billed and unbilled)
as of December 31, 2014 were comprised of receivables from NIAID and BARDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Goodwill</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal">Goodwill represents
the excess of purchase price over the fair value of net identifiable assets associated with acquisitions. We review the recoverability
of goodwill annually at the end of our fiscal year and whenever events or changes in circumstances indicate that it is more likely
than not that impairment exists. Recoverability of goodwill is reviewed by comparing our market value (as measured by our stock
price multiplied by the number of outstanding shares as of the end of the year) to the net book value of our equity. If our market
value exceeds our net book value, no further analysis is required. We completed our annual impairment assessment of goodwill on
December 31, 2014 and determined that there was no impairment as of that date. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-style: normal">Changes in our business
strategy or adverse changes in market conditions could impact the impairment analyses and require the recognition of an impairment
charge equal to the excess of the carrying value over its estimated fair value.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Restructuring Expense</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the Realignment Plan,
we recorded approximately $2.1 million of restructuring expense during the nine months ended September 30, 2015, including
approximately $2.0 million of related severance expense, and the remainder being legal and other employee related expenses.
Additionally, as a result of the September 2, 2015 sublease of a portion of the Company's leased office space, we recorded
approximately $0.4 million of additional restructuring expense (see Note 4 - <I>Commitments and Contingencies -
Leases</I>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financial Instruments</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our financial instruments, and/or embedded
features contained in those instruments, often are classified as derivative liabilities and are recorded at their fair values.
The determination of fair value of these instruments and features requires estimates and judgments. Some of our stock purchase
warrants are considered to be derivative liabilities due to the presence of net settlement features and/or non-standard anti-dilution
provisions; the fair value of our warrants is determined based on the Black-Scholes option pricing model. Use of the Black-Scholes
option pricing model requires the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends.
See Note 3 &ndash; <I>Fair Value Measurements</I> for further details.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Revenue Recognition</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We generate our revenue from different
types of contractual arrangements: cost-plus-fee contracts and fixed price contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues on cost-plus-fee contracts are
recognized in an amount equal to the costs incurred during the period plus an estimate of the applicable fee earned. The estimate
of the applicable fee earned is determined by reference to the contract: if the contract defines the fee in terms of risk-based
milestones and specifies the fees to be earned upon the completion of each milestone, then the fee is recognized when the related
milestones are earned, as further described below; otherwise, we estimate the fee earned in a given period by using a proportional
performance method based on costs incurred during the period as compared to total estimated project costs and application of the
resulting fraction to the total project fee specified in the contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the milestone method of revenue recognition,
milestone payments (including milestone payments for fees) contained in research and development arrangements are recognized as
revenue when: (i) the milestones are achieved; (ii) no further performance obligations with respect to the milestone exist; (iii)
collection is reasonably assured; and (iv) substantive effort was necessary to achieve the milestone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A milestone is considered
substantive if all of the following conditions are met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">it is commensurate with either our performance to meet the milestone or the enhancement of the
value of the delivered item or items as a result of a specific outcome resulting from our performance to achieve the milestone,</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">it relates solely to past performance, and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the value of the milestone is reasonable relative to all the deliverables and payment terms (including
other potential milestone consideration) within the arrangement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If a milestone is deemed not to be substantive,
the Company recognizes the portion of the milestone payment as revenue that correlates to work already performed using the proportional
performance method; the remaining portion of the milestone payment is deferred and recognized as revenue as the Company completes
its performance obligations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue on fixed price contracts (without
substantive milestones as described above) is recognized on the percentage-of-completion method. The percentage-of-completion method
recognizes income as the contract progresses (generally related to the costs incurred in providing the services required under
the contract). The use of the percentage-of-completion method depends on the ability to make reasonable dependable estimates and
the fact that circumstances may necessitate frequent revision of estimates does not indicate that the estimates are unreliable
for the purpose for which they are used.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of our revenue recognition
policies and the billing provisions contained in our contracts, the timing of customer billings may differ from the timing of recognizing
revenue. Amounts invoiced to customers in excess of revenue recognized are reflected on the balance sheet as deferred revenue.
Amounts recognized as revenue in excess of amounts billed to customers are reflected on the balance sheet as unbilled accounts
receivable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Upon notice of termination of a contract
from the government, all related termination costs are expensed. Revenue is recognized on the termination costs to the extent those
costs are allowable and billable under the contract. Because the government may require an audit of incurred costs, revenue is
recognized when the Company is reasonably assured of collection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Share-Based Compensation</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expense the estimated fair value of
share-based awards granted to employees, non-employee directors, and consultants under our stock compensation plans. The fair value
of stock options granted to employees and non-employee directors is determined at the grant date using the Black-Scholes option
pricing model. The Black-Scholes option pricing model considers, among other factors, the expected life of the award and the expected
volatility of our stock price. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line
basis over the employee&rsquo;s requisite service period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of share-based awards granted
to consultants is determined at the grant date using the Black-Scholes option pricing model and re-measured at each quarterly reporting
date over their requisite service period. The value of awards that are ultimately expected to vest is recognized as expense on
a straight-line basis over their requisite service period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of restricted stock grants
is determined based on the closing price of our common stock on the award date and is recognized as expense ratably over the requisite
service period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Share-based compensation expense
recognized in the three months and nine months ended September 30, 2015 and 2014 was calculated based on awards ultimately
expected to vest and has been reduced for estimated forfeitures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Share-based compensation expense for the
three months ended September 30, 2015 and 2014 was:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Three months ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; font-size: 10pt; text-align: left">Research and development</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">12,034</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">52,434</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">General and administrative</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">81,723</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">228,286</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total share-based compensation expense</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">93,757</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">280,720</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the three months ended September
30, 2015, we granted options to purchase 100,000 shares of common stock to non-employee directors and made no grants of options
or shares of restricted stock to employees and consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Share-based compensation expense for the
nine months ended September 30, 2015 and 2014 was:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Nine months ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 68%; font-size: 10pt; text-align: left">Research and development</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">85,259</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">329,655</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">General and administrative</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">395,470</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">843,048</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Restructuring benefit</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(53,741</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total share-based compensation expense</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">426,988</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,172,703</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the restructuring and termination
of employees, during the nine months ended September 30, 2015, we recognized approximately $75,000 of share-based compensation
expense resulting from our agreement to extend the exercise period of the vested stock options for several of the executives who
were terminated. In addition, approximately $129,000 of previously recognized share-based compensation expense was reversed for
unvested stock options forfeited as a result of the restructuring and termination of employees. The $53,741 net reversal of share-based
compensation expense is reflected in restructuring benefit in the above table.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the nine months ended September
30, 2015, we granted options to purchase 112,000 shares of common stock to employees and non-employee directors and granted 117,500
shares of restricted stock to employees. During the nine months ended September 30, 2014, we granted options to purchase 1,357,755
shares of common stock to employees, non-employee directors and consultants and made no restricted stock grants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At September 30, 2015, we had total unrecognized
share-based compensation expense related to unvested awards of approximately $0.8 million net of estimated forfeitures, which we
expect to recognize as expense over a weighted-average period of 2.2 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Income Taxes</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We account for income taxes using the asset
and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between
the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce
deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if
it is &ldquo;more likely than not&rdquo; that the position is sustainable based on its technical merits. Our policy is to recognize
interest and penalties on uncertain tax positions as a component of income tax expense. As of September 30, 2015 and December 31,
2014, we had recognized a full valuation allowance since the likelihood of realization of our tax deferred assets does not meet
the more likely than not threshold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our income tax expense was
$0.02 million and $0.03 million during the three months ended September 30, 2015 and 2014, respectively, and $0.05 million
during the nine months ended September 30, 2015 and 2014, relating exclusively to the generation of a deferred tax liability
associated with the tax amortization of goodwill, which is included as a component of other long-term liabilities on our
condensed consolidated balance sheets. The income tax expense results from the difference between the treatment of goodwill
for income tax purposes and for U.S. GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Basic and Diluted Net Loss Per Share</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Income (loss) per share:</I> Basic
income (loss) per share is computed by dividing consolidated net income (loss) by the weighted average number of common shares
outstanding during the period, excluding unvested restricted stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For periods of net income when the effects
are not anti-dilutive, diluted earnings per share is computed by dividing our net income by the weighted average number of shares
outstanding and the impact of all potential dilutive common shares, consisting primarily of stock options, unvested restricted
stock and stock purchase warrants. The dilutive impact of our potentially dilutive common shares resulting from stock options and
stock purchase warrants is determined by applying the treasury stock method. For periods of net loss, diluted loss per share is
calculated similarly to basic loss per share because the impact of all potentially dilutive common shares is anti-dilutive due
to the net losses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A total of approximately 6.0 million and
10.9 million potentially dilutive securities have been excluded in the calculation of diluted net loss per share in the
nine months ended September 30, 2015 and 2014, respectively, because their inclusion would be anti-dilutive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Recent Accounting Pronouncements</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2014, the Financial Accounting Standards
Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;) No. 2014-09, Revenue from Contracts with Customers
(Topic 606) (&ldquo;ASU No. 2014-09&rdquo;). ASU No. 2014-09 clarifies the principles for recognizing revenue to depict the transfer
of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled
in exchange for those goods or services. This guidance affects entities that enter into contracts with customers to transfer goods
or services, and supersedes prior GAAP guidance, namely Accounting Standards Codification Topic 605 &ndash; Revenue Recognition.
On July 9, 2015, the FASB voted and approved to defer the effective date of ASU No. 2014-09 by one year. As a result, ASU No. 2014-09
will be effective for fiscal years beginning after December 15, 2017, with early adoption permitted but not prior to the original
effective date of annual periods beginning after December 15, 2016. ASU No. 2014-09 is to be applied retrospectively, or on a modified
retrospective basis. We are currently evaluating the impact of adopting ASU No. 2014-09 on our consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In April 2015, the FASB issued ASU No.
2015-03, Interest &ndash; Imputation of Interest, or ASU No. 2015-03. To simplify presentation of debt issuance costs, the amendments
in this update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct
deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance
for debt issuance costs are not affected by the amendments in this update. The amendments in this update are effective for financial
statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. We expect
that the impact of adoption on our consolidated financial statements will be immaterial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 3 - Fair Value Measurements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The carrying amounts of our short-term
financial instruments, which primarily include cash and cash equivalents, accounts receivable (billed and unbilled), and accounts
payable approximate their fair values due to their short-term maturities. We define fair value as the exchange price that would
be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset
or liability in an orderly transaction between market participants at the measurement date. We report assets and liabilities that
are measured at fair value using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This
hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used
to measure fair value are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level 1 &mdash; Quoted prices in active markets for identical assets or liabilities.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level 2 &mdash; Observable inputs other than quoted prices included in Level 1, such as quoted
prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets
that are not active; or other inputs that are observable or can be corroborated by observable market data.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Level 3 &mdash; Unobservable inputs that are supported by little or no market activity and that
are significant to the fair value of the assets or liabilities. This includes certain pricing models, discounted cash flow methodologies
and similar techniques that use significant unobservable inputs.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">An asset&rsquo;s or liability&rsquo;s level
within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At
each reporting period, we perform a detailed analysis of our assets and liabilities that are measured at fair value. All assets
and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently
and therefore have little or no price transparency are classified as Level 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have segregated our financial assets
and liabilities that are measured at fair value into the most appropriate level within the fair value hierarchy based on the inputs
used to determine the fair value at the measurement date in the table below. We have no non-financial assets and liabilities that
are measured at fair value on a recurring basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table represents the Company&rsquo;s
fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">As of September 30, 2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Level 1</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Level 2</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Level 3</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Balance</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 44%; font-size: 10pt; text-align: left; padding-bottom: 1pt">Investment in money market funds<font style="font: normal 10pt Times New Roman, Times, Serif"><sup>(1)</sup></font></TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,430,038</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,430,038</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total investment in money market funds</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">6,430,038</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">6,430,038</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">Liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Current portion of derivative instruments related to stock purchase warrants</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2,355</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2,355</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Non-current portion of derivative instruments related to stock purchase warrants</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">227,898</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">227,898</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total derivative instruments related to stock purchase warrants</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">230,253</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">230,253</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="14" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">As of December 31, 2014</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Level 1</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Level 2</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Level 3</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Balance</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">Assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 44%; font-size: 10pt; text-align: left; padding-bottom: 1pt">Investment in money market funds<font style="font: normal 10pt Times New Roman, Times, Serif"><sup>(1)</sup></font></TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,429,104</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">6,429,104</TD><TD STYLE="width: 1%; padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total investment in money market funds</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">6,429,104</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">6,429,104</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold">Liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Current portion of derivative instruments related to stock purchase warrants</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">178,509</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">178,509</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Non-current portion of derivative instruments related to stock purchase warrants</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">629,170</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">629,170</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total derivative instruments related to stock purchase warrants</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">807,679</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">807,679</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><SUP>(1)</SUP></TD><TD>Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth a summary of changes in the fair
value of the Company&rsquo;s Level 3 liabilities for the nine months ended September 30, 2015 and 2014:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Exercised</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Balance&nbsp;as&nbsp;of</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Unrealized</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Stock Purchase</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Balance&nbsp;as&nbsp;of</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">December 31,</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">(Gains)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Warrants</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">September 30,</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">Description</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; font-size: 10pt; text-align: left">Derivative liabilities related to stock purchase warrants</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">807,679</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(577,426</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">-</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">230,253</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Exercised</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Balance&nbsp;as&nbsp;of</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Unrealized</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Stock Purchase</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Balance&nbsp;as&nbsp;of</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">December&nbsp;31,</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">(Gains)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">Warrants</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center">September 30,</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">Description</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2013</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 44%; font-size: 10pt; text-align: left">Derivative liabilities related to stock purchase warrants</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1,740,235</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(464,703</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(423,739</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">851,793</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At September 30, 2015 and 2014, derivative
liabilities are comprised of warrants to purchase 1,775,419 shares of common stock. The warrants are considered to be derivative
liabilities due to the presence of net settlement features and/or non-standard anti-dilution provisions, and as a result, are recorded
at fair value at each balance sheet date, with changes in fair value recorded in the accompanying unaudited condensed consolidated
statements of operations. The fair value of our warrants is determined based on the Black-Scholes option pricing model. Use of
the Black-Scholes option pricing model requires the use of unobservable inputs such as the expected term, anticipated volatility
and expected dividends. Changes in any of the assumptions related to the unobservable inputs identified above may change the stock
purchase warrants&rsquo; fair value; increases in expected term, anticipated volatility and expected dividends generally result
in increases in fair value, while decreases in the unobservable inputs generally result in decreases in fair value. Unrealized
gains and losses on the fair value adjustments for these derivative instruments are classified in other income (expense) as the
change in fair value of derivative instruments in the accompanying unaudited condensed consolidated statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="7" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Quantitative Information about Level 3 Fair Value Measurements</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="7" STYLE="font-size: 10pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Fair Value at September 30, 2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Valuation&nbsp;&nbsp;Technique</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Unobservable Inputs</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 26%; font-size: 10pt; text-align: right">230,253</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 34%; font-size: 10pt; text-align: left">&nbsp;Black-Scholes option pricing model</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 34%; font-size: 10pt; text-align: left">Expected term</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Expected dividends</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">Anticipated volatility</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Assets Measured at Fair Value on a Nonrecurring Basis</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company measures its long-lived
assets, including, property and equipment and goodwill, at fair value on a nonrecurring basis. These assets are recognized at
fair value when they are deemed to be other-than-temporarily impaired. During the three months ended September 30, 2015, the
Company recorded an impairment charge for property and equipment in the amount of $36,981. These assets were written down to
their fair value of $0 in conjunction with the sublease of the Company's leased office space (see Note 4 - <I>Commitments and
Contingencies - Leases</I>). As of September 30, 2015, the Company had no other assets or liabilities that were measured at
fair value on a nonrecurring basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 4 - Commitments and Contingencies</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">SIGA Litigation</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2006, we filed a complaint
against SIGA in the Delaware Court of Chancery. The complaint alleged, among other things, that we have the exclusive right to
license, development and marketing rights for SIGA&rsquo;s drug candidate, Arestvyr<SUP>&trade;</SUP> (Tecovirimat), pursuant to
a merger agreement between the parties that was terminated in 2006. The complaint also alleged that SIGA failed to negotiate in
good faith the terms of such a license pursuant to the terminated merger agreement with SIGA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2011, the Delaware Court of
Chancery issued an opinion in the case finding that SIGA had breached certain contractual obligations to us upholding our claims
of promissory estoppel, and awarding us damages. SIGA appealed aspects of the decision to the Delaware Supreme Court. In response,
we cross-appealed other aspects of the decision. In May 2013, the Delaware Supreme Court issued its ruling on the appeal, affirming
the Delaware Court of Chancery&rsquo;s finding that SIGA had breached certain contractual obligations to us, reversed its finding
of promissory estoppel, and remanded the case back to the Delaware Court of Chancery to reconsider the remedy and award in light
of the Delaware Supreme Court&rsquo;s opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 8, 2014, the Delaware Court of
Chancery issued a Memorandum Opinion and Order, or August 2014 Order, finding that we are entitled to receive lump sum expectation
damages for the value of the Company&rsquo;s lost profits for Tecovirimat. In addition, the Delaware Court of Chancery found that
the Company is entitled to receive pre-judgment interest and varying percentages of the Company&rsquo;s reasonable attorneys&rsquo;
and expert witness fees. On October 17, 2014, the Company and SIGA each filed opinions of our respective financial experts and
Draft Orders and Judgments in accordance with the instructions of the August 2014 Order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 16, 2014, SIGA announced that
it filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in the U.S. Bankruptcy Court for
the Southern District of New York. In connection therewith, SIGA filed with the Bankruptcy Court an affidavit indicating, among
other things, that it expects to continue to perform under its contract with BARDA. SIGA&rsquo;s petition for bankruptcy initiated
a process whereby its assets are protected from creditors, including us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 7, 2015, the Delaware Court
of Chancery issued a letter Opinion and Order, directing the Company to submit a Revised Proposed Judgment that reflects a lump
sum award of approximately $113 million in contract expectation damages, plus pre-judgment interest on that amount from 2006 through
the date of such order. In accordance with the instructions of the court, the Company submitted a draft Revised Proposed Judgment
under seal on January 9, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 15, 2015, the Delaware Court
of Chancery issued a Final Order and Judgment, finding that we are entitled to receive a lump sum award of $194.6 million, or the
Total Judgment, comprised of (1) expectation damages of $113.1 million for the value of the Company&rsquo;s lost profits for Tecovirimat,
also known as ST-246<SUP>&reg;</SUP> (formerly referred to as &ldquo;Arestvyr<SUP>&trade;</SUP>&rdquo; and referred to by SIGA
in its recent SEC filings as &ldquo;Tecovirimat&rdquo;), plus (2) pre-judgment interest on that amount from 2006 and varying percentages
of the Company&rsquo;s reasonable attorneys&rsquo; and expert witness fees, totaling $81.5 million. Under the Final Order and Judgment,
PharmAthene is also entitled to post-judgment simple interest. PharmAthene&rsquo;s entitlement to interest from and after SIGA&rsquo;s
bankruptcy filing may be negatively impacted by the proceedings under the Bankruptcy Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SIGA filed a notice of appeal with the
Delaware Supreme Court in which it challenges various findings of the Court of Chancery and seeks to set aside the Final Order
and Judgment, and we filed a notice of cross-appeal. On March 2, 2015, SIGA filed their opening brief, and PharmAthene filed a
response on April 1, 2015. SIGA took the opportunity to file their reply brief on May 1, 2015, and PharmAthene filed their reply
brief on cross-appeal on May 11, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 7, 2015, oral arguments in SIGA&rsquo;s
appeal and PharmAthene&rsquo;s cross-appeal of the January 15, 2015 Final Order and Judgement took place in the Delaware Supreme
Court. There can be no assurances that the Delaware Supreme Court will rule in PharmAthene&rsquo;s favor, or that PharmAthene will
receive any payments from SIGA. As a result, the decision could be reversed, remanded or otherwise changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While we believe that we may have a right
to receive a significant amount under a possible damages award, because SIGA has filed a notice of appeal with the Delaware Supreme
Court and because there can be no assurance that SIGA will not be successful in any such appeal, we have not yet recorded any amount
due from SIGA in relation to this case. There can be no assurances if or when the Company will receive any payments from SIGA as
a result of the Judgment. SIGA has stated publicly that it does not currently have cash sufficient to satisfy the award. It is
also uncertain whether SIGA will have such cash in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">PharmAthene&rsquo;s ability to collect
the Judgment depends upon a number of factors, including SIGA&rsquo;s financial and operational success, which is subject to a
number of significant risks and uncertainties (certain of which are outlined in SIGA&rsquo;s filings with the SEC), as to which
we have limited knowledge and which we have no ability to control, mitigate or fully evaluate. SIGA disclosed in its Current Report
on Form 8-K filed April 29, 2015 that it entered into a modification to its contract with BARDA on April 29, 2015 to increase the
provisional dosage of Tecovirimat and extend the delivery schedule. The modification was subject to approval by the Bankruptcy
Court, which was granted on April 27, 2015. Furthermore, because SIGA has filed for protection under the federal bankruptcy laws,
the Company is automatically stayed from taking any enforcement action in the Delaware Court of Chancery. By agreement of the parties,
and with the approval of the Bankruptcy Court, the automatic stay has been lifted for the sole purpose of allowing the Delaware
Court of Chancery to enter a money judgment and to allow the parties to exercise their appellate rights. The Company&rsquo;s ability
to collect a money judgment from SIGA, if any, remains subject to further proceedings in the Bankruptcy Court. The Company has
not recognized any potential proceeds from these actions in its financial statements to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Government Contracting</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payments to the Company on cost-plus-fee
contracts are provisional. The accuracy and appropriateness of costs charged to U.S. Government contracts are subject to regulation,
audit and possible disallowance by the Defense Contract Audit Agency (&ldquo;DCAA&rdquo;) and other government agencies such as
BARDA. Accordingly, costs billed or billable to U.S. Government customers are subject to potential adjustment upon audit by such
agencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have agreed to rate provisions with
DCAA for 2006, 2007 and 2008. In 2014, BARDA audited indirect costs or rates charged by us on the SparVax<SUP>&reg;</SUP> contract
for the years 2008 through 2013. As a result of the audit, in March of 2015, we were able to record revenue, and invoice BARDA
in the amount of $5.8 million in connection with these costs, all of which was collected in April 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BARDA has started an audit of our 2014
costs related to the partial termination for convenience of the SparVax<SUP>&reg;</SUP> contract. While we do not currently believe
the results of this audit will have an adverse effect on the Company, we cannot provide assurances that it will not have such an
effect. The Company has billed and recognized revenue using the provisional rates as defined in the contract. While the actual
rates for 2014, which reflect the actual costs incurred by us, have been higher than the provisional rates, we have no assurance
on either the amount of additional funds we may receive as a result of these higher rates or the amount of time it may take to
recover these funds. The amount of any such funds is determined as a result of future audits by BARDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Changes in government policies, priorities
or funding levels through agency or program budget reductions by the U.S. Congress or executive agencies could materially adversely
affect the Company&rsquo;s financial condition or results of operations. Furthermore, contracts with the U.S. Government may be
terminated or suspended by the U.S. Government at any time, with or without cause. Such contract suspensions or terminations could
result in unreimbursable expenses or charges or otherwise adversely affect the Company&rsquo;s financial condition and/or results
of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Registration Rights Agreements</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We entered into a Registration Rights Agreement
with the investors who participated in the July 2009 private placement of convertible notes and related warrants. We subsequently
filed two registration statements on Form S-3 with the SEC to register the resale of the shares issuable upon conversion of the
convertible notes and exercise of the related warrants, which have been declared effective. We are obligated to maintain the registration
statements effective until the date when such shares (and any other securities issued or issuable with respect to or in exchange
for such shares) have been sold or are eligible for resale without restrictions under Rule 144. The convertible notes were converted
or extinguished in 2010. The warrants expired on January 28, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the terms of the convertible notes,
which were converted or extinguished in 2010, if after the 2nd consecutive business day (other than during an allowable blackout
period) on which sales of all of the securities required to be included on the registration statement cannot be made pursuant to
the registration statement (a &ldquo;Maintenance Failure&rdquo;), we will be required to pay to each selling stockholder a one-time
payment of 1.0% of the aggregate principal amount of the convertible notes relating to the affected shares on the initial day of
a Maintenance Failure. Our total maximum obligation under this provision at September 30, 2015, which is not probable of payment,
would be approximately $0.2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Following a Maintenance Failure, we will
also be required to make to each selling stockholder monthly payments of 1.0% of the aggregate principal amount of the convertible
notes relating to the affected shares on every 30th day after the initial day of a Maintenance Failure, in each case prorated for
shorter periods and until the failure is cured. Our total maximum obligation under this provision, which is not probable of payment,
would be approximately $0.2 million for each month until the failure, if it occurs, is cured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have separate registration rights agreements
with investors, under which we have obligations to keep the corresponding registration statements effective until the registrable
securities (as defined in each agreement) have been sold, and under which we may have separate obligations to file registration
statements in the future on either a demand or &ldquo;piggy-back&rdquo; basis or both.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">License Agreements</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2015, PharmAthene signed a
license agreement with ImmunoVaccine for the exclusive use of the DepoVax<SUP>TM </SUP>vaccine platform, to develop an
anthrax vaccine utilizing PharmAthene&rsquo;s recombinant protective antigen (&ldquo;rPA&rdquo;). ImmunoVaccine is a
clinical-stage vaccine development company located in Halifax, Nova Scotia. PharmAthene will reimburse up to $210,000
to ImmunoVaccine for their efforts in developing this vaccine. In addition, ImmunoVaccine will receive annual payments of
$200,000, and additional payments for the achievement of certain milestones relating to contracting with the U.S. Government
as well as achieving certain clinical/regulatory and commercial milestones, and achievement of sales targets.
Additionally, ImmunoVaccine will receive a royalty on sales related to the use of DepoVax<SUP>TM</SUP>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Leases</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company leases its office under a 10-year
operating lease, which commenced on May 1, 2007. On September 2, 2015, the Company entered into a sublease agreement with a third party with respect to a portion
of its leased office space in Annapolis, Maryland at an amount less than the Company's leased amount. As a result, we realized
a loss of $0.4 million in restructuring expense our condensed consolidated statements of operations for the nine months ended September
30, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The present value of the
Company&rsquo;s remaining lease liability (net of the sublease rental income), is included on the balance sheet as a
component of accrued restructuring expenses as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 69%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Description</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Present Value at September 30, 2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 35%; font-size: 10pt; text-align: left">Accrued restructuring expenses</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 30%; font-size: 10pt; text-align: right">244,769</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Accrued restructuring expenses - long term</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">184,018</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Note 5 - Stockholders&rsquo; Equity</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Long-Term Incentive Plan</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2007, the Company&rsquo;s stockholders
approved the 2007 Long-Term Incentive Compensation Plan (the &ldquo;2007 Plan&rdquo;) which provides for the granting of incentive
and non-qualified stock options, stock appreciation rights, performance units, restricted stock awards and performance bonuses
(collectively &ldquo;awards&rdquo;) to Company officers and employees. Additionally, the 2007 Plan authorizes the granting of non-qualified
stock options and restricted stock awards to Company directors and to independent consultants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2008, our stockholders approved amendments
to the 2007 Plan, increasing from 3.5 million shares to 4.6 million shares the maximum number of shares authorized for issuance
under the plan and adding an evergreen provision pursuant to which the number of shares authorized for issuance under the plan
would increase automatically in each year, beginning in 2009, in accordance with certain limits set forth in the 2007 Plan. Under
the terms of the evergreen provision, the annual increases were to continue through 2015, subject, however, to an aggregate limitation
on the number of shares that could be authorized for issuance pursuant to such increases. This aggregate limitation was reached
on January 1, 2014, so that the number of shares authorized for issuance under the plan did not automatically increase on January
1, 2015. At September 30, 2015, there are approximately 10.3 million shares approved for issuance under the 2007 Plan, of which
approximately 4.4 million shares are available for grant. The Board of Directors in conjunction with management determines who
receives awards, the vesting conditions and the exercise price. Options may have a maximum term of ten years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrants</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At September 30, 2015, there were
warrants outstanding to purchase 1,922,781 shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Warrants to purchase 2,572,775 shares of
common stock expired on January 28, 2015 without being exercised. The warrants were classified as equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The warrants outstanding as of September 30,
2015, all of which are exercisable, were as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Number of Common Shares Underlying Warrants<BR>
 As of September 30, 2015</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Issue Date</TD><TD NOWRAP STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Exercise Price</TD><TD NOWRAP STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD NOWRAP STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Expiration Date</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 31%; font-size: 10pt; text-align: right">100,778</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD NOWRAP STYLE="width: 4%; font-size: 10pt; text-align: left"><SUP>(1)</SUP></TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 18%; font-size: 10pt; text-align: right">March 2007</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 18%; font-size: 10pt; text-align: right">3.97</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 18%; font-size: 10pt; text-align: right">March 2017</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">500,000</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: left"><SUP>(2) (3)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">April 2010</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.89</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">October 2015</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">903,996</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: left"><SUP>(2)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">July 2010</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.63</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">January 2017</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">371,423</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: left"><SUP>(2)</SUP></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">June 2011</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">3.50</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right">June 2016</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">46,584</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt"><SUP>(1)</SUP></TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right; padding-bottom: 1pt">March 2012</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">$</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: right">1.61</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: right; padding-bottom: 1pt">March 2022</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1,922,781</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><SUP>(1)</SUP></TD><TD>These warrants to purchase common stock are classified as equity.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><SUP>(2)</SUP></TD><TD STYLE="text-align: justify">Because of the presence of net settlement provisions, these warrants to purchase common stock are
classified as derivative liabilities. The fair value of these liabilities (see Note 3 &ndash; <I>Fair Value Measurements</I>) is
remeasured at the end of every reporting period and the change in fair value is reported in the accompanying unaudited condensed
consolidated statements of operations as other income (expense).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>(3)</SUP></TD><TD STYLE="text-align: justify">Warrants to purchase 500,000 shares of common stock expired
on October 13, 2015 without being exercised. The warrants were classified as derivative liabilities.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Note 6 &ndash; Financing Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Controlled Equity Offering</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 25, 2013, we entered into a controlled
equity offering sales agreement with a sales agent, and filed with the SEC a prospectus supplement, dated March 25, 2013 to our
prospectus dated July 27, 2011, or the 2011 Prospectus, pursuant to which we could offer and sell, from time to time, through the
agent, shares of our common stock having an aggregate offering price of up to $15.0 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 23, 2014, we entered into an amendment,
or the 2014 Amendment, to the controlled equity offering sales agreement with the sales agent, pursuant to which we may offer and
sell, from time to time, through the agent, shares of our common stock having an aggregate offering price of up to an additional
$15.0 million. On that day, we filed a prospectus supplement to the 2011 Prospectus for use in any sales of these additional shares
of common stock through July 26, 2014, the date the underlying registration statement (File No. 333-175394) expired. As a result
of this expiration, the 2011 Prospectus, as supplemented on March 25, 2013 and May 23, 2014, may no longer be used for the sale
of shares of common stock under the controlled equity offering sales agreement, as amended. On May 23, 2014, we also filed a new
universal shelf registration statement (File No. 333-196265) containing, among other things, a prospectus, or the 2014 Prospectus,
for use in sales of the common stock under the 2014 Amendment. This registration statement was declared effective on May 30, 2014.
Since the expiration of the 2011 Prospectus, all sales under the controlled equity offering sales agreement, as amended, are being
effected under the 2014 Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the controlled equity offering sales
agreement, as amended, the agent may sell shares by any method permitted by law and deemed to be an &ldquo;at-the-market&rdquo;
offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on NYSE
MKT, or any other existing trading market for our common stock or to or through a market maker. Subject to the terms and conditions
of that agreement, the agent will use commercially reasonable efforts, consistent with its normal trading and sales practices and
applicable state and federal law, rules and regulations and the rules of NYSE MKT, to sell shares from time to time based upon
our instructions. We are not obligated to sell any shares under the arrangement. We are obligated to pay the agent a commission
of 3.0% of the aggregate gross proceeds from each sale of shares under the arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2015, shares
having an aggregate offering price of $3.0 million remained available under the controlled equity offering sales agreement,
as amended. During the three and nine months ended September 30, 2015, we did not sell any shares of our common stock under
this arrangement. The expiration date of the existing universal shelf registration statement is May 29, 2017, three years after it became effective.
The controlled equity offering sales agreement, as amended, will expire on the same date, unless amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Termination of Loan Agreement with GE
Capital</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 3, 2015,  we satisfied
in full our remaining obligations under our March 2012 Loan Agreement with GE Capital. The Loan Agreement was scheduled to
terminate on September 29, 2015. The Loan Agreement provided for a senior secured debt facility including a $2.5 million term
loan and a revolving line of credit of up to $5.0 million based on our outstanding qualified accounts receivable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The final payment fee was accrued and expensed
over the term of the Loan Agreement, using the effective interest method. Financing costs incurred in connection with this agreement
were also amortized over the term of the agreement using the effective interest method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The termination of the Loan Agreement released
from us our obligations under the Loan Agreement, which were collateralized by a security interest in substantially all of our
assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Loan Agreement,
we issued to GE Capital a warrant to purchase 46,584 shares of the Company&rsquo;s common stock at an exercise price of $1.61 per
share. The warrant, which expires in March 2022, was not affected by the termination. The warrant was exercisable immediately and
subject to customary and standard anti-dilution adjustments. The warrant is classified in equity and, as a result, the fair value
of the warrant was charged to additional paid-in-capital resulting in a debt discount at the date of issuance. The debt discount
was amortized over the term of the Loan Agreement using the effective interest method.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_002"></A>Item 2. Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Quarterly Report on Form 10-Q contains forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. This information may involve known and unknown risks, uncertainties and other factors that are difficult
to predict and may cause our actual results, performance or achievements to be materially different from future results, performance
or achievements expressed or implied by any forward-looking statements. These risks, uncertainties and other factors include, but
are not limited to, risks associated with the following:</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>our interest in the judgment relating to SIGA&rsquo;s
Tecovirimat, also known as ST-246<SUP>&reg;</SUP> (formerly referred to as &ldquo;Arestvyr<SUP>&trade;</SUP>&rdquo; and referred
to by SIGA in its recent SEC filings as &ldquo;Tecovirimat&rdquo;), including the risk that we will not be able to collect any
amounts related thereto,</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>the reliability of the results of the studies relating
to human safety and possible adverse effects resulting from the administration of our product candidates,</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>funding
delays, reductions in or elimination of U.S. Government funding and/or non-renewal of expiring funding under our September 2014
contract with NIAID after we receive funding of approximately $7.5 million over the base period and the first option,</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>our common stock,</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>the continuation of availability of our net operating loss carryforwards, or
                                                                                                                               NOLs,</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>delays caused by third parties challenging government
contracts awarded to us,</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>unforeseen safety and efficacy issues,</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>our Realignment Plan,</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>accomplishing any future strategic partnerships
or business combinations,</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>continuing funding requirements and dilution relating
thereto,</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>our ability to continue to satisfy the listing
requirements of the NYSE MKT,</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">as well as risks detailed under the caption &ldquo;Risk
Factors&rdquo; in our annual report on Form 10-K and in our other reports filed with the U.S. Securities and Exchange Commission,
or the SEC, from time to time hereafter.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">In particular, in its August 2014 decision, the Delaware
Court of Chancery awarded to us lump sum expectation damages for the value of lost profits for Tecovirimat. On January 15, 2015,
the Delaware Court of Chancery issued its Final Order and Judgment, finding that we are entitled to receive the Total Judgment,
comprised of (1) expectation damages of $113.1 million for the value of the Company&rsquo;s lost profits for Tecovirimat, plus
(2) pre-judgment interest on that amount from 2006 and varying percentages of the Company&rsquo;s reasonable attorneys&rsquo; and
expert witness fees, totaling $81.5 million. Under the Final Order and Judgment, PharmAthene is also entitled to post-judgment
simple interest. PharmAthene&rsquo;s entitlement to interest from and after SIGA&rsquo;s bankruptcy filing may be negatively impacted
by the proceedings under the Bankruptcy Code.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>SIGA filed a notice of appeal with the
Delaware Supreme Court in which it challenges various findings of the Court of Chancery and seeks to set aside the Final Order
and Judgment, and we filed a notice of cross-appeal. On March 2, 2015, SIGA filed their opening brief, and PharmAthene filed a
response on April 1, 2015. SIGA took the opportunity to file their reply brief on May 1, 2015, and PharmAthene filed their reply
brief on cross-appeal on May 11, 2015. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>On October 7, 2015 oral arguments in
SIGA&rsquo;s appeal and PharmAthene&rsquo;s cross-appeal of the January 15, 2015 Final Order and Judgement took place in the Delaware
Supreme Court. There can be no assurances that the Delaware Supreme Court will rule in PharmAthene&rsquo;s favor, or that PharmAthene
will receive any payments from SIGA. As a result, the decision could be reversed, remanded or otherwise changed.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">There can be no assurances if or when we will receive
any payments from SIGA as a result of the Judgment. SIGA has stated publicly that it does not currently have cash sufficient to
satisfy the potential award. It is also uncertain whether SIGA will have such cash in the future. PharmAthene&rsquo;s ability to
collect the Judgment depends upon a number of factors, including SIGA&rsquo;s financial and operational success, which is subject
to a number of significant risks and uncertainties (certain of which are outlined in SIGA&rsquo;s filings with the SEC), as to
which we have limited knowledge and which we have no ability to control, mitigate or fully evaluate. SIGA disclosed in its Current
Report on Form 8-K filed April 29, 2015 that it entered into a modification to its contract with BARDA on April 29, 2015 to increase
the provisional dosage of Tecovirimat and extend the delivery schedule. Furthermore, because SIGA has filed for protection under
the federal bankruptcy laws, we are automatically stayed from taking any enforcement action in the Delaware Court of Chancery.
By agreement of the parties, and with the approval of the Bankruptcy Court, the automatic stay has been lifted for the sole purpose
of allowing the Delaware Court of Chancery to enter a money judgment and to allow the parties to exercise their appellate rights.
Our ability to collect a money judgment from SIGA, if any, remains subject to further proceedings in the Bankruptcy Court.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Moreover, at this point, future government funding to
support the development of Valortim<SUP>&reg;</SUP>, recombinant butyrylcholinesterase (&ldquo;rBChE&rdquo;) bioscavenger and liquid
SparVax<SUP>&reg; </SUP>is unlikely. Even if we received such funding, significant additional non-clinical animal studies, human
clinical trials, and manufacturing development work remain to be completed for our product candidates. It is also uncertain whether
any of our product candidates will be shown to be safe and effective and approved by regulatory authorities for use in humans.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Forward-looking statements describe management&rsquo;s
current expectations regarding our future plans, strategies and objectives and are generally identifiable by use of the words &ldquo;may,&rdquo;
&ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;believe,&rdquo; &ldquo;intend,&rdquo; &ldquo;project,&rdquo; &ldquo;potential&rdquo; or &ldquo;plan&rdquo; or the negative
of these words or other variations on these words or comparable terminology. Such statements include, but are not limited to, statements
relating to:</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>anticipated results of pending legal proceedings,</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>potential payments under government contracts or
grants,</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>potential future government contracts or grant
awards,</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>potential regulatory approvals,</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>future product advancements, and</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><I>anticipated financial or operational results.</I></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Finally, PharmAthene can offer no assurances that it
has correctly estimated the resources necessary to execute under its NIAID contract and seek partners, co-developers or acquirers
for its other programs under its realignment plan. If a larger workforce or one with a different skillset is ultimately required
to implement the realignment plan successfully, or if PharmAthene inaccurately estimated the cash and cash equivalents necessary
to finance its operations until SIGA&rsquo;s appeal has been adjudicated and it has received SIGA&rsquo;s payment, if PharmAthene
prevails on appeal, its business, results of operations, financial condition and cash flows may be materially and adversely affected.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Forward-looking statements are based on assumptions that
may be incorrect, and we cannot assure you that the projections included in the forward-looking statements will come to pass.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have based the forward-looking statements included
in this quarterly report on Form 10-Q on information available to us on the date of this quarterly report, and we assume no obligation
to update any such forward-looking statements, other than as required by law. Although we undertake no obligation to revise or
update any forward-looking statements, whether as a result of new information, future events or otherwise, you are advised to consult
any additional disclosures that we may make directly to you or through reports that we, in the future, may file with the SEC, including
annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">All forward-looking statements included herein are expressly
qualified in their entirety by the cautionary statements contained or referred to above. Unless otherwise indicated, the information
in this quarterly report is as of September 30, 2015.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following discussion should be read
in conjunction with our unaudited condensed consolidated financial statements which present our results of operations for the three
and nine months ended September 30, 2015 and 2014, as well as our financial positions at September 30, 2015 and December 31, 2014,
contained elsewhere in this quarterly report on Form 10-Q. The following discussion should also be read in conjunction with the
annual report on Form 10-K for the year ended December 31, 2014, including the consolidated financial statements contained therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Overview</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Since 2001, we have been a biodefense company
engaged in the development of next generation medical counter measures against biological and chemical threats. Our efforts are
focused on the development of the improved anthrax vaccines utilizing our base recombinant PA technology platform. We currently
have one active program funded by NIAID under a contract awarded in September 2014 for up to $28.1 million assuming all options
are exercised.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Realignment Plan</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 9, 2015, our Board of Directors
approved a plan to preserve and maximize, for the benefit of our stockholders, the value of any proceeds from our litigation with
SIGA and our existing biodefense assets. The plan eliminated approximately two-thirds of our workforce and aimed to preserve sufficient
cash and cash equivalents to finance our continued operations through a period of time expected to extend beyond the adjudication
of SIGA&rsquo;s appeal of the decision of the Delaware Chancery Court awarding us $194.6 million plus post-judgment interest. We
refer to the plan as the &ldquo;Realignment Plan.&rdquo; Under the Realignment Plan, we intend to maintain sufficient resources
and personnel so that we can seek partners, co-developers or acquirers for our biodefense programs and continue to execute under
our anthrax government contract with NIAID.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As part of the Realignment Plan, our Board
terminated Eric Richman as President and Chief Executive Officer and Linda Chang as Chief Financial Officer, Treasurer and Secretary,
as well as our executive officers Francesca Cook and Wayne Morges. Mr. Richman remains a member of our Board of Directors, and,
as such, will continue to play a key role in managing the ongoing litigation, other legal matters and any strategic transactions.
In addition, Messrs. Joel McCleary and Brian Markison resigned from our Board of Directors effective March 11, 2015, and our Board
has reduced the number of directors from eight to six.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">John Gill, a member of our Board of Directors,
began serving as President and Chief Executive Officer effective March 12, 2015, and Vice President and Controller Philip MacNeill began serving as Chief Financial Officer, Treasurer and Secretary
effective May 1, 2015. Mr. Gill is expected to devote the necessary time to carry out his duties as President and Chief Executive
Officer, and although he does not have other employment, he is not expected to devote his full time to the business of the Company,
which is reflected in his compensation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The terminations of the departing executive
officers were without &ldquo;cause&rdquo; as defined under their respective employment agreements and the departing officers will
therefore receive cash payments in accordance with the terms of such agreements. The Company estimates total severance payments
to executives and non-executives in connection with the Realignment Plan to amount to approximately $2.0 million, with substantially
all such severance expenses expected to be paid in 2015. Mr. Richman, Ms. Chang, Ms. Cook and Dr. Morges furthermore entered into
separation agreements with the Company. These agreements extend exercise periods of options and health benefits. In light of his
continuing service as director, Mr. Richman&rsquo;s options will continue vesting for as long as he serves on our Board of Directors,
with his then-vested options terminating 90 days after Mr. Richman leaves our Board. Ms. Chang&rsquo;s, Dr. Morges&rsquo; and Ms.
Cook&rsquo;s options will remain exercisable for the duration of their respective severance periods under their employment agreements.
Changes to the exercise period of these options were made in accordance with the terms of the Company&rsquo;s 2007 Long-Term Incentive
Compensation Plan, as amended. We recognized approximately $75,000 of share-based compensation expense resulting from our agreement
to extend the exercise period. In addition, to the extent that the executive officers elect COBRA coverage, the premiums payable
by the officers during their respective severance periods will equal those payable by active employees of the Company for the same
level of group health coverage, and will be deducted from the officers&rsquo; severance pay. The separation agreements contain
releases by the executive officers and the Company. The agreements with Ms. Chang, Dr. Morges and Ms. Cook furthermore obligate
them to cooperate with the Company in connection with the SIGA litigation. The agreement with Dr. Morges also provides that for
six months following termination, Dr. Morges may be called upon from time to time to assist the Company with matters relating to
his duties and responsibilities prior to termination at an hourly rate of $169.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We can offer no assurances that we have
correctly estimated the resources or personnel necessary to seek partners, co-developers or acquirers for our biodefense programs
or execute under our NIAID contract. If a larger workforce or one with a different skillset is ultimately required to implement
our Realignment Plan successfully, we may be unable to maximize the value of the SIGA litigation and our existing biodefense assets.
In addition, executive officers who have served the Company for many years have been terminated, and, with the exception of Mr.
Richman&rsquo;s continued service on the Board, will no longer be available to guide the Company. We also cannot assure you that
we have accurately estimated the cash and cash equivalents necessary to finance our operations until SIGA&rsquo;s appeal has been
adjudicated and we have received SIGA&rsquo;s payment, if we prevail on appeal. If revenues from our NIAID contract are less than
we anticipate, if operating expenses exceed our expectations or cannot be adjusted accordingly, or if we have underestimated the
time it will take for us to prevail in SIGA&rsquo;s appeal, or enforce payment of or collect any damages award from SIGA, if we
do prevail, then our business, results of operations, financial condition and cash flows will be materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">License Agreements</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 6, 2015, PharmAthene signed a
license agreement with ImmunoVaccine for the exclusive use of the DepoVax<SUP>TM </SUP>vaccine platform, to develop an
anthrax vaccine utilizing PharmAthene&rsquo;s recombinant protective antigen (&ldquo;rPA&rdquo;). ImmunoVaccine is a
clinical-stage vaccine development company located in Halifax, Nova Scotia. PharmAthene will reimburse up to $210,000
to ImmunoVaccine for their efforts in developing this vaccine. In addition, ImmunoVaccine will receive annual payments of
$200,000, and additional payments for the achievement of certain milestones relating to contracting with the U.S. Government
as well as achieving certain clinical/regulatory and commercial milestones, and achievement of sales targets.
Additionally, ImmunoVaccine will receive a royalty on sales related to the use of DepoVax<SUP>TM</SUP>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Leases</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 2, 2015, the Company entered into a sublease agreement with a third party with respect to a portion of its leased office space.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Other Recent Developments</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 15, 2015, the Delaware Court
of Chancery issued a Final Order and Judgment, finding that we are entitled to receive the Total Judgment, comprised of (1) expectation
damages of $113.1 million, for the value of the Company&rsquo;s lost profits for Tecovirimat, plus (2) pre-judgment interest on
that amount from 2006 and varying percentages of the Company&rsquo;s reasonable attorneys&rsquo; and expert witness fees, totaling
$81.5 million. Under the Final Order and Judgment, PharmAthene is also entitled to post-judgment simple interest. PharmAthene&rsquo;s
entitlement to interest from and after SIGA&rsquo;s bankruptcy filing may be negatively impacted by the Bankruptcy Code. SIGA filed
a notice of appeal with the Delaware Supreme Court in which it challenges various findings of the Court of Chancery and seeks to
set aside the Final Order and Judgment, and we filed a notice of cross-appeal. Subsequently, both SIGA and PharmAthene have filed
appeals and reply briefs. As a result, the decision could be reversed, remanded or otherwise changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There can be no assurances if or when the
Company will receive any payments from SIGA as a result of the Judgment. SIGA has stated publicly that it does not currently have
cash sufficient to satisfy the potential award. It is also uncertain whether SIGA will have such cash in the future. PharmAthene&rsquo;s
ability to collect the Judgment depends upon a number of factors, including SIGA&rsquo;s financial and operational success, which
is subject to a number of significant risks and uncertainties (certain of which are outlined in SIGA&rsquo;s filings with the SEC),
as to which we have limited knowledge and which we have no ability to control, mitigate or fully evaluate. SIGA disclosed in its
Current Report on Form 8-K filed April 29, 2015 that it entered into a modification to its contract with BARDA on April 29, 2015
to increase the provisional dosage of Tecovirimat and extend the delivery schedule. Furthermore, because SIGA has filed for protection
under the federal bankruptcy laws, PharmAthene is automatically stayed from taking any enforcement action in the Delaware Court
of Chancery. By agreement of the parties, and with the approval of the Bankruptcy Court, the automatic stay has been lifted for
the sole purpose of allowing the Delaware Court of Chancery to enter a money judgment and to allow the parties to exercise their
appellate rights. The Company&rsquo;s ability to collect a money judgment from SIGA, if any, remains subject to further proceedings
in the Bankruptcy Court, and the Company therefore has not recorded any potential proceeds to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Critical Accounting Policies</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A &ldquo;critical accounting policy&rdquo;
is one that is both important to the portrayal of our financial condition and results of operations and that requires management&rsquo;s
most difficult, subjective or complex judgments. Such judgments are often the result of a need to make estimates about the effect
of matters that are inherently uncertain. The preparation of our financial statements in conformity with accounting principles
generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported
amounts of revenues and expenses during the reporting period. Actual results could differ materially from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that the disclosures provided
herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements
are read in conjunction with the audited consolidated financial statements and notes included in our Annual Report on Form 10-K
for the year ended December 31, 2014, filed with the U.S. Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no significant changes in critical
accounting policies from those at December 31, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Revenue</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We recognized revenue of $1.2 million and
$1.0 million during the three months ended September 30, 2015 and 2014, respectively. We recognized revenue of $9.4 million and
$8.4 million during the nine months ended September 30, 2015 and 2014, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Three months ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">Revenue ($ in millions)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">% Change</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 58%; font-size: 10pt; text-align: left">SparVax<font style="font: normal 10pt Times New Roman, Times, Serif"><sup>&reg;</sup>and next generation anthrax vaccine</font></TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1.2</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1.0</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">20.0</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">rBChE bioscavenger</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total revenue</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1.2</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1.0</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">20.0</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">%</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Nine months ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">Revenue ($ in millions)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">% Change</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 58%; font-size: 10pt; text-align: left">SparVax<font style="font: normal 10pt Times New Roman, Times, Serif"><sup>&reg;</sup>and next generation anthrax vaccine</font></TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">9.4</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">7.9</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">19.0</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">rBChE bioscavenger</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.5</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(100.0</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total revenue</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">9.4</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">8.4</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">11.9</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">%</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the three and nine months ended September 30, 2015, our
revenue was derived primarily from contracts with the U.S. Government for the development of anthrax vaccine programs. During the
three and nine months ended September 30, 2014, our revenue was derived primarily from contracts with the U.S. Government for the
development of anthrax vaccine programs.&nbsp;Our revenue in the three and nine months ended September
30, 2015 changed from the comparable period of 2014 primarily due to the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: normal 10pt Symbol">&middot;</FONT></TD><TD><FONT STYLE="font-weight: normal">Under our contract for the development of SparVax<SUP>&reg;</SUP> (the liquid second generation
rPA) with BARDA, we did not recognize any revenue for the three months ended September 30, 2015, and recognized $1.0 million for
the three months ended September 30, 2014. We recognized approximately $6.1 million and $7.9 million for the nine months ended
September 30, 2015 and 2014, respectively. During the nine months ended September 30, 2015, revenue was primarily attributable
to the receipt of a one-time payment as a result of an audit completed by BARDA and contract wind-up activity. On April 4, 2014,
we received notification from BARDA, advising us of its decision to de-scope the SparVax<SUP>&reg;</SUP> anthrax vaccine contract
through a partial termination for convenience. The contract formally expired on February 28, 2015. We do not expect that we will
receive additional funding from BARDA for the further development of SparVax<SUP>&reg;</SUP> as a liquid product. Therefore, we
anticipate that revenues for this program in 2015 will be significantly less than in 2014.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In 2014, BARDA audited indirect
costs or rates charged by us on the SparVax<SUP>&reg;</SUP> contract for the years 2008 through 2013. We billed and recognized
revenue using the provisional rates as defined in the contract. As a result of the audit, we recognized revenue of $5.8 million
in the first quarter of 2015, representing the difference between actual rates (i.e., actual cost to us) and the provisional rates
used to calculate previously billed and recognized revenue. We received payment of this amount in the second quarter of 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">BARDA has started an audit of
our 2014 costs related to the partial termination for convenience of the SparVax<SUP>&reg;</SUP> contract. While we do not currently
believe the results of this audit will have an adverse effect on the Company, we cannot provide assurances that it will not have
such an effect. The Company has billed and recognized revenue using the provisional rates as defined in the contract. While the
actual rates for 2014 which reflect the actual costs incurred by us, have been higher than the provisional rates, we have no assurance
on either the amount of additional funds we may receive as a result of these higher rates or the amount of time it may take to
recover these funds. The amount of any such funds is determined as a result of future audits by BARDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">On September 9, 2014, we entered
into a contract with NIAID for the development of a next generation lyophilized anthrax vaccine based on the Company&rsquo;s proprietary
technology platform which contributes the rPA bulk drug substance that is used in the liquid SparVax<SUP>&reg;</SUP> formulation.
On September 10, 2015, NIAID exercised the first option under this agreement. The option provides additional funding of approximately
$2.3 million and an extension of the period of performance through September 30, 2016. During the three and nine months ended September
30, 2015, we recognized approximately $1.2 million and $3.3 million in revenue, respectively. We recognized milestone revenue of
approximately $0.2 million in fixed fee during the three months ended September 30, 2015, relating to the successful completion
of the manufacturing of two lyophilized anthrax vaccine candidates which utilize the same rPA bulk drug substance that is used
in the liquid SparVax<SUP>&reg;</SUP> product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font: 10pt Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Our contract with Chemical Biological Medical Systems (&ldquo;CBMS&rsquo;), for our second generation
rBChE bioscavenger ended on September 8, 2014. We do not foresee any additional funding for this program and expect that revenues
from this program in the future will be minimal. Revenue in support of contract activities for the nine months ended September 30, 2014 was $0.5 million.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and Development Expenses</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our research and development expenses were
$1.1 million and $1.7 million for the three months ended September 30, 2015 and 2014, respectively. In 2015, these expenses related
to the lyophilized anthrax vaccine candidates as well as the stability program for the liquid product. In 2014, these expenses
resulted from research and development activities in all periods relating primarily to our SparVax<SUP>&reg;</SUP> and rBChE bioscavenger
programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses for the
three and nine months ended September 30, 2015 and 2014 were attributable to research programs as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Three months ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">Expenses ($ in millions)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">% Change</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 58%; font-size: 10pt; text-align: left">SparVax<font style="font: normal 10pt Times New Roman, Times, Serif"><sup>&reg;</sup>and next generation anthrax vaccine</font></TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1.1</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">1.7</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(35.3</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">rBChE bioscavenger</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total research and development expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1.1</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">1.7</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(35.3</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)%</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="10" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Nine months ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; border-bottom: Black 1pt solid">Expenses ($ in millions)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">% Change</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 58%; font-size: 10pt; text-align: left">SparVax<font style="font: normal 10pt Times New Roman, Times, Serif"><sup>&reg;</sup>and next generation anthrax vaccine</font></TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">4.0</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">7.1</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right">(43.7</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">rBChE bioscavenger</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">0.4</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(100.0</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total research and development expenses</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">4.0</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">7.5</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(46.7</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)%</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For the three and nine months ended September
30, 2015, research and development expenses decreased $0.6 million and $3.5 million, respectively, from the same period in the
prior year, primarily due to decreased costs relating to our BARDA sponsored SparVax<SUP>&reg;</SUP> program, as a result of BARDA&rsquo;s
de-scoping of the contract, and the expiration of the period of performance under our rBChE bioscavenger contract on September
8, 2014. Costs were incurred in 2015 to further the NIAID (lyophilized) program and internal research and development funds were
expensed for release and stability testing for the liquid product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">General and Administrative Expenses</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative functions include
executive management, finance and administration, government affairs and regulations, corporate development, human resources, legal,
and compliance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Expenses associated with general and
administrative functions were $1.2 million and $3.2 million for the three months ended September 30, 2015 and 2014,
respectively. The $2.0 million decrease when comparing the three months ended September 30, 2015 to the three months ended
September 30, 2014 was primarily due to a reduction in employee costs resulting from our implementation of the Realignment
Plan, which eliminated approximately two-thirds of our workforce and a reduction in legal expenses. We expect
general and administrative expenses for the last quarter of 2015 to be consistent with the third quarter of 2015. Expenses
associated with general and administrative functions were $5.2 million and $8.3 million for the nine months ended September
30, 2015 and 2014, respectively. Similarly, the reduction in expenses of $3.1 million was attributable to a reduction in
workforce, and legal expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Restructuring Expense</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Restructuring expense was $0.4 million and $2.5 million
for the three and nine months ended September 30, 2015, respectively. Pursuant to the Realignment Plan, we recorded severance
expense of $2.0 million. An additional $0.1 million was related to legal and other employee related Realignment Plan expenses.
Twenty-four employees were terminated with some payments extending into 2016, although the majority of the payments are expected
to be made during 2015. The remaining restructuring expense consisted of $0.4 million resulting from the sublease and related
impairment.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other Income (Expense)</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other income (expense) primarily consists of the realization
of cumulative translation adjustment on substantially completing the liquidation of our wholly-owned United Kingdom subsidiary,
PharmAthene UK Limited, changes in the fair value of our derivative financial instruments and interest expense on our debt and
other financial obligations. For the three months ended September 30, 2015, other income was $0.3 million compared to other expense
of $0.6 million for the three months ended September 30, 2014. For the nine months ended September 30, 2015 and 2014, other income
was $0.3 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In June 2015, we substantially completed the liquidation of
our United Kingdom subsidiary, PharmAthene UK Limited, which we had acquired in 2008. Prior to substantially liquidating the UK
subsidiary, currency fluctuations were recorded as foreign currency translation adjustments, a component of other comprehensive
income. As a result of the substantially completed liquidation, we realized an approximate loss of $0.2 million in our condensed
consolidated statement of operations, which represents the amount of previously recorded foreign currency translation adjustments
related to our UK subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other income related to the change in the fair value of our
derivative instruments was $0.4 million for the three months ended September 30, 2015, compared to other expense of $0.6 million
for the three months ended September 30, 2014. For the nine months ended September 30, 2015 and 2014, other income related to the
change in the fair value of our derivative instruments was $0.6 million and $0.5 million, respectively. The fair value of our derivative
instruments is estimated using the Black-Scholes option pricing model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Income Taxes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The provision for income taxes was $0.02
million and $0.03 million for the three months ended September 30, 2015 and 2014, respectively. The provision for income taxes
was $0.05 million during the nine months ended September 30, 2015 and 2014. Our provision for income taxes results from the difference
between the treatment of goodwill for income tax purposes and for U.S. GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Liquidity and Capital Resources</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Overview</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our primary sources of cash during the
three and nine months ended September 30, 2015 were the receipt of a $5.8 million one-time payment as the result of an audit completed
by BARDA, and proceeds paid under our contract with NIAID. Our primary sources of cash during the three and nine months ended September
30, 2014 were amounts paid under our development contract for SparVax<SUP>&reg;</SUP> and proceeds from sales of shares of our
common stock under the controlled equity offering arrangement. Our cash and cash equivalents were $17.4 million and $18.6 million
at September 30, 2015 and December 31, 2014, respectively. We believe, based on the operating cash requirements and capital expenditures
expected for 2015, the Company&rsquo;s cash on hand at September 30, 2015 is adequate to fund operations through at least the end
of 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In 2014, BARDA audited indirect costs or
rates charged by us on the SparVax<SUP>&reg;</SUP> contract for the years 2008 through 2013. We had billed and recognized revenue
using the provisional rates as defined in the contract. As a result of that audit, we were able to record revenue of $5.8 million
in the first quarter of 2015, representing the difference between actual rates (i.e., actual cost to us) and the provisional rates
used to calculate previously billed and recognized revenue. BARDA has started an audit of our 2014 costs related to the partial
termination for convenience of the SparVax<SUP>&reg;</SUP> contract. While we do not currently believe the results of this audit
will have an adverse effect on the Company, we cannot provide assurances that it will not have such an effect; furthermore, in
2014, our actual rates exceeded our provisional rates. We also do not control the timing of the audit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our sole sources of revenue consist of
(1) revenues related to the audit of the BARDA contract and (2) revenues under our September 2014 agreement with NIAID for the
development of a next generation lyophilized anthrax vaccine based on the Company&rsquo;s proprietary technology platform which
contributes the rPA bulk drug substance that is used in the liquid SparVax<SUP>&reg;</SUP> formulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The NIAID agreement is incrementally funded.
Over the base period of the agreement, we were awarded initial funding of approximately $5.2 million, which includes a cost reimbursement
component and a fixed fee component payable upon achievement of certain milestones. On September 10, 2015, NIAID exercised the
first option under this agreement. The option provides additional funding of approximately $2.3 million and an extension of the
period of performance through September 30, 2016. The contract has a total value of up to approximately $28.1 million, if all technical
milestones are met and all eight contract options are exercised by NIAID. NIAID may exercise the options in its sole discretion.
If NIAID exercises all options, the contract would continue approximately five years. If NIAID does not exercise any additional
options, the contract would expire by its terms on September 30, 2016. Due to the current economic environment, the U.S. Government
may be forced or choose to reduce or delay spending in the biodefense field, which would decrease the likelihood that the government
will exercise its right to extend its existing contract with us, the likelihood of future government contract awards, and/or the
likelihood that the government would procure products from us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have incurred significant losses since
we commenced operations. As of September 30, 2015, we had accumulated losses of $222.5 million since our inception. While we have
undertaken efforts to reduce expenses, if we continue to incur losses and are not able to raise adequate funds to cover
those losses, we may be required to cease operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Historically, we have not generated positive
cash flows from operations. To bridge the gap between payments made to us under our U.S. Government contracts and grants and our
operating and capital needs, we have had to rely on a variety of financing sources, including the issuance of equity and equity-linked
securities and proceeds from loans and other borrowings. On March 25, 2013, we entered into a controlled equity offering arrangement
pursuant to which we could offer and sell, from time to time, through a sales agent, shares of our common stock having an aggregate
offering price of up to $15.0 million, which we later amended on May 23, 2014 to increase the offering amount by $15.0 million.
During the three and nine months ended September 30, 2014, we generated net proceeds of approximately $10.4 million and $15.5 million,
respectively, under the controlled equity offering sales agreement, as amended. During the three and nine months ended September
30, 2015, we did not sell any shares of our common stock under this arrangement. Aggregate gross proceeds of up to $3.0 million
remain available under this arrangement. We have no current plans to sell any shares under the controlled equity agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 3, 2015, following a payment of $81,347, representing a $75,000 final payment fee pursuant to the March 30, 2012
Loan Agreement, $10 outstanding principal balance, $208 accrued interest, and $6,129 legal fees of the lender, we satisfied
in full our remaining obligation under our March 2012 Loan Agreement with GE Capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 9, 2015, our Board of Directors
approved our Realignment Plan with the goal of preserving and maximizing, for the benefit of our stockholders, the value of any
proceeds from the SIGA litigation and our existing biodefense assets. The plan eliminated approximately two-thirds of our workforce
and aimed to preserve sufficient cash and cash equivalents to finance our continued operations through a period of time expected
to extend beyond the adjudication of SIGA&rsquo;s appeal. We intend to maintain sufficient resources and personnel so that we can
seek partners, co-developers or acquirers for our biodefense programs and continue to execute under our government contract with
NIAID. The Company estimates total severance payments to executives and non-executives in connection with the Realignment Plan
to amount to approximately $2.0 million, with substantially all such severance expenses expected to be paid in 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We can offer no assurances that we have
correctly estimated the resources or personnel necessary to seek partners, co-developers or acquirers for our biodefense programs
or execute under our NIAID contract. If a larger workforce or one with a different skillset is ultimately required to implement
our Realignment Plan successfully, we may be unable to maximize the value of the SIGA litigation and our existing biodefense assets.
In addition, executive officers who have served the Company for many years have been terminated, and, with the exception of Mr.
Richman&rsquo;s continued service on the Board, will no longer be available to guide the Company. We also cannot assure you that
we have accurately estimated the cash and cash equivalents necessary to finance our operations until SIGA&rsquo;s appeal has been
adjudicated and we have received SIGA&rsquo;s payment, if we prevail on appeal. If revenues from our NIAID contract are less than
we anticipate, if operating expenses exceed our expectations or cannot be adjusted accordingly, or if we have underestimated the
time it will take for us to prevail in SIGA&rsquo;s appeal, or enforce payment of or collect the damages award from SIGA, if we
do prevail, then our business, results of operations, financial condition and cash flows will be materially and adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, we may voluntarily elect to
raise additional capital to strengthen our financial position. There can be no assurances that we would be successful in raising
additional funds on acceptable terms or at all. Additional sales of common stock may be made at prices that are dilutive to existing
stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cash Flows</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The following table provides information
regarding our cash flows for the nine months ended September 30, 2015 and 2014:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">Nine months ended September 30,</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2015</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; text-align: center; border-bottom: Black 1pt solid">2014</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Net cash provided by (used in):</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 68%; font-size: 10pt; text-align: left">Operating activities</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">(1,387,028</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD><TD STYLE="width: 2%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">(4,951,585</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left">Investing activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(60,677</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(84,269</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Financing activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">193,594</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">14,182,852</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Effects of exchange rates on cash</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">169</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(7,585</TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 2.5pt">Total (decrease) increase in cash and cash equivalents</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,253,942</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">9,139,413</TD><TD STYLE="padding-bottom: 2.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Operating Activities</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used by operating activities was
$1.4 million and $5.0 million for the nine months ended September 30, 2015 and 2014, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used by operating activities during
the nine months ended September 30, 2015 reflects our net loss of $2.2 million, adjusted for the realization of a cumulative translation
adjustment of $0.2 million, non-cash share-based compensation expense of $0.4 million, the decrease in the fair value of our derivative
instruments of $0.6 million, and other non-cash expenses of $0.1 million<B>. </B>Receivables (billed and unbilled) and prepaid expenses
increased by $0.3 million. Accounts payable decreased $0.1 million, and accrued expenses and other liabilities increased by $0.2 million. Accrued restructuring
expenses were $0.8 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in operating activities during
the nine months ended September 30, 2014 reflects our net loss of $7.3 million, adjusted for non-cash share-based compensation
expense of $1.2 million and the decrease in the fair value of our derivative instruments of $0.5 million. A decrease in receivables
(billed and unbilled) of approximately $3.3 million was offset by a decrease in liabilities and deferred revenue of $1.6 million
and $0.3 million, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investing Activities</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There were no significant investing activities
during the nine months ended September 30, 2015 and September 30, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Financing Activities</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by financing activities
was $0.2 million and $14.2 million for the nine months ended September 30, 2015 and 2014, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by financing activities
during the nine months ended September 30, 2015 was primarily due to $0.9 million in proceeds received from the issuance of common
stock due to stock options exercised, partially offset by a $0.8 million repayment of the term loan. Net cash provided by financing
activities during the nine months ended September 30, 2014 was primarily due to net proceeds received of $15.3 million from the
sale of our common stock under the controlled equity offering arrangement and stock options exercised, and net proceeds received
of $0.7 million from the exercise of warrants. This was partially offset by a $1.1 million repayment of the revolving credit agreement
and $0.8 million repayment of the term loan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 25, 2013, we entered into a controlled
equity offering sales agreement with a sales agent, and filed with the SEC a prospectus supplement, dated March 25, 2013, to our
prospectus, dated July 27, 2011, or the 2011 Prospectus, pursuant to which we could offer and sell, from time to time, through
the agent, shares of our common stock having an aggregate offering price of up to $15.0 million. On May 23, 2014, we entered into
an amendment, or the 2014 Amendment, to the controlled equity offering sales agreement with the sales agent, pursuant to which
we may offer and sell, from time to time, through the agent, shares of our common stock having an aggregate offering price of up
to an additional $15.0 million. On that day, we filed a prospectus supplement to the 2011 Prospectus for use in any sales of these
additional shares of common stock through July 26, 2014, the date the underlying registration statement (File No. 333-175394) expired.
As a result of this expiration, the 2011 Prospectus, as supplemented on March 25, 2013 and May 23, 2014, may no longer be used
for the sale of shares of common stock under the controlled equity offering sales agreement, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On May 23, 2014, we also filed a new universal
shelf registration statement (File No. 333-196265) containing, among other things, a prospectus, or the 2014 Prospectus, for use
in sales of the common stock under the 2014 Amendment. This registration statement was declared effective on May 30, 2014. Since
the expiration of the 2011 Prospectus, all sales under the controlled equity offering sales agreement, as amended, have been effected
under the 2014 Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the controlled equity offering sales
agreement, as amended, the agent may sell shares by any method permitted by law and deemed to be an &ldquo;at-the-market&rdquo;
offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on NYSE
MKT, or any other existing trading market for our common stock or to or through a market maker. Subject to the terms and conditions
of that agreement, the agent will use commercially reasonable efforts, consistent with its normal trading and sales practices and
applicable state and federal law, rules and regulations and the rules of NYSE MKT, to sell shares from time to time based upon
our instructions. We are not obligated to sell any shares under the arrangement. We are obligated to pay the agent a commission
of 3.0% of the aggregate gross proceeds from each sale of shares under the arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">During the first, second and third quarters
of 2015, we did not generate any net proceeds under the controlled equity offering sales agreement, as amended. Aggregate gross
proceeds of up to $3.0 million remain available under this arrangement. We have no current plans to sell any shares under the controlled
equity agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Off-Balance Sheet Arrangements</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not have any off-balance sheet arrangements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Contractual Obligations</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-weight: normal">The following are contractual
obligations at September 30, 2015:</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Contractual&nbsp;Obligations<SUP>(1)</SUP></FONT></TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Total</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">Less&nbsp;than&nbsp;1 <BR>Year</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">1-3&nbsp;Years</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">3-5&nbsp;Years</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="2" NOWRAP STYLE="text-align: center; border-bottom: Black 1pt solid">More&nbsp;than 5 <BR>Years</TD><TD NOWRAP STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 45%; text-align: left">Operating facility leases</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">1,413,095</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">842,037</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">571,058</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 8%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt">Research and development agreements</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">756,652</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">756,652</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt">Total contractual obligations</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">2,169,747</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">1,598,689</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">571,058</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2.5pt; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal"><SUP>(1)</SUP></FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-weight: normal">This table does not include any royalty payments relating to
future sales of products subject to license agreements the Company has entered into in relation to its in-licensed technology,
as the timing and likelihood of such payments are not known. The table also excludes any obligations related to registration rights
agreements, as a result of a maintenance failure (as defined in such agreements), as the likelihood of any such payment is not
probable. </FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_003"></A>Item 3. Quantitative and Qualitative
Disclosures about Market Risk.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company&rsquo;s current operations
in foreign countries are minimal. We had maintained only nominal operations in the United Kingdom, but those operations were substantially
liquidated in the second quarter of 2015. A 10% change in exchange rates (against the U.S. dollar) would not have a material impact
on earnings, fair values or cash flow.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because of the short-term maturities of
our cash and cash equivalents, we do not believe that an increase in market interest rates would have a significant impact on their
realized value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The change in fair value of our derivative
instruments is calculated utilizing the Black-Scholes option pricing model; therefore, a 10% increase/decrease in the closing price
of the Company&rsquo;s common stock at September 30, 2015, would result in a change in fair value of derivative instruments and
our earnings of approximately $0.07 million and $0.06 million, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_004"></A>Item 4. Controls and Procedures.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Evaluation of Disclosure Controls and Procedures</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management, including our principal
executive and principal financial officers, has evaluated the effectiveness of our disclosure controls and procedures as of September
30, 2015. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to
be disclosed in reports we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized
and reported within the time periods specified in the Securities and Exchange Commission&rsquo;s rules and forms, and that such
information is accumulated and communicated to our management, including our principal executive and principal financial officers,
to allow timely decisions regarding required disclosure. Based on that evaluation, our principal executive and principal financial
officers have concluded that our disclosure controls and procedures are effective at the reasonable assurance level.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Changes in Internal Control Over Financial Reporting</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our management, including our principal
executive and principal financial officers, has evaluated any changes in our internal control over financial reporting that occurred
during the quarterly period ended September 30, 2015, and has concluded that there was no change that occurred during the quarterly
period ended September 30, 2015 that has materially affected, or is reasonably likely to materially affect, our internal control
over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><A NAME="a_005"></A>PART II &mdash; OTHER
INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_006"></A>Item 1. Legal Proceedings</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Except as noted below, we are not a party
to any material legal proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2006, we filed a complaint
against SIGA in the Delaware Court of Chancery. The complaint alleged, among other things, that we have the right to license exclusively
the development and marketing rights for SIGA&rsquo;s drug candidate, Tecovirimat, pursuant to a merger agreement between the parties
that was terminated in 2006. The complaint also alleged that SIGA failed to negotiate in good faith the terms of such a license
pursuant to the terminated merger agreement with us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In September 2011, the Delaware Court of
Chancery issued an opinion in the case finding that SIGA had breached certain contractual obligations to us, upholding our claims
of promissory estoppel, and awarding us damages. SIGA appealed aspects of the decision to the Delaware Supreme Court. In response,
we cross-appealed other aspects of the decision. In May 2013, the Delaware Supreme Court issued its ruling on the appeal, affirming
the Delaware Court of Chancery&rsquo;s finding that SIGA had breached certain contractual obligations to us, reversed its finding
of promissory estoppel, and remanded the case back to the Delaware Court of Chancery to reconsider the remedy and award in light
of the Delaware Supreme Court&rsquo;s opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 8, 2014, the Delaware Court of
Chancery issued a Memorandum Opinion and Order, or August 2014 Order, finding that we are entitled to receive lump sum expectation
damages for the value of the Company&rsquo;s lost profits for Tecovirimat. In addition, the Delaware Court of Chancery found that
the Company is entitled to receive pre-judgment interest and varying percentages of the Company&rsquo;s reasonable attorneys&rsquo;
and expert witness fees. On October 17, 2014, the Company and SIGA each filed opinions of our respective financial experts and
Draft Orders and Judgments in accordance with the instructions of the August 2014 Order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 16, 2014, SIGA announced that
it filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in the U.S. Bankruptcy Court for
the Southern District of New York. In connection therewith, SIGA filed with the Bankruptcy Court an affidavit indicating, among
other things, that it expects to continue to perform under its contract with BARDA. SIGA&rsquo;s petition for bankruptcy initiated
a process whereby its assets are protected from creditors, including us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 7, 2015, the Delaware Court
of Chancery issued a letter Opinion and Order, directing the Company to submit a Revised Proposed Judgment that reflects a lump
sum award of approximately $113 million in contract expectation damages, plus pre-judgment interest on that amount from 2006 through
the date of such order. In accordance with the instructions of the court, the Company submitted a draft Revised Proposed Judgment
under seal on January 9, 2015.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 15, 2015, the Delaware Court
of Chancery issued a Final Order and Judgment, finding that we are entitled to receive a lump sum award of $194.6 million, or the
Total Judgment, comprised of (1) expectation damages of $113.1 million, for the value of the Company&rsquo;s lost profits for Tecovirimat,
also known as ST-246<SUP>&reg;</SUP> (formerly referred to as &ldquo;Arestvyr&trade;&rdquo; and referred to by SIGA in its recent
SEC filings as &ldquo;Tecovirimat&rdquo;), plus (2) pre-judgment interest on that amount from 2006 and varying percentages of the
Company&rsquo;s reasonable attorneys&rsquo; and expert witness fees, totaling $81.5 million. Under the Final Order and Judgment,
PharmAthene is also entitled to post-judgment simple interest. PharmAthene&rsquo;s entitlement to interest from and after SIGA&rsquo;s
bankruptcy filing may be negatively impacted by the Bankruptcy Code. SIGA filed a notice of appeal with the Delaware Supreme Court
in which it challenges various findings of the Court of Chancery and seeks to set aside the Final Order and Judgment, and we filed
a notice of cross-appeal. Subsequently, both SIGA and PharmAthene have filed appeals and reply briefs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 7, 2015 oral arguments in SIGA&rsquo;s
appeal and PharmAthene&rsquo;s cross-appeal of the January 15, 2015 Final Order and Judgement took place in the Delaware Supreme
Court. There can be no assurances that the Delaware Supreme Court will rule in PharmAthene&rsquo;s favor, or that PharmAthene will
receive any payments from SIGA. As a result, the decision could be reversed, remanded or otherwise changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">There can be no assurances if or when the
Company will receive any payments from SIGA as a result of the Judgment. SIGA has stated publicly that it does not currently have
cash sufficient to satisfy the award. It is also uncertain whether SIGA will have such cash in the future. PharmAthene&rsquo;s
ability to collect the Judgment depends upon a number of factors, including SIGA&rsquo;s financial and operational success, which
is subject to a number of significant risks and uncertainties (certain of which are outlined in SIGA&rsquo;s filings with the SEC),
as to which we have limited knowledge and which we have no ability to control, mitigate or fully evaluate. SIGA disclosed in its
Current Report on Form 8-K filed April 29, 2015 that it entered into a modification to its contract with BARDA on April 29, 2015
to increase the provisional dosage of Tecovirimat and extend the delivery schedule. Furthermore, because SIGA has filed for protection
under the federal bankruptcy laws, the Company is automatically stayed from taking any enforcement action in the Delaware Court
of Chancery. By agreement of the parties, and with the approval of the Bankruptcy Court, the automatic stay has been lifted for
the sole purpose of allowing the Delaware Court of Chancery to enter a money judgment and to allow the parties to exercise their
appellate rights. The Company&rsquo;s ability to collect a money judgment from SIGA, if any, remains subject to further proceedings
in the Bankruptcy Court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_007"></A>Item 1A. Risk Factors</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investing in our securities involves risks. In addition
to the other information in this quarterly report on Form 10-Q, stockholders and potential investors should carefully consider
the risks and uncertainties discussed in the section titled &ldquo;Item 1A. Risk Factors&rdquo; in our annual report on Form 10-K
for the year ended December 31, 2014. There have been no material changes to the risk factors included in the section titled &ldquo;Item
1A. Risk Factors&rdquo; in our annual report on Form 10-K for the year ended December 31, 2014.</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_008"></A>Item 2. Unregistered Sales of Equity
Securities and Use of Proceeds</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_009"></A>Item 3. Default upon Senior Securities</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_010"></A>Item 4. Mine Safety Disclosures</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_011"></A>Item 5. Other Information</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Departure of Directors or Certain Officers; Appointment
of Certain Officers; Compensatory Arrangements of Certain Officers</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with his services to the
Company as its President and Chief Executive Officer, the Company entered into an employment agreement with John M. Gill (the &quot;Employment
Agreement&quot;), dated as of November 5, 2015, for the period commencing on September 17, 2015 and initially ending on the
first anniversary thereof. On each anniversary of the Employment Agreement, the term of the agreement automatically extends for
an additional one-year period, unless either party provides the other party with 90 days&rsquo; prior written notice of non-extension.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the Employment Agreement,
among other customary terms, Mr. Gill: (i) will continue to be employed by the Company in the position of President and Chief
Executive Officer; (ii) will receive a base salary of $200,000 and a special lump sum bonus of $50,000, for the period
between September 17, 2015 to December 31, 2015; (iii) will receive a base salary of $300,000 per year, subject to annual
review and increase at the option of the Compensation Committee of the Board of Directors (the &quot;Compensation
Committee&quot;), beginning in 2016 and for each year thereafter; (iv) will be eligible to receive, at the sole discretion of
the Compensation Committee and the Board of Directors,  an annual cash bonus of up to 50% of his base salary based on the
achievement of certain pre-determined performance milestones established by the Compensation Committee and the Board of
Directors,  beginning in 2016; (v) will be granted an award (the &quot;Incentive Compensation&quot;) of restricted stock
award under the Company&rsquo;s 2007 Long-Term Incentive Plan for 612,244 shares of the Company&rsquo;s common stock (valued
in the aggregate at $900,000 based on the closing price of the Company&rsquo;s common stock on the NYSE MKT on September 17,
2015), which will vest upon the earliest to occur of (a) a &quot;change in control,&quot; (b) each of three pre-determined
milestones, or (c) the termination of Mr. Gill&rsquo;s employment for any reason other than (1) a termination for
&quot;cause&quot; or (2) a &quot;voluntary resignation.&quot;; (vi) will receive, if terminated without cause or for
&quot;good reason&quot; or upon a written notice of non-extension, (a) unpaid salary, housing allowance and expenses, (b)
payment of a pro-rata portion of the $50,000 bonus for services rendered in 2015, (c) payment of a pro-rata portion of the
annual cash bonus and (d) if, upon the occurrence of a &quot;change of in control,&quot; the Incentive Compensation; (vii)
will continue to be provided with corporate housing in the Annapolis, Maryland area comparable to that previously provided;
(viii) will be required to devote an average of three days per week to the business of the Company; (ix) will be entitled to
receive reimbursements for certain expenses, in accordance with the practices of the Company in effect from time to time; and
(x) will be subject to certain work-for-hire, confidentiality, non-disparagement and non-competition covenants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><A NAME="a_012"></A>Item 6. Exhibits</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 9%; border-bottom: black 1pt solid">No.</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 90%; border-bottom: black 1pt solid">Description</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>31.1</td>
    <td>&nbsp;</td>
    <td>Certification of Principal Executive Officer Pursuant to SEC Rule 13a-14(a)/15d-14(a)</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>31.2</td>
    <td>&nbsp;</td>
    <td>Certification of Principal Financial Officer Pursuant to SEC Rule 13a-14(a)/15d-14(a)</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>32.1</td>
    <td>&nbsp;</td>
    <td>Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>32.2</td>
    <td>&nbsp;</td>
    <td>Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>(101)</td>
    <td>&nbsp;</td>
    <td style="text-align: justify">The following condensed consolidated financial statements from the PharmAthene, Inc. Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2015, formatted in Extensive Business Reporting Language (&ldquo;XBRL&rdquo;): (i) Condensed Consolidated Balance Sheets as of September 30, 2015 and December 31, 2014, (ii) Unaudited Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2015 and 2014, (iii) Unaudited Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2015 and 2014, (iv) Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2015 and 2014, and (v) Notes to consolidated financial statements.</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>101.INS</td>
    <td>&nbsp;</td>
    <td>Instance Document</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>101.SCH</td>
    <td>&nbsp;</td>
    <td>XBRL Taxonomy Extension Schema Document</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>101.CAL</td>
    <td>&nbsp;</td>
    <td>XBRL Taxonomy Extension Calculation Linkbase Document</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>101.DEF</td>
    <td>&nbsp;</td>
    <td>XBRL Taxonomy Extension Definition Linkbase Document</td></tr>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr style="vertical-align: top">
    <td>101.LAB</td>
    <td>&nbsp;</td>
    <td>XBRL Taxonomy Extension Label Linkbase Document</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>101.PRE</td>
    <td>&nbsp;</td>
    <td>XBRL Taxonomy Extension Presentation Linkbase Document</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of Section
13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused the report to be signed on its behalf by the
undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<table cellspacing="0" cellpadding="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2">PHARMATHENE, INC.</td></tr>
<tr style="vertical-align: top">
    <td style="width: 50%">&nbsp;</td>
    <td style="width: 4%">&nbsp;</td>
    <td style="width: 46%">&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>Dated: November 6, 2015</td>
    <td>By:</td>
    <td style="border-bottom: black 1pt solid">/s/ John M. Gill</td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <td>Name: John M. Gill</td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <td>Title: President and Chief Executive Officer</td></tr>
<tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top">
    <td>Dated: November 6, 2015</td>
    <td>By:</td>
    <td style="border-bottom: black 1pt solid">/s/ Philip MacNeill</td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="text-align: right">&nbsp;</td>
    <td>Name: Philip MacNeill</td></tr>
<tr style="vertical-align: top">
    <td colspan="2" style="text-align: center">&nbsp;</td>
    <td>Title: Vice President, Chief Financial Officer, Treasurer and Secretary</td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%"></TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>v422632_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Certification of Principal Executive
Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to SEC Rule&nbsp;13a-14(a)/15d-14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, John M. Gill, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Form&nbsp;10-Q of PharmAthene,&nbsp;Inc.
for the period ended September 30, 2015;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.2pt; text-indent: -46.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any
untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.2pt; text-indent: -46.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and
other financial information included in this report, fairly present in all material respects the financial condition, results
of operations and cash flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.2pt; text-indent: -46.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s)&nbsp;and
I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f))
for the registrant and have:</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.2pt; text-indent: -46.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures,
or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating
to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 94.6pt; text-indent: -46.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance
regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 94.6pt; text-indent: -46.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s
disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such evaluation; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 94.6pt; text-indent: -46.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,
the registrant&rsquo;s internal control over financial reporting; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 94.6pt; text-indent: -46.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s)&nbsp;and
I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.2pt; text-indent: -46.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">(a)</TD>
    <TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">(b)</TD>
    <TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 94.6pt; text-indent: -46.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Dated:&nbsp;&nbsp;November 6, 2015</TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid">/s/ John M. Gill</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name: John M. Gill</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title: President and Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>





</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>v422632_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification of Principal Financial
Officer</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Pursuant to SEC Rule&nbsp;13a-14(a)/15d-14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 27.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">I, Philip MacNeill, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Form&nbsp;10-Q of PharmAthene,&nbsp;Inc.
for the period ended September 30, 2015;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.2pt; text-indent: -46.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any
untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.2pt; text-indent: -46.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and
other financial information included in this report, fairly present in all material respects the financial condition, results
of operations and cash flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.2pt; text-indent: -46.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s)&nbsp;and
I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and
15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f))
for the registrant and have:</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.2pt; text-indent: -46.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">(a)</TD>
    <TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 94.6pt; text-indent: -46.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">(b)</TD>
    <TD STYLE="text-align: justify">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 94.6pt; text-indent: -46.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">(c)</TD>
    <TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 94.6pt; text-indent: -46.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">(d)</TD>
    <TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 94.6pt; text-indent: -46.2pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s)&nbsp;and
I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s
auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 46.2pt; text-indent: -46.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">(a)</TD>
    <TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 27.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px">&nbsp;</TD>
    <TD STYLE="width: 24px">(b)</TD>
    <TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 94.6pt; text-indent: -46.2pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">Dated:&nbsp;&nbsp;November 6, 2015</TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid">/s/ Philip MacNeill</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name: Philip MacNeill</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title: Vice President, Chief Financial Officer, Treasurer and Secretary</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>v422632_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Certification Pursuant to Section&nbsp;1350
of Chapter&nbsp;63</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>of Title&nbsp;18 of the United States
Code</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt">In connection with
the Quarterly Report on Form 10-Q of PharmAthene,&nbsp;Inc. (the &ldquo;Company&rdquo;) for the period ended September 30, 2015,
as filed with the Securities and Exchange Commission (the &ldquo;Report&rdquo;), I, John M. Gill, Chief Executive Officer of the
Company, certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of
2002, that to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 42.9pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 2%; padding-left: 10pt; text-indent: -10pt">1.</TD>
    <TD STYLE="vertical-align: bottom; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 97%; text-align: justify">The Report fully complies with the requirements of Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Securities Exchange Act of 1934.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 10pt; text-indent: -10pt">2.</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: black 1pt solid">/s/ John M. Gill</TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Name:&nbsp;&nbsp;John M. Gill</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">Title: President and Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2">November 6, 2015</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A signed original of
this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained
by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This certification
is being furnished pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed &ldquo;filed&rdquo; for purposes
of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section.&nbsp;This certification
will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange
Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>v422632_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Certification Pursuant to Section&nbsp;1350
of Chapter&nbsp;63</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>of Title&nbsp;18 of the United States
Code</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 42.9pt">In connection with
the Quarterly Report on Form 10-Q of PharmAthene,&nbsp;Inc. (the &ldquo;Company&rdquo;) for the period ended September 30, 2015,
as filed with the Securities and Exchange Commission (the &ldquo;Report&rdquo;), I, Philip MacNeill, Chief Financial Officer of
the Company, certify, pursuant to 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act
of 2002, that to the best of my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 42.9pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; padding-left: 10pt; text-indent: -10pt">1.</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: justify">The Report fully complies with the requirements of Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Securities Exchange Act of 1934.</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 2%; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 90%">&nbsp;</TD>
    <TD STYLE="width: 7%">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-left: 10pt; text-indent: -10pt">2.</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: justify">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 52%; border-bottom: black 1pt solid">/s/ Philip MacNeill</TD>
    <TD STYLE="width: 48%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Name: Philip MacNeill</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>Title: Vice President, Chief Financial Officer, Treasurer and Secretary</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>November 6, 2015</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A signed original of
this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained
by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This certification
is being furnished pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not be deemed &ldquo;filed&rdquo; for purposes
of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section.&nbsp;This certification
will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange
Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>pip-20150930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by The Vintage Group, Powered by IRIS Carbon-->
<xbrli:xbrl xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:pip="http://www.pharmathene.com/20150930">
  <link:schemaRef xlink:type="simple" xlink:href="pip-20150930.xsd" />
  <xbrli:context id="I2015-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_To_2015-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_To_2014-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-03-09">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-09</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30_FairValueInputsLevel1Member_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30_FairValueInputsLevel3Member_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_FairValueInputsLevel1Member_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_FairValueInputsLevel3Member_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-12-31_FairValueInputsLevel3Member_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_To_2015-09-30_FairValueInputsLevel3Member_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30_FairValueInputsLevel3Member_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-12-31_FairValueInputsLevel3Member_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_To_2014-09-30_FairValueInputsLevel3Member_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-09-30_FairValueInputsLevel3Member_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30_FairValueInputsLevel3Member_DerivativeLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">pip:DerivativeLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-09-30_FairValueInputsLevel3Member_DerivativeLiabilitiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">pip:DerivativeLiabilitiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-01-07">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-01-07</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-11_To_2015-01-15">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-11</xbrli:startDate>
      <xbrli:endDate>2015-01-15</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-01-15">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-01-15</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_To_2015-09-30_GroupThreeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pip:GroupThreeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_To_2015-09-30_GroupFourMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pip:GroupFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-04-01_To_2015-04-30_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pip:BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-04-01</xbrli:startDate>
      <xbrli:endDate>2015-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2007-12-31_StockIncentivePlanTwentyZeroSevenMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pip:StockIncentivePlanTwentyZeroSevenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2007-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2008-12-31_StockIncentivePlanTwentyZeroSevenMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pip:StockIncentivePlanTwentyZeroSevenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2008-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30_StockIncentivePlanTwentyZeroSevenMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pip:StockIncentivePlanTwentyZeroSevenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_To_2015-09-30_StockIncentivePlanTwentyZeroSevenMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pip:StockIncentivePlanTwentyZeroSevenMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-21_To_2015-01-28_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-21</xbrli:startDate>
      <xbrli:endDate>2015-01-28</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30_ShareBasedCompensationWarrantsPriceRangeOneMember_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pip:ShareBasedCompensationWarrantsPriceRangeOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30_DerivativeInstrumentWarrantsMember_ShareBasedCompensationWarrantsPriceRangeFourMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">pip:DerivativeInstrumentWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pip:ShareBasedCompensationWarrantsPriceRangeFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30_DerivativeInstrumentWarrantsMember_ShareBasedCompensationWarrantsPriceRangeFiveMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">pip:DerivativeInstrumentWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pip:ShareBasedCompensationWarrantsPriceRangeFiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30_DerivativeInstrumentWarrantsMember_ShareBasedCompensationWarrantsPriceRangeSixMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">pip:DerivativeInstrumentWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pip:ShareBasedCompensationWarrantsPriceRangeSixMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30_ShareBasedCompensationWarrantsPriceRangeSevenMember_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pip:ShareBasedCompensationWarrantsPriceRangeSevenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2009-07-01_To_2009-07-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-07-01</xbrli:startDate>
      <xbrli:endDate>2009-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_To_2015-09-30_ShareBasedCompensationWarrantsPriceRangeOneMember_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pip:ShareBasedCompensationWarrantsPriceRangeOneMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_To_2015-09-30_DerivativeInstrumentWarrantsMember_ShareBasedCompensationWarrantsPriceRangeFourMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">pip:DerivativeInstrumentWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pip:ShareBasedCompensationWarrantsPriceRangeFourMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_To_2015-09-30_DerivativeInstrumentWarrantsMember_ShareBasedCompensationWarrantsPriceRangeFiveMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">pip:DerivativeInstrumentWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pip:ShareBasedCompensationWarrantsPriceRangeFiveMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_To_2015-09-30_DerivativeInstrumentWarrantsMember_ShareBasedCompensationWarrantsPriceRangeSixMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">pip:DerivativeInstrumentWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pip:ShareBasedCompensationWarrantsPriceRangeSixMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_To_2015-09-30_ShareBasedCompensationWarrantsPriceRangeSevenMember_WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">pip:ShareBasedCompensationWarrantsPriceRangeSevenMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30_LoansPayableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_To_2015-09-30_LoansPayableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012-03-30_LoansPayableMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-03-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2012-03-30_LineOfCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-03-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2013-03-25_EquityOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="pip:EquityOfferingAxis">pip:EquityOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-03-25</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2014-05-23_AmendmentToControlledEquityOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="pip:EquityOfferingAxis">pip:AmendmentToControlledEquityOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-05-23</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-30_EquityOfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="pip:EquityOfferingAxis">pip:EquityOfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_To_2015-09-30_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_To_2014-09-30_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_To_2015-09-30_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_To_2014-09-30_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_To_2015-09-30_RestructuringChargesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-01-01_To_2014-09-30_RestructuringChargesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-07-01_To_2015-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-07-01_To_2014-09-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-07-01_To_2015-09-30_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-07-01_To_2014-09-30_ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-07-01_To_2015-09-30_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-07-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2014-07-01_To_2014-09-30_GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-07-01</xbrli:startDate>
      <xbrli:endDate>2014-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-11-04">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-11-04</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="I2015-09-03_LineOfCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-09-03</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-09-02_To_2015-09-03_LineOfCreditMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-09-02</xbrli:startDate>
      <xbrli:endDate>2015-09-03</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-10-12_To_2015-10-13_WarrantMember_SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-10-12</xbrli:startDate>
      <xbrli:endDate>2015-10-13</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_To_2015-09-30_EmployeeSeveranceMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="D2015-01-01_To_2015-09-30_FacilityClosingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001326190</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:FacilityClosingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:unit id="USD">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="USDPerShare">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="Shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="Pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Tag1" contextRef="I2015-09-30" unitRef="USD" decimals="0">196478</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="Tag2" contextRef="I2014-12-31" unitRef="USD" decimals="0">199194</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="Tag3" contextRef="I2015-09-30" unitRef="USD" decimals="0">18245550</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="Tag4" contextRef="I2014-12-31" unitRef="USD" decimals="0">19250632</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="Tag5" contextRef="I2015-09-30" unitRef="USD" decimals="0">248270</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="Tag6" contextRef="I2014-12-31" unitRef="USD" decimals="0">325772</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:OtherAssetsNoncurrent id="Tag7" contextRef="I2015-09-30" unitRef="USD" decimals="0">53384</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="Tag8" contextRef="I2014-12-31" unitRef="USD" decimals="0">53384</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Goodwill id="Tag9" contextRef="I2015-09-30" unitRef="USD" decimals="0">2348453</us-gaap:Goodwill>
  <us-gaap:Goodwill id="Tag10" contextRef="I2014-12-31" unitRef="USD" decimals="0">2348453</us-gaap:Goodwill>
  <us-gaap:Assets id="Tag11" contextRef="I2015-09-30" unitRef="USD" decimals="0">20895657</us-gaap:Assets>
  <us-gaap:Assets id="Tag12" contextRef="I2014-12-31" unitRef="USD" decimals="0">21978241</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent id="Tag13" contextRef="I2015-09-30" unitRef="USD" decimals="0">306172</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="Tag14" contextRef="I2014-12-31" unitRef="USD" decimals="0">391396</us-gaap:AccountsPayableCurrent>
  <pip:AccruedExpensesAndOtherCurrentLiabilities id="Tag15" contextRef="I2015-09-30" unitRef="USD" decimals="0">1453123</pip:AccruedExpensesAndOtherCurrentLiabilities>
  <pip:AccruedExpensesAndOtherCurrentLiabilities id="Tag16" contextRef="I2014-12-31" unitRef="USD" decimals="0">1195412</pip:AccruedExpensesAndOtherCurrentLiabilities>
  <us-gaap:RestructuringReserveCurrent id="Tag17" contextRef="I2015-09-30" unitRef="USD" decimals="0">619119</us-gaap:RestructuringReserveCurrent>
  <us-gaap:RestructuringReserveCurrent id="Tag18" contextRef="I2014-12-31" unitRef="USD" xsi:nil="true" />
  <us-gaap:LongTermDebtCurrent id="Tag19" contextRef="I2015-09-30" unitRef="USD" xsi:nil="true" />
  <us-gaap:LongTermDebtCurrent id="Tag20" contextRef="I2014-12-31" unitRef="USD" decimals="0">746146</us-gaap:LongTermDebtCurrent>
  <us-gaap:OtherLiabilitiesCurrent id="Tag21" contextRef="I2014-12-31" unitRef="USD" decimals="0">70326</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:DerivativeInstrumentsAndHedgesLiabilities id="Tag22" contextRef="I2015-09-30" unitRef="USD" decimals="0">2355</us-gaap:DerivativeInstrumentsAndHedgesLiabilities>
  <us-gaap:DerivativeInstrumentsAndHedgesLiabilities id="Tag23" contextRef="I2014-12-31" unitRef="USD" decimals="0">178509</us-gaap:DerivativeInstrumentsAndHedgesLiabilities>
  <us-gaap:LiabilitiesCurrent id="Tag24" contextRef="I2015-09-30" unitRef="USD" decimals="0">2380769</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="Tag25" contextRef="I2014-12-31" unitRef="USD" decimals="0">2581789</us-gaap:LiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesNoncurrent id="Tag26" contextRef="I2015-09-30" unitRef="USD" decimals="0">431015</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent id="Tag27" contextRef="I2014-12-31" unitRef="USD" decimals="0">493137</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent id="Tag28" contextRef="I2015-09-30" unitRef="USD" decimals="0">227898</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent id="Tag29" contextRef="I2014-12-31" unitRef="USD" decimals="0">629170</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag30" contextRef="I2015-09-30" unitRef="USD" decimals="0">17389409</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:Liabilities id="Tag31" contextRef="I2015-09-30" unitRef="USD" decimals="0">3223700</us-gaap:Liabilities>
  <us-gaap:Liabilities id="Tag32" contextRef="I2014-12-31" unitRef="USD" decimals="0">3704096</us-gaap:Liabilities>
  <us-gaap:CommonStockParOrStatedValuePerShare id="Tag33" contextRef="I2015-09-30" unitRef="USDPerShare" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="Tag34" contextRef="I2015-09-30" unitRef="Shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="Tag35" contextRef="I2015-09-30" unitRef="Shares" decimals="INF">64358834</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="Tag36" contextRef="I2014-12-31" unitRef="Shares" decimals="INF">63603303</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockValue id="Tag37" contextRef="I2015-09-30" unitRef="USD" decimals="0">6436</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="Tag38" contextRef="I2014-12-31" unitRef="USD" decimals="0">6360</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="Tag39" contextRef="I2015-09-30" unitRef="USD" decimals="0">240151146</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="Tag40" contextRef="I2014-12-31" unitRef="USD" decimals="0">238780633</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag41" contextRef="I2014-12-31" unitRef="USD" decimals="0">18643351</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax id="Tag42" contextRef="I2015-09-30" unitRef="USD" xsi:nil="true" />
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax id="Tag43" contextRef="I2014-12-31" unitRef="USD" decimals="0">-229528</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="Tag44" contextRef="I2015-09-30" unitRef="USD" decimals="0">-222485625</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="Tag45" contextRef="I2014-12-31" unitRef="USD" decimals="0">-220283320</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity id="Tag46" contextRef="I2015-09-30" unitRef="USD" decimals="0">17671957</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="Tag47" contextRef="I2014-12-31" unitRef="USD" decimals="0">18274145</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Tag48" contextRef="I2015-09-30" unitRef="USD" decimals="0">20895657</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="Tag49" contextRef="I2014-12-31" unitRef="USD" decimals="0">21978241</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:BilledContractReceivables id="Tag50" contextRef="I2015-09-30" unitRef="USD" xsi:nil="true" />
  <us-gaap:BilledContractReceivables id="Tag51" contextRef="I2014-12-31" unitRef="USD" decimals="0">110656</us-gaap:BilledContractReceivables>
  <us-gaap:UnbilledContractsReceivable id="Tag52" contextRef="I2015-09-30" unitRef="USD" decimals="0">659663</us-gaap:UnbilledContractsReceivable>
  <us-gaap:UnbilledContractsReceivable id="Tag53" contextRef="I2014-12-31" unitRef="USD" decimals="0">297431</us-gaap:UnbilledContractsReceivable>
  <us-gaap:CommonStockSharesOutstanding id="Tag54" contextRef="I2014-12-31" unitRef="Shares" decimals="INF">63603303</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="Tag55" contextRef="I2015-09-30" unitRef="Shares" decimals="INF">64358834</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesAuthorized id="Tag56" contextRef="I2014-12-31" unitRef="Shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockParOrStatedValuePerShare id="Tag57" contextRef="I2014-12-31" unitRef="USDPerShare" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag58" contextRef="D2015-01-01_To_2015-09-30" unitRef="USDPerShare" decimals="2">-0.03</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag59" contextRef="D2014-01-01_To_2014-09-30" unitRef="USDPerShare" decimals="2">-0.13</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag60" contextRef="D2015-01-01_To_2015-09-30" unitRef="Shares" decimals="0">63858500</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag61" contextRef="D2014-01-01_To_2014-09-30" unitRef="Shares" decimals="0">55577550</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:ContractsRevenue id="Tag62" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">9374155</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue id="Tag63" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">8363909</us-gaap:ContractsRevenue>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag64" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">3962019</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag65" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">7528616</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Tag66" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">5246396</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Tag67" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">8289788</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:RestructuringCharges id="Tag68" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">2519273</us-gaap:RestructuringCharges>
  <us-gaap:RestructuringCharges id="Tag69" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" xsi:nil="true" />
  <us-gaap:Depreciation id="Tag70" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">108798</us-gaap:Depreciation>
  <us-gaap:Depreciation id="Tag71" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">113272</us-gaap:Depreciation>
  <us-gaap:OperatingExpenses id="Tag72" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">11836486</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="Tag73" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">15931676</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="Tag74" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">-2462331</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="Tag75" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">-7567767</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestExpense id="Tag76" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">48492</us-gaap:InterestExpense>
  <us-gaap:InterestExpense id="Tag77" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">173356</us-gaap:InterestExpense>
  <us-gaap:UnrealizedGainLossOnDerivatives id="Tag78" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">577426</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives id="Tag79" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">464703</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:OtherNonoperatingIncomeExpense id="Tag80" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">6594</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="Tag81" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">-1470</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="Tag82" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">306336</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="Tag83" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">289877</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="Tag84" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">-2155995</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="Tag85" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">-7277890</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxExpenseBenefit id="Tag86" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">46310</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit id="Tag87" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">48105</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:NetIncomeLoss id="Tag88" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">-2202305</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="Tag89" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">-7325995</us-gaap:NetIncomeLoss>
  <us-gaap:ContractsRevenue id="Tag90" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="0">1155839</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue id="Tag91" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="0">962451</us-gaap:ContractsRevenue>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag92" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="0">1125865</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="Tag93" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="0">1728929</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Tag94" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="0">1231035</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="Tag95" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="0">3192427</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:RestructuringCharges id="Tag96" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="0">422482</us-gaap:RestructuringCharges>
  <us-gaap:Depreciation id="Tag97" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="0">35005</us-gaap:Depreciation>
  <us-gaap:Depreciation id="Tag98" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="0">37125</us-gaap:Depreciation>
  <us-gaap:OperatingExpenses id="Tag99" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="0">2814387</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="Tag100" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="0">4958481</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="Tag101" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="0">-1658548</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="Tag102" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="0">-3996030</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestExpense id="Tag103" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="0">9888</us-gaap:InterestExpense>
  <us-gaap:InterestExpense id="Tag104" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="0">46930</us-gaap:InterestExpense>
  <us-gaap:UnrealizedGainLossOnDerivatives id="Tag105" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="0">359796</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:UnrealizedGainLossOnDerivatives id="Tag106" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="0">-560487</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:OtherNonoperatingIncomeExpense id="Tag107" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="0">-691</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense id="Tag108" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="0">80</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="Tag109" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="0">349217</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense id="Tag110" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="0">-607337</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="Tag111" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="0">-1309331</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments id="Tag112" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="0">-4603367</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
  <us-gaap:IncomeTaxExpenseBenefit id="Tag113" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="0">15437</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit id="Tag114" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="0">25068</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:NetIncomeLoss id="Tag115" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="0">-1324768</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="Tag116" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="0">-4628435</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag117" contextRef="D2015-07-01_To_2015-09-30" unitRef="USDPerShare" decimals="2">-0.02</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="Tag118" contextRef="D2014-07-01_To_2014-09-30" unitRef="USDPerShare" decimals="2">-0.08</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag119" contextRef="D2015-07-01_To_2015-09-30" unitRef="Shares" decimals="0">64187618</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="Tag120" contextRef="D2014-07-01_To_2014-09-30" unitRef="Shares" decimals="0">58952731</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:RestructuringCharges id="Tag121" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" xsi:nil="true" />
  <pip:OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation id="Tag122" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" xsi:nil="true" />
  <pip:OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation id="Tag123" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" xsi:nil="true" />
  <pip:OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation id="Tag124" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">229192</pip:OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation>
  <pip:OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation id="Tag125" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" xsi:nil="true" />
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax id="Tag126" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">336</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax id="Tag127" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">-7162</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="Tag128" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">-1972777</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="Tag129" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">-7333157</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax id="Tag130" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" xsi:nil="true" />
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax id="Tag131" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="0">-5869</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="Tag132" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="0">-1324768</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="Tag133" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="0">-4634304</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax id="Tag134" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" xsi:nil="true" />
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax id="Tag135" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" xsi:nil="true" />
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax id="Tag136" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">-229192</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax>
  <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax id="Tag137" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" xsi:nil="true" />
  <us-gaap:ShareBasedCompensation id="Tag138" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">426988</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="Tag139" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">1172703</us-gaap:ShareBasedCompensation>
  <us-gaap:DeferredIncomeTaxExpenseBenefit id="Tag140" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">46310</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit id="Tag141" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">48105</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:PaidInKindInterest id="Tag142" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">-51820</us-gaap:PaidInKindInterest>
  <us-gaap:PaidInKindInterest id="Tag143" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">68130</us-gaap:PaidInKindInterest>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="Tag144" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">7600</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="Tag145" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">5393</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="Tag146" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">-110656</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="Tag147" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">-1427113</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInUnbilledReceivables id="Tag148" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">362232</us-gaap:IncreaseDecreaseInUnbilledReceivables>
  <us-gaap:IncreaseDecreaseInUnbilledReceivables id="Tag149" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">-1895858</us-gaap:IncreaseDecreaseInUnbilledReceivables>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Tag150" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">9602</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="Tag151" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">-23869</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="Tag152" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">-85175</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable id="Tag153" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">-846090</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:RestructuringReservePeriodIncreaseDecrease id="Tag154" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">800769</us-gaap:RestructuringReservePeriodIncreaseDecrease>
  <us-gaap:RestructuringReservePeriodIncreaseDecrease id="Tag155" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" xsi:nil="true" />
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities id="Tag156" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">149438</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities id="Tag157" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">-773517</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="Tag158" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" xsi:nil="true" />
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="Tag159" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">-284937</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag160" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">-1387028</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="Tag161" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">-4951585</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Tag162" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">68277</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="Tag163" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">92269</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="Tag164" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">7600</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment id="Tag165" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">8000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Tag166" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">-60677</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="Tag167" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">-84269</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromRepaymentsOfOtherLongTermDebt id="Tag168" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">-750007</us-gaap:ProceedsFromRepaymentsOfOtherLongTermDebt>
  <us-gaap:ProceedsFromRepaymentsOfOtherLongTermDebt id="Tag169" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">-749997</us-gaap:ProceedsFromRepaymentsOfOtherLongTermDebt>
  <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit id="Tag170" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" xsi:nil="true" />
  <us-gaap:ProceedsFromRepaymentsOfLinesOfCredit id="Tag171" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">-1091740</us-gaap:ProceedsFromRepaymentsOfLinesOfCredit>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="Tag172" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">943601</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="Tag173" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">15341264</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag174" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">193594</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="Tag175" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">14182852</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="Tag176" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">169</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents id="Tag177" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">-7585</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="Tag178" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">-1253942</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="Tag179" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">9139413</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag180" contextRef="I2013-12-31" unitRef="USD" decimals="0">10480979</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="Tag181" contextRef="I2014-09-30" unitRef="USD" decimals="0">19620392</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:InterestPaid id="Tag182" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">108134</us-gaap:InterestPaid>
  <us-gaap:InterestPaid id="Tag183" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">105916</us-gaap:InterestPaid>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag184" contextRef="D2015-01-01_To_2015-09-30_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">395470</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag185" contextRef="D2014-01-01_To_2014-09-30_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">843048</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag186" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">426988</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag187" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">1172703</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod id="Tag188" contextRef="D2015-01-01_To_2015-09-30" unitRef="Shares" decimals="INF">112000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <pip:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod id="Tag189" contextRef="D2015-01-01_To_2015-09-30" unitRef="Shares" decimals="INF">117500</pip:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod id="Tag190" contextRef="D2014-01-01_To_2014-09-30" unitRef="Shares" decimals="INF">1357755</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="Tag191" contextRef="I2015-09-30" unitRef="USD" decimals="-5">800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock id="Tag192" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p&gt;&lt;b style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;Note 1 &amp;#150; Business, Liquidity and Organization&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;Since&amp;#160;&lt;font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;2001, PharmAthene, Inc. ("we", the "Company") has been a biodefense company engaged in the development of next generation medical counter measures against biological and chemical threats. During this time, we have devoted substantial effort and resources to the development of the prevention and treatment of anthrax infection and nerve agent poisoning.&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;On March 9, 2015, our Board of Directors approved our realignment plan (the &amp;#147;Realignment Plan&amp;#148;) with the goal of preserving and maximizing, for the benefit of our stockholders, the value of any proceeds from our litigation with SIGA Technologies, Inc. (&amp;#147;SIGA&amp;#148;) and our existing biodefense assets. The plan eliminated approximately two-thirds of our workforce and aimed to preserve sufficient cash and cash equivalents to finance our continued operations through a period of time that is expected to extend beyond the adjudication of SIGA's appeal. We intend to maintain sufficient resources and personnel so that we can seek partners, co-developers or acquirers for our biodefense programs and continue to execute under our government contract with the National Institutes of Allergy and Infectious Diseases (&amp;#147;NIAID&amp;#148;). The Company estimates total severance payments to executives and non-executives in connection with the Realignment Plan to amount to approximately $&lt;font&gt;2&lt;/font&gt;&amp;#160;million (all of which was expensed&amp;#160;as of September 30, 2015), with substantially all such severance expenses expected to be paid in 2015. Historically, the Company has performed under government contracts and grants and raised funds from investors (including additional debt and equity issued in 2015 and 2014) to sustain our operations. The Company has spent substantial funds in the research, development, clinical and preclinical testing in excess of revenues, to support the Company's product candidates and to market and sell its products. We have incurred losses in each year since inception, and have an accumulated deficit of $222.5&amp;#160;million. If we continue to incur losses and are not able to raise adequate funds to cover those losses, we may be required to cease operations.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;As of September 30, 2015, our cash balance was $17.4&amp;#160;million, our unbilled accounts receivable balance&amp;#160;was $&lt;font&gt;0.7&lt;/font&gt;&amp;#160;million, and our current liabilities were $2.4&amp;#160;million. As of September 30, 2015, we had approximately $&lt;font&gt;3.0&lt;/font&gt; million of remaining availability under our controlled equity offering arrangement, although we did not sell any shares of common stock under such facility during the three and nine months ended September 30, 2015 (see Note 6 &amp;#150; &lt;i&gt;Financing Transactions &amp;#150; Controlled Equity Offering&lt;/i&gt;). We believe, b&lt;font&gt;ased on the operating cash requirements and capital expenditures expected for 2015,&amp;#160;&lt;/font&gt;the Company's cash on hand at September 30, 2015 is adequate to fund operations through at least the end of 2016.&amp;#160;On September 3, 2015, following a payment of $&lt;font&gt;81,347&lt;/font&gt;, representing a $&lt;font&gt;75,000&lt;/font&gt; final payment fee pursuant to the March 30, 2012 Loan Agreement, $&lt;font&gt;10&lt;/font&gt; outstanding principal balance, $&lt;font&gt;208&lt;/font&gt; accrued interest, and $&lt;font&gt;6,129&lt;/font&gt; legal fees of the lender, we satisfied in full our remaining obligation under our March 2012 Loan Agreement with General Electric Capital Corporation (&amp;#147;GE Capital&amp;#148;), as discussed further in Note 6- &lt;em&gt;Financing Transactions&lt;/em&gt;.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;On July 6, 2015, PharmAthene signed a license agreement with ImmunoVaccine for the exclusive use of the DepoVaxTM vaccine platform, to develop an anthrax vaccine utilizing PharmAthene's recombinant protective antigen (&amp;#147;rPA&amp;#148;). ImmunoVaccine is a clinical-stage vaccine development company located in Halifax, Nova Scotia. PharmAthene will reimburse up to $&lt;font&gt;210,000&lt;/font&gt; to ImmunoVaccine for their efforts in developing this vaccine. In addition, ImmunoVaccine will receive annual payments of $&lt;font&gt;200,000&lt;/font&gt;, and additional payments for the achievement of certain milestones relating to contracting with the U.S. Government as well as achieving certain clinical/regulatory and commercial milestones, and achievement of sales targets. Additionally, ImmunoVaccine will receive a royalty on sales related to the use of DepoVaxTM.&lt;br/&gt; &lt;br/&gt;On September 2, 2015, the Company entered into a sublease agreement with a third party with respect to a portion of its leased office space in Annapolis, Maryland. See Note 4 -&amp;#160;&lt;em&gt;Commitments and Contingencies - Leases&lt;/em&gt;.&lt;br/&gt; &lt;br/&gt;On September 10, 2015, NIAID exercised the first option under our September 2014 contract for the development of a next generation lyophilized anthrax vaccine. The option provides additional funding of approximately $&lt;font&gt;2.3&lt;/font&gt; million and an extension of the period of performance through September 30, 2016.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;We can offer no assurances that we have correctly estimated the resources or personnel necessary to seek partners, co-developers or acquirers for our biodefense programs or execute under our NIAID contract. If a larger workforce or one with a different skillset is ultimately required to implement our Realignment Plan successfully, we may be unable to maximize the value of the SIGA litigation and our existing biodefense assets.&amp;#160;In addition, in connection with the Realignment Plan, executive officers who have served the Company for many&amp;#160;years have been terminated, and, with the exception of Mr. Richman's continued service on the Board, will no longer be available to guide the Company. We also cannot assure you that we have accurately estimated the cash and cash equivalents necessary to finance our operations until SIGA's appeal has been adjudicated and we have received SIGA's payment, if any. If revenues from our NIAID contract are less than we anticipate, if operating expenses exceed our expectations or cannot be adjusted accordingly, or if we have underestimated the time it will take for us to prevail in SIGA's appeal, or enforce payment of or collect any damages award from SIGA, or if we do not prevail on appeal, then our business, results of operations, financial condition and cash flows will be materially and adversely affected.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;In addition, we may raise additional capital to strengthen our financial position. There can be no assurances that we would be successful in raising additional funds on acceptable terms or at all. Additional sales of common stock may be made at prices that are dilutive to existing stockholders.&lt;/p&gt;
&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <pip:BilledAndUnbilledAccountsReceivableNet id="Tag193" contextRef="I2015-09-30" unitRef="USD" decimals="-5">700000</pip:BilledAndUnbilledAccountsReceivableNet>
  <pip:AdditionalCommonStockAggregateGrossSales id="Tag194" contextRef="I2015-09-30" unitRef="USD" decimals="-5">3000000</pip:AdditionalCommonStockAggregateGrossSales>
  <us-gaap:RestructuringAndRelatedCostExpectedCost1 id="Tag195" contextRef="I2015-03-09" unitRef="USD" decimals="-6">2000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
  <us-gaap:NumberOfOperatingSegments id="Tag196" contextRef="D2015-01-01_To_2015-09-30" unitRef="Pure" decimals="INF">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="Tag197" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="6" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Nine months ended September 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: 'Times New Roman'; text-align: center; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;strong&gt;2015&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: 'Times New Roman'; text-align: center; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;strong&gt;2014&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Research and development&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 85,259 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 329,655 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;General and administrative&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 395,470 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 843,048 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"&gt;&lt;font style="font-size: 13.3333330154419px;"&gt;Restructuring benefit&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"&gt;&lt;font style="font-size: 13.3333330154419px;"&gt;&lt;font&gt; (53,741 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;)&amp;#160;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"&gt;&lt;font style="font-size: 13.3333330154419px;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;Total share-based compensation expense&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 426,988 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;1,172,703&lt;/font&gt; &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;

&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Three months ended September 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Research and development&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 12,034 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 52,434 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;General and administrative&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 81,723 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 228,286 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Total share-based compensation expense&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 93,757 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;font&gt; 280,720 &lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;br/&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag198" contextRef="D2015-01-01_To_2015-09-30_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">85259</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag199" contextRef="D2014-01-01_To_2014-09-30_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">329655</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="Tag200" contextRef="D2015-01-01_To_2015-09-30">P2Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag201" contextRef="D2015-01-01_To_2015-09-30" unitRef="Shares" decimals="-5">6000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount id="Tag202" contextRef="D2014-01-01_To_2014-09-30" unitRef="Shares" decimals="-5">10900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock id="Tag203" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Our unaudited condensed consolidated financial statements include the accounts of PharmAthene, Inc. and its wholly-owned subsidiary. All significant intercompany transactions and balances have been eliminated in consolidation. Our unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&amp;#147;U.S. GAAP&amp;#148;). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The condensed consolidated balance sheet at December 31, 2014 has been derived from audited consolidated financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission (&amp;#147;SEC&amp;#148;). We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included in our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC. We currently operate in &lt;font&gt;one&lt;/font&gt; business segment.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:UseOfEstimates id="Tag204" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period.&amp;#160;Our unaudited condensed consolidated financial statements include significant estimates for our share-based compensation and the value of our financial instruments, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ProceedsFromWarrantExercises id="Tag205" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" decimals="0">683325</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse id="Tag206" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">36981</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse id="Tag207" contextRef="D2014-01-01_To_2014-09-30" unitRef="USD" xsi:nil="true" />
  <pip:ProceedsFromAdditionalFunding id="Tag208" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="-5">2300000</pip:ProceedsFromAdditionalFunding>
  <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock id="Tag209" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Foreign Currency Translation&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;The functional currency of our wholly-owned foreign subsidiary, PharmAthene UK Limited, is its local currency. Assets and liabilities of our foreign subsidiary are translated into United States dollars based on the exchange rate at the end of the reporting period. Income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. Translation adjustments for subsidiaries that have not been sold, substantially liquidated or otherwise disposed of, are accumulated in other comprehensive loss, a component of stockholders' equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive loss at December 31, 2014. Transaction gains or losses are included in the determination of net income (loss).&lt;br/&gt;&lt;br/&gt;&lt;/font&gt;&lt;font style="font-size: 10pt;"&gt;In June 2015, we substantially completed the liquidation of PharmAthene UK Limited, which we had acquired in 2008. Prior to substantially liquidating the UK subsidiary, currency fluctuations were recorded as foreign currency translation adjustments, a component of other comprehensive income. As a result of the substantially completed liquidation, we realized an approximate loss of $&lt;font&gt;0.2&lt;/font&gt; million in our condensed consolidated statements of operations, which represents the amount of previously recorded foreign currency translation adjustments related to our UK subsidiary.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock id="Tag210" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;Cash and cash equivalents are stated at cost which approximates market value and include investments in money market funds with financial institutions which are stated at market value. The Company maintains cash balances with financial institutions in excess of insured limits. The Company does not anticipate any losses on such cash balances.&lt;/p&gt;
&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:MajorCustomersPolicyPolicyTextBlock id="Tag211" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Significant Customers and Accounts Receivable&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Our primary customers are NIAID, and the Biomedical Advanced Research and Development Authority (&amp;#147;BARDA&amp;#148;). As of September 30, 2015, the Company's unbilled accounts receivable balance was comprised of receivables from NIAID. The Company's receivable balances (both billed and unbilled) as of December 31, 2014 were comprised of receivables from NIAID and BARDA.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:MajorCustomersPolicyPolicyTextBlock>
  <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy id="Tag212" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Goodwill&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Goodwill represents the excess of purchase price over the fair value of net identifiable assets associated with acquisitions. We review the recoverability of goodwill annually at the end of our fiscal year and whenever events or changes in circumstances indicate that it is more likely than not that impairment exists. Recoverability of goodwill is reviewed by comparing our market value (as measured by our stock price multiplied by the number of outstanding shares as of the end of the year) to the net book value of our equity. If our market value exceeds our net book value, no further analysis is required. We completed our annual impairment assessment of goodwill on December 31, 2014 and determined that there was no impairment as of that date.&lt;br/&gt;&lt;br/&gt; Changes in our business strategy or adverse changes in market conditions could impact the impairment analyses and require the recognition of an impairment charge equal to the excess of the carrying value over its estimated fair value.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
  <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock id="Tag213" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Restructuring Expense&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;As a result of the Realignment Plan, we recorded approximately $&lt;font&gt;2.1&lt;/font&gt; million of restructuring expense during the nine months ended September 30, 2015, including approximately $&lt;font&gt;2.0&lt;/font&gt; million of related severance expense, and the remainder being&amp;#160;legal and other employee related expenses. &lt;font style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;Additionally, as a result of the September 2, 2015 sublease of a portion of the Company's leased office space, we recorded approximately $&lt;font&gt;0.4&lt;/font&gt; million of additional restructuring expense (see Note 4 - &lt;i&gt;Commitments and Contingencies - Leases&lt;/i&gt;).&lt;/font&gt; &lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy id="Tag214" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Financial Instruments&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Our financial instruments, and/or embedded features contained in those instruments, often are classified as derivative liabilities and are recorded at their fair values. The determination of fair value of these instruments and features requires estimates and judgments. Some of our stock purchase warrants are considered to be derivative liabilities due to the presence of net settlement features and/or non-standard anti-dilution provisions; the fair value of our warrants is determined based on the Black-Scholes option pricing model.&amp;#160;&amp;#160;Use of the Black-Scholes option pricing model requires the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. See Note 3 &amp;#150;&amp;#160;&lt;i&gt;Fair Value Measurements&lt;/i&gt; for further details.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:RevenueRecognitionPolicyTextBlock id="Tag215" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;We generate our revenue from different types of contractual arrangements: cost-plus-fee contracts and fixed price contracts.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.5pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Revenues on cost-plus-fee contracts are recognized in an amount equal to the costs incurred during the period plus an estimate of the applicable fee earned. The estimate of the applicable fee earned is determined by reference to the contract: if the contract defines the fee in terms of risk-based milestones and specifies the fees to be earned upon the completion of each milestone, then the fee is recognized when the related milestones are earned, as further described below; otherwise, we estimate the fee earned in a given period by using a proportional performance method based on costs incurred during the period as compared to total estimated project costs and application of the resulting fraction to the total project fee specified in the contract.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Under the milestone method of revenue recognition, milestone payments (including milestone payments for fees) contained in research and development arrangements are recognized as revenue when: (i) the milestones are achieved; (ii) no further performance obligations with respect to the milestone exist; (iii) collection is reasonably assured; and (iv) substantive effort was necessary to achieve the milestone.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;A milestone is considered substantive if all of the following conditions are met:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.5pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 6%; font-family: 'times new roman';"&gt;&amp;#149;&lt;/td&gt;
&lt;td style="width: 91%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;it is commensurate with either our performance to meet the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from our performance to achieve the milestone,&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -16.5pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 6%; font-family: 'times new roman';"&gt;&amp;#149;&lt;/td&gt;
&lt;td style="width: 91%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;it relates solely to past performance, and&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -16.5pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 6%; font-family: 'times new roman';"&gt;&amp;#149;&lt;/td&gt;
&lt;td style="width: 91%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.5pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;If a milestone is deemed not to be substantive, the Company recognizes the portion of the milestone payment as revenue that correlates to work already performed using the proportional performance method; the remaining portion of the milestone payment is deferred and recognized as revenue as the Company completes its performance obligations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.5pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Revenue on fixed price contracts (without substantive milestones as described above) is recognized on the percentage-of-completion method. The percentage-of-completion method recognizes income as the contract progresses (generally related to the costs incurred in providing the services required under the contract). The use of the percentage-of-completion method depends on the ability to make reasonable dependable estimates and the fact that circumstances may necessitate frequent revision of estimates does not indicate that the estimates are unreliable for the purpose for which they are used.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.5pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;As a result of our revenue recognition policies and the billing provisions contained in our contracts, the timing of customer billings may differ from the timing of recognizing revenue. Amounts invoiced to customers in excess of revenue recognized are reflected on the balance sheet as deferred revenue. Amounts recognized as revenue in excess of amounts billed to customers are reflected on the balance sheet as unbilled accounts receivable.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Upon notice of termination of a contract from the government, all related termination costs are expensed. Revenue is recognized on the termination costs to the extent those costs are allowable and billable under the contract. Because the government may require an audit of incurred costs, revenue is recognized when the Company is reasonably assured of collection.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="Tag216" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Share-Based Compensation&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;We expense the estimated fair value of share-based awards granted to employees, non-employee directors, and consultants under our stock compensation plans. The fair value of stock options granted to employees and non-employee directors is determined at the grant date using the Black-Scholes option pricing model. The Black-Scholes option pricing model considers, among other factors, the expected life of the award and the expected volatility of our stock price. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the employee's requisite service period.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;The fair value of share-based awards granted to consultants is determined at the grant date using the Black-Scholes option pricing model and re-measured at each quarterly reporting date over their requisite service period. The value of awards that are ultimately expected to vest is recognized as expense on a straight-line basis over their requisite service period.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;The fair value of restricted stock grants is determined based on the closing price of our common stock on the award date and is recognized as expense ratably over the requisite service period.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Share-based compensation expense recognized in the three months and nine months ended September 30, 2015 and 2014 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;/font&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Share-based compensation expense for the three months ended September 30, 2015 and 2014 was:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div class="CursorPointer"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Three months ended September 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Research and development&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 12,034 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 52,434 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;General and administrative&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 81,723 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 228,286 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Total share-based compensation expense&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 93,757 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;font&gt; 280,720 &lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;br/&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;/font&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;During the three months ended September 30, 2015, we granted options to purchase&amp;#160;&lt;font&gt;100,000&lt;/font&gt;&amp;#160;shares of common stock to non-employee directors and made&amp;#160;no grants of options or shares of restricted stock to employees and consultants.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify;"&gt;&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Share-based compensation expense for the nine months ended September 30, 2015 and 2014 was:&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="6" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Nine months ended September 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: 'Times New Roman'; text-align: center; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;strong&gt;2015&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: 'Times New Roman'; text-align: center; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;strong&gt;2014&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Research and development&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 85,259 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 329,655 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;General and administrative&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 395,470 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 843,048 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"&gt;&lt;font style="font-size: 13.3333330154419px;"&gt;Restructuring benefit&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"&gt;&lt;font style="font-size: 13.3333330154419px;"&gt;&lt;font&gt; (53,741 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;)&amp;#160;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"&gt;&lt;font style="font-size: 13.3333330154419px;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;Total share-based compensation expense&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 426,988 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;1,172,703&lt;/font&gt; &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify;"&gt;As a result of the restructuring and termination of employees, during the nine months ended September 30, 2015, we recognized approximately $&lt;font&gt;75,000&lt;/font&gt; of share-based compensation expense resulting from our agreement to extend the exercise period of the vested stock options for several of the executives who were terminated. In addition, approximately $&lt;font&gt;129,000&lt;/font&gt; of previously recognized share-based compensation expense was reversed for unvested stock options forfeited as a result of the restructuring and termination of employees. The $&lt;font&gt;53,741&lt;/font&gt;&amp;#160;net reversal of share-based compensation expense is reflected&amp;#160;&lt;font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;in restructuring benefit in the above table.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;During the nine months ended September 30, 2015, we granted options to purchase &lt;font&gt;112,000&lt;/font&gt;&amp;#160;shares of common stock to employees and non-employee directors and granted&amp;#160;&lt;font&gt;117,500&lt;/font&gt; shares of restricted stock to employees. During the nine months ended September 30, 2014, we granted options to purchase &lt;font&gt;1,357,755&lt;/font&gt;&amp;#160;shares of common stock to employees, non-employee&amp;#160;directors and consultants and made &lt;font&gt;no&lt;/font&gt; restricted stock grants. &lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;/font&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;At September 30, 2015, we had total unrecognized share-based compensation expense related to unvested awards of approximately $&lt;font&gt;0.8&lt;/font&gt;&amp;#160;million net of estimated forfeitures, which we expect to recognize as expense over a weighted-average period of &lt;font&gt;2.2&lt;/font&gt;&amp;#160;years.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:IncomeTaxPolicyTextBlock id="Tag217" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is &amp;#147;more likely than not&amp;#148; that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense. As of September 30, 2015 and December 31, 2014, we had recognized a full valuation allowance since the likelihood of realization of our tax deferred assets does not meet the more likely than not threshold.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Our income tax expense was $&lt;font&gt;0.02&lt;/font&gt;&amp;#160;million and $&lt;font&gt;0.03&lt;/font&gt;&amp;#160;million during the three months ended September 30, 2015 and 2014, respectively, and $&lt;font&gt;0.05&lt;/font&gt;&amp;#160;million during the nine months ended September 30, 2015 and 2014, relating exclusively to the generation of a deferred tax liability associated with the tax amortization of goodwill, which is included as a component of other long-term liabilities on our condensed consolidated balance sheets. The income tax expense results from the difference between the treatment of goodwill for income tax purposes and for U.S. GAAP.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <pip:AnnualLicensePayment id="Tag218" contextRef="I2015-09-30" unitRef="USD" decimals="0">200000</pip:AnnualLicensePayment>
  <us-gaap:EarningsPerSharePolicyTextBlock id="Tag219" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Basic and Diluted Net Loss Per Share&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Income (loss) per share:&lt;/i&gt; &amp;#160;Basic income (loss) per share is computed by dividing consolidated net income (loss) by the weighted average number of common shares outstanding during the period, excluding unvested restricted stock.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;For periods of net income when the effects are not anti-dilutive, diluted earnings per share is computed by dividing our net income by the weighted average number of shares outstanding and the impact of all potential dilutive common shares, consisting&amp;#160;&amp;#160;primarily of stock options, unvested restricted stock and stock purchase warrants.&amp;#160;The dilutive impact of our potentially dilutive common shares resulting from stock options and stock purchase warrants is determined by applying the treasury stock method.&amp;#160;&amp;#160; For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potentially dilutive common shares is anti-dilutive due to the net losses.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;A total of approximately &lt;font&gt;6.0&lt;/font&gt;&amp;#160;million and &lt;font&gt;10.9&lt;/font&gt;&amp;#160;million potentially dilutive securities have been excluded in the calculation of diluted net loss per share in the&amp;#160;nine months ended September 30, 2015 and 2014, respectively, because their inclusion would be anti-dilutive.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="Tag220" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#147;FASB&amp;#148;) issued Accounting Standards Update (&amp;#147;ASU&amp;#148;) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (&amp;#147;ASU No. 2014-09&amp;#148;). ASU No. 2014-09 clarifies the principles for recognizing revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance affects entities that enter into contracts with customers to transfer goods or services, and supersedes prior GAAP guidance, namely Accounting Standards Codification Topic 605 - Revenue Recognition. On July 9, 2015, the FASB voted and approved to defer the effective date of ASU No. 2014-09 by one year. As a result, ASU No. 2014-09 will be effective for fiscal years beginning after December 15, 2017, with early adoption permitted but not prior to the original effective date of annual periods beginning after December 15, 2016. ASU No. 2014-09 is to be applied retrospectively, or on a modified retrospective basis. We are currently evaluating the impact of adopting ASU No. 2014-09 on our consolidated financial statements.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;In April 2015, the FASB issued ASU No. 2015-03, Interest &amp;#150; Imputation of Interest, or ASU No. 2015-03. To simplify presentation of debt issuance costs, the amendments in this update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this update. The amendments in this update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. We expect that the impact of adoption on our consolidated financial statements will be immaterial.&lt;/p&gt;
&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock id="Tag221" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Note 2 - Summary of Significant Accounting Policies&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Our unaudited condensed consolidated financial statements include the accounts of PharmAthene, Inc. and its wholly-owned subsidiary. All significant intercompany transactions and balances have been eliminated in consolidation. Our unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&amp;#147;U.S. GAAP&amp;#148;). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The condensed consolidated balance sheet at December 31, 2014 has been derived from audited consolidated financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission (&amp;#147;SEC&amp;#148;). We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included in our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC. We currently operate in &lt;font&gt;one&lt;/font&gt; business segment.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period.&amp;#160;Our unaudited condensed consolidated financial statements include significant estimates for our share-based compensation and the value of our financial instruments, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Foreign Currency Translation&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;The functional currency of our wholly-owned foreign subsidiary, PharmAthene UK Limited, is its local currency. Assets and liabilities of our foreign subsidiary are translated into United States dollars based on the exchange rate at the end of the reporting period. Income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. Translation adjustments for subsidiaries that have not been sold, substantially liquidated or otherwise disposed of, are accumulated in other comprehensive loss, a component of stockholders' equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive loss at December 31, 2014. Transaction gains or losses are included in the determination of net income (loss).&lt;br/&gt;&lt;br/&gt;&lt;/font&gt;&lt;font style="font-size: 10pt;"&gt;In June 2015, we substantially completed the liquidation of PharmAthene UK Limited, which we had acquired in 2008. Prior to substantially liquidating the UK subsidiary, currency fluctuations were recorded as foreign currency translation adjustments, a component of other comprehensive income. As a result of the substantially completed liquidation, we realized an approximate loss of $&lt;font&gt;0.2&lt;/font&gt; million in our condensed consolidated statements of operations, which represents the amount of previously recorded foreign currency translation adjustments related to our UK subsidiary.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;Cash and cash equivalents are stated at cost which approximates market value and include investments in money market funds with financial institutions which are stated at market value. The Company maintains cash balances with financial institutions in excess of insured limits. The Company does not anticipate any losses on such cash balances.&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;/font&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Significant Customers and Accounts Receivable&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Our primary customers are NIAID, and the Biomedical Advanced Research and Development Authority (&amp;#147;BARDA&amp;#148;). As of September 30, 2015, the Company's unbilled accounts receivable balance was comprised of receivables from NIAID. The Company's receivable balances (both billed and unbilled) as of December 31, 2014 were comprised of receivables from NIAID and BARDA.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Goodwill&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Goodwill represents the excess of purchase price over the fair value of net identifiable assets associated with acquisitions. We review the recoverability of goodwill annually at the end of our fiscal year and whenever events or changes in circumstances indicate that it is more likely than not that impairment exists. Recoverability of goodwill is reviewed by comparing our market value (as measured by our stock price multiplied by the number of outstanding shares as of the end of the year) to the net book value of our equity. If our market value exceeds our net book value, no further analysis is required. We completed our annual impairment assessment of goodwill on December 31, 2014 and determined that there was no impairment as of that date.&lt;br/&gt;&lt;br/&gt; Changes in our business strategy or adverse changes in market conditions could impact the impairment analyses and require the recognition of an impairment charge equal to the excess of the carrying value over its estimated fair value.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Restructuring Expense&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;As a result of the Realignment Plan, we recorded approximately $&lt;font&gt;2.1&lt;/font&gt; million of restructuring expense during the nine months ended September 30, 2015, including approximately $&lt;font&gt;2.0&lt;/font&gt; million of related severance expense, and the remainder being&amp;#160;legal and other employee related expenses. &lt;font style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"&gt;Additionally, as a result of the September 2, 2015 sublease of a portion of the Company's leased office space, we recorded approximately $&lt;font&gt;0.4&lt;/font&gt; million of additional restructuring expense (see Note 4 - &lt;i&gt;Commitments and Contingencies - Leases&lt;/i&gt;).&lt;/font&gt; &lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Financial Instruments&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Our financial instruments, and/or embedded features contained in those instruments, often are classified as derivative liabilities and are recorded at their fair values. The determination of fair value of these instruments and features requires estimates and judgments. Some of our stock purchase warrants are considered to be derivative liabilities due to the presence of net settlement features and/or non-standard anti-dilution provisions; the fair value of our warrants is determined based on the Black-Scholes option pricing model.&amp;#160;&amp;#160;Use of the Black-Scholes option pricing model requires the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. See Note 3 &amp;#150;&amp;#160;&lt;i&gt;Fair Value Measurements&lt;/i&gt; for further details.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;We generate our revenue from different types of contractual arrangements: cost-plus-fee contracts and fixed price contracts.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.5pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Revenues on cost-plus-fee contracts are recognized in an amount equal to the costs incurred during the period plus an estimate of the applicable fee earned. The estimate of the applicable fee earned is determined by reference to the contract: if the contract defines the fee in terms of risk-based milestones and specifies the fees to be earned upon the completion of each milestone, then the fee is recognized when the related milestones are earned, as further described below; otherwise, we estimate the fee earned in a given period by using a proportional performance method based on costs incurred during the period as compared to total estimated project costs and application of the resulting fraction to the total project fee specified in the contract.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Under the milestone method of revenue recognition, milestone payments (including milestone payments for fees) contained in research and development arrangements are recognized as revenue when: (i) the milestones are achieved; (ii) no further performance obligations with respect to the milestone exist; (iii) collection is reasonably assured; and (iv) substantive effort was necessary to achieve the milestone.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;A milestone is considered substantive if all of the following conditions are met:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.5pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 6%; font-family: 'times new roman';"&gt;&amp;#149;&lt;/td&gt;
&lt;td style="width: 91%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;it is commensurate with either our performance to meet the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from our performance to achieve the milestone,&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -16.5pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 6%; font-family: 'times new roman';"&gt;&amp;#149;&lt;/td&gt;
&lt;td style="width: 91%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;it relates solely to past performance, and&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -16.5pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 6%; font-family: 'times new roman';"&gt;&amp;#149;&lt;/td&gt;
&lt;td style="width: 91%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.5pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;If a milestone is deemed not to be substantive, the Company recognizes the portion of the milestone payment as revenue that correlates to work already performed using the proportional performance method; the remaining portion of the milestone payment is deferred and recognized as revenue as the Company completes its performance obligations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.5pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Revenue on fixed price contracts (without substantive milestones as described above) is recognized on the percentage-of-completion method. The percentage-of-completion method recognizes income as the contract progresses (generally related to the costs incurred in providing the services required under the contract). The use of the percentage-of-completion method depends on the ability to make reasonable dependable estimates and the fact that circumstances may necessitate frequent revision of estimates does not indicate that the estimates are unreliable for the purpose for which they are used.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.5pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;As a result of our revenue recognition policies and the billing provisions contained in our contracts, the timing of customer billings may differ from the timing of recognizing revenue. Amounts invoiced to customers in excess of revenue recognized are reflected on the balance sheet as deferred revenue. Amounts recognized as revenue in excess of amounts billed to customers are reflected on the balance sheet as unbilled accounts receivable.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Upon notice of termination of a contract from the government, all related termination costs are expensed. Revenue is recognized on the termination costs to the extent those costs are allowable and billable under the contract. Because the government may require an audit of incurred costs, revenue is recognized when the Company is reasonably assured of collection.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.5pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Share-Based Compensation&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;We expense the estimated fair value of share-based awards granted to employees, non-employee directors, and consultants under our stock compensation plans. The fair value of stock options granted to employees and non-employee directors is determined at the grant date using the Black-Scholes option pricing model. The Black-Scholes option pricing model considers, among other factors, the expected life of the award and the expected volatility of our stock price. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the employee's requisite service period.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;The fair value of share-based awards granted to consultants is determined at the grant date using the Black-Scholes option pricing model and re-measured at each quarterly reporting date over their requisite service period. The value of awards that are ultimately expected to vest is recognized as expense on a straight-line basis over their requisite service period.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;The fair value of restricted stock grants is determined based on the closing price of our common stock on the award date and is recognized as expense ratably over the requisite service period.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Share-based compensation expense recognized in the three months and nine months ended September 30, 2015 and 2014 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;/font&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Share-based compensation expense for the three months ended September 30, 2015 and 2014 was:&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div class="CursorPointer"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Three months ended September 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td colspan="2" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;2015&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td colspan="6" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;2014&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Research and development&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 12,034 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 52,434 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;General and administrative&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 81,723 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 228,286 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Total share-based compensation expense&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 93,757 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;font&gt; 280,720 &lt;/font&gt;&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in;"&gt;&amp;#160;&lt;br/&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;/font&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify;"&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;During the three months ended September 30, 2015, we granted options to purchase&amp;#160;&lt;font&gt;100,000&lt;/font&gt;&amp;#160;shares of common stock to non-employee directors and made&amp;#160;no grants of options or shares of restricted stock to employees and consultants.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify;"&gt;&amp;#160;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Share-based compensation expense for the nine months ended September 30, 2015 and 2014 was:&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="6" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Nine months ended September 30,&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: 'Times New Roman'; text-align: center; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;strong&gt;2015&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; font-family: 'Times New Roman'; text-align: center; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;strong&gt;2014&lt;/strong&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;Research and development&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 85,259 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 329,655 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;General and administrative&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 395,470 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 843,048 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"&gt;&lt;font style="font-size: 13.3333330154419px;"&gt;Restructuring benefit&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"&gt;&lt;font style="font-size: 13.3333330154419px;"&gt;&lt;font&gt; (53,741 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;)&amp;#160;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"&gt;&lt;font style="font-size: 13.3333330154419px;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;Total share-based compensation expense&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 426,988 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;&lt;font style="font-size: 10pt; font-family: 'Times New Roman', serif;"&gt;1,172,703&lt;/font&gt; &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify;"&gt;As a result of the restructuring and termination of employees, during the nine months ended September 30, 2015, we recognized approximately $&lt;font&gt;75,000&lt;/font&gt; of share-based compensation expense resulting from our agreement to extend the exercise period of the vested stock options for several of the executives who were terminated. In addition, approximately $&lt;font&gt;129,000&lt;/font&gt; of previously recognized share-based compensation expense was reversed for unvested stock options forfeited as a result of the restructuring and termination of employees. The $&lt;font&gt;53,741&lt;/font&gt;&amp;#160;net reversal of share-based compensation expense is reflected&amp;#160;&lt;font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;in restructuring benefit in the above table.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;During the nine months ended September 30, 2015, we granted options to purchase &lt;font&gt;112,000&lt;/font&gt;&amp;#160;shares of common stock to employees and non-employee directors and granted&amp;#160;&lt;font&gt;117,500&lt;/font&gt; shares of restricted stock to employees. During the nine months ended September 30, 2014, we granted options to purchase &lt;font&gt;1,357,755&lt;/font&gt;&amp;#160;shares of common stock to employees, non-employee&amp;#160;directors and consultants and made &lt;font&gt;no&lt;/font&gt; restricted stock grants. &lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;/font&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;At September 30, 2015, we had total unrecognized share-based compensation expense related to unvested awards of approximately $&lt;font&gt;0.8&lt;/font&gt;&amp;#160;million net of estimated forfeitures, which we expect to recognize as expense over a weighted-average period of &lt;font&gt;2.2&lt;/font&gt;&amp;#160;years.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is &amp;#147;more likely than not&amp;#148; that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense. As of September 30, 2015 and December 31, 2014, we had recognized a full valuation allowance since the likelihood of realization of our tax deferred assets does not meet the more likely than not threshold.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Our income tax expense was $&lt;font&gt;0.02&lt;/font&gt;&amp;#160;million and $&lt;font&gt;0.03&lt;/font&gt;&amp;#160;million during the three months ended September 30, 2015 and 2014, respectively, and $&lt;font&gt;0.05&lt;/font&gt;&amp;#160;million during the nine months ended September 30, 2015 and 2014, relating exclusively to the generation of a deferred tax liability associated with the tax amortization of goodwill, which is included as a component of other long-term liabilities on our condensed consolidated balance sheets. The income tax expense results from the difference between the treatment of goodwill for income tax purposes and for U.S. GAAP.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Basic and Diluted Net Loss Per Share&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Income (loss) per share:&lt;/i&gt; &amp;#160;Basic income (loss) per share is computed by dividing consolidated net income (loss) by the weighted average number of common shares outstanding during the period, excluding unvested restricted stock.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;For periods of net income when the effects are not anti-dilutive, diluted earnings per share is computed by dividing our net income by the weighted average number of shares outstanding and the impact of all potential dilutive common shares, consisting&amp;#160;&amp;#160;primarily of stock options, unvested restricted stock and stock purchase warrants.&amp;#160;The dilutive impact of our potentially dilutive common shares resulting from stock options and stock purchase warrants is determined by applying the treasury stock method.&amp;#160;&amp;#160; For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potentially dilutive common shares is anti-dilutive due to the net losses.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;A total of approximately &lt;font&gt;6.0&lt;/font&gt;&amp;#160;million and &lt;font&gt;10.9&lt;/font&gt;&amp;#160;million potentially dilutive securities have been excluded in the calculation of diluted net loss per share in the&amp;#160;nine months ended September 30, 2015 and 2014, respectively, because their inclusion would be anti-dilutive.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#147;FASB&amp;#148;) issued Accounting Standards Update (&amp;#147;ASU&amp;#148;) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (&amp;#147;ASU No. 2014-09&amp;#148;). ASU No. 2014-09 clarifies the principles for recognizing revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance affects entities that enter into contracts with customers to transfer goods or services, and supersedes prior GAAP guidance, namely Accounting Standards Codification Topic 605 - Revenue Recognition. On July 9, 2015, the FASB voted and approved to defer the effective date of ASU No. 2014-09 by one year. As a result, ASU No. 2014-09 will be effective for fiscal years beginning after December 15, 2017, with early adoption permitted but not prior to the original effective date of annual periods beginning after December 15, 2016. ASU No. 2014-09 is to be applied retrospectively, or on a modified retrospective basis. We are currently evaluating the impact of adopting ASU No. 2014-09 on our consolidated financial statements.&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;"&gt;In April 2015, the FASB issued ASU No. 2015-03, Interest &amp;#150; Imputation of Interest, or ASU No. 2015-03. To simplify presentation of debt issuance costs, the amendments in this update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this update. The amendments in this update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. We expect that the impact of adoption on our consolidated financial statements will be immaterial.&lt;/p&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <pip:ShareBasedCompensationExtensionOfExercisePeriod id="Tag222" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">75000</pip:ShareBasedCompensationExtensionOfExercisePeriod>
  <pip:ShareBasedCompensationReversalFromStockOptionForfeitures id="Tag223" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">129000</pip:ShareBasedCompensationReversalFromStockOptionForfeitures>
  <pip:ShareBasedCompensationReversalNet id="Tag224" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" decimals="0">53741</pip:ShareBasedCompensationReversalNet>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag225" contextRef="D2015-01-01_To_2015-09-30_RestructuringChargesMember" unitRef="USD" decimals="0">-53741</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag226" contextRef="D2014-01-01_To_2014-09-30_RestructuringChargesMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag227" contextRef="D2015-07-01_To_2015-09-30_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">12034</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag228" contextRef="D2015-07-01_To_2015-09-30_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">81723</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag229" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="0">93757</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag230" contextRef="D2014-07-01_To_2014-09-30_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">52434</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag231" contextRef="D2014-07-01_To_2014-09-30_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0">228286</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="Tag232" contextRef="D2014-07-01_To_2014-09-30" unitRef="USD" decimals="0">280720</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod id="Tag233" contextRef="D2015-07-01_To_2015-09-30" unitRef="Shares" decimals="INF">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <pip:ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod id="Tag234" contextRef="D2014-01-01_To_2014-09-30" unitRef="Shares" xsi:nil="true" />
  <us-gaap:InvestmentsFairValueDisclosure id="Tag235" contextRef="I2015-09-30_FairValueInputsLevel1Member_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">6430038</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:InvestmentsFairValueDisclosure id="Tag236" contextRef="I2015-09-30_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:InvestmentsFairValueDisclosure id="Tag237" contextRef="I2015-09-30_FairValueInputsLevel3Member_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:InvestmentsFairValueDisclosure id="Tag238" contextRef="I2015-09-30_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">6430038</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:DerivativeAssets id="Tag239" contextRef="I2015-09-30_FairValueInputsLevel1Member_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">6430038</us-gaap:DerivativeAssets>
  <us-gaap:DerivativeAssets id="Tag240" contextRef="I2015-09-30_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:DerivativeAssets id="Tag241" contextRef="I2015-09-30_FairValueInputsLevel3Member_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:DerivativeAssets id="Tag242" contextRef="I2015-09-30_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">6430038</us-gaap:DerivativeAssets>
  <us-gaap:DerivativeLiabilitiesCurrent id="Tag243" contextRef="I2015-09-30_FairValueInputsLevel1Member_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:DerivativeLiabilitiesCurrent id="Tag244" contextRef="I2015-09-30_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:DerivativeLiabilitiesCurrent id="Tag245" contextRef="I2015-09-30_FairValueInputsLevel3Member_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">2355</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent id="Tag246" contextRef="I2015-09-30_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">2355</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent id="Tag247" contextRef="I2015-09-30_FairValueInputsLevel1Member_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:DerivativeLiabilitiesNoncurrent id="Tag248" contextRef="I2015-09-30_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:DerivativeLiabilitiesNoncurrent id="Tag249" contextRef="I2015-09-30_FairValueInputsLevel3Member_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">227898</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent id="Tag250" contextRef="I2015-09-30_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">227898</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilities id="Tag251" contextRef="I2015-09-30_FairValueInputsLevel1Member_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:DerivativeLiabilities id="Tag252" contextRef="I2015-09-30_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:DerivativeLiabilities id="Tag253" contextRef="I2015-09-30_FairValueInputsLevel3Member_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">230253</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities id="Tag254" contextRef="I2015-09-30_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">230253</us-gaap:DerivativeLiabilities>
  <us-gaap:InvestmentsFairValueDisclosure id="Tag255" contextRef="I2014-12-31_FairValueInputsLevel1Member_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">6429104</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:InvestmentsFairValueDisclosure id="Tag256" contextRef="I2014-12-31_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:InvestmentsFairValueDisclosure id="Tag257" contextRef="I2014-12-31_FairValueInputsLevel3Member_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:InvestmentsFairValueDisclosure id="Tag258" contextRef="I2014-12-31_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">6429104</us-gaap:InvestmentsFairValueDisclosure>
  <us-gaap:DerivativeAssets id="Tag259" contextRef="I2014-12-31_FairValueInputsLevel1Member_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">6429104</us-gaap:DerivativeAssets>
  <us-gaap:DerivativeAssets id="Tag260" contextRef="I2014-12-31_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:DerivativeAssets id="Tag261" contextRef="I2014-12-31_FairValueInputsLevel3Member_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:DerivativeAssets id="Tag262" contextRef="I2014-12-31_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">6429104</us-gaap:DerivativeAssets>
  <us-gaap:DerivativeLiabilitiesCurrent id="Tag263" contextRef="I2014-12-31_FairValueInputsLevel1Member_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:DerivativeLiabilitiesCurrent id="Tag264" contextRef="I2014-12-31_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:DerivativeLiabilitiesCurrent id="Tag265" contextRef="I2014-12-31_FairValueInputsLevel3Member_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">178509</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent id="Tag266" contextRef="I2014-12-31_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">178509</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent id="Tag267" contextRef="I2014-12-31_FairValueInputsLevel1Member_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:DerivativeLiabilitiesNoncurrent id="Tag268" contextRef="I2014-12-31_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:DerivativeLiabilitiesNoncurrent id="Tag269" contextRef="I2014-12-31_FairValueInputsLevel3Member_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">629170</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent id="Tag270" contextRef="I2014-12-31_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">629170</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilities id="Tag271" contextRef="I2014-12-31_FairValueInputsLevel1Member_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:DerivativeLiabilities id="Tag272" contextRef="I2014-12-31_FairValueInputsLevel2Member_FairValueMeasurementsRecurringMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:DerivativeLiabilities id="Tag273" contextRef="I2014-12-31_FairValueInputsLevel3Member_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">807679</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities id="Tag274" contextRef="I2014-12-31_FairValueMeasurementsRecurringMember" unitRef="USD" decimals="0">807679</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities id="Tag275" contextRef="I2014-12-31_FairValueInputsLevel3Member_WarrantMember" unitRef="USD" decimals="0">807679</us-gaap:DerivativeLiabilities>
  <us-gaap:UnrealizedGainLossOnDerivatives id="Tag276" contextRef="D2015-01-01_To_2015-09-30_FairValueInputsLevel3Member_WarrantMember" unitRef="USD" decimals="0">-577426</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:DerivativeLiabilities id="Tag277" contextRef="I2015-09-30_FairValueInputsLevel3Member_WarrantMember" unitRef="USD" decimals="0">230253</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities id="Tag278" contextRef="I2013-12-31_FairValueInputsLevel3Member_WarrantMember" unitRef="USD" decimals="0">1740235</us-gaap:DerivativeLiabilities>
  <us-gaap:UnrealizedGainLossOnDerivatives id="Tag279" contextRef="D2014-01-01_To_2014-09-30_FairValueInputsLevel3Member_WarrantMember" unitRef="USD" decimals="0">-464703</us-gaap:UnrealizedGainLossOnDerivatives>
  <us-gaap:DerivativeLiabilities id="Tag280" contextRef="I2014-09-30_FairValueInputsLevel3Member_WarrantMember" unitRef="USD" decimals="0">851793</us-gaap:DerivativeLiabilities>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="Tag281" contextRef="I2015-09-30_FairValueInputsLevel3Member_DerivativeLiabilitiesMember" unitRef="Shares" decimals="INF">1775419</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:DerivativeLiabilities id="Tag282" contextRef="I2015-09-30" unitRef="USD" decimals="0">230253</us-gaap:DerivativeLiabilities>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock id="Tag283" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="14" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;As of September 30, 2015&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Level 1&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Level 2&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Level 3&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Balance&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;Investment in money market funds&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 6,430,038 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 6,430,038 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;Total investment in money market funds&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 6,430,038 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 6,430,038 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'Times New Roman';" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Liabilities&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;Current portion of derivative instruments related to stock purchase warrants&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 2,355 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 2,355 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;Non-current portion of derivative instruments related to stock purchase warrants&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 227,898 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 227,898 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;Total derivative instruments related to stock purchase warrants&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 230,253 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 230,253 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="14" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;As of December 31, 2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Level 1&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Level 2&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Level 3&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Balance&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;Investment in money market funds&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;6,429,104&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;6,429,104&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;Total investment in money market funds&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;6,429,104&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;6,429,104&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'Times New Roman';" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Liabilities&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;Current portion of derivative instruments related to stock purchase warrants&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;178,509&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;178,509&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;Non-current portion of derivative instruments related to stock purchase warrants&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;629,170&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;629,170&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;Total derivative instruments related to stock purchase warrants&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;807,679&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;807,679&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 3%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 94%; font-family: 'times new roman';"&gt;
&lt;div&gt;Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets.&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock id="Tag284" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman'; width: 20px; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Exercised Stock&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Balance as of&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Unrealized&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman'; width: 20px; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Purchase&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Balance&amp;#160;as&amp;#160;of&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;December 31,&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;(Gains)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman'; width: 20px; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Warrants&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;September 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Description&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;2015&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 20px; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;2015&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;2015&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;Derivative liabilities related to stock purchase warrants&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;807,679&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;(577,426&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20px; text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;230,253&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="margin: 0; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Balance as of&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Unrealized&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman'; width: 20px; padding: 0px; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Exercised Stock Purchase&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Balance&amp;#160;as&amp;#160;of&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;December 31,&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;(Gains)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman'; width: 20px; padding: 0px; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Warrants&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;September 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Description&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 20px; text-align: center; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;Derivative liabilities related to stock purchase warrants&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;1,740,235&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;(464,703&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20px; text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;(423,739&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;851,793&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="Tag285" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Note 3 - Fair Value Measurements&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;The carrying amounts of our short term financial instruments, which primarily include cash and cash equivalents, accounts receivable (billed and unbilled), and accounts payable approximate their fair values due to their short term maturities. We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. We report assets and liabilities that are measured at fair value using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs.&lt;font style="mso-spacerun: yes;"&gt;&amp;#160; &lt;/font&gt;The three levels of inputs used to measure fair value are as follows:&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 2%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 2%; font-family: 'times new roman';"&gt;&amp;#149;&lt;/td&gt;
&lt;td style="width: 96%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;Level 1 &amp;#151; Quoted prices in active markets for identical assets or liabilities.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 2%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 2%; font-family: 'times new roman';"&gt;&amp;#149;&lt;/td&gt;
&lt;td style="width: 96%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;Level 2 &amp;#151; Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 2%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 2%; font-family: 'times new roman';"&gt;&amp;#149;&lt;/td&gt;
&lt;td style="width: 96%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;Level 3 &amp;#151; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&amp;#160;&amp;#160;This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;An asset's or liability's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&amp;#160;&amp;#160;At each reporting period, we perform a detailed analysis of our assets and liabilities that are measured at fair value.&amp;#160;All assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;We have segregated our financial assets and liabilities that are measured at fair value into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below.&amp;#160;We have no non-financial assets and liabilities that are measured at fair value on a recurring basis.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;/font&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="14" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;As of September 30, 2015&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Level 1&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Level 2&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Level 3&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Balance&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;Investment in money market funds&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 6,430,038 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 6,430,038 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;Total investment in money market funds&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 6,430,038 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 6,430,038 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'Times New Roman';" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Liabilities&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;Current portion of derivative instruments related to stock purchase warrants&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 2,355 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 2,355 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;Non-current portion of derivative instruments related to stock purchase warrants&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 227,898 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 227,898 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;Total derivative instruments related to stock purchase warrants&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 230,253 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 230,253 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="14" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;As of December 31, 2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Level 1&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Level 2&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Level 3&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Balance&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;Investment in money market funds&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;6,429,104&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;6,429,104&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;Total investment in money market funds&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;6,429,104&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;6,429,104&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="font-family: 'Times New Roman';" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Liabilities&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;Current portion of derivative instruments related to stock purchase warrants&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;178,509&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;178,509&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;Non-current portion of derivative instruments related to stock purchase warrants&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;629,170&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;629,170&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;Total derivative instruments related to stock purchase warrants&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;807,679&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;807,679&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 3%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 94%; font-family: 'times new roman';"&gt;
&lt;div&gt;Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets.&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;/font&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; margin: 0px; text-align: left;"&gt;&lt;font style="font-size: 10pt;"&gt;The following table sets forth a summary of changes in the fair value of the Company's Level 3 liabilities for the nine months ended September 30, 2015 and 2014:&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman'; width: 20px; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Exercised Stock&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Balance as of&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Unrealized&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman'; width: 20px; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Purchase&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Balance&amp;#160;as&amp;#160;of&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;December 31,&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;(Gains)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman'; width: 20px; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Warrants&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;September 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Description&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;2015&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 20px; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;2015&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;2015&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;Derivative liabilities related to stock purchase warrants&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;807,679&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;(577,426&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20px; text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;-&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;230,253&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="margin: 0; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Balance as of&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Unrealized&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman'; width: 20px; padding: 0px; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Exercised Stock Purchase&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;br/&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Balance&amp;#160;as&amp;#160;of&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;December 31,&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;(Gains)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman'; width: 20px; padding: 0px; text-align: center;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Warrants&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;September 30,&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'Times New Roman';" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Description&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;2013&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; width: 20px; text-align: center; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;2014&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"&gt;&lt;font style="font-size: 10pt;"&gt;Derivative liabilities related to stock purchase warrants&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;"&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;1,740,235&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;(464,703&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20px; text-align: right;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;(423,739&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;851,793&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;At September 30, 2015 and 2014, derivative liabilities are comprised of warrants to purchase &lt;font&gt;1,775,419&lt;/font&gt;&amp;#160;shares of common stock. The warrants are considered to be derivative liabilities due to the presence of net settlement features and/or non-standard anti-dilution provisions, and as a result, are recorded at fair value at each balance sheet date, with changes in fair value recorded in the accompanying unaudited condensed consolidated statements of operations. The fair value of our warrants is determined based on the Black-Scholes option pricing model. Use of the Black-Scholes option pricing model requires the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. Changes in any of the assumptions related to the unobservable inputs identified above may change the stock purchase warrants' fair value; increases in expected term, anticipated volatility and expected dividends generally result in increases in fair value, while decreases in the unobservable inputs generally result in decreases in fair value. Unrealized gains and losses on the fair value adjustments for these derivative instruments are classified in other income (expense) as the change in fair value of derivative instruments in the accompanying unaudited condensed consolidated statements of operations.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;" width="100%"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="7" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Quantitative Information about Level 3 Fair Value Measurements&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px; width: 20px;" nowrap="nowrap" colspan="7"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Fair Value at September 30, 2015&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Valuation Technique&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Unobservable Inputs&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;230,253&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;Black-Scholes option pricing model&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;Expected term&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;Expected dividends&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;Anticipated volatility&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Assets Measured at Fair Value on a Nonrecurring Basis&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;The Company measures its long-lived assets, including, property and equipment and goodwill, at fair value on a nonrecurring basis. These assets are recognized at fair value when they are deemed to be other-than-temporarily impaired. During the three months ended September 30, 2015, the Company recorded an impairment charge for property and equipment in the amount of $&lt;font&gt;36,981&lt;/font&gt;. These assets were written down to their fair value of $&lt;font&gt;0&lt;/font&gt; in conjunction with the sublease of the Company's leased office space (see Note 4 - &lt;em&gt;Commitments and Contingencies - Leases&lt;/em&gt;). As of September 30, 2015, the Company had no other assets or liabilities that were measured at fair value on a nonrecurring basis.&lt;/font&gt;&lt;/p&gt;
&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock id="Tag286" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;" width="100%"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="7" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Quantitative Information about Level 3 Fair Value Measurements&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; padding: 0px; width: 20px;" nowrap="nowrap" colspan="7"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Fair Value at September 30, 2015&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Valuation Technique&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Unobservable Inputs&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt;230,253&lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;Black-Scholes option pricing model&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;Expected term&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;Expected dividends&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;Anticipated volatility&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;</us-gaap:FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="Tag287" contextRef="I2007-12-31_StockIncentivePlanTwentyZeroSevenMember" unitRef="Shares" decimals="-5">3500000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="Tag288" contextRef="I2008-12-31_StockIncentivePlanTwentyZeroSevenMember" unitRef="Shares" decimals="-5">4600000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="Tag289" contextRef="I2015-09-30_StockIncentivePlanTwentyZeroSevenMember" unitRef="Shares" decimals="-5">10300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant id="Tag290" contextRef="I2015-09-30_StockIncentivePlanTwentyZeroSevenMember" unitRef="Shares" decimals="-5">4400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <pip:StockOptionsContractualTerm id="Tag291" contextRef="D2015-01-01_To_2015-09-30_StockIncentivePlanTwentyZeroSevenMember">P10Y</pip:StockOptionsContractualTerm>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="Tag292" contextRef="I2015-09-30" unitRef="Shares" decimals="INF">1922781</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="Tag293" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;b&gt;Note 4 - Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;i&gt;SIGA Litigation&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;In December 2006, we filed a complaint against SIGA in the Delaware Court of Chancery. The complaint alleged, among other things, that we have the exclusive right to license, development and marketing rights for SIGA's drug candidate, Arestvyr&amp;#153; (Tecovirimat), pursuant to a merger agreement between the parties that was terminated in 2006. The complaint also alleged that SIGA failed to negotiate in good faith the terms of such a license pursuant to the terminated merger agreement with SIGA.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;In September 2011, the Delaware Court of Chancery issued an opinion in the case finding that SIGA had breached certain contractual obligations to us upholding our claims of promissory estoppel, and awarding us damages. SIGA appealed aspects of the decision to the Delaware Supreme Court. In response, we cross-appealed other aspects of the decision. In May 2013, the Delaware Supreme Court issued its ruling on the appeal, affirming the Delaware Court of Chancery's finding that SIGA had breached certain contractual obligations to us, reversed its finding of promissory estoppel, and remanded the case back to the Delaware Court of Chancery to reconsider the remedy and award in light of the Delaware Supreme Court's opinion.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;On August 8, 2014, the Delaware Court of Chancery issued a Memorandum Opinion and Order, or August 2014 Order, finding that we are entitled to receive lump sum expectation damages for the value of the Company's lost profits for Tecovirimat. In addition, the Delaware Court of Chancery found that the Company is entitled to receive pre-judgment interest and varying percentages of the Company's reasonable attorneys' and expert witness fees. On October 17, 2014, the Company and SIGA each filed opinions of our respective financial experts and Draft Orders and Judgments in accordance with the instructions of the August 2014 Order.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;On September 16, 2014, SIGA announced that it filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of New York. In connection therewith, SIGA filed with the Bankruptcy Court an affidavit indicating, among other things, that it expects to continue to perform under its contract with BARDA. SIGA's petition for bankruptcy initiated a process whereby its assets are protected from creditors, including us.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;On January 7, 2015, the Delaware Court of Chancery issued a letter Opinion and Order, directing the Company to submit a Revised Proposed Judgment that reflects a lump sum award of approximately $&lt;font&gt;113&lt;/font&gt; million in contract expectation damages, plus pre-judgment interest on that amount from 2006 through the date of such order. In accordance with the instructions of the court, the Company submitted a draft Revised Proposed Judgment under seal on January 9, 2015.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;On January 15, 2015, the Delaware Court of Chancery issued a Final Order and Judgment, finding that we are entitled to receive a lump sum award of $&lt;font&gt;194.6&lt;/font&gt;&amp;#160;million, or the Total Judgment, comprised of (1) expectation damages of $&lt;font&gt;113.1&lt;/font&gt;&amp;#160;million for the value of the Company's lost profits for Tecovirimat, also known as ST-246&lt;sup&gt;&amp;#174;&lt;/sup&gt; (formerly referred to as &amp;#147;Arestvyr&lt;sup&gt;&amp;#153;&lt;/sup&gt;&amp;#148; and referred to by SIGA in its recent SEC filings as &amp;#147;Tecovirimat&amp;#148;), plus (2) pre-judgment interest on that amount from 2006 and varying percentages of the Company's reasonable attorneys' and expert witness fees, totaling $&lt;font&gt;81.5&lt;/font&gt;&amp;#160;million. Under the Final Order and Judgment, PharmAthene is also entitled to post-judgment simple interest. PharmAthene's entitlement to interest from and after SIGA's bankruptcy filing may be negatively impacted by the proceedings under the Bankruptcy Code.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;SIGA filed a notice of appeal with the Delaware Supreme Court in which it challenges various findings of the Court of Chancery and seeks to set aside the Final Order and Judgment, and we filed a notice of cross-appeal. On March 2, 2015, SIGA filed their opening brief, and PharmAthene filed a response on April 1, 2015. SIGA took the opportunity to file their reply brief on May 1, 2015, and PharmAthene filed their reply brief on cross-appeal on May 11, 2015.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;On October 7, 2015, oral arguments in SIGA's appeal and PharmAthene's cross-appeal of the January 15, 2015 Final Order and Judgement took place in the Delaware Supreme Court. There can be no assurances that the Delaware Supreme Court will rule in PharmAthene's favor, or that PharmAthene will receive any payments from SIGA. As a result, the decision could be reversed, remanded or otherwise changed.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;While we believe that we may have a right to receive a significant amount under a possible damages award, because SIGA has filed a notice of appeal with the Delaware Supreme Court and because there can be no assurance that SIGA will not be successful in any such appeal, we have not yet recorded any amount due from SIGA in relation to this case. There can be no assurances if or when the Company will receive any payments from SIGA as a result of the Judgment. SIGA has stated publicly that it does not currently have cash sufficient to satisfy the award. It is also uncertain whether SIGA will have such cash in the future.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;PharmAthene's ability to collect the Judgment depends upon a number of factors, including SIGA's financial and operational success, which is subject to a number of significant risks and uncertainties (certain of which are outlined in SIGA's filings with the SEC), as to which we have limited knowledge and which we have no ability to control, mitigate or fully evaluate. SIGA disclosed in its Current Report on Form 8-K filed April 29, 2015 that it entered into a modification to its contract with BARDA on April 29, 2015 to increase the provisional dosage of Tecovirimat and extend the delivery schedule. The modification was subject to approval by the Bankruptcy Court, which was granted on April 27, 2015. Furthermore, because SIGA has filed for protection under the federal bankruptcy laws, the Company is automatically stayed from taking any enforcement action in the Delaware Court of Chancery. By agreement of the parties, and with the approval of the Bankruptcy Court, the automatic stay has been lifted for the sole purpose of allowing the Delaware Court of Chancery to enter a money judgment and to allow the parties to exercise their appellate rights. The Company's ability to collect a money judgment from SIGA, if any, remains subject to further proceedings in the Bankruptcy Court. &lt;font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;"&gt;The Company has not &lt;/font&gt;&lt;font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px;"&gt;recognized any potential proceeds from these actions in its financial statements to date.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;i&gt;Government Contracting&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;Payments to the Company on cost-plus-fee contracts are provisional. The accuracy and appropriateness of costs charged to U.S. Government contracts are subject to regulation, audit and possible disallowance by the Defense Contract Audit Agency (&amp;#147;DCAA&amp;#148;) and other government agencies such as BARDA. Accordingly, costs billed or billable to U.S. Government customers are subject to potential adjustment upon audit by such agencies.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;We have agreed to rate provisions with DCAA for 2006, 2007 and 2008. In 2014, BARDA audited indirect costs or rates charged by us on the SparVax&lt;sup&gt;&amp;#174;&lt;/sup&gt; contract for the years 2008 through 2013. As a result of the audit, in March of 2015, we were able to record revenue, and invoice BARDA&amp;#160;in the amount of $&lt;font&gt;5.8&lt;/font&gt; million in connection with these costs, all of which was collected in April 2015.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;BARDA has started an audit of our 2014 costs related to the partial termination for convenience of the SparVax&lt;sup&gt;&amp;#174;&lt;/sup&gt; contract. While we do not currently believe the results of this audit will have an adverse effect on the Company, we cannot provide assurances that it will not have such an effect. The Company has billed and recognized revenue using the provisional rates as defined in the contract. While the actual rates for 2014, which reflect the actual costs incurred by us, have been higher than the provisional rates, we have no assurance on either the amount of additional funds we may receive as a result of these higher rates or the amount of time it may take to recover these funds.&amp;#160;The amount of any such funds is determined as a result of future audits by BARDA.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;Changes in government policies, priorities or funding levels through agency or program budget reductions by the U.S. Congress or executive agencies could materially adversely affect the Company's financial condition or results of operations. Furthermore, contracts with the U.S. Government may be terminated or suspended by the U.S. Government at any time, with or without cause. Such contract suspensions or terminations could result in unreimbursable expenses or charges or otherwise adversely affect the Company's financial condition and/or results of operations.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;i&gt;Registration Rights Agreements&lt;/i&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;We entered into a Registration Rights Agreement with the investors who participated in the July 2009 private placement of convertible notes and related warrants. We subsequently filed two registration statements on Form S-3 with the SEC to register the resale of the shares issuable upon conversion of the convertible notes and exercise of the related warrants, which have been declared effective. We are obligated to maintain the registration statements effective until the date when such shares (and any other securities issued or issuable with respect to or in exchange for such shares) have been sold or are eligible for resale without restrictions under Rule 144. The convertible notes were converted or extinguished in 2010. The warrants expired on January 28, 2015.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;Under the terms of the convertible notes, which were converted or extinguished in 2010, if after the 2nd consecutive business day (other than during an allowable blackout period) on which sales of all of the securities required to be included on the registration statement cannot be made pursuant to the registration statement (a &amp;#147;Maintenance Failure&amp;#148;), we will be required to pay to each selling stockholder a one-time payment of &lt;font&gt;1.0&lt;/font&gt;% of the aggregate principal amount of the convertible notes relating to the affected shares on the initial day of a Maintenance Failure. Our total maximum obligation under this provision at September 30, 2015, which is not probable of payment, would be approximately $&lt;font&gt;0.2&lt;/font&gt; million.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;Following a Maintenance Failure, we will also be required to make to each selling stockholder monthly payments of &lt;font&gt;1.0&lt;/font&gt;% of the aggregate principal amount of the convertible notes relating to the affected shares on every 30th day after the initial day of a Maintenance Failure, in each case prorated for shorter periods and until the failure is cured. Our total maximum obligation under this provision, which is not probable of payment, would be approximately $&lt;font&gt;0.2&lt;/font&gt; million for each month until the failure, if it occurs, is cured.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;We have separate registration rights agreements with investors, under which we have obligations to keep the corresponding registration statements effective until the registrable securities (as defined in each agreement) have been sold, and under which we may have separate obligations to file registration statements in the future on either a demand or &amp;#147;piggy-back&amp;#148; basis or both.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;i&gt;&lt;font style="font-size: 10.0pt;"&gt;License Agreements&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;i&gt;&lt;font style="font-size: 10.0pt;"&gt;&amp;#160;&amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="margin: 0in 0in 0.0001pt; text-align: justify; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt;"&gt;On July 6, 2015, PharmAthene signed a license agreement with ImmunoVaccine for the exclusive use of the DepoVax&lt;sup&gt;TM &lt;/sup&gt;vaccine platform, to develop an anthrax vaccine utilizing PharmAthene's recombinant protective antigen (&amp;#147;rPA&amp;#148;). ImmunoVaccine is a clinical-stage vaccine development company located in Halifax, Nova Scotia. PharmAthene will reimburse up to $&lt;font&gt;210,000&lt;/font&gt; to ImmunoVaccine for their efforts in developing this vaccine. In addition, ImmunoVaccine will receive annual payments of $&lt;font&gt;200,000&lt;/font&gt;, and additional payments for the achievement of certain milestones relating to contracting with the U.S. Government as well as achieving certain clinical/regulatory and commercial milestones, and achievement of sales targets. Additionally, ImmunoVaccine will receive a royalty on sales related to the use of DepoVax&lt;sup&gt;TM&lt;/sup&gt;.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0in 0in 0.0001pt; text-align: justify; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;i&gt;&lt;font style="font-size: 10.0pt;"&gt;Leases&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;i&gt;&lt;font style="font-size: 10.0pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/i&gt;&lt;/p&gt;
&lt;p style="margin: 0in 0in 0.0001pt; text-align: justify; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt;"&gt;The Company leases its office under a &lt;font&gt;10&lt;/font&gt;-year operating lease, which commenced on May 1, 2007. On September 2, 2015, the Company entered into a sublease agreement with a third party with respect to a portion of its leased office space in Annapolis, Maryland at an amount less than the Company's leased amount. As a result, we realized a loss of $&lt;font&gt;0.4&lt;/font&gt;&amp;#160;million in restructuring expense our condensed consolidated statements of operations for the nine months ended September 30, 2015.&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0in 0in 0.0001pt; text-align: justify; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin: 0in 0in 0.0001pt; text-align: justify; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt;"&gt;The present value of the Company's remaining lease liability (net of the sublease rental income), is included on the balance sheet as a component of accrued restructuring expenses&amp;#160;as follows:&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin: 0in 0in 0.0001pt; text-align: justify; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div align="center"&gt;
&lt;div&gt;
&lt;div style="display: block;"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="69%" style="width: 69%; border-collapse: collapse; margin-left: 0.1px; margin-right: 0.1px;"&gt;

&lt;tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes;"&gt;
&lt;td valign="bottom" style="border-style: none none solid; border-bottom-color: black; border-bottom-width: 1pt; padding: 0in;"&gt;
&lt;p align="center" style="text-align: center; margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt; Description &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" style="padding: 0in 0in 1.0pt 0in;"&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt; &amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="border-style: none none solid; border-bottom-color: black; border-bottom-width: 1pt; padding: 0in;"&gt;
&lt;p align="center" style="text-align: center; margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt; Present Value at September 30, 2015 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" style="padding: 0in 0in 1.0pt 0in;"&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt; &amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 1;"&gt;
&lt;td width="35%" valign="bottom" style="width: 35.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;"&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt;Accrued restructuring expenses&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="2%" valign="bottom" style="width: 2.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;"&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt; &amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="width: 1.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;"&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt; $ &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="30%" valign="bottom" style="width: 30.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;"&gt;
&lt;p align="right" style="text-align: right; margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt; &lt;font&gt;244,769&lt;/font&gt; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="width: 1.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;"&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt; &amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 2; mso-yfti-lastrow: yes;"&gt;
&lt;td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;"&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt;Accrued restructuring expenses - long term&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;"&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt; &amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;"&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;"&gt;
&lt;p align="right" style="text-align: right; margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt; &lt;font&gt;184,018&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;"&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt; &amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;div align="center"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:LossContingencyEstimateOfPossibleLoss id="Tag294" contextRef="I2015-01-07" unitRef="USD" decimals="-6">113000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
  <us-gaap:LossContingencyDamagesAwardedValue id="Tag295" contextRef="D2015-01-11_To_2015-01-15" unitRef="USD" decimals="-5">194600000</us-gaap:LossContingencyDamagesAwardedValue>
  <us-gaap:LossContingencyEstimateOfPossibleLoss id="Tag296" contextRef="I2015-01-15" unitRef="USD" decimals="-5">113100000</us-gaap:LossContingencyEstimateOfPossibleLoss>
  <us-gaap:LitigationSettlementExpense id="Tag297" contextRef="D2015-01-11_To_2015-01-15" unitRef="USD" decimals="-5">81500000</us-gaap:LitigationSettlementExpense>
  <pip:PercentageOfAggregatePrincipalAmountRedemption id="Tag298" contextRef="D2015-01-01_To_2015-09-30_GroupThreeMember" unitRef="Pure" decimals="3">0.010</pip:PercentageOfAggregatePrincipalAmountRedemption>
  <pip:NotesPayableAggregatePrincipalRepaymentAmount id="Tag299" contextRef="D2015-01-01_To_2015-09-30_GroupThreeMember" unitRef="USD" decimals="-5">200000</pip:NotesPayableAggregatePrincipalRepaymentAmount>
  <pip:PercentageOfAggregatePrincipalAmountRedemption id="Tag300" contextRef="D2015-01-01_To_2015-09-30_GroupFourMember" unitRef="Pure" decimals="3">0.010</pip:PercentageOfAggregatePrincipalAmountRedemption>
  <pip:NotesPayableAggregatePrincipalRepaymentAmount id="Tag301" contextRef="D2015-01-01_To_2015-09-30_GroupFourMember" unitRef="USD" decimals="-5">200000</pip:NotesPayableAggregatePrincipalRepaymentAmount>
  <pip:RevenueRecognizedFromContractAudit id="Tag302" contextRef="D2015-04-01_To_2015-04-30_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" unitRef="USD" decimals="-5">5800000</pip:RevenueRecognizedFromContractAudit>
  <pip:ClassOfWarrantOrRightOutstandingNumberOfSharesExpired id="Tag303" contextRef="D2015-01-21_To_2015-01-28_WarrantMember" unitRef="Shares" decimals="INF">2572775</pip:ClassOfWarrantOrRightOutstandingNumberOfSharesExpired>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="Tag304" contextRef="I2015-09-30_ShareBasedCompensationWarrantsPriceRangeOneMember_WarrantMember" unitRef="Shares" decimals="INF">100778</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Tag305" contextRef="I2015-09-30_ShareBasedCompensationWarrantsPriceRangeOneMember_WarrantMember" unitRef="USDPerShare" decimals="2">3.97</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="Tag306" contextRef="I2015-09-30_DerivativeInstrumentWarrantsMember_ShareBasedCompensationWarrantsPriceRangeFourMember" unitRef="Shares" decimals="INF">500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Tag307" contextRef="I2015-09-30_DerivativeInstrumentWarrantsMember_ShareBasedCompensationWarrantsPriceRangeFourMember" unitRef="USDPerShare" decimals="2">1.89</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="Tag308" contextRef="I2015-09-30_DerivativeInstrumentWarrantsMember_ShareBasedCompensationWarrantsPriceRangeFiveMember" unitRef="Shares" decimals="INF">903996</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Tag309" contextRef="I2015-09-30_DerivativeInstrumentWarrantsMember_ShareBasedCompensationWarrantsPriceRangeFiveMember" unitRef="USDPerShare" decimals="2">1.63</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="Tag310" contextRef="I2015-09-30_DerivativeInstrumentWarrantsMember_ShareBasedCompensationWarrantsPriceRangeSixMember" unitRef="Shares" decimals="INF">371423</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Tag311" contextRef="I2015-09-30_DerivativeInstrumentWarrantsMember_ShareBasedCompensationWarrantsPriceRangeSixMember" unitRef="USDPerShare" decimals="2">3.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights id="Tag312" contextRef="I2015-09-30_ShareBasedCompensationWarrantsPriceRangeSevenMember_WarrantMember" unitRef="Shares" decimals="INF">46584</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Tag313" contextRef="I2015-09-30_ShareBasedCompensationWarrantsPriceRangeSevenMember_WarrantMember" unitRef="USDPerShare" decimals="2">1.61</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <pip:ClassOfWarrantOrRightIssuanceDate id="Tag314" contextRef="D2015-01-01_To_2015-09-30_DerivativeInstrumentWarrantsMember_ShareBasedCompensationWarrantsPriceRangeFourMember">2010-04-01</pip:ClassOfWarrantOrRightIssuanceDate>
  <pip:WarrantExpirationDate id="Tag315" contextRef="D2015-01-01_To_2015-09-30_DerivativeInstrumentWarrantsMember_ShareBasedCompensationWarrantsPriceRangeFiveMember">2017-01-01</pip:WarrantExpirationDate>
  <pip:WarrantExpirationDate id="Tag316" contextRef="D2009-07-01_To_2009-07-31">2015-01-28</pip:WarrantExpirationDate>
  <pip:ClassOfWarrantOrRightIssuanceDate id="Tag317" contextRef="D2015-01-01_To_2015-09-30_DerivativeInstrumentWarrantsMember_ShareBasedCompensationWarrantsPriceRangeSixMember">2011-06-01</pip:ClassOfWarrantOrRightIssuanceDate>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock id="Tag318" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Number of Common Shares&lt;/font&gt;&lt;br/&gt;&lt;font style="font-size: 10pt;"&gt; Underlying Warrants As of&lt;/font&gt;&lt;br/&gt;&lt;font style="font-size: 10pt;"&gt; September 30, 2015&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Issue&amp;#160;Date&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Exercise&amp;#160;Price&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Expiration&amp;#160;Date&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 100,778 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt; March 2007 &lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 3.97 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt; March 2017 &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 500,000 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;sup&gt;(2) (3)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt; April 2010 &lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 1.89 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt; October 2015 &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 903,996 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt; July 2010 &lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 1.63 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt; January 2017 &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 371,423 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt; June 2011 &lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 3.50 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt; June 2016 &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 46,584 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt; March 2012 &lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 1.61 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt; March 2022 &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 1,922,781 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 5%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 92%; font-family: 'times new roman';"&gt;
&lt;div&gt;&lt;font style="font-size: 10pt;"&gt;These warrants to purchase common stock are classified as equity.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 1722px;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 5%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 92%; font-family: 'times new roman';"&gt;
&lt;div&gt;&lt;font style="font-size: 10pt;"&gt;Because of the presence of net settlement provisions, these warrants to purchase common stock are classified as derivative liabilities. The fair value of these liabilities (see Note 3 &amp;#150; &lt;i&gt;Fair Value Measurements&lt;/i&gt; ) is remeasured at the end of every reporting period and the change in fair value is reported in the accompanying unaudited condensed consolidated statements of operations as other income (expense).&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p&gt;&amp;#160;&lt;br/&gt;&lt;/p&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="100%" style="width: 100.0%; mso-cellspacing: 0in; mso-yfti-tbllook: 1184; mso-padding-alt: 0in 0in 0in 0in;"&gt;

&lt;tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes; mso-yfti-lastrow: yes;"&gt;
&lt;td width="24" valign="top" style="width: .25in; padding: 0in 0in 0in 0in;"&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10pt; color: #ffffff;"&gt;&amp;#160; _______&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="24" valign="top" style="width: .25in; padding: 0in 0in 0in 0in;"&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;sup&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt;(3)&lt;font style="color: #ffffff;"&gt;___________&lt;/font&gt;&lt;/font&gt;&lt;/sup&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top" style="padding: 0in 0in 0in 0in;"&gt;
&lt;p style="text-align: justify; margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt;&lt;/font&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div&gt;&lt;font style="font-size: 10pt;"&gt;Warrants to purchase &lt;font&gt;500,000&lt;/font&gt; shares of common stock expired on October 13, 2015 without being exercised. The warrants were classified as derivative liabilities.&lt;/font&gt;&lt;/div&gt;

&lt;p&gt;&lt;br/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="Tag319" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;Note 5 - Stockholders' Equity&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Long-Term Incentive Plan&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;In 2007, the Company's stockholders approved the 2007 Long-Term Incentive Compensation Plan (the &amp;#147;2007 Plan&amp;#148;) which provides for the granting of incentive and non-qualified stock options, stock appreciation rights, performance units, restricted stock awards and performance bonuses (collectively &amp;#147;awards&amp;#148;) to Company officers and employees. Additionally, the 2007 Plan authorizes the granting of non-qualified stock options and restricted stock awards to Company directors and to independent consultants.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;In 2008, our stockholders approved amendments to the 2007 Plan, increasing from &lt;font&gt;3.5&lt;/font&gt;&amp;#160;million shares to &lt;font&gt;4.6&lt;/font&gt; million shares the maximum number of shares authorized for issuance under the plan and adding an evergreen provision pursuant to which the number of shares authorized for issuance under the plan would increase automatically in each year, beginning in 2009, in accordance with certain limits set forth in the 2007 Plan. Under the terms of the evergreen provision, the annual increases were to continue through 2015, subject, however, to an aggregate limitation on the number of shares that could be authorized for issuance pursuant to such increases. This aggregate limitation was reached on January 1, 2014, so that the number of shares authorized for issuance under the plan did not automatically increase on January 1, 2015. At September 30, 2015, there are approximately &lt;font&gt;10.3&lt;/font&gt;&amp;#160;million shares approved for issuance under the 2007 Plan, of which approximately &lt;font&gt;4.4&lt;/font&gt;&amp;#160;million shares are available for grant. The Board of Directors in conjunction with management determines who receives awards, the vesting conditions and the exercise price. Options may have a maximum term of &lt;font&gt;ten&lt;/font&gt; years.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;At September 30, 2015, there were warrants outstanding to purchase &lt;font&gt;1,922,781&lt;/font&gt;&amp;#160;shares of our common stock.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Warrants to purchase &lt;font&gt;2,572,775&lt;/font&gt; shares of common stock expired on January 28, 2015 without being exercised. The warrants were classified as equity.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;The warrants outstanding as of September 30, 2015, all of which are exercisable, were as follows:&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;"&gt;

&lt;tr style="vertical-align: bottom;"&gt;
&lt;td style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Number of Common Shares&lt;/font&gt;&lt;br/&gt;&lt;font style="font-size: 10pt;"&gt; Underlying Warrants As of&lt;/font&gt;&lt;br/&gt;&lt;font style="font-size: 10pt;"&gt; September 30, 2015&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Issue&amp;#160;Date&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Exercise&amp;#160;Price&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap"&gt;&lt;font style="font-size: 10pt;"&gt;Expiration&amp;#160;Date&lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 100,778 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt; March 2007 &lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 3.97 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt; March 2017 &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 500,000 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;sup&gt;(2) (3)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt; April 2010 &lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 1.89 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt; October 2015 &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 903,996 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt; July 2010 &lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 1.63 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt; January 2017 &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 371,423 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt; June 2011 &lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 3.50 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt; June 2016 &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 46,584 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 8pt;"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt; March 2012 &lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 1.61 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt; March 2022 &lt;/font&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: white;"&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;font&gt; 1,922,781 &lt;/font&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 5%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 92%; font-family: 'times new roman';"&gt;
&lt;div&gt;&lt;font style="font-size: 10pt;"&gt;These warrants to purchase common stock are classified as equity.&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div class="CursorPointer"&gt;
&lt;table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 1722px;"&gt;

&lt;tr style="vertical-align: top;"&gt;
&lt;td style="width: 3%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 5%; font-family: 'times new roman';"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;sup&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 92%; font-family: 'times new roman';"&gt;
&lt;div&gt;&lt;font style="font-size: 10pt;"&gt;Because of the presence of net settlement provisions, these warrants to purchase common stock are classified as derivative liabilities. The fair value of these liabilities (see Note 3 &amp;#150; &lt;i&gt;Fair Value Measurements&lt;/i&gt; ) is remeasured at the end of every reporting period and the change in fair value is reported in the accompanying unaudited condensed consolidated statements of operations as other income (expense).&lt;/font&gt;&lt;/div&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;p&gt;&amp;#160;&lt;br/&gt;&lt;/p&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="100%" style="width: 100.0%; mso-cellspacing: 0in; mso-yfti-tbllook: 1184; mso-padding-alt: 0in 0in 0in 0in;"&gt;

&lt;tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes; mso-yfti-lastrow: yes;"&gt;
&lt;td width="24" valign="top" style="width: .25in; padding: 0in 0in 0in 0in;"&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10pt; color: #ffffff;"&gt;&amp;#160; _______&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="24" valign="top" style="width: .25in; padding: 0in 0in 0in 0in;"&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;sup&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt;(3)&lt;font style="color: #ffffff;"&gt;___________&lt;/font&gt;&lt;/font&gt;&lt;/sup&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="top" style="padding: 0in 0in 0in 0in;"&gt;
&lt;p style="text-align: justify; margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt;&lt;/font&gt;&lt;br/&gt;&lt;/p&gt;
&lt;div&gt;&lt;font style="font-size: 10pt;"&gt;Warrants to purchase &lt;font&gt;500,000&lt;/font&gt; shares of common stock expired on October 13, 2015 without being exercised. The warrants were classified as derivative liabilities.&lt;/font&gt;&lt;/div&gt;

&lt;p&gt;&lt;br/&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <pip:WarrantExpirationDate id="Tag320" contextRef="D2015-01-01_To_2015-09-30_DerivativeInstrumentWarrantsMember_ShareBasedCompensationWarrantsPriceRangeSixMember">2016-06-01</pip:WarrantExpirationDate>
  <pip:WarrantExpirationDate id="Tag321" contextRef="D2015-01-01_To_2015-09-30_ShareBasedCompensationWarrantsPriceRangeOneMember_WarrantMember">2017-03-01</pip:WarrantExpirationDate>
  <pip:ClassOfWarrantOrRightIssuanceDate id="Tag322" contextRef="D2015-01-01_To_2015-09-30_DerivativeInstrumentWarrantsMember_ShareBasedCompensationWarrantsPriceRangeFiveMember">2010-07-01</pip:ClassOfWarrantOrRightIssuanceDate>
  <pip:WarrantExpirationDate id="Tag323" contextRef="D2015-01-01_To_2015-09-30_DerivativeInstrumentWarrantsMember_ShareBasedCompensationWarrantsPriceRangeFourMember">2015-10-01</pip:WarrantExpirationDate>
  <pip:WarrantExpirationDate id="Tag324" contextRef="D2015-01-01_To_2015-09-30_ShareBasedCompensationWarrantsPriceRangeSevenMember_WarrantMember">2022-03-01</pip:WarrantExpirationDate>
  <pip:ClassOfWarrantOrRightIssuanceDate id="Tag325" contextRef="D2015-01-01_To_2015-09-30_ShareBasedCompensationWarrantsPriceRangeSevenMember_WarrantMember">2012-03-01</pip:ClassOfWarrantOrRightIssuanceDate>
  <pip:ClassOfWarrantOrRightIssuanceDate id="Tag326" contextRef="D2015-01-01_To_2015-09-30_ShareBasedCompensationWarrantsPriceRangeOneMember_WarrantMember">2007-03-01</pip:ClassOfWarrantOrRightIssuanceDate>
  <pip:MaximumValueOfStockIssuableUnderStockOffering id="Tag327" contextRef="I2013-03-25_EquityOfferingMember" unitRef="USD" decimals="-5">15000000</pip:MaximumValueOfStockIssuableUnderStockOffering>
  <pip:MaximumValueOfStockIssuableUnderStockOffering id="Tag328" contextRef="I2014-05-23_AmendmentToControlledEquityOfferingMember" unitRef="USD" decimals="-5">15000000</pip:MaximumValueOfStockIssuableUnderStockOffering>
  <pip:CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares id="Tag329" contextRef="I2013-03-25_EquityOfferingMember" unitRef="Pure" decimals="3">0.030</pip:CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares>
  <pip:RemainingValueOfStockIssuableUnderStockOffering id="Tag330" contextRef="I2015-09-30_EquityOfferingMember" unitRef="USD" decimals="-5">3000000</pip:RemainingValueOfStockIssuableUnderStockOffering>
  <us-gaap:DebtInstrumentCarryingAmount id="Tag331" contextRef="I2012-03-30_LoansPayableMember" unitRef="USD" decimals="-5">2500000</us-gaap:DebtInstrumentCarryingAmount>
  <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity id="Tag332" contextRef="I2012-03-30_LineOfCreditMember" unitRef="USD" decimals="-5">5000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
  <pip:WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement id="Tag333" contextRef="D2015-01-01_To_2015-09-30_LoansPayableMember" unitRef="Shares" decimals="INF">46584</pip:WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 id="Tag334" contextRef="I2015-09-30_LoansPayableMember" unitRef="USDPerShare" decimals="2">1.61</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales id="Tag335" contextRef="D2015-01-01_To_2015-09-30_FairValueInputsLevel3Member_WarrantMember" unitRef="USD" xsi:nil="true" />
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales id="Tag336" contextRef="D2014-01-01_To_2014-09-30_FairValueInputsLevel3Member_WarrantMember" unitRef="USD" decimals="0">423739</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales>
  <us-gaap:ClassOfWarrantOrRightOutstanding id="Tag337" contextRef="I2014-09-30_FairValueInputsLevel3Member_DerivativeLiabilitiesMember" unitRef="Shares" decimals="INF">1775419</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:AdditionalFinancialInformationDisclosureTextBlock id="Tag338" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;b&gt;Note 6 &amp;#150; Financing Transactions&lt;/b&gt;&lt;br/&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Controlled Equity Offering&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;On March 25, 2013, we entered into a controlled equity offering sales agreement with a sales agent, and filed with the SEC a prospectus supplement, dated March 25, 2013 to our prospectus dated July 27, 2011, or the 2011 Prospectus, pursuant to which we could offer and sell, from time to time, through the agent, shares of our common stock having an aggregate offering price of up to $&lt;font&gt;15.0&lt;/font&gt;&amp;#160;million.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;On May 23, 2014, we entered into an amendment, or the 2014 Amendment, to the controlled equity offering sales agreement with the sales agent, pursuant to which we may offer and sell, from time to time, through the agent, shares of our common stock having an aggregate offering price of up to an additional $&lt;font&gt;15.0&lt;/font&gt; million. On that day, we filed a prospectus supplement to the 2011 Prospectus for use in any sales of these additional shares of common stock through July 26, 2014, the date the underlying registration statement (File No. 333-175394) expired. As a result of this expiration, the 2011 Prospectus, as supplemented on March 25, 2013 and May 23, 2014, may no longer be used for the sale of shares of common stock under the controlled equity offering sales agreement, as amended. On May 23, 2014, we also filed a new universal shelf registration statement (File No. 333-196265) containing, among other things, a prospectus, or the 2014 Prospectus, for use in sales of the common stock under the 2014 Amendment. This registration statement was declared effective on May 30, 2014. Since the expiration of the 2011 Prospectus, all sales under the controlled equity offering sales agreement, as amended, are being effected under the 2014 Prospectus.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;Under the controlled equity offering sales agreement, as amended, the agent may sell shares by any method permitted by law and deemed to be an &amp;#147;at-the-market&amp;#148; offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on NYSE MKT, or any other existing trading market for our common stock or to or through a market maker. Subject to the terms and conditions of that agreement, the agent will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of NYSE MKT, to sell shares from time to time based upon our instructions. We are not obligated to sell any shares under the arrangement. We are obligated to pay the agent a commission of &lt;font&gt;3.0&lt;/font&gt;% of the aggregate gross proceeds from each sale of shares under the arrangement.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;As of September 30, 2015, shares having an aggregate offering price of $&lt;font&gt;3.0&lt;/font&gt; million remained available under the controlled equity offering sales agreement, as amended. During the three and nine months ended September 30, 2015, we did not sell any shares of our common stock under this arrangement.&amp;#160;The expiration date of the existing universal shelf registration statement is May 29, 2017, three years after it became effective. The controlled equity offering sales agreement, as amended, will expire on the same date, unless amended.&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&lt;i&gt;Termination of Loan Agreement with GE Capital&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&lt;font style="font-size: 10pt;"&gt;On&amp;#160;&lt;/font&gt;September 3, 2015, we satisfied in full our remaining obligations under our March 2012 Loan Agreement with GE Capital. The Loan Agreement was scheduled to terminate on September 29, 2015. The Loan Agreement provided for a senior secured debt facility including a $&lt;font&gt;2.5&lt;/font&gt;&amp;#160;million term loan and a revolving line of credit of up to $&lt;font&gt;5.0&lt;/font&gt;&amp;#160;million based on our outstanding qualified accounts receivable.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"&gt;The final payment fee was accrued and expensed over the term of the Loan Agreement, using the effective interest method. Financing costs incurred in connection with this agreement were also amortized over the term of the agreement using the effective interest method.&lt;br/&gt; &lt;br/&gt;The termination of the Loan Agreement released from us our obligations under the Loan Agreement, which were collateralized by a security interest in substantially all of our assets.&lt;br/&gt; &lt;br/&gt;In connection with the Loan Agreement, we issued to GE Capital a warrant to purchase &lt;font&gt;46,584&lt;/font&gt; shares of the Company's common stock at an exercise price of $&lt;font&gt;1.61&lt;/font&gt;&amp;#160;per share. The warrant, which expires in March 2022, was not affected by the termination. The warrant was exercisable immediately and subject to customary and standard anti-dilution adjustments. The warrant is classified in equity and, as a result, the fair value of the warrant was charged to additional paid-in-capital resulting in a debt discount at the date of issuance. The debt discount was amortized over the term of the Loan Agreement using the effective interest method.&lt;/p&gt;
&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
  <dei:AmendmentFlag id="Tag339" contextRef="D2015-01-01_To_2015-09-30">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate id="Tag340" contextRef="D2015-01-01_To_2015-09-30">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentPeriodEndDate id="Tag341" contextRef="D2015-01-01_To_2015-09-30">2015-09-30</dei:DocumentPeriodEndDate>
  <dei:TradingSymbol id="Tag342" contextRef="D2015-01-01_To_2015-09-30">PIP</dei:TradingSymbol>
  <dei:EntityFilerCategory id="Tag343" contextRef="D2015-01-01_To_2015-09-30">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName id="Tag344" contextRef="D2015-01-01_To_2015-09-30">PHARMATHENE, INC</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="Tag345" contextRef="D2015-01-01_To_2015-09-30">0001326190</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding id="Tag346" contextRef="I2015-11-04" unitRef="Shares" decimals="INF">64451334</dei:EntityCommonStockSharesOutstanding>
  <dei:DocumentFiscalYearFocus id="Tag347" contextRef="D2015-01-01_To_2015-09-30">2015</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="Tag348" contextRef="D2015-01-01_To_2015-09-30">Q3</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentType id="Tag349" contextRef="D2015-01-01_To_2015-09-30">10-Q</dei:DocumentType>
  <us-gaap:ProceedsFromWarrantExercises id="Tag350" contextRef="D2015-01-01_To_2015-09-30" unitRef="USD" xsi:nil="true" />
  <us-gaap:OtherLiabilitiesTableTextBlock id="Tag351" contextRef="D2015-01-01_To_2015-09-30">&lt;div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';"&gt;
&lt;div style="display: block;"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" width="69%" style="width: 69%; border-collapse: collapse; margin-left: 0.1px; margin-right: 0.1px;"&gt;

&lt;tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes;"&gt;
&lt;td valign="bottom" style="border-style: none none solid; border-bottom-color: black; border-bottom-width: 1pt; padding: 0in;"&gt;
&lt;p align="center" style="text-align: center; margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt; Description &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" style="padding: 0in 0in 1.0pt 0in;"&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt; &amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td colspan="2" valign="bottom" style="border-style: none none solid; border-bottom-color: black; border-bottom-width: 1pt; padding: 0in;"&gt;
&lt;p align="center" style="text-align: center; margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt; Present Value at September 30, 2015 &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" style="padding: 0in 0in 1.0pt 0in;"&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt; &amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 1;"&gt;
&lt;td width="35%" valign="bottom" style="width: 35.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;"&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt;Accrued restructuring expenses&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="2%" valign="bottom" style="width: 2.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;"&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt; &amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="width: 1.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;"&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt; $ &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="30%" valign="bottom" style="width: 30.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;"&gt;
&lt;p align="right" style="text-align: right; margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt; &lt;font&gt;244,769&lt;/font&gt; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td width="1%" valign="bottom" style="width: 1.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;"&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt; &amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="mso-yfti-irow: 2; mso-yfti-lastrow: yes;"&gt;
&lt;td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;"&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt;Accrued restructuring expenses - long term&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;"&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt; &amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;"&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10pt;"&gt;$&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;"&gt;
&lt;p align="right" style="text-align: right; margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt; &lt;font&gt;184,018&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;"&gt;
&lt;p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"&gt;&lt;font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"&gt; &amp;#160; &lt;/font&gt;&lt;/p&gt;
&lt;/td&gt;
&lt;/tr&gt;

&lt;/table&gt;
&lt;/div&gt;
&lt;/div&gt;</us-gaap:OtherLiabilitiesTableTextBlock>
  <us-gaap:AccruedRentCurrent id="Tag352" contextRef="I2015-09-30" unitRef="USD" decimals="0">244769</us-gaap:AccruedRentCurrent>
  <us-gaap:AccruedRentNoncurrent id="Tag353" contextRef="I2015-09-30" unitRef="USD" decimals="0">184018</us-gaap:AccruedRentNoncurrent>
  <us-gaap:RestructuringCharges id="Tag354" contextRef="D2015-01-01_To_2015-09-30_FacilityClosingMember" unitRef="USD" decimals="-5">400000</us-gaap:RestructuringCharges>
  <us-gaap:DerivativeLiabilitiesCurrent id="Tag355" contextRef="I2015-09-30" unitRef="USD" decimals="0">2355</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:RestructuringReserveNoncurrent id="Tag356" contextRef="I2015-09-30" unitRef="USD" decimals="0">184018</us-gaap:RestructuringReserveNoncurrent>
  <us-gaap:RestructuringReserveNoncurrent id="Tag357" contextRef="I2014-12-31" unitRef="USD" xsi:nil="true" />
  <pip:ClassOfWarrantOrRightOutstandingNumberOfSharesExpired id="Tag358" contextRef="D2015-10-12_To_2015-10-13_WarrantMember_SubsequentEventMember" unitRef="Shares" decimals="INF">500000</pip:ClassOfWarrantOrRightOutstandingNumberOfSharesExpired>
  <pip:MaximumAmountOfReimbursement id="Tag359" contextRef="I2015-09-30" unitRef="USD" decimals="0">210000</pip:MaximumAmountOfReimbursement>
  <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse id="Tag360" contextRef="D2015-07-01_To_2015-09-30" unitRef="USD" decimals="0">36981</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
  <us-gaap:PropertySubjectToOrAvailableForOperatingLeaseNet id="Tag361" contextRef="I2015-09-30" unitRef="USD" decimals="0">0</us-gaap:PropertySubjectToOrAvailableForOperatingLeaseNet>
  <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid id="Tag362" contextRef="I2015-09-03_LineOfCreditMember" unitRef="USD" decimals="0">81347</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
  <us-gaap:LoanProcessingFee id="Tag363" contextRef="D2015-09-02_To_2015-09-03_LineOfCreditMember" unitRef="USD" decimals="0">75000</us-gaap:LoanProcessingFee>
  <us-gaap:ShortTermBorrowings id="Tag364" contextRef="I2015-09-03_LineOfCreditMember" unitRef="USD" decimals="0">10</us-gaap:ShortTermBorrowings>
  <us-gaap:InterestPaid id="Tag365" contextRef="D2015-09-02_To_2015-09-03_LineOfCreditMember" unitRef="USD" decimals="0">208</us-gaap:InterestPaid>
  <us-gaap:LegalFees id="Tag366" contextRef="D2015-09-02_To_2015-09-03_LineOfCreditMember" unitRef="USD" decimals="0">6129</us-gaap:LegalFees>
  <us-gaap:RestructuringCharges id="Tag367" contextRef="D2015-01-01_To_2015-09-30_EmployeeSeveranceMember" unitRef="USD" decimals="-5">2100000</us-gaap:RestructuringCharges>
  <us-gaap:DerivativeLiabilitiesCurrent id="Tag368" contextRef="I2014-12-31" unitRef="USD" decimals="0">178509</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilities id="Tag369" contextRef="I2014-12-31" unitRef="USD" decimals="0">807679</us-gaap:DerivativeLiabilities>
  <link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:label="value1" xlink:href="#Tag235" />
    <link:loc xlink:type="locator" xlink:label="value1" xlink:href="#Tag236" />
    <link:loc xlink:type="locator" xlink:label="value1" xlink:href="#Tag237" />
    <link:loc xlink:type="locator" xlink:label="value1" xlink:href="#Tag238" />
    <link:loc xlink:type="locator" xlink:label="value1" xlink:href="#Tag255" />
    <link:loc xlink:type="locator" xlink:label="value1" xlink:href="#Tag256" />
    <link:loc xlink:type="locator" xlink:label="value1" xlink:href="#Tag257" />
    <link:loc xlink:type="locator" xlink:label="value1" xlink:href="#Tag258" />
    <link:loc xlink:type="locator" xlink:label="value2" xlink:href="#Tag304" />
    <link:loc xlink:type="locator" xlink:label="value3" xlink:href="#Tag306" />
    <link:loc xlink:type="locator" xlink:label="value49" xlink:href="#Tag306" />
    <link:loc xlink:type="locator" xlink:label="value3" xlink:href="#Tag308" />
    <link:loc xlink:type="locator" xlink:label="value3" xlink:href="#Tag310" />
    <link:loc xlink:type="locator" xlink:label="value2" xlink:href="#Tag312" />
    <link:footnote xlink:type="resource" xml:lang="en-US" xlink:label="footnote1" xlink:role="http://www.xbrl.org/2003/role/footnote">Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:from="value1" xlink:to="footnote1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="1" />
    <link:footnote xlink:type="resource" xml:lang="en-US" xlink:label="footnote2" xlink:role="http://www.xbrl.org/2003/role/footnote">These warrants to purchase common stock are classified as equity.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:from="value2" xlink:to="footnote2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="2" />
    <link:footnote xlink:type="resource" xml:lang="en-US" xlink:label="footnote3" xlink:role="http://www.xbrl.org/2003/role/footnote">Because of the presence of net settlement provisions, these warrants to purchase common stock are classified as derivative liabilities. The fair value of these liabilities (see Note 3 &#x2013; Fair Value Measurements ) is remeasured at the end of every reporting period and the change in fair value is reported in the accompanying unaudited condensed consolidated statements of operations as other income (expense).</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:from="value3" xlink:to="footnote3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="3" />
    <link:footnote xlink:type="resource" xml:lang="en-US" xlink:label="footnote49" xlink:role="http://www.xbrl.org/2003/role/footnote">Warrants to purchase 500,000 shares of common stock expired on October 13, 2015 without being exercised. The warrants were classified as derivative liabilities.</link:footnote>
    <link:footnoteArc xlink:type="arc" xlink:from="value49" xlink:to="footnote49" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" order="49" />
  </link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>pip-20150930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by The Vintage Group, Powered by IRIS Carbon-->
<xsd:schema xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:pip="http://www.pharmathene.com/20150930" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pharmathene.com/20150930">
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="pip-20150930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pip-20150930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pip-20150930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pip-20150930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://www.pharmathene.com/role/pip-daei" id="pip-daei">
        <link:definition>001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDBALANCESHEETS" id="Statement-CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" id="Statement-CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" id="Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" id="Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" id="Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/Disclosure-BusinessLiquidityandOrganization" id="Disclosure-BusinessLiquidityandOrganization">
        <link:definition>101 - Disclosure - Business, Liquidity and Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/pip-sosap" id="pip-sosap">
        <link:definition>102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/pip-fvm" id="pip-fvm">
        <link:definition>103 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/pip-cac" id="pip-cac">
        <link:definition>104 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/pip-se" id="pip-se">
        <link:definition>105 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/pip-ft" id="pip-ft">
        <link:definition>106 - Disclosure - Financing Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/pip-se1" id="pip-se1">
        <link:definition>107 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/pip-sosapp" id="pip-sosapp">
        <link:definition>202 - Disclosure - Summary of Significant Accounting Policies (Policy)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/pip-sosapt" id="pip-sosapt">
        <link:definition>302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/pip-fvmt" id="pip-fvmt">
        <link:definition>303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/pip-set" id="pip-set">
        <link:definition>305 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/pip-ftt" id="pip-ftt">
        <link:definition>306 - Disclosure - Financing Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/Disclosure-BusinessLiquidityandOrganizationDetails" id="Disclosure-BusinessLiquidityandOrganizationDetails">
        <link:definition>40101 - Disclosure - Business, Liquidity and Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/pip-sosapnd" id="pip-sosapnd">
        <link:definition>40201 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/pip-sosapsosced" id="pip-sosapsosced">
        <link:definition>40203 - Disclosure - Summary of Significant Accounting Policies (Schedule of Share-based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/pip-fvmnd" id="pip-fvmnd">
        <link:definition>40303 - Disclosure - Fair Value Measurements (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/pip-fvmsoqialfvmd" id="pip-fvmsoqialfvmd">
        <link:definition>40304 - Disclosure - Fair Value Measurements (Schedule of Quantitative Information about Level 3 Fair Value Measurements) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/pip-send" id="pip-send">
        <link:definition>40501 - Disclosure - Stockholders' Equity (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/pip-sesowd" id="pip-sesowd">
        <link:definition>40502 - Disclosure - Stockholders' Equity (Schedule of Warrants) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/pip-ftceod" id="pip-ftceod">
        <link:definition>40601 - Disclosure - Financing Transactions (Controlled Equity Offering) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/pip-ftlawgcd" id="pip-ftlawgcd">
        <link:definition>40602 - Disclosure - Financing Transactions (Loan Agreement with GE Capital) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/pip-ftppotld" id="pip-ftppotld">
        <link:definition>40603 - Disclosure - Financing Transactions (Principal Payments on the Term Loan) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/pip-fvmsolmafvd" id="pip-fvmsolmafvd">
        <link:definition>40301 - Disclosure - Fair Value Measurements (Schedule of Assets and Liabilities Measured at Fair Value) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/pip-fvmsocifvolld" id="pip-fvmsocifvolld">
        <link:definition>40302 - Disclosure - Fair Value Measurements (Summary of Changes in Fair Value of Level 3 Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/Disclosure-CommitmentsandContingenciesDetails" id="Disclosure-CommitmentsandContingenciesDetails">
        <link:definition>40401 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/Disclosure-CommitmentsandContingenciesTables" id="Disclosure-CommitmentsandContingenciesTables">
        <link:definition>304 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.pharmathene.com/role/Disclosure-CommitmentsandContingenciesLeasesDetails" id="Disclosure-CommitmentsandContingenciesLeasesDetails">
        <link:definition>40402 - Disclosure - Commitments and Contingencies (Leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2006/ref" schemaLocation="http://www.xbrl.org/2006/ref-2006-02-27.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/XLink" schemaLocation="http://www.xbrl.org/2003/xl-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd" />
  <xsd:element name="AccruedExpensesAndOtherCurrentLiabilities" id="pip_AccruedExpensesAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="AdditionalCommonStockAggregateGrossSales" id="pip_AdditionalCommonStockAggregateGrossSales" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="AdjustableDebtInstrumentReferenceInterestRateFloorPercentage" id="pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="AmendmentToControlledEquityOfferingMember" id="pip_AmendmentToControlledEquityOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="BilledAndUnbilledAccountsReceivableNet" id="pip_BilledAndUnbilledAccountsReceivableNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="BreachOfContractualCommitmentAwardPeriod" id="pip_BreachOfContractualCommitmentAwardPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="CashEquivalentsMaturityPeriod" id="pip_CashEquivalentsMaturityPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ClassOfWarrantOrRightIssuanceDate" id="pip_ClassOfWarrantOrRightIssuanceDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares" id="pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="CommitmentAndContingenciesTable" id="pip_CommitmentAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="CommitmentsAndContingenciesLineItems" id="pip_CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="CourtAwardedFees" id="pip_CourtAwardedFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="DebtInstrumentInterestRateFloorPercentage" id="pip_DebtInstrumentInterestRateFloorPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="DebtInstrumentsMaturityDateMonthAndYear" id="pip_DebtInstrumentsMaturityDateMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="DerivativeInstrumentWarrantsMember" id="pip_DerivativeInstrumentWarrantsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="DerivativeLiabilitiesMember" id="pip_DerivativeLiabilitiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="pip_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="EquityOfferingAxis" id="pip_EquityOfferingAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="EquityOfferingDomain" id="pip_EquityOfferingDomain" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="EquityOfferingLineItems" id="pip_EquityOfferingLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="EquityOfferingMember" id="pip_EquityOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="EquityOfferingTable" id="pip_EquityOfferingTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="FairValueMeasurementsLineItems" id="pip_FairValueMeasurementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="FairValueMeasurementsTable" id="pip_FairValueMeasurementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="FinalPaymentFeeOfTermLoanBalancePercent" id="pip_FinalPaymentFeeOfTermLoanBalancePercent" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="FutureValueSettled" id="pip_FutureValueSettled" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="GroupFourMember" id="pip_GroupFourMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="GroupOneMember" id="pip_GroupOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="GroupThreeMember" id="pip_GroupThreeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="GroupTwoMember" id="pip_GroupTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable" id="pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl" id="pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="LiquidityArrangementsMember" id="pip_LiquidityArrangementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="LongTermDebtExcludingDiscount" id="pip_LongTermDebtExcludingDiscount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="LongTermDebtPrepaymentPremiumPercentOfPrincipal" id="pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo" id="pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="MaximumValueOfStockIssuableUnderStockOffering" id="pip_MaximumValueOfStockIssuableUnderStockOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract" id="pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="NotesPayableAggregatePrincipalRepaymentAmount" id="pip_NotesPayableAggregatePrincipalRepaymentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfAggregatePrincipalAmountRedemption" id="pip_PercentageOfAggregatePrincipalAmountRedemption" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfNetProfitAwarded" id="pip_PercentageOfNetProfitAwarded" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="PharmAtheneMember" id="pip_PharmAtheneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="PreviousProceedsFromIssuanceOfCommonStockReceived" id="pip_PreviousProceedsFromIssuanceOfCommonStockReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="RemainingValueOfStockIssuableUnderStockOffering" id="pip_RemainingValueOfStockIssuableUnderStockOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate" id="pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod" id="pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationWarrantsPriceRangeFiveMember" id="pip_ShareBasedCompensationWarrantsPriceRangeFiveMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationWarrantsPriceRangeFourMember" id="pip_ShareBasedCompensationWarrantsPriceRangeFourMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationWarrantsPriceRangeOneMember" id="pip_ShareBasedCompensationWarrantsPriceRangeOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationWarrantsPriceRangeSevenMember" id="pip_ShareBasedCompensationWarrantsPriceRangeSevenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationWarrantsPriceRangeSixMember" id="pip_ShareBasedCompensationWarrantsPriceRangeSixMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationWarrantsPriceRangeThreeMember" id="pip_ShareBasedCompensationWarrantsPriceRangeThreeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationWarrantsPriceRangeTwoMember" id="pip_ShareBasedCompensationWarrantsPriceRangeTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SignificantAccountingPoliciesLineItems" id="pip_SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SignificantAccountingPoliciesTable" id="pip_SignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="StockholdersEquityLineItems" id="pip_StockholdersEquityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="StockholdersEquityTable" id="pip_StockholdersEquityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="StockIncentivePlanTwentyZeroSevenMember" id="pip_StockIncentivePlanTwentyZeroSevenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedValueConvertibleNotesAndStockPurchaseWarrants" id="pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockOptionsContractualTerm" id="pip_StockOptionsContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ValueOfWarrantIssuedToLenderInConnectionWithLoan" id="pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="WarrantExpirationDate" id="pip_WarrantExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement" id="pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" id="pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" id="pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromInitialFunding" id="pip_ProceedsFromInitialFunding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ValueOfAgreement" id="pip_ValueOfAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="NumberOfOptionsExercised" id="pip_NumberOfOptionsExercised" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption" id="pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" id="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" id="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" id="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" id="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="InitialDerivativeFairValue" id="pip_InitialDerivativeFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="BiologicLicenseApplicationApprovalMember" id="pip_BiologicLicenseApplicationApprovalMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="MilestonePaymentsMember" id="pip_MilestonePaymentsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="StudiesOrTrailsMember" id="pip_StudiesOrTrailsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SublicenseFeePercent" id="pip_SublicenseFeePercent" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="UpfrontPaymentMember" id="pip_UpfrontPaymentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="LitigationSettlementInterestPercentage" id="pip_LitigationSettlementInterestPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="ShareBasedCompensationExtensionOfExercisePeriod" id="pip_ShareBasedCompensationExtensionOfExercisePeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationReversalFromStockOptionForfeitures" id="pip_ShareBasedCompensationReversalFromStockOptionForfeitures" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationReversalNet" id="pip_ShareBasedCompensationReversalNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="GovernmentContractMember" id="pip_GovernmentContractMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="RevenueRecognizedFromContractAudit" id="pip_RevenueRecognizedFromContractAudit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" id="pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="AnnualLicensePayment" id="pip_AnnualLicensePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="ImmunovaccineMember" id="pip_ImmunovaccineMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromAdditionalFunding" id="pip_ProceedsFromAdditionalFunding" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="MonthlyRentAmount" id="pip_MonthlyRentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="FinalMonthlyRentAmount" id="pip_FinalMonthlyRentAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="IncomeLossFromOperatingLeaseCessation" id="pip_IncomeLossFromOperatingLeaseCessation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="EstimatedLeasePaymentsFromSublessee" id="pip_EstimatedLeasePaymentsFromSublessee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ExpectedSubletCashIncome" id="pip_ExpectedSubletCashIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="PresentValueOfGrossIncomeLoss" id="pip_PresentValueOfGrossIncomeLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="MaximumAmountOfReimbursement" id="pip_MaximumAmountOfReimbursement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>pip-20150930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by The Vintage Group, Powered by IRIS Carbon-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="pip-20150930.xsd#Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-ftppotld" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-ftppotld" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-fvmsolmafvd" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-fvmsolmafvd" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="pip-20150930.xsd#Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="pip-20150930.xsd#Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="pip-20150930.xsd#Statement-CONDENSEDCONSOLIDATEDBALANCESHEETS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:title="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:title="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:title="Calculation : us-gaap_ComprehensiveIncomeNetOfTax to us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" xlink:title="Calculation : us-gaap_ComprehensiveIncomeNetOfTax to us-gaap_NetIncomeLoss" order="12" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:title="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:title="Calculation : us-gaap_ComprehensiveIncomeNetOfTax to us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" order="2" weight="-1" use="optional" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-ftppotld">
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_LongTermDebtExcludingDiscount" xlink:label="pip_LongTermDebtExcludingDiscount" xlink:title="pip_LongTermDebtExcludingDiscount" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pip_LongTermDebtExcludingDiscount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:title="Calculation : pip_LongTermDebtExcludingDiscount to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="pip_LongTermDebtExcludingDiscount" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="Calculation : pip_LongTermDebtExcludingDiscount to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="2" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-fvmsolmafvd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeAssets" xlink:label="us-gaap_DerivativeAssets" xlink:title="us-gaap_DerivativeAssets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" xlink:title="us-gaap_InvestmentsFairValueDisclosure" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DerivativeAssets" xlink:to="us-gaap_InvestmentsFairValueDisclosure" xlink:title="Calculation : us-gaap_DerivativeAssets to us-gaap_InvestmentsFairValueDisclosure" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" xlink:title="us-gaap_DerivativeLiabilities" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="us-gaap_DerivativeLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="Calculation : us-gaap_DerivativeLiabilities to us-gaap_DerivativeLiabilitiesCurrent" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:title="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:title="Calculation : us-gaap_DerivativeLiabilities to us-gaap_DerivativeLiabilitiesNoncurrent" order="2" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="Calculation : us-gaap_NetIncomeLoss to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:title="us-gaap_NonoperatingIncomeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:title="Calculation : us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to us-gaap_NonoperatingIncomeExpense" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="us-gaap_InterestAndDividendIncomeOperating" xlink:title="us-gaap_InterestAndDividendIncomeOperating" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestAndDividendIncomeOperating" xlink:title="Calculation : us-gaap_NonoperatingIncomeExpense to us-gaap_InterestAndDividendIncomeOperating" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:title="us-gaap_InterestExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" xlink:title="Calculation : us-gaap_NonoperatingIncomeExpense to us-gaap_InterestExpense" order="3" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" xlink:title="us-gaap_UnrealizedGainLossOnDerivatives" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" xlink:title="Calculation : us-gaap_NonoperatingIncomeExpense to us-gaap_UnrealizedGainLossOnDerivatives" order="13" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:title="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:title="Calculation : us-gaap_NonoperatingIncomeExpense to us-gaap_OtherNonoperatingIncomeExpense" order="23" weight="1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" xlink:label="pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" xlink:title="pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" xlink:title="Calculation : us-gaap_NonoperatingIncomeExpense to pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" order="33" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:title="us-gaap_OperatingIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_OperatingIncomeLoss" xlink:title="Calculation : us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to us-gaap_OperatingIncomeLoss" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="us-gaap_ContractsRevenue" xlink:title="us-gaap_ContractsRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ContractsRevenue" xlink:title="Calculation : us-gaap_OperatingIncomeLoss to us-gaap_ContractsRevenue" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:title="us-gaap_OperatingExpenses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" xlink:title="Calculation : us-gaap_OperatingIncomeLoss to us-gaap_OperatingExpenses" order="2" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:title="us-gaap_ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:title="Calculation : us-gaap_OperatingExpenses to us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:title="us-gaap_Depreciation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_Depreciation" xlink:title="Calculation : us-gaap_OperatingExpenses to us-gaap_Depreciation" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:title="us-gaap_GeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:title="Calculation : us-gaap_OperatingExpenses to us-gaap_GeneralAndAdministrativeExpense" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" xlink:title="us-gaap_RestructuringCharges" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_RestructuringCharges" xlink:title="Calculation : us-gaap_OperatingExpenses to us-gaap_RestructuringCharges" order="13" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:title="us-gaap_IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:title="Calculation : us-gaap_NetIncomeLoss to us-gaap_IncomeTaxExpenseBenefit" order="2" weight="-1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="Calculation : us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="Calculation : us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt" xlink:title="us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:label="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:title="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:title="us-gaap_ProceedsFromWarrantExercises" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to us-gaap_ProceedsFromWarrantExercises" order="4" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:title="us-gaap_PaymentsOfFinancingCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsOfFinancingCosts" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to us-gaap_PaymentsOfFinancingCosts" order="5" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="Calculation : us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="4" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="Calculation : us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="5" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:title="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_DeferredIncomeTaxExpenseBenefit" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:title="us-gaap_Depreciation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_Depreciation" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_Depreciation" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_IncreaseDecreaseInDeferredRevenue" order="4" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_IncreaseDecreaseInAccountsPayable" order="5" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="6" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:label="us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:title="us-gaap_IncreaseDecreaseInUnbilledReceivables" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_IncreaseDecreaseInUnbilledReceivables" order="7" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_IncreaseDecreaseInAccountsReceivable" order="8" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" xlink:title="us-gaap_PaidInKindInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_PaidInKindInterest" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_PaidInKindInterest" order="9" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:title="us-gaap_ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_ShareBasedCompensation" order="10" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:title="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="11" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" xlink:title="us-gaap_UnrealizedGainLossOnDerivatives" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_UnrealizedGainLossOnDerivatives" order="12" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_NetIncomeLoss" order="13" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:label="us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:title="us-gaap_RestructuringReservePeriodIncreaseDecrease" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_RestructuringReservePeriodIncreaseDecrease" order="14" weight="1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" xlink:label="pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" xlink:title="pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" order="15" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="16" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:title="us-gaap_Assets" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:title="us-gaap_AssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:title="Calculation : us-gaap_Assets to us-gaap_AssetsCurrent" order="1.06" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="Calculation : us-gaap_AssetsCurrent to us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.01" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BilledContractReceivables" xlink:label="us-gaap_BilledContractReceivables" xlink:title="us-gaap_BilledContractReceivables" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_BilledContractReceivables" xlink:title="Calculation : us-gaap_AssetsCurrent to us-gaap_BilledContractReceivables" order="1.02" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnbilledContractsReceivable" xlink:label="us-gaap_UnbilledContractsReceivable" xlink:title="us-gaap_UnbilledContractsReceivable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_UnbilledContractsReceivable" xlink:title="Calculation : us-gaap_AssetsCurrent to us-gaap_UnbilledContractsReceivable" order="1.03" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="Calculation : us-gaap_AssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.04" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="Calculation : us-gaap_Assets to us-gaap_PropertyPlantAndEquipmentNet" order="1.07" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:title="us-gaap_OtherAssetsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:title="Calculation : us-gaap_Assets to us-gaap_OtherAssetsNoncurrent" order="1.08" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:title="us-gaap_Goodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" xlink:title="Calculation : us-gaap_Assets to us-gaap_Goodwill" order="1.09" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:title="us-gaap_Liabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:title="Calculation : us-gaap_LiabilitiesAndStockholdersEquity to us-gaap_Liabilities" order="1.18" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:title="us-gaap_LiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:title="Calculation : us-gaap_Liabilities to us-gaap_LiabilitiesCurrent" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent" xlink:title="us-gaap_RestructuringReserveCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_RestructuringReserveCurrent" xlink:title="Calculation : us-gaap_LiabilitiesCurrent to us-gaap_RestructuringReserveCurrent" order="1" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgesLiabilities" xlink:label="us-gaap_DerivativeInstrumentsAndHedgesLiabilities" xlink:title="us-gaap_DerivativeInstrumentsAndHedgesLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DerivativeInstrumentsAndHedgesLiabilities" xlink:title="Calculation : us-gaap_LiabilitiesCurrent to us-gaap_DerivativeInstrumentsAndHedgesLiabilities" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:title="us-gaap_AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:title="Calculation : us-gaap_LiabilitiesCurrent to us-gaap_AccountsPayableCurrent" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="pip_AccruedExpensesAndOtherCurrentLiabilities" xlink:title="pip_AccruedExpensesAndOtherCurrentLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="pip_AccruedExpensesAndOtherCurrentLiabilities" xlink:title="Calculation : us-gaap_LiabilitiesCurrent to pip_AccruedExpensesAndOtherCurrentLiabilities" order="4" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:title="us-gaap_LongTermDebtCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtCurrent" xlink:title="Calculation : us-gaap_LiabilitiesCurrent to us-gaap_LongTermDebtCurrent" order="5" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:title="us-gaap_OtherLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:title="Calculation : us-gaap_LiabilitiesCurrent to us-gaap_OtherLiabilitiesCurrent" order="16" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:title="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:title="Calculation : us-gaap_Liabilities to us-gaap_OtherLiabilitiesNoncurrent" order="2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserveNoncurrent" xlink:label="us-gaap_RestructuringReserveNoncurrent" xlink:title="us-gaap_RestructuringReserveNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_RestructuringReserveNoncurrent" xlink:title="Calculation : us-gaap_Liabilities to us-gaap_RestructuringReserveNoncurrent" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:title="us-gaap_LongTermDebtNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:title="Calculation : us-gaap_Liabilities to us-gaap_LongTermDebtNoncurrent" order="4" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:title="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:title="Calculation : us-gaap_Liabilities to us-gaap_DerivativeLiabilitiesNoncurrent" order="5" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:title="us-gaap_StockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:title="Calculation : us-gaap_LiabilitiesAndStockholdersEquity to us-gaap_StockholdersEquity" order="1.23" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:title="us-gaap_CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:title="Calculation : us-gaap_StockholdersEquity to us-gaap_CommonStockValue" order="1.19" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:title="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:title="Calculation : us-gaap_StockholdersEquity to us-gaap_AdditionalPaidInCapitalCommonStock" order="1.2" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:title="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:title="Calculation : us-gaap_StockholdersEquity to us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" order="1.21" weight="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="Calculation : us-gaap_StockholdersEquity to us-gaap_RetainedEarningsAccumulatedDeficit" order="1.22" weight="1" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>pip-20150930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by The Vintage Group, Powered by IRIS Carbon-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-sosapsosced" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-sosapsosced" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-send" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-send" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-ftceod" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-ftceod" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-fvmsolmafvd" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-fvmsolmafvd" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-fvmsocifvolld" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-fvmsocifvolld" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-sesowd" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-sesowd" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/Disclosure-CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="pip-20150930.xsd#Disclosure-CommitmentsandContingenciesDetails" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-fvmnd" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-fvmnd" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/Disclosure-BusinessLiquidityandOrganizationDetails" xlink:type="simple" xlink:href="pip-20150930.xsd#Disclosure-BusinessLiquidityandOrganizationDetails" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/Disclosure-CommitmentsandContingenciesLeasesDetails" xlink:type="simple" xlink:href="pip-20150930.xsd#Disclosure-CommitmentsandContingenciesLeasesDetails" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-sosapnd" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-sosapnd" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-ftlawgcd" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-ftlawgcd" />
  <link:definitionLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-sosapsosced">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:title="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:title="us-gaap_IncomeStatementLocationDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:title="Definition : us-gaap_IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="Definition : us-gaap_IncomeStatementLocationDomain to us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1.04" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_1" xlink:title="Definition : us-gaap_IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="Definition : us-gaap_IncomeStatementLocationDomain to us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:title="Definition : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="55" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="100" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="us-gaap_RestructuringChargesMember" xlink:title="us-gaap_RestructuringChargesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_RestructuringChargesMember" xlink:title="Definition : us-gaap_IncomeStatementLocationDomain to us-gaap_RestructuringChargesMember" xlink:type="arc" use="optional" order="12" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-send">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:title="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="Definition : us-gaap_FinancialInstrumentAxis to us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:title="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:title="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightAxis to us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:title="us-gaap_PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:title="us-gaap_PlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:title="Definition : us-gaap_PlanNameAxis to us-gaap_PlanNameDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_StockIncentivePlanTwentyZeroSevenMember" xlink:label="pip_StockIncentivePlanTwentyZeroSevenMember" xlink:title="pip_StockIncentivePlanTwentyZeroSevenMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="pip_StockIncentivePlanTwentyZeroSevenMember" xlink:title="Definition : us-gaap_PlanNameDomain to pip_StockIncentivePlanTwentyZeroSevenMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_StockholdersEquityLineItems" xlink:label="pip_StockholdersEquityLineItems" xlink:title="pip_StockholdersEquityLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="Definition : pip_StockholdersEquityLineItems to us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_StockholdersEquityTable" xlink:label="pip_StockholdersEquityTable" xlink:title="pip_StockholdersEquityTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pip_StockholdersEquityTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:title="Definition : pip_StockholdersEquityTable to us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:title="us-gaap_WarrantMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" xlink:title="Definition : us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to us-gaap_WarrantMember" xlink:type="arc" order="1.03" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_GroupOneMember" xlink:label="pip_GroupOneMember" xlink:title="pip_GroupOneMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pip_GroupOneMember" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightDomain to pip_GroupOneMember" xlink:type="arc" order="1.1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_GroupTwoMember" xlink:label="pip_GroupTwoMember" xlink:title="pip_GroupTwoMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pip_GroupTwoMember" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightDomain to pip_GroupTwoMember" xlink:type="arc" order="1.11" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightAxis to us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_1" xlink:title="Definition : us-gaap_PlanNameAxis to us-gaap_PlanNameDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="Definition : pip_StockholdersEquityLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pip_StockholdersEquityTable" xlink:to="us-gaap_PlanNameAxis" xlink:title="Definition : pip_StockholdersEquityTable to us-gaap_PlanNameAxis" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="Definition : pip_StockholdersEquityLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pip_StockholdersEquityTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:title="Definition : pip_StockholdersEquityTable to us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_StockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="Definition : pip_StockholdersEquityLineItems to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" xlink:label="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" xlink:title="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_StockholdersEquityLineItems" xlink:to="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" xlink:title="Definition : pip_StockholdersEquityLineItems to pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" xlink:label="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" xlink:title="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_StockholdersEquityLineItems" xlink:to="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" xlink:title="Definition : pip_StockholdersEquityLineItems to pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_StockOptionsContractualTerm" xlink:label="pip_StockOptionsContractualTerm" xlink:title="pip_StockOptionsContractualTerm" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_StockholdersEquityLineItems" xlink:to="pip_StockOptionsContractualTerm" xlink:title="Definition : pip_StockholdersEquityLineItems to pip_StockOptionsContractualTerm" xlink:type="arc" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_StockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="Definition : pip_StockholdersEquityLineItems to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan" xlink:label="pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan" xlink:title="pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_StockholdersEquityLineItems" xlink:to="pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan" xlink:title="Definition : pip_StockholdersEquityLineItems to pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan" xlink:type="arc" order="9" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pip_StockholdersEquityLineItems" xlink:to="pip_StockholdersEquityTable" xlink:title="Definition : pip_StockholdersEquityLineItems to pip_StockholdersEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" xbrldt:contextElement="segment" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-ftceod">
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_EquityOfferingLineItems" xlink:label="pip_EquityOfferingLineItems" xlink:title="pip_EquityOfferingLineItems" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_EquityOfferingTable" xlink:label="pip_EquityOfferingTable" xlink:title="pip_EquityOfferingTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pip_EquityOfferingLineItems" xlink:to="pip_EquityOfferingTable" xlink:title="Definition : pip_EquityOfferingLineItems to pip_EquityOfferingTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_EquityOfferingAxis" xlink:label="pip_EquityOfferingAxis" xlink:title="pip_EquityOfferingAxis" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_EquityOfferingDomain" xlink:label="pip_EquityOfferingDomain" xlink:title="pip_EquityOfferingDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="pip_EquityOfferingAxis" xlink:to="pip_EquityOfferingDomain" xlink:title="Definition : pip_EquityOfferingAxis to pip_EquityOfferingDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:title="us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:title="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:title="Definition : us-gaap_SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:title="us-gaap_SubsequentEventMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:title="Definition : us-gaap_SubsequentEventTypeDomain to us-gaap_SubsequentEventMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_EquityOfferingMember" xlink:label="pip_EquityOfferingMember" xlink:title="pip_EquityOfferingMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_EquityOfferingDomain" xlink:to="pip_EquityOfferingMember" xlink:title="Definition : pip_EquityOfferingDomain to pip_EquityOfferingMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pip_EquityOfferingTable" xlink:to="pip_EquityOfferingAxis" xlink:title="Definition : pip_EquityOfferingTable to pip_EquityOfferingAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_EquityOfferingDomain" xlink:label="pip_EquityOfferingDomain_1" xlink:title="pip_EquityOfferingDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="pip_EquityOfferingAxis" xlink:to="pip_EquityOfferingDomain_1" xlink:title="Definition : pip_EquityOfferingAxis to pip_EquityOfferingDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_MaximumValueOfStockIssuableUnderStockOffering" xlink:label="pip_MaximumValueOfStockIssuableUnderStockOffering" xlink:title="pip_MaximumValueOfStockIssuableUnderStockOffering" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_EquityOfferingLineItems" xlink:to="pip_MaximumValueOfStockIssuableUnderStockOffering" xlink:title="Definition : pip_EquityOfferingLineItems to pip_MaximumValueOfStockIssuableUnderStockOffering" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pip_EquityOfferingTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:title="Definition : pip_EquityOfferingTable to us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_FutureValueSettled" xlink:label="pip_FutureValueSettled" xlink:title="pip_FutureValueSettled" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_EquityOfferingLineItems" xlink:to="pip_FutureValueSettled" xlink:title="Definition : pip_EquityOfferingLineItems to pip_FutureValueSettled" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares" xlink:label="pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares" xlink:title="pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_EquityOfferingLineItems" xlink:to="pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares" xlink:title="Definition : pip_EquityOfferingLineItems to pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_PreviousProceedsFromIssuanceOfCommonStockReceived" xlink:label="pip_PreviousProceedsFromIssuanceOfCommonStockReceived" xlink:title="pip_PreviousProceedsFromIssuanceOfCommonStockReceived" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_EquityOfferingLineItems" xlink:to="pip_PreviousProceedsFromIssuanceOfCommonStockReceived" xlink:title="Definition : pip_EquityOfferingLineItems to pip_PreviousProceedsFromIssuanceOfCommonStockReceived" xlink:type="arc" order="4.5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:title="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_EquityOfferingLineItems" xlink:to="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:title="Definition : pip_EquityOfferingLineItems to us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:type="arc" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_EquityOfferingLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Definition : pip_EquityOfferingLineItems to us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_RemainingValueOfStockIssuableUnderStockOffering" xlink:label="pip_RemainingValueOfStockIssuableUnderStockOffering" xlink:title="pip_RemainingValueOfStockIssuableUnderStockOffering" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_EquityOfferingLineItems" xlink:to="pip_RemainingValueOfStockIssuableUnderStockOffering" xlink:title="Definition : pip_EquityOfferingLineItems to pip_RemainingValueOfStockIssuableUnderStockOffering" xlink:type="arc" order="9" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_AmendmentToControlledEquityOfferingMember" xlink:label="pip_AmendmentToControlledEquityOfferingMember" xlink:title="pip_AmendmentToControlledEquityOfferingMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_EquityOfferingDomain" xlink:to="pip_AmendmentToControlledEquityOfferingMember" xlink:title="Definition : pip_EquityOfferingDomain to pip_AmendmentToControlledEquityOfferingMember" xlink:type="arc" order="11" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-fvmsolmafvd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="Definition : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:title="Definition : us-gaap_FairValueByMeasurementFrequencyAxis to us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="Definition : us-gaap_FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:title="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:title="Definition : us-gaap_FairValueMeasurementFrequencyDomain to us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:title="us-gaap_FairValueInputsLevel1Member" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:title="Definition : us-gaap_FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:title="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="us-gaap_DerivativeLiabilitiesCurrent" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="Definition : us-gaap_LiabilitiesFairValueDisclosureAbstract to us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xlink:title="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" xlink:title="us-gaap_InvestmentsFairValueDisclosure" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" xlink:title="Definition : us-gaap_AssetsFairValueDisclosureAbstract to us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:title="Definition : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="Definition : us-gaap_FairValueByMeasurementFrequencyAxis to us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="Definition : us-gaap_FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" xlink:title="Definition : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:title="us-gaap_FairValueInputsLevel2Member" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:title="Definition : us-gaap_FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:title="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:title="Definition : us-gaap_LiabilitiesFairValueDisclosureAbstract to us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeAssets" xlink:label="us-gaap_DerivativeAssets" xlink:title="us-gaap_DerivativeAssets" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeAssets" xlink:title="Definition : us-gaap_AssetsFairValueDisclosureAbstract to us-gaap_DerivativeAssets" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="Definition : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:title="us-gaap_FairValueInputsLevel3Member" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:title="Definition : us-gaap_FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" xlink:title="us-gaap_DerivativeLiabilities" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilities" xlink:title="Definition : us-gaap_LiabilitiesFairValueDisclosureAbstract to us-gaap_DerivativeLiabilities" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:title="Definition : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="3" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-fvmsocifvolld">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:title="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:title="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:title="Definition : us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems to us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="Definition : us-gaap_FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:title="us-gaap_FinancialInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="Definition : us-gaap_FinancialInstrumentAxis to us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:title="us-gaap_FairValueInputsLevel3Member" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:title="Definition : us-gaap_FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1.02" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:title="us-gaap_WarrantMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" xlink:title="Definition : us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to us-gaap_WarrantMember" xlink:type="arc" order="1.03" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" xlink:title="us-gaap_DerivativeLiabilities" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DerivativeLiabilities" xlink:title="Definition : us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems to us-gaap_DerivativeLiabilities" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="Definition : us-gaap_FairValueByBalanceSheetGroupingTable to us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" xlink:title="us-gaap_UnrealizedGainLossOnDerivatives" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" xlink:title="Definition : us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems to us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:title="Definition : us-gaap_FairValueByBalanceSheetGroupingTable to us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:title="Definition : us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_InitialDerivativeFairValue" xlink:label="pip_InitialDerivativeFairValue" xlink:title="pip_InitialDerivativeFairValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="pip_InitialDerivativeFairValue" xlink:title="Definition : us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems to pip_InitialDerivativeFairValue" xlink:type="arc" order="5" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-sesowd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="Definition : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationWarrantsPriceRangeOneMember" xlink:label="pip_ShareBasedCompensationWarrantsPriceRangeOneMember" xlink:title="pip_ShareBasedCompensationWarrantsPriceRangeOneMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pip_ShareBasedCompensationWarrantsPriceRangeOneMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to pip_ShareBasedCompensationWarrantsPriceRangeOneMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationWarrantsPriceRangeTwoMember" xlink:label="pip_ShareBasedCompensationWarrantsPriceRangeTwoMember" xlink:title="pip_ShareBasedCompensationWarrantsPriceRangeTwoMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pip_ShareBasedCompensationWarrantsPriceRangeTwoMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to pip_ShareBasedCompensationWarrantsPriceRangeTwoMember" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationWarrantsPriceRangeThreeMember" xlink:label="pip_ShareBasedCompensationWarrantsPriceRangeThreeMember" xlink:title="pip_ShareBasedCompensationWarrantsPriceRangeThreeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pip_ShareBasedCompensationWarrantsPriceRangeThreeMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to pip_ShareBasedCompensationWarrantsPriceRangeThreeMember" xlink:type="arc" order="4" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationWarrantsPriceRangeFourMember" xlink:label="pip_ShareBasedCompensationWarrantsPriceRangeFourMember" xlink:title="pip_ShareBasedCompensationWarrantsPriceRangeFourMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pip_ShareBasedCompensationWarrantsPriceRangeFourMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to pip_ShareBasedCompensationWarrantsPriceRangeFourMember" xlink:type="arc" order="5" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationWarrantsPriceRangeFiveMember" xlink:label="pip_ShareBasedCompensationWarrantsPriceRangeFiveMember" xlink:title="pip_ShareBasedCompensationWarrantsPriceRangeFiveMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pip_ShareBasedCompensationWarrantsPriceRangeFiveMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to pip_ShareBasedCompensationWarrantsPriceRangeFiveMember" xlink:type="arc" order="6" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationWarrantsPriceRangeSixMember" xlink:label="pip_ShareBasedCompensationWarrantsPriceRangeSixMember" xlink:title="pip_ShareBasedCompensationWarrantsPriceRangeSixMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pip_ShareBasedCompensationWarrantsPriceRangeSixMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to pip_ShareBasedCompensationWarrantsPriceRangeSixMember" xlink:type="arc" order="7" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationWarrantsPriceRangeSevenMember" xlink:label="pip_ShareBasedCompensationWarrantsPriceRangeSevenMember" xlink:title="pip_ShareBasedCompensationWarrantsPriceRangeSevenMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pip_ShareBasedCompensationWarrantsPriceRangeSevenMember" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to pip_ShareBasedCompensationWarrantsPriceRangeSevenMember" xlink:type="arc" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="us-gaap_DerivativeByNatureAxis" xlink:title="us-gaap_DerivativeByNatureAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_DerivativeByNatureAxis" xlink:title="Definition : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to us-gaap_DerivativeByNatureAxis" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="us-gaap_DerivativeNameDomain" xlink:title="us-gaap_DerivativeNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeByNatureAxis" xlink:to="us-gaap_DerivativeNameDomain" xlink:title="Definition : us-gaap_DerivativeByNatureAxis to us-gaap_DerivativeNameDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="us-gaap_DerivativeNameDomain_1" xlink:title="us-gaap_DerivativeNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeByNatureAxis" xlink:to="us-gaap_DerivativeNameDomain_1" xlink:title="Definition : us-gaap_DerivativeByNatureAxis to us-gaap_DerivativeNameDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_DerivativeInstrumentWarrantsMember" xlink:label="pip_DerivativeInstrumentWarrantsMember" xlink:title="pip_DerivativeInstrumentWarrantsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeNameDomain" xlink:to="pip_DerivativeInstrumentWarrantsMember" xlink:title="Definition : us-gaap_DerivativeNameDomain to pip_DerivativeInstrumentWarrantsMember" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Definition : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to us-gaap_AwardTypeAxis" xlink:type="arc" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Definition : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="Definition : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:title="us-gaap_WarrantMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_WarrantMember" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_WarrantMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:title="us-gaap_SubsequentEventTypeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:title="Definition : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:title="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:title="Definition : us-gaap_SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:title="us-gaap_SubsequentEventMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:title="Definition : us-gaap_SubsequentEventTypeDomain to us-gaap_SubsequentEventMember" xlink:type="arc" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_1" xlink:title="Definition : us-gaap_SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ClassOfWarrantOrRightIssuanceDate" xlink:label="pip_ClassOfWarrantOrRightIssuanceDate" xlink:title="pip_ClassOfWarrantOrRightIssuanceDate" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="pip_ClassOfWarrantOrRightIssuanceDate" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to pip_ClassOfWarrantOrRightIssuanceDate" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:title="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="arc" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="6" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_WarrantExpirationDate" xlink:label="pip_WarrantExpirationDate" xlink:title="pip_WarrantExpirationDate" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="pip_WarrantExpirationDate" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to pip_WarrantExpirationDate" xlink:type="arc" order="7" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" xlink:label="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" xlink:title="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" xlink:title="Definition : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" xlink:type="arc" order="8" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/Disclosure-CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_CommitmentsAndContingenciesLineItems" xlink:label="pip_CommitmentsAndContingenciesLineItems" xlink:title="pip_CommitmentsAndContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_CommitmentAndContingenciesTable" xlink:label="pip_CommitmentAndContingenciesTable" xlink:title="pip_CommitmentAndContingenciesTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="pip_CommitmentAndContingenciesTable" xlink:title="Definition : pip_CommitmentsAndContingenciesLineItems to pip_CommitmentAndContingenciesTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:title="us-gaap_StatementBusinessSegmentsAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pip_CommitmentAndContingenciesTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:title="Definition : pip_CommitmentAndContingenciesTable to us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:title="us-gaap_SegmentDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:title="Definition : us-gaap_StatementBusinessSegmentsAxis to us-gaap_SegmentDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_1" xlink:title="us-gaap_SegmentDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain_1" xlink:title="Definition : us-gaap_StatementBusinessSegmentsAxis to us-gaap_SegmentDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_PharmAtheneMember" xlink:label="pip_PharmAtheneMember" xlink:title="pip_PharmAtheneMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentDomain" xlink:to="pip_PharmAtheneMember" xlink:title="Definition : us-gaap_SegmentDomain to pip_PharmAtheneMember" xlink:type="arc" order="1.09" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:title="us-gaap_LossContingenciesByNatureOfContingencyAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pip_CommitmentAndContingenciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:title="Definition : pip_CommitmentAndContingenciesTable to us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain" xlink:title="us-gaap_LossContingencyNatureDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" xlink:title="Definition : us-gaap_LossContingenciesByNatureOfContingencyAxis to us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain_1" xlink:title="us-gaap_LossContingencyNatureDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain_1" xlink:title="Definition : us-gaap_LossContingenciesByNatureOfContingencyAxis to us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_GroupThreeMember" xlink:label="pip_GroupThreeMember" xlink:title="pip_GroupThreeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="pip_GroupThreeMember" xlink:title="Definition : us-gaap_LossContingencyNatureDomain to pip_GroupThreeMember" xlink:type="arc" order="1.12" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_GroupFourMember" xlink:label="pip_GroupFourMember" xlink:title="pip_GroupFourMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="pip_GroupFourMember" xlink:title="Definition : us-gaap_LossContingencyNatureDomain to pip_GroupFourMember" xlink:type="arc" order="1.13" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:title="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pip_CommitmentAndContingenciesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:title="Definition : pip_CommitmentAndContingenciesTable to us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:title="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightAxis to us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightAxis to us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_GroupOneMember" xlink:label="pip_GroupOneMember" xlink:title="pip_GroupOneMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pip_GroupOneMember" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightDomain to pip_GroupOneMember" xlink:type="arc" order="1.11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="us-gaap_RangeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pip_CommitmentAndContingenciesTable" xlink:to="us-gaap_RangeAxis" xlink:title="Definition : pip_CommitmentAndContingenciesTable to us-gaap_RangeAxis" xlink:type="arc" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="us-gaap_RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Definition : us-gaap_RangeAxis to us-gaap_RangeMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_1" xlink:title="us-gaap_RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_1" xlink:title="Definition : us-gaap_RangeAxis to us-gaap_RangeMember" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="us-gaap_MaximumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Definition : us-gaap_RangeMember to us-gaap_MaximumMember" xlink:type="arc" order="1.1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pip_CommitmentAndContingenciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:title="Definition : pip_CommitmentAndContingenciesTable to us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="56.5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:title="Definition : us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis to us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_UpfrontPaymentMember" xlink:label="pip_UpfrontPaymentMember" xlink:title="pip_UpfrontPaymentMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pip_UpfrontPaymentMember" xlink:title="Definition : us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain to pip_UpfrontPaymentMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_MilestonePaymentsMember" xlink:label="pip_MilestonePaymentsMember" xlink:title="pip_MilestonePaymentsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pip_MilestonePaymentsMember" xlink:title="Definition : us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain to pip_MilestonePaymentsMember" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_StudiesOrTrailsMember" xlink:label="pip_StudiesOrTrailsMember" xlink:title="pip_StudiesOrTrailsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pip_StudiesOrTrailsMember" xlink:title="Definition : us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain to pip_StudiesOrTrailsMember" xlink:type="arc" order="3" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_BiologicLicenseApplicationApprovalMember" xlink:label="pip_BiologicLicenseApplicationApprovalMember" xlink:title="pip_BiologicLicenseApplicationApprovalMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pip_BiologicLicenseApplicationApprovalMember" xlink:title="Definition : us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain to pip_BiologicLicenseApplicationApprovalMember" xlink:type="arc" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="Definition : us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis to us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:title="dei_LegalEntityAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pip_CommitmentAndContingenciesTable" xlink:to="dei_LegalEntityAxis" xlink:title="Definition : pip_CommitmentAndContingenciesTable to dei_LegalEntityAxis" xlink:type="arc" order="66" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:title="dei_EntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:title="Definition : dei_LegalEntityAxis to dei_EntityDomain" xlink:type="arc" order="10" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:label="pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:title="pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:title="Definition : dei_EntityDomain to pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:type="arc" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_1" xlink:title="Definition : dei_LegalEntityAxis to dei_EntityDomain" xlink:type="arc" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:title="us-gaap_SubsequentEventTypeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pip_CommitmentAndContingenciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:title="Definition : pip_CommitmentAndContingenciesTable to us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="76" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:title="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:title="Definition : us-gaap_SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:title="us-gaap_SubsequentEventMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:title="Definition : us-gaap_SubsequentEventTypeDomain to us-gaap_SubsequentEventMember" xlink:type="arc" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_1" xlink:title="Definition : us-gaap_SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="20" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_PercentageOfNetProfitAwarded" xlink:label="pip_PercentageOfNetProfitAwarded" xlink:title="pip_PercentageOfNetProfitAwarded" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="pip_PercentageOfNetProfitAwarded" xlink:title="Definition : pip_CommitmentsAndContingenciesLineItems to pip_PercentageOfNetProfitAwarded" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_BreachOfContractualCommitmentAwardPeriod" xlink:label="pip_BreachOfContractualCommitmentAwardPeriod" xlink:title="pip_BreachOfContractualCommitmentAwardPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="pip_BreachOfContractualCommitmentAwardPeriod" xlink:title="Definition : pip_CommitmentsAndContingenciesLineItems to pip_BreachOfContractualCommitmentAwardPeriod" xlink:type="arc" order="3" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract" xlink:label="pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract" xlink:title="pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract" xlink:title="Definition : pip_CommitmentsAndContingenciesLineItems to pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract" xlink:type="arc" order="4" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_CourtAwardedFees" xlink:label="pip_CourtAwardedFees" xlink:title="pip_CourtAwardedFees" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="pip_CourtAwardedFees" xlink:title="Definition : pip_CommitmentsAndContingenciesLineItems to pip_CourtAwardedFees" xlink:type="arc" order="5" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_WarrantExpirationDate" xlink:label="pip_WarrantExpirationDate" xlink:title="pip_WarrantExpirationDate" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="pip_WarrantExpirationDate" xlink:title="Definition : pip_CommitmentsAndContingenciesLineItems to pip_WarrantExpirationDate" xlink:type="arc" order="6" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_PercentageOfAggregatePrincipalAmountRedemption" xlink:label="pip_PercentageOfAggregatePrincipalAmountRedemption" xlink:title="pip_PercentageOfAggregatePrincipalAmountRedemption" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="pip_PercentageOfAggregatePrincipalAmountRedemption" xlink:title="Definition : pip_CommitmentsAndContingenciesLineItems to pip_PercentageOfAggregatePrincipalAmountRedemption" xlink:type="arc" order="7" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:title="us-gaap_LossContingencyEstimateOfPossibleLoss" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:title="Definition : pip_CommitmentsAndContingenciesLineItems to us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="us-gaap_LossContingencyDamagesAwardedValue" xlink:title="us-gaap_LossContingencyDamagesAwardedValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LossContingencyDamagesAwardedValue" xlink:title="Definition : pip_CommitmentsAndContingenciesLineItems to us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="9" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_NotesPayableAggregatePrincipalRepaymentAmount" xlink:label="pip_NotesPayableAggregatePrincipalRepaymentAmount" xlink:title="pip_NotesPayableAggregatePrincipalRepaymentAmount" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="pip_NotesPayableAggregatePrincipalRepaymentAmount" xlink:title="Definition : pip_CommitmentsAndContingenciesLineItems to pip_NotesPayableAggregatePrincipalRepaymentAmount" xlink:type="arc" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense" xlink:title="us-gaap_LitigationSettlementExpense" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LitigationSettlementExpense" xlink:title="Definition : pip_CommitmentsAndContingenciesLineItems to us-gaap_LitigationSettlementExpense" xlink:type="arc" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseCosts" xlink:label="us-gaap_LicenseCosts" xlink:title="us-gaap_LicenseCosts" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LicenseCosts" xlink:title="Definition : pip_CommitmentsAndContingenciesLineItems to us-gaap_LicenseCosts" xlink:type="arc" order="12" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_SublicenseFeePercent" xlink:label="pip_SublicenseFeePercent" xlink:title="pip_SublicenseFeePercent" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="pip_SublicenseFeePercent" xlink:title="Definition : pip_CommitmentsAndContingenciesLineItems to pip_SublicenseFeePercent" xlink:type="arc" order="13" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaintenanceCosts" xlink:label="us-gaap_MaintenanceCosts" xlink:title="us-gaap_MaintenanceCosts" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_MaintenanceCosts" xlink:title="Definition : pip_CommitmentsAndContingenciesLineItems to us-gaap_MaintenanceCosts" xlink:type="arc" order="14" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_LitigationSettlementInterestPercentage" xlink:label="pip_LitigationSettlementInterestPercentage" xlink:title="pip_LitigationSettlementInterestPercentage" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="pip_LitigationSettlementInterestPercentage" xlink:title="Definition : pip_CommitmentsAndContingenciesLineItems to pip_LitigationSettlementInterestPercentage" xlink:type="arc" order="15" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_RevenueRecognizedFromContractAudit" xlink:label="pip_RevenueRecognizedFromContractAudit" xlink:title="pip_RevenueRecognizedFromContractAudit" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="pip_RevenueRecognizedFromContractAudit" xlink:title="Definition : pip_CommitmentsAndContingenciesLineItems to pip_RevenueRecognizedFromContractAudit" xlink:type="arc" order="16" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_AnnualLicensePayment" xlink:label="pip_AnnualLicensePayment" xlink:title="pip_AnnualLicensePayment" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="pip_AnnualLicensePayment" xlink:title="Definition : pip_CommitmentsAndContingenciesLineItems to pip_AnnualLicensePayment" xlink:type="arc" order="17" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_MaximumAmountOfReimbursement" xlink:label="pip_MaximumAmountOfReimbursement" xlink:title="pip_MaximumAmountOfReimbursement" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="pip_MaximumAmountOfReimbursement" xlink:title="Definition : pip_CommitmentsAndContingenciesLineItems to pip_MaximumAmountOfReimbursement" xlink:type="arc" order="18" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-fvmnd">
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_FairValueMeasurementsLineItems" xlink:label="pip_FairValueMeasurementsLineItems" xlink:title="pip_FairValueMeasurementsLineItems" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_FairValueMeasurementsTable" xlink:label="pip_FairValueMeasurementsTable" xlink:title="pip_FairValueMeasurementsTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pip_FairValueMeasurementsLineItems" xlink:to="pip_FairValueMeasurementsTable" xlink:title="Definition : pip_FairValueMeasurementsLineItems to pip_FairValueMeasurementsTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pip_FairValueMeasurementsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="Definition : pip_FairValueMeasurementsTable to us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="Definition : us-gaap_FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="Definition : us-gaap_FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:title="us-gaap_FairValueInputsLevel3Member" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:title="Definition : us-gaap_FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1.06" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:title="us-gaap_FinancialInstrumentAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pip_FairValueMeasurementsTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:title="Definition : pip_FairValueMeasurementsTable to us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="Definition : us-gaap_FinancialInstrumentAxis to us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="Definition : us-gaap_FinancialInstrumentAxis to us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:title="us-gaap_WarrantMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" xlink:title="Definition : us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to us-gaap_WarrantMember" xlink:type="arc" order="1.05" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:title="us-gaap_FairValueByLiabilityClassAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pip_FairValueMeasurementsTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" xlink:title="Definition : pip_FairValueMeasurementsTable to us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="Definition : us-gaap_FairValueByLiabilityClassAxis to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" xlink:title="Definition : us-gaap_FairValueByLiabilityClassAxis to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_DerivativeLiabilitiesMember" xlink:label="pip_DerivativeLiabilitiesMember" xlink:title="pip_DerivativeLiabilitiesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="pip_DerivativeLiabilitiesMember" xlink:title="Definition : us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain to pip_DerivativeLiabilitiesMember" xlink:type="arc" order="1.04" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:title="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_FairValueMeasurementsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:title="Definition : pip_FairValueMeasurementsLineItems to us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" xlink:label="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" xlink:title="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_FairValueMeasurementsLineItems" xlink:to="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" xlink:title="Definition : pip_FairValueMeasurementsLineItems to pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" xlink:type="arc" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" xlink:title="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_FairValueMeasurementsLineItems" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" xlink:title="Definition : pip_FairValueMeasurementsLineItems to us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" xlink:type="arc" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_FairValueMeasurementsLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="Definition : pip_FairValueMeasurementsLineItems to us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="5" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/Disclosure-BusinessLiquidityandOrganizationDetails">
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:title="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:title="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:title="Definition : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" xlink:title="us-gaap_MajorCustomersAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_MajorCustomersAxis" xlink:title="Definition : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable to us-gaap_MajorCustomersAxis" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain" xlink:title="us-gaap_NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" xlink:title="Definition : us-gaap_MajorCustomersAxis to us-gaap_NameOfMajorCustomerDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:title="pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:title="Definition : us-gaap_NameOfMajorCustomerDomain to pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:label="pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:title="pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:title="Definition : us-gaap_NameOfMajorCustomerDomain to pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain_1" xlink:title="us-gaap_NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain_1" xlink:title="Definition : us-gaap_MajorCustomersAxis to us-gaap_NameOfMajorCustomerDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="us-gaap_RangeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_RangeAxis" xlink:title="Definition : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable to us-gaap_RangeAxis" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="us-gaap_RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Definition : us-gaap_RangeAxis to us-gaap_RangeMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="us-gaap_MaximumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Definition : us-gaap_RangeMember to us-gaap_MaximumMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:title="us-gaap_LongtermDebtTypeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:title="Definition : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable to us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="12" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:title="us-gaap_LongtermDebtTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:title="Definition : us-gaap_LongtermDebtTypeAxis to us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" xlink:title="us-gaap_LineOfCreditMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LineOfCreditMember" xlink:title="Definition : us-gaap_LongtermDebtTypeDomain to us-gaap_LineOfCreditMember" xlink:type="arc" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_1" xlink:title="Definition : us-gaap_LongtermDebtTypeAxis to us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="20" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ProceedsFromInitialFunding" xlink:label="pip_ProceedsFromInitialFunding" xlink:title="pip_ProceedsFromInitialFunding" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pip_ProceedsFromInitialFunding" xlink:title="Definition : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to pip_ProceedsFromInitialFunding" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ValueOfAgreement" xlink:label="pip_ValueOfAgreement" xlink:title="pip_ValueOfAgreement" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pip_ValueOfAgreement" xlink:title="Definition : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to pip_ValueOfAgreement" xlink:type="arc" order="3" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_NumberOfOptionsExercised" xlink:label="pip_NumberOfOptionsExercised" xlink:title="pip_NumberOfOptionsExercised" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pip_NumberOfOptionsExercised" xlink:title="Definition : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to pip_NumberOfOptionsExercised" xlink:type="arc" order="4" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption" xlink:label="pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption" xlink:title="pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption" xlink:title="Definition : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption" xlink:type="arc" order="5" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_AnnualLicensePayment" xlink:label="pip_AnnualLicensePayment" xlink:title="pip_AnnualLicensePayment" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pip_AnnualLicensePayment" xlink:title="Definition : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to pip_AnnualLicensePayment" xlink:type="arc" order="6" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ProceedsFromAdditionalFunding" xlink:label="pip_ProceedsFromAdditionalFunding" xlink:title="pip_ProceedsFromAdditionalFunding" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pip_ProceedsFromAdditionalFunding" xlink:title="Definition : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to pip_ProceedsFromAdditionalFunding" xlink:type="arc" order="7" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_MaximumAmountOfReimbursement" xlink:label="pip_MaximumAmountOfReimbursement" xlink:title="pip_MaximumAmountOfReimbursement" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pip_MaximumAmountOfReimbursement" xlink:title="Definition : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to pip_MaximumAmountOfReimbursement" xlink:type="arc" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" xlink:title="us-gaap_LegalFees" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_LegalFees" xlink:title="Definition : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to us-gaap_LegalFees" xlink:type="arc" order="9" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" xlink:title="us-gaap_InterestPaid" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_InterestPaid" xlink:title="Definition : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to us-gaap_InterestPaid" xlink:type="arc" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LoanProcessingFee" xlink:label="us-gaap_LoanProcessingFee" xlink:title="us-gaap_LoanProcessingFee" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_LoanProcessingFee" xlink:title="Definition : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to us-gaap_LoanProcessingFee" xlink:type="arc" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:title="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:title="Definition : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:type="arc" order="12" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" xlink:title="us-gaap_ShortTermBorrowings" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ShortTermBorrowings" xlink:title="Definition : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to us-gaap_ShortTermBorrowings" xlink:type="arc" order="14" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/Disclosure-CommitmentsandContingenciesLeasesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" xlink:title="us-gaap_RestructuringCostAndReserveLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" xlink:title="us-gaap_RestructuringCharges" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" xlink:title="Definition : us-gaap_RestructuringCostAndReserveLineItems to us-gaap_RestructuringCharges" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:title="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:title="Definition : us-gaap_RestructuringCostAndReserveLineItems to us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:title="us-gaap_RestructuringCostAndReserveAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" xlink:title="Definition : us-gaap_ScheduleOfRestructuringAndRelatedCostsTable to us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:title="us-gaap_TypeOfRestructuringDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" xlink:title="Definition : us-gaap_RestructuringCostAndReserveAxis to us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FacilityClosingMember" xlink:label="us-gaap_FacilityClosingMember" xlink:title="us-gaap_FacilityClosingMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_FacilityClosingMember" xlink:title="Definition : us-gaap_TypeOfRestructuringDomain to us-gaap_FacilityClosingMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_1" xlink:title="us-gaap_TypeOfRestructuringDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_1" xlink:title="Definition : us-gaap_RestructuringCostAndReserveAxis to us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="2" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-sosapnd">
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_SignificantAccountingPoliciesLineItems" xlink:label="pip_SignificantAccountingPoliciesLineItems" xlink:title="pip_SignificantAccountingPoliciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_SignificantAccountingPoliciesTable" xlink:label="pip_SignificantAccountingPoliciesTable" xlink:title="pip_SignificantAccountingPoliciesTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="pip_SignificantAccountingPoliciesLineItems" xlink:to="pip_SignificantAccountingPoliciesTable" xlink:title="Definition : pip_SignificantAccountingPoliciesLineItems to pip_SignificantAccountingPoliciesTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:title="us-gaap_LongtermDebtTypeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pip_SignificantAccountingPoliciesTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:title="Definition : pip_SignificantAccountingPoliciesTable to us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:title="us-gaap_LongtermDebtTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:title="Definition : us-gaap_LongtermDebtTypeAxis to us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" xlink:title="us-gaap_LineOfCreditMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LineOfCreditMember" xlink:title="Definition : us-gaap_LongtermDebtTypeDomain to us-gaap_LineOfCreditMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_1" xlink:title="Definition : us-gaap_LongtermDebtTypeAxis to us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="us-gaap_RangeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pip_SignificantAccountingPoliciesTable" xlink:to="us-gaap_RangeAxis" xlink:title="Definition : pip_SignificantAccountingPoliciesTable to us-gaap_RangeAxis" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="us-gaap_RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Definition : us-gaap_RangeAxis to us-gaap_RangeMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="us-gaap_MaximumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Definition : us-gaap_RangeMember to us-gaap_MaximumMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember_1" xlink:title="us-gaap_RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_1" xlink:title="Definition : us-gaap_RangeAxis to us-gaap_RangeMember" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:title="us-gaap_CashAndCashEquivalentsAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pip_SignificantAccountingPoliciesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" xlink:title="Definition : pip_SignificantAccountingPoliciesTable to us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="Definition : us-gaap_CashAndCashEquivalentsAxis to us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_LiquidityArrangementsMember" xlink:label="pip_LiquidityArrangementsMember" xlink:title="pip_LiquidityArrangementsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="pip_LiquidityArrangementsMember" xlink:title="Definition : us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember to pip_LiquidityArrangementsMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="Definition : us-gaap_CashAndCashEquivalentsAxis to us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" xlink:title="us-gaap_MajorCustomersAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pip_SignificantAccountingPoliciesTable" xlink:to="us-gaap_MajorCustomersAxis" xlink:title="Definition : pip_SignificantAccountingPoliciesTable to us-gaap_MajorCustomersAxis" xlink:type="arc" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain" xlink:title="us-gaap_NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" xlink:title="Definition : us-gaap_MajorCustomersAxis to us-gaap_NameOfMajorCustomerDomain" xlink:type="arc" order="10" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_GovernmentContractMember" xlink:label="pip_GovernmentContractMember" xlink:title="pip_GovernmentContractMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="pip_GovernmentContractMember" xlink:title="Definition : us-gaap_NameOfMajorCustomerDomain to pip_GovernmentContractMember" xlink:type="arc" order="10" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain_1" xlink:title="us-gaap_NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain_1" xlink:title="Definition : us-gaap_MajorCustomersAxis to us-gaap_NameOfMajorCustomerDomain" xlink:type="arc" order="20" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:title="us-gaap_RestructuringCostAndReserveAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="pip_SignificantAccountingPoliciesTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" xlink:title="Definition : pip_SignificantAccountingPoliciesTable to us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:title="us-gaap_TypeOfRestructuringDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" xlink:title="Definition : us-gaap_RestructuringCostAndReserveAxis to us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" xlink:title="us-gaap_EmployeeSeveranceMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" xlink:title="Definition : us-gaap_TypeOfRestructuringDomain to us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FacilityClosingMember" xlink:label="us-gaap_FacilityClosingMember" xlink:title="us-gaap_FacilityClosingMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_FacilityClosingMember" xlink:title="Definition : us-gaap_TypeOfRestructuringDomain to us-gaap_FacilityClosingMember" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain_1" xlink:title="us-gaap_TypeOfRestructuringDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain_1" xlink:title="Definition : us-gaap_RestructuringCostAndReserveAxis to us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_CashEquivalentsMaturityPeriod" xlink:label="pip_CashEquivalentsMaturityPeriod" xlink:title="pip_CashEquivalentsMaturityPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_SignificantAccountingPoliciesLineItems" xlink:to="pip_CashEquivalentsMaturityPeriod" xlink:title="Definition : pip_SignificantAccountingPoliciesLineItems to pip_CashEquivalentsMaturityPeriod" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" xlink:title="us-gaap_RestructuringCharges" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestructuringCharges" xlink:title="Definition : pip_SignificantAccountingPoliciesLineItems to us-gaap_RestructuringCharges" xlink:type="arc" order="3" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_RevenueRecognizedFromContractAudit" xlink:label="pip_RevenueRecognizedFromContractAudit" xlink:title="pip_RevenueRecognizedFromContractAudit" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="pip_SignificantAccountingPoliciesLineItems" xlink:to="pip_RevenueRecognizedFromContractAudit" xlink:title="Definition : pip_SignificantAccountingPoliciesLineItems to pip_RevenueRecognizedFromContractAudit" xlink:type="arc" order="4" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-ftlawgcd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:title="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xlink:title="us-gaap_DebtInstrumentTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentTable" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:title="us-gaap_LongtermDebtTypeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:title="Definition : us-gaap_DebtInstrumentTable to us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:title="us-gaap_LongtermDebtTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:title="Definition : us-gaap_LongtermDebtTypeAxis to us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" xlink:title="us-gaap_LineOfCreditMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LineOfCreditMember" xlink:title="Definition : us-gaap_LongtermDebtTypeDomain to us-gaap_LineOfCreditMember" xlink:type="arc" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember" xlink:title="us-gaap_LoansPayableMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LoansPayableMember" xlink:title="Definition : us-gaap_LongtermDebtTypeDomain to us-gaap_LoansPayableMember" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:title="us-gaap_DebtInstrumentCarryingAmount" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentIssuanceDate1" xlink:label="us-gaap_DebtInstrumentIssuanceDate1" xlink:title="us-gaap_DebtInstrumentIssuanceDate1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIssuanceDate1" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentIssuanceDate1" xlink:type="arc" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:title="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:type="arc" order="5" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms" xlink:title="us-gaap_DebtInstrumentPaymentTerms" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPaymentTerms" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentPaymentTerms" xlink:type="arc" order="6" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_DebtInstrumentsMaturityDateMonthAndYear" xlink:label="pip_DebtInstrumentsMaturityDateMonthAndYear" xlink:title="pip_DebtInstrumentsMaturityDateMonthAndYear" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pip_DebtInstrumentsMaturityDateMonthAndYear" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to pip_DebtInstrumentsMaturityDateMonthAndYear" xlink:type="arc" order="8" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" xlink:label="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" xlink:title="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" xlink:type="arc" order="9" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable" xlink:label="pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable" xlink:title="pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable" xlink:type="arc" order="10" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl" xlink:label="pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl" xlink:title="pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl" xlink:type="arc" order="11" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="12" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage" xlink:label="pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage" xlink:title="pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage" xlink:type="arc" order="13" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="14" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_DebtInstrumentInterestRateFloorPercentage" xlink:label="pip_DebtInstrumentInterestRateFloorPercentage" xlink:title="pip_DebtInstrumentInterestRateFloorPercentage" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pip_DebtInstrumentInterestRateFloorPercentage" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to pip_DebtInstrumentInterestRateFloorPercentage" xlink:type="arc" order="15" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:title="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="16" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:title="us-gaap_DebtInstrumentMaturityDate" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentMaturityDate" xlink:type="arc" order="17" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal" xlink:label="pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal" xlink:title="pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal" xlink:type="arc" order="18" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo" xlink:label="pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo" xlink:title="pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo" xlink:type="arc" order="19" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement" xlink:label="pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement" xlink:title="pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement" xlink:type="arc" order="20" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_FinalPaymentFeeOfTermLoanBalancePercent" xlink:label="pip_FinalPaymentFeeOfTermLoanBalancePercent" xlink:title="pip_FinalPaymentFeeOfTermLoanBalancePercent" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pip_FinalPaymentFeeOfTermLoanBalancePercent" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to pip_FinalPaymentFeeOfTermLoanBalancePercent" xlink:type="arc" order="21" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="22" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants" xlink:label="pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants" xlink:title="pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants" xlink:type="arc" order="23" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="24" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="25" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:title="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="26" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:title="us-gaap_InducedConversionOfConvertibleDebtExpense" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:type="arc" order="27" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:title="us-gaap_ConvertibleLongTermNotesPayable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc" order="28" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:title="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="29" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:title="us-gaap_InterestExpenseDebt" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to us-gaap_InterestExpenseDebt" xlink:type="arc" order="30" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>pip-20150930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by The Vintage Group, Powered by IRIS Carbon-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="pip_AccruedExpensesAndOtherCurrentLiabilities" xlink:title="pip_AccruedExpensesAndOtherCurrentLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_pip_AccruedExpensesAndOtherCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_AccruedExpensesAndOtherCurrentLiabilities" xml:lang="en-US" id="label_pip_AccruedExpensesAndOtherCurrentLiabilities">Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Also includes the aggregate carrying amount, as of the balance sheet date, of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed in the balance sheet. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="label_pip_AccruedExpensesAndOtherCurrentLiabilities" xlink:title="Label : pip_AccruedExpensesAndOtherCurrentLiabilities to label_pip_AccruedExpensesAndOtherCurrentLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_pip_AccruedExpensesAndOtherCurrentLiabilities_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_AccruedExpensesAndOtherCurrentLiabilities_1" xml:lang="en-US" id="label_pip_AccruedExpensesAndOtherCurrentLiabilities_1">Accrued Expenses And Other Current Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="label_pip_AccruedExpensesAndOtherCurrentLiabilities_1" xlink:title="Label : pip_AccruedExpensesAndOtherCurrentLiabilities to label_pip_AccruedExpensesAndOtherCurrentLiabilities_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_AccruedExpensesAndOtherCurrentLiabilities_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_AccruedExpensesAndOtherCurrentLiabilities_2" xml:lang="en-US" id="label_pip_AccruedExpensesAndOtherCurrentLiabilities_2">Accrued expenses and other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_AccruedExpensesAndOtherCurrentLiabilities" xlink:to="label_pip_AccruedExpensesAndOtherCurrentLiabilities_2" xlink:title="Label : pip_AccruedExpensesAndOtherCurrentLiabilities to label_pip_AccruedExpensesAndOtherCurrentLiabilities_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_AdditionalCommonStockAggregateGrossSales" xlink:label="pip_AdditionalCommonStockAggregateGrossSales" xlink:title="pip_AdditionalCommonStockAggregateGrossSales" />
    <link:label xlink:type="resource" xlink:label="label_pip_AdditionalCommonStockAggregateGrossSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_AdditionalCommonStockAggregateGrossSales" xml:lang="en-US" id="label_pip_AdditionalCommonStockAggregateGrossSales">Additional Common Stock Aggregate Gross Sales available under the controlled equity offering arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_AdditionalCommonStockAggregateGrossSales" xlink:to="label_pip_AdditionalCommonStockAggregateGrossSales" xlink:title="Label : pip_AdditionalCommonStockAggregateGrossSales to label_pip_AdditionalCommonStockAggregateGrossSales" />
    <link:label xlink:type="resource" xlink:label="label_pip_AdditionalCommonStockAggregateGrossSales_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_AdditionalCommonStockAggregateGrossSales_1" xml:lang="en-US" id="label_pip_AdditionalCommonStockAggregateGrossSales_1">Additional Common Stock Aggregate Gross Sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_AdditionalCommonStockAggregateGrossSales" xlink:to="label_pip_AdditionalCommonStockAggregateGrossSales_1" xlink:title="Label : pip_AdditionalCommonStockAggregateGrossSales to label_pip_AdditionalCommonStockAggregateGrossSales_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_AdditionalCommonStockAggregateGrossSales_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_AdditionalCommonStockAggregateGrossSales_2" xml:lang="en-US" id="label_pip_AdditionalCommonStockAggregateGrossSales_2">Additional Common Stock Aggregate Gross Sales available under the controlled equity offering arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_AdditionalCommonStockAggregateGrossSales" xlink:to="label_pip_AdditionalCommonStockAggregateGrossSales_2" xlink:title="Label : pip_AdditionalCommonStockAggregateGrossSales to label_pip_AdditionalCommonStockAggregateGrossSales_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage" xlink:label="pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage" xlink:title="pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage" />
    <link:label xlink:type="resource" xlink:label="label_pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage" xml:lang="en-US" id="label_pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage">Adjustable interest rate reference rate, based up 3-month London Interbank Offered Rate (LIBOR), with a floor of 1.5%.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage" xlink:to="label_pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage" xlink:title="Label : pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage to label_pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage" />
    <link:label xlink:type="resource" xlink:label="label_pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage_1" xml:lang="en-US" id="label_pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage_1">Adjustable Debt Instrument Reference Interest Rate Floor Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage" xlink:to="label_pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage_1" xlink:title="Label : pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage to label_pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage_2" xml:lang="en-US" id="label_pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage_2">Adjustable interest rate, reference rate, floor percentage 1.5%</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage" xlink:to="label_pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage_2" xlink:title="Label : pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage to label_pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_AmendmentToControlledEquityOfferingMember" xlink:label="pip_AmendmentToControlledEquityOfferingMember" xlink:title="pip_AmendmentToControlledEquityOfferingMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_AmendmentToControlledEquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_AmendmentToControlledEquityOfferingMember" xml:lang="en-US" id="label_pip_AmendmentToControlledEquityOfferingMember">Amendment to the Controlled Equity Offering [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_AmendmentToControlledEquityOfferingMember" xlink:to="label_pip_AmendmentToControlledEquityOfferingMember" xlink:title="Label : pip_AmendmentToControlledEquityOfferingMember to label_pip_AmendmentToControlledEquityOfferingMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_AmendmentToControlledEquityOfferingMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_AmendmentToControlledEquityOfferingMember_1" xml:lang="en-US" id="label_pip_AmendmentToControlledEquityOfferingMember_1">Amendment to the Controlled Equity Offering [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_AmendmentToControlledEquityOfferingMember" xlink:to="label_pip_AmendmentToControlledEquityOfferingMember_1" xlink:title="Label : pip_AmendmentToControlledEquityOfferingMember to label_pip_AmendmentToControlledEquityOfferingMember_1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_BilledAndUnbilledAccountsReceivableNet" xlink:label="pip_BilledAndUnbilledAccountsReceivableNet" xlink:title="pip_BilledAndUnbilledAccountsReceivableNet" />
    <link:label xlink:type="resource" xlink:label="label_pip_BilledAndUnbilledAccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_BilledAndUnbilledAccountsReceivableNet" xml:lang="en-US" id="label_pip_BilledAndUnbilledAccountsReceivableNet">Accounts receivable, billed and unbilled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_BilledAndUnbilledAccountsReceivableNet" xlink:to="label_pip_BilledAndUnbilledAccountsReceivableNet" xlink:title="Label : pip_BilledAndUnbilledAccountsReceivableNet to label_pip_BilledAndUnbilledAccountsReceivableNet" />
    <link:label xlink:type="resource" xlink:label="label_pip_BilledAndUnbilledAccountsReceivableNet_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_BilledAndUnbilledAccountsReceivableNet_1" xml:lang="en-US" id="label_pip_BilledAndUnbilledAccountsReceivableNet_1">Billed And Unbilled Accounts Receivable Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_BilledAndUnbilledAccountsReceivableNet" xlink:to="label_pip_BilledAndUnbilledAccountsReceivableNet_1" xlink:title="Label : pip_BilledAndUnbilledAccountsReceivableNet to label_pip_BilledAndUnbilledAccountsReceivableNet_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_BilledAndUnbilledAccountsReceivableNet_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_BilledAndUnbilledAccountsReceivableNet_2" xml:lang="en-US" id="label_pip_BilledAndUnbilledAccountsReceivableNet_2">Accounts receivable (billed and unbilled)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_BilledAndUnbilledAccountsReceivableNet" xlink:to="label_pip_BilledAndUnbilledAccountsReceivableNet_2" xlink:title="Label : pip_BilledAndUnbilledAccountsReceivableNet to label_pip_BilledAndUnbilledAccountsReceivableNet_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_BreachOfContractualCommitmentAwardPeriod" xlink:label="pip_BreachOfContractualCommitmentAwardPeriod" xlink:title="pip_BreachOfContractualCommitmentAwardPeriod" />
    <link:label xlink:type="resource" xlink:label="label_pip_BreachOfContractualCommitmentAwardPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_BreachOfContractualCommitmentAwardPeriod" xml:lang="en-US" id="label_pip_BreachOfContractualCommitmentAwardPeriod">Breach of contractual commitment award period - number of years following initial commercial sale of ArestvyrTM.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_BreachOfContractualCommitmentAwardPeriod" xlink:to="label_pip_BreachOfContractualCommitmentAwardPeriod" xlink:title="Label : pip_BreachOfContractualCommitmentAwardPeriod to label_pip_BreachOfContractualCommitmentAwardPeriod" />
    <link:label xlink:type="resource" xlink:label="label_pip_BreachOfContractualCommitmentAwardPeriod_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_BreachOfContractualCommitmentAwardPeriod_1" xml:lang="en-US" id="label_pip_BreachOfContractualCommitmentAwardPeriod_1">Breach Of Contractual Commitment Award Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_BreachOfContractualCommitmentAwardPeriod" xlink:to="label_pip_BreachOfContractualCommitmentAwardPeriod_1" xlink:title="Label : pip_BreachOfContractualCommitmentAwardPeriod to label_pip_BreachOfContractualCommitmentAwardPeriod_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_BreachOfContractualCommitmentAwardPeriod_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_BreachOfContractualCommitmentAwardPeriod_2" xml:lang="en-US" id="label_pip_BreachOfContractualCommitmentAwardPeriod_2">SIGA breach of contractual obligation award period following initial commercial sale</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_BreachOfContractualCommitmentAwardPeriod" xlink:to="label_pip_BreachOfContractualCommitmentAwardPeriod_2" xlink:title="Label : pip_BreachOfContractualCommitmentAwardPeriod to label_pip_BreachOfContractualCommitmentAwardPeriod_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_CashEquivalentsMaturityPeriod" xlink:label="pip_CashEquivalentsMaturityPeriod" xlink:title="pip_CashEquivalentsMaturityPeriod" />
    <link:label xlink:type="resource" xlink:label="label_pip_CashEquivalentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_CashEquivalentsMaturityPeriod" xml:lang="en-US" id="label_pip_CashEquivalentsMaturityPeriod">Cash Equivalents, Maturity Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_CashEquivalentsMaturityPeriod" xlink:to="label_pip_CashEquivalentsMaturityPeriod" xlink:title="Label : pip_CashEquivalentsMaturityPeriod to label_pip_CashEquivalentsMaturityPeriod" />
    <link:label xlink:type="resource" xlink:label="label_pip_CashEquivalentsMaturityPeriod_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_CashEquivalentsMaturityPeriod_1" xml:lang="en-US" id="label_pip_CashEquivalentsMaturityPeriod_1">Cash Equivalents Maturity Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_CashEquivalentsMaturityPeriod" xlink:to="label_pip_CashEquivalentsMaturityPeriod_1" xlink:title="Label : pip_CashEquivalentsMaturityPeriod to label_pip_CashEquivalentsMaturityPeriod_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_CashEquivalentsMaturityPeriod_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_CashEquivalentsMaturityPeriod_2" xml:lang="en-US" id="label_pip_CashEquivalentsMaturityPeriod_2">Cash liquidity maturity period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_CashEquivalentsMaturityPeriod" xlink:to="label_pip_CashEquivalentsMaturityPeriod_2" xlink:title="Label : pip_CashEquivalentsMaturityPeriod to label_pip_CashEquivalentsMaturityPeriod_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ClassOfWarrantOrRightIssuanceDate" xlink:label="pip_ClassOfWarrantOrRightIssuanceDate" xlink:title="pip_ClassOfWarrantOrRightIssuanceDate" />
    <link:label xlink:type="resource" xlink:label="label_pip_ClassOfWarrantOrRightIssuanceDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_ClassOfWarrantOrRightIssuanceDate" xml:lang="en-US" id="label_pip_ClassOfWarrantOrRightIssuanceDate">Class Of Warrant Or Right, Issuance Date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ClassOfWarrantOrRightIssuanceDate" xlink:to="label_pip_ClassOfWarrantOrRightIssuanceDate" xlink:title="Label : pip_ClassOfWarrantOrRightIssuanceDate to label_pip_ClassOfWarrantOrRightIssuanceDate" />
    <link:label xlink:type="resource" xlink:label="label_pip_ClassOfWarrantOrRightIssuanceDate_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_ClassOfWarrantOrRightIssuanceDate_1" xml:lang="en-US" id="label_pip_ClassOfWarrantOrRightIssuanceDate_1">Class Of Warrant Or Right Issuance Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ClassOfWarrantOrRightIssuanceDate" xlink:to="label_pip_ClassOfWarrantOrRightIssuanceDate_1" xlink:title="Label : pip_ClassOfWarrantOrRightIssuanceDate to label_pip_ClassOfWarrantOrRightIssuanceDate_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_ClassOfWarrantOrRightIssuanceDate_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_ClassOfWarrantOrRightIssuanceDate_2" xml:lang="en-US" id="label_pip_ClassOfWarrantOrRightIssuanceDate_2">Issue Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ClassOfWarrantOrRightIssuanceDate" xlink:to="label_pip_ClassOfWarrantOrRightIssuanceDate_2" xlink:title="Label : pip_ClassOfWarrantOrRightIssuanceDate to label_pip_ClassOfWarrantOrRightIssuanceDate_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares" xlink:label="pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares" xlink:title="pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares" />
    <link:label xlink:type="resource" xlink:label="label_pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares" xml:lang="en-US" id="label_pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares">Commission owed to sales agent, expressed as percentage of aggregate gross proceeds from each sale of shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares" xlink:to="label_pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares" xlink:title="Label : pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares to label_pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares" />
    <link:label xlink:type="resource" xlink:label="label_pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares_1" xml:lang="en-US" id="label_pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares_1">Commission Owed To Sales Agent Expressed As Percentage Of Aggregate Gross Proceeds From Each Sale Of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares" xlink:to="label_pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares_1" xlink:title="Label : pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares to label_pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares_2" xml:lang="en-US" id="label_pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares_2">Commission owed to sales agent, expressed as percentage of aggregate gross proceeds from each sale of shares of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares" xlink:to="label_pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares_2" xlink:title="Label : pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares to label_pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_CommitmentAndContingenciesTable" xlink:label="pip_CommitmentAndContingenciesTable" xlink:title="pip_CommitmentAndContingenciesTable" />
    <link:label xlink:type="resource" xlink:label="label_pip_CommitmentAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_CommitmentAndContingenciesTable" xml:lang="en-US" id="label_pip_CommitmentAndContingenciesTable">Commitment And Contingencies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_CommitmentAndContingenciesTable" xlink:to="label_pip_CommitmentAndContingenciesTable" xlink:title="Label : pip_CommitmentAndContingenciesTable to label_pip_CommitmentAndContingenciesTable" />
    <link:label xlink:type="resource" xlink:label="label_pip_CommitmentAndContingenciesTable_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_CommitmentAndContingenciesTable_1" xml:lang="en-US" id="label_pip_CommitmentAndContingenciesTable_1">Commitment And Contingencies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_CommitmentAndContingenciesTable" xlink:to="label_pip_CommitmentAndContingenciesTable_1" xlink:title="Label : pip_CommitmentAndContingenciesTable to label_pip_CommitmentAndContingenciesTable_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_CommitmentAndContingenciesTable_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_CommitmentAndContingenciesTable_2" xml:lang="en-US" id="label_pip_CommitmentAndContingenciesTable_2">Commitment And Contingencies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_CommitmentAndContingenciesTable" xlink:to="label_pip_CommitmentAndContingenciesTable_2" xlink:title="Label : pip_CommitmentAndContingenciesTable to label_pip_CommitmentAndContingenciesTable_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_CommitmentsAndContingenciesLineItems" xlink:label="pip_CommitmentsAndContingenciesLineItems" xlink:title="pip_CommitmentsAndContingenciesLineItems" />
    <link:label xlink:type="resource" xlink:label="label_pip_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_CommitmentsAndContingenciesLineItems" xml:lang="en-US" id="label_pip_CommitmentsAndContingenciesLineItems">Commitments and Contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="label_pip_CommitmentsAndContingenciesLineItems" xlink:title="Label : pip_CommitmentsAndContingenciesLineItems to label_pip_CommitmentsAndContingenciesLineItems" />
    <link:label xlink:type="resource" xlink:label="label_pip_CommitmentsAndContingenciesLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_CommitmentsAndContingenciesLineItems_1" xml:lang="en-US" id="label_pip_CommitmentsAndContingenciesLineItems_1">Commitments And Contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="label_pip_CommitmentsAndContingenciesLineItems_1" xlink:title="Label : pip_CommitmentsAndContingenciesLineItems to label_pip_CommitmentsAndContingenciesLineItems_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_CommitmentsAndContingenciesLineItems_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_CommitmentsAndContingenciesLineItems_2" xml:lang="en-US" id="label_pip_CommitmentsAndContingenciesLineItems_2">Commitments and Contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="label_pip_CommitmentsAndContingenciesLineItems_2" xlink:title="Label : pip_CommitmentsAndContingenciesLineItems to label_pip_CommitmentsAndContingenciesLineItems_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:title="dei_AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="label_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_AmendmentFlag" xml:lang="en-US" id="label_dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="label_dei_AmendmentFlag" xlink:title="Label : dei_AmendmentFlag to label_dei_AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="label_dei_AmendmentFlag_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_dei_AmendmentFlag_1" xml:lang="en-US" id="label_dei_AmendmentFlag_1">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="label_dei_AmendmentFlag_1" xlink:title="Label : dei_AmendmentFlag to label_dei_AmendmentFlag_1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_CourtAwardedFees" xlink:label="pip_CourtAwardedFees" xlink:title="pip_CourtAwardedFees" />
    <link:label xlink:type="resource" xlink:label="label_pip_CourtAwardedFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_CourtAwardedFees" xml:lang="en-US" id="label_pip_CourtAwardedFees">Court awarded fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_CourtAwardedFees" xlink:to="label_pip_CourtAwardedFees" xlink:title="Label : pip_CourtAwardedFees to label_pip_CourtAwardedFees" />
    <link:label xlink:type="resource" xlink:label="label_pip_CourtAwardedFees_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_CourtAwardedFees_1" xml:lang="en-US" id="label_pip_CourtAwardedFees_1">Court Awarded Fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_CourtAwardedFees" xlink:to="label_pip_CourtAwardedFees_1" xlink:title="Label : pip_CourtAwardedFees to label_pip_CourtAwardedFees_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_CourtAwardedFees_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_CourtAwardedFees_2" xml:lang="en-US" id="label_pip_CourtAwardedFees_2">Awarded 1/3 reasonable attorney's fees and expert witness fees, plus interest.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_CourtAwardedFees" xlink:to="label_pip_CourtAwardedFees_2" xlink:title="Label : pip_CourtAwardedFees to label_pip_CourtAwardedFees_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_DebtInstrumentInterestRateFloorPercentage" xlink:label="pip_DebtInstrumentInterestRateFloorPercentage" xlink:title="pip_DebtInstrumentInterestRateFloorPercentage" />
    <link:label xlink:type="resource" xlink:label="label_pip_DebtInstrumentInterestRateFloorPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_DebtInstrumentInterestRateFloorPercentage" xml:lang="en-US" id="label_pip_DebtInstrumentInterestRateFloorPercentage">The portion of the carrying amount of short-term borrowings outstanding as of the balance sheet date, which accrues interest at a rate subject to change from time to time, however, with a floor of 1.5%.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_DebtInstrumentInterestRateFloorPercentage" xlink:to="label_pip_DebtInstrumentInterestRateFloorPercentage" xlink:title="Label : pip_DebtInstrumentInterestRateFloorPercentage to label_pip_DebtInstrumentInterestRateFloorPercentage" />
    <link:label xlink:type="resource" xlink:label="label_pip_DebtInstrumentInterestRateFloorPercentage_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_DebtInstrumentInterestRateFloorPercentage_1" xml:lang="en-US" id="label_pip_DebtInstrumentInterestRateFloorPercentage_1">Debt Instrument Interest Rate Floor Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_DebtInstrumentInterestRateFloorPercentage" xlink:to="label_pip_DebtInstrumentInterestRateFloorPercentage_1" xlink:title="Label : pip_DebtInstrumentInterestRateFloorPercentage to label_pip_DebtInstrumentInterestRateFloorPercentage_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_DebtInstrumentInterestRateFloorPercentage_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_DebtInstrumentInterestRateFloorPercentage_2" xml:lang="en-US" id="label_pip_DebtInstrumentInterestRateFloorPercentage_2">Variable interest rate, with floor of 1.5%</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_DebtInstrumentInterestRateFloorPercentage" xlink:to="label_pip_DebtInstrumentInterestRateFloorPercentage_2" xlink:title="Label : pip_DebtInstrumentInterestRateFloorPercentage to label_pip_DebtInstrumentInterestRateFloorPercentage_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_DebtInstrumentsMaturityDateMonthAndYear" xlink:label="pip_DebtInstrumentsMaturityDateMonthAndYear" xlink:title="pip_DebtInstrumentsMaturityDateMonthAndYear" />
    <link:label xlink:type="resource" xlink:label="label_pip_DebtInstrumentsMaturityDateMonthAndYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_DebtInstrumentsMaturityDateMonthAndYear" xml:lang="en-US" id="label_pip_DebtInstrumentsMaturityDateMonthAndYear">Debt Instruments Maturity Date Month and Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_DebtInstrumentsMaturityDateMonthAndYear" xlink:to="label_pip_DebtInstrumentsMaturityDateMonthAndYear" xlink:title="Label : pip_DebtInstrumentsMaturityDateMonthAndYear to label_pip_DebtInstrumentsMaturityDateMonthAndYear" />
    <link:label xlink:type="resource" xlink:label="label_pip_DebtInstrumentsMaturityDateMonthAndYear_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_DebtInstrumentsMaturityDateMonthAndYear_1" xml:lang="en-US" id="label_pip_DebtInstrumentsMaturityDateMonthAndYear_1">Debt Instruments Maturity Date Month And Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_DebtInstrumentsMaturityDateMonthAndYear" xlink:to="label_pip_DebtInstrumentsMaturityDateMonthAndYear_1" xlink:title="Label : pip_DebtInstrumentsMaturityDateMonthAndYear to label_pip_DebtInstrumentsMaturityDateMonthAndYear_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_DebtInstrumentsMaturityDateMonthAndYear_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_DebtInstrumentsMaturityDateMonthAndYear_2" xml:lang="en-US" id="label_pip_DebtInstrumentsMaturityDateMonthAndYear_2">Term loan and line of credit, maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_DebtInstrumentsMaturityDateMonthAndYear" xlink:to="label_pip_DebtInstrumentsMaturityDateMonthAndYear_2" xlink:title="Label : pip_DebtInstrumentsMaturityDateMonthAndYear to label_pip_DebtInstrumentsMaturityDateMonthAndYear_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_DerivativeInstrumentWarrantsMember" xlink:label="pip_DerivativeInstrumentWarrantsMember" xlink:title="pip_DerivativeInstrumentWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_DerivativeInstrumentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_DerivativeInstrumentWarrantsMember" xml:lang="en-US" id="label_pip_DerivativeInstrumentWarrantsMember">Derivative Instrument Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_DerivativeInstrumentWarrantsMember" xlink:to="label_pip_DerivativeInstrumentWarrantsMember" xlink:title="Label : pip_DerivativeInstrumentWarrantsMember to label_pip_DerivativeInstrumentWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_DerivativeInstrumentWarrantsMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_DerivativeInstrumentWarrantsMember_1" xml:lang="en-US" id="label_pip_DerivativeInstrumentWarrantsMember_1">Derivative Instrument Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_DerivativeInstrumentWarrantsMember" xlink:to="label_pip_DerivativeInstrumentWarrantsMember_1" xlink:title="Label : pip_DerivativeInstrumentWarrantsMember to label_pip_DerivativeInstrumentWarrantsMember_1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_DerivativeLiabilitiesMember" xlink:label="pip_DerivativeLiabilitiesMember" xlink:title="pip_DerivativeLiabilitiesMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_DerivativeLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_DerivativeLiabilitiesMember" xml:lang="en-US" id="label_pip_DerivativeLiabilitiesMember">Derivative Liabilities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_DerivativeLiabilitiesMember" xlink:to="label_pip_DerivativeLiabilitiesMember" xlink:title="Label : pip_DerivativeLiabilitiesMember to label_pip_DerivativeLiabilitiesMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_DerivativeLiabilitiesMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_DerivativeLiabilitiesMember_1" xml:lang="en-US" id="label_pip_DerivativeLiabilitiesMember_1">Derivative Liabilities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_DerivativeLiabilitiesMember" xlink:to="label_pip_DerivativeLiabilitiesMember_1" xlink:title="Label : pip_DerivativeLiabilitiesMember to label_pip_DerivativeLiabilitiesMember_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_DerivativeLiabilitiesMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_DerivativeLiabilitiesMember_2" xml:lang="en-US" id="label_pip_DerivativeLiabilitiesMember_2">Derivative Liabilities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_DerivativeLiabilitiesMember" xlink:to="label_pip_DerivativeLiabilitiesMember_2" xlink:title="Label : pip_DerivativeLiabilitiesMember to label_pip_DerivativeLiabilitiesMember_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_DocumentAndEntityInformationAbstract" xlink:label="pip_DocumentAndEntityInformationAbstract" xlink:title="pip_DocumentAndEntityInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_pip_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_DocumentAndEntityInformationAbstract" xml:lang="en-US" id="label_pip_DocumentAndEntityInformationAbstract">Document and Entity Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_DocumentAndEntityInformationAbstract" xlink:to="label_pip_DocumentAndEntityInformationAbstract" xlink:title="Label : pip_DocumentAndEntityInformationAbstract to label_pip_DocumentAndEntityInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_pip_DocumentAndEntityInformationAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_DocumentAndEntityInformationAbstract_1" xml:lang="en-US" id="label_pip_DocumentAndEntityInformationAbstract_1">Document and Entity Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_DocumentAndEntityInformationAbstract" xlink:to="label_pip_DocumentAndEntityInformationAbstract_1" xlink:title="Label : pip_DocumentAndEntityInformationAbstract to label_pip_DocumentAndEntityInformationAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_EquityOfferingAxis" xlink:label="pip_EquityOfferingAxis" xlink:title="pip_EquityOfferingAxis" />
    <link:label xlink:type="resource" xlink:label="label_pip_EquityOfferingAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_EquityOfferingAxis" xml:lang="en-US" id="label_pip_EquityOfferingAxis">Equity Offering [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_EquityOfferingAxis" xlink:to="label_pip_EquityOfferingAxis" xlink:title="Label : pip_EquityOfferingAxis to label_pip_EquityOfferingAxis" />
    <link:label xlink:type="resource" xlink:label="label_pip_EquityOfferingAxis_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_EquityOfferingAxis_1" xml:lang="en-US" id="label_pip_EquityOfferingAxis_1">Equity Offering [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_EquityOfferingAxis" xlink:to="label_pip_EquityOfferingAxis_1" xlink:title="Label : pip_EquityOfferingAxis to label_pip_EquityOfferingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_EquityOfferingDomain" xlink:label="pip_EquityOfferingDomain" xlink:title="pip_EquityOfferingDomain" />
    <link:label xlink:type="resource" xlink:label="label_pip_EquityOfferingDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_EquityOfferingDomain" xml:lang="en-US" id="label_pip_EquityOfferingDomain">Equity Offering [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_EquityOfferingDomain" xlink:to="label_pip_EquityOfferingDomain" xlink:title="Label : pip_EquityOfferingDomain to label_pip_EquityOfferingDomain" />
    <link:label xlink:type="resource" xlink:label="label_pip_EquityOfferingDomain_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_EquityOfferingDomain_1" xml:lang="en-US" id="label_pip_EquityOfferingDomain_1">Equity Offering [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_EquityOfferingDomain" xlink:to="label_pip_EquityOfferingDomain_1" xlink:title="Label : pip_EquityOfferingDomain to label_pip_EquityOfferingDomain_1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_EquityOfferingLineItems" xlink:label="pip_EquityOfferingLineItems" xlink:title="pip_EquityOfferingLineItems" />
    <link:label xlink:type="resource" xlink:label="label_pip_EquityOfferingLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_EquityOfferingLineItems" xml:lang="en-US" id="label_pip_EquityOfferingLineItems">Equity Offering [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_EquityOfferingLineItems" xlink:to="label_pip_EquityOfferingLineItems" xlink:title="Label : pip_EquityOfferingLineItems to label_pip_EquityOfferingLineItems" />
    <link:label xlink:type="resource" xlink:label="label_pip_EquityOfferingLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_EquityOfferingLineItems_1" xml:lang="en-US" id="label_pip_EquityOfferingLineItems_1">Equity Offering [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_EquityOfferingLineItems" xlink:to="label_pip_EquityOfferingLineItems_1" xlink:title="Label : pip_EquityOfferingLineItems to label_pip_EquityOfferingLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_EquityOfferingMember" xlink:label="pip_EquityOfferingMember" xlink:title="pip_EquityOfferingMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_EquityOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_EquityOfferingMember" xml:lang="en-US" id="label_pip_EquityOfferingMember">Equity Offering [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_EquityOfferingMember" xlink:to="label_pip_EquityOfferingMember" xlink:title="Label : pip_EquityOfferingMember to label_pip_EquityOfferingMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_EquityOfferingMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_EquityOfferingMember_1" xml:lang="en-US" id="label_pip_EquityOfferingMember_1">Equity Offering [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_EquityOfferingMember" xlink:to="label_pip_EquityOfferingMember_1" xlink:title="Label : pip_EquityOfferingMember to label_pip_EquityOfferingMember_1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_EquityOfferingTable" xlink:label="pip_EquityOfferingTable" xlink:title="pip_EquityOfferingTable" />
    <link:label xlink:type="resource" xlink:label="label_pip_EquityOfferingTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_EquityOfferingTable" xml:lang="en-US" id="label_pip_EquityOfferingTable">Equity Offering [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_EquityOfferingTable" xlink:to="label_pip_EquityOfferingTable" xlink:title="Label : pip_EquityOfferingTable to label_pip_EquityOfferingTable" />
    <link:label xlink:type="resource" xlink:label="label_pip_EquityOfferingTable_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_EquityOfferingTable_1" xml:lang="en-US" id="label_pip_EquityOfferingTable_1">Equity Offering [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_EquityOfferingTable" xlink:to="label_pip_EquityOfferingTable_1" xlink:title="Label : pip_EquityOfferingTable to label_pip_EquityOfferingTable_1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_FairValueMeasurementsLineItems" xlink:label="pip_FairValueMeasurementsLineItems" xlink:title="pip_FairValueMeasurementsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_pip_FairValueMeasurementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_FairValueMeasurementsLineItems" xml:lang="en-US" id="label_pip_FairValueMeasurementsLineItems">Fair Value Measurements [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_FairValueMeasurementsLineItems" xlink:to="label_pip_FairValueMeasurementsLineItems" xlink:title="Label : pip_FairValueMeasurementsLineItems to label_pip_FairValueMeasurementsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_pip_FairValueMeasurementsLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_FairValueMeasurementsLineItems_1" xml:lang="en-US" id="label_pip_FairValueMeasurementsLineItems_1">Fair Value Measurements [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_FairValueMeasurementsLineItems" xlink:to="label_pip_FairValueMeasurementsLineItems_1" xlink:title="Label : pip_FairValueMeasurementsLineItems to label_pip_FairValueMeasurementsLineItems_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_FairValueMeasurementsLineItems_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_FairValueMeasurementsLineItems_2" xml:lang="en-US" id="label_pip_FairValueMeasurementsLineItems_2">Fair Value Measurements [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_FairValueMeasurementsLineItems" xlink:to="label_pip_FairValueMeasurementsLineItems_2" xlink:title="Label : pip_FairValueMeasurementsLineItems to label_pip_FairValueMeasurementsLineItems_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_FairValueMeasurementsTable" xlink:label="pip_FairValueMeasurementsTable" xlink:title="pip_FairValueMeasurementsTable" />
    <link:label xlink:type="resource" xlink:label="label_pip_FairValueMeasurementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_FairValueMeasurementsTable" xml:lang="en-US" id="label_pip_FairValueMeasurementsTable">Fair Value Measurements [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_FairValueMeasurementsTable" xlink:to="label_pip_FairValueMeasurementsTable" xlink:title="Label : pip_FairValueMeasurementsTable to label_pip_FairValueMeasurementsTable" />
    <link:label xlink:type="resource" xlink:label="label_pip_FairValueMeasurementsTable_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_FairValueMeasurementsTable_1" xml:lang="en-US" id="label_pip_FairValueMeasurementsTable_1">Fair Value Measurements [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_FairValueMeasurementsTable" xlink:to="label_pip_FairValueMeasurementsTable_1" xlink:title="Label : pip_FairValueMeasurementsTable to label_pip_FairValueMeasurementsTable_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_FairValueMeasurementsTable_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_FairValueMeasurementsTable_2" xml:lang="en-US" id="label_pip_FairValueMeasurementsTable_2">Fair Value Measurements [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_FairValueMeasurementsTable" xlink:to="label_pip_FairValueMeasurementsTable_2" xlink:title="Label : pip_FairValueMeasurementsTable to label_pip_FairValueMeasurementsTable_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_FinalPaymentFeeOfTermLoanBalancePercent" xlink:label="pip_FinalPaymentFeeOfTermLoanBalancePercent" xlink:title="pip_FinalPaymentFeeOfTermLoanBalancePercent" />
    <link:label xlink:type="resource" xlink:label="label_pip_FinalPaymentFeeOfTermLoanBalancePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_FinalPaymentFeeOfTermLoanBalancePercent" xml:lang="en-US" id="label_pip_FinalPaymentFeeOfTermLoanBalancePercent">Final payment fee payable on term loan balance, percent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_FinalPaymentFeeOfTermLoanBalancePercent" xlink:to="label_pip_FinalPaymentFeeOfTermLoanBalancePercent" xlink:title="Label : pip_FinalPaymentFeeOfTermLoanBalancePercent to label_pip_FinalPaymentFeeOfTermLoanBalancePercent" />
    <link:label xlink:type="resource" xlink:label="label_pip_FinalPaymentFeeOfTermLoanBalancePercent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_FinalPaymentFeeOfTermLoanBalancePercent_1" xml:lang="en-US" id="label_pip_FinalPaymentFeeOfTermLoanBalancePercent_1">Final Payment Fee Of Term Loan Balance Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_FinalPaymentFeeOfTermLoanBalancePercent" xlink:to="label_pip_FinalPaymentFeeOfTermLoanBalancePercent_1" xlink:title="Label : pip_FinalPaymentFeeOfTermLoanBalancePercent to label_pip_FinalPaymentFeeOfTermLoanBalancePercent_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_FinalPaymentFeeOfTermLoanBalancePercent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_FinalPaymentFeeOfTermLoanBalancePercent_2" xml:lang="en-US" id="label_pip_FinalPaymentFeeOfTermLoanBalancePercent_2">Final payment fee payable on term loan balance, percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_FinalPaymentFeeOfTermLoanBalancePercent" xlink:to="label_pip_FinalPaymentFeeOfTermLoanBalancePercent_2" xlink:title="Label : pip_FinalPaymentFeeOfTermLoanBalancePercent to label_pip_FinalPaymentFeeOfTermLoanBalancePercent_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_FutureValueSettled" xlink:label="pip_FutureValueSettled" xlink:title="pip_FutureValueSettled" />
    <link:label xlink:type="resource" xlink:label="label_pip_FutureValueSettled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_FutureValueSettled" xml:lang="en-US" id="label_pip_FutureValueSettled">Future Value Settled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_FutureValueSettled" xlink:to="label_pip_FutureValueSettled" xlink:title="Label : pip_FutureValueSettled to label_pip_FutureValueSettled" />
    <link:label xlink:type="resource" xlink:label="label_pip_FutureValueSettled_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_FutureValueSettled_1" xml:lang="en-US" id="label_pip_FutureValueSettled_1">Future Value Settled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_FutureValueSettled" xlink:to="label_pip_FutureValueSettled_1" xlink:title="Label : pip_FutureValueSettled to label_pip_FutureValueSettled_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_FutureValueSettled_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_FutureValueSettled_2" xml:lang="en-US" id="label_pip_FutureValueSettled_2">Proceeds later settled</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_FutureValueSettled" xlink:to="label_pip_FutureValueSettled_2" xlink:title="Label : pip_FutureValueSettled to label_pip_FutureValueSettled_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_GroupFourMember" xlink:label="pip_GroupFourMember" xlink:title="pip_GroupFourMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_GroupFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_GroupFourMember" xml:lang="en-US" id="label_pip_GroupFourMember">Group Four [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_GroupFourMember" xlink:to="label_pip_GroupFourMember" xlink:title="Label : pip_GroupFourMember to label_pip_GroupFourMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_GroupFourMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_GroupFourMember_1" xml:lang="en-US" id="label_pip_GroupFourMember_1">Group Four [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_GroupFourMember" xlink:to="label_pip_GroupFourMember_1" xlink:title="Label : pip_GroupFourMember to label_pip_GroupFourMember_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_GroupFourMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_GroupFourMember_2" xml:lang="en-US" id="label_pip_GroupFourMember_2">Every 30 days until failure is cured [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_GroupFourMember" xlink:to="label_pip_GroupFourMember_2" xlink:title="Label : pip_GroupFourMember to label_pip_GroupFourMember_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:title="dei_CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="label_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_CurrentFiscalYearEndDate" xml:lang="en-US" id="label_dei_CurrentFiscalYearEndDate">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="label_dei_CurrentFiscalYearEndDate" xlink:title="Label : dei_CurrentFiscalYearEndDate to label_dei_CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="label_dei_CurrentFiscalYearEndDate_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_dei_CurrentFiscalYearEndDate_1" xml:lang="en-US" id="label_dei_CurrentFiscalYearEndDate_1">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="label_dei_CurrentFiscalYearEndDate_1" xlink:title="Label : dei_CurrentFiscalYearEndDate to label_dei_CurrentFiscalYearEndDate_1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_GroupOneMember" xlink:label="pip_GroupOneMember" xlink:title="pip_GroupOneMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_GroupOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_GroupOneMember" xml:lang="en-US" id="label_pip_GroupOneMember">Group One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_GroupOneMember" xlink:to="label_pip_GroupOneMember" xlink:title="Label : pip_GroupOneMember to label_pip_GroupOneMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_GroupOneMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_GroupOneMember_1" xml:lang="en-US" id="label_pip_GroupOneMember_1">Group One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_GroupOneMember" xlink:to="label_pip_GroupOneMember_1" xlink:title="Label : pip_GroupOneMember to label_pip_GroupOneMember_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_GroupOneMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_GroupOneMember_2" xml:lang="en-US" id="label_pip_GroupOneMember_2">Expiration 2015</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_GroupOneMember" xlink:to="label_pip_GroupOneMember_2" xlink:title="Label : pip_GroupOneMember to label_pip_GroupOneMember_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_GroupThreeMember" xlink:label="pip_GroupThreeMember" xlink:title="pip_GroupThreeMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_GroupThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_GroupThreeMember" xml:lang="en-US" id="label_pip_GroupThreeMember">Initial maximum maintenance failure obligation and additional maximum obligation every 30th daily after initial maintenance failure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_GroupThreeMember" xlink:to="label_pip_GroupThreeMember" xlink:title="Label : pip_GroupThreeMember to label_pip_GroupThreeMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_GroupThreeMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_GroupThreeMember_1" xml:lang="en-US" id="label_pip_GroupThreeMember_1">Group Three [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_GroupThreeMember" xlink:to="label_pip_GroupThreeMember_1" xlink:title="Label : pip_GroupThreeMember to label_pip_GroupThreeMember_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_GroupThreeMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_GroupThreeMember_2" xml:lang="en-US" id="label_pip_GroupThreeMember_2">Initial Maximum Maintenance Failure Obligation [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_GroupThreeMember" xlink:to="label_pip_GroupThreeMember_2" xlink:title="Label : pip_GroupThreeMember to label_pip_GroupThreeMember_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_GroupTwoMember" xlink:label="pip_GroupTwoMember" xlink:title="pip_GroupTwoMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_GroupTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_GroupTwoMember" xml:lang="en-US" id="label_pip_GroupTwoMember">Group Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_GroupTwoMember" xlink:to="label_pip_GroupTwoMember" xlink:title="Label : pip_GroupTwoMember to label_pip_GroupTwoMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_GroupTwoMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_GroupTwoMember_1" xml:lang="en-US" id="label_pip_GroupTwoMember_1">Group Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_GroupTwoMember" xlink:to="label_pip_GroupTwoMember_1" xlink:title="Label : pip_GroupTwoMember to label_pip_GroupTwoMember_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_GroupTwoMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_GroupTwoMember_2" xml:lang="en-US" id="label_pip_GroupTwoMember_2">Expiration 2017 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_GroupTwoMember" xlink:to="label_pip_GroupTwoMember_2" xlink:title="Label : pip_GroupTwoMember to label_pip_GroupTwoMember_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable" xlink:label="pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable" xlink:title="pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable" />
    <link:label xlink:type="resource" xlink:label="label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable" xml:lang="en-US" id="label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable">Line Of Credit Facility Borrowing Capacity Percent Of Qualified Billed Accounts Receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable" xlink:to="label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable" xlink:title="Label : pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable to label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable" />
    <link:label xlink:type="resource" xlink:label="label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable_1" xml:lang="en-US" id="label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable_1">Line Of Credit Facility Borrowing Capacity Percent Of Qualified Billed Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable" xlink:to="label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable_1" xlink:title="Label : pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable to label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable_2" xml:lang="en-US" id="label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable_2">Line of credit facility borrowing capacity, qualified billed accounts receivable, percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable" xlink:to="label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable_2" xlink:title="Label : pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable to label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl" xlink:label="pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl" xlink:title="pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl" />
    <link:label xlink:type="resource" xlink:label="label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl" xml:lang="en-US" id="label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl">Line Of Credit Facility Borrowing Capacity Percent Of Qualified Unbilled Accounts Receivable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl" xlink:to="label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl" xlink:title="Label : pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl to label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl" />
    <link:label xlink:type="resource" xlink:label="label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl_1" xml:lang="en-US" id="label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl_1">Line Of Credit Facility Borrowing Capacity Percent Of Qualified Unbilled Accounts Receivabl</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl" xlink:to="label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl_1" xlink:title="Label : pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl to label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl_2" xml:lang="en-US" id="label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl_2">Line of credit facility borrowing capacity, qualified unbilled accounts receivable, percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl" xlink:to="label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl_2" xlink:title="Label : pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl to label_pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_LiquidityArrangementsMember" xlink:label="pip_LiquidityArrangementsMember" xlink:title="pip_LiquidityArrangementsMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_LiquidityArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_LiquidityArrangementsMember" xml:lang="en-US" id="label_pip_LiquidityArrangementsMember">Liquidity Arrangements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_LiquidityArrangementsMember" xlink:to="label_pip_LiquidityArrangementsMember" xlink:title="Label : pip_LiquidityArrangementsMember to label_pip_LiquidityArrangementsMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_LiquidityArrangementsMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_LiquidityArrangementsMember_1" xml:lang="en-US" id="label_pip_LiquidityArrangementsMember_1">Liquidity Arrangements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_LiquidityArrangementsMember" xlink:to="label_pip_LiquidityArrangementsMember_1" xlink:title="Label : pip_LiquidityArrangementsMember to label_pip_LiquidityArrangementsMember_1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_LongTermDebtExcludingDiscount" xlink:label="pip_LongTermDebtExcludingDiscount" xlink:title="pip_LongTermDebtExcludingDiscount" />
    <link:label xlink:type="resource" xlink:label="label_pip_LongTermDebtExcludingDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_LongTermDebtExcludingDiscount" xml:lang="en-US" id="label_pip_LongTermDebtExcludingDiscount">Long Term Debt Excluding Discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_LongTermDebtExcludingDiscount" xlink:to="label_pip_LongTermDebtExcludingDiscount" xlink:title="Label : pip_LongTermDebtExcludingDiscount to label_pip_LongTermDebtExcludingDiscount" />
    <link:label xlink:type="resource" xlink:label="label_pip_LongTermDebtExcludingDiscount_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_LongTermDebtExcludingDiscount_1" xml:lang="en-US" id="label_pip_LongTermDebtExcludingDiscount_1">Long Term Debt Excluding Discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_LongTermDebtExcludingDiscount" xlink:to="label_pip_LongTermDebtExcludingDiscount_1" xlink:title="Label : pip_LongTermDebtExcludingDiscount to label_pip_LongTermDebtExcludingDiscount_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_LongTermDebtExcludingDiscount_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_pip_LongTermDebtExcludingDiscount_2" xml:lang="en-US" id="label_pip_LongTermDebtExcludingDiscount_2">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_LongTermDebtExcludingDiscount" xlink:to="label_pip_LongTermDebtExcludingDiscount_2" xlink:title="Label : pip_LongTermDebtExcludingDiscount to label_pip_LongTermDebtExcludingDiscount_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal" xlink:label="pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal" xlink:title="pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal" />
    <link:label xlink:type="resource" xlink:label="label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal" xml:lang="en-US" id="label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal">Prepayment premium, if we prepay the term loan and terminate the revolving line of credit prior to the scheduled maturity date.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal" xlink:to="label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal" xlink:title="Label : pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal to label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal" />
    <link:label xlink:type="resource" xlink:label="label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal_1" xml:lang="en-US" id="label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal_1">Long Term Debt Prepayment Premium Percent Of Principal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal" xlink:to="label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal_1" xlink:title="Label : pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal to label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal_2" xml:lang="en-US" id="label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal_2">Prepayment premium, if we prepay the term loan and terminate the revolving line of credit prior to the scheduled maturity date, percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal" xlink:to="label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal_2" xlink:title="Label : pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal to label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo" xlink:label="pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo" xlink:title="pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo" />
    <link:label xlink:type="resource" xlink:label="label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo" xml:lang="en-US" id="label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo">Prepayment premium, if paid after the first two years of the term loan, percent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo" xlink:to="label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo" xlink:title="Label : pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo to label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo" />
    <link:label xlink:type="resource" xlink:label="label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo_1" xml:lang="en-US" id="label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo_1">Long Term Debt Prepayment Premium Percent Of Principal Period Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo" xlink:to="label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo_1" xlink:title="Label : pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo to label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo_2" xml:lang="en-US" id="label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo_2">Prepayment premium, if paid after the first two years of the term loan, percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo" xlink:to="label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo_2" xlink:title="Label : pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo to label_pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_MaximumValueOfStockIssuableUnderStockOffering" xlink:label="pip_MaximumValueOfStockIssuableUnderStockOffering" xlink:title="pip_MaximumValueOfStockIssuableUnderStockOffering" />
    <link:label xlink:type="resource" xlink:label="label_pip_MaximumValueOfStockIssuableUnderStockOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_MaximumValueOfStockIssuableUnderStockOffering" xml:lang="en-US" id="label_pip_MaximumValueOfStockIssuableUnderStockOffering">The maximum value of common stock issuable under the controlled equity offering arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_MaximumValueOfStockIssuableUnderStockOffering" xlink:to="label_pip_MaximumValueOfStockIssuableUnderStockOffering" xlink:title="Label : pip_MaximumValueOfStockIssuableUnderStockOffering to label_pip_MaximumValueOfStockIssuableUnderStockOffering" />
    <link:label xlink:type="resource" xlink:label="label_pip_MaximumValueOfStockIssuableUnderStockOffering_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_MaximumValueOfStockIssuableUnderStockOffering_1" xml:lang="en-US" id="label_pip_MaximumValueOfStockIssuableUnderStockOffering_1">Maximum Value Of Stock Issuable Under Stock Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_MaximumValueOfStockIssuableUnderStockOffering" xlink:to="label_pip_MaximumValueOfStockIssuableUnderStockOffering_1" xlink:title="Label : pip_MaximumValueOfStockIssuableUnderStockOffering to label_pip_MaximumValueOfStockIssuableUnderStockOffering_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_MaximumValueOfStockIssuableUnderStockOffering_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_MaximumValueOfStockIssuableUnderStockOffering_2" xml:lang="en-US" id="label_pip_MaximumValueOfStockIssuableUnderStockOffering_2">The maximum value of common stock issuable under the controlled equity offering arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_MaximumValueOfStockIssuableUnderStockOffering" xlink:to="label_pip_MaximumValueOfStockIssuableUnderStockOffering_2" xlink:title="Label : pip_MaximumValueOfStockIssuableUnderStockOffering to label_pip_MaximumValueOfStockIssuableUnderStockOffering_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract" xlink:label="pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract" xlink:title="pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract" />
    <link:label xlink:type="resource" xlink:label="label_pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract" xml:lang="en-US" id="label_pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract">Net profit on ArestvyrTM (as defined in court's final judgement) before distribution for breach of contract.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract" xlink:to="label_pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract" xlink:title="Label : pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract to label_pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract" />
    <link:label xlink:type="resource" xlink:label="label_pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract_1" xml:lang="en-US" id="label_pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract_1">Net Profit Retention From Sales Before Distribution For Breach Of Contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract" xlink:to="label_pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract_1" xlink:title="Label : pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract to label_pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract_2" xml:lang="en-US" id="label_pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract_2">SIGA net profits (as defined in courts final judgement) before distribution for breach of contract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract" xlink:to="label_pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract_2" xlink:title="Label : pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract to label_pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:title="dei_DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="label_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_DocumentPeriodEndDate" xml:lang="en-US" id="label_dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="label_dei_DocumentPeriodEndDate" xlink:title="Label : dei_DocumentPeriodEndDate to label_dei_DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="label_dei_DocumentPeriodEndDate_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_dei_DocumentPeriodEndDate_1" xml:lang="en-US" id="label_dei_DocumentPeriodEndDate_1">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="label_dei_DocumentPeriodEndDate_1" xlink:title="Label : dei_DocumentPeriodEndDate to label_dei_DocumentPeriodEndDate_1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_NotesPayableAggregatePrincipalRepaymentAmount" xlink:label="pip_NotesPayableAggregatePrincipalRepaymentAmount" xlink:title="pip_NotesPayableAggregatePrincipalRepaymentAmount" />
    <link:label xlink:type="resource" xlink:label="label_pip_NotesPayableAggregatePrincipalRepaymentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_NotesPayableAggregatePrincipalRepaymentAmount" xml:lang="en-US" id="label_pip_NotesPayableAggregatePrincipalRepaymentAmount">Initial maximum maintenance failure obligation and additional maximum obligation every 30th daily after initial maintenance failure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_NotesPayableAggregatePrincipalRepaymentAmount" xlink:to="label_pip_NotesPayableAggregatePrincipalRepaymentAmount" xlink:title="Label : pip_NotesPayableAggregatePrincipalRepaymentAmount to label_pip_NotesPayableAggregatePrincipalRepaymentAmount" />
    <link:label xlink:type="resource" xlink:label="label_pip_NotesPayableAggregatePrincipalRepaymentAmount_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_NotesPayableAggregatePrincipalRepaymentAmount_1" xml:lang="en-US" id="label_pip_NotesPayableAggregatePrincipalRepaymentAmount_1">Notes Payable Aggregate Principal Repayment Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_NotesPayableAggregatePrincipalRepaymentAmount" xlink:to="label_pip_NotesPayableAggregatePrincipalRepaymentAmount_1" xlink:title="Label : pip_NotesPayableAggregatePrincipalRepaymentAmount to label_pip_NotesPayableAggregatePrincipalRepaymentAmount_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_NotesPayableAggregatePrincipalRepaymentAmount_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_NotesPayableAggregatePrincipalRepaymentAmount_2" xml:lang="en-US" id="label_pip_NotesPayableAggregatePrincipalRepaymentAmount_2">Aggregate principal amount of obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_NotesPayableAggregatePrincipalRepaymentAmount" xlink:to="label_pip_NotesPayableAggregatePrincipalRepaymentAmount_2" xlink:title="Label : pip_NotesPayableAggregatePrincipalRepaymentAmount to label_pip_NotesPayableAggregatePrincipalRepaymentAmount_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_PercentageOfAggregatePrincipalAmountRedemption" xlink:label="pip_PercentageOfAggregatePrincipalAmountRedemption" xlink:title="pip_PercentageOfAggregatePrincipalAmountRedemption" />
    <link:label xlink:type="resource" xlink:label="label_pip_PercentageOfAggregatePrincipalAmountRedemption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_PercentageOfAggregatePrincipalAmountRedemption" xml:lang="en-US" id="label_pip_PercentageOfAggregatePrincipalAmountRedemption">Percentage of aggregate principal amount of convertible notes relating to the affected shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_PercentageOfAggregatePrincipalAmountRedemption" xlink:to="label_pip_PercentageOfAggregatePrincipalAmountRedemption" xlink:title="Label : pip_PercentageOfAggregatePrincipalAmountRedemption to label_pip_PercentageOfAggregatePrincipalAmountRedemption" />
    <link:label xlink:type="resource" xlink:label="label_pip_PercentageOfAggregatePrincipalAmountRedemption_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_PercentageOfAggregatePrincipalAmountRedemption_1" xml:lang="en-US" id="label_pip_PercentageOfAggregatePrincipalAmountRedemption_1">Percentage Of Aggregate Principal Amount Redemption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_PercentageOfAggregatePrincipalAmountRedemption" xlink:to="label_pip_PercentageOfAggregatePrincipalAmountRedemption_1" xlink:title="Label : pip_PercentageOfAggregatePrincipalAmountRedemption to label_pip_PercentageOfAggregatePrincipalAmountRedemption_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_PercentageOfAggregatePrincipalAmountRedemption_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_PercentageOfAggregatePrincipalAmountRedemption_2" xml:lang="en-US" id="label_pip_PercentageOfAggregatePrincipalAmountRedemption_2">Percentage of aggregate principal amount of convertible Notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_PercentageOfAggregatePrincipalAmountRedemption" xlink:to="label_pip_PercentageOfAggregatePrincipalAmountRedemption_2" xlink:title="Label : pip_PercentageOfAggregatePrincipalAmountRedemption to label_pip_PercentageOfAggregatePrincipalAmountRedemption_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_PercentageOfNetProfitAwarded" xlink:label="pip_PercentageOfNetProfitAwarded" xlink:title="pip_PercentageOfNetProfitAwarded" />
    <link:label xlink:type="resource" xlink:label="label_pip_PercentageOfNetProfitAwarded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_PercentageOfNetProfitAwarded" xml:lang="en-US" id="label_pip_PercentageOfNetProfitAwarded">Percentage of net profits awarded on the sales of ST-246 and related products.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_PercentageOfNetProfitAwarded" xlink:to="label_pip_PercentageOfNetProfitAwarded" xlink:title="Label : pip_PercentageOfNetProfitAwarded to label_pip_PercentageOfNetProfitAwarded" />
    <link:label xlink:type="resource" xlink:label="label_pip_PercentageOfNetProfitAwarded_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_PercentageOfNetProfitAwarded_1" xml:lang="en-US" id="label_pip_PercentageOfNetProfitAwarded_1">Percentage Of Net Profit Awarded</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_PercentageOfNetProfitAwarded" xlink:to="label_pip_PercentageOfNetProfitAwarded_1" xlink:title="Label : pip_PercentageOfNetProfitAwarded to label_pip_PercentageOfNetProfitAwarded_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_PercentageOfNetProfitAwarded_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_PercentageOfNetProfitAwarded_2" xml:lang="en-US" id="label_pip_PercentageOfNetProfitAwarded_2">SIGA breach of contractual obligation awarded, percentage of net profits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_PercentageOfNetProfitAwarded" xlink:to="label_pip_PercentageOfNetProfitAwarded_2" xlink:title="Label : pip_PercentageOfNetProfitAwarded to label_pip_PercentageOfNetProfitAwarded_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_PharmAtheneMember" xlink:label="pip_PharmAtheneMember" xlink:title="pip_PharmAtheneMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_PharmAtheneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_PharmAtheneMember" xml:lang="en-US" id="label_pip_PharmAtheneMember">PharmAthene [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_PharmAtheneMember" xlink:to="label_pip_PharmAtheneMember" xlink:title="Label : pip_PharmAtheneMember to label_pip_PharmAtheneMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_PharmAtheneMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_PharmAtheneMember_1" xml:lang="en-US" id="label_pip_PharmAtheneMember_1">Pharm Athene [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_PharmAtheneMember" xlink:to="label_pip_PharmAtheneMember_1" xlink:title="Label : pip_PharmAtheneMember to label_pip_PharmAtheneMember_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_PharmAtheneMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_PharmAtheneMember_2" xml:lang="en-US" id="label_pip_PharmAtheneMember_2">PharmAthene</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_PharmAtheneMember" xlink:to="label_pip_PharmAtheneMember_2" xlink:title="Label : pip_PharmAtheneMember to label_pip_PharmAtheneMember_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_PreviousProceedsFromIssuanceOfCommonStockReceived" xlink:label="pip_PreviousProceedsFromIssuanceOfCommonStockReceived" xlink:title="pip_PreviousProceedsFromIssuanceOfCommonStockReceived" />
    <link:label xlink:type="resource" xlink:label="label_pip_PreviousProceedsFromIssuanceOfCommonStockReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_PreviousProceedsFromIssuanceOfCommonStockReceived" xml:lang="en-US" id="label_pip_PreviousProceedsFromIssuanceOfCommonStockReceived">Previous Proceeds From Issuance Of Common Stock Received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_PreviousProceedsFromIssuanceOfCommonStockReceived" xlink:to="label_pip_PreviousProceedsFromIssuanceOfCommonStockReceived" xlink:title="Label : pip_PreviousProceedsFromIssuanceOfCommonStockReceived to label_pip_PreviousProceedsFromIssuanceOfCommonStockReceived" />
    <link:label xlink:type="resource" xlink:label="label_pip_PreviousProceedsFromIssuanceOfCommonStockReceived_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_PreviousProceedsFromIssuanceOfCommonStockReceived_1" xml:lang="en-US" id="label_pip_PreviousProceedsFromIssuanceOfCommonStockReceived_1">Previous Proceeds From Issuance Of Common Stock Received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_PreviousProceedsFromIssuanceOfCommonStockReceived" xlink:to="label_pip_PreviousProceedsFromIssuanceOfCommonStockReceived_1" xlink:title="Label : pip_PreviousProceedsFromIssuanceOfCommonStockReceived to label_pip_PreviousProceedsFromIssuanceOfCommonStockReceived_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_PreviousProceedsFromIssuanceOfCommonStockReceived_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_PreviousProceedsFromIssuanceOfCommonStockReceived_2" xml:lang="en-US" id="label_pip_PreviousProceedsFromIssuanceOfCommonStockReceived_2">Proceeds from issuance of common stock, net of issuance costs received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_PreviousProceedsFromIssuanceOfCommonStockReceived" xlink:to="label_pip_PreviousProceedsFromIssuanceOfCommonStockReceived_2" xlink:title="Label : pip_PreviousProceedsFromIssuanceOfCommonStockReceived to label_pip_PreviousProceedsFromIssuanceOfCommonStockReceived_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AwardTypeAxis" xml:lang="en-US" id="label_us-gaap_AwardTypeAxis">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="label_us-gaap_AwardTypeAxis" xlink:title="Label : us-gaap_AwardTypeAxis to label_us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_RemainingValueOfStockIssuableUnderStockOffering" xlink:label="pip_RemainingValueOfStockIssuableUnderStockOffering" xlink:title="pip_RemainingValueOfStockIssuableUnderStockOffering" />
    <link:label xlink:type="resource" xlink:label="label_pip_RemainingValueOfStockIssuableUnderStockOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_RemainingValueOfStockIssuableUnderStockOffering" xml:lang="en-US" id="label_pip_RemainingValueOfStockIssuableUnderStockOffering">The remaining value of common stock issuable under the controlled equity offering arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_RemainingValueOfStockIssuableUnderStockOffering" xlink:to="label_pip_RemainingValueOfStockIssuableUnderStockOffering" xlink:title="Label : pip_RemainingValueOfStockIssuableUnderStockOffering to label_pip_RemainingValueOfStockIssuableUnderStockOffering" />
    <link:label xlink:type="resource" xlink:label="label_pip_RemainingValueOfStockIssuableUnderStockOffering_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_RemainingValueOfStockIssuableUnderStockOffering_1" xml:lang="en-US" id="label_pip_RemainingValueOfStockIssuableUnderStockOffering_1">Remaining Value Of Stock Issuable Under Stock Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_RemainingValueOfStockIssuableUnderStockOffering" xlink:to="label_pip_RemainingValueOfStockIssuableUnderStockOffering_1" xlink:title="Label : pip_RemainingValueOfStockIssuableUnderStockOffering to label_pip_RemainingValueOfStockIssuableUnderStockOffering_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_RemainingValueOfStockIssuableUnderStockOffering_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_RemainingValueOfStockIssuableUnderStockOffering_2" xml:lang="en-US" id="label_pip_RemainingValueOfStockIssuableUnderStockOffering_2">Amount remaining available under controlled equity offering sale arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_RemainingValueOfStockIssuableUnderStockOffering" xlink:to="label_pip_RemainingValueOfStockIssuableUnderStockOffering_2" xlink:title="Label : pip_RemainingValueOfStockIssuableUnderStockOffering to label_pip_RemainingValueOfStockIssuableUnderStockOffering_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate" xlink:label="pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate" xlink:title="pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate" xml:lang="en-US" id="label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate">Share based Compensation Arrangement by Share based Payment Award, Fair Value Assumptions, Annual Forfeiture Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate" xlink:to="label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate" xlink:title="Label : pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate to label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate_1" xml:lang="en-US" id="label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate_1">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Annual Forfeiture Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate" xlink:to="label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate_1" xlink:title="Label : pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate to label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate_2" xml:lang="en-US" id="label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate_2">Share-based compensation expense, forfeitures rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate" xlink:to="label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate_2" xlink:title="Label : pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate to label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:title="dei_EntityDomain" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityDomain" xml:lang="en-US" id="label_dei_EntityDomain">Entity [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="label_dei_EntityDomain" xlink:title="Label : dei_EntityDomain to label_dei_EntityDomain" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod" xlink:label="pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod" xlink:title="pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod" xml:lang="en-US" id="label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod">Share Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Granted in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod" xlink:to="label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod" xlink:title="Label : pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod to label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod_1" xml:lang="en-US" id="label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod_1">Share Based Compensation Arrangement By Share Based Payment Award Restricted Stock Units Granted In Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod" xlink:to="label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod_1" xlink:title="Label : pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod to label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod_2" xml:lang="en-US" id="label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod_2">Restricted stock granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod" xlink:to="label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod_2" xlink:title="Label : pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod to label_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationWarrantsPriceRangeFiveMember" xlink:label="pip_ShareBasedCompensationWarrantsPriceRangeFiveMember" xlink:title="pip_ShareBasedCompensationWarrantsPriceRangeFiveMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationWarrantsPriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_ShareBasedCompensationWarrantsPriceRangeFiveMember" xml:lang="en-US" id="label_pip_ShareBasedCompensationWarrantsPriceRangeFiveMember">Share Based Compensation Warrants Price Range Five Member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationWarrantsPriceRangeFiveMember" xlink:to="label_pip_ShareBasedCompensationWarrantsPriceRangeFiveMember" xlink:title="Label : pip_ShareBasedCompensationWarrantsPriceRangeFiveMember to label_pip_ShareBasedCompensationWarrantsPriceRangeFiveMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationWarrantsPriceRangeFiveMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_ShareBasedCompensationWarrantsPriceRangeFiveMember_1" xml:lang="en-US" id="label_pip_ShareBasedCompensationWarrantsPriceRangeFiveMember_1">Share Based Compensation Warrants Price Range Five [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationWarrantsPriceRangeFiveMember" xlink:to="label_pip_ShareBasedCompensationWarrantsPriceRangeFiveMember_1" xlink:title="Label : pip_ShareBasedCompensationWarrantsPriceRangeFiveMember to label_pip_ShareBasedCompensationWarrantsPriceRangeFiveMember_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationWarrantsPriceRangeFiveMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_ShareBasedCompensationWarrantsPriceRangeFiveMember_2" xml:lang="en-US" id="label_pip_ShareBasedCompensationWarrantsPriceRangeFiveMember_2">1.63 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationWarrantsPriceRangeFiveMember" xlink:to="label_pip_ShareBasedCompensationWarrantsPriceRangeFiveMember_2" xlink:title="Label : pip_ShareBasedCompensationWarrantsPriceRangeFiveMember to label_pip_ShareBasedCompensationWarrantsPriceRangeFiveMember_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationWarrantsPriceRangeFourMember" xlink:label="pip_ShareBasedCompensationWarrantsPriceRangeFourMember" xlink:title="pip_ShareBasedCompensationWarrantsPriceRangeFourMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationWarrantsPriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_ShareBasedCompensationWarrantsPriceRangeFourMember" xml:lang="en-US" id="label_pip_ShareBasedCompensationWarrantsPriceRangeFourMember">Share Based Compensation Warrants Price Range Four Member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationWarrantsPriceRangeFourMember" xlink:to="label_pip_ShareBasedCompensationWarrantsPriceRangeFourMember" xlink:title="Label : pip_ShareBasedCompensationWarrantsPriceRangeFourMember to label_pip_ShareBasedCompensationWarrantsPriceRangeFourMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationWarrantsPriceRangeFourMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_ShareBasedCompensationWarrantsPriceRangeFourMember_1" xml:lang="en-US" id="label_pip_ShareBasedCompensationWarrantsPriceRangeFourMember_1">Share Based Compensation Warrants Price Range Four [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationWarrantsPriceRangeFourMember" xlink:to="label_pip_ShareBasedCompensationWarrantsPriceRangeFourMember_1" xlink:title="Label : pip_ShareBasedCompensationWarrantsPriceRangeFourMember to label_pip_ShareBasedCompensationWarrantsPriceRangeFourMember_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationWarrantsPriceRangeFourMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_ShareBasedCompensationWarrantsPriceRangeFourMember_2" xml:lang="en-US" id="label_pip_ShareBasedCompensationWarrantsPriceRangeFourMember_2">1.89 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationWarrantsPriceRangeFourMember" xlink:to="label_pip_ShareBasedCompensationWarrantsPriceRangeFourMember_2" xlink:title="Label : pip_ShareBasedCompensationWarrantsPriceRangeFourMember to label_pip_ShareBasedCompensationWarrantsPriceRangeFourMember_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationWarrantsPriceRangeOneMember" xlink:label="pip_ShareBasedCompensationWarrantsPriceRangeOneMember" xlink:title="pip_ShareBasedCompensationWarrantsPriceRangeOneMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationWarrantsPriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_ShareBasedCompensationWarrantsPriceRangeOneMember" xml:lang="en-US" id="label_pip_ShareBasedCompensationWarrantsPriceRangeOneMember">Share Based Compensation Warrants Price Range One Member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationWarrantsPriceRangeOneMember" xlink:to="label_pip_ShareBasedCompensationWarrantsPriceRangeOneMember" xlink:title="Label : pip_ShareBasedCompensationWarrantsPriceRangeOneMember to label_pip_ShareBasedCompensationWarrantsPriceRangeOneMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationWarrantsPriceRangeOneMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_ShareBasedCompensationWarrantsPriceRangeOneMember_1" xml:lang="en-US" id="label_pip_ShareBasedCompensationWarrantsPriceRangeOneMember_1">Share Based Compensation Warrants Price Range One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationWarrantsPriceRangeOneMember" xlink:to="label_pip_ShareBasedCompensationWarrantsPriceRangeOneMember_1" xlink:title="Label : pip_ShareBasedCompensationWarrantsPriceRangeOneMember to label_pip_ShareBasedCompensationWarrantsPriceRangeOneMember_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationWarrantsPriceRangeOneMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_ShareBasedCompensationWarrantsPriceRangeOneMember_2" xml:lang="en-US" id="label_pip_ShareBasedCompensationWarrantsPriceRangeOneMember_2">3.97 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationWarrantsPriceRangeOneMember" xlink:to="label_pip_ShareBasedCompensationWarrantsPriceRangeOneMember_2" xlink:title="Label : pip_ShareBasedCompensationWarrantsPriceRangeOneMember to label_pip_ShareBasedCompensationWarrantsPriceRangeOneMember_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationWarrantsPriceRangeSevenMember" xlink:label="pip_ShareBasedCompensationWarrantsPriceRangeSevenMember" xlink:title="pip_ShareBasedCompensationWarrantsPriceRangeSevenMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationWarrantsPriceRangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_ShareBasedCompensationWarrantsPriceRangeSevenMember" xml:lang="en-US" id="label_pip_ShareBasedCompensationWarrantsPriceRangeSevenMember">Share Based Compensation Warrants Price Range Seven Member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationWarrantsPriceRangeSevenMember" xlink:to="label_pip_ShareBasedCompensationWarrantsPriceRangeSevenMember" xlink:title="Label : pip_ShareBasedCompensationWarrantsPriceRangeSevenMember to label_pip_ShareBasedCompensationWarrantsPriceRangeSevenMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationWarrantsPriceRangeSevenMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_ShareBasedCompensationWarrantsPriceRangeSevenMember_1" xml:lang="en-US" id="label_pip_ShareBasedCompensationWarrantsPriceRangeSevenMember_1">Share Based Compensation Warrants Price Range Seven [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationWarrantsPriceRangeSevenMember" xlink:to="label_pip_ShareBasedCompensationWarrantsPriceRangeSevenMember_1" xlink:title="Label : pip_ShareBasedCompensationWarrantsPriceRangeSevenMember to label_pip_ShareBasedCompensationWarrantsPriceRangeSevenMember_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationWarrantsPriceRangeSevenMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_ShareBasedCompensationWarrantsPriceRangeSevenMember_2" xml:lang="en-US" id="label_pip_ShareBasedCompensationWarrantsPriceRangeSevenMember_2">1.61 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationWarrantsPriceRangeSevenMember" xlink:to="label_pip_ShareBasedCompensationWarrantsPriceRangeSevenMember_2" xlink:title="Label : pip_ShareBasedCompensationWarrantsPriceRangeSevenMember to label_pip_ShareBasedCompensationWarrantsPriceRangeSevenMember_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationWarrantsPriceRangeSixMember" xlink:label="pip_ShareBasedCompensationWarrantsPriceRangeSixMember" xlink:title="pip_ShareBasedCompensationWarrantsPriceRangeSixMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationWarrantsPriceRangeSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_ShareBasedCompensationWarrantsPriceRangeSixMember" xml:lang="en-US" id="label_pip_ShareBasedCompensationWarrantsPriceRangeSixMember">Share Based Compensation Warrants Price Range Six Member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationWarrantsPriceRangeSixMember" xlink:to="label_pip_ShareBasedCompensationWarrantsPriceRangeSixMember" xlink:title="Label : pip_ShareBasedCompensationWarrantsPriceRangeSixMember to label_pip_ShareBasedCompensationWarrantsPriceRangeSixMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationWarrantsPriceRangeSixMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_ShareBasedCompensationWarrantsPriceRangeSixMember_1" xml:lang="en-US" id="label_pip_ShareBasedCompensationWarrantsPriceRangeSixMember_1">Share Based Compensation Warrants Price Range Six [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationWarrantsPriceRangeSixMember" xlink:to="label_pip_ShareBasedCompensationWarrantsPriceRangeSixMember_1" xlink:title="Label : pip_ShareBasedCompensationWarrantsPriceRangeSixMember to label_pip_ShareBasedCompensationWarrantsPriceRangeSixMember_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationWarrantsPriceRangeSixMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_ShareBasedCompensationWarrantsPriceRangeSixMember_2" xml:lang="en-US" id="label_pip_ShareBasedCompensationWarrantsPriceRangeSixMember_2">3.50 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationWarrantsPriceRangeSixMember" xlink:to="label_pip_ShareBasedCompensationWarrantsPriceRangeSixMember_2" xlink:title="Label : pip_ShareBasedCompensationWarrantsPriceRangeSixMember to label_pip_ShareBasedCompensationWarrantsPriceRangeSixMember_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationWarrantsPriceRangeThreeMember" xlink:label="pip_ShareBasedCompensationWarrantsPriceRangeThreeMember" xlink:title="pip_ShareBasedCompensationWarrantsPriceRangeThreeMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationWarrantsPriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_ShareBasedCompensationWarrantsPriceRangeThreeMember" xml:lang="en-US" id="label_pip_ShareBasedCompensationWarrantsPriceRangeThreeMember">Share Based Compensation Warrants Price Range Three Member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationWarrantsPriceRangeThreeMember" xlink:to="label_pip_ShareBasedCompensationWarrantsPriceRangeThreeMember" xlink:title="Label : pip_ShareBasedCompensationWarrantsPriceRangeThreeMember to label_pip_ShareBasedCompensationWarrantsPriceRangeThreeMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationWarrantsPriceRangeThreeMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_ShareBasedCompensationWarrantsPriceRangeThreeMember_1" xml:lang="en-US" id="label_pip_ShareBasedCompensationWarrantsPriceRangeThreeMember_1">Share Based Compensation Warrants Price Range Three [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationWarrantsPriceRangeThreeMember" xlink:to="label_pip_ShareBasedCompensationWarrantsPriceRangeThreeMember_1" xlink:title="Label : pip_ShareBasedCompensationWarrantsPriceRangeThreeMember to label_pip_ShareBasedCompensationWarrantsPriceRangeThreeMember_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationWarrantsPriceRangeThreeMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_ShareBasedCompensationWarrantsPriceRangeThreeMember_2" xml:lang="en-US" id="label_pip_ShareBasedCompensationWarrantsPriceRangeThreeMember_2">2.50 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationWarrantsPriceRangeThreeMember" xlink:to="label_pip_ShareBasedCompensationWarrantsPriceRangeThreeMember_2" xlink:title="Label : pip_ShareBasedCompensationWarrantsPriceRangeThreeMember to label_pip_ShareBasedCompensationWarrantsPriceRangeThreeMember_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationWarrantsPriceRangeTwoMember" xlink:label="pip_ShareBasedCompensationWarrantsPriceRangeTwoMember" xlink:title="pip_ShareBasedCompensationWarrantsPriceRangeTwoMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationWarrantsPriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_ShareBasedCompensationWarrantsPriceRangeTwoMember" xml:lang="en-US" id="label_pip_ShareBasedCompensationWarrantsPriceRangeTwoMember">Share Based Compensation Warrants Price Range Two Member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationWarrantsPriceRangeTwoMember" xlink:to="label_pip_ShareBasedCompensationWarrantsPriceRangeTwoMember" xlink:title="Label : pip_ShareBasedCompensationWarrantsPriceRangeTwoMember to label_pip_ShareBasedCompensationWarrantsPriceRangeTwoMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationWarrantsPriceRangeTwoMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_ShareBasedCompensationWarrantsPriceRangeTwoMember_1" xml:lang="en-US" id="label_pip_ShareBasedCompensationWarrantsPriceRangeTwoMember_1">Share Based Compensation Warrants Price Range Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationWarrantsPriceRangeTwoMember" xlink:to="label_pip_ShareBasedCompensationWarrantsPriceRangeTwoMember_1" xlink:title="Label : pip_ShareBasedCompensationWarrantsPriceRangeTwoMember to label_pip_ShareBasedCompensationWarrantsPriceRangeTwoMember_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationWarrantsPriceRangeTwoMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_ShareBasedCompensationWarrantsPriceRangeTwoMember_2" xml:lang="en-US" id="label_pip_ShareBasedCompensationWarrantsPriceRangeTwoMember_2">3.00 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationWarrantsPriceRangeTwoMember" xlink:to="label_pip_ShareBasedCompensationWarrantsPriceRangeTwoMember_2" xlink:title="Label : pip_ShareBasedCompensationWarrantsPriceRangeTwoMember to label_pip_ShareBasedCompensationWarrantsPriceRangeTwoMember_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_SignificantAccountingPoliciesLineItems" xlink:label="pip_SignificantAccountingPoliciesLineItems" xlink:title="pip_SignificantAccountingPoliciesLineItems" />
    <link:label xlink:type="resource" xlink:label="label_pip_SignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_SignificantAccountingPoliciesLineItems" xml:lang="en-US" id="label_pip_SignificantAccountingPoliciesLineItems">Significant Accounting Policies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_SignificantAccountingPoliciesLineItems" xlink:to="label_pip_SignificantAccountingPoliciesLineItems" xlink:title="Label : pip_SignificantAccountingPoliciesLineItems to label_pip_SignificantAccountingPoliciesLineItems" />
    <link:label xlink:type="resource" xlink:label="label_pip_SignificantAccountingPoliciesLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_SignificantAccountingPoliciesLineItems_1" xml:lang="en-US" id="label_pip_SignificantAccountingPoliciesLineItems_1">Significant Accounting Policies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_SignificantAccountingPoliciesLineItems" xlink:to="label_pip_SignificantAccountingPoliciesLineItems_1" xlink:title="Label : pip_SignificantAccountingPoliciesLineItems to label_pip_SignificantAccountingPoliciesLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_SignificantAccountingPoliciesTable" xlink:label="pip_SignificantAccountingPoliciesTable" xlink:title="pip_SignificantAccountingPoliciesTable" />
    <link:label xlink:type="resource" xlink:label="label_pip_SignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_SignificantAccountingPoliciesTable" xml:lang="en-US" id="label_pip_SignificantAccountingPoliciesTable">Significant Accounting Policies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_SignificantAccountingPoliciesTable" xlink:to="label_pip_SignificantAccountingPoliciesTable" xlink:title="Label : pip_SignificantAccountingPoliciesTable to label_pip_SignificantAccountingPoliciesTable" />
    <link:label xlink:type="resource" xlink:label="label_pip_SignificantAccountingPoliciesTable_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_SignificantAccountingPoliciesTable_1" xml:lang="en-US" id="label_pip_SignificantAccountingPoliciesTable_1">Significant Accounting Policies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_SignificantAccountingPoliciesTable" xlink:to="label_pip_SignificantAccountingPoliciesTable_1" xlink:title="Label : pip_SignificantAccountingPoliciesTable to label_pip_SignificantAccountingPoliciesTable_1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_StockholdersEquityLineItems" xlink:label="pip_StockholdersEquityLineItems" xlink:title="pip_StockholdersEquityLineItems" />
    <link:label xlink:type="resource" xlink:label="label_pip_StockholdersEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_StockholdersEquityLineItems" xml:lang="en-US" id="label_pip_StockholdersEquityLineItems">Stockholders Equity [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_StockholdersEquityLineItems" xlink:to="label_pip_StockholdersEquityLineItems" xlink:title="Label : pip_StockholdersEquityLineItems to label_pip_StockholdersEquityLineItems" />
    <link:label xlink:type="resource" xlink:label="label_pip_StockholdersEquityLineItems_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_StockholdersEquityLineItems_1" xml:lang="en-US" id="label_pip_StockholdersEquityLineItems_1">Stockholders Equity [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_StockholdersEquityLineItems" xlink:to="label_pip_StockholdersEquityLineItems_1" xlink:title="Label : pip_StockholdersEquityLineItems to label_pip_StockholdersEquityLineItems_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_StockholdersEquityLineItems_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_StockholdersEquityLineItems_2" xml:lang="en-US" id="label_pip_StockholdersEquityLineItems_2">Stockholders Equity [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_StockholdersEquityLineItems" xlink:to="label_pip_StockholdersEquityLineItems_2" xlink:title="Label : pip_StockholdersEquityLineItems to label_pip_StockholdersEquityLineItems_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_StockholdersEquityTable" xlink:label="pip_StockholdersEquityTable" xlink:title="pip_StockholdersEquityTable" />
    <link:label xlink:type="resource" xlink:label="label_pip_StockholdersEquityTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_StockholdersEquityTable" xml:lang="en-US" id="label_pip_StockholdersEquityTable">Stockholders' Equity [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_StockholdersEquityTable" xlink:to="label_pip_StockholdersEquityTable" xlink:title="Label : pip_StockholdersEquityTable to label_pip_StockholdersEquityTable" />
    <link:label xlink:type="resource" xlink:label="label_pip_StockholdersEquityTable_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_StockholdersEquityTable_1" xml:lang="en-US" id="label_pip_StockholdersEquityTable_1">Stockholders Equity [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_StockholdersEquityTable" xlink:to="label_pip_StockholdersEquityTable_1" xlink:title="Label : pip_StockholdersEquityTable to label_pip_StockholdersEquityTable_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_StockholdersEquityTable_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_StockholdersEquityTable_2" xml:lang="en-US" id="label_pip_StockholdersEquityTable_2">Stockholders' Equity [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_StockholdersEquityTable" xlink:to="label_pip_StockholdersEquityTable_2" xlink:title="Label : pip_StockholdersEquityTable to label_pip_StockholdersEquityTable_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_StockIncentivePlanTwentyZeroSevenMember" xlink:label="pip_StockIncentivePlanTwentyZeroSevenMember" xlink:title="pip_StockIncentivePlanTwentyZeroSevenMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_StockIncentivePlanTwentyZeroSevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_StockIncentivePlanTwentyZeroSevenMember" xml:lang="en-US" id="label_pip_StockIncentivePlanTwentyZeroSevenMember">Stock Incentive Plan 2007 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_StockIncentivePlanTwentyZeroSevenMember" xlink:to="label_pip_StockIncentivePlanTwentyZeroSevenMember" xlink:title="Label : pip_StockIncentivePlanTwentyZeroSevenMember to label_pip_StockIncentivePlanTwentyZeroSevenMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_StockIncentivePlanTwentyZeroSevenMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_StockIncentivePlanTwentyZeroSevenMember_1" xml:lang="en-US" id="label_pip_StockIncentivePlanTwentyZeroSevenMember_1">Stock Incentive Plan Twenty Zero Seven [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_StockIncentivePlanTwentyZeroSevenMember" xlink:to="label_pip_StockIncentivePlanTwentyZeroSevenMember_1" xlink:title="Label : pip_StockIncentivePlanTwentyZeroSevenMember to label_pip_StockIncentivePlanTwentyZeroSevenMember_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_StockIncentivePlanTwentyZeroSevenMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_StockIncentivePlanTwentyZeroSevenMember_2" xml:lang="en-US" id="label_pip_StockIncentivePlanTwentyZeroSevenMember_2">2007 Long Term Incentive Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_StockIncentivePlanTwentyZeroSevenMember" xlink:to="label_pip_StockIncentivePlanTwentyZeroSevenMember_2" xlink:title="Label : pip_StockIncentivePlanTwentyZeroSevenMember to label_pip_StockIncentivePlanTwentyZeroSevenMember_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants" xlink:label="pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants" xlink:title="pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants" />
    <link:label xlink:type="resource" xlink:label="label_pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants" xml:lang="en-US" id="label_pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants">Stock Issued Value Convertible Notes And Stock Purchase Warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants" xlink:to="label_pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants" xlink:title="Label : pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants to label_pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants" />
    <link:label xlink:type="resource" xlink:label="label_pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants_1" xml:lang="en-US" id="label_pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants_1">Stock Issued Value Convertible Notes And Stock Purchase Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants" xlink:to="label_pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants_1" xlink:title="Label : pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants to label_pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants_2" xml:lang="en-US" id="label_pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants_2">Stock issued of convertible notes and stock purchase warrants, Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants" xlink:to="label_pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants_2" xlink:title="Label : pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants to label_pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_StockOptionsContractualTerm" xlink:label="pip_StockOptionsContractualTerm" xlink:title="pip_StockOptionsContractualTerm" />
    <link:label xlink:type="resource" xlink:label="label_pip_StockOptionsContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_StockOptionsContractualTerm" xml:lang="en-US" id="label_pip_StockOptionsContractualTerm">Stock Options Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_StockOptionsContractualTerm" xlink:to="label_pip_StockOptionsContractualTerm" xlink:title="Label : pip_StockOptionsContractualTerm to label_pip_StockOptionsContractualTerm" />
    <link:label xlink:type="resource" xlink:label="label_pip_StockOptionsContractualTerm_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_StockOptionsContractualTerm_1" xml:lang="en-US" id="label_pip_StockOptionsContractualTerm_1">Stock Options Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_StockOptionsContractualTerm" xlink:to="label_pip_StockOptionsContractualTerm_1" xlink:title="Label : pip_StockOptionsContractualTerm to label_pip_StockOptionsContractualTerm_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_StockOptionsContractualTerm_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_StockOptionsContractualTerm_2" xml:lang="en-US" id="label_pip_StockOptionsContractualTerm_2">Options award term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_StockOptionsContractualTerm" xlink:to="label_pip_StockOptionsContractualTerm_2" xlink:title="Label : pip_StockOptionsContractualTerm to label_pip_StockOptionsContractualTerm_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan" xlink:label="pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan" xlink:title="pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan" />
    <link:label xlink:type="resource" xlink:label="label_pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan" xml:lang="en-US" id="label_pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan">Value of warrants issued to lender in connection with loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan" xlink:to="label_pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan" xlink:title="Label : pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan to label_pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan" />
    <link:label xlink:type="resource" xlink:label="label_pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan_1" xml:lang="en-US" id="label_pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan_1">Value Of Warrant Issued To Lender In Connection With Loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan" xlink:to="label_pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan_1" xlink:title="Label : pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan to label_pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan_2" xml:lang="en-US" id="label_pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan_2">Value of warrants issued to lender in connection with loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan" xlink:to="label_pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan_2" xlink:title="Label : pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan to label_pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_WarrantExpirationDate" xlink:label="pip_WarrantExpirationDate" xlink:title="pip_WarrantExpirationDate" />
    <link:label xlink:type="resource" xlink:label="label_pip_WarrantExpirationDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_WarrantExpirationDate" xml:lang="en-US" id="label_pip_WarrantExpirationDate">Warrant, Expiration Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_WarrantExpirationDate" xlink:to="label_pip_WarrantExpirationDate" xlink:title="Label : pip_WarrantExpirationDate to label_pip_WarrantExpirationDate" />
    <link:label xlink:type="resource" xlink:label="label_pip_WarrantExpirationDate_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_WarrantExpirationDate_1" xml:lang="en-US" id="label_pip_WarrantExpirationDate_1">Warrant Expiration Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_WarrantExpirationDate" xlink:to="label_pip_WarrantExpirationDate_1" xlink:title="Label : pip_WarrantExpirationDate to label_pip_WarrantExpirationDate_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_WarrantExpirationDate_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_WarrantExpirationDate_2" xml:lang="en-US" id="label_pip_WarrantExpirationDate_2">Expiration Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_WarrantExpirationDate" xlink:to="label_pip_WarrantExpirationDate_2" xlink:title="Label : pip_WarrantExpirationDate to label_pip_WarrantExpirationDate_2" />
    <link:label xlink:type="resource" xlink:label="label_pip_WarrantExpirationDate_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_pip_WarrantExpirationDate_3" xml:lang="en-US" id="label_pip_WarrantExpirationDate_3">Warrant expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_WarrantExpirationDate" xlink:to="label_pip_WarrantExpirationDate_3" xlink:title="Label : pip_WarrantExpirationDate to label_pip_WarrantExpirationDate_3" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement" xlink:label="pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement" xlink:title="pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement" />
    <link:label xlink:type="resource" xlink:label="label_pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement" xml:lang="en-US" id="label_pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement">Warrants Issued To Purchase Common Stock In Connection With Loan Agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement" xlink:to="label_pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement" xlink:title="Label : pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement to label_pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement" />
    <link:label xlink:type="resource" xlink:label="label_pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement_1" xml:lang="en-US" id="label_pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement_1">Warrants Issued To Purchase Common Stock In Connection To Loan Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement" xlink:to="label_pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement_1" xlink:title="Label : pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement to label_pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement_2" xml:lang="en-US" id="label_pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement_2">Warrants issued to purchase common stock, in connection with loan agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement" xlink:to="label_pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement_2" xlink:title="Label : pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement to label_pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:title="pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xml:lang="en-US" id="label_pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember">Represents information pertaining to National Institute of Allergy and Infectious Diseases ("NIAID").</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="label_pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:title="Label : pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember to label_pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember_1" xml:lang="en-US" id="label_pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember_1">National Institute of Allergy and Infectious Diseases [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="label_pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember_1" xlink:title="Label : pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember to label_pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember_2" xml:lang="en-US" id="label_pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember_2">NIAID</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:to="label_pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember_2" xlink:title="Label : pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember to label_pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:label="pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:title="pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xml:lang="en-US" id="label_pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">Represents information pertaining to Biomedical Advanced Research and Development Authority.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:to="label_pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:title="Label : pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember to label_pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_1" xml:lang="en-US" id="label_pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_1">Biomedical Advanced Research and Development Authority [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:to="label_pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_1" xlink:title="Label : pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember to label_pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_2" xml:lang="en-US" id="label_pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_2">BARDA [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:to="label_pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_2" xlink:title="Label : pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember to label_pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ProceedsFromInitialFunding" xlink:label="pip_ProceedsFromInitialFunding" xlink:title="pip_ProceedsFromInitialFunding" />
    <link:label xlink:type="resource" xlink:label="label_pip_ProceedsFromInitialFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_ProceedsFromInitialFunding" xml:lang="en-US" id="label_pip_ProceedsFromInitialFunding">Represents the amount of cash inflow from initial funding as per the agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ProceedsFromInitialFunding" xlink:to="label_pip_ProceedsFromInitialFunding" xlink:title="Label : pip_ProceedsFromInitialFunding to label_pip_ProceedsFromInitialFunding" />
    <link:label xlink:type="resource" xlink:label="label_pip_ProceedsFromInitialFunding_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_ProceedsFromInitialFunding_1" xml:lang="en-US" id="label_pip_ProceedsFromInitialFunding_1">Proceeds from Initial Funding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ProceedsFromInitialFunding" xlink:to="label_pip_ProceedsFromInitialFunding_1" xlink:title="Label : pip_ProceedsFromInitialFunding to label_pip_ProceedsFromInitialFunding_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_ProceedsFromInitialFunding_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_ProceedsFromInitialFunding_2" xml:lang="en-US" id="label_pip_ProceedsFromInitialFunding_2">Amount received from initial funding as per agreement, which includes a cost reimbursement component and a fixed fee component payable upon achievement of certain milestone events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ProceedsFromInitialFunding" xlink:to="label_pip_ProceedsFromInitialFunding_2" xlink:title="Label : pip_ProceedsFromInitialFunding to label_pip_ProceedsFromInitialFunding_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ValueOfAgreement" xlink:label="pip_ValueOfAgreement" xlink:title="pip_ValueOfAgreement" />
    <link:label xlink:type="resource" xlink:label="label_pip_ValueOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_ValueOfAgreement" xml:lang="en-US" id="label_pip_ValueOfAgreement">Represents the value of the agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ValueOfAgreement" xlink:to="label_pip_ValueOfAgreement" xlink:title="Label : pip_ValueOfAgreement to label_pip_ValueOfAgreement" />
    <link:label xlink:type="resource" xlink:label="label_pip_ValueOfAgreement_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_ValueOfAgreement_1" xml:lang="en-US" id="label_pip_ValueOfAgreement_1">Value of Agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ValueOfAgreement" xlink:to="label_pip_ValueOfAgreement_1" xlink:title="Label : pip_ValueOfAgreement to label_pip_ValueOfAgreement_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_ValueOfAgreement_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_ValueOfAgreement_2" xml:lang="en-US" id="label_pip_ValueOfAgreement_2">Total value of the agreement, assuming all development milestones are met and all contract options are exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ValueOfAgreement" xlink:to="label_pip_ValueOfAgreement_2" xlink:title="Label : pip_ValueOfAgreement to label_pip_ValueOfAgreement_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_NumberOfOptionsExercised" xlink:label="pip_NumberOfOptionsExercised" xlink:title="pip_NumberOfOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_pip_NumberOfOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_NumberOfOptionsExercised" xml:lang="en-US" id="label_pip_NumberOfOptionsExercised">Represents the number of options that can be exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_NumberOfOptionsExercised" xlink:to="label_pip_NumberOfOptionsExercised" xlink:title="Label : pip_NumberOfOptionsExercised to label_pip_NumberOfOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="label_pip_NumberOfOptionsExercised_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_NumberOfOptionsExercised_1" xml:lang="en-US" id="label_pip_NumberOfOptionsExercised_1">Number of Options Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_NumberOfOptionsExercised" xlink:to="label_pip_NumberOfOptionsExercised_1" xlink:title="Label : pip_NumberOfOptionsExercised to label_pip_NumberOfOptionsExercised_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_NumberOfOptionsExercised_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_NumberOfOptionsExercised_2" xml:lang="en-US" id="label_pip_NumberOfOptionsExercised_2">Number of options elected to be exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_NumberOfOptionsExercised" xlink:to="label_pip_NumberOfOptionsExercised_2" xlink:title="Label : pip_NumberOfOptionsExercised to label_pip_NumberOfOptionsExercised_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption" xlink:label="pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption" xlink:title="pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption" />
    <link:label xlink:type="resource" xlink:label="label_pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption" xml:lang="en-US" id="label_pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption">Represents the aggregate funding amounts to be received upon the exercise of each option.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption" xlink:to="label_pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption" xlink:title="Label : pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption to label_pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption" />
    <link:label xlink:type="resource" xlink:label="label_pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption_1" xml:lang="en-US" id="label_pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption_1">Aggregate Funding Amounts to be Received Upon Exercise of Each Option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption" xlink:to="label_pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption_1" xlink:title="Label : pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption to label_pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption_2" xml:lang="en-US" id="label_pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption_2">Aggregate funding amounts to be received upon the exercise of each option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption" xlink:to="label_pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption_2" xlink:title="Label : pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption to label_pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:title="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" />
    <link:label xlink:type="resource" xlink:label="label_pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xml:lang="en-US" id="label_pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable">Disclosure of information about organization, consolidation and basis of presentation of financial statements disclosure.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="label_pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:title="Label : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable to label_pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" />
    <link:label xlink:type="resource" xlink:label="label_pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_1" xml:lang="en-US" id="label_pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_1">Organization Consolidation and Presentation of Financial Statements Disclosure [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="label_pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_1" xlink:title="Label : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable to label_pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable_1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:title="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xml:lang="en-US" id="label_pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">Organization Consolidation and Presentation of Financial Statements [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="label_pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:title="Label : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to label_pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1" xml:lang="en-US" id="label_pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1">Organization and Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="label_pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1" xlink:title="Label : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to label_pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" xlink:label="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" xlink:title="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" />
    <link:label xlink:type="resource" xlink:label="label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" xml:lang="en-US" id="label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised">Represents the number of common shares exercised underlying stock purchase warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" xlink:to="label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" xlink:title="Label : pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised to label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" />
    <link:label xlink:type="resource" xlink:label="label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised_1" xml:lang="en-US" id="label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised_1">Class of Warrant or Right Outstanding Number of Shares Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" xlink:to="label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised_1" xlink:title="Label : pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised to label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised_2" xml:lang="en-US" id="label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised_2">Number of common shares exercised underlying stock purchase warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" xlink:to="label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised_2" xlink:title="Label : pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised to label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" xlink:label="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" xlink:title="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" />
    <link:label xlink:type="resource" xlink:label="label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" xml:lang="en-US" id="label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired">Represents the number of common shares expired underlying stock purchase warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" xlink:to="label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" xlink:title="Label : pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired to label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" />
    <link:label xlink:type="resource" xlink:label="label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired_1" xml:lang="en-US" id="label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired_1">Class of Warrant or Right Outstanding Number of Shares Expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" xlink:to="label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired_1" xlink:title="Label : pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired to label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired_2" xml:lang="en-US" id="label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired_2">Number of common shares expired underlying stock purchase warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" xlink:to="label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired_2" xlink:title="Label : pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired to label_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:title="dei_TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="label_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_TradingSymbol" xml:lang="en-US" id="label_dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="label_dei_TradingSymbol" xlink:title="Label : dei_TradingSymbol to label_dei_TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="label_dei_TradingSymbol_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_dei_TradingSymbol_1" xml:lang="en-US" id="label_dei_TradingSymbol_1">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="label_dei_TradingSymbol_1" xlink:title="Label : dei_TradingSymbol to label_dei_TradingSymbol_1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_InitialDerivativeFairValue" xlink:label="pip_InitialDerivativeFairValue" xlink:title="pip_InitialDerivativeFairValue" />
    <link:label xlink:type="resource" xlink:label="label_pip_InitialDerivativeFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_InitialDerivativeFairValue" xml:lang="en-US" id="label_pip_InitialDerivativeFairValue">Initial carrying value of derivative instruments issued during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_InitialDerivativeFairValue" xlink:to="label_pip_InitialDerivativeFairValue" xlink:title="Label : pip_InitialDerivativeFairValue to label_pip_InitialDerivativeFairValue" />
    <link:label xlink:type="resource" xlink:label="label_pip_InitialDerivativeFairValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_InitialDerivativeFairValue_1" xml:lang="en-US" id="label_pip_InitialDerivativeFairValue_1">Initial Derivative Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_InitialDerivativeFairValue" xlink:to="label_pip_InitialDerivativeFairValue_1" xlink:title="Label : pip_InitialDerivativeFairValue to label_pip_InitialDerivativeFairValue_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_InitialDerivativeFairValue_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_InitialDerivativeFairValue_2" xml:lang="en-US" id="label_pip_InitialDerivativeFairValue_2">New Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_InitialDerivativeFairValue" xlink:to="label_pip_InitialDerivativeFairValue_2" xlink:title="Label : pip_InitialDerivativeFairValue to label_pip_InitialDerivativeFairValue_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_BiologicLicenseApplicationApprovalMember" xlink:label="pip_BiologicLicenseApplicationApprovalMember" xlink:title="pip_BiologicLicenseApplicationApprovalMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_BiologicLicenseApplicationApprovalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_BiologicLicenseApplicationApprovalMember" xml:lang="en-US" id="label_pip_BiologicLicenseApplicationApprovalMember">Biologic License Application Approval Member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_BiologicLicenseApplicationApprovalMember" xlink:to="label_pip_BiologicLicenseApplicationApprovalMember" xlink:title="Label : pip_BiologicLicenseApplicationApprovalMember to label_pip_BiologicLicenseApplicationApprovalMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_BiologicLicenseApplicationApprovalMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_BiologicLicenseApplicationApprovalMember_1" xml:lang="en-US" id="label_pip_BiologicLicenseApplicationApprovalMember_1">Biologic License Application Approval [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_BiologicLicenseApplicationApprovalMember" xlink:to="label_pip_BiologicLicenseApplicationApprovalMember_1" xlink:title="Label : pip_BiologicLicenseApplicationApprovalMember to label_pip_BiologicLicenseApplicationApprovalMember_1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_MilestonePaymentsMember" xlink:label="pip_MilestonePaymentsMember" xlink:title="pip_MilestonePaymentsMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_MilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_MilestonePaymentsMember" xml:lang="en-US" id="label_pip_MilestonePaymentsMember">Milestone Payments Member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_MilestonePaymentsMember" xlink:to="label_pip_MilestonePaymentsMember" xlink:title="Label : pip_MilestonePaymentsMember to label_pip_MilestonePaymentsMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_MilestonePaymentsMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_MilestonePaymentsMember_1" xml:lang="en-US" id="label_pip_MilestonePaymentsMember_1">Milestone Payments [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_MilestonePaymentsMember" xlink:to="label_pip_MilestonePaymentsMember_1" xlink:title="Label : pip_MilestonePaymentsMember to label_pip_MilestonePaymentsMember_1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_StudiesOrTrailsMember" xlink:label="pip_StudiesOrTrailsMember" xlink:title="pip_StudiesOrTrailsMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_StudiesOrTrailsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_StudiesOrTrailsMember" xml:lang="en-US" id="label_pip_StudiesOrTrailsMember">Studies Or Trails Member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_StudiesOrTrailsMember" xlink:to="label_pip_StudiesOrTrailsMember" xlink:title="Label : pip_StudiesOrTrailsMember to label_pip_StudiesOrTrailsMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_StudiesOrTrailsMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_StudiesOrTrailsMember_1" xml:lang="en-US" id="label_pip_StudiesOrTrailsMember_1">Studies Or Trails [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_StudiesOrTrailsMember" xlink:to="label_pip_StudiesOrTrailsMember_1" xlink:title="Label : pip_StudiesOrTrailsMember to label_pip_StudiesOrTrailsMember_1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_SublicenseFeePercent" xlink:label="pip_SublicenseFeePercent" xlink:title="pip_SublicenseFeePercent" />
    <link:label xlink:type="resource" xlink:label="label_pip_SublicenseFeePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_SublicenseFeePercent" xml:lang="en-US" id="label_pip_SublicenseFeePercent">Sublicense Fee Percent.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_SublicenseFeePercent" xlink:to="label_pip_SublicenseFeePercent" xlink:title="Label : pip_SublicenseFeePercent to label_pip_SublicenseFeePercent" />
    <link:label xlink:type="resource" xlink:label="label_pip_SublicenseFeePercent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_SublicenseFeePercent_1" xml:lang="en-US" id="label_pip_SublicenseFeePercent_1">Sublicense Fee Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_SublicenseFeePercent" xlink:to="label_pip_SublicenseFeePercent_1" xlink:title="Label : pip_SublicenseFeePercent to label_pip_SublicenseFeePercent_1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_UpfrontPaymentMember" xlink:label="pip_UpfrontPaymentMember" xlink:title="pip_UpfrontPaymentMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_UpfrontPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_UpfrontPaymentMember" xml:lang="en-US" id="label_pip_UpfrontPaymentMember">Upfront Payment Member.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_UpfrontPaymentMember" xlink:to="label_pip_UpfrontPaymentMember" xlink:title="Label : pip_UpfrontPaymentMember to label_pip_UpfrontPaymentMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_UpfrontPaymentMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_UpfrontPaymentMember_1" xml:lang="en-US" id="label_pip_UpfrontPaymentMember_1">Upfront Payment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_UpfrontPaymentMember" xlink:to="label_pip_UpfrontPaymentMember_1" xlink:title="Label : pip_UpfrontPaymentMember to label_pip_UpfrontPaymentMember_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_UpfrontPaymentMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_UpfrontPaymentMember_2" xml:lang="en-US" id="label_pip_UpfrontPaymentMember_2">Upfront Payment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_UpfrontPaymentMember" xlink:to="label_pip_UpfrontPaymentMember_2" xlink:title="Label : pip_UpfrontPaymentMember to label_pip_UpfrontPaymentMember_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_LitigationSettlementInterestPercentage" xlink:label="pip_LitigationSettlementInterestPercentage" xlink:title="pip_LitigationSettlementInterestPercentage" />
    <link:label xlink:type="resource" xlink:label="label_pip_LitigationSettlementInterestPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_LitigationSettlementInterestPercentage" xml:lang="en-US" id="label_pip_LitigationSettlementInterestPercentage">The percent of interest to be paid as part of a litigation settlement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_LitigationSettlementInterestPercentage" xlink:to="label_pip_LitigationSettlementInterestPercentage" xlink:title="Label : pip_LitigationSettlementInterestPercentage to label_pip_LitigationSettlementInterestPercentage" />
    <link:label xlink:type="resource" xlink:label="label_pip_LitigationSettlementInterestPercentage_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_LitigationSettlementInterestPercentage_1" xml:lang="en-US" id="label_pip_LitigationSettlementInterestPercentage_1">Litigation Settlement Interest Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_LitigationSettlementInterestPercentage" xlink:to="label_pip_LitigationSettlementInterestPercentage_1" xlink:title="Label : pip_LitigationSettlementInterestPercentage to label_pip_LitigationSettlementInterestPercentage_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_LitigationSettlementInterestPercentage_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_LitigationSettlementInterestPercentage_2" xml:lang="en-US" id="label_pip_LitigationSettlementInterestPercentage_2">Post-judgment simple interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_LitigationSettlementInterestPercentage" xlink:to="label_pip_LitigationSettlementInterestPercentage_2" xlink:title="Label : pip_LitigationSettlementInterestPercentage to label_pip_LitigationSettlementInterestPercentage_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationExtensionOfExercisePeriod" xlink:label="pip_ShareBasedCompensationExtensionOfExercisePeriod" xlink:title="pip_ShareBasedCompensationExtensionOfExercisePeriod" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationExtensionOfExercisePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_ShareBasedCompensationExtensionOfExercisePeriod" xml:lang="en-US" id="label_pip_ShareBasedCompensationExtensionOfExercisePeriod">Amount of share based compensation expense incurred during the period due to the extension of the exercise period of vested stock options.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationExtensionOfExercisePeriod" xlink:to="label_pip_ShareBasedCompensationExtensionOfExercisePeriod" xlink:title="Label : pip_ShareBasedCompensationExtensionOfExercisePeriod to label_pip_ShareBasedCompensationExtensionOfExercisePeriod" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationExtensionOfExercisePeriod_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_ShareBasedCompensationExtensionOfExercisePeriod_1" xml:lang="en-US" id="label_pip_ShareBasedCompensationExtensionOfExercisePeriod_1">Share Based Compensation Extension Of Exercise Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationExtensionOfExercisePeriod" xlink:to="label_pip_ShareBasedCompensationExtensionOfExercisePeriod_1" xlink:title="Label : pip_ShareBasedCompensationExtensionOfExercisePeriod to label_pip_ShareBasedCompensationExtensionOfExercisePeriod_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationExtensionOfExercisePeriod_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_ShareBasedCompensationExtensionOfExercisePeriod_2" xml:lang="en-US" id="label_pip_ShareBasedCompensationExtensionOfExercisePeriod_2">Share-based compensation expense, extension of exercise period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationExtensionOfExercisePeriod" xlink:to="label_pip_ShareBasedCompensationExtensionOfExercisePeriod_2" xlink:title="Label : pip_ShareBasedCompensationExtensionOfExercisePeriod to label_pip_ShareBasedCompensationExtensionOfExercisePeriod_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationReversalFromStockOptionForfeitures" xlink:label="pip_ShareBasedCompensationReversalFromStockOptionForfeitures" xlink:title="pip_ShareBasedCompensationReversalFromStockOptionForfeitures" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationReversalFromStockOptionForfeitures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_ShareBasedCompensationReversalFromStockOptionForfeitures" xml:lang="en-US" id="label_pip_ShareBasedCompensationReversalFromStockOptionForfeitures">Reversal of share based compensation expense due to unvested stock options forfeited during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationReversalFromStockOptionForfeitures" xlink:to="label_pip_ShareBasedCompensationReversalFromStockOptionForfeitures" xlink:title="Label : pip_ShareBasedCompensationReversalFromStockOptionForfeitures to label_pip_ShareBasedCompensationReversalFromStockOptionForfeitures" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationReversalFromStockOptionForfeitures_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_ShareBasedCompensationReversalFromStockOptionForfeitures_1" xml:lang="en-US" id="label_pip_ShareBasedCompensationReversalFromStockOptionForfeitures_1">Share Based Compensation, Reversal From Stock Option Forfeitures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationReversalFromStockOptionForfeitures" xlink:to="label_pip_ShareBasedCompensationReversalFromStockOptionForfeitures_1" xlink:title="Label : pip_ShareBasedCompensationReversalFromStockOptionForfeitures to label_pip_ShareBasedCompensationReversalFromStockOptionForfeitures_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationReversalFromStockOptionForfeitures_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_ShareBasedCompensationReversalFromStockOptionForfeitures_2" xml:lang="en-US" id="label_pip_ShareBasedCompensationReversalFromStockOptionForfeitures_2">Share-based compensation, reversal from stock option forfeitures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationReversalFromStockOptionForfeitures" xlink:to="label_pip_ShareBasedCompensationReversalFromStockOptionForfeitures_2" xlink:title="Label : pip_ShareBasedCompensationReversalFromStockOptionForfeitures to label_pip_ShareBasedCompensationReversalFromStockOptionForfeitures_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationReversalNet" xlink:label="pip_ShareBasedCompensationReversalNet" xlink:title="pip_ShareBasedCompensationReversalNet" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationReversalNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_ShareBasedCompensationReversalNet" xml:lang="en-US" id="label_pip_ShareBasedCompensationReversalNet">The net reversal amount of share based compensation due to adjustments during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationReversalNet" xlink:to="label_pip_ShareBasedCompensationReversalNet" xlink:title="Label : pip_ShareBasedCompensationReversalNet to label_pip_ShareBasedCompensationReversalNet" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationReversalNet_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_ShareBasedCompensationReversalNet_1" xml:lang="en-US" id="label_pip_ShareBasedCompensationReversalNet_1">Share Based Compensation, Reversal, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationReversalNet" xlink:to="label_pip_ShareBasedCompensationReversalNet_1" xlink:title="Label : pip_ShareBasedCompensationReversalNet to label_pip_ShareBasedCompensationReversalNet_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_ShareBasedCompensationReversalNet_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_ShareBasedCompensationReversalNet_2" xml:lang="en-US" id="label_pip_ShareBasedCompensationReversalNet_2">Net reversal of share-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ShareBasedCompensationReversalNet" xlink:to="label_pip_ShareBasedCompensationReversalNet_2" xlink:title="Label : pip_ShareBasedCompensationReversalNet to label_pip_ShareBasedCompensationReversalNet_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_GovernmentContractMember" xlink:label="pip_GovernmentContractMember" xlink:title="pip_GovernmentContractMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_GovernmentContractMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_GovernmentContractMember" xml:lang="en-US" id="label_pip_GovernmentContractMember">Government Contract [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_GovernmentContractMember" xlink:to="label_pip_GovernmentContractMember" xlink:title="Label : pip_GovernmentContractMember to label_pip_GovernmentContractMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_GovernmentContractMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_GovernmentContractMember_1" xml:lang="en-US" id="label_pip_GovernmentContractMember_1">Government Contract [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_GovernmentContractMember" xlink:to="label_pip_GovernmentContractMember_1" xlink:title="Label : pip_GovernmentContractMember to label_pip_GovernmentContractMember_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_GovernmentContractMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_GovernmentContractMember_2" xml:lang="en-US" id="label_pip_GovernmentContractMember_2">Government Contract A [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_GovernmentContractMember" xlink:to="label_pip_GovernmentContractMember_2" xlink:title="Label : pip_GovernmentContractMember to label_pip_GovernmentContractMember_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:title="dei_EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityFilerCategory" xml:lang="en-US" id="label_dei_EntityFilerCategory">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="label_dei_EntityFilerCategory" xlink:title="Label : dei_EntityFilerCategory to label_dei_EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityFilerCategory_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_dei_EntityFilerCategory_1" xml:lang="en-US" id="label_dei_EntityFilerCategory_1">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="label_dei_EntityFilerCategory_1" xlink:title="Label : dei_EntityFilerCategory to label_dei_EntityFilerCategory_1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_RevenueRecognizedFromContractAudit" xlink:label="pip_RevenueRecognizedFromContractAudit" xlink:title="pip_RevenueRecognizedFromContractAudit" />
    <link:label xlink:type="resource" xlink:label="label_pip_RevenueRecognizedFromContractAudit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_RevenueRecognizedFromContractAudit" xml:lang="en-US" id="label_pip_RevenueRecognizedFromContractAudit">Revenue recognized during the period based on auditing of a contract.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_RevenueRecognizedFromContractAudit" xlink:to="label_pip_RevenueRecognizedFromContractAudit" xlink:title="Label : pip_RevenueRecognizedFromContractAudit to label_pip_RevenueRecognizedFromContractAudit" />
    <link:label xlink:type="resource" xlink:label="label_pip_RevenueRecognizedFromContractAudit_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_RevenueRecognizedFromContractAudit_1" xml:lang="en-US" id="label_pip_RevenueRecognizedFromContractAudit_1">Revenue Recognized From Contract Audit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_RevenueRecognizedFromContractAudit" xlink:to="label_pip_RevenueRecognizedFromContractAudit_1" xlink:title="Label : pip_RevenueRecognizedFromContractAudit to label_pip_RevenueRecognizedFromContractAudit_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_RevenueRecognizedFromContractAudit_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_RevenueRecognizedFromContractAudit_2" xml:lang="en-US" id="label_pip_RevenueRecognizedFromContractAudit_2">Audited BARDA revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_RevenueRecognizedFromContractAudit" xlink:to="label_pip_RevenueRecognizedFromContractAudit_2" xlink:title="Label : pip_RevenueRecognizedFromContractAudit to label_pip_RevenueRecognizedFromContractAudit_2" />
    <link:label xlink:type="resource" xlink:label="label_pip_RevenueRecognizedFromContractAudit_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_pip_RevenueRecognizedFromContractAudit_3" xml:lang="en-US" id="label_pip_RevenueRecognizedFromContractAudit_3">Audited BARDA revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_RevenueRecognizedFromContractAudit" xlink:to="label_pip_RevenueRecognizedFromContractAudit_3" xlink:title="Label : pip_RevenueRecognizedFromContractAudit to label_pip_RevenueRecognizedFromContractAudit_3" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" xlink:label="pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" xlink:title="pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" />
    <link:label xlink:type="resource" xlink:label="label_pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" xml:lang="en-US" id="label_pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation">Income statement impact of the reclassification adjustment for translation gain (loss) realized upon the sale or complete or substantially complete liquidation of an investment in a foreign entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" xlink:to="label_pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" xlink:title="Label : pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation to label_pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" />
    <link:label xlink:type="resource" xlink:label="label_pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation_1" xml:lang="en-US" id="label_pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation_1">Other Income Loss Foreign Currency Transaction And Translation Reclassification Adjustment Realized Upon Sale Or Liquidation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" xlink:to="label_pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation_1" xlink:title="Label : pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation to label_pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation_2" xml:lang="en-US" id="label_pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation_2">Realization of cumulative translation adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" xlink:to="label_pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation_2" xlink:title="Label : pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation to label_pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation_2" />
    <link:label xlink:type="resource" xlink:label="label_pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation_3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation_3" xml:lang="en-US" id="label_pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation_3">Realization of cumulative translation adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" xlink:to="label_pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation_3" xlink:title="Label : pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation to label_pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation_3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:title="dei_EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityRegistrantName" xml:lang="en-US" id="label_dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="label_dei_EntityRegistrantName" xlink:title="Label : dei_EntityRegistrantName to label_dei_EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityRegistrantName_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_dei_EntityRegistrantName_1" xml:lang="en-US" id="label_dei_EntityRegistrantName_1">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="label_dei_EntityRegistrantName_1" xlink:title="Label : dei_EntityRegistrantName to label_dei_EntityRegistrantName_1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_AnnualLicensePayment" xlink:label="pip_AnnualLicensePayment" xlink:title="pip_AnnualLicensePayment" />
    <link:label xlink:type="resource" xlink:label="label_pip_AnnualLicensePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_AnnualLicensePayment" xml:lang="en-US" id="label_pip_AnnualLicensePayment">Annual payment due under the licensing agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_AnnualLicensePayment" xlink:to="label_pip_AnnualLicensePayment" xlink:title="Label : pip_AnnualLicensePayment to label_pip_AnnualLicensePayment" />
    <link:label xlink:type="resource" xlink:label="label_pip_AnnualLicensePayment_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_AnnualLicensePayment_1" xml:lang="en-US" id="label_pip_AnnualLicensePayment_1">Annual License Payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_AnnualLicensePayment" xlink:to="label_pip_AnnualLicensePayment_1" xlink:title="Label : pip_AnnualLicensePayment to label_pip_AnnualLicensePayment_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:title="dei_EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityCentralIndexKey" xml:lang="en-US" id="label_dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="label_dei_EntityCentralIndexKey" xlink:title="Label : dei_EntityCentralIndexKey to label_dei_EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityCentralIndexKey_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_dei_EntityCentralIndexKey_1" xml:lang="en-US" id="label_dei_EntityCentralIndexKey_1">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="label_dei_EntityCentralIndexKey_1" xlink:title="Label : dei_EntityCentralIndexKey to label_dei_EntityCentralIndexKey_1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ImmunovaccineMember" xlink:label="pip_ImmunovaccineMember" xlink:title="pip_ImmunovaccineMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_ImmunovaccineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_ImmunovaccineMember" xml:lang="en-US" id="label_pip_ImmunovaccineMember">Immunovaccine [Member].</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ImmunovaccineMember" xlink:to="label_pip_ImmunovaccineMember" xlink:title="Label : pip_ImmunovaccineMember to label_pip_ImmunovaccineMember" />
    <link:label xlink:type="resource" xlink:label="label_pip_ImmunovaccineMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_ImmunovaccineMember_1" xml:lang="en-US" id="label_pip_ImmunovaccineMember_1">Immunovaccine [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ImmunovaccineMember" xlink:to="label_pip_ImmunovaccineMember_1" xlink:title="Label : pip_ImmunovaccineMember to label_pip_ImmunovaccineMember_1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ProceedsFromAdditionalFunding" xlink:label="pip_ProceedsFromAdditionalFunding" xlink:title="pip_ProceedsFromAdditionalFunding" />
    <link:label xlink:type="resource" xlink:label="label_pip_ProceedsFromAdditionalFunding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_ProceedsFromAdditionalFunding" xml:lang="en-US" id="label_pip_ProceedsFromAdditionalFunding">Represents the amount of cash inflow from additional funding as per the agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ProceedsFromAdditionalFunding" xlink:to="label_pip_ProceedsFromAdditionalFunding" xlink:title="Label : pip_ProceedsFromAdditionalFunding to label_pip_ProceedsFromAdditionalFunding" />
    <link:label xlink:type="resource" xlink:label="label_pip_ProceedsFromAdditionalFunding_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_ProceedsFromAdditionalFunding_1" xml:lang="en-US" id="label_pip_ProceedsFromAdditionalFunding_1">Proceeds from Additional Funding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ProceedsFromAdditionalFunding" xlink:to="label_pip_ProceedsFromAdditionalFunding_1" xlink:title="Label : pip_ProceedsFromAdditionalFunding to label_pip_ProceedsFromAdditionalFunding_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_ProceedsFromAdditionalFunding_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_ProceedsFromAdditionalFunding_2" xml:lang="en-US" id="label_pip_ProceedsFromAdditionalFunding_2">Additional funding received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ProceedsFromAdditionalFunding" xlink:to="label_pip_ProceedsFromAdditionalFunding_2" xlink:title="Label : pip_ProceedsFromAdditionalFunding to label_pip_ProceedsFromAdditionalFunding_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_MonthlyRentAmount" xlink:label="pip_MonthlyRentAmount" xlink:title="pip_MonthlyRentAmount" />
    <link:label xlink:type="resource" xlink:label="label_pip_MonthlyRentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_MonthlyRentAmount" xml:lang="en-US" id="label_pip_MonthlyRentAmount">Monthly rent amount under the operating lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_MonthlyRentAmount" xlink:to="label_pip_MonthlyRentAmount" xlink:title="Label : pip_MonthlyRentAmount to label_pip_MonthlyRentAmount" />
    <link:label xlink:type="resource" xlink:label="label_pip_MonthlyRentAmount_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_MonthlyRentAmount_1" xml:lang="en-US" id="label_pip_MonthlyRentAmount_1">Monthly Rent Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_MonthlyRentAmount" xlink:to="label_pip_MonthlyRentAmount_1" xlink:title="Label : pip_MonthlyRentAmount to label_pip_MonthlyRentAmount_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_MonthlyRentAmount_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_MonthlyRentAmount_2" xml:lang="en-US" id="label_pip_MonthlyRentAmount_2">Monthly rent amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_MonthlyRentAmount" xlink:to="label_pip_MonthlyRentAmount_2" xlink:title="Label : pip_MonthlyRentAmount to label_pip_MonthlyRentAmount_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_FinalMonthlyRentAmount" xlink:label="pip_FinalMonthlyRentAmount" xlink:title="pip_FinalMonthlyRentAmount" />
    <link:label xlink:type="resource" xlink:label="label_pip_FinalMonthlyRentAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_FinalMonthlyRentAmount" xml:lang="en-US" id="label_pip_FinalMonthlyRentAmount">Monthly rent amount by the end of the operating lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_FinalMonthlyRentAmount" xlink:to="label_pip_FinalMonthlyRentAmount" xlink:title="Label : pip_FinalMonthlyRentAmount to label_pip_FinalMonthlyRentAmount" />
    <link:label xlink:type="resource" xlink:label="label_pip_FinalMonthlyRentAmount_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_FinalMonthlyRentAmount_1" xml:lang="en-US" id="label_pip_FinalMonthlyRentAmount_1">Final Monthly Rent Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_FinalMonthlyRentAmount" xlink:to="label_pip_FinalMonthlyRentAmount_1" xlink:title="Label : pip_FinalMonthlyRentAmount to label_pip_FinalMonthlyRentAmount_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_FinalMonthlyRentAmount_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_FinalMonthlyRentAmount_2" xml:lang="en-US" id="label_pip_FinalMonthlyRentAmount_2">Final monthly rent amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_FinalMonthlyRentAmount" xlink:to="label_pip_FinalMonthlyRentAmount_2" xlink:title="Label : pip_FinalMonthlyRentAmount to label_pip_FinalMonthlyRentAmount_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:title="dei_EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US" id="label_dei_EntityCommonStockSharesOutstanding">Entity Common Stock Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="label_dei_EntityCommonStockSharesOutstanding" xlink:title="Label : dei_EntityCommonStockSharesOutstanding to label_dei_EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_dei_EntityCommonStockSharesOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_dei_EntityCommonStockSharesOutstanding_1" xml:lang="en-US" id="label_dei_EntityCommonStockSharesOutstanding_1">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="label_dei_EntityCommonStockSharesOutstanding_1" xlink:title="Label : dei_EntityCommonStockSharesOutstanding to label_dei_EntityCommonStockSharesOutstanding_1" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_IncomeLossFromOperatingLeaseCessation" xlink:label="pip_IncomeLossFromOperatingLeaseCessation" xlink:title="pip_IncomeLossFromOperatingLeaseCessation" />
    <link:label xlink:type="resource" xlink:label="label_pip_IncomeLossFromOperatingLeaseCessation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_IncomeLossFromOperatingLeaseCessation" xml:lang="en-US" id="label_pip_IncomeLossFromOperatingLeaseCessation">Income (loss) from operating lease cessation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_IncomeLossFromOperatingLeaseCessation" xlink:to="label_pip_IncomeLossFromOperatingLeaseCessation" xlink:title="Label : pip_IncomeLossFromOperatingLeaseCessation to label_pip_IncomeLossFromOperatingLeaseCessation" />
    <link:label xlink:type="resource" xlink:label="label_pip_IncomeLossFromOperatingLeaseCessation_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_IncomeLossFromOperatingLeaseCessation_1" xml:lang="en-US" id="label_pip_IncomeLossFromOperatingLeaseCessation_1">Income (Loss) From Operating Lease Cessation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_IncomeLossFromOperatingLeaseCessation" xlink:to="label_pip_IncomeLossFromOperatingLeaseCessation_1" xlink:title="Label : pip_IncomeLossFromOperatingLeaseCessation to label_pip_IncomeLossFromOperatingLeaseCessation_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_IncomeLossFromOperatingLeaseCessation_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_IncomeLossFromOperatingLeaseCessation_2" xml:lang="en-US" id="label_pip_IncomeLossFromOperatingLeaseCessation_2">Gross loss from operating lease cessation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_IncomeLossFromOperatingLeaseCessation" xlink:to="label_pip_IncomeLossFromOperatingLeaseCessation_2" xlink:title="Label : pip_IncomeLossFromOperatingLeaseCessation to label_pip_IncomeLossFromOperatingLeaseCessation_2" />
    <link:label xlink:type="resource" xlink:label="label_pip_IncomeLossFromOperatingLeaseCessation_3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_pip_IncomeLossFromOperatingLeaseCessation_3" xml:lang="en-US" id="label_pip_IncomeLossFromOperatingLeaseCessation_3">Loss from lease cessation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_IncomeLossFromOperatingLeaseCessation" xlink:to="label_pip_IncomeLossFromOperatingLeaseCessation_3" xlink:title="Label : pip_IncomeLossFromOperatingLeaseCessation to label_pip_IncomeLossFromOperatingLeaseCessation_3" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_EstimatedLeasePaymentsFromSublessee" xlink:label="pip_EstimatedLeasePaymentsFromSublessee" xlink:title="pip_EstimatedLeasePaymentsFromSublessee" />
    <link:label xlink:type="resource" xlink:label="label_pip_EstimatedLeasePaymentsFromSublessee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_EstimatedLeasePaymentsFromSublessee" xml:lang="en-US" id="label_pip_EstimatedLeasePaymentsFromSublessee">Estimated lease payments from sublessee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_EstimatedLeasePaymentsFromSublessee" xlink:to="label_pip_EstimatedLeasePaymentsFromSublessee" xlink:title="Label : pip_EstimatedLeasePaymentsFromSublessee to label_pip_EstimatedLeasePaymentsFromSublessee" />
    <link:label xlink:type="resource" xlink:label="label_pip_EstimatedLeasePaymentsFromSublessee_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_EstimatedLeasePaymentsFromSublessee_1" xml:lang="en-US" id="label_pip_EstimatedLeasePaymentsFromSublessee_1">Estimated Lease Payments From Sublessee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_EstimatedLeasePaymentsFromSublessee" xlink:to="label_pip_EstimatedLeasePaymentsFromSublessee_1" xlink:title="Label : pip_EstimatedLeasePaymentsFromSublessee to label_pip_EstimatedLeasePaymentsFromSublessee_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_EstimatedLeasePaymentsFromSublessee_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_EstimatedLeasePaymentsFromSublessee_2" xml:lang="en-US" id="label_pip_EstimatedLeasePaymentsFromSublessee_2">Estimated lease payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_EstimatedLeasePaymentsFromSublessee" xlink:to="label_pip_EstimatedLeasePaymentsFromSublessee_2" xlink:title="Label : pip_EstimatedLeasePaymentsFromSublessee to label_pip_EstimatedLeasePaymentsFromSublessee_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ExpectedSubletCashIncome" xlink:label="pip_ExpectedSubletCashIncome" xlink:title="pip_ExpectedSubletCashIncome" />
    <link:label xlink:type="resource" xlink:label="label_pip_ExpectedSubletCashIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_ExpectedSubletCashIncome" xml:lang="en-US" id="label_pip_ExpectedSubletCashIncome">Expected sublet cash income.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ExpectedSubletCashIncome" xlink:to="label_pip_ExpectedSubletCashIncome" xlink:title="Label : pip_ExpectedSubletCashIncome to label_pip_ExpectedSubletCashIncome" />
    <link:label xlink:type="resource" xlink:label="label_pip_ExpectedSubletCashIncome_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_ExpectedSubletCashIncome_1" xml:lang="en-US" id="label_pip_ExpectedSubletCashIncome_1">Expected Sublet Cash Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ExpectedSubletCashIncome" xlink:to="label_pip_ExpectedSubletCashIncome_1" xlink:title="Label : pip_ExpectedSubletCashIncome to label_pip_ExpectedSubletCashIncome_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_ExpectedSubletCashIncome_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_ExpectedSubletCashIncome_2" xml:lang="en-US" id="label_pip_ExpectedSubletCashIncome_2">Expected sublet cash income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_ExpectedSubletCashIncome" xlink:to="label_pip_ExpectedSubletCashIncome_2" xlink:title="Label : pip_ExpectedSubletCashIncome to label_pip_ExpectedSubletCashIncome_2" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_PresentValueOfGrossIncomeLoss" xlink:label="pip_PresentValueOfGrossIncomeLoss" xlink:title="pip_PresentValueOfGrossIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_pip_PresentValueOfGrossIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_PresentValueOfGrossIncomeLoss" xml:lang="en-US" id="label_pip_PresentValueOfGrossIncomeLoss">Present value of gross income (loss).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_PresentValueOfGrossIncomeLoss" xlink:to="label_pip_PresentValueOfGrossIncomeLoss" xlink:title="Label : pip_PresentValueOfGrossIncomeLoss to label_pip_PresentValueOfGrossIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_pip_PresentValueOfGrossIncomeLoss_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_PresentValueOfGrossIncomeLoss_1" xml:lang="en-US" id="label_pip_PresentValueOfGrossIncomeLoss_1">Present Value of Gross Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_PresentValueOfGrossIncomeLoss" xlink:to="label_pip_PresentValueOfGrossIncomeLoss_1" xlink:title="Label : pip_PresentValueOfGrossIncomeLoss to label_pip_PresentValueOfGrossIncomeLoss_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_PresentValueOfGrossIncomeLoss_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_PresentValueOfGrossIncomeLoss_2" xml:lang="en-US" id="label_pip_PresentValueOfGrossIncomeLoss_2">Present value of gross loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_PresentValueOfGrossIncomeLoss" xlink:to="label_pip_PresentValueOfGrossIncomeLoss_2" xlink:title="Label : pip_PresentValueOfGrossIncomeLoss to label_pip_PresentValueOfGrossIncomeLoss_2" />
    <link:label xlink:type="resource" xlink:label="label_pip_PresentValueOfGrossIncomeLoss_3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_pip_PresentValueOfGrossIncomeLoss_3" xml:lang="en-US" id="label_pip_PresentValueOfGrossIncomeLoss_3">Present value of gross loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_PresentValueOfGrossIncomeLoss" xlink:to="label_pip_PresentValueOfGrossIncomeLoss_3" xlink:title="Label : pip_PresentValueOfGrossIncomeLoss to label_pip_PresentValueOfGrossIncomeLoss_3" />
    <link:label xlink:type="resource" xlink:label="label_pip_PresentValueOfGrossIncomeLoss_4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:title="label_pip_PresentValueOfGrossIncomeLoss_4" xml:lang="en-US" id="label_pip_PresentValueOfGrossIncomeLoss_4">Loss in restructuring expense realized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_PresentValueOfGrossIncomeLoss" xlink:to="label_pip_PresentValueOfGrossIncomeLoss_4" xlink:title="Label : pip_PresentValueOfGrossIncomeLoss to label_pip_PresentValueOfGrossIncomeLoss_4" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_MaximumAmountOfReimbursement" xlink:label="pip_MaximumAmountOfReimbursement" xlink:title="pip_MaximumAmountOfReimbursement" />
    <link:label xlink:type="resource" xlink:label="label_pip_MaximumAmountOfReimbursement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_pip_MaximumAmountOfReimbursement" xml:lang="en-US" id="label_pip_MaximumAmountOfReimbursement">Maximum amount of reimbursement to be paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_MaximumAmountOfReimbursement" xlink:to="label_pip_MaximumAmountOfReimbursement" xlink:title="Label : pip_MaximumAmountOfReimbursement to label_pip_MaximumAmountOfReimbursement" />
    <link:label xlink:type="resource" xlink:label="label_pip_MaximumAmountOfReimbursement_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_pip_MaximumAmountOfReimbursement_1" xml:lang="en-US" id="label_pip_MaximumAmountOfReimbursement_1">Maximum Amount Of Reimbursement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_MaximumAmountOfReimbursement" xlink:to="label_pip_MaximumAmountOfReimbursement_1" xlink:title="Label : pip_MaximumAmountOfReimbursement to label_pip_MaximumAmountOfReimbursement_1" />
    <link:label xlink:type="resource" xlink:label="label_pip_MaximumAmountOfReimbursement_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_pip_MaximumAmountOfReimbursement_2" xml:lang="en-US" id="label_pip_MaximumAmountOfReimbursement_2">Maximum amount of reimbursement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="pip_MaximumAmountOfReimbursement" xlink:to="label_pip_MaximumAmountOfReimbursement_2" xlink:title="Label : pip_MaximumAmountOfReimbursement to label_pip_MaximumAmountOfReimbursement_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:title="dei_DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="label_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_DocumentFiscalYearFocus" xml:lang="en-US" id="label_dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="label_dei_DocumentFiscalYearFocus" xlink:title="Label : dei_DocumentFiscalYearFocus to label_dei_DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="label_dei_DocumentFiscalYearFocus_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_dei_DocumentFiscalYearFocus_1" xml:lang="en-US" id="label_dei_DocumentFiscalYearFocus_1">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="label_dei_DocumentFiscalYearFocus_1" xlink:title="Label : dei_DocumentFiscalYearFocus to label_dei_DocumentFiscalYearFocus_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:title="dei_DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="label_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="label_dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="label_dei_DocumentFiscalPeriodFocus" xlink:title="Label : dei_DocumentFiscalPeriodFocus to label_dei_DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="label_dei_DocumentFiscalPeriodFocus_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_dei_DocumentFiscalPeriodFocus_1" xml:lang="en-US" id="label_dei_DocumentFiscalPeriodFocus_1">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="label_dei_DocumentFiscalPeriodFocus_1" xlink:title="Label : dei_DocumentFiscalPeriodFocus to label_dei_DocumentFiscalPeriodFocus_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:title="dei_LegalEntityAxis" />
    <link:label xlink:type="resource" xlink:label="label_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_LegalEntityAxis" xml:lang="en-US" id="label_dei_LegalEntityAxis">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="label_dei_LegalEntityAxis" xlink:title="Label : dei_LegalEntityAxis to label_dei_LegalEntityAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:title="dei_DocumentType" />
    <link:label xlink:type="resource" xlink:label="label_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_dei_DocumentType" xml:lang="en-US" id="label_dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="label_dei_DocumentType" xlink:title="Label : dei_DocumentType to label_dei_DocumentType" />
    <link:label xlink:type="resource" xlink:label="label_dei_DocumentType_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_dei_DocumentType_1" xml:lang="en-US" id="label_dei_DocumentType_1">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="label_dei_DocumentType_1" xlink:title="Label : dei_DocumentType to label_dei_DocumentType_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="us-gaap_AccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US" id="label_us-gaap_AccountingPoliciesAbstract">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="label_us-gaap_AccountingPoliciesAbstract" xlink:title="Label : us-gaap_AccountingPoliciesAbstract to label_us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:title="us-gaap_AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccountsPayableCurrent" xml:lang="en-US" id="label_us-gaap_AccountsPayableCurrent">Accounts Payable Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="label_us-gaap_AccountsPayableCurrent" xlink:title="Label : us-gaap_AccountsPayableCurrent to label_us-gaap_AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccountsPayableCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccountsPayableCurrent_1" xml:lang="en-US" id="label_us-gaap_AccountsPayableCurrent_1">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="label_us-gaap_AccountsPayableCurrent_1" xlink:title="Label : us-gaap_AccountsPayableCurrent to label_us-gaap_AccountsPayableCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="us-gaap_AccruedRentCurrent" xlink:title="us-gaap_AccruedRentCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedRentCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccruedRentCurrent" xml:lang="en-US" id="label_us-gaap_AccruedRentCurrent">Accrued Rent, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRentCurrent" xlink:to="label_us-gaap_AccruedRentCurrent" xlink:title="Label : us-gaap_AccruedRentCurrent to label_us-gaap_AccruedRentCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedRentCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccruedRentCurrent_1" xml:lang="en-US" id="label_us-gaap_AccruedRentCurrent_1">Accrued restructuring expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRentCurrent" xlink:to="label_us-gaap_AccruedRentCurrent_1" xlink:title="Label : us-gaap_AccruedRentCurrent to label_us-gaap_AccruedRentCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedRentNoncurrent" xlink:label="us-gaap_AccruedRentNoncurrent" xlink:title="us-gaap_AccruedRentNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedRentNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccruedRentNoncurrent" xml:lang="en-US" id="label_us-gaap_AccruedRentNoncurrent">Accrued Rent, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRentNoncurrent" xlink:to="label_us-gaap_AccruedRentNoncurrent" xlink:title="Label : us-gaap_AccruedRentNoncurrent to label_us-gaap_AccruedRentNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccruedRentNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccruedRentNoncurrent_1" xml:lang="en-US" id="label_us-gaap_AccruedRentNoncurrent_1">Accrued restructuring expenses - long term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRentNoncurrent" xlink:to="label_us-gaap_AccruedRentNoncurrent_1" xlink:title="Label : us-gaap_AccruedRentNoncurrent to label_us-gaap_AccruedRentNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:title="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xml:lang="en-US" id="label_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="label_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:title="Label : us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax to label_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_1" xml:lang="en-US" id="label_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_1">Accumulated other comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="label_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_1" xlink:title="Label : us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax to label_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:title="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US" id="label_us-gaap_AdditionalPaidInCapitalCommonStock">Additional Paid In Capital Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="label_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:title="Label : us-gaap_AdditionalPaidInCapitalCommonStock to label_us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdditionalPaidInCapitalCommonStock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AdditionalPaidInCapitalCommonStock_1" xml:lang="en-US" id="label_us-gaap_AdditionalPaidInCapitalCommonStock_1">Additional paid-in-capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="label_us-gaap_AdditionalPaidInCapitalCommonStock_1" xlink:title="Label : us-gaap_AdditionalPaidInCapitalCommonStock to label_us-gaap_AdditionalPaidInCapitalCommonStock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:title="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:title="Label : us-gaap_AdditionalFinancialInformationDisclosureTextBlock to label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1" xml:lang="en-US" id="label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1">Financing Transactions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1" xlink:title="Label : us-gaap_AdditionalFinancialInformationDisclosureTextBlock to label_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="Label : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xml:lang="en-US" id="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:title="Label : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to label_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US" id="label_us-gaap_AllocatedShareBasedCompensationExpense">Allocated Share Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="label_us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="Label : us-gaap_AllocatedShareBasedCompensationExpense to label_us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AllocatedShareBasedCompensationExpense_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AllocatedShareBasedCompensationExpense_1" xml:lang="en-US" id="label_us-gaap_AllocatedShareBasedCompensationExpense_1">Total share-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="label_us-gaap_AllocatedShareBasedCompensationExpense_1" xlink:title="Label : us-gaap_AllocatedShareBasedCompensationExpense to label_us-gaap_AllocatedShareBasedCompensationExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US" id="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="Label : us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xml:lang="en-US" id="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1">Anti-dilutive securities excluded from computation of earnings per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xlink:title="Label : us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to label_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xlink:title="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_AssetsFairValueDisclosureAbstract">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="label_us-gaap_AssetsFairValueDisclosureAbstract" xlink:title="Label : us-gaap_AssetsFairValueDisclosureAbstract to label_us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsFairValueDisclosureAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AssetsFairValueDisclosureAbstract_1" xml:lang="en-US" id="label_us-gaap_AssetsFairValueDisclosureAbstract_1">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="label_us-gaap_AssetsFairValueDisclosureAbstract_1" xlink:title="Label : us-gaap_AssetsFairValueDisclosureAbstract to label_us-gaap_AssetsFairValueDisclosureAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:title="us-gaap_AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AssetsAbstract" xml:lang="en-US" id="label_us-gaap_AssetsAbstract">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="label_us-gaap_AssetsAbstract" xlink:title="Label : us-gaap_AssetsAbstract to label_us-gaap_AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AssetsAbstract_1" xml:lang="en-US" id="label_us-gaap_AssetsAbstract_1">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="label_us-gaap_AssetsAbstract_1" xlink:title="Label : us-gaap_AssetsAbstract to label_us-gaap_AssetsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:title="us-gaap_Assets" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_Assets" xml:lang="en-US" id="label_us-gaap_Assets">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="label_us-gaap_Assets" xlink:title="Label : us-gaap_Assets to label_us-gaap_Assets" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Assets_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_Assets_1" xml:lang="en-US" id="label_us-gaap_Assets_1">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="label_us-gaap_Assets_1" xlink:title="Label : us-gaap_Assets to label_us-gaap_Assets_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:title="us-gaap_AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AssetsCurrent" xml:lang="en-US" id="label_us-gaap_AssetsCurrent">Assets Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="label_us-gaap_AssetsCurrent" xlink:title="Label : us-gaap_AssetsCurrent to label_us-gaap_AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_AssetsCurrent_1" xml:lang="en-US" id="label_us-gaap_AssetsCurrent_1">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="label_us-gaap_AssetsCurrent_1" xlink:title="Label : us-gaap_AssetsCurrent to label_us-gaap_AssetsCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:title="us-gaap_AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_AssetsCurrentAbstract" xml:lang="en-US" id="label_us-gaap_AssetsCurrentAbstract">Assets Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="label_us-gaap_AssetsCurrentAbstract" xlink:title="Label : us-gaap_AssetsCurrentAbstract to label_us-gaap_AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_AssetsCurrentAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_AssetsCurrentAbstract_1" xml:lang="en-US" id="label_us-gaap_AssetsCurrentAbstract_1">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="label_us-gaap_AssetsCurrentAbstract_1" xlink:title="Label : us-gaap_AssetsCurrentAbstract to label_us-gaap_AssetsCurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xml:lang="en-US" id="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">Basis Of Presentation And Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="Label : us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock to label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1" xml:lang="en-US" id="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1" xlink:title="Label : us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock to label_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BilledContractReceivables" xlink:label="us-gaap_BilledContractReceivables" xlink:title="us-gaap_BilledContractReceivables" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_BilledContractReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_BilledContractReceivables" xml:lang="en-US" id="label_us-gaap_BilledContractReceivables">Billed Contract Receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BilledContractReceivables" xlink:to="label_us-gaap_BilledContractReceivables" xlink:title="Label : us-gaap_BilledContractReceivables to label_us-gaap_BilledContractReceivables" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_BilledContractReceivables_1" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:title="label_us-gaap_BilledContractReceivables_1" xml:lang="en-US" id="label_us-gaap_BilledContractReceivables_1">Outstanding billed accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BilledContractReceivables" xlink:to="label_us-gaap_BilledContractReceivables_1" xlink:title="Label : us-gaap_BilledContractReceivables to label_us-gaap_BilledContractReceivables_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_BilledContractReceivables_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_BilledContractReceivables_2" xml:lang="en-US" id="label_us-gaap_BilledContractReceivables_2">Billed accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BilledContractReceivables" xlink:to="label_us-gaap_BilledContractReceivables_2" xlink:title="Label : us-gaap_BilledContractReceivables to label_us-gaap_BilledContractReceivables_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_BilledContractReceivables_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_BilledContractReceivables_3" xml:lang="en-US" id="label_us-gaap_BilledContractReceivables_3">Billed receivable balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BilledContractReceivables" xlink:to="label_us-gaap_BilledContractReceivables_3" xlink:title="Label : us-gaap_BilledContractReceivables to label_us-gaap_BilledContractReceivables_3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock">Cash And Cash Equivalents Policy [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:title="Label : us-gaap_CashAndCashEquivalentsPolicyTextBlock to label_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="label_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1" xlink:title="Label : us-gaap_CashAndCashEquivalentsPolicyTextBlock to label_us-gaap_CashAndCashEquivalentsPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:title="us-gaap_CashAndCashEquivalentsAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CashAndCashEquivalentsAxis" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsAxis">Cash and Cash Equivalents [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="label_us-gaap_CashAndCashEquivalentsAxis" xlink:title="Label : us-gaap_CashAndCashEquivalentsAxis to label_us-gaap_CashAndCashEquivalentsAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsAtCarryingValue">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="label_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="Label : us-gaap_CashAndCashEquivalentsAtCarryingValue to label_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_1">Cash and cash equivalents, at end of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xlink:title="Label : us-gaap_CashAndCashEquivalentsAtCarryingValue to label_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_2">Cash and cash equivalents, at beginning of period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" xlink:title="Label : us-gaap_CashAndCashEquivalentsAtCarryingValue to label_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_3">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="label_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" xlink:title="Label : us-gaap_CashAndCashEquivalentsAtCarryingValue to label_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">Cash And Cash Equivalents Period Increase Decrease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="Label : us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1" xml:lang="en-US" id="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1">(Decrease) increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1" xlink:title="Label : us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease to label_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US" id="label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="Label : us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1" xml:lang="en-US" id="label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1">Warrant, Exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1" xlink:title="Label : us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" xml:lang="en-US" id="label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2">Warrant exercise price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" xlink:title="Label : us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to label_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:title="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US" id="label_us-gaap_ClassOfWarrantOrRightDomain">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="label_us-gaap_ClassOfWarrantOrRightDomain" xlink:title="Label : us-gaap_ClassOfWarrantOrRightDomain to label_us-gaap_ClassOfWarrantOrRightDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ClassOfWarrantOrRightDomain_1" xml:lang="en-US" id="label_us-gaap_ClassOfWarrantOrRightDomain_1">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="label_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="Label : us-gaap_ClassOfWarrantOrRightDomain to label_us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:title="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xml:lang="en-US" id="label_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="label_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:title="Label : us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable to label_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_1" xml:lang="en-US" id="label_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_1">Exercisable Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="label_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_1" xlink:title="Label : us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable to label_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:title="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US" id="label_us-gaap_ClassOfWarrantOrRightAxis">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="label_us-gaap_ClassOfWarrantOrRightAxis" xlink:title="Label : us-gaap_ClassOfWarrantOrRightAxis to label_us-gaap_ClassOfWarrantOrRightAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ClassOfWarrantOrRightAxis_1" xml:lang="en-US" id="label_us-gaap_ClassOfWarrantOrRightAxis_1">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="label_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="Label : us-gaap_ClassOfWarrantOrRightAxis to label_us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US" id="label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="Label : us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1" xml:lang="en-US" id="label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1">Number of Common Shares Underlying Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1" xlink:title="Label : us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2" xml:lang="en-US" id="label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2">Warrants issued to purchase shares of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2" xlink:title="Label : us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to label_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:title="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US" id="label_us-gaap_ClassOfWarrantOrRightOutstanding">Class Of Warrant Or Right Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="label_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:title="Label : us-gaap_ClassOfWarrantOrRightOutstanding to label_us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ClassOfWarrantOrRightOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ClassOfWarrantOrRightOutstanding_1" xml:lang="en-US" id="label_us-gaap_ClassOfWarrantOrRightOutstanding_1">Warrants to purchase common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="label_us-gaap_ClassOfWarrantOrRightOutstanding_1" xlink:title="Label : us-gaap_ClassOfWarrantOrRightOutstanding to label_us-gaap_ClassOfWarrantOrRightOutstanding_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="label_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="Label : us-gaap_CommitmentsAndContingenciesDisclosureTextBlock to label_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" xml:lang="en-US" id="label_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="label_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" xlink:title="Label : us-gaap_CommitmentsAndContingenciesDisclosureTextBlock to label_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">Commitments and Contingencies [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="label_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="Label : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to label_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:title="us-gaap_CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockValue" xml:lang="en-US" id="label_us-gaap_CommonStockValue">Common Stock Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="label_us-gaap_CommonStockValue" xlink:title="Label : us-gaap_CommonStockValue to label_us-gaap_CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockValue_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommonStockValue_1" xml:lang="en-US" id="label_us-gaap_CommonStockValue_1">Common stock, $0.0001 par value; 100,000,000 shares authorized; 64,358,834 and 63,603,303 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="label_us-gaap_CommonStockValue_1" xlink:title="Label : us-gaap_CommonStockValue to label_us-gaap_CommonStockValue_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:title="us-gaap_CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockSharesIssued" xml:lang="en-US" id="label_us-gaap_CommonStockSharesIssued">Common Stock Shares Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="label_us-gaap_CommonStockSharesIssued" xlink:title="Label : us-gaap_CommonStockSharesIssued to label_us-gaap_CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesIssued_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_CommonStockSharesIssued_1" xml:lang="en-US" id="label_us-gaap_CommonStockSharesIssued_1">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="label_us-gaap_CommonStockSharesIssued_1" xlink:title="Label : us-gaap_CommonStockSharesIssued to label_us-gaap_CommonStockSharesIssued_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:title="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xml:lang="en-US" id="label_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable">Common Stock, Share Subscribed but Unissued, Subscriptions Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:to="label_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:title="Label : us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable to label_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_1" xml:lang="en-US" id="label_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_1">Common stock - receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:to="label_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_1" xlink:title="Label : us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable to label_us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:title="us-gaap_CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US" id="label_us-gaap_CommonStockSharesAuthorized">Common Stock Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="label_us-gaap_CommonStockSharesAuthorized" xlink:title="Label : us-gaap_CommonStockSharesAuthorized to label_us-gaap_CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesAuthorized_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommonStockSharesAuthorized_1" xml:lang="en-US" id="label_us-gaap_CommonStockSharesAuthorized_1">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="label_us-gaap_CommonStockSharesAuthorized_1" xlink:title="Label : us-gaap_CommonStockSharesAuthorized to label_us-gaap_CommonStockSharesAuthorized_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US" id="label_us-gaap_CommonStockParOrStatedValuePerShare">Common Stock Par Or Stated Value Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="label_us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="Label : us-gaap_CommonStockParOrStatedValuePerShare to label_us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockParOrStatedValuePerShare_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommonStockParOrStatedValuePerShare_1" xml:lang="en-US" id="label_us-gaap_CommonStockParOrStatedValuePerShare_1">Common stock, par value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="label_us-gaap_CommonStockParOrStatedValuePerShare_1" xlink:title="Label : us-gaap_CommonStockParOrStatedValuePerShare to label_us-gaap_CommonStockParOrStatedValuePerShare_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:title="us-gaap_CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US" id="label_us-gaap_CommonStockSharesOutstanding">Common Stock Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="label_us-gaap_CommonStockSharesOutstanding" xlink:title="Label : us-gaap_CommonStockSharesOutstanding to label_us-gaap_CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockSharesOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommonStockSharesOutstanding_1" xml:lang="en-US" id="label_us-gaap_CommonStockSharesOutstanding_1">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="label_us-gaap_CommonStockSharesOutstanding_1" xlink:title="Label : us-gaap_CommonStockSharesOutstanding to label_us-gaap_CommonStockSharesOutstanding_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US" id="label_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">Common Stock Capital Shares Reserved For Future Issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="label_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="Label : us-gaap_CommonStockCapitalSharesReservedForFutureIssuance to label_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1" xml:lang="en-US" id="label_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1">Common stock reserved</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="label_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1" xlink:title="Label : us-gaap_CommonStockCapitalSharesReservedForFutureIssuance to label_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:title="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="label_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:title="Label : us-gaap_ComprehensiveIncomePolicyPolicyTextBlock to label_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1">Comprehensive Loss and Accumulated Other Comprehensive Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="label_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1" xlink:title="Label : us-gaap_ComprehensiveIncomePolicyPolicyTextBlock to label_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:title="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US" id="label_us-gaap_ComprehensiveIncomeNetOfTax">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="label_us-gaap_ComprehensiveIncomeNetOfTax" xlink:title="Label : us-gaap_ComprehensiveIncomeNetOfTax to label_us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ComprehensiveIncomeNetOfTax_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_ComprehensiveIncomeNetOfTax_1" xml:lang="en-US" id="label_us-gaap_ComprehensiveIncomeNetOfTax_1">Comprehensive loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="label_us-gaap_ComprehensiveIncomeNetOfTax_1" xlink:title="Label : us-gaap_ComprehensiveIncomeNetOfTax to label_us-gaap_ComprehensiveIncomeNetOfTax_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="us-gaap_ContractsRevenue" xlink:title="us-gaap_ContractsRevenue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ContractsRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ContractsRevenue" xml:lang="en-US" id="label_us-gaap_ContractsRevenue">Contracts Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractsRevenue" xlink:to="label_us-gaap_ContractsRevenue" xlink:title="Label : us-gaap_ContractsRevenue to label_us-gaap_ContractsRevenue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ContractsRevenue_1" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:title="label_us-gaap_ContractsRevenue_1" xml:lang="en-US" id="label_us-gaap_ContractsRevenue_1">Contract revenue recorded and invoiced from the government</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractsRevenue" xlink:to="label_us-gaap_ContractsRevenue_1" xlink:title="Label : us-gaap_ContractsRevenue to label_us-gaap_ContractsRevenue_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ContractsRevenue_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ContractsRevenue_2" xml:lang="en-US" id="label_us-gaap_ContractsRevenue_2">Contract revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractsRevenue" xlink:to="label_us-gaap_ContractsRevenue_2" xlink:title="Label : us-gaap_ContractsRevenue to label_us-gaap_ContractsRevenue_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ContractsRevenue_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_ContractsRevenue_3" xml:lang="en-US" id="label_us-gaap_ContractsRevenue_3">Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractsRevenue" xlink:to="label_us-gaap_ContractsRevenue_3" xlink:title="Label : us-gaap_ContractsRevenue to label_us-gaap_ContractsRevenue_3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:title="us-gaap_ConvertibleLongTermNotesPayable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConvertibleLongTermNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ConvertibleLongTermNotesPayable" xml:lang="en-US" id="label_us-gaap_ConvertibleLongTermNotesPayable">Convertible Notes Payable, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="label_us-gaap_ConvertibleLongTermNotesPayable" xlink:title="Label : us-gaap_ConvertibleLongTermNotesPayable to label_us-gaap_ConvertibleLongTermNotesPayable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ConvertibleLongTermNotesPayable_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ConvertibleLongTermNotesPayable_1" xml:lang="en-US" id="label_us-gaap_ConvertibleLongTermNotesPayable_1">Convertible note payable, cash paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="label_us-gaap_ConvertibleLongTermNotesPayable_1" xlink:title="Label : us-gaap_ConvertibleLongTermNotesPayable to label_us-gaap_ConvertibleLongTermNotesPayable_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:title="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock">Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:to="label_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:title="Label : us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock to label_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_1">Restructuring Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:to="label_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_1" xlink:title="Label : us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock to label_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:title="us-gaap_DebtInstrumentLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentLineItems" xml:lang="en-US" id="label_us-gaap_DebtInstrumentLineItems">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="label_us-gaap_DebtInstrumentLineItems" xlink:title="Label : us-gaap_DebtInstrumentLineItems to label_us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:title="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xml:lang="en-US" id="label_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="label_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:title="Label : us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid to label_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_1" xml:lang="en-US" id="label_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_1">Debt termination payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="label_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_1" xlink:title="Label : us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid to label_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:title="us-gaap_DebtDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_DebtDisclosureAbstract">Financing Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="label_us-gaap_DebtDisclosureAbstract" xlink:title="Label : us-gaap_DebtDisclosureAbstract to label_us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xlink:title="us-gaap_DebtInstrumentTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentTable" xml:lang="en-US" id="label_us-gaap_DebtInstrumentTable">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="label_us-gaap_DebtInstrumentTable" xlink:title="Label : us-gaap_DebtInstrumentTable to label_us-gaap_DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentIssuanceDate1" xlink:label="us-gaap_DebtInstrumentIssuanceDate1" xlink:title="us-gaap_DebtInstrumentIssuanceDate1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentIssuanceDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentIssuanceDate1" xml:lang="en-US" id="label_us-gaap_DebtInstrumentIssuanceDate1">Debt Instrument, Issuance Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIssuanceDate1" xlink:to="label_us-gaap_DebtInstrumentIssuanceDate1" xlink:title="Label : us-gaap_DebtInstrumentIssuanceDate1 to label_us-gaap_DebtInstrumentIssuanceDate1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xml:lang="en-US" id="label_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="label_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="Label : us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 to label_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1" xml:lang="en-US" id="label_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1">Loan payable, interest rate spread</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="label_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1" xlink:title="Label : us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 to label_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:title="us-gaap_DebtInstrumentCarryingAmount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US" id="label_us-gaap_DebtInstrumentCarryingAmount">Debt Instrument Carrying Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="label_us-gaap_DebtInstrumentCarryingAmount" xlink:title="Label : us-gaap_DebtInstrumentCarryingAmount to label_us-gaap_DebtInstrumentCarryingAmount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentCarryingAmount_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtInstrumentCarryingAmount_1" xml:lang="en-US" id="label_us-gaap_DebtInstrumentCarryingAmount_1">Debt instrument, carrying amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentCarryingAmount" xlink:to="label_us-gaap_DebtInstrumentCarryingAmount_1" xlink:title="Label : us-gaap_DebtInstrumentCarryingAmount to label_us-gaap_DebtInstrumentCarryingAmount_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:title="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentConvertibleConversionPrice1" xml:lang="en-US" id="label_us-gaap_DebtInstrumentConvertibleConversionPrice1">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="label_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:title="Label : us-gaap_DebtInstrumentConvertibleConversionPrice1 to label_us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentConvertibleConversionPrice1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtInstrumentConvertibleConversionPrice1_1" xml:lang="en-US" id="label_us-gaap_DebtInstrumentConvertibleConversionPrice1_1">Debt conversion, price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="label_us-gaap_DebtInstrumentConvertibleConversionPrice1_1" xlink:title="Label : us-gaap_DebtInstrumentConvertibleConversionPrice1 to label_us-gaap_DebtInstrumentConvertibleConversionPrice1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:title="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US" id="label_us-gaap_DebtInstrumentUnamortizedDiscount">Debt Instrument, Unamortized Discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="label_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:title="Label : us-gaap_DebtInstrumentUnamortizedDiscount to label_us-gaap_DebtInstrumentUnamortizedDiscount" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentUnamortizedDiscount_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtInstrumentUnamortizedDiscount_1" xml:lang="en-US" id="label_us-gaap_DebtInstrumentUnamortizedDiscount_1">Debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="label_us-gaap_DebtInstrumentUnamortizedDiscount_1" xlink:title="Label : us-gaap_DebtInstrumentUnamortizedDiscount to label_us-gaap_DebtInstrumentUnamortizedDiscount_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:title="us-gaap_DebtInstrumentMaturityDate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US" id="label_us-gaap_DebtInstrumentMaturityDate">Debt Instrument, Maturity Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="label_us-gaap_DebtInstrumentMaturityDate" xlink:title="Label : us-gaap_DebtInstrumentMaturityDate to label_us-gaap_DebtInstrumentMaturityDate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentMaturityDate_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtInstrumentMaturityDate_1" xml:lang="en-US" id="label_us-gaap_DebtInstrumentMaturityDate_1">Repayment date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="label_us-gaap_DebtInstrumentMaturityDate_1" xlink:title="Label : us-gaap_DebtInstrumentMaturityDate to label_us-gaap_DebtInstrumentMaturityDate_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentMaturityDate_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_DebtInstrumentMaturityDate_2" xml:lang="en-US" id="label_us-gaap_DebtInstrumentMaturityDate_2">Debt instrument, maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="label_us-gaap_DebtInstrumentMaturityDate_2" xlink:title="Label : us-gaap_DebtInstrumentMaturityDate to label_us-gaap_DebtInstrumentMaturityDate_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:title="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US" id="label_us-gaap_DebtInstrumentInterestRateEffectivePercentage">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="label_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:title="Label : us-gaap_DebtInstrumentInterestRateEffectivePercentage to label_us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1" xml:lang="en-US" id="label_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1">Incremental borrowing rate used to calculate discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="label_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1" xlink:title="Label : us-gaap_DebtInstrumentInterestRateEffectivePercentage to label_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms" xlink:title="us-gaap_DebtInstrumentPaymentTerms" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentPaymentTerms" xml:lang="en-US" id="label_us-gaap_DebtInstrumentPaymentTerms">Debt Instrument Payment Terms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPaymentTerms" xlink:to="label_us-gaap_DebtInstrumentPaymentTerms" xlink:title="Label : us-gaap_DebtInstrumentPaymentTerms to label_us-gaap_DebtInstrumentPaymentTerms" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentPaymentTerms_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_DebtInstrumentPaymentTerms_1" xml:lang="en-US" id="label_us-gaap_DebtInstrumentPaymentTerms_1">Term loan, payment terms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPaymentTerms" xlink:to="label_us-gaap_DebtInstrumentPaymentTerms_1" xlink:title="Label : us-gaap_DebtInstrumentPaymentTerms to label_us-gaap_DebtInstrumentPaymentTerms_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US" id="label_us-gaap_DebtInstrumentInterestRateStatedPercentage">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="label_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="Label : us-gaap_DebtInstrumentInterestRateStatedPercentage to label_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtInstrumentInterestRateStatedPercentage_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtInstrumentInterestRateStatedPercentage_1" xml:lang="en-US" id="label_us-gaap_DebtInstrumentInterestRateStatedPercentage_1">Fixed interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="label_us-gaap_DebtInstrumentInterestRateStatedPercentage_1" xlink:title="Label : us-gaap_DebtInstrumentInterestRateStatedPercentage to label_us-gaap_DebtInstrumentInterestRateStatedPercentage_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:title="us-gaap_DebtPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DebtPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_DebtPolicyTextBlock">Debt Policy [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="label_us-gaap_DebtPolicyTextBlock" xlink:title="Label : us-gaap_DebtPolicyTextBlock to label_us-gaap_DebtPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DebtPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DebtPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_DebtPolicyTextBlock_1">Termination of Revolving Line of Credit and Term Loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="label_us-gaap_DebtPolicyTextBlock_1" xlink:title="Label : us-gaap_DebtPolicyTextBlock to label_us-gaap_DebtPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:title="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US" id="label_us-gaap_DeferredIncomeTaxExpenseBenefit">Deferred Income Tax Expense Benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="label_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:title="Label : us-gaap_DeferredIncomeTaxExpenseBenefit to label_us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredIncomeTaxExpenseBenefit_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredIncomeTaxExpenseBenefit_1" xml:lang="en-US" id="label_us-gaap_DeferredIncomeTaxExpenseBenefit_1">Deferred income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="label_us-gaap_DeferredIncomeTaxExpenseBenefit_1" xlink:title="Label : us-gaap_DeferredIncomeTaxExpenseBenefit to label_us-gaap_DeferredIncomeTaxExpenseBenefit_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit" xlink:title="us-gaap_DeferredRentCredit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredRentCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DeferredRentCredit" xml:lang="en-US" id="label_us-gaap_DeferredRentCredit">Deferred Rent Credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCredit" xlink:to="label_us-gaap_DeferredRentCredit" xlink:title="Label : us-gaap_DeferredRentCredit to label_us-gaap_DeferredRentCredit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DeferredRentCredit_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DeferredRentCredit_1" xml:lang="en-US" id="label_us-gaap_DeferredRentCredit_1">Deferred rent liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCredit" xlink:to="label_us-gaap_DeferredRentCredit_1" xlink:title="Label : us-gaap_DeferredRentCredit to label_us-gaap_DeferredRentCredit_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:title="us-gaap_Depreciation" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_Depreciation" xml:lang="en-US" id="label_us-gaap_Depreciation">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="label_us-gaap_Depreciation" xlink:title="Label : us-gaap_Depreciation to label_us-gaap_Depreciation" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Depreciation_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_Depreciation_1" xml:lang="en-US" id="label_us-gaap_Depreciation_1">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="label_us-gaap_Depreciation_1" xlink:title="Label : us-gaap_Depreciation to label_us-gaap_Depreciation_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Depreciation_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_Depreciation_2" xml:lang="en-US" id="label_us-gaap_Depreciation_2">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="label_us-gaap_Depreciation_2" xlink:title="Label : us-gaap_Depreciation to label_us-gaap_Depreciation_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeAssets" xlink:label="us-gaap_DerivativeAssets" xlink:title="us-gaap_DerivativeAssets" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DerivativeAssets" xml:lang="en-US" id="label_us-gaap_DerivativeAssets">Derivative Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAssets" xlink:to="label_us-gaap_DerivativeAssets" xlink:title="Label : us-gaap_DerivativeAssets to label_us-gaap_DerivativeAssets" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DerivativeAssets_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_DerivativeAssets_1" xml:lang="en-US" id="label_us-gaap_DerivativeAssets_1">Total investment in money market funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeAssets" xlink:to="label_us-gaap_DerivativeAssets_1" xlink:title="Label : us-gaap_DerivativeAssets to label_us-gaap_DerivativeAssets_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="us-gaap_DerivativeLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DerivativeLiabilitiesCurrent" xml:lang="en-US" id="label_us-gaap_DerivativeLiabilitiesCurrent">Derivative Liability, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="label_us-gaap_DerivativeLiabilitiesCurrent" xlink:title="Label : us-gaap_DerivativeLiabilitiesCurrent to label_us-gaap_DerivativeLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DerivativeLiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DerivativeLiabilitiesCurrent_1" xml:lang="en-US" id="label_us-gaap_DerivativeLiabilitiesCurrent_1">Current portion of derivative instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="label_us-gaap_DerivativeLiabilitiesCurrent_1" xlink:title="Label : us-gaap_DerivativeLiabilitiesCurrent to label_us-gaap_DerivativeLiabilitiesCurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DerivativeLiabilitiesCurrent_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_DerivativeLiabilitiesCurrent_2" xml:lang="en-US" id="label_us-gaap_DerivativeLiabilitiesCurrent_2">Current portion of derivative instruments related to stock purchase warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="label_us-gaap_DerivativeLiabilitiesCurrent_2" xlink:title="Label : us-gaap_DerivativeLiabilitiesCurrent to label_us-gaap_DerivativeLiabilitiesCurrent_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="us-gaap_DerivativeByNatureAxis" xlink:title="us-gaap_DerivativeByNatureAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DerivativeByNatureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DerivativeByNatureAxis" xml:lang="en-US" id="label_us-gaap_DerivativeByNatureAxis">Derivative, by Nature [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeByNatureAxis" xlink:to="label_us-gaap_DerivativeByNatureAxis" xlink:title="Label : us-gaap_DerivativeByNatureAxis to label_us-gaap_DerivativeByNatureAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" xlink:title="us-gaap_DerivativeLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DerivativeLiabilities" xml:lang="en-US" id="label_us-gaap_DerivativeLiabilities">Derivative Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="label_us-gaap_DerivativeLiabilities" xlink:title="Label : us-gaap_DerivativeLiabilities to label_us-gaap_DerivativeLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DerivativeLiabilities_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_us-gaap_DerivativeLiabilities_1" xml:lang="en-US" id="label_us-gaap_DerivativeLiabilities_1">Ending Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="label_us-gaap_DerivativeLiabilities_1" xlink:title="Label : us-gaap_DerivativeLiabilities to label_us-gaap_DerivativeLiabilities_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DerivativeLiabilities_2" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_us-gaap_DerivativeLiabilities_2" xml:lang="en-US" id="label_us-gaap_DerivativeLiabilities_2">Beginning Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="label_us-gaap_DerivativeLiabilities_2" xlink:title="Label : us-gaap_DerivativeLiabilities to label_us-gaap_DerivativeLiabilities_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DerivativeLiabilities_3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DerivativeLiabilities_3" xml:lang="en-US" id="label_us-gaap_DerivativeLiabilities_3">Derivatives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="label_us-gaap_DerivativeLiabilities_3" xlink:title="Label : us-gaap_DerivativeLiabilities to label_us-gaap_DerivativeLiabilities_3" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DerivativeLiabilities_4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_DerivativeLiabilities_4" xml:lang="en-US" id="label_us-gaap_DerivativeLiabilities_4">Total derivative instruments related to stock purchase warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilities" xlink:to="label_us-gaap_DerivativeLiabilities_4" xlink:title="Label : us-gaap_DerivativeLiabilities to label_us-gaap_DerivativeLiabilities_4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:title="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DerivativeLiabilitiesNoncurrent" xml:lang="en-US" id="label_us-gaap_DerivativeLiabilitiesNoncurrent">Derivative Liabilities Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="label_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:title="Label : us-gaap_DerivativeLiabilitiesNoncurrent to label_us-gaap_DerivativeLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DerivativeLiabilitiesNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DerivativeLiabilitiesNoncurrent_1" xml:lang="en-US" id="label_us-gaap_DerivativeLiabilitiesNoncurrent_1">Derivative instruments, less current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="label_us-gaap_DerivativeLiabilitiesNoncurrent_1" xlink:title="Label : us-gaap_DerivativeLiabilitiesNoncurrent to label_us-gaap_DerivativeLiabilitiesNoncurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DerivativeLiabilitiesNoncurrent_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_DerivativeLiabilitiesNoncurrent_2" xml:lang="en-US" id="label_us-gaap_DerivativeLiabilitiesNoncurrent_2">Non-current portion of derivative instruments related to stock purchase warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="label_us-gaap_DerivativeLiabilitiesNoncurrent_2" xlink:title="Label : us-gaap_DerivativeLiabilitiesNoncurrent to label_us-gaap_DerivativeLiabilitiesNoncurrent_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="us-gaap_DerivativeNameDomain" xlink:title="us-gaap_DerivativeNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DerivativeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DerivativeNameDomain" xml:lang="en-US" id="label_us-gaap_DerivativeNameDomain">Derivative, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeNameDomain" xlink:to="label_us-gaap_DerivativeNameDomain" xlink:title="Label : us-gaap_DerivativeNameDomain to label_us-gaap_DerivativeNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgesLiabilities" xlink:label="us-gaap_DerivativeInstrumentsAndHedgesLiabilities" xlink:title="us-gaap_DerivativeInstrumentsAndHedgesLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DerivativeInstrumentsAndHedgesLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DerivativeInstrumentsAndHedgesLiabilities" xml:lang="en-US" id="label_us-gaap_DerivativeInstrumentsAndHedgesLiabilities">Derivative Instruments and Hedges, Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgesLiabilities" xlink:to="label_us-gaap_DerivativeInstrumentsAndHedgesLiabilities" xlink:title="Label : us-gaap_DerivativeInstrumentsAndHedgesLiabilities to label_us-gaap_DerivativeInstrumentsAndHedgesLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DerivativeInstrumentsAndHedgesLiabilities_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DerivativeInstrumentsAndHedgesLiabilities_1" xml:lang="en-US" id="label_us-gaap_DerivativeInstrumentsAndHedgesLiabilities_1">Current portion of derivative instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgesLiabilities" xlink:to="label_us-gaap_DerivativeInstrumentsAndHedgesLiabilities_1" xlink:title="Label : us-gaap_DerivativeInstrumentsAndHedgesLiabilities to label_us-gaap_DerivativeInstrumentsAndHedgesLiabilities_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xml:lang="en-US" id="label_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:to="label_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:title="Label : us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment to label_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_1" xml:lang="en-US" id="label_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_1">Assets Held-for-sale, consisting of land and buildings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:to="label_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_1" xlink:title="Label : us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment to label_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US" id="label_us-gaap_EarningsPerSharePolicyTextBlock">Earnings Per Share Policy [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="label_us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="Label : us-gaap_EarningsPerSharePolicyTextBlock to label_us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerSharePolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EarningsPerSharePolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_EarningsPerSharePolicyTextBlock_1">Basic and Diluted Net Loss Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="label_us-gaap_EarningsPerSharePolicyTextBlock_1" xlink:title="Label : us-gaap_EarningsPerSharePolicyTextBlock to label_us-gaap_EarningsPerSharePolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US" id="label_us-gaap_EarningsPerShareBasicAndDiluted">Earnings Per Share Basic And Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="label_us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="Label : us-gaap_EarningsPerShareBasicAndDiluted to label_us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareBasicAndDiluted_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EarningsPerShareBasicAndDiluted_1" xml:lang="en-US" id="label_us-gaap_EarningsPerShareBasicAndDiluted_1">Basic and diluted net loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="label_us-gaap_EarningsPerShareBasicAndDiluted_1" xlink:title="Label : us-gaap_EarningsPerShareBasicAndDiluted to label_us-gaap_EarningsPerShareBasicAndDiluted_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:title="us-gaap_EarningsPerShareBasic" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EarningsPerShareBasic" xml:lang="en-US" id="label_us-gaap_EarningsPerShareBasic">Earnings Per Share, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="label_us-gaap_EarningsPerShareBasic" xlink:title="Label : us-gaap_EarningsPerShareBasic to label_us-gaap_EarningsPerShareBasic" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareBasic_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EarningsPerShareBasic_1" xml:lang="en-US" id="label_us-gaap_EarningsPerShareBasic_1">Basic net income (loss) per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="label_us-gaap_EarningsPerShareBasic_1" xlink:title="Label : us-gaap_EarningsPerShareBasic to label_us-gaap_EarningsPerShareBasic_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:title="us-gaap_EarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EarningsPerShareDiluted" xml:lang="en-US" id="label_us-gaap_EarningsPerShareDiluted">Earnings Per Share, Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="label_us-gaap_EarningsPerShareDiluted" xlink:title="Label : us-gaap_EarningsPerShareDiluted to label_us-gaap_EarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EarningsPerShareDiluted_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EarningsPerShareDiluted_1" xml:lang="en-US" id="label_us-gaap_EarningsPerShareDiluted_1">Diluted net income (loss) per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="label_us-gaap_EarningsPerShareDiluted_1" xlink:title="Label : us-gaap_EarningsPerShareDiluted to label_us-gaap_EarningsPerShareDiluted_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xml:lang="en-US" id="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">Effect Of Exchange Rate On Cash And Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="Label : us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents to label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_1" xml:lang="en-US" id="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_1">Effects of exchange rates on cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_1" xlink:title="Label : us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents to label_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="Label : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1" xlink:title="Label : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to label_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition 1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="Label : us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1">Unrecognized share-based compensation expense related to unvested awards expected to be recognized in the period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" xlink:title="Label : us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="Label : us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized to label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1" xml:lang="en-US" id="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1">Unrecognized share-based compensation expense related to unvested awards, net of forfeitures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1" xlink:title="Label : us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized to label_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" xlink:title="us-gaap_EmployeeSeveranceMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_EmployeeSeveranceMember" xml:lang="en-US" id="label_us-gaap_EmployeeSeveranceMember">Employee Severance [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeSeveranceMember" xlink:to="label_us-gaap_EmployeeSeveranceMember" xlink:title="Label : us-gaap_EmployeeSeveranceMember to label_us-gaap_EmployeeSeveranceMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FacilityClosingMember" xlink:label="us-gaap_FacilityClosingMember" xlink:title="us-gaap_FacilityClosingMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FacilityClosingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FacilityClosingMember" xml:lang="en-US" id="label_us-gaap_FacilityClosingMember">Facility Closing [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FacilityClosingMember" xlink:to="label_us-gaap_FacilityClosingMember" xlink:title="Label : us-gaap_FacilityClosingMember to label_us-gaap_FacilityClosingMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:title="us-gaap_FairValueByLiabilityClassAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueByLiabilityClassAxis" xml:lang="en-US" id="label_us-gaap_FairValueByLiabilityClassAxis">Fair Value By Liability Class [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="label_us-gaap_FairValueByLiabilityClassAxis" xlink:title="Label : us-gaap_FairValueByLiabilityClassAxis to label_us-gaap_FairValueByLiabilityClassAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueByLiabilityClassAxis_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FairValueByLiabilityClassAxis_1" xml:lang="en-US" id="label_us-gaap_FairValueByLiabilityClassAxis_1">Liability Class [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="label_us-gaap_FairValueByLiabilityClassAxis_1" xlink:title="Label : us-gaap_FairValueByLiabilityClassAxis to label_us-gaap_FairValueByLiabilityClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xml:lang="en-US" id="label_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:to="label_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:title="Label : us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales to label_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_1" xml:lang="en-US" id="label_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_1">Exercised Stock Purchase Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:to="label_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_1" xlink:title="Label : us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales to label_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_2" xml:lang="en-US" id="label_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_2">Exercised Stock Purchase Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:to="label_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_2" xlink:title="Label : us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales to label_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="us-gaap_FairValueInputsDiscountRate" xlink:title="us-gaap_FairValueInputsDiscountRate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueInputsDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueInputsDiscountRate" xml:lang="en-US" id="label_us-gaap_FairValueInputsDiscountRate">Fair Value Inputs, Discount Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsDiscountRate" xlink:to="label_us-gaap_FairValueInputsDiscountRate" xlink:title="Label : us-gaap_FairValueInputsDiscountRate to label_us-gaap_FairValueInputsDiscountRate" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueInputsDiscountRate_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FairValueInputsDiscountRate_1" xml:lang="en-US" id="label_us-gaap_FairValueInputsDiscountRate_1">Discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsDiscountRate" xlink:to="label_us-gaap_FairValueInputsDiscountRate_1" xlink:title="Label : us-gaap_FairValueInputsDiscountRate to label_us-gaap_FairValueInputsDiscountRate_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US" id="label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="Label : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US" id="label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="Label : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to label_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:title="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US" id="label_us-gaap_FairValueMeasurementsRecurringMember">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="label_us-gaap_FairValueMeasurementsRecurringMember" xlink:title="Label : us-gaap_FairValueMeasurementsRecurringMember to label_us-gaap_FairValueMeasurementsRecurringMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueMeasurementsRecurringMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FairValueMeasurementsRecurringMember_1" xml:lang="en-US" id="label_us-gaap_FairValueMeasurementsRecurringMember_1">Recurring [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="label_us-gaap_FairValueMeasurementsRecurringMember_1" xlink:title="Label : us-gaap_FairValueMeasurementsRecurringMember to label_us-gaap_FairValueMeasurementsRecurringMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:title="us-gaap_FairValueDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US" id="label_us-gaap_FairValueDisclosuresAbstract">Fair Value Measurements [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="label_us-gaap_FairValueDisclosuresAbstract" xlink:title="Label : us-gaap_FairValueDisclosuresAbstract to label_us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US" id="label_us-gaap_FairValueByMeasurementFrequencyAxis">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="label_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:title="Label : us-gaap_FairValueByMeasurementFrequencyAxis to label_us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US" id="label_us-gaap_FairValueByFairValueHierarchyLevelAxis">Fair Value, Hierarchy [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="label_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="Label : us-gaap_FairValueByFairValueHierarchyLevelAxis to label_us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xml:lang="en-US" id="label_us-gaap_FairValueByFairValueHierarchyLevelAxis_1">Fair Value, Hierarchy [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="label_us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="Label : us-gaap_FairValueByFairValueHierarchyLevelAxis to label_us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" xlink:label="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" xlink:title="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" xml:lang="en-US" id="label_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock">Fair Value Inputs, Liabilities, Quantitative Information [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" xlink:to="label_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" xlink:title="Label : us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock to label_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_1" xml:lang="en-US" id="label_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_1">Schedule of Quantitative Information about Level 3 Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" xlink:to="label_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_1" xlink:title="Label : us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock to label_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xml:lang="en-US" id="label_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="label_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="Label : us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain to label_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" xml:lang="en-US" id="label_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1">Fair Value by Liability Class [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="label_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" xlink:title="Label : us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain to label_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:title="us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US" id="label_us-gaap_FairValueDisclosuresTextBlock">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="label_us-gaap_FairValueDisclosuresTextBlock" xlink:title="Label : us-gaap_FairValueDisclosuresTextBlock to label_us-gaap_FairValueDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueDisclosuresTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FairValueDisclosuresTextBlock_1" xml:lang="en-US" id="label_us-gaap_FairValueDisclosuresTextBlock_1">Fair Value Measurements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="label_us-gaap_FairValueDisclosuresTextBlock_1" xlink:title="Label : us-gaap_FairValueDisclosuresTextBlock to label_us-gaap_FairValueDisclosuresTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:title="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US" id="label_us-gaap_FairValueOfFinancialInstrumentsPolicy">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="label_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:title="Label : us-gaap_FairValueOfFinancialInstrumentsPolicy to label_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueOfFinancialInstrumentsPolicy_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FairValueOfFinancialInstrumentsPolicy_1" xml:lang="en-US" id="label_us-gaap_FairValueOfFinancialInstrumentsPolicy_1">Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="label_us-gaap_FairValueOfFinancialInstrumentsPolicy_1" xlink:title="Label : us-gaap_FairValueOfFinancialInstrumentsPolicy to label_us-gaap_FairValueOfFinancialInstrumentsPolicy_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US" id="label_us-gaap_FairValueMeasurementsFairValueHierarchyDomain">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="label_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="Label : us-gaap_FairValueMeasurementsFairValueHierarchyDomain to label_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xml:lang="en-US" id="label_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="label_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="Label : us-gaap_FairValueMeasurementsFairValueHierarchyDomain to label_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US" id="label_us-gaap_FairValueMeasurementFrequencyDomain">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="label_us-gaap_FairValueMeasurementFrequencyDomain" xlink:title="Label : us-gaap_FairValueMeasurementFrequencyDomain to label_us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:title="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueByBalanceSheetGroupingTable" xml:lang="en-US" id="label_us-gaap_FairValueByBalanceSheetGroupingTable">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="label_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:title="Label : us-gaap_FairValueByBalanceSheetGroupingTable to label_us-gaap_FairValueByBalanceSheetGroupingTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueByBalanceSheetGroupingTable_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FairValueByBalanceSheetGroupingTable_1" xml:lang="en-US" id="label_us-gaap_FairValueByBalanceSheetGroupingTable_1">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="label_us-gaap_FairValueByBalanceSheetGroupingTable_1" xlink:title="Label : us-gaap_FairValueByBalanceSheetGroupingTable to label_us-gaap_FairValueByBalanceSheetGroupingTable_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:title="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xml:lang="en-US" id="label_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="label_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:title="Label : us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems to label_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_1" xml:lang="en-US" id="label_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_1">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="label_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_1" xlink:title="Label : us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems to label_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:title="us-gaap_FairValueInputsLevel3Member" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US" id="label_us-gaap_FairValueInputsLevel3Member">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="label_us-gaap_FairValueInputsLevel3Member" xlink:title="Label : us-gaap_FairValueInputsLevel3Member to label_us-gaap_FairValueInputsLevel3Member" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueInputsLevel3Member_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FairValueInputsLevel3Member_1" xml:lang="en-US" id="label_us-gaap_FairValueInputsLevel3Member_1">Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="label_us-gaap_FairValueInputsLevel3Member_1" xlink:title="Label : us-gaap_FairValueInputsLevel3Member to label_us-gaap_FairValueInputsLevel3Member_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:title="us-gaap_FairValueInputsLevel1Member" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US" id="label_us-gaap_FairValueInputsLevel1Member">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="label_us-gaap_FairValueInputsLevel1Member" xlink:title="Label : us-gaap_FairValueInputsLevel1Member to label_us-gaap_FairValueInputsLevel1Member" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueInputsLevel1Member_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FairValueInputsLevel1Member_1" xml:lang="en-US" id="label_us-gaap_FairValueInputsLevel1Member_1">Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="label_us-gaap_FairValueInputsLevel1Member_1" xlink:title="Label : us-gaap_FairValueInputsLevel1Member to label_us-gaap_FairValueInputsLevel1Member_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:title="us-gaap_FairValueInputsLevel2Member" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US" id="label_us-gaap_FairValueInputsLevel2Member">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="label_us-gaap_FairValueInputsLevel2Member" xlink:title="Label : us-gaap_FairValueInputsLevel2Member to label_us-gaap_FairValueInputsLevel2Member" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueInputsLevel2Member_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FairValueInputsLevel2Member_1" xml:lang="en-US" id="label_us-gaap_FairValueInputsLevel2Member_1">Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="label_us-gaap_FairValueInputsLevel2Member_1" xlink:title="Label : us-gaap_FairValueInputsLevel2Member to label_us-gaap_FairValueInputsLevel2Member_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xml:lang="en-US" id="label_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="label_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="Label : us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock to label_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1" xml:lang="en-US" id="label_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1">Summary of Changes in Fair Value of Level 3 Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="label_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1" xlink:title="Label : us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock to label_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:title="us-gaap_FinancialInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_FinancialInstrumentAxis" xml:lang="en-US" id="label_us-gaap_FinancialInstrumentAxis">Financial Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="label_us-gaap_FinancialInstrumentAxis" xlink:title="Label : us-gaap_FinancialInstrumentAxis to label_us-gaap_FinancialInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_FinancialInstrumentAxis_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_FinancialInstrumentAxis_1" xml:lang="en-US" id="label_us-gaap_FinancialInstrumentAxis_1">Financial Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="label_us-gaap_FinancialInstrumentAxis_1" xlink:title="Label : us-gaap_FinancialInstrumentAxis to label_us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:title="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">Foreign Currency Transactions And Translations Policy [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:title="Label : us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock to label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1">Foreign Currency Translation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1" xlink:title="Label : us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock to label_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:title="us-gaap_GainLossOnDispositionOfAssets" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_GainLossOnDispositionOfAssets" xml:lang="en-US" id="label_us-gaap_GainLossOnDispositionOfAssets">Gain (Loss) on Disposition of Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="label_us-gaap_GainLossOnDispositionOfAssets" xlink:title="Label : us-gaap_GainLossOnDispositionOfAssets to label_us-gaap_GainLossOnDispositionOfAssets" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GainLossOnDispositionOfAssets_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_GainLossOnDispositionOfAssets_1" xml:lang="en-US" id="label_us-gaap_GainLossOnDispositionOfAssets_1">Gain on the sale of assets held for sale</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets" xlink:to="label_us-gaap_GainLossOnDispositionOfAssets_1" xlink:title="Label : us-gaap_GainLossOnDispositionOfAssets to label_us-gaap_GainLossOnDispositionOfAssets_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:title="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US" id="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">Gain Loss On Sale Of Property Plant Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:title="Label : us-gaap_GainLossOnSaleOfPropertyPlantEquipment to label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1" xml:lang="en-US" id="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1">Gain on the disposal of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1" xlink:title="Label : us-gaap_GainLossOnSaleOfPropertyPlantEquipment to label_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:title="us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US" id="label_us-gaap_GeneralAndAdministrativeExpense">General And Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="label_us-gaap_GeneralAndAdministrativeExpense" xlink:title="Label : us-gaap_GeneralAndAdministrativeExpense to label_us-gaap_GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GeneralAndAdministrativeExpense_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_GeneralAndAdministrativeExpense_1" xml:lang="en-US" id="label_us-gaap_GeneralAndAdministrativeExpense_1">General and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="label_us-gaap_GeneralAndAdministrativeExpense_1" xlink:title="Label : us-gaap_GeneralAndAdministrativeExpense to label_us-gaap_GeneralAndAdministrativeExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US" id="label_us-gaap_GeneralAndAdministrativeExpenseMember">General And Administrative Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="label_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="Label : us-gaap_GeneralAndAdministrativeExpenseMember to label_us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GeneralAndAdministrativeExpenseMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_GeneralAndAdministrativeExpenseMember_1" xml:lang="en-US" id="label_us-gaap_GeneralAndAdministrativeExpenseMember_1">General and administrative [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="label_us-gaap_GeneralAndAdministrativeExpenseMember_1" xlink:title="Label : us-gaap_GeneralAndAdministrativeExpenseMember to label_us-gaap_GeneralAndAdministrativeExpenseMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:title="us-gaap_Goodwill" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_Goodwill" xml:lang="en-US" id="label_us-gaap_Goodwill">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="label_us-gaap_Goodwill" xlink:title="Label : us-gaap_Goodwill to label_us-gaap_Goodwill" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Goodwill_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_Goodwill_1" xml:lang="en-US" id="label_us-gaap_Goodwill_1">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="label_us-gaap_Goodwill_1" xlink:title="Label : us-gaap_Goodwill to label_us-gaap_Goodwill_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:title="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xml:lang="en-US" id="label_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="label_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:title="Label : us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy to label_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_1" xml:lang="en-US" id="label_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_1">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="label_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_1" xlink:title="Label : us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy to label_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:title="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xml:lang="en-US" id="label_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="label_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:title="Label : us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill to label_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1" xml:lang="en-US" id="label_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1">Impairment charges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="label_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1" xlink:title="Label : us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill to label_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US" id="label_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">Impairment of Long-Lived Assets Held-for-use</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="label_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="Label : us-gaap_ImpairmentOfLongLivedAssetsHeldForUse to label_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1" xml:lang="en-US" id="label_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1">Impairment of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="label_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1" xlink:title="Label : us-gaap_ImpairmentOfLongLivedAssetsHeldForUse to label_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:title="us-gaap_IncomeStatementLocationAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US" id="label_us-gaap_IncomeStatementLocationAxis">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="label_us-gaap_IncomeStatementLocationAxis" xlink:title="Label : us-gaap_IncomeStatementLocationAxis to label_us-gaap_IncomeStatementLocationAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeStatementLocationAxis_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncomeStatementLocationAxis_1" xml:lang="en-US" id="label_us-gaap_IncomeStatementLocationAxis_1">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="label_us-gaap_IncomeStatementLocationAxis_1" xlink:title="Label : us-gaap_IncomeStatementLocationAxis to label_us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:title="us-gaap_IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeStatementAbstract" xml:lang="en-US" id="label_us-gaap_IncomeStatementAbstract">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="label_us-gaap_IncomeStatementAbstract" xlink:title="Label : us-gaap_IncomeStatementAbstract to label_us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US" id="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="Label : us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1" xml:lang="en-US" id="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1">Net loss before income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1" xlink:title="Label : us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments to label_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:title="us-gaap_IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US" id="label_us-gaap_IncomeStatementLocationDomain">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="label_us-gaap_IncomeStatementLocationDomain" xlink:title="Label : us-gaap_IncomeStatementLocationDomain to label_us-gaap_IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeStatementLocationDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncomeStatementLocationDomain_1" xml:lang="en-US" id="label_us-gaap_IncomeStatementLocationDomain_1">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="label_us-gaap_IncomeStatementLocationDomain_1" xlink:title="Label : us-gaap_IncomeStatementLocationDomain to label_us-gaap_IncomeStatementLocationDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:title="us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US" id="label_us-gaap_IncomeTaxExpenseBenefit">Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="label_us-gaap_IncomeTaxExpenseBenefit" xlink:title="Label : us-gaap_IncomeTaxExpenseBenefit to label_us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxExpenseBenefit_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncomeTaxExpenseBenefit_1" xml:lang="en-US" id="label_us-gaap_IncomeTaxExpenseBenefit_1">Income tax expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="label_us-gaap_IncomeTaxExpenseBenefit_1" xlink:title="Label : us-gaap_IncomeTaxExpenseBenefit to label_us-gaap_IncomeTaxExpenseBenefit_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxExpenseBenefit_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_IncomeTaxExpenseBenefit_2" xml:lang="en-US" id="label_us-gaap_IncomeTaxExpenseBenefit_2">Income tax provision</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="label_us-gaap_IncomeTaxExpenseBenefit_2" xlink:title="Label : us-gaap_IncomeTaxExpenseBenefit to label_us-gaap_IncomeTaxExpenseBenefit_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:title="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_IncomeTaxPolicyTextBlock">Income Tax Policy [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="label_us-gaap_IncomeTaxPolicyTextBlock" xlink:title="Label : us-gaap_IncomeTaxPolicyTextBlock to label_us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncomeTaxPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncomeTaxPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_IncomeTaxPolicyTextBlock_1">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="label_us-gaap_IncomeTaxPolicyTextBlock_1" xlink:title="Label : us-gaap_IncomeTaxPolicyTextBlock to label_us-gaap_IncomeTaxPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">Increase Decrease In Accrued Liabilities And Other Operating Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="label_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="Label : us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities to label_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1">Accrued expenses and other liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="label_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1" xlink:title="Label : us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities to label_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccountsReceivable">Increase Decrease In Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="label_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="Label : us-gaap_IncreaseDecreaseInAccountsReceivable to label_us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsReceivable_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_IncreaseDecreaseInAccountsReceivable_1" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccountsReceivable_1">Billed accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="label_us-gaap_IncreaseDecreaseInAccountsReceivable_1" xlink:title="Label : us-gaap_IncreaseDecreaseInAccountsReceivable to label_us-gaap_IncreaseDecreaseInAccountsReceivable_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccountsPayable">Increase Decrease In Accounts Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="label_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:title="Label : us-gaap_IncreaseDecreaseInAccountsPayable to label_us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInAccountsPayable_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncreaseDecreaseInAccountsPayable_1" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInAccountsPayable_1">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="label_us-gaap_IncreaseDecreaseInAccountsPayable_1" xlink:title="Label : us-gaap_IncreaseDecreaseInAccountsPayable to label_us-gaap_IncreaseDecreaseInAccountsPayable_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInDeferredRevenue">Increase (Decrease) in Deferred Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="label_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="Label : us-gaap_IncreaseDecreaseInDeferredRevenue to label_us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInDeferredRevenue_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncreaseDecreaseInDeferredRevenue_1" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInDeferredRevenue_1">Deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="label_us-gaap_IncreaseDecreaseInDeferredRevenue_1" xlink:title="Label : us-gaap_IncreaseDecreaseInDeferredRevenue to label_us-gaap_IncreaseDecreaseInDeferredRevenue_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="Label : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1" xlink:title="Label : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to label_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:label="us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:title="us-gaap_IncreaseDecreaseInUnbilledReceivables" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInUnbilledReceivables" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInUnbilledReceivables">Increase Decrease In Unbilled Receivables</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:to="label_us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:title="Label : us-gaap_IncreaseDecreaseInUnbilledReceivables to label_us-gaap_IncreaseDecreaseInUnbilledReceivables" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInUnbilledReceivables_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_IncreaseDecreaseInUnbilledReceivables_1" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInUnbilledReceivables_1">Unbilled accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:to="label_us-gaap_IncreaseDecreaseInUnbilledReceivables_1" xlink:title="Label : us-gaap_IncreaseDecreaseInUnbilledReceivables to label_us-gaap_IncreaseDecreaseInUnbilledReceivables_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="label_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="Label : us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to label_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xml:lang="en-US" id="label_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="label_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xlink:title="Label : us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to label_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:title="us-gaap_InducedConversionOfConvertibleDebtExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InducedConversionOfConvertibleDebtExpense" xml:lang="en-US" id="label_us-gaap_InducedConversionOfConvertibleDebtExpense">Induced Conversion of Convertible Debt Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:to="label_us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:title="Label : us-gaap_InducedConversionOfConvertibleDebtExpense to label_us-gaap_InducedConversionOfConvertibleDebtExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InducedConversionOfConvertibleDebtExpense_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InducedConversionOfConvertibleDebtExpense_1" xml:lang="en-US" id="label_us-gaap_InducedConversionOfConvertibleDebtExpense_1">Early Conversion offer expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:to="label_us-gaap_InducedConversionOfConvertibleDebtExpense_1" xlink:title="Label : us-gaap_InducedConversionOfConvertibleDebtExpense to label_us-gaap_InducedConversionOfConvertibleDebtExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:title="us-gaap_InterestExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InterestExpense" xml:lang="en-US" id="label_us-gaap_InterestExpense">Interest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="label_us-gaap_InterestExpense" xlink:title="Label : us-gaap_InterestExpense to label_us-gaap_InterestExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestExpense_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_InterestExpense_1" xml:lang="en-US" id="label_us-gaap_InterestExpense_1">Interest expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="label_us-gaap_InterestExpense_1" xlink:title="Label : us-gaap_InterestExpense to label_us-gaap_InterestExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="us-gaap_InterestAndDividendIncomeOperating" xlink:title="us-gaap_InterestAndDividendIncomeOperating" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestAndDividendIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InterestAndDividendIncomeOperating" xml:lang="en-US" id="label_us-gaap_InterestAndDividendIncomeOperating">Interest and Dividend Income, Operating</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDividendIncomeOperating" xlink:to="label_us-gaap_InterestAndDividendIncomeOperating" xlink:title="Label : us-gaap_InterestAndDividendIncomeOperating to label_us-gaap_InterestAndDividendIncomeOperating" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestAndDividendIncomeOperating_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InterestAndDividendIncomeOperating_1" xml:lang="en-US" id="label_us-gaap_InterestAndDividendIncomeOperating_1">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDividendIncomeOperating" xlink:to="label_us-gaap_InterestAndDividendIncomeOperating_1" xlink:title="Label : us-gaap_InterestAndDividendIncomeOperating to label_us-gaap_InterestAndDividendIncomeOperating_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:title="us-gaap_InterestIncomeExpenseNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InterestIncomeExpenseNet" xml:lang="en-US" id="label_us-gaap_InterestIncomeExpenseNet">Interest Income (Expense), Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="label_us-gaap_InterestIncomeExpenseNet" xlink:title="Label : us-gaap_InterestIncomeExpenseNet to label_us-gaap_InterestIncomeExpenseNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestIncomeExpenseNet_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InterestIncomeExpenseNet_1" xml:lang="en-US" id="label_us-gaap_InterestIncomeExpenseNet_1">Interest income and expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="label_us-gaap_InterestIncomeExpenseNet_1" xlink:title="Label : us-gaap_InterestIncomeExpenseNet to label_us-gaap_InterestIncomeExpenseNet_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:title="us-gaap_InterestExpenseDebt" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InterestExpenseDebt" xml:lang="en-US" id="label_us-gaap_InterestExpenseDebt">Interest Expense, Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="label_us-gaap_InterestExpenseDebt" xlink:title="Label : us-gaap_InterestExpenseDebt to label_us-gaap_InterestExpenseDebt" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestExpenseDebt_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InterestExpenseDebt_1" xml:lang="en-US" id="label_us-gaap_InterestExpenseDebt_1">Interest expense related to convertible notes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="label_us-gaap_InterestExpenseDebt_1" xlink:title="Label : us-gaap_InterestExpenseDebt to label_us-gaap_InterestExpenseDebt_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" xlink:title="us-gaap_InterestPaid" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InterestPaid" xml:lang="en-US" id="label_us-gaap_InterestPaid">Interest Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="label_us-gaap_InterestPaid" xlink:title="Label : us-gaap_InterestPaid to label_us-gaap_InterestPaid" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestPaid_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InterestPaid_1" xml:lang="en-US" id="label_us-gaap_InterestPaid_1">Cash paid for interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="label_us-gaap_InterestPaid_1" xlink:title="Label : us-gaap_InterestPaid to label_us-gaap_InterestPaid_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InterestPaid_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_InterestPaid_2" xml:lang="en-US" id="label_us-gaap_InterestPaid_2">Accrued interest paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="label_us-gaap_InterestPaid_2" xlink:title="Label : us-gaap_InterestPaid to label_us-gaap_InterestPaid_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" xlink:title="us-gaap_InvestmentsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_InvestmentsFairValueDisclosure" xml:lang="en-US" id="label_us-gaap_InvestmentsFairValueDisclosure">Investments, Fair Value Disclosure</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="label_us-gaap_InvestmentsFairValueDisclosure" xlink:title="Label : us-gaap_InvestmentsFairValueDisclosure to label_us-gaap_InvestmentsFairValueDisclosure" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_InvestmentsFairValueDisclosure_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_InvestmentsFairValueDisclosure_1" xml:lang="en-US" id="label_us-gaap_InvestmentsFairValueDisclosure_1">Investment in money market funds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsFairValueDisclosure" xlink:to="label_us-gaap_InvestmentsFairValueDisclosure_1" xlink:title="Label : us-gaap_InvestmentsFairValueDisclosure to label_us-gaap_InvestmentsFairValueDisclosure_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:title="us-gaap_LongtermDebtTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US" id="label_us-gaap_LongtermDebtTypeAxis">Long-term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="label_us-gaap_LongtermDebtTypeAxis" xlink:title="Label : us-gaap_LongtermDebtTypeAxis to label_us-gaap_LongtermDebtTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:title="us-gaap_LongtermDebtTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US" id="label_us-gaap_LongtermDebtTypeDomain">Long-term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="label_us-gaap_LongtermDebtTypeDomain" xlink:title="Label : us-gaap_LongtermDebtTypeDomain to label_us-gaap_LongtermDebtTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasePolicyTextBlock" xlink:label="us-gaap_LeasePolicyTextBlock" xlink:title="us-gaap_LeasePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LeasePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LeasePolicyTextBlock" xml:lang="en-US" id="label_us-gaap_LeasePolicyTextBlock">Lease, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasePolicyTextBlock" xlink:to="label_us-gaap_LeasePolicyTextBlock" xlink:title="Label : us-gaap_LeasePolicyTextBlock to label_us-gaap_LeasePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LeasePolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LeasePolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_LeasePolicyTextBlock_1">Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasePolicyTextBlock" xlink:to="label_us-gaap_LeasePolicyTextBlock_1" xlink:title="Label : us-gaap_LeasePolicyTextBlock to label_us-gaap_LeasePolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" xlink:title="us-gaap_LegalFees" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LegalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LegalFees" xml:lang="en-US" id="label_us-gaap_LegalFees">Legal Fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="label_us-gaap_LegalFees" xlink:title="Label : us-gaap_LegalFees to label_us-gaap_LegalFees" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LegalFees_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LegalFees_1" xml:lang="en-US" id="label_us-gaap_LegalFees_1">Legal fees of the lender</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="label_us-gaap_LegalFees_1" xlink:title="Label : us-gaap_LegalFees to label_us-gaap_LegalFees_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:title="us-gaap_LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesCurrent" xml:lang="en-US" id="label_us-gaap_LiabilitiesCurrent">Liabilities Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="label_us-gaap_LiabilitiesCurrent" xlink:title="Label : us-gaap_LiabilitiesCurrent to label_us-gaap_LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_LiabilitiesCurrent_1" xml:lang="en-US" id="label_us-gaap_LiabilitiesCurrent_1">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="label_us-gaap_LiabilitiesCurrent_1" xlink:title="Label : us-gaap_LiabilitiesCurrent to label_us-gaap_LiabilitiesCurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesCurrent_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_LiabilitiesCurrent_2" xml:lang="en-US" id="label_us-gaap_LiabilitiesCurrent_2">Liabilities current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="label_us-gaap_LiabilitiesCurrent_2" xlink:title="Label : us-gaap_LiabilitiesCurrent to label_us-gaap_LiabilitiesCurrent_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:title="us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US" id="label_us-gaap_LiabilitiesCurrentAbstract">Liabilities Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="label_us-gaap_LiabilitiesCurrentAbstract" xlink:title="Label : us-gaap_LiabilitiesCurrentAbstract to label_us-gaap_LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesCurrentAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LiabilitiesCurrentAbstract_1" xml:lang="en-US" id="label_us-gaap_LiabilitiesCurrentAbstract_1">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="label_us-gaap_LiabilitiesCurrentAbstract_1" xlink:title="Label : us-gaap_LiabilitiesCurrentAbstract to label_us-gaap_LiabilitiesCurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:title="us-gaap_Liabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_Liabilities" xml:lang="en-US" id="label_us-gaap_Liabilities">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="label_us-gaap_Liabilities" xlink:title="Label : us-gaap_Liabilities to label_us-gaap_Liabilities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_Liabilities_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_Liabilities_1" xml:lang="en-US" id="label_us-gaap_Liabilities_1">Total liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="label_us-gaap_Liabilities_1" xlink:title="Label : us-gaap_Liabilities to label_us-gaap_Liabilities_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US" id="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="Label : us-gaap_LiabilitiesAndStockholdersEquityAbstract to label_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1" xml:lang="en-US" id="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="label_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1" xlink:title="Label : us-gaap_LiabilitiesAndStockholdersEquityAbstract to label_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:title="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesFairValueDisclosureAbstract" xml:lang="en-US" id="label_us-gaap_LiabilitiesFairValueDisclosureAbstract">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="label_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:title="Label : us-gaap_LiabilitiesFairValueDisclosureAbstract to label_us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesFairValueDisclosureAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LiabilitiesFairValueDisclosureAbstract_1" xml:lang="en-US" id="label_us-gaap_LiabilitiesFairValueDisclosureAbstract_1">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="label_us-gaap_LiabilitiesFairValueDisclosureAbstract_1" xlink:title="Label : us-gaap_LiabilitiesFairValueDisclosureAbstract to label_us-gaap_LiabilitiesFairValueDisclosureAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US" id="label_us-gaap_LiabilitiesAndStockholdersEquity">Liabilities And Stockholders Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="label_us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="Label : us-gaap_LiabilitiesAndStockholdersEquity to label_us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LiabilitiesAndStockholdersEquity_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US" id="label_us-gaap_LiabilitiesAndStockholdersEquity_1">Total liabilities and stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="label_us-gaap_LiabilitiesAndStockholdersEquity_1" xlink:title="Label : us-gaap_LiabilitiesAndStockholdersEquity to label_us-gaap_LiabilitiesAndStockholdersEquity_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseCosts" xlink:label="us-gaap_LicenseCosts" xlink:title="us-gaap_LicenseCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LicenseCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LicenseCosts" xml:lang="en-US" id="label_us-gaap_LicenseCosts">License Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseCosts" xlink:to="label_us-gaap_LicenseCosts" xlink:title="Label : us-gaap_LicenseCosts to label_us-gaap_LicenseCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LicenseCosts_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LicenseCosts_1" xml:lang="en-US" id="label_us-gaap_LicenseCosts_1">License costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseCosts" xlink:to="label_us-gaap_LicenseCosts_1" xlink:title="Label : us-gaap_LicenseCosts to label_us-gaap_LicenseCosts_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US" id="label_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">Line Of Credit Facility Maximum Borrowing Capacity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="label_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="Label : us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity to label_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1" xml:lang="en-US" id="label_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1">Line of credit facility, maximum borrowing capacity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="label_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1" xlink:title="Label : us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity to label_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" xlink:title="us-gaap_LineOfCreditMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LineOfCreditMember" xml:lang="en-US" id="label_us-gaap_LineOfCreditMember">Line of Credit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditMember" xlink:to="label_us-gaap_LineOfCreditMember" xlink:title="Label : us-gaap_LineOfCreditMember to label_us-gaap_LineOfCreditMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" xlink:label="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" xlink:title="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" xml:lang="en-US" id="label_us-gaap_LineOfCreditFacilityBorrowingCapacityDescription">Line of Credit Facility, Borrowing Capacity, Description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" xlink:to="label_us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" xlink:title="Label : us-gaap_LineOfCreditFacilityBorrowingCapacityDescription to label_us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LineOfCreditFacilityBorrowingCapacityDescription_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LineOfCreditFacilityBorrowingCapacityDescription_1" xml:lang="en-US" id="label_us-gaap_LineOfCreditFacilityBorrowingCapacityDescription_1">Line of credit borrowing capacity description</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" xlink:to="label_us-gaap_LineOfCreditFacilityBorrowingCapacityDescription_1" xlink:title="Label : us-gaap_LineOfCreditFacilityBorrowingCapacityDescription to label_us-gaap_LineOfCreditFacilityBorrowingCapacityDescription_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:title="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xml:lang="en-US" id="label_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">Line of Credit Facility, Current Borrowing Capacity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="label_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:title="Label : us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity to label_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_1" xml:lang="en-US" id="label_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_1">Current borrowing capacity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="label_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_1" xlink:title="Label : us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity to label_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_2" xml:lang="en-US" id="label_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_2">Current borrowing capacity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="label_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_2" xlink:title="Label : us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity to label_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense" xlink:title="us-gaap_LitigationSettlementExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LitigationSettlementExpense" xml:lang="en-US" id="label_us-gaap_LitigationSettlementExpense">Litigation Settlement, Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementExpense" xlink:to="label_us-gaap_LitigationSettlementExpense" xlink:title="Label : us-gaap_LitigationSettlementExpense to label_us-gaap_LitigationSettlementExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LitigationSettlementExpense_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LitigationSettlementExpense_1" xml:lang="en-US" id="label_us-gaap_LitigationSettlementExpense_1">Expert witness fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementExpense" xlink:to="label_us-gaap_LitigationSettlementExpense_1" xlink:title="Label : us-gaap_LitigationSettlementExpense to label_us-gaap_LitigationSettlementExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LoanProcessingFee" xlink:label="us-gaap_LoanProcessingFee" xlink:title="us-gaap_LoanProcessingFee" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LoanProcessingFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LoanProcessingFee" xml:lang="en-US" id="label_us-gaap_LoanProcessingFee">Loan Processing Fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoanProcessingFee" xlink:to="label_us-gaap_LoanProcessingFee" xlink:title="Label : us-gaap_LoanProcessingFee to label_us-gaap_LoanProcessingFee" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LoanProcessingFee_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LoanProcessingFee_1" xml:lang="en-US" id="label_us-gaap_LoanProcessingFee_1">Final payment fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoanProcessingFee" xlink:to="label_us-gaap_LoanProcessingFee_1" xlink:title="Label : us-gaap_LoanProcessingFee to label_us-gaap_LoanProcessingFee_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember" xlink:title="us-gaap_LoansPayableMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LoansPayableMember" xml:lang="en-US" id="label_us-gaap_LoansPayableMember">Loans Payable [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayableMember" xlink:to="label_us-gaap_LoansPayableMember" xlink:title="Label : us-gaap_LoansPayableMember to label_us-gaap_LoansPayableMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xml:lang="en-US" id="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:title="Label : us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear to label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_1" xml:lang="en-US" id="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_1">2015</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_1" xlink:title="Label : us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear to label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:title="us-gaap_LongTermDebtCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LongTermDebtCurrent" xml:lang="en-US" id="label_us-gaap_LongTermDebtCurrent">Long Term Debt Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="label_us-gaap_LongTermDebtCurrent" xlink:title="Label : us-gaap_LongTermDebtCurrent to label_us-gaap_LongTermDebtCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LongTermDebtCurrent_1" xml:lang="en-US" id="label_us-gaap_LongTermDebtCurrent_1">Short-term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="label_us-gaap_LongTermDebtCurrent_1" xlink:title="Label : us-gaap_LongTermDebtCurrent to label_us-gaap_LongTermDebtCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xml:lang="en-US" id="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">Long Term Debt Maturities Repayments Of Principal In Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="Label : us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo to label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1" xml:lang="en-US" id="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1">2016</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1" xlink:title="Label : us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo to label_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:title="us-gaap_LongTermDebtNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LongTermDebtNoncurrent" xml:lang="en-US" id="label_us-gaap_LongTermDebtNoncurrent">Long Term Debt Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="label_us-gaap_LongTermDebtNoncurrent" xlink:title="Label : us-gaap_LongTermDebtNoncurrent to label_us-gaap_LongTermDebtNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LongTermDebtNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LongTermDebtNoncurrent_1" xml:lang="en-US" id="label_us-gaap_LongTermDebtNoncurrent_1">Long-term debt, less current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="label_us-gaap_LongTermDebtNoncurrent_1" xlink:title="Label : us-gaap_LongTermDebtNoncurrent to label_us-gaap_LongTermDebtNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="us-gaap_LossContingencyDamagesAwardedValue" xlink:title="us-gaap_LossContingencyDamagesAwardedValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LossContingencyDamagesAwardedValue" xml:lang="en-US" id="label_us-gaap_LossContingencyDamagesAwardedValue">Loss Contingency, Damages Awarded, Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesAwardedValue" xlink:to="label_us-gaap_LossContingencyDamagesAwardedValue" xlink:title="Label : us-gaap_LossContingencyDamagesAwardedValue to label_us-gaap_LossContingencyDamagesAwardedValue" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LossContingencyDamagesAwardedValue_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LossContingencyDamagesAwardedValue_1" xml:lang="en-US" id="label_us-gaap_LossContingencyDamagesAwardedValue_1">Amount of award</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyDamagesAwardedValue" xlink:to="label_us-gaap_LossContingencyDamagesAwardedValue_1" xlink:title="Label : us-gaap_LossContingencyDamagesAwardedValue to label_us-gaap_LossContingencyDamagesAwardedValue_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:title="us-gaap_LossContingencyEstimateOfPossibleLoss" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LossContingencyEstimateOfPossibleLoss" xml:lang="en-US" id="label_us-gaap_LossContingencyEstimateOfPossibleLoss">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="label_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:title="Label : us-gaap_LossContingencyEstimateOfPossibleLoss to label_us-gaap_LossContingencyEstimateOfPossibleLoss" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LossContingencyEstimateOfPossibleLoss_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LossContingencyEstimateOfPossibleLoss_1" xml:lang="en-US" id="label_us-gaap_LossContingencyEstimateOfPossibleLoss_1">Amount of contract expectation damages</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="label_us-gaap_LossContingencyEstimateOfPossibleLoss_1" xlink:title="Label : us-gaap_LossContingencyEstimateOfPossibleLoss to label_us-gaap_LossContingencyEstimateOfPossibleLoss_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:title="us-gaap_LossContingenciesByNatureOfContingencyAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LossContingenciesByNatureOfContingencyAxis" xml:lang="en-US" id="label_us-gaap_LossContingenciesByNatureOfContingencyAxis">Loss Contingency Nature [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="label_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:title="Label : us-gaap_LossContingenciesByNatureOfContingencyAxis to label_us-gaap_LossContingenciesByNatureOfContingencyAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LossContingenciesByNatureOfContingencyAxis_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LossContingenciesByNatureOfContingencyAxis_1" xml:lang="en-US" id="label_us-gaap_LossContingenciesByNatureOfContingencyAxis_1">Loss Contingency Nature [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="label_us-gaap_LossContingenciesByNatureOfContingencyAxis_1" xlink:title="Label : us-gaap_LossContingenciesByNatureOfContingencyAxis to label_us-gaap_LossContingenciesByNatureOfContingencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain" xlink:title="us-gaap_LossContingencyNatureDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_LossContingencyNatureDomain" xml:lang="en-US" id="label_us-gaap_LossContingencyNatureDomain">Loss Contingency, Nature [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="label_us-gaap_LossContingencyNatureDomain" xlink:title="Label : us-gaap_LossContingencyNatureDomain to label_us-gaap_LossContingencyNatureDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_LossContingencyNatureDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_LossContingencyNatureDomain_1" xml:lang="en-US" id="label_us-gaap_LossContingencyNatureDomain_1">Loss Contingency, Nature [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="label_us-gaap_LossContingencyNatureDomain_1" xlink:title="Label : us-gaap_LossContingencyNatureDomain to label_us-gaap_LossContingencyNatureDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaintenanceCosts" xlink:label="us-gaap_MaintenanceCosts" xlink:title="us-gaap_MaintenanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_MaintenanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_MaintenanceCosts" xml:lang="en-US" id="label_us-gaap_MaintenanceCosts">Maintenance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaintenanceCosts" xlink:to="label_us-gaap_MaintenanceCosts" xlink:title="Label : us-gaap_MaintenanceCosts to label_us-gaap_MaintenanceCosts" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:label="us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:title="us-gaap_MajorCustomersPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_MajorCustomersPolicyPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_MajorCustomersPolicyPolicyTextBlock">Major Customers, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:to="label_us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:title="Label : us-gaap_MajorCustomersPolicyPolicyTextBlock to label_us-gaap_MajorCustomersPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_MajorCustomersPolicyPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_MajorCustomersPolicyPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_MajorCustomersPolicyPolicyTextBlock_1">Significant Customers and Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:to="label_us-gaap_MajorCustomersPolicyPolicyTextBlock_1" xlink:title="Label : us-gaap_MajorCustomersPolicyPolicyTextBlock to label_us-gaap_MajorCustomersPolicyPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" xlink:title="us-gaap_MajorCustomersAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_MajorCustomersAxis" xml:lang="en-US" id="label_us-gaap_MajorCustomersAxis">Customer [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="label_us-gaap_MajorCustomersAxis" xlink:title="Label : us-gaap_MajorCustomersAxis to label_us-gaap_MajorCustomersAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="us-gaap_MaximumMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_MaximumMember" xml:lang="en-US" id="label_us-gaap_MaximumMember">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="label_us-gaap_MaximumMember" xlink:title="Label : us-gaap_MaximumMember to label_us-gaap_MaximumMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_MaximumMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_MaximumMember_1" xml:lang="en-US" id="label_us-gaap_MaximumMember_1">Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="label_us-gaap_MaximumMember_1" xlink:title="Label : us-gaap_MaximumMember to label_us-gaap_MaximumMember_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_MaximumMember_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_MaximumMember_2" xml:lang="en-US" id="label_us-gaap_MaximumMember_2">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="label_us-gaap_MaximumMember_2" xlink:title="Label : us-gaap_MaximumMember to label_us-gaap_MaximumMember_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain" xlink:title="us-gaap_NameOfMajorCustomerDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NameOfMajorCustomerDomain" xml:lang="en-US" id="label_us-gaap_NameOfMajorCustomerDomain">Customer [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="label_us-gaap_NameOfMajorCustomerDomain" xlink:title="Label : us-gaap_NameOfMajorCustomerDomain to label_us-gaap_NameOfMajorCustomerDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="Label : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1">Financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" xlink:title="Label : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:title="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xml:lang="en-US" id="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:title="Label : us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted to label_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1" xml:lang="en-US" id="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1">Net income (loss) attributable to common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1" xlink:title="Label : us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted to label_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2" xml:lang="en-US" id="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2">Numerator for diluted income per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="label_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2" xlink:title="Label : us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted to label_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="Label : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1" xlink:title="Label : us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="Label : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1" xlink:title="Label : us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetIncomeLoss" xml:lang="en-US" id="label_us-gaap_NetIncomeLoss">Net Income Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="label_us-gaap_NetIncomeLoss" xlink:title="Label : us-gaap_NetIncomeLoss to label_us-gaap_NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLoss_1" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:title="label_us-gaap_NetIncomeLoss_1" xml:lang="en-US" id="label_us-gaap_NetIncomeLoss_1">Net income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="label_us-gaap_NetIncomeLoss_1" xlink:title="Label : us-gaap_NetIncomeLoss to label_us-gaap_NetIncomeLoss_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLoss_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NetIncomeLoss_2" xml:lang="en-US" id="label_us-gaap_NetIncomeLoss_2">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="label_us-gaap_NetIncomeLoss_2" xlink:title="Label : us-gaap_NetIncomeLoss to label_us-gaap_NetIncomeLoss_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLoss_3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_NetIncomeLoss_3" xml:lang="en-US" id="label_us-gaap_NetIncomeLoss_3">Net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="label_us-gaap_NetIncomeLoss_3" xlink:title="Label : us-gaap_NetIncomeLoss to label_us-gaap_NetIncomeLoss_3" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetIncomeLoss_4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_NetIncomeLoss_4" xml:lang="en-US" id="label_us-gaap_NetIncomeLoss_4">Net income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="label_us-gaap_NetIncomeLoss_4" xlink:title="Label : us-gaap_NetIncomeLoss to label_us-gaap_NetIncomeLoss_4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="Label : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1">Investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1" xlink:title="Label : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to label_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="Label : us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract to label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1">Operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:title="Label : us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract to label_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="Label : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1" xml:lang="en-US" id="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1" xlink:title="Label : us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations to label_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="Label : us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock to label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1">Recent Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xlink:title="Label : us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock to label_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:title="us-gaap_NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US" id="label_us-gaap_NonoperatingIncomeExpense">Nonoperating Income Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="label_us-gaap_NonoperatingIncomeExpense" xlink:title="Label : us-gaap_NonoperatingIncomeExpense to label_us-gaap_NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NonoperatingIncomeExpense_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_NonoperatingIncomeExpense_1" xml:lang="en-US" id="label_us-gaap_NonoperatingIncomeExpense_1">Total other income (expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="label_us-gaap_NonoperatingIncomeExpense_1" xlink:title="Label : us-gaap_NonoperatingIncomeExpense to label_us-gaap_NonoperatingIncomeExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:title="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US" id="label_us-gaap_NonoperatingIncomeExpenseAbstract">Nonoperating Income Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="label_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:title="Label : us-gaap_NonoperatingIncomeExpenseAbstract to label_us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NonoperatingIncomeExpenseAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NonoperatingIncomeExpenseAbstract_1" xml:lang="en-US" id="label_us-gaap_NonoperatingIncomeExpenseAbstract_1">Other income (expense):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="label_us-gaap_NonoperatingIncomeExpenseAbstract_1" xlink:title="Label : us-gaap_NonoperatingIncomeExpenseAbstract to label_us-gaap_NonoperatingIncomeExpenseAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:title="us-gaap_NumberOfOperatingSegments" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_NumberOfOperatingSegments" xml:lang="en-US" id="label_us-gaap_NumberOfOperatingSegments">Number Of Operating Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="label_us-gaap_NumberOfOperatingSegments" xlink:title="Label : us-gaap_NumberOfOperatingSegments to label_us-gaap_NumberOfOperatingSegments" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_NumberOfOperatingSegments_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_NumberOfOperatingSegments_1" xml:lang="en-US" id="label_us-gaap_NumberOfOperatingSegments_1">Number of operating segment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="label_us-gaap_NumberOfOperatingSegments_1" xlink:title="Label : us-gaap_NumberOfOperatingSegments to label_us-gaap_NumberOfOperatingSegments_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:title="us-gaap_OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingExpensesAbstract" xml:lang="en-US" id="label_us-gaap_OperatingExpensesAbstract">Operating Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="label_us-gaap_OperatingExpensesAbstract" xlink:title="Label : us-gaap_OperatingExpensesAbstract to label_us-gaap_OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingExpensesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OperatingExpensesAbstract_1" xml:lang="en-US" id="label_us-gaap_OperatingExpensesAbstract_1">Operating expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="label_us-gaap_OperatingExpensesAbstract_1" xlink:title="Label : us-gaap_OperatingExpensesAbstract to label_us-gaap_OperatingExpensesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:title="us-gaap_OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingExpenses" xml:lang="en-US" id="label_us-gaap_OperatingExpenses">Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="label_us-gaap_OperatingExpenses" xlink:title="Label : us-gaap_OperatingExpenses to label_us-gaap_OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingExpenses_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_OperatingExpenses_1" xml:lang="en-US" id="label_us-gaap_OperatingExpenses_1">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="label_us-gaap_OperatingExpenses_1" xlink:title="Label : us-gaap_OperatingExpenses to label_us-gaap_OperatingExpenses_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:title="us-gaap_OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OperatingIncomeLoss" xml:lang="en-US" id="label_us-gaap_OperatingIncomeLoss">Operating Income Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="label_us-gaap_OperatingIncomeLoss" xlink:title="Label : us-gaap_OperatingIncomeLoss to label_us-gaap_OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OperatingIncomeLoss_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_OperatingIncomeLoss_1" xml:lang="en-US" id="label_us-gaap_OperatingIncomeLoss_1">Loss from operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="label_us-gaap_OperatingIncomeLoss_1" xlink:title="Label : us-gaap_OperatingIncomeLoss to label_us-gaap_OperatingIncomeLoss_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="Label : us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock to label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" xml:lang="en-US" id="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1">Business, Liquidity and Organization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" xlink:title="Label : us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock to label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US" id="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">Business, Liquidity and Organization [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="Label : us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to label_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:title="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xml:lang="en-US" id="label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:to="label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:title="Label : us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax to label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_1" xml:lang="en-US" id="label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_1">Realization of cumulative translation adjustment included in net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:to="label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_1" xlink:title="Label : us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax to label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_2" xml:lang="en-US" id="label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_2">Realization of cumulative translation adjustment included in net loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:to="label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_2" xlink:title="Label : us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax to label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherLiabilitiesTableTextBlock" xlink:title="us-gaap_OtherLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherLiabilitiesTableTextBlock" xml:lang="en-US" id="label_us-gaap_OtherLiabilitiesTableTextBlock">Other Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesTableTextBlock" xlink:to="label_us-gaap_OtherLiabilitiesTableTextBlock" xlink:title="Label : us-gaap_OtherLiabilitiesTableTextBlock to label_us-gaap_OtherLiabilitiesTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:title="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US" id="label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:title="Label : us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax to label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1" xml:lang="en-US" id="label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1">Foreign currency translation adjustments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1" xlink:title="Label : us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax to label_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:title="us-gaap_OtherAssetsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US" id="label_us-gaap_OtherAssetsNoncurrent">Other Assets Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="label_us-gaap_OtherAssetsNoncurrent" xlink:title="Label : us-gaap_OtherAssetsNoncurrent to label_us-gaap_OtherAssetsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherAssetsNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OtherAssetsNoncurrent_1" xml:lang="en-US" id="label_us-gaap_OtherAssetsNoncurrent_1">Other long-term assets and deferred costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="label_us-gaap_OtherAssetsNoncurrent_1" xlink:title="Label : us-gaap_OtherAssetsNoncurrent to label_us-gaap_OtherAssetsNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:title="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xml:lang="en-US" id="label_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="label_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:title="Label : us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract to label_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1" xml:lang="en-US" id="label_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1">Other comprehensive income (loss):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="label_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1" xlink:title="Label : us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract to label_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:title="us-gaap_OtherLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherLiabilitiesCurrent" xml:lang="en-US" id="label_us-gaap_OtherLiabilitiesCurrent">Other Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="label_us-gaap_OtherLiabilitiesCurrent" xlink:title="Label : us-gaap_OtherLiabilitiesCurrent to label_us-gaap_OtherLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherLiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OtherLiabilitiesCurrent_1" xml:lang="en-US" id="label_us-gaap_OtherLiabilitiesCurrent_1">Other short-term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="label_us-gaap_OtherLiabilitiesCurrent_1" xlink:title="Label : us-gaap_OtherLiabilitiesCurrent to label_us-gaap_OtherLiabilitiesCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:title="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US" id="label_us-gaap_OtherLiabilitiesNoncurrent">Other Liabilities Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="label_us-gaap_OtherLiabilitiesNoncurrent" xlink:title="Label : us-gaap_OtherLiabilitiesNoncurrent to label_us-gaap_OtherLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherLiabilitiesNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OtherLiabilitiesNoncurrent_1" xml:lang="en-US" id="label_us-gaap_OtherLiabilitiesNoncurrent_1">Other long-term liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="label_us-gaap_OtherLiabilitiesNoncurrent_1" xlink:title="Label : us-gaap_OtherLiabilitiesNoncurrent to label_us-gaap_OtherLiabilitiesNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:title="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US" id="label_us-gaap_OtherNonoperatingIncomeExpense">Other Nonoperating Income Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="label_us-gaap_OtherNonoperatingIncomeExpense" xlink:title="Label : us-gaap_OtherNonoperatingIncomeExpense to label_us-gaap_OtherNonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_OtherNonoperatingIncomeExpense_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_OtherNonoperatingIncomeExpense_1" xml:lang="en-US" id="label_us-gaap_OtherNonoperatingIncomeExpense_1">Other income (expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="label_us-gaap_OtherNonoperatingIncomeExpense_1" xlink:title="Label : us-gaap_OtherNonoperatingIncomeExpense to label_us-gaap_OtherNonoperatingIncomeExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" xlink:title="us-gaap_PaidInKindInterest" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PaidInKindInterest" xml:lang="en-US" id="label_us-gaap_PaidInKindInterest">Paid In Kind Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="label_us-gaap_PaidInKindInterest" xlink:title="Label : us-gaap_PaidInKindInterest to label_us-gaap_PaidInKindInterest" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaidInKindInterest_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PaidInKindInterest_1" xml:lang="en-US" id="label_us-gaap_PaidInKindInterest_1">Non-cash interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="label_us-gaap_PaidInKindInterest_1" xlink:title="Label : us-gaap_PaidInKindInterest to label_us-gaap_PaidInKindInterest_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US" id="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">Payments To Acquire Property Plant And Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="Label : us-gaap_PaymentsToAcquirePropertyPlantAndEquipment to label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US" id="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1">Purchases of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xlink:title="Label : us-gaap_PaymentsToAcquirePropertyPlantAndEquipment to label_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:title="us-gaap_PaymentsOfFinancingCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PaymentsOfFinancingCosts" xml:lang="en-US" id="label_us-gaap_PaymentsOfFinancingCosts">Payments Of Financing Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="label_us-gaap_PaymentsOfFinancingCosts" xlink:title="Label : us-gaap_PaymentsOfFinancingCosts to label_us-gaap_PaymentsOfFinancingCosts" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PaymentsOfFinancingCosts_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_PaymentsOfFinancingCosts_1" xml:lang="en-US" id="label_us-gaap_PaymentsOfFinancingCosts_1">Deferred financing costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="label_us-gaap_PaymentsOfFinancingCosts_1" xlink:title="Label : us-gaap_PaymentsOfFinancingCosts to label_us-gaap_PaymentsOfFinancingCosts_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:title="us-gaap_PlanNameAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PlanNameAxis" xml:lang="en-US" id="label_us-gaap_PlanNameAxis">Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="label_us-gaap_PlanNameAxis" xlink:title="Label : us-gaap_PlanNameAxis to label_us-gaap_PlanNameAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PlanNameAxis_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PlanNameAxis_1" xml:lang="en-US" id="label_us-gaap_PlanNameAxis_1">Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="label_us-gaap_PlanNameAxis_1" xlink:title="Label : us-gaap_PlanNameAxis to label_us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:title="us-gaap_PlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PlanNameDomain" xml:lang="en-US" id="label_us-gaap_PlanNameDomain">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="label_us-gaap_PlanNameDomain" xlink:title="Label : us-gaap_PlanNameDomain to label_us-gaap_PlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PlanNameDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PlanNameDomain_1" xml:lang="en-US" id="label_us-gaap_PlanNameDomain_1">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="label_us-gaap_PlanNameDomain_1" xlink:title="Label : us-gaap_PlanNameDomain to label_us-gaap_PlanNameDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US" id="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">Prepaid Expense And Other Assets Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="Label : us-gaap_PrepaidExpenseAndOtherAssetsCurrent to label_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1" xml:lang="en-US" id="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="label_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1" xlink:title="Label : us-gaap_PrepaidExpenseAndOtherAssetsCurrent to label_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:title="us-gaap_ProceedsFromWarrantExercises" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US" id="label_us-gaap_ProceedsFromWarrantExercises">Proceeds from Warrant Exercises</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="label_us-gaap_ProceedsFromWarrantExercises" xlink:title="Label : us-gaap_ProceedsFromWarrantExercises to label_us-gaap_ProceedsFromWarrantExercises" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromWarrantExercises_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromWarrantExercises_1" xml:lang="en-US" id="label_us-gaap_ProceedsFromWarrantExercises_1">Net proceeds from exercise of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="label_us-gaap_ProceedsFromWarrantExercises_1" xlink:title="Label : us-gaap_ProceedsFromWarrantExercises to label_us-gaap_ProceedsFromWarrantExercises_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt" xlink:title="us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt" xml:lang="en-US" id="label_us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt">Proceeds from (Repayments of) Other Long-term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt" xlink:to="label_us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt" xlink:title="Label : us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt to label_us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt_1" xml:lang="en-US" id="label_us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt_1">Repayment of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt" xlink:to="label_us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt_1" xlink:title="Label : us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt to label_us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:label="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:title="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xml:lang="en-US" id="label_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit">Proceeds From Repayments Of Lines Of Credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:to="label_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:title="Label : us-gaap_ProceedsFromRepaymentsOfLinesOfCredit to label_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_1" xml:lang="en-US" id="label_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_1">Net repayment of revolving credit agreement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:to="label_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_1" xlink:title="Label : us-gaap_ProceedsFromRepaymentsOfLinesOfCredit to label_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US" id="label_us-gaap_ProceedsFromIssuanceOfCommonStock">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="label_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="Label : us-gaap_ProceedsFromIssuanceOfCommonStock to label_us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromIssuanceOfCommonStock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromIssuanceOfCommonStock_1" xml:lang="en-US" id="label_us-gaap_ProceedsFromIssuanceOfCommonStock_1">Proceeds from issuance of common stock, including exercise of stock options, net of offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="label_us-gaap_ProceedsFromIssuanceOfCommonStock_1" xlink:title="Label : us-gaap_ProceedsFromIssuanceOfCommonStock to label_us-gaap_ProceedsFromIssuanceOfCommonStock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US" id="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">Proceeds From Sale Of Property Plant And Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="Label : us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment to label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1" xml:lang="en-US" id="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1">Proceeds from the sale of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1" xlink:title="Label : us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment to label_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentNet">Property Plant And Equipment Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="label_us-gaap_PropertyPlantAndEquipmentNet" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentNet to label_us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertyPlantAndEquipmentNet_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PropertyPlantAndEquipmentNet_1" xml:lang="en-US" id="label_us-gaap_PropertyPlantAndEquipmentNet_1">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="label_us-gaap_PropertyPlantAndEquipmentNet_1" xlink:title="Label : us-gaap_PropertyPlantAndEquipmentNet to label_us-gaap_PropertyPlantAndEquipmentNet_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" xlink:title="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" xml:lang="en-US" id="label_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet">Property Subject to or Available for Operating Lease, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" xlink:to="label_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" xlink:title="Label : us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet to label_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet_1" xml:lang="en-US" id="label_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet_1">Fair value of leased assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" xlink:to="label_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet_1" xlink:title="Label : us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet to label_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="us-gaap_RangeMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RangeMember" xml:lang="en-US" id="label_us-gaap_RangeMember">Range [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="label_us-gaap_RangeMember" xlink:title="Label : us-gaap_RangeMember to label_us-gaap_RangeMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RangeMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RangeMember_1" xml:lang="en-US" id="label_us-gaap_RangeMember_1">Range [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="label_us-gaap_RangeMember_1" xlink:title="Label : us-gaap_RangeMember to label_us-gaap_RangeMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="us-gaap_RangeAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RangeAxis" xml:lang="en-US" id="label_us-gaap_RangeAxis">Range [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="label_us-gaap_RangeAxis" xlink:title="Label : us-gaap_RangeAxis to label_us-gaap_RangeAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RangeAxis_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RangeAxis_1" xml:lang="en-US" id="label_us-gaap_RangeAxis_1">Range [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="label_us-gaap_RangeAxis_1" xlink:title="Label : us-gaap_RangeAxis to label_us-gaap_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:title="us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentExpense">Research And Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="label_us-gaap_ResearchAndDevelopmentExpense" xlink:title="Label : us-gaap_ResearchAndDevelopmentExpense to label_us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentExpense_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ResearchAndDevelopmentExpense_1" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentExpense_1">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="label_us-gaap_ResearchAndDevelopmentExpense_1" xlink:title="Label : us-gaap_ResearchAndDevelopmentExpense to label_us-gaap_ResearchAndDevelopmentExpense_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:title="Label : us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis to label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:title="Label : us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis to label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:title="Label : us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain to label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="Label : us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain to label_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentExpenseMember">Research And Development Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="label_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="Label : us-gaap_ResearchAndDevelopmentExpenseMember to label_us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ResearchAndDevelopmentExpenseMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ResearchAndDevelopmentExpenseMember_1" xml:lang="en-US" id="label_us-gaap_ResearchAndDevelopmentExpenseMember_1">Research and development [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="label_us-gaap_ResearchAndDevelopmentExpenseMember_1" xlink:title="Label : us-gaap_ResearchAndDevelopmentExpenseMember to label_us-gaap_ResearchAndDevelopmentExpenseMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xml:lang="en-US" id="label_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember">Cash and Cash Equivalents [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="label_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="Label : us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember to label_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" xlink:title="us-gaap_RestructuringCharges" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RestructuringCharges" xml:lang="en-US" id="label_us-gaap_RestructuringCharges">Restructuring Charges</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="label_us-gaap_RestructuringCharges" xlink:title="Label : us-gaap_RestructuringCharges to label_us-gaap_RestructuringCharges" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestructuringCharges_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RestructuringCharges_1" xml:lang="en-US" id="label_us-gaap_RestructuringCharges_1">Restructuring expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="label_us-gaap_RestructuringCharges_1" xlink:title="Label : us-gaap_RestructuringCharges to label_us-gaap_RestructuringCharges_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserveNoncurrent" xlink:label="us-gaap_RestructuringReserveNoncurrent" xlink:title="us-gaap_RestructuringReserveNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestructuringReserveNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RestructuringReserveNoncurrent" xml:lang="en-US" id="label_us-gaap_RestructuringReserveNoncurrent">Restructuring Reserve, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveNoncurrent" xlink:to="label_us-gaap_RestructuringReserveNoncurrent" xlink:title="Label : us-gaap_RestructuringReserveNoncurrent to label_us-gaap_RestructuringReserveNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestructuringReserveNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RestructuringReserveNoncurrent_1" xml:lang="en-US" id="label_us-gaap_RestructuringReserveNoncurrent_1">Accrued restructuring expenses - long term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveNoncurrent" xlink:to="label_us-gaap_RestructuringReserveNoncurrent_1" xlink:title="Label : us-gaap_RestructuringReserveNoncurrent to label_us-gaap_RestructuringReserveNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="us-gaap_RestructuringChargesMember" xlink:title="us-gaap_RestructuringChargesMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RestructuringChargesMember" xml:lang="en-US" id="label_us-gaap_RestructuringChargesMember">Restructuring Charges [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringChargesMember" xlink:to="label_us-gaap_RestructuringChargesMember" xlink:title="Label : us-gaap_RestructuringChargesMember to label_us-gaap_RestructuringChargesMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestructuringChargesMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RestructuringChargesMember_1" xml:lang="en-US" id="label_us-gaap_RestructuringChargesMember_1">Restructuring benefit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringChargesMember" xlink:to="label_us-gaap_RestructuringChargesMember_1" xlink:title="Label : us-gaap_RestructuringChargesMember to label_us-gaap_RestructuringChargesMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent" xlink:title="us-gaap_RestructuringReserveCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestructuringReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RestructuringReserveCurrent" xml:lang="en-US" id="label_us-gaap_RestructuringReserveCurrent">Restructuring Reserve, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveCurrent" xlink:to="label_us-gaap_RestructuringReserveCurrent" xlink:title="Label : us-gaap_RestructuringReserveCurrent to label_us-gaap_RestructuringReserveCurrent" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestructuringReserveCurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RestructuringReserveCurrent_1" xml:lang="en-US" id="label_us-gaap_RestructuringReserveCurrent_1">Accrued restructuring expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReserveCurrent" xlink:to="label_us-gaap_RestructuringReserveCurrent_1" xlink:title="Label : us-gaap_RestructuringReserveCurrent to label_us-gaap_RestructuringReserveCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:title="us-gaap_RestructuringAndRelatedCostExpectedCost1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RestructuringAndRelatedCostExpectedCost1" xml:lang="en-US" id="label_us-gaap_RestructuringAndRelatedCostExpectedCost1">Restructuring and Related Cost, Expected Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="label_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:title="Label : us-gaap_RestructuringAndRelatedCostExpectedCost1 to label_us-gaap_RestructuringAndRelatedCostExpectedCost1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestructuringAndRelatedCostExpectedCost1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RestructuringAndRelatedCostExpectedCost1_1" xml:lang="en-US" id="label_us-gaap_RestructuringAndRelatedCostExpectedCost1_1">Expected severance cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="label_us-gaap_RestructuringAndRelatedCostExpectedCost1_1" xlink:title="Label : us-gaap_RestructuringAndRelatedCostExpectedCost1 to label_us-gaap_RestructuringAndRelatedCostExpectedCost1_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestructuringAndRelatedCostExpectedCost1_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_RestructuringAndRelatedCostExpectedCost1_2" xml:lang="en-US" id="label_us-gaap_RestructuringAndRelatedCostExpectedCost1_2">Expected restructuring cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="label_us-gaap_RestructuringAndRelatedCostExpectedCost1_2" xlink:title="Label : us-gaap_RestructuringAndRelatedCostExpectedCost1 to label_us-gaap_RestructuringAndRelatedCostExpectedCost1_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:label="us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:title="us-gaap_RestructuringReservePeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RestructuringReservePeriodIncreaseDecrease" xml:lang="en-US" id="label_us-gaap_RestructuringReservePeriodIncreaseDecrease">Restructuring Reserve, Period Increase (Decrease)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:to="label_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:title="Label : us-gaap_RestructuringReservePeriodIncreaseDecrease to label_us-gaap_RestructuringReservePeriodIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestructuringReservePeriodIncreaseDecrease_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RestructuringReservePeriodIncreaseDecrease_1" xml:lang="en-US" id="label_us-gaap_RestructuringReservePeriodIncreaseDecrease_1">Accrued restructuring expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:to="label_us-gaap_RestructuringReservePeriodIncreaseDecrease_1" xlink:title="Label : us-gaap_RestructuringReservePeriodIncreaseDecrease to label_us-gaap_RestructuringReservePeriodIncreaseDecrease_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestructuringReservePeriodIncreaseDecrease_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_RestructuringReservePeriodIncreaseDecrease_2" xml:lang="en-US" id="label_us-gaap_RestructuringReservePeriodIncreaseDecrease_2">Decrease in accrued restructuring expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:to="label_us-gaap_RestructuringReservePeriodIncreaseDecrease_2" xlink:title="Label : us-gaap_RestructuringReservePeriodIncreaseDecrease to label_us-gaap_RestructuringReservePeriodIncreaseDecrease_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:title="us-gaap_RestructuringCostAndReserveAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RestructuringCostAndReserveAxis" xml:lang="en-US" id="label_us-gaap_RestructuringCostAndReserveAxis">Restructuring Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="label_us-gaap_RestructuringCostAndReserveAxis" xlink:title="Label : us-gaap_RestructuringCostAndReserveAxis to label_us-gaap_RestructuringCostAndReserveAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" xlink:title="us-gaap_RestructuringCostAndReserveLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RestructuringCostAndReserveLineItems" xml:lang="en-US" id="label_us-gaap_RestructuringCostAndReserveLineItems">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="label_us-gaap_RestructuringCostAndReserveLineItems" xlink:title="Label : us-gaap_RestructuringCostAndReserveLineItems to label_us-gaap_RestructuringCostAndReserveLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US" id="label_us-gaap_RetainedEarningsAccumulatedDeficit">Retained Earnings Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="label_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="Label : us-gaap_RetainedEarningsAccumulatedDeficit to label_us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RetainedEarningsAccumulatedDeficit_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RetainedEarningsAccumulatedDeficit_1" xml:lang="en-US" id="label_us-gaap_RetainedEarningsAccumulatedDeficit_1">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="label_us-gaap_RetainedEarningsAccumulatedDeficit_1" xlink:title="Label : us-gaap_RetainedEarningsAccumulatedDeficit to label_us-gaap_RetainedEarningsAccumulatedDeficit_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RetainedEarningsAccumulatedDeficit_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_RetainedEarningsAccumulatedDeficit_2" xml:lang="en-US" id="label_us-gaap_RetainedEarningsAccumulatedDeficit_2">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="label_us-gaap_RetainedEarningsAccumulatedDeficit_2" xlink:title="Label : us-gaap_RetainedEarningsAccumulatedDeficit to label_us-gaap_RetainedEarningsAccumulatedDeficit_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:title="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US" id="label_us-gaap_RevenueRecognitionPolicyTextBlock">Revenue Recognition Policy [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="label_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:title="Label : us-gaap_RevenueRecognitionPolicyTextBlock to label_us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_RevenueRecognitionPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_RevenueRecognitionPolicyTextBlock_1" xml:lang="en-US" id="label_us-gaap_RevenueRecognitionPolicyTextBlock_1">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="label_us-gaap_RevenueRecognitionPolicyTextBlock_1" xlink:title="Label : us-gaap_RevenueRecognitionPolicyTextBlock to label_us-gaap_RevenueRecognitionPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="label_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="Label : us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock to label_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1" xml:lang="en-US" id="label_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1">Schedule of Assets and Liabilities Measured at Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="label_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1" xlink:title="Label : us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock to label_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xlink:title="us-gaap_ScheduleOfDebtTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfDebtTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfDebtTableTextBlock">Schedule of Debt [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="label_us-gaap_ScheduleOfDebtTableTextBlock" xlink:title="Label : us-gaap_ScheduleOfDebtTableTextBlock to label_us-gaap_ScheduleOfDebtTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfDebtTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfDebtTableTextBlock_1" xml:lang="en-US" id="label_us-gaap_ScheduleOfDebtTableTextBlock_1">Term Loan, Net of Debt Discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="label_us-gaap_ScheduleOfDebtTableTextBlock_1" xlink:title="Label : us-gaap_ScheduleOfDebtTableTextBlock to label_us-gaap_ScheduleOfDebtTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:title="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="label_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:title="Label : us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock to label_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1" xml:lang="en-US" id="label_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1">Principal Payments on the Term Loan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="label_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1" xlink:title="Label : us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock to label_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="label_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="Label : us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock to label_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" xml:lang="en-US" id="label_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1">Schedule of Basic and Diluted Earnings Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="label_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" xlink:title="Label : us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock to label_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="Label : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xml:lang="en-US" id="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:title="Label : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="Label : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" xml:lang="en-US" id="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1">Schedule of Share-based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" xlink:title="Label : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to label_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:title="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="label_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:title="Label : us-gaap_ScheduleOfRestructuringAndRelatedCostsTable to label_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xml:lang="en-US" id="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:title="Label : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to label_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US" id="label_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="label_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="Label : us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock to label_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1" xml:lang="en-US" id="label_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1">Summary of Warrants Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="label_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1" xlink:title="Label : us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock to label_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:title="us-gaap_SegmentDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SegmentDomain" xml:lang="en-US" id="label_us-gaap_SegmentDomain">Segment [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="label_us-gaap_SegmentDomain" xlink:title="Label : us-gaap_SegmentDomain to label_us-gaap_SegmentDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SegmentDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SegmentDomain_1" xml:lang="en-US" id="label_us-gaap_SegmentDomain_1">Segment [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="label_us-gaap_SegmentDomain_1" xlink:title="Label : us-gaap_SegmentDomain to label_us-gaap_SegmentDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1">Warrants outstanding, not exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:title="us-gaap_ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensation" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensation">Share Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="label_us-gaap_ShareBasedCompensation" xlink:title="Label : us-gaap_ShareBasedCompensation to label_us-gaap_ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensation_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensation_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensation_1">Share-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="label_us-gaap_ShareBasedCompensation_1" xlink:title="Label : us-gaap_ShareBasedCompensation to label_us-gaap_ShareBasedCompensation_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1">Stock options granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1">Shares available for grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1">Shares approved for issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized to label_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">Share Based Compensation Option And Incentive Plans Policy</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="Label : us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy to label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1">Share-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xlink:title="Label : us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy to label_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">Exercise Price Range [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain">Award Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Label : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to label_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xml:lang="en-US" id="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="Label : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to label_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" xlink:title="us-gaap_ShortTermBorrowings" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_ShortTermBorrowings" xml:lang="en-US" id="label_us-gaap_ShortTermBorrowings">Short Term Borrowings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="label_us-gaap_ShortTermBorrowings" xlink:title="Label : us-gaap_ShortTermBorrowings to label_us-gaap_ShortTermBorrowings" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShortTermBorrowings_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_ShortTermBorrowings_1" xml:lang="en-US" id="label_us-gaap_ShortTermBorrowings_1">Short-term debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="label_us-gaap_ShortTermBorrowings_1" xlink:title="Label : us-gaap_ShortTermBorrowings to label_us-gaap_ShortTermBorrowings_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_ShortTermBorrowings_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_ShortTermBorrowings_2" xml:lang="en-US" id="label_us-gaap_ShortTermBorrowings_2">Outstanding principal balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermBorrowings" xlink:to="label_us-gaap_ShortTermBorrowings_2" xlink:title="Label : us-gaap_ShortTermBorrowings to label_us-gaap_ShortTermBorrowings_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:title="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US" id="label_us-gaap_SignificantAccountingPoliciesTextBlock">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="label_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:title="Label : us-gaap_SignificantAccountingPoliciesTextBlock to label_us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SignificantAccountingPoliciesTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SignificantAccountingPoliciesTextBlock_1" xml:lang="en-US" id="label_us-gaap_SignificantAccountingPoliciesTextBlock_1">Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="label_us-gaap_SignificantAccountingPoliciesTextBlock_1" xlink:title="Label : us-gaap_SignificantAccountingPoliciesTextBlock to label_us-gaap_SignificantAccountingPoliciesTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:title="us-gaap_StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US" id="label_us-gaap_StatementOfCashFlowsAbstract">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="label_us-gaap_StatementOfCashFlowsAbstract" xlink:title="Label : us-gaap_StatementOfCashFlowsAbstract to label_us-gaap_StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:title="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xml:lang="en-US" id="label_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="label_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:title="Label : us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract to label_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:title="us-gaap_StatementBusinessSegmentsAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementBusinessSegmentsAxis" xml:lang="en-US" id="label_us-gaap_StatementBusinessSegmentsAxis">Business Segments [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="label_us-gaap_StatementBusinessSegmentsAxis" xlink:title="Label : us-gaap_StatementBusinessSegmentsAxis to label_us-gaap_StatementBusinessSegmentsAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementBusinessSegmentsAxis_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StatementBusinessSegmentsAxis_1" xml:lang="en-US" id="label_us-gaap_StatementBusinessSegmentsAxis_1">Business Segments [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="label_us-gaap_StatementBusinessSegmentsAxis_1" xlink:title="Label : us-gaap_StatementBusinessSegmentsAxis to label_us-gaap_StatementBusinessSegmentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:title="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US" id="label_us-gaap_StatementOfFinancialPositionAbstract">CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="label_us-gaap_StatementOfFinancialPositionAbstract" xlink:title="Label : us-gaap_StatementOfFinancialPositionAbstract to label_us-gaap_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="Label : us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities to label_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1">Conversion of July 2009 Convertible Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="label_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1" xlink:title="Label : us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities to label_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesNewIssues to label_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1">Number of shares sold</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesNewIssues to label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2">Number of new stock issued during the period under the controlled equity offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesNewIssues to label_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities to label_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1" xml:lang="en-US" id="label_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1">Conversion of July 2009 Convertible Debt (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="label_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1" xlink:title="Label : us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities to label_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US" id="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock">Stockholders Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="Label : us-gaap_StockholdersEquityNoteDisclosureTextBlock to label_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" xml:lang="en-US" id="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1">Stockholders' Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" xlink:title="Label : us-gaap_StockholdersEquityNoteDisclosureTextBlock to label_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:title="us-gaap_StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockholdersEquityAbstract" xml:lang="en-US" id="label_us-gaap_StockholdersEquityAbstract">Stockholders Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="label_us-gaap_StockholdersEquityAbstract" xlink:title="Label : us-gaap_StockholdersEquityAbstract to label_us-gaap_StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_StockholdersEquityAbstract_1" xml:lang="en-US" id="label_us-gaap_StockholdersEquityAbstract_1">Stockholders' equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="label_us-gaap_StockholdersEquityAbstract_1" xlink:title="Label : us-gaap_StockholdersEquityAbstract to label_us-gaap_StockholdersEquityAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:title="us-gaap_StockholdersEquityNoteAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US" id="label_us-gaap_StockholdersEquityNoteAbstract">Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="label_us-gaap_StockholdersEquityNoteAbstract" xlink:title="Label : us-gaap_StockholdersEquityNoteAbstract to label_us-gaap_StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:title="us-gaap_StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_StockholdersEquity" xml:lang="en-US" id="label_us-gaap_StockholdersEquity">Stockholders Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="label_us-gaap_StockholdersEquity" xlink:title="Label : us-gaap_StockholdersEquity to label_us-gaap_StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_StockholdersEquity_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_StockholdersEquity_1" xml:lang="en-US" id="label_us-gaap_StockholdersEquity_1">Total stockholders' equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="label_us-gaap_StockholdersEquity_1" xlink:title="Label : us-gaap_StockholdersEquity to label_us-gaap_StockholdersEquity_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:title="us-gaap_SubsequentEventTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US" id="label_us-gaap_SubsequentEventTypeAxis">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="label_us-gaap_SubsequentEventTypeAxis" xlink:title="Label : us-gaap_SubsequentEventTypeAxis to label_us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:title="us-gaap_SubsequentEventMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsequentEventMember" xml:lang="en-US" id="label_us-gaap_SubsequentEventMember">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="label_us-gaap_SubsequentEventMember" xlink:title="Label : us-gaap_SubsequentEventMember to label_us-gaap_SubsequentEventMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SubsequentEventMember_1" xml:lang="en-US" id="label_us-gaap_SubsequentEventMember_1">Subsequent Event</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="label_us-gaap_SubsequentEventMember_1" xlink:title="Label : us-gaap_SubsequentEventMember to label_us-gaap_SubsequentEventMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:title="us-gaap_SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US" id="label_us-gaap_SubsequentEventsTextBlock">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="label_us-gaap_SubsequentEventsTextBlock" xlink:title="Label : us-gaap_SubsequentEventsTextBlock to label_us-gaap_SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventsTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SubsequentEventsTextBlock_1" xml:lang="en-US" id="label_us-gaap_SubsequentEventsTextBlock_1">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="label_us-gaap_SubsequentEventsTextBlock_1" xlink:title="Label : us-gaap_SubsequentEventsTextBlock to label_us-gaap_SubsequentEventsTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:title="us-gaap_SubsequentEventsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsequentEventsAbstract" xml:lang="en-US" id="label_us-gaap_SubsequentEventsAbstract">Subsequent Events [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="label_us-gaap_SubsequentEventsAbstract" xlink:title="Label : us-gaap_SubsequentEventsAbstract to label_us-gaap_SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:title="us-gaap_SubsequentEventTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US" id="label_us-gaap_SubsequentEventTypeDomain">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="label_us-gaap_SubsequentEventTypeDomain" xlink:title="Label : us-gaap_SubsequentEventTypeDomain to label_us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US" id="label_us-gaap_SupplementalCashFlowInformationAbstract">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="label_us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="Label : us-gaap_SupplementalCashFlowInformationAbstract to label_us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_SupplementalCashFlowInformationAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_SupplementalCashFlowInformationAbstract_1" xml:lang="en-US" id="label_us-gaap_SupplementalCashFlowInformationAbstract_1">Supplemental disclosure of cash flow information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="label_us-gaap_SupplementalCashFlowInformationAbstract_1" xlink:title="Label : us-gaap_SupplementalCashFlowInformationAbstract to label_us-gaap_SupplementalCashFlowInformationAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US" id="label_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain">Types of Financial Instruments [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="label_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="Label : us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to label_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xml:lang="en-US" id="label_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1">Types of Financial Instruments [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="label_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="Label : us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to label_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:title="us-gaap_TypeOfRestructuringDomain" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_TypeOfRestructuringDomain" xml:lang="en-US" id="label_us-gaap_TypeOfRestructuringDomain">Type of Restructuring [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="label_us-gaap_TypeOfRestructuringDomain" xlink:title="Label : us-gaap_TypeOfRestructuringDomain to label_us-gaap_TypeOfRestructuringDomain" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnbilledContractsReceivable" xlink:label="us-gaap_UnbilledContractsReceivable" xlink:title="us-gaap_UnbilledContractsReceivable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_UnbilledContractsReceivable" xml:lang="en-US" id="label_us-gaap_UnbilledContractsReceivable">Unbilled Contracts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnbilledContractsReceivable" xlink:to="label_us-gaap_UnbilledContractsReceivable" xlink:title="Label : us-gaap_UnbilledContractsReceivable to label_us-gaap_UnbilledContractsReceivable" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_UnbilledContractsReceivable_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_UnbilledContractsReceivable_1" xml:lang="en-US" id="label_us-gaap_UnbilledContractsReceivable_1">Unbilled accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnbilledContractsReceivable" xlink:to="label_us-gaap_UnbilledContractsReceivable_1" xlink:title="Label : us-gaap_UnbilledContractsReceivable to label_us-gaap_UnbilledContractsReceivable_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" xlink:title="us-gaap_UnrealizedGainLossOnDerivatives" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_UnrealizedGainLossOnDerivatives" xml:lang="en-US" id="label_us-gaap_UnrealizedGainLossOnDerivatives">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="label_us-gaap_UnrealizedGainLossOnDerivatives" xlink:title="Label : us-gaap_UnrealizedGainLossOnDerivatives to label_us-gaap_UnrealizedGainLossOnDerivatives" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_UnrealizedGainLossOnDerivatives_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_UnrealizedGainLossOnDerivatives_1" xml:lang="en-US" id="label_us-gaap_UnrealizedGainLossOnDerivatives_1">Change in fair value of derivative instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="label_us-gaap_UnrealizedGainLossOnDerivatives_1" xlink:title="Label : us-gaap_UnrealizedGainLossOnDerivatives to label_us-gaap_UnrealizedGainLossOnDerivatives_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_UnrealizedGainLossOnDerivatives_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_UnrealizedGainLossOnDerivatives_2" xml:lang="en-US" id="label_us-gaap_UnrealizedGainLossOnDerivatives_2">Unrealized (Gains)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="label_us-gaap_UnrealizedGainLossOnDerivatives_2" xlink:title="Label : us-gaap_UnrealizedGainLossOnDerivatives to label_us-gaap_UnrealizedGainLossOnDerivatives_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_UnrealizedGainLossOnDerivatives_3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_us-gaap_UnrealizedGainLossOnDerivatives_3" xml:lang="en-US" id="label_us-gaap_UnrealizedGainLossOnDerivatives_3">Change in fair value of derivative instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="label_us-gaap_UnrealizedGainLossOnDerivatives_3" xlink:title="Label : us-gaap_UnrealizedGainLossOnDerivatives to label_us-gaap_UnrealizedGainLossOnDerivatives_3" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_UnrealizedGainLossOnDerivatives_4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:title="label_us-gaap_UnrealizedGainLossOnDerivatives_4" xml:lang="en-US" id="label_us-gaap_UnrealizedGainLossOnDerivatives_4">Unrealized (Gains) Losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="label_us-gaap_UnrealizedGainLossOnDerivatives_4" xlink:title="Label : us-gaap_UnrealizedGainLossOnDerivatives to label_us-gaap_UnrealizedGainLossOnDerivatives_4" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:title="us-gaap_UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_UseOfEstimates" xml:lang="en-US" id="label_us-gaap_UseOfEstimates">Use Of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="label_us-gaap_UseOfEstimates" xlink:title="Label : us-gaap_UseOfEstimates to label_us-gaap_UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_UseOfEstimates_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_UseOfEstimates_1" xml:lang="en-US" id="label_us-gaap_UseOfEstimates_1">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="label_us-gaap_UseOfEstimates_1" xlink:title="Label : us-gaap_UseOfEstimates to label_us-gaap_UseOfEstimates_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:title="us-gaap_WarrantMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_WarrantMember" xml:lang="en-US" id="label_us-gaap_WarrantMember">Warrant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="label_us-gaap_WarrantMember" xlink:title="Label : us-gaap_WarrantMember to label_us-gaap_WarrantMember" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WarrantMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_WarrantMember_1" xml:lang="en-US" id="label_us-gaap_WarrantMember_1">Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="label_us-gaap_WarrantMember_1" xlink:title="Label : us-gaap_WarrantMember to label_us-gaap_WarrantMember_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="Label : us-gaap_WeightedAverageNumberOfSharesOutstandingBasic to label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1">Weighted average shares used in calculation of basic net loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" xlink:title="Label : us-gaap_WeightedAverageNumberOfSharesOutstandingBasic to label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2">Denominator for basic income per share Weighted average outstanding common shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2" xlink:title="Label : us-gaap_WeightedAverageNumberOfSharesOutstandingBasic to label_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="Label : us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted to label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1">Weighted average shares used in calculation of basic and diluted net loss per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" xlink:title="Label : us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted to label_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="Label : us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding to label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1">Weighted average shares used in calculation of diluted net income (loss) per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xlink:title="Label : us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding to label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2">Denominator for diluted income per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2" xlink:title="Label : us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding to label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2" />
    <link:label xlink:type="resource" xlink:label="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3" xml:lang="en-US" id="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3">Denominator for diluted income per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3" xlink:title="Label : us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding to label_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>pip-20150930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by The Vintage Group, Powered by IRIS Carbon-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.pharmathene.com/role/Disclosure-CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="pip-20150930.xsd#Disclosure-CommitmentsandContingenciesDetails" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-daei" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-daei" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-ftceod" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-ftceod" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-fvmnd" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-fvmnd" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-sesowd" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-sesowd" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-sosapnd" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-sosapnd" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-send" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-send" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/Disclosure-BusinessLiquidityandOrganizationDetails" xlink:type="simple" xlink:href="pip-20150930.xsd#Disclosure-BusinessLiquidityandOrganizationDetails" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-sosapp" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-sosapp" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-sosapt" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-sosapt" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-sosapsosced" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-sosapsosced" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-sosap" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-sosap" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="pip-20150930.xsd#Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-fvmsolmafvd" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-fvmsolmafvd" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="pip-20150930.xsd#Statement-CONDENSEDCONSOLIDATEDBALANCESHEETS" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/Disclosure-CommitmentsandContingenciesLeasesDetails" xlink:type="simple" xlink:href="pip-20150930.xsd#Disclosure-CommitmentsandContingenciesLeasesDetails" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-cac" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-cac" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/Disclosure-CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="pip-20150930.xsd#Disclosure-CommitmentsandContingenciesTables" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-ftlawgcd" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-ftlawgcd" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-ftppotld" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-ftppotld" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-ft" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-ft" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-ftt" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-ftt" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-fvmsoqialfvmd" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-fvmsoqialfvmd" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-fvmt" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-fvmt" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-fvm" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-fvm" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-fvmsocifvolld" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-fvmsocifvolld" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="pip-20150930.xsd#Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/Disclosure-BusinessLiquidityandOrganization" xlink:type="simple" xlink:href="pip-20150930.xsd#Disclosure-BusinessLiquidityandOrganization" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="pip-20150930.xsd#Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="pip-20150930.xsd#Statement-CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-set" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-set" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-se" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-se" />
  <link:roleRef roleURI="http://www.pharmathene.com/role/pip-se1" xlink:type="simple" xlink:href="pip-20150930.xsd#pip-se1" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/Disclosure-CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_CommitmentAndContingenciesTable" xlink:label="pip_CommitmentAndContingenciesTable" xlink:title="pip_CommitmentAndContingenciesTable" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_CommitmentsAndContingenciesLineItems" xlink:label="pip_CommitmentsAndContingenciesLineItems" xlink:title="pip_CommitmentsAndContingenciesLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_CommitmentAndContingenciesTable" xlink:to="pip_CommitmentsAndContingenciesLineItems" xlink:title="Presentation : pip_CommitmentAndContingenciesTable to pip_CommitmentsAndContingenciesLineItems" order="120" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:title="dei_LegalEntityAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_CommitmentAndContingenciesTable" xlink:to="dei_LegalEntityAxis" xlink:title="Presentation : pip_CommitmentAndContingenciesTable to dei_LegalEntityAxis" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:title="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_CommitmentAndContingenciesTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:title="Presentation : pip_CommitmentAndContingenciesTable to us-gaap_ClassOfWarrantOrRightAxis" order="56.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:title="us-gaap_LossContingenciesByNatureOfContingencyAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_CommitmentAndContingenciesTable" xlink:to="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:title="Presentation : pip_CommitmentAndContingenciesTable to us-gaap_LossContingenciesByNatureOfContingencyAxis" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="us-gaap_RangeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_CommitmentAndContingenciesTable" xlink:to="us-gaap_RangeAxis" xlink:title="Presentation : pip_CommitmentAndContingenciesTable to us-gaap_RangeAxis" order="100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_CommitmentAndContingenciesTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:title="Presentation : pip_CommitmentAndContingenciesTable to us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="110" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:title="us-gaap_StatementBusinessSegmentsAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_CommitmentAndContingenciesTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:title="Presentation : pip_CommitmentAndContingenciesTable to us-gaap_StatementBusinessSegmentsAxis" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:title="us-gaap_SubsequentEventTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_CommitmentAndContingenciesTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:title="Presentation : pip_CommitmentAndContingenciesTable to us-gaap_SubsequentEventTypeAxis" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_BreachOfContractualCommitmentAwardPeriod" xlink:label="pip_BreachOfContractualCommitmentAwardPeriod" xlink:title="pip_BreachOfContractualCommitmentAwardPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="pip_BreachOfContractualCommitmentAwardPeriod" xlink:title="Presentation : pip_CommitmentsAndContingenciesLineItems to pip_BreachOfContractualCommitmentAwardPeriod" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_CourtAwardedFees" xlink:label="pip_CourtAwardedFees" xlink:title="pip_CourtAwardedFees" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="pip_CourtAwardedFees" xlink:title="Presentation : pip_CommitmentsAndContingenciesLineItems to pip_CourtAwardedFees" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract" xlink:label="pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract" xlink:title="pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract" xlink:title="Presentation : pip_CommitmentsAndContingenciesLineItems to pip_NetProfitRetentionFromSalesBeforeDistributionForBreachOfContract" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_NotesPayableAggregatePrincipalRepaymentAmount" xlink:label="pip_NotesPayableAggregatePrincipalRepaymentAmount" xlink:title="pip_NotesPayableAggregatePrincipalRepaymentAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="pip_NotesPayableAggregatePrincipalRepaymentAmount" xlink:title="Presentation : pip_CommitmentsAndContingenciesLineItems to pip_NotesPayableAggregatePrincipalRepaymentAmount" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_PercentageOfAggregatePrincipalAmountRedemption" xlink:label="pip_PercentageOfAggregatePrincipalAmountRedemption" xlink:title="pip_PercentageOfAggregatePrincipalAmountRedemption" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="pip_PercentageOfAggregatePrincipalAmountRedemption" xlink:title="Presentation : pip_CommitmentsAndContingenciesLineItems to pip_PercentageOfAggregatePrincipalAmountRedemption" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_PercentageOfNetProfitAwarded" xlink:label="pip_PercentageOfNetProfitAwarded" xlink:title="pip_PercentageOfNetProfitAwarded" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="pip_PercentageOfNetProfitAwarded" xlink:title="Presentation : pip_CommitmentsAndContingenciesLineItems to pip_PercentageOfNetProfitAwarded" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_WarrantExpirationDate" xlink:label="pip_WarrantExpirationDate" xlink:title="pip_WarrantExpirationDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="pip_WarrantExpirationDate" xlink:title="Presentation : pip_CommitmentsAndContingenciesLineItems to pip_WarrantExpirationDate" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_SublicenseFeePercent" xlink:label="pip_SublicenseFeePercent" xlink:title="pip_SublicenseFeePercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="pip_SublicenseFeePercent" xlink:title="Presentation : pip_CommitmentsAndContingenciesLineItems to pip_SublicenseFeePercent" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_LitigationSettlementInterestPercentage" xlink:label="pip_LitigationSettlementInterestPercentage" xlink:title="pip_LitigationSettlementInterestPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="pip_LitigationSettlementInterestPercentage" xlink:title="Presentation : pip_CommitmentsAndContingenciesLineItems to pip_LitigationSettlementInterestPercentage" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_RevenueRecognizedFromContractAudit" xlink:label="pip_RevenueRecognizedFromContractAudit" xlink:title="pip_RevenueRecognizedFromContractAudit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="pip_RevenueRecognizedFromContractAudit" xlink:title="Presentation : pip_CommitmentsAndContingenciesLineItems to pip_RevenueRecognizedFromContractAudit" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_AnnualLicensePayment" xlink:label="pip_AnnualLicensePayment" xlink:title="pip_AnnualLicensePayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="pip_AnnualLicensePayment" xlink:title="Presentation : pip_CommitmentsAndContingenciesLineItems to pip_AnnualLicensePayment" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_MaximumAmountOfReimbursement" xlink:label="pip_MaximumAmountOfReimbursement" xlink:title="pip_MaximumAmountOfReimbursement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="pip_MaximumAmountOfReimbursement" xlink:title="Presentation : pip_CommitmentsAndContingenciesLineItems to pip_MaximumAmountOfReimbursement" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseCosts" xlink:label="us-gaap_LicenseCosts" xlink:title="us-gaap_LicenseCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LicenseCosts" xlink:title="Presentation : pip_CommitmentsAndContingenciesLineItems to us-gaap_LicenseCosts" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense" xlink:title="us-gaap_LitigationSettlementExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LitigationSettlementExpense" xlink:title="Presentation : pip_CommitmentsAndContingenciesLineItems to us-gaap_LitigationSettlementExpense" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyDamagesAwardedValue" xlink:label="us-gaap_LossContingencyDamagesAwardedValue" xlink:title="us-gaap_LossContingencyDamagesAwardedValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LossContingencyDamagesAwardedValue" xlink:title="Presentation : pip_CommitmentsAndContingenciesLineItems to us-gaap_LossContingencyDamagesAwardedValue" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:title="us-gaap_LossContingencyEstimateOfPossibleLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:title="Presentation : pip_CommitmentsAndContingenciesLineItems to us-gaap_LossContingencyEstimateOfPossibleLoss" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaintenanceCosts" xlink:label="us-gaap_MaintenanceCosts" xlink:title="us-gaap_MaintenanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_MaintenanceCosts" xlink:title="Presentation : pip_CommitmentsAndContingenciesLineItems to us-gaap_MaintenanceCosts" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:title="dei_EntityDomain" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:label="pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:title="pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain" xlink:to="pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:title="Presentation : dei_EntityDomain to pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:title="Presentation : dei_LegalEntityAxis to dei_EntityDomain" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:title="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_GroupOneMember" xlink:label="pip_GroupOneMember" xlink:title="pip_GroupOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pip_GroupOneMember" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightDomain to pip_GroupOneMember" order="1.11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightAxis to us-gaap_ClassOfWarrantOrRightDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pip_CommitmentAndContingenciesTable" xlink:title="Presentation : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to pip_CommitmentAndContingenciesTable" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="us-gaap_LossContingencyNatureDomain" xlink:title="us-gaap_LossContingencyNatureDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="us-gaap_LossContingencyNatureDomain" xlink:title="Presentation : us-gaap_LossContingenciesByNatureOfContingencyAxis to us-gaap_LossContingencyNatureDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_GroupFourMember" xlink:label="pip_GroupFourMember" xlink:title="pip_GroupFourMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="pip_GroupFourMember" xlink:title="Presentation : us-gaap_LossContingencyNatureDomain to pip_GroupFourMember" order="1.13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_GroupThreeMember" xlink:label="pip_GroupThreeMember" xlink:title="pip_GroupThreeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LossContingencyNatureDomain" xlink:to="pip_GroupThreeMember" xlink:title="Presentation : us-gaap_LossContingencyNatureDomain to pip_GroupThreeMember" order="1.12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="us-gaap_RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="us-gaap_MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MaximumMember" order="1.1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Presentation : us-gaap_RangeAxis to us-gaap_RangeMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:title="Presentation : us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis to us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_BiologicLicenseApplicationApprovalMember" xlink:label="pip_BiologicLicenseApplicationApprovalMember" xlink:title="pip_BiologicLicenseApplicationApprovalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pip_BiologicLicenseApplicationApprovalMember" xlink:title="Presentation : us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain to pip_BiologicLicenseApplicationApprovalMember" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_MilestonePaymentsMember" xlink:label="pip_MilestonePaymentsMember" xlink:title="pip_MilestonePaymentsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pip_MilestonePaymentsMember" xlink:title="Presentation : us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain to pip_MilestonePaymentsMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_StudiesOrTrailsMember" xlink:label="pip_StudiesOrTrailsMember" xlink:title="pip_StudiesOrTrailsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pip_StudiesOrTrailsMember" xlink:title="Presentation : us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain to pip_StudiesOrTrailsMember" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_UpfrontPaymentMember" xlink:label="pip_UpfrontPaymentMember" xlink:title="pip_UpfrontPaymentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="pip_UpfrontPaymentMember" xlink:title="Presentation : us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain to pip_UpfrontPaymentMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" xlink:title="us-gaap_SegmentDomain" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_PharmAtheneMember" xlink:label="pip_PharmAtheneMember" xlink:title="pip_PharmAtheneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain" xlink:to="pip_PharmAtheneMember" xlink:title="Presentation : us-gaap_SegmentDomain to pip_PharmAtheneMember" order="1.09" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" xlink:title="Presentation : us-gaap_StatementBusinessSegmentsAxis to us-gaap_SegmentDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:title="us-gaap_SubsequentEventTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:title="Presentation : us-gaap_SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeDomain" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:title="us-gaap_SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:title="Presentation : us-gaap_SubsequentEventTypeDomain to us-gaap_SubsequentEventMember" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-daei">
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_DocumentAndEntityInformationAbstract" xlink:label="pip_DocumentAndEntityInformationAbstract" xlink:title="pip_DocumentAndEntityInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:title="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" xlink:title="Presentation : pip_DocumentAndEntityInformationAbstract to dei_AmendmentFlag" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:title="dei_CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" xlink:title="Presentation : pip_DocumentAndEntityInformationAbstract to dei_CurrentFiscalYearEndDate" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:title="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" xlink:title="Presentation : pip_DocumentAndEntityInformationAbstract to dei_DocumentPeriodEndDate" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:title="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" xlink:title="Presentation : pip_DocumentAndEntityInformationAbstract to dei_TradingSymbol" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:title="dei_EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" xlink:title="Presentation : pip_DocumentAndEntityInformationAbstract to dei_EntityFilerCategory" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:title="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" xlink:title="Presentation : pip_DocumentAndEntityInformationAbstract to dei_EntityRegistrantName" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:title="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" xlink:title="Presentation : pip_DocumentAndEntityInformationAbstract to dei_EntityCentralIndexKey" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:title="dei_EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:title="Presentation : pip_DocumentAndEntityInformationAbstract to dei_EntityCommonStockSharesOutstanding" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:title="dei_DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="Presentation : pip_DocumentAndEntityInformationAbstract to dei_DocumentFiscalYearFocus" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:title="dei_DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="Presentation : pip_DocumentAndEntityInformationAbstract to dei_DocumentFiscalPeriodFocus" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:title="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" xlink:title="Presentation : pip_DocumentAndEntityInformationAbstract to dei_DocumentType" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-ftceod">
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_EquityOfferingAxis" xlink:label="pip_EquityOfferingAxis" xlink:title="pip_EquityOfferingAxis" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_EquityOfferingDomain" xlink:label="pip_EquityOfferingDomain" xlink:title="pip_EquityOfferingDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_EquityOfferingAxis" xlink:to="pip_EquityOfferingDomain" xlink:title="Presentation : pip_EquityOfferingAxis to pip_EquityOfferingDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_AmendmentToControlledEquityOfferingMember" xlink:label="pip_AmendmentToControlledEquityOfferingMember" xlink:title="pip_AmendmentToControlledEquityOfferingMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_EquityOfferingDomain" xlink:to="pip_AmendmentToControlledEquityOfferingMember" xlink:title="Presentation : pip_EquityOfferingDomain to pip_AmendmentToControlledEquityOfferingMember" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_EquityOfferingMember" xlink:label="pip_EquityOfferingMember" xlink:title="pip_EquityOfferingMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_EquityOfferingDomain" xlink:to="pip_EquityOfferingMember" xlink:title="Presentation : pip_EquityOfferingDomain to pip_EquityOfferingMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_EquityOfferingLineItems" xlink:label="pip_EquityOfferingLineItems" xlink:title="pip_EquityOfferingLineItems" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares" xlink:label="pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares" xlink:title="pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_EquityOfferingLineItems" xlink:to="pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares" xlink:title="Presentation : pip_EquityOfferingLineItems to pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_FutureValueSettled" xlink:label="pip_FutureValueSettled" xlink:title="pip_FutureValueSettled" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_EquityOfferingLineItems" xlink:to="pip_FutureValueSettled" xlink:title="Presentation : pip_EquityOfferingLineItems to pip_FutureValueSettled" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_MaximumValueOfStockIssuableUnderStockOffering" xlink:label="pip_MaximumValueOfStockIssuableUnderStockOffering" xlink:title="pip_MaximumValueOfStockIssuableUnderStockOffering" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_EquityOfferingLineItems" xlink:to="pip_MaximumValueOfStockIssuableUnderStockOffering" xlink:title="Presentation : pip_EquityOfferingLineItems to pip_MaximumValueOfStockIssuableUnderStockOffering" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_PreviousProceedsFromIssuanceOfCommonStockReceived" xlink:label="pip_PreviousProceedsFromIssuanceOfCommonStockReceived" xlink:title="pip_PreviousProceedsFromIssuanceOfCommonStockReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_EquityOfferingLineItems" xlink:to="pip_PreviousProceedsFromIssuanceOfCommonStockReceived" xlink:title="Presentation : pip_EquityOfferingLineItems to pip_PreviousProceedsFromIssuanceOfCommonStockReceived" order="4.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_RemainingValueOfStockIssuableUnderStockOffering" xlink:label="pip_RemainingValueOfStockIssuableUnderStockOffering" xlink:title="pip_RemainingValueOfStockIssuableUnderStockOffering" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_EquityOfferingLineItems" xlink:to="pip_RemainingValueOfStockIssuableUnderStockOffering" xlink:title="Presentation : pip_EquityOfferingLineItems to pip_RemainingValueOfStockIssuableUnderStockOffering" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:label="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:title="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_EquityOfferingLineItems" xlink:to="us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" xlink:title="Presentation : pip_EquityOfferingLineItems to us-gaap_CommonStockShareSubscribedButUnissuedSubscriptionsReceivable" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_EquityOfferingLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Presentation : pip_EquityOfferingLineItems to us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_EquityOfferingTable" xlink:label="pip_EquityOfferingTable" xlink:title="pip_EquityOfferingTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_EquityOfferingTable" xlink:to="pip_EquityOfferingAxis" xlink:title="Presentation : pip_EquityOfferingTable to pip_EquityOfferingAxis" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_EquityOfferingTable" xlink:to="pip_EquityOfferingLineItems" xlink:title="Presentation : pip_EquityOfferingTable to pip_EquityOfferingLineItems" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:title="us-gaap_SubsequentEventTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_EquityOfferingTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:title="Presentation : pip_EquityOfferingTable to us-gaap_SubsequentEventTypeAxis" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:title="us-gaap_DebtDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="pip_EquityOfferingTable" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to pip_EquityOfferingTable" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:title="us-gaap_SubsequentEventTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:title="Presentation : us-gaap_SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:title="us-gaap_SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:title="Presentation : us-gaap_SubsequentEventTypeDomain to us-gaap_SubsequentEventMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-fvmnd">
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_FairValueMeasurementsLineItems" xlink:label="pip_FairValueMeasurementsLineItems" xlink:title="pip_FairValueMeasurementsLineItems" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" xlink:label="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" xlink:title="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_FairValueMeasurementsLineItems" xlink:to="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" xlink:title="Presentation : pip_FairValueMeasurementsLineItems to pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:title="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_FairValueMeasurementsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:title="Presentation : pip_FairValueMeasurementsLineItems to us-gaap_ClassOfWarrantOrRightOutstanding" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_FairValueMeasurementsLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="Presentation : pip_FairValueMeasurementsLineItems to us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" xlink:title="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_FairValueMeasurementsLineItems" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" xlink:title="Presentation : pip_FairValueMeasurementsLineItems to us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_FairValueMeasurementsTable" xlink:label="pip_FairValueMeasurementsTable" xlink:title="pip_FairValueMeasurementsTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_FairValueMeasurementsTable" xlink:to="pip_FairValueMeasurementsLineItems" xlink:title="Presentation : pip_FairValueMeasurementsTable to pip_FairValueMeasurementsLineItems" order="100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:title="us-gaap_FairValueByLiabilityClassAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_FairValueMeasurementsTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" xlink:title="Presentation : pip_FairValueMeasurementsTable to us-gaap_FairValueByLiabilityClassAxis" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_FairValueMeasurementsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="Presentation : pip_FairValueMeasurementsTable to us-gaap_FairValueByFairValueHierarchyLevelAxis" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:title="us-gaap_FinancialInstrumentAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_FairValueMeasurementsTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:title="Presentation : pip_FairValueMeasurementsTable to us-gaap_FinancialInstrumentAxis" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:title="Presentation : us-gaap_FairValueByLiabilityClassAxis to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:title="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="pip_FairValueMeasurementsTable" xlink:title="Presentation : us-gaap_FairValueDisclosuresAbstract to pip_FairValueMeasurementsTable" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="Presentation : us-gaap_FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_DerivativeLiabilitiesMember" xlink:label="pip_DerivativeLiabilitiesMember" xlink:title="pip_DerivativeLiabilitiesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="pip_DerivativeLiabilitiesMember" xlink:title="Presentation : us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain to pip_DerivativeLiabilitiesMember" order="1.04" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:title="us-gaap_FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:title="Presentation : us-gaap_FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueInputsLevel3Member" order="1.06" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="Presentation : us-gaap_FinancialInstrumentAxis to us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:title="us-gaap_WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" xlink:title="Presentation : us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to us-gaap_WarrantMember" order="1.05" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-sesowd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Presentation : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="us-gaap_DerivativeByNatureAxis" xlink:title="us-gaap_DerivativeByNatureAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="us-gaap_DerivativeNameDomain" xlink:title="us-gaap_DerivativeNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeByNatureAxis" xlink:to="us-gaap_DerivativeNameDomain" xlink:title="Presentation : us-gaap_DerivativeByNatureAxis to us-gaap_DerivativeNameDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_DerivativeInstrumentWarrantsMember" xlink:label="pip_DerivativeInstrumentWarrantsMember" xlink:title="pip_DerivativeInstrumentWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeNameDomain" xlink:to="pip_DerivativeInstrumentWarrantsMember" xlink:title="Presentation : us-gaap_DerivativeNameDomain to pip_DerivativeInstrumentWarrantsMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:title="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to us-gaap_AwardTypeAxis" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_DerivativeByNatureAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to us-gaap_DerivativeByNatureAxis" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:title="us-gaap_SubsequentEventTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable to us-gaap_SubsequentEventTypeAxis" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:title="us-gaap_WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_WarrantMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_WarrantMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ClassOfWarrantOrRightIssuanceDate" xlink:label="pip_ClassOfWarrantOrRightIssuanceDate" xlink:title="pip_ClassOfWarrantOrRightIssuanceDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="pip_ClassOfWarrantOrRightIssuanceDate" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to pip_ClassOfWarrantOrRightIssuanceDate" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_WarrantExpirationDate" xlink:label="pip_WarrantExpirationDate" xlink:title="pip_WarrantExpirationDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="pip_WarrantExpirationDate" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to pip_WarrantExpirationDate" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" xlink:label="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" xlink:title="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:title="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationWarrantsPriceRangeFiveMember" xlink:label="pip_ShareBasedCompensationWarrantsPriceRangeFiveMember" xlink:title="pip_ShareBasedCompensationWarrantsPriceRangeFiveMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pip_ShareBasedCompensationWarrantsPriceRangeFiveMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to pip_ShareBasedCompensationWarrantsPriceRangeFiveMember" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationWarrantsPriceRangeFourMember" xlink:label="pip_ShareBasedCompensationWarrantsPriceRangeFourMember" xlink:title="pip_ShareBasedCompensationWarrantsPriceRangeFourMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pip_ShareBasedCompensationWarrantsPriceRangeFourMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to pip_ShareBasedCompensationWarrantsPriceRangeFourMember" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationWarrantsPriceRangeOneMember" xlink:label="pip_ShareBasedCompensationWarrantsPriceRangeOneMember" xlink:title="pip_ShareBasedCompensationWarrantsPriceRangeOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pip_ShareBasedCompensationWarrantsPriceRangeOneMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to pip_ShareBasedCompensationWarrantsPriceRangeOneMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationWarrantsPriceRangeSevenMember" xlink:label="pip_ShareBasedCompensationWarrantsPriceRangeSevenMember" xlink:title="pip_ShareBasedCompensationWarrantsPriceRangeSevenMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pip_ShareBasedCompensationWarrantsPriceRangeSevenMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to pip_ShareBasedCompensationWarrantsPriceRangeSevenMember" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationWarrantsPriceRangeSixMember" xlink:label="pip_ShareBasedCompensationWarrantsPriceRangeSixMember" xlink:title="pip_ShareBasedCompensationWarrantsPriceRangeSixMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pip_ShareBasedCompensationWarrantsPriceRangeSixMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to pip_ShareBasedCompensationWarrantsPriceRangeSixMember" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationWarrantsPriceRangeThreeMember" xlink:label="pip_ShareBasedCompensationWarrantsPriceRangeThreeMember" xlink:title="pip_ShareBasedCompensationWarrantsPriceRangeThreeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pip_ShareBasedCompensationWarrantsPriceRangeThreeMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to pip_ShareBasedCompensationWarrantsPriceRangeThreeMember" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationWarrantsPriceRangeTwoMember" xlink:label="pip_ShareBasedCompensationWarrantsPriceRangeTwoMember" xlink:title="pip_ShareBasedCompensationWarrantsPriceRangeTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="pip_ShareBasedCompensationWarrantsPriceRangeTwoMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to pip_ShareBasedCompensationWarrantsPriceRangeTwoMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:title="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:title="Presentation : us-gaap_StockholdersEquityNoteAbstract to us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:title="us-gaap_SubsequentEventTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:title="Presentation : us-gaap_SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeDomain" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:title="us-gaap_SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:title="Presentation : us-gaap_SubsequentEventTypeDomain to us-gaap_SubsequentEventMember" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-sosapnd">
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_SignificantAccountingPoliciesLineItems" xlink:label="pip_SignificantAccountingPoliciesLineItems" xlink:title="pip_SignificantAccountingPoliciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_CashEquivalentsMaturityPeriod" xlink:label="pip_CashEquivalentsMaturityPeriod" xlink:title="pip_CashEquivalentsMaturityPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_SignificantAccountingPoliciesLineItems" xlink:to="pip_CashEquivalentsMaturityPeriod" xlink:title="Presentation : pip_SignificantAccountingPoliciesLineItems to pip_CashEquivalentsMaturityPeriod" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_RevenueRecognizedFromContractAudit" xlink:label="pip_RevenueRecognizedFromContractAudit" xlink:title="pip_RevenueRecognizedFromContractAudit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_SignificantAccountingPoliciesLineItems" xlink:to="pip_RevenueRecognizedFromContractAudit" xlink:title="Presentation : pip_SignificantAccountingPoliciesLineItems to pip_RevenueRecognizedFromContractAudit" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" xlink:title="us-gaap_RestructuringCharges" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RestructuringCharges" xlink:title="Presentation : pip_SignificantAccountingPoliciesLineItems to us-gaap_RestructuringCharges" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_SignificantAccountingPoliciesTable" xlink:label="pip_SignificantAccountingPoliciesTable" xlink:title="pip_SignificantAccountingPoliciesTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_SignificantAccountingPoliciesTable" xlink:to="pip_SignificantAccountingPoliciesLineItems" xlink:title="Presentation : pip_SignificantAccountingPoliciesTable to pip_SignificantAccountingPoliciesLineItems" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xlink:title="us-gaap_CashAndCashEquivalentsAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_SignificantAccountingPoliciesTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" xlink:title="Presentation : pip_SignificantAccountingPoliciesTable to us-gaap_CashAndCashEquivalentsAxis" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:title="us-gaap_LongtermDebtTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_SignificantAccountingPoliciesTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:title="Presentation : pip_SignificantAccountingPoliciesTable to us-gaap_LongtermDebtTypeAxis" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" xlink:title="us-gaap_MajorCustomersAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_SignificantAccountingPoliciesTable" xlink:to="us-gaap_MajorCustomersAxis" xlink:title="Presentation : pip_SignificantAccountingPoliciesTable to us-gaap_MajorCustomersAxis" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="us-gaap_RangeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_SignificantAccountingPoliciesTable" xlink:to="us-gaap_RangeAxis" xlink:title="Presentation : pip_SignificantAccountingPoliciesTable to us-gaap_RangeAxis" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:title="us-gaap_RestructuringCostAndReserveAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_SignificantAccountingPoliciesTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" xlink:title="Presentation : pip_SignificantAccountingPoliciesTable to us-gaap_RestructuringCostAndReserveAxis" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate" xlink:label="pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate" xlink:title="pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAnnualForfeitureRate" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod" xlink:label="pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod" xlink:title="pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pip_SignificantAccountingPoliciesTable" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to pip_SignificantAccountingPoliciesTable" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationExtensionOfExercisePeriod" xlink:label="pip_ShareBasedCompensationExtensionOfExercisePeriod" xlink:title="pip_ShareBasedCompensationExtensionOfExercisePeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pip_ShareBasedCompensationExtensionOfExercisePeriod" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to pip_ShareBasedCompensationExtensionOfExercisePeriod" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationReversalFromStockOptionForfeitures" xlink:label="pip_ShareBasedCompensationReversalFromStockOptionForfeitures" xlink:title="pip_ShareBasedCompensationReversalFromStockOptionForfeitures" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pip_ShareBasedCompensationReversalFromStockOptionForfeitures" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to pip_ShareBasedCompensationReversalFromStockOptionForfeitures" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ShareBasedCompensationReversalNet" xlink:label="pip_ShareBasedCompensationReversalNet" xlink:title="pip_ShareBasedCompensationReversalNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="pip_ShareBasedCompensationReversalNet" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to pip_ShareBasedCompensationReversalNet" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:title="us-gaap_DebtInstrumentMaturityDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtInstrumentMaturityDate" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_DebtInstrumentMaturityDate" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:title="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:title="us-gaap_GainLossOnDispositionOfAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_GainLossOnDispositionOfAssets" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:title="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:title="us-gaap_IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_IncomeTaxExpenseBenefit" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:title="us-gaap_NumberOfOperatingSegments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_NumberOfOperatingSegments" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:title="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:title="us-gaap_RestructuringAndRelatedCostExpectedCost1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_RestructuringAndRelatedCostExpectedCost1" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:title="Presentation : us-gaap_CashAndCashEquivalentsAxis to us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:title="us-gaap_LongtermDebtTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:title="Presentation : us-gaap_LongtermDebtTypeAxis to us-gaap_LongtermDebtTypeDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" xlink:title="us-gaap_LineOfCreditMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LineOfCreditMember" xlink:title="Presentation : us-gaap_LongtermDebtTypeDomain to us-gaap_LineOfCreditMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain" xlink:title="us-gaap_NameOfMajorCustomerDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" xlink:title="Presentation : us-gaap_MajorCustomersAxis to us-gaap_NameOfMajorCustomerDomain" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_GovernmentContractMember" xlink:label="pip_GovernmentContractMember" xlink:title="pip_GovernmentContractMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="pip_GovernmentContractMember" xlink:title="Presentation : us-gaap_NameOfMajorCustomerDomain to pip_GovernmentContractMember" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="us-gaap_RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="us-gaap_MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MaximumMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Presentation : us-gaap_RangeAxis to us-gaap_RangeMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_LiquidityArrangementsMember" xlink:label="pip_LiquidityArrangementsMember" xlink:title="pip_LiquidityArrangementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="pip_LiquidityArrangementsMember" xlink:title="Presentation : us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember to pip_LiquidityArrangementsMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:title="us-gaap_TypeOfRestructuringDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" xlink:title="Presentation : us-gaap_RestructuringCostAndReserveAxis to us-gaap_TypeOfRestructuringDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="us-gaap_EmployeeSeveranceMember" xlink:title="us-gaap_EmployeeSeveranceMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_EmployeeSeveranceMember" xlink:title="Presentation : us-gaap_TypeOfRestructuringDomain to us-gaap_EmployeeSeveranceMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FacilityClosingMember" xlink:label="us-gaap_FacilityClosingMember" xlink:title="us-gaap_FacilityClosingMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_FacilityClosingMember" xlink:title="Presentation : us-gaap_TypeOfRestructuringDomain to us-gaap_FacilityClosingMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-send">
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_StockholdersEquityLineItems" xlink:label="pip_StockholdersEquityLineItems" xlink:title="pip_StockholdersEquityLineItems" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_StockOptionsContractualTerm" xlink:label="pip_StockOptionsContractualTerm" xlink:title="pip_StockOptionsContractualTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_StockholdersEquityLineItems" xlink:to="pip_StockOptionsContractualTerm" xlink:title="Presentation : pip_StockholdersEquityLineItems to pip_StockOptionsContractualTerm" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan" xlink:label="pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan" xlink:title="pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_StockholdersEquityLineItems" xlink:to="pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan" xlink:title="Presentation : pip_StockholdersEquityLineItems to pip_ValueOfWarrantIssuedToLenderInConnectionWithLoan" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" xlink:label="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" xlink:title="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_StockholdersEquityLineItems" xlink:to="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" xlink:title="Presentation : pip_StockholdersEquityLineItems to pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExercised" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" xlink:label="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" xlink:title="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_StockholdersEquityLineItems" xlink:to="pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" xlink:title="Presentation : pip_StockholdersEquityLineItems to pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_StockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="Presentation : pip_StockholdersEquityLineItems to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_StockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="Presentation : pip_StockholdersEquityLineItems to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="Presentation : pip_StockholdersEquityLineItems to us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="Presentation : pip_StockholdersEquityLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:title="Presentation : pip_StockholdersEquityLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_StockholdersEquityTable" xlink:label="pip_StockholdersEquityTable" xlink:title="pip_StockholdersEquityTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_StockholdersEquityTable" xlink:to="pip_StockholdersEquityLineItems" xlink:title="Presentation : pip_StockholdersEquityTable to pip_StockholdersEquityLineItems" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:title="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_StockholdersEquityTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:title="Presentation : pip_StockholdersEquityTable to us-gaap_ClassOfWarrantOrRightAxis" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:title="us-gaap_FinancialInstrumentAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_StockholdersEquityTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:title="Presentation : pip_StockholdersEquityTable to us-gaap_FinancialInstrumentAxis" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:title="us-gaap_PlanNameAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_StockholdersEquityTable" xlink:to="us-gaap_PlanNameAxis" xlink:title="Presentation : pip_StockholdersEquityTable to us-gaap_PlanNameAxis" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:title="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_GroupOneMember" xlink:label="pip_GroupOneMember" xlink:title="pip_GroupOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pip_GroupOneMember" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightDomain to pip_GroupOneMember" order="1.1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_GroupTwoMember" xlink:label="pip_GroupTwoMember" xlink:title="pip_GroupTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="pip_GroupTwoMember" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightDomain to pip_GroupTwoMember" order="2.11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightAxis to us-gaap_ClassOfWarrantOrRightDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="Presentation : us-gaap_FinancialInstrumentAxis to us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:title="us-gaap_PlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:title="Presentation : us-gaap_PlanNameAxis to us-gaap_PlanNameDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_StockIncentivePlanTwentyZeroSevenMember" xlink:label="pip_StockIncentivePlanTwentyZeroSevenMember" xlink:title="pip_StockIncentivePlanTwentyZeroSevenMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="pip_StockIncentivePlanTwentyZeroSevenMember" xlink:title="Presentation : us-gaap_PlanNameDomain to pip_StockIncentivePlanTwentyZeroSevenMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:title="us-gaap_StockholdersEquityNoteAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="pip_StockholdersEquityTable" xlink:title="Presentation : us-gaap_StockholdersEquityNoteAbstract to pip_StockholdersEquityTable" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:title="us-gaap_WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" xlink:title="Presentation : us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to us-gaap_WarrantMember" order="1.03" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/Disclosure-BusinessLiquidityandOrganizationDetails">
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:label="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:title="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:title="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:title="Presentation : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable to pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:title="us-gaap_LongtermDebtTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:title="Presentation : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable to us-gaap_LongtermDebtTypeAxis" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="us-gaap_MajorCustomersAxis" xlink:title="us-gaap_MajorCustomersAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_MajorCustomersAxis" xlink:title="Presentation : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable to us-gaap_MajorCustomersAxis" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:title="us-gaap_RangeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:to="us-gaap_RangeAxis" xlink:title="Presentation : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable to us-gaap_RangeAxis" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ProceedsFromInitialFunding" xlink:label="pip_ProceedsFromInitialFunding" xlink:title="pip_ProceedsFromInitialFunding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pip_ProceedsFromInitialFunding" xlink:title="Presentation : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to pip_ProceedsFromInitialFunding" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ValueOfAgreement" xlink:label="pip_ValueOfAgreement" xlink:title="pip_ValueOfAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pip_ValueOfAgreement" xlink:title="Presentation : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to pip_ValueOfAgreement" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_NumberOfOptionsExercised" xlink:label="pip_NumberOfOptionsExercised" xlink:title="pip_NumberOfOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pip_NumberOfOptionsExercised" xlink:title="Presentation : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to pip_NumberOfOptionsExercised" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption" xlink:label="pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption" xlink:title="pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption" xlink:title="Presentation : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to pip_AggregateFundingAmountsToBeReceivedUponExerciseOfEachOption" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_AnnualLicensePayment" xlink:label="pip_AnnualLicensePayment" xlink:title="pip_AnnualLicensePayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pip_AnnualLicensePayment" xlink:title="Presentation : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to pip_AnnualLicensePayment" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ProceedsFromAdditionalFunding" xlink:label="pip_ProceedsFromAdditionalFunding" xlink:title="pip_ProceedsFromAdditionalFunding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pip_ProceedsFromAdditionalFunding" xlink:title="Presentation : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to pip_ProceedsFromAdditionalFunding" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_MaximumAmountOfReimbursement" xlink:label="pip_MaximumAmountOfReimbursement" xlink:title="pip_MaximumAmountOfReimbursement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="pip_MaximumAmountOfReimbursement" xlink:title="Presentation : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to pip_MaximumAmountOfReimbursement" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:title="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:title="Presentation : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" xlink:title="us-gaap_InterestPaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_InterestPaid" xlink:title="Presentation : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to us-gaap_InterestPaid" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees" xlink:title="us-gaap_LegalFees" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_LegalFees" xlink:title="Presentation : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to us-gaap_LegalFees" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LoanProcessingFee" xlink:label="us-gaap_LoanProcessingFee" xlink:title="us-gaap_LoanProcessingFee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_LoanProcessingFee" xlink:title="Presentation : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to us-gaap_LoanProcessingFee" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="us-gaap_ShortTermBorrowings" xlink:title="us-gaap_ShortTermBorrowings" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_ShortTermBorrowings" xlink:title="Presentation : pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems to us-gaap_ShortTermBorrowings" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:title="us-gaap_LongtermDebtTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:title="Presentation : us-gaap_LongtermDebtTypeAxis to us-gaap_LongtermDebtTypeDomain" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" xlink:title="us-gaap_LineOfCreditMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LineOfCreditMember" xlink:title="Presentation : us-gaap_LongtermDebtTypeDomain to us-gaap_LineOfCreditMember" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="us-gaap_NameOfMajorCustomerDomain" xlink:title="us-gaap_NameOfMajorCustomerDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorCustomersAxis" xlink:to="us-gaap_NameOfMajorCustomerDomain" xlink:title="Presentation : us-gaap_MajorCustomersAxis to us-gaap_NameOfMajorCustomerDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:title="pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:title="Presentation : us-gaap_NameOfMajorCustomerDomain to pip_NationalInstituteOfAllergyAndInfectiousDiseasesMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:label="pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:title="pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NameOfMajorCustomerDomain" xlink:to="pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" xlink:title="Presentation : us-gaap_NameOfMajorCustomerDomain to pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_AdditionalCommonStockAggregateGrossSales" xlink:label="pip_AdditionalCommonStockAggregateGrossSales" xlink:title="pip_AdditionalCommonStockAggregateGrossSales" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="pip_AdditionalCommonStockAggregateGrossSales" xlink:title="Presentation : us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to pip_AdditionalCommonStockAggregateGrossSales" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_BilledAndUnbilledAccountsReceivableNet" xlink:label="pip_BilledAndUnbilledAccountsReceivableNet" xlink:title="pip_BilledAndUnbilledAccountsReceivableNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="pip_BilledAndUnbilledAccountsReceivableNet" xlink:title="Presentation : us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to pip_BilledAndUnbilledAccountsReceivableNet" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" xlink:title="Presentation : us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to pip_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTable" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="Presentation : us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_CashAndCashEquivalentsAtCarryingValue" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:title="us-gaap_LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:title="Presentation : us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_LiabilitiesCurrent" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:title="us-gaap_LongTermDebtCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_LongTermDebtCurrent" xlink:title="Presentation : us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_LongTermDebtCurrent" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:title="us-gaap_RestructuringAndRelatedCostExpectedCost1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:title="Presentation : us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_RestructuringAndRelatedCostExpectedCost1" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="Presentation : us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_RetainedEarningsAccumulatedDeficit" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:title="us-gaap_RangeMember" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:title="us-gaap_MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:title="Presentation : us-gaap_RangeMember to us-gaap_MaximumMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:title="Presentation : us-gaap_RangeAxis to us-gaap_RangeMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-sosapp">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:title="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:title="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:title="us-gaap_DebtPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_DebtPolicyTextBlock" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_EarningsPerSharePolicyTextBlock" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:title="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_FairValueOfFinancialInstrumentsPolicy" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:title="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:title="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:title="us-gaap_IncomeTaxPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_IncomeTaxPolicyTextBlock" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeasePolicyTextBlock" xlink:label="us-gaap_LeasePolicyTextBlock" xlink:title="us-gaap_LeasePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LeasePolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_LeasePolicyTextBlock" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:label="us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:title="us-gaap_MajorCustomersPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MajorCustomersPolicyPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_MajorCustomersPolicyPolicyTextBlock" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:title="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_RevenueRecognitionPolicyTextBlock" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:title="us-gaap_UseOfEstimates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_UseOfEstimates" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-sosapt">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" use="optional" priority="0" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-sosapsosced">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="Presentation : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_AllocatedShareBasedCompensationExpense" order="1.04" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:title="us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:title="us-gaap_IncomeStatementLocationDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:title="Presentation : us-gaap_IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="Presentation : us-gaap_IncomeStatementLocationDomain to us-gaap_GeneralAndAdministrativeExpenseMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="Presentation : us-gaap_IncomeStatementLocationDomain to us-gaap_ResearchAndDevelopmentExpenseMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringChargesMember" xlink:label="us-gaap_RestructuringChargesMember" xlink:title="us-gaap_RestructuringChargesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_RestructuringChargesMember" xlink:title="Presentation : us-gaap_IncomeStatementLocationDomain to us-gaap_RestructuringChargesMember" use="optional" priority="0" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="Presentation : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:title="Presentation : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_IncomeStatementLocationAxis" order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-sosap">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:title="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_SignificantAccountingPoliciesTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" xlink:label="pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" xlink:title="pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:title="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_DeferredIncomeTaxExpenseBenefit" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:title="us-gaap_Depreciation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_Depreciation" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:title="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" xlink:title="us-gaap_PaidInKindInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_PaidInKindInterest" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_PaidInKindInterest" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:title="us-gaap_ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_ShareBasedCompensation" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" xlink:title="us-gaap_UnrealizedGainLossOnDerivatives" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" xlink:title="Presentation : us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_UnrealizedGainLossOnDerivatives" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInAccountsReceivable" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInAccountsPayable" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInDeferredRevenue" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:label="us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:title="us-gaap_IncreaseDecreaseInUnbilledReceivables" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInUnbilledReceivables" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInUnbilledReceivables" order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:label="us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:title="us-gaap_RestructuringReservePeriodIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_RestructuringReservePeriodIncreaseDecrease" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:title="us-gaap_PaymentsOfFinancingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_PaymentsOfFinancingCosts" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:title="us-gaap_ProceedsFromWarrantExercises" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_ProceedsFromWarrantExercises" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt" xlink:title="us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:label="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:title="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_ProceedsFromRepaymentsOfLinesOfCredit" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_ProceedsFromIssuanceOfCommonStock" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetIncomeLoss" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:title="us-gaap_StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_CashAndCashEquivalentsAtCarryingValue" order="34" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_CashAndCashEquivalentsAtCarryingValue" order="33" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_SupplementalCashFlowInformationAbstract" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" xlink:title="us-gaap_InterestPaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaid" xlink:title="Presentation : us-gaap_SupplementalCashFlowInformationAbstract to us-gaap_InterestPaid" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-fvmsolmafvd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xlink:title="us-gaap_AssetsFairValueDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeAssets" xlink:label="us-gaap_DerivativeAssets" xlink:title="us-gaap_DerivativeAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeAssets" xlink:title="Presentation : us-gaap_AssetsFairValueDisclosureAbstract to us-gaap_DerivativeAssets" order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure" xlink:label="us-gaap_InvestmentsFairValueDisclosure" xlink:title="us-gaap_InvestmentsFairValueDisclosure" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_InvestmentsFairValueDisclosure" xlink:title="Presentation : us-gaap_AssetsFairValueDisclosureAbstract to us-gaap_InvestmentsFairValueDisclosure" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_FairValueByMeasurementFrequencyAxis" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable to us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_AssetsFairValueDisclosureAbstract" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:title="us-gaap_LiabilitiesFairValueDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_LiabilitiesFairValueDisclosureAbstract" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:title="us-gaap_FairValueDisclosuresAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:title="Presentation : us-gaap_FairValueDisclosuresAbstract to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:title="Presentation : us-gaap_FairValueByMeasurementFrequencyAxis to us-gaap_FairValueMeasurementFrequencyDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="Presentation : us-gaap_FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:title="us-gaap_FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:title="Presentation : us-gaap_FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueInputsLevel3Member" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:title="us-gaap_FairValueInputsLevel1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:title="Presentation : us-gaap_FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueInputsLevel1Member" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:title="us-gaap_FairValueInputsLevel2Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:title="Presentation : us-gaap_FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueInputsLevel2Member" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:title="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:title="Presentation : us-gaap_FairValueMeasurementFrequencyDomain to us-gaap_FairValueMeasurementsRecurringMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="us-gaap_DerivativeLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="Presentation : us-gaap_LiabilitiesFairValueDisclosureAbstract to us-gaap_DerivativeLiabilitiesCurrent" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" xlink:title="us-gaap_DerivativeLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilities" xlink:title="Presentation : us-gaap_LiabilitiesFairValueDisclosureAbstract to us-gaap_DerivativeLiabilities" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:title="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:title="Presentation : us-gaap_LiabilitiesFairValueDisclosureAbstract to us-gaap_DerivativeLiabilitiesNoncurrent" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDBALANCESHEETS">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:title="us-gaap_AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:title="us-gaap_Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_Assets" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:title="us-gaap_AssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_AssetsCurrentAbstract" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:title="us-gaap_Goodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_Goodwill" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:title="us-gaap_OtherAssetsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_OtherAssetsNoncurrent" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_PropertyPlantAndEquipmentNet" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:title="us-gaap_AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_AssetsCurrent" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BilledContractReceivables" xlink:label="us-gaap_BilledContractReceivables" xlink:title="us-gaap_BilledContractReceivables" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_BilledContractReceivables" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_BilledContractReceivables" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnbilledContractsReceivable" xlink:label="us-gaap_UnbilledContractsReceivable" xlink:title="us-gaap_UnbilledContractsReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_UnbilledContractsReceivable" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_UnbilledContractsReceivable" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:title="us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_AccruedExpensesAndOtherCurrentLiabilities" xlink:label="pip_AccruedExpensesAndOtherCurrentLiabilities" xlink:title="pip_AccruedExpensesAndOtherCurrentLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="pip_AccruedExpensesAndOtherCurrentLiabilities" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to pip_AccruedExpensesAndOtherCurrentLiabilities" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:title="us-gaap_AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_AccountsPayableCurrent" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgesLiabilities" xlink:label="us-gaap_DerivativeInstrumentsAndHedgesLiabilities" xlink:title="us-gaap_DerivativeInstrumentsAndHedgesLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgesLiabilities" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_DerivativeInstrumentsAndHedgesLiabilities" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:title="us-gaap_LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrent" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:title="us-gaap_LongTermDebtCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_LongTermDebtCurrent" order="2.75" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:title="us-gaap_OtherLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_OtherLiabilitiesCurrent" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="us-gaap_RestructuringReserveCurrent" xlink:title="us-gaap_RestructuringReserveCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_RestructuringReserveCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_RestructuringReserveCurrent" order="2.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:title="us-gaap_DerivativeLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DerivativeLiabilitiesNoncurrent" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_DerivativeLiabilitiesNoncurrent" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesCurrentAbstract" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:title="us-gaap_Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_Liabilities" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquity" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:title="us-gaap_LongTermDebtNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_LongTermDebtNoncurrent" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:title="us-gaap_OtherLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_OtherLiabilitiesNoncurrent" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringReserveNoncurrent" xlink:label="us-gaap_RestructuringReserveNoncurrent" xlink:title="us-gaap_RestructuringReserveNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_RestructuringReserveNoncurrent" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_RestructuringReserveNoncurrent" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:title="us-gaap_StockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:title="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_AssetsAbstract" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:title="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" order="3.04" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:title="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_AdditionalPaidInCapitalCommonStock" order="2.03" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:title="us-gaap_CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_CommonStockValue" order="1.02" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_RetainedEarningsAccumulatedDeficit" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:title="us-gaap_StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_StockholdersEquity" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/Disclosure-CommitmentsandContingenciesLeasesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_MonthlyRentAmount" xlink:label="pip_MonthlyRentAmount" xlink:title="pip_MonthlyRentAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pip_MonthlyRentAmount" xlink:title="Presentation : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to pip_MonthlyRentAmount" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_FinalMonthlyRentAmount" xlink:label="pip_FinalMonthlyRentAmount" xlink:title="pip_FinalMonthlyRentAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pip_FinalMonthlyRentAmount" xlink:title="Presentation : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to pip_FinalMonthlyRentAmount" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_IncomeLossFromOperatingLeaseCessation" xlink:label="pip_IncomeLossFromOperatingLeaseCessation" xlink:title="pip_IncomeLossFromOperatingLeaseCessation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pip_IncomeLossFromOperatingLeaseCessation" xlink:title="Presentation : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to pip_IncomeLossFromOperatingLeaseCessation" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_EstimatedLeasePaymentsFromSublessee" xlink:label="pip_EstimatedLeasePaymentsFromSublessee" xlink:title="pip_EstimatedLeasePaymentsFromSublessee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pip_EstimatedLeasePaymentsFromSublessee" xlink:title="Presentation : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to pip_EstimatedLeasePaymentsFromSublessee" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_ExpectedSubletCashIncome" xlink:label="pip_ExpectedSubletCashIncome" xlink:title="pip_ExpectedSubletCashIncome" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pip_ExpectedSubletCashIncome" xlink:title="Presentation : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to pip_ExpectedSubletCashIncome" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_PresentValueOfGrossIncomeLoss" xlink:label="pip_PresentValueOfGrossIncomeLoss" xlink:title="pip_PresentValueOfGrossIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="pip_PresentValueOfGrossIncomeLoss" xlink:title="Presentation : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to pip_PresentValueOfGrossIncomeLoss" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="us-gaap_AccruedRentCurrent" xlink:title="us-gaap_AccruedRentCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_AccruedRentCurrent" xlink:title="Presentation : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to us-gaap_AccruedRentCurrent" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedRentNoncurrent" xlink:label="us-gaap_AccruedRentNoncurrent" xlink:title="us-gaap_AccruedRentNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_AccruedRentNoncurrent" xlink:title="Presentation : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to us-gaap_AccruedRentNoncurrent" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="us-gaap_DeferredRentCredit" xlink:title="us-gaap_DeferredRentCredit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_DeferredRentCredit" xlink:title="Presentation : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to us-gaap_DeferredRentCredit" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="us-gaap_FairValueInputsDiscountRate" xlink:title="us-gaap_FairValueInputsDiscountRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_FairValueInputsDiscountRate" xlink:title="Presentation : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to us-gaap_FairValueInputsDiscountRate" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:title="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:title="Presentation : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="us-gaap_RestructuringCostAndReserveAxis" xlink:title="us-gaap_RestructuringCostAndReserveAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="us-gaap_TypeOfRestructuringDomain" xlink:title="us-gaap_TypeOfRestructuringDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveAxis" xlink:to="us-gaap_TypeOfRestructuringDomain" xlink:title="Presentation : us-gaap_RestructuringCostAndReserveAxis to us-gaap_TypeOfRestructuringDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="us-gaap_RestructuringCostAndReserveLineItems" xlink:title="us-gaap_RestructuringCostAndReserveLineItems" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" xlink:title="us-gaap_RestructuringCharges" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestructuringCostAndReserveLineItems" xlink:to="us-gaap_RestructuringCharges" xlink:title="Presentation : us-gaap_RestructuringCostAndReserveLineItems to us-gaap_RestructuringCharges" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveAxis" xlink:title="Presentation : us-gaap_ScheduleOfRestructuringAndRelatedCostsTable to us-gaap_RestructuringCostAndReserveAxis" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="us-gaap_RestructuringCostAndReserveLineItems" xlink:title="Presentation : us-gaap_ScheduleOfRestructuringAndRelatedCostsTable to us-gaap_RestructuringCostAndReserveLineItems" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FacilityClosingMember" xlink:label="us-gaap_FacilityClosingMember" xlink:title="us-gaap_FacilityClosingMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfRestructuringDomain" xlink:to="us-gaap_FacilityClosingMember" xlink:title="Presentation : us-gaap_TypeOfRestructuringDomain to us-gaap_FacilityClosingMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-cac">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="Presentation : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/Disclosure-CommitmentsandContingenciesTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherLiabilitiesTableTextBlock" xlink:title="us-gaap_OtherLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesTableTextBlock" xlink:title="Presentation : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to us-gaap_OtherLiabilitiesTableTextBlock" order="1" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-ftlawgcd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:title="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage" xlink:label="pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage" xlink:title="pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to pip_AdjustableDebtInstrumentReferenceInterestRateFloorPercentage" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_DebtInstrumentInterestRateFloorPercentage" xlink:label="pip_DebtInstrumentInterestRateFloorPercentage" xlink:title="pip_DebtInstrumentInterestRateFloorPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pip_DebtInstrumentInterestRateFloorPercentage" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to pip_DebtInstrumentInterestRateFloorPercentage" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_DebtInstrumentsMaturityDateMonthAndYear" xlink:label="pip_DebtInstrumentsMaturityDateMonthAndYear" xlink:title="pip_DebtInstrumentsMaturityDateMonthAndYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pip_DebtInstrumentsMaturityDateMonthAndYear" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to pip_DebtInstrumentsMaturityDateMonthAndYear" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_FinalPaymentFeeOfTermLoanBalancePercent" xlink:label="pip_FinalPaymentFeeOfTermLoanBalancePercent" xlink:title="pip_FinalPaymentFeeOfTermLoanBalancePercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pip_FinalPaymentFeeOfTermLoanBalancePercent" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to pip_FinalPaymentFeeOfTermLoanBalancePercent" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable" xlink:label="pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable" xlink:title="pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedBilledAccountsReceivable" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl" xlink:label="pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl" xlink:title="pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to pip_LineOfCreditFacilityBorrowingCapacityPercentOfQualifiedUnbilledAccountsReceivabl" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal" xlink:label="pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal" xlink:title="pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to pip_LongTermDebtPrepaymentPremiumPercentOfPrincipal" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo" xlink:label="pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo" xlink:title="pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to pip_LongTermDebtPrepaymentPremiumPercentOfPrincipalPeriodTwo" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants" xlink:label="pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants" xlink:title="pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to pip_StockIssuedValueConvertibleNotesAndStockPurchaseWarrants" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement" xlink:label="pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement" xlink:title="pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="26" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:title="us-gaap_ConvertibleLongTermNotesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_ConvertibleLongTermNotesPayable" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentIssuanceDate1" xlink:label="us-gaap_DebtInstrumentIssuanceDate1" xlink:title="us-gaap_DebtInstrumentIssuanceDate1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentIssuanceDate1" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentIssuanceDate1" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:title="us-gaap_DebtInstrumentCarryingAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentCarryingAmount" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentCarryingAmount" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:title="us-gaap_DebtInstrumentConvertibleConversionPrice1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentConvertibleConversionPrice1" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:title="us-gaap_DebtInstrumentUnamortizedDiscount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentUnamortizedDiscount" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:title="us-gaap_DebtInstrumentMaturityDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentMaturityDate" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:title="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentInterestRateEffectivePercentage" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentPaymentTerms" xlink:label="us-gaap_DebtInstrumentPaymentTerms" xlink:title="us-gaap_DebtInstrumentPaymentTerms" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPaymentTerms" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentPaymentTerms" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentInterestRateStatedPercentage" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:label="us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:title="us-gaap_InducedConversionOfConvertibleDebtExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InducedConversionOfConvertibleDebtExpense" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_InducedConversionOfConvertibleDebtExpense" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:title="us-gaap_InterestExpenseDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_InterestExpenseDebt" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_InterestExpenseDebt" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" xlink:label="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" xlink:title="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_LineOfCreditFacilityBorrowingCapacityDescription" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:title="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:title="us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" xlink:title="us-gaap_DebtInstrumentTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentTable" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_DebtInstrumentTable" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentLineItems" xlink:title="Presentation : us-gaap_DebtInstrumentTable to us-gaap_DebtInstrumentLineItems" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:title="us-gaap_LongtermDebtTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:title="Presentation : us-gaap_DebtInstrumentTable to us-gaap_LongtermDebtTypeAxis" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:title="us-gaap_LongtermDebtTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:title="Presentation : us-gaap_LongtermDebtTypeAxis to us-gaap_LongtermDebtTypeDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="us-gaap_LineOfCreditMember" xlink:title="us-gaap_LineOfCreditMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LineOfCreditMember" xlink:title="Presentation : us-gaap_LongtermDebtTypeDomain to us-gaap_LineOfCreditMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LoansPayableMember" xlink:label="us-gaap_LoansPayableMember" xlink:title="us-gaap_LoansPayableMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LoansPayableMember" xlink:title="Presentation : us-gaap_LongtermDebtTypeDomain to us-gaap_LoansPayableMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-ftppotld">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:title="us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_LongTermDebtExcludingDiscount" xlink:label="pip_LongTermDebtExcludingDiscount" xlink:title="pip_LongTermDebtExcludingDiscount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="pip_LongTermDebtExcludingDiscount" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to pip_LongTermDebtExcludingDiscount" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-ft">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:title="us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:title="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_AdditionalFinancialInformationDisclosureTextBlock" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-ftt">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:title="us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xlink:title="us-gaap_ScheduleOfDebtTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_ScheduleOfDebtTableTextBlock" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:title="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-fvmsoqialfvmd">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:title="us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" xlink:title="us-gaap_DerivativeLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_DerivativeLiabilities" xlink:title="Presentation : us-gaap_FairValueDisclosuresAbstract to us-gaap_DerivativeLiabilities" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-fvmt">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:title="us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" xlink:label="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" xlink:title="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" xlink:title="Presentation : us-gaap_FairValueDisclosuresAbstract to us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:title="Presentation : us-gaap_FairValueDisclosuresAbstract to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:title="Presentation : us-gaap_FairValueDisclosuresAbstract to us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="1.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-fvm">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:title="us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:title="us-gaap_FairValueDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:title="Presentation : us-gaap_FairValueDisclosuresAbstract to us-gaap_FairValueDisclosuresTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-fvmsocifvolld">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:title="us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:title="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:title="Presentation : us-gaap_FairValueDisclosuresAbstract to us-gaap_FairValueByBalanceSheetGroupingTable" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="Presentation : us-gaap_FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:title="us-gaap_FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:title="Presentation : us-gaap_FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueInputsLevel3Member" order="1.02" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="Presentation : us-gaap_FairValueByBalanceSheetGroupingTable to us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:title="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:title="Presentation : us-gaap_FairValueByBalanceSheetGroupingTable to us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="100" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:title="us-gaap_FinancialInstrumentAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:title="Presentation : us-gaap_FairValueByBalanceSheetGroupingTable to us-gaap_FinancialInstrumentAxis" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_InitialDerivativeFairValue" xlink:label="pip_InitialDerivativeFairValue" xlink:title="pip_InitialDerivativeFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="pip_InitialDerivativeFairValue" xlink:title="Presentation : us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems to pip_InitialDerivativeFairValue" order="8000" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities" xlink:title="us-gaap_DerivativeLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DerivativeLiabilities" xlink:title="Presentation : us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems to us-gaap_DerivativeLiabilities" order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="us-gaap_DerivativeLiabilities_1" xlink:title="us-gaap_DerivativeLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_DerivativeLiabilities_1" xlink:title="Presentation : us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems to us-gaap_DerivativeLiabilities" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:title="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:title="Presentation : us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems to us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" xlink:title="us-gaap_UnrealizedGainLossOnDerivatives" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" xlink:title="Presentation : us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems to us-gaap_UnrealizedGainLossOnDerivatives" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="Presentation : us-gaap_FinancialInstrumentAxis to us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:title="us-gaap_WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_WarrantMember" xlink:title="Presentation : us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to us-gaap_WarrantMember" order="1.03" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:title="us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="us-gaap_ContractsRevenue" xlink:title="us-gaap_ContractsRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ContractsRevenue" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_ContractsRevenue" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="us-gaap_EarningsPerShareBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_EarningsPerShareBasicAndDiluted" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:title="us-gaap_EarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_EarningsPerShareBasic" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:title="us-gaap_EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_EarningsPerShareDiluted" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:title="us-gaap_IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_IncomeTaxExpenseBenefit" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:title="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_NetIncomeLoss" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:title="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_NonoperatingIncomeExpenseAbstract" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:title="us-gaap_OperatingExpensesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_OperatingExpensesAbstract" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:title="us-gaap_OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_OperatingIncomeLoss" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="pip-20150930.xsd#pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" xlink:label="pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" xlink:title="pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" xlink:title="Presentation : us-gaap_NonoperatingIncomeExpenseAbstract to pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:title="us-gaap_InterestExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" xlink:title="Presentation : us-gaap_NonoperatingIncomeExpenseAbstract to us-gaap_InterestExpense" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestAndDividendIncomeOperating" xlink:label="us-gaap_InterestAndDividendIncomeOperating" xlink:title="us-gaap_InterestAndDividendIncomeOperating" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestAndDividendIncomeOperating" xlink:title="Presentation : us-gaap_NonoperatingIncomeExpenseAbstract to us-gaap_InterestAndDividendIncomeOperating" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:title="us-gaap_InterestIncomeExpenseNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" xlink:title="Presentation : us-gaap_NonoperatingIncomeExpenseAbstract to us-gaap_InterestIncomeExpenseNet" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:title="us-gaap_NonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:title="Presentation : us-gaap_NonoperatingIncomeExpenseAbstract to us-gaap_NonoperatingIncomeExpense" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:title="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:title="Presentation : us-gaap_NonoperatingIncomeExpenseAbstract to us-gaap_OtherNonoperatingIncomeExpense" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" xlink:title="us-gaap_UnrealizedGainLossOnDerivatives" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives" xlink:title="Presentation : us-gaap_NonoperatingIncomeExpenseAbstract to us-gaap_UnrealizedGainLossOnDerivatives" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:title="us-gaap_Depreciation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_Depreciation" xlink:title="Presentation : us-gaap_OperatingExpensesAbstract to us-gaap_Depreciation" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:title="us-gaap_GeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:title="Presentation : us-gaap_OperatingExpensesAbstract to us-gaap_GeneralAndAdministrativeExpense" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:title="us-gaap_OperatingExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:title="Presentation : us-gaap_OperatingExpensesAbstract to us-gaap_OperatingExpenses" order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:title="us-gaap_ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:title="Presentation : us-gaap_OperatingExpensesAbstract to us-gaap_ResearchAndDevelopmentExpense" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" xlink:title="us-gaap_RestructuringCharges" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_RestructuringCharges" xlink:title="Presentation : us-gaap_OperatingExpensesAbstract to us-gaap_RestructuringCharges" order="3.5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/Disclosure-BusinessLiquidityandOrganization">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="Presentation : us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:title="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:title="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" xlink:title="Presentation : us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract to us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax" use="optional" priority="0" order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:title="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:title="Presentation : us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract to us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:title="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:title="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:title="Presentation : us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract to us-gaap_ComprehensiveIncomeNetOfTax" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:title="Presentation : us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract to us-gaap_NetIncomeLoss" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:title="Presentation : us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract to us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:title="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:title="us-gaap_CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_CommonStockSharesIssued" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:title="us-gaap_CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_CommonStockSharesAuthorized" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_CommonStockParOrStatedValuePerShare" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:title="us-gaap_CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_CommonStockSharesOutstanding" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-set">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:title="us-gaap_StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="Presentation : us-gaap_StockholdersEquityNoteAbstract to us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-se">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:title="us-gaap_StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="Presentation : us-gaap_StockholdersEquityNoteAbstract to us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://www.pharmathene.com/role/pip-se1">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:title="us-gaap_SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:title="us-gaap_SubsequentEventsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:title="Presentation : us-gaap_SubsequentEventsAbstract to us-gaap_SubsequentEventsTextBlock" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0````(``*(9D?U42*BIP$``&<4```3````6T-O;G1E;G1?5'EP97-=
M+GAM;,V8RV[",!!%?P5E6Q%CT]*'@$WIMD5J?\!-)L3"CBW;!/C[V@&J-J(5
MM$2:31[<\=R;C',6C-^V!EQOHV3E)DGIO7D@Q&4E*.Y2;:`*2J&MXC[<V@4Q
M/%OR!1`V&(Q(IBL/E>_[V".9CE]JL%;DT'O<";'W).'&2)%Q+W1%ZBIO=>WK
MHA`9Y#I;J;`D]<$:KH*>].;<^F>N0@NRD:01=D>:1IU<QM`9"SQW)8!7,G5^
M*\$=\]\I!^<9%'PE_5G&^W>76I!-C2N%V5L];4(7%WZ;)$%U)SFT%_Z63*@X
M-%,MOJV(]W]\EM9+K)6<6;X6+8.ZLS'%<ZJXJ(Z-:JWM\EWKY26W"<2GRB'O
M&QL*K1='=DDHG@?5D=#Z7]Z'G9)I"R<9QL(./XJ26\A?O0WS/?YM?"WH+D><
M:W/]T]`;T9'FU"$DSLK!D.08(LEQC23'#9(<(R0Y;I'DN$.2XQY)#CK`$@0+
M42D6I%(L3*58H$JQ4)5BP2K%PE6*!:P4"UD9%K(R+&1E6,C*L)"582$KPT)6
MAH6L#`M9&1:R,BQD'7Z2E33_+TX_`%!+`P04````"``"B&9'2'4%[L4````K
M`@``"P```%]R96QS+RYR96QSK9++;L)`#$5_)9I]<4HE%A%AQ88=0OR`.^,\
ME,QXY#$B_?N.V(#"0ZW$TJ][CZZ\#JFL#C2B]AQ2U\=43'X,J<K]VG2JL0)(
MMB./:<&10IXV+!XUE])"1#M@2[`LRQ7(K8[9K.?:Q<[51G;NTQ1'E):T-M,(
M9Y;AFWE89.D\^(GT%V-NFM[2ENW)4]`'_K,-`\]YEE<>QW8OG*\M"_V/Z'D4
MX$G1H>)%]2-F`Q+M*;V"^GH`A3&^.R6:E((C-Z."N[_8_`)02P,$%`````@`
M`HAF1Z^6X@AN`0``-Q,``!H```!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L
M<\782VZ#,!#&\:M$'"!FAKR59)5-MFTO8)$)H/"2[:K-[4M95/3A41>1O@T(
M+(W_JQ\6^]:GNR>I;:BZUI=5[V?O3=WZW?#^D)0A]#MC?%Y*8_V\ZZ4=5J^=
M:VP8'EUA>IO?;"&&TW1EW'1.<MS_G#T[7PZ).U\HF;U85T@X)&^=N_E2)'@S
MWF@^;#`LWWOYS_;=]5KE<NKRUT;:\$>%^=H@,?$@C@<Q)"B+!V60H$4\:`$)
M6L:#EI"@53QH!0E:QX/6D*!-/&@#"=K&@[:0($H5&5-,DH8U1FM2N":,UZ2`
M31BQ22&;,&:3@C9AU":%;<*X30K<A)&;%+H)8S<I>!-&;U;T9HS>K.C-H+.V
M=MC&Z,V*WHS1FQ6]&:,W*WHS1F]6]&:,WJSHS1B]6=&;,7JSHC=C],X4O3.,
MWME$;U]:)Y?GX*JV\(^N^39<+9K@[<.]EL>GC%/5AHG68=A)S'A]^-=LG/H9
M8G[](SM^`%!+`P04````"``"B&9'%J/<N(8"``!6"0``$````&1O8U!R;W!S
M+V%P<"YX;6R]5M]OFS`0_E<L7I9)6Z%I5VU1BI0F3*N4)I5@W?/5',0JV,PV
M4=._?@<T&6E)-/*PO.1\ON]^?'>V&4OCC>ZU*E!;@88]YYDT(U)>.RMKBY'K
M&K["',P9F4C:393.P=)2IZY*$L%QIGB9H[3NT/.N7'RV*&.,/Q<[IXX_KJ),
MBB(3'*Q0TK\37"NC$LN"9X[9V'UK4"/(<XB\U,)N?*^Q::MJFY!#AE.*Y2>0
M&6RL_BIKFZG*"Y`;MUG-A7PR/XM(S<!B&[6_T7A?@<:8@NYYWREKFQ\;JC.K
ML-,5R!3CMNW[S2T7#ZA-5>GY\,RCWXZ"K;[QC1`+F=Z#T,8?K^UHC=PJ_=JF
MM3VU2['B5=/-0T3Y&8<]@L%*O';6H`5(ZS`C7F@Y=)JPC;:6L\)8[?]2^LFL
M$*T9NSME+;9MV[*X]"^\VH*D?4MW5YG_2MM>W94F$C9#LTSN0=O_1$5=TY:(
M"\]I5;]UP4#&+)"6QI'=RB84-:]-R4Z:+A>S8!$&,T92N)S?SB81+6XF\\EB
M&K`3,!=],&%$?W?!X@3,EQ,P5YV8F]((B<9\8G/QNQ1QQ5M%X5*G(,5+)R8L
M\QSTAJF$A2*5@EI(0\,FG*N2F._$?*?!80^0E<CN$$RIL>J6Z:Y#Y;FP]7Z=
MRU215SJJDM/=U9V15?QII;*8CNH'%E`A=M.=AI!`;F3*(@W2`*^&XX#/8U6>
M=W?Z..:R#S-L$,%C=J#>HPRQP3]SM`WRL?]LG'\]@8%O_3%#KQ]K(5TV<=D3
M4R?0#[,`K<'VSVW8/05'.SH\<-Z/8KK/>_<4-,6(-?;`-$1GV'U/=A\T-JAR
MU"KKA9DKD&R2OGO6VN_3F]?(W?^*\O\`4$L#!!0````(``*(9D=-5VRM/@$`
M`&D#```1````9&]C4')O<',O8V]R92YX;6S-D\%.PS`,AE\%]=XEV<20HJX'
M0)R8A,00B%M(O"VL3:+$4]>W)\NZE@&7WKC5M?_/O^.DD(Y+Z^')6P<>-82K
M0UV9P*5;9%M$QPD)<@NU")-886)R;7TM,(9^0YR0.[$!,J5T3FI`H00*<@3F
MKB=F9:$DEQX$6M_AE>SQ;N^K!%.20`4U&`R$31C)RA>S,[8Q!1GT91$=5R+@
MTBJ]UJ!NVZ'L=RIV1O!U.,E!]>W3WS\]I`S)NLI#T'U5TS239I;JXL",O"T?
MG]/9Y-H$%$9"5`7-L76PR,Z=7V=W]ZN'K)Q2=ITSEM/YBMUP2CEE[\?)+OP-
MANMNB'_K^&PP;1<U5C!RMTFCTG+39P(I"-)KA]J:4;B$^29.L+#_^`2)XT&=
M,%VV';2-]2J4Z7X-T?'EQ)5MK&]/J1_1Q:LJOP!02P,$%`````@``HAF1YE<
MG",0!@``G"<``!,```!X;"]T:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X
M9_9M"\8V@;:T$W-I=MNTF83M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/`0L
MZ?O.14?GZ#AY\^XN8NB&B)3R>&#9+]O6N[<OWN!7,B0103`9IZ_PP`JE3%ZU
M6FD`PSA]R1,2P]R"BPA+>!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#0
M5%%:;U\@M.4?,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@
M?\YOI^1.6HCA5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSV
MQ.V?C,K:=#1M&N#C\7@XMLO2BW`<!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&F
MJHU33]/W?=_KFVB<"HU;3]-K=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN
M:Z3I%FA"1N/K>A(5M>5`TR``6'!VULS2`Y9>*?IUE!K9';O=05SP6.XYB1'^
MQL4$UFG2&98T1G*=D`4.`#?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"
M(<7<K_WUE[O)I#-ZG7TZSFN4?VFK`:?MNYO/D_QSZ.2?IY/734+.<+PL"?'[
M(UMAAR=N.Q-R.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98
M??9/1VXCUZG`LR+7E$8D19_(+;KD$3BU20TR$S\(G8:8:E`<`J0),9:AAOBT
MQJP1X!-]M[X(R-^-B/>K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RC
MEU@5`9<8WS2J-2S%UGB5P/&MG#P=$Q+-E`L&08:7)"82J3E^34@3_BNEVOZ<
MTT#PE"\D^DJ1CVFS(Z=T)LWH,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&
M(81IN_`>KR2.FJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@
MR.S-D77.UI$.$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&
MU3-L+([W1]072N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*
M-Y;&O%"N@GL!_]':-\*K^(+`.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[
MKC':US0N*&-7<LW(QU2ODRG8.9_`[/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X
M_(O*\"K$">AD6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y
M/%_GM,T+,T.W<DOJMI2^M28X2O2QS'!.'LL,.V<\DAVV=Z`=-?OV77;D(Z4P
M4Y=#N!I"O@-MNIW<.CB>F)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!
M4;"C[SR6'<>(\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D
M8"V@!X.O40+R4E5@,5O&`RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2
M.<)IF!-GJ\K>9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S
M&5.^YRM)Q%4XOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M#`DL
M6XA9$N)-7>W5YYN<KGHB=OJ7=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,
MG'G%$0%T10(CE1P&%A<RY%#NDI`&$P'-E,E$\`*"9*8<@)CZ"[WR#+DI%<ZM
M/CE_12R#ADY>TB42%(JP#`4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R
M0]A4)?.NVB8+A=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZ
MN,)%K/]8UA[Y,M\Y<-LZW@->YA,L0Z1^P7V*BH`1JV*^NJ]/^26<.[1[\8$@
MF_S6VZ3VW>`,?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS
M#*%F.-^'19H:,]6+K#F-"F]!U4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O
M#;#"Q([A[8N_`5!+`P04````"``"B&9'4+S5)U4"``#6"@``#0```'AL+W-T
M>6QE<RYX;6S-5EUKVS`4_2M"*:.%$=O9FG:K;1B%P&`KA>9A;T6V94>@#T^6
M,Z>_?OIP[,20IDG34K_HZNC><X^D:U^'E5I1_+#`6(&&45Y%<*%4^=WSJG2!
M&:K&HL1<K^1",J3T5!9>54J,LLH$,>I-?'_J,40XC$->LQE3%4A%S54$OW80
M</&W(L,1?#S_]+<6ZN8,N''T>33R'R]NAOBY7;B`P''\S"(83"^A]W+2L:^?
MG<QV=4`_/9#^.?(!]=5AU,\P#XBO#;'7GGT<YH+W5S"!#HC#Z@DL$=7^@7%/
M!142*'W'6H%%.&+8>=PB2A))#)@C1NC*P1,#V+)H_1CA0MK<+L,PS]CO,\DB
MB:#?/B]/E_3L=C#;(Y1N;T\#<5@BI;#D,ST!K3U?E7IS7'#L1%J_/=Z%1*M@
M<KD18`>=-Q$RP[++',`U%(<4YTH'2%(LS*A$::0+I0331D90(3BBAG(=T1J:
M-L64/IB7\$^^Q=WDP/F8._8A,"K6ICZ(UNS+P!ZJM\GFN#=IC^,%3=XET-&H
M+.GJ!R4%9]B)==!,M+-]],$.^CA$:U:P$)(\:7]3"*D&L(1@B:4BZ2;R3Z)R
MCAO55K#7Y+L4'KOEM]1T^E/KU>@2?._C.3JYA>YJEF`YLY_%PR5]N=I_9?;M
MA`.9[ULU1T@XP>&8GOEAI4T_KK2WJ:F32+M^I32O[0P;[6>K^70H2&I"%>%K
M#<C\+MP9W72K+_2-1W-F3=]S[*I"B?[)W,JBR3*<HYJJ>[(4RBY&L+=_&?G!
MM/.:=Q01[.W?.",U^V85]'^R\7]02P,$%`````@``HAF1_+=S=5.`P``$`L`
M``\```!X;"]W;W)K8F]O:RYX;6R5EFUOVC`0@/^*E2_KI&DD+M`6E4H4Z%:)
MTFF@[K-)#)SJV,QVUI=?OW-2UF,UJ/V4V$D>V^?'ESMWO0=C[Q?&W+/'4FG7
ML_UD[?VFUVJY?"U+X;Z:C=3X;&EL*3PV[:IEEDO(Y<CD52FU;_$T[;:L5,*#
MT6X-&Y>\T-Q[:&YCI2C<6DI?J@96"M#)Q;GK+4').VD=@IG8;*:BE/WD425,
M">?'!7A9]),V-LV#W.FPU>:R`A4:G;23M`)LN]0?EN6FD`ULO@;WZ^5!P@JY
M%)7R<YSL=MQ^DO$VY]V&$5Z[`_G@*#!T,)%[^"/G8M%/TH2)RILK4%[:D?#R
MFS75!O0*60E;@G5^%I9;OUF"AA*>P[RQY=;FX;NQ\&RT%VJ66Z-4_55X4'^$
M([A_/3A'#_G.BUXL?H:=Z"?=%(%_P,$"%/BG?E+?*QE6TOIO*77X7^^8KH.S
MW6(F=,'&VB.%7>MF\S`T80[X\G51#VQ[@#?VNLB:4%'0\'8Z&D]GXQ'#N]GM
MY'HTF&/C<C`93(=C1D"<@/A'0<<$=$Q`Q^\&S>9XN1E/":A-0.V/@CH$U"&@
MSD=!70+J$E#W+>BR<J"E<U_8!'Y74(1="QMX:U="PS,!G1#0R5O0K"I+89^8
M6;(9K#3@J1<HPR#/384R$-`I`9V^!5T)L.Q.J$JR&RE<966PRA'`&0&<16)C
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M>N6U1,$J#4]S$0HX5P^#%5`>JCJ\-#FXW0F'+[1OL-+K)Z$<P\JK4FJ(?;<:
MQZR+EH:\K>,N_@)02P,$%`````@``HAF1\#D4A9.`@``]`<``!@```!X;"]W
M;W)K<VAE971S+W-H965T,2YX;6R-E=F.FS`4AE\%\0`#-DL6$:1)JJJ]J#2:
MB_;:29R`QF!J.V'Z]O5"B'&MP@U>^/_S>3TN>LH^>(6Q"#X;TO)=6`G1;:.(
MGRK<(/Y".]S*/Q?*&B1DDUTCWC&,SMK4D`C&<1XUJ&[#LM!];ZPLZ$V0NL5O
M+."WID'LSQX3VN]"$#XZWNMK)51'5!;1Z#O7#6YY3=N`X<LN?`7;`TB51"M^
MUKCG5CU0@S]2^J$:W\^[,%9CP`2?A`J!9'''!TR(BB3)OX>@3Z8RVO5']*]Z
MNG+X1\3Q@9)?]5E4<K1Q&)SQ!=V(>*?]-SS,(5,!3Y1P_0U.-RYH\["$08,^
M35FWNNS-GS09;'X#'`QP-(#U?PW)8$B>!KUTD1F9GM<7)%!9,-H'O$-JM\%6
MRID*(B,'<C)<-_5RF=Y[&1?17869*/9&`;4"C(I(QO8"X!2PAY8=^@`'6Y',
M`Q)G!HFV)]J>SMM3QYYJ>ZKMF7<!;$4^#\@<0&;95UZ`K5C/`W('D%OVC1=@
M*T`\3U@YA)7M!U-$:Q!&DIEMCD$V#UD[D+4-\9Z4O9'D1K+@J&P<Q,9&I%[$
M1+)@%B!V+U1L1\C]5VJB62V@_'-M@1UA[=V209,-RP5SL%FP]P"Z*&BC_`=L
MHH%+*.XM!HD=`?@I$PU<0'$O.[#O,DQ\RW88-&;9\C3-0)*X>26RDFR#V54_
M/CPXT5LK3#8=>\<'[A7J)/V4ET6'KO@'8M>ZY<&1"IGJ=9:_4"JP'$K\(C-#
M)9_@L4'P1:CJ2M:9>91,0]#N\<:.#WWY%U!+`P04````"``"B&9',^J@\R($
M``!'$@``&````'AL+W=O<FMS:&5E=',O<VAE970R+GAM;(V836_C-A"&_XKA
M>U><X9<8.`9J%45[*+#80WM68B8V5K)<28FW_[[41[)#[FBC2RPI[Y`O.>3#
MD7:WIOW:G;SO-]_JZM+=;T]]?[W+LN[QY.NR^]1<_27\YZEIZ[(/M^USUEU;
M7Q['H+K*4`B3U>7YLMWOQF>?V_VN>>FK\\5_;C?=2UV7[7\'7S6W^RULWQY\
M.3^?^N%!MM]E[W''<^TOW;FY;%K_=+_]%>X**0;)J/C[[&\=N=X,YA^:YNMP
M\^?Q?BL&#[[RC_W01!E^7GWAJVIH*?3\[]SH]SZ'0'K]UOKOXW"#_8>R\T53
M_7,^]J?@5FPW1_]4OE3]E^;VAY_'H(<&'YNJ&_]N'E^ZOJG?0K:;NOPV_9XO
MX^]M^D\NYC`^`.<`?`\`]=,`.0?()"";G(WC^JWLR_VN;6Z;[EH.V8:[(&^'
M1D++FS"8;KP=IVMZ^KI'M<M>AW8BR6&2X"3A%$6DT.^2+/3/FL#$!([Q<HHW
M'\?+)%Z.\6J*M['%RS2(26)'"5B9.R4<)RPB86Z4E!H^=J021XHZRMEIC22\
METFB)R\@C%XQ-SIQHDDW4K!SH\F0C7;&2-:-)F[06257S(M)W!CJ!E@WA@[:
M&65SUDTL<^#4QVYLXL92-\BZL;2;')76FIW$(A(ZU,*0%A<=Y8FCG#IBTW#(
M:1I4CI;W0V42M;4KW+C$C:-N%.O&D6ZTE#FK*I95BUY`I*02U(UFW<R:>7*D
MRI7FU_)/A<N>?J`G4$^&]P2T*Y$[;33+J")6@K-AO:W88Y#B%"A/I5W10@I4
MH$25[`8\S)IYA0D#EMU!1:QS(-T*BD$*5*"XE"PN#Q#Q,F04<"'[BD(>G%:P
M8G=`BE:@;%4\6R&"*[C0&W^$:OXX6':3HA4H6Q5PO1PBS<*A,VLFQU894&OR
ME:(5*%O5PLJ@S+1"KCGZ(24F4&0J'IFSQLZ[7;/P*(`B$VRNQ9HTI,P$"DW%
M0Q-<1)]<6+.0"T>-ZSRX6N$)4W0B1:?BT8F4B)`K`6S94D1MK5FHF$(3*305
M#TVD*`R5A@`^9[-NFB#E)*S!'?Y0?R)UQ!>0LV;.&89$\'5)I#/H@)S/RXY2
M`",%L.(!C!%8$:45?"D0"ZT(I>^*G88I@E&18T6MR7P*3*20X^NH`](R,Y3?
M[/HH8I4T:^8X!292&&J^&$4*0PR;0@/P2[9`$V]JFX<2<$51@2DZD:)3LV]<
MATBS`'*D>/T%T6GR)K)L)P4L4L#RY=0!*6!#5Z$NU087MFP>VQ*82XEK$IBB
M%BEJ-8]:=!'4C0VG/5]]Q<I05RM0*]YE90I;20')'S6'66,_K@EC)5\39N25
M_UH^^[_*]OE\Z38/3=\W]?CAX*EI>A_:$Y_"QCGY\OA^4_FG?KBTX;J=OG-,
M-WUS??ML\_[M:/\_4$L#!!0````(``*(9D=EBR'IX`$``&H%```8````>&PO
M=V]R:W-H965T<R]S:&5E=#,N>&ULC93=CILP$(5?Q>(!8H/!22."U%!5[46E
MU5ZTUTXP`:V-J>V$[=O7/R0EB$W*!?;8Y\Q\`[+S0:HWW3!FP+O@G=Y%C3']
M%D)];)B@>B5[UMF=6BI!C0W5">I>,5IYD^`P08A`0=LN*G*_]J**7)X-;SOV
MHH`^"T'5GSWC<MA%<71=>&U/C7$+L,CAS5>U@G6ZE1U0K-Y%G^-M29S""WZV
M;-"3.7#L!RG?7/"]VD7((3#.CL9EH':XL))Q[A+9PK_'G/]*.N-T?LW^U7=K
MZ0]4LU+R7VUE&@N+(E"QFIZY>97#-S:VD+F$1\FU?X/C61LIKI8("/H>QK;S
MXQ!VR'JT+1N2T9#<#''ZT(!'`YX98"#S?7VAAA:YD@/0/74_.]Y:N7));&9@
MF]$^])\KK%Z*C.3PXO+<2?9!DGA)LJ0H[Q3930)M_46(9`:1>#\.$.OG?CSS
M8^]/@W]SC]B%)H)DXR5HA1"*EV3E`]F'-.F,)IW2?%JD"9+,2V(T/HM`CY4?
M,F4SIFS"1!8K[;-))9+B;+/!Z2+2G1`3A#'"SXG(C(A,B19_QI[\+Q%Y3@0G
MQZ*G)_:#JE/;:7"0QIXP?[AJ*0VSZ=#*=MC8B^\6<%8;-UW;N0IW00B,[*\W
MV^UZ+?X"4$L#!!0````(``*(9D>Y5W'@K`0``!$4```8````>&PO=V]R:W-H
M965T<R]S:&5E=#0N>&ULC5A+<]LX#/XK'M\3$WPSXWBFDM79/>Q,IX?M68F5
MV%/+<B4E[O[[I1YV0`:J?8DD^@.(#P`!A,M35?]LMD71SGZ7^T/S.-^V[?%A
ML6B>MT69-_?5L3CX7UZJNLQ;_UF_+IIC7>2;7JC<+SAC>E'FN\-\M>S7OM6K
M9?76[G>'XEL]:][*,J__2XI]=7J<P_R\\'WWNFV[A<5JN;C(;79E<6AVU6%6
M%R^/\R_PD''>07K$O[OBU*#W66?\4U7][#[^WCS.66=#L2^>VTY%[A_O15KL
M]YTFO_.O4>G'GIT@?C]K_]K3]>8_Y4V15OL?NTV[]=:R^6Q3O.1O^_9[=?JK
M&#FH3N%SM6_ZO[/GMZ:MRK/(?%;FOX?G[M`_3\,OEHUBM``?!?A%X+(/+2!&
M`?$A(/\H($<!>>L.:A10T0Z+@7OON77>YJME79UFS3'O\@D>/+SNE'C-,^^N
MIO_L`S*LOJ\T7R[>.ST!)!D@?(`("K+&$+@@%GY_T@@>&I%P)$[:D&*$EJ0-
M5Y5D$THFS121KT0O+P9Y=5U>1O*REY>#O`Y-/`R>&"!F<"0H986C<"G&.<VE
M`@JV#F#"2*^1PF489X46CKGK]%1$3V'WF.OR.I+7V#V6=,\`4:-[N+*:Y),&
M.,.MXZ0;UQ@GO!\9D+@,XXSB5H.^SL]$_`SF1^Z3&&PW%\`$S<^@>`EP7')#
M\L/Z%)<^L&3:95B?]>XRUE[G9R-^%O$SC.1GD3V2<VGITXXU340.:^+*N\"0
ME2F;4#5)RD6D'"9%'K+$X212C-$A<SADQN<N20OK`F:-(\]!YH(R(;CAUYD!
MBTL_P]PXR6W$C'ZV((4E,RT-@-(I*RU=D@(@@*\VTM))&2*5$Z#-#<<./K4X
MP#P%S1/07G>@E562='T:(H5SF@DRV=<ATI\^+@3IDRQ$&J6-N:6``H^9<E2"
MS0T=#N(6!P+[BLS19,0,V7?GK)UP5`"3VDVY26#RTDI'IF(6Z@,CA+HE&^(F
M#+@+&TT5C23`Q`5HK%%_Q)RIR2`#N(.8VUBEII1-TXJ;+RA,BSRCR8@9:Y!R
MANX&:8"[4YI)^M"O1^#87XR1?.(D8X522\/$#13C^0#P@&#H`0%PI[[3CCQO
M:8"R$VF),5HY23,+]@.)^MXTL7@P`#P9&'HR`-S*A3\C,%&'3>``YH_)1.P"
MA4P+,1$[C/.C@36W5*9X-@#<AVF/)V`#7PKF)NIE&B*EK\!"3[`,D-S/O\[1
M(W"(--P8ZVX)9CPP`)X8Z!Z8@`N8*DG'*`UQ7#%Z+%Z'.#_F`>GA+,)98#?\
M%\/CN8'CN2&>X$:&(^9<K`67AK8]#9&^25I)#[WK$,DYXX*>M;(0:00/HC[-
M-)X<.)X<+#TYC!@W[,7N&>F0]!.,CN0G&+EI%L/@AGK*XVF!<\R.K&_)B!FK
MH`1K-$S$$2.5=<I/Y/0$&.H4UL]:C,[74*?R'4:I^$PNT'U'6=2O_4U3,WNN
MW@[M,`I=5B^W65_ZRZQH/8&'%(CU-3QDPUW5A_K5\IB_%O_D]>ONT,R>JK:M
MROZ"YJ6JVL*;SNZ]T[=%OKE\[(N7MGLU732&&ZOAHZV.YPNXRRW@ZG]02P,$
M%`````@``HAF1ZI2(\QZ`@``0P@``!@```!X;"]W;W)K<VAE971S+W-H965T
M-2YX;6R-5DV/FS`0_2N(>Q>P`4-$D#8?57NHM-I#>W82)Z`%3+$3MO^^_B#$
M("?92\#FO3?SAL&3K*?=!RL(X<YG735LZ1:<MPO/8_N"U)B]T)8TXLF1=C7F
M8MF=/-9V!!\4J:X\X/NQ5^.R<?-,[;UU>4;/O"H;\M8Y[%S7N/NW(A7MEV[@
M7C?>RU/!Y8:79][(.Y0U:5A)&Z<CQZ7[&BRVB40HP.^2],RX=V3N.TH_Y.+G
M8>GZ,@52D3V7"EA<+F1-JDH*B<!_!\U;2$DT[Z_JWY5;D?T.,[*FU9_RP`N1
MK.\Z!W+$YXJ_T_X'&2Q$4G!/*Z9^G?V9<5I?*:Y3XT]]+1MU[?43Y`\T.P$,
M!#`2QCAV`AP(\$8('Q+"@1!^-4(T$*)9!$][5Y7;8([SK*.]PUHLVRE8"'@G
M182R(\K%U%*]$+U[R9,H\RY29P)9:0A0D!C:(!L3$HP(3\2W)@&F2:R`00>V
M`&L3$8?6')Z*;.^(W$T3SFH%%1_J6L7/^>&,'RI^J/FS%!M="0U!"O(M@"!$
M<6(#KB?`,`9)"",;<#,!`N`#Z%N!VPD001"E:?3<8S3S&)DU0L_Y\8P?FS5*
MK/UH0D!JK4YL>HF2V(K::%2D4!#&UJI,E%`0@^>6T,P2,BVE5DOH@:7A"W@$
M&?P@PP\`:9#:/X,[2G?])#,_B<%/?6L;)U]MXV3:QC"$?FCU-E5,$4`(65]8
M,FUC"(-HWH:><436I#NIX<2</3TW7/?NN#O.OU<@C]C9_BI8K`/+_D;,2SW>
M;O)YUN(3^86[4]DP9T>Y.-C5F7ZDE!.1N?\BREV(B3XN*G+D\A;)]Z"'G%YP
MVEY']OB_(?\/4$L#!!0````(``*(9D>]+]\[SP0``!86```8````>&PO=V]R
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MXNW4?:VO?Y33&+*^P>?ZU`Y_%\]O;5=7MY#EHBI^C+_'\_!['?]CQ!3&!^`4
M@/>`>S]\`$T!]!X@AY&.SH9Q_59TQ7;3U-=%>RGZV88')V_Z1ES+"S>8=K@=
MTC4^_;ZUL%E_[]L))+M1@H/D7;%VC;,]8-C##KUPY#K(?862'_=`T1AHB*=Q
M#/AQO(SBY1`OAW@363R/@Q@E>I"L$`62R#AA'@@U869M]K&C+'*4^2.BC^-5
M%*^\$6G%CFB49..TH`7+SXW?$MJ/G>C(B?;BK62=:,^)1&6-83.KO<P":-0B
M(3$FLF/\Q&C6CO'LK#*MG2763Z"32B;YL9$?ZZ>'75$[Z_4#PFC+IR>0`:%.
MV`@@8AH(WP^_<";--%^*0+!^0ID!D;`-X"<Z@>^'GZ])<YLP,#AC"+P%I`R0
M2#"$L2'T#;$SL9LTHR%RZYG%:AXTE;*U(.8>D&_&\F;(SXY68B8YY',KHQ3H
M0,Q1D!ZV0*3D-P8?9'Y29O*;!4M=J(S?H*%.HG;;(L%2S%+P$4AL^G;@TW1%
M"I'8]T@>",'8S&0FP5-,5?"Q2L![\KFZLDK,./)E2$:EK,08J^!SE6:F+0"F
MR4#S;]!)-RU%(Y6P*2LI)BOX:)4ST^9#TPBAE>6WJOW%K8HQ6-$'*_%;==),
M;SAI)9_(/-"MM":7R@1+,5O19RL(OO8+1,CZSC$`,!II*<5/C%;$P`]?ATVB
M:>Q`1@N>$CGZ%%Y)FX';:PFV8L@B!5!+(`C&7$09C(RO@B;1Y%<9Y,N3/-19
MQ)0-BS%G,0LL\94'^@"=?74$*K>)$C8KQHQ%%=CA"P\,(*N$FLM0H#,R+4,Q
M8E$'\YZRHF,JH@E&Q6,1`]SIS"5P9E@!/[6TUJ:8BKF(-C#%`F^',\`+_/CP
M7+F60,N$N:<8C>2C$>)J<C(4B&8,D5]Q*D/NXRO!3HQ%"K`(_+N5_%K2@5K%
M^+Q9\M$(&4G`I`_<F(T4L!%X-I)//+"4\=];>:B3KF`V6<+'`OWTV4V!*>)-
M^?4GQ._7FZ.P2$T"-<64I8"RP%.6`GH"NDI7\G51H+3@="G5(\6@I0"TP(.6
M@DK5*$GNG<Z["I1"&F%U`MTH!BX%P`4>N!04JYJ,E3$O;K8"I54H*.4@AF+H
M4@#=E+*&8NA2`%W@H4L^=!V9@6:V2JC+K)>IT=+:.VZKRN9U.(9L%\_UV[D;
MS[3N3^]'G9^Q/ZZ+GN_@(1\/+-^;V6XNQ6OY5]&\'L_MXJGNNKH:S@%?ZKHK
MG4'QR:V'0UGL[S>G\J7K+[6[;L9CR_&FJR^W4]C[4?#V?U!+`P04````"``"
MB&9'<H@Z>J`!``"Q`P``&````'AL+W=O<FMS:&5E=',O<VAE970W+GAM;(53
MVT[C,!#]%<L?@!,WL&R51J*L$/NP$N*!?7:3R478GF`[#?OW^-*&MD++2SPS
M.>?,&5_*&<VK[0$<>5=2VPWMG1O7C-FZ!R7L%8Z@_9\6C1+.IZ9C=C0@FDA2
MDO$LNV%*#)I69:P]F:K$R<E!PY,A=E)*F'];D#AO:$Z/A>>AZUTHL*ID"Z\9
M%&@[H"8&V@V]R]?;(B`BX&6`V9[$)'C?(;Z&Y'>SH5FP`!)J%Q2$7_9P#U(&
M(=_X[:#YV3(03^.C^D.<UKO?"0OW*/\.C>N]V8R2!EHQ2?>,\R,<1K@.@C5*
M&[^DGJQ#=:10HL1[6@<=USG]*6X/M*\)_$#@"^$VB\93HVCSEW"B*@W.Q(XB
MG%V^]G`31+PR\=YL3./TJ;JO\OQGR?9!Z`RS31B>,`N">?4O6_#S%EM^0N??
MTU<7#E>1ODK=>?:]0'$A4$2!XK\CGF'XY9#L9$\5F"Y>'4MJG+1+F[=4E]MY
MQ^.9?,*K<A0=_!&F&[0E.W3^9..AMH@.O(GLZIJ2WK^?)9'0NA#^\+%)5RHE
M#L?C`UE>:?4!4$L#!!0````(``*(9D=6W\X5GP$``+$#```8````>&PO=V]R
M:W-H965T<R]S:&5E=#@N>&ULA5/;;J,P$/T5BP^HB4.ZJX@@-5U5[4.EJ@^[
MSPX,8-7V4-N$[M^O+X0F4;5]P3/#.6?.^%).:-YL#^#(AY+:[K+>N6%+J:U[
M4-S>X`#:_VG1*.Y\:CIJ!P.\B20E*<OS6ZJXT%E5QMJ+J4H<G10:7@RQHU+<
M_-V#Q&F7K;)3X55TO0L%6I5TX35"@;8"-3'0[K*[U79?!$0$_!8PV;.8!.\'
MQ+>0/#6[+`\60$+M@@+WRQ'N0<H@Y!N_SYJ?+0/Q/#ZI/\1IO?L#MW"/\H]H
M7._-YAEIH.6C=*\X/<(\PB8(UBAM_))ZM`[5B9(1Q3_2*G1<I_1G4\RTKPEL
M)K"%\#./QE.C:/,7=[PJ#4[$#CR<W6KKX2:(>&7BO=F8QNE3]5BM&"OI,0A=
M8/8)PQ)F05"O_F4+=MEBS\[H['OZ^LKA.M+7L\/U]P+%E4`1!8K_CGB)*:Z:
MT+,]56"Z>'4LJ7'4+FW>4EUNYQV+9_()K\J!=_#,32>T)0=T_F3CH;:(#KR)
M_&:3D=Z_GR61T+H0_O"Q25<J)0Z'TP-97FGU#U!+`P04````"``"B&9'#=FO
M`)\!``"Q`P``&````'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;(53RV[;,!#\
M%8(?$,JTG12&+"!.4;2'`D$.[9F65A(1DJN2E)7^??FP%-L(FHNXNYJ9G>6C
MG-"^NA[`DS>MC-O3WOMAQYBK>]#"W>$`)OQIT6KA0VH[Y@8+HDDDK1@OBGNF
MA32T*E/MV58ECEY)`\^6N%%K8?\>0.&TIRLZ%UYDU_M88%7)%EXC-1@GT1`+
M[9X^KG:'340DP"\)D[N(2?1^1'R-R8]F3XMH`134/BJ(L)S@"92*0J'QG[/F
M>\M(O(QG]6]IVN#^*!P\H?HM&]\'LP4E#;1B5/X%I^]P'F$;!6M4+GU)/3J/
M>J90HL5;7J5)ZY3_K&?:QP1^)O"%\*5(QG.C9/.K\*(J+4[$#2*>W6H7X#:*
M!&42O+F4INES]52M^+9DIRATA3ED#,^8!<&"^H<M^'6+`[^@\\_IZQN'ZT1?
MGQW>?RZPN1'8)('-?T>\QCS<-&$7>ZK!=NGJ.%+C:'S>O*6ZW,Y'GL[D'5Z5
M@^C@I["=-(X<T8>338?:(GH()HJ[+25]>#]+HJ#U,7P(L<U7*B<>A_F!+*^T
M^@=02P,$%`````@``HAF1R`,EP:A`0``L0,``!D```!X;"]W;W)K<VAE971S
M+W-H965T,3`N>&ULA5/+;MLP$/P5@A\02K32IH8L($X1M(<"00[MF996$A&2
MJY"4E?Y]24I6;"-H+N+N:F9VEH]R0OOB>@!/WK0R;D=[[X<M8Z[N00MW@P.8
M\*=%JX4/J>V8&RR()I&T8CS+OC`MI*%5F6I/MBIQ]$H:>++$C5H+^W</"J<=
MS>FI\"R[WL<"JTJV\AJIP3B)AEAH=_0^W^Z+B$B`WQ(F=Q:3Z/V`^!*3G\V.
M9M$"**A]5!!A.<(#*!6%0N/71?.]922>QR?UQS1M<'\0#AY0_9&-[X/9C)(&
M6C$J_XS3#UA&N(V"-2J7OJ0>G4=]HE"BQ=N\2I/6:?Y3Y`OM8P)?"'PEW&7)
M^-PHV?PNO*A*BQ-Q@XAGEV\#W$:1H$R"-Y?2-/U</58YORO9,0I=8/8SAL^8
M%<&"^H<M^&6+/3^C\\_IFRN'FT3?+`Z_?2Y07`D42:#X[X@7F$UVU82=[:D&
MVZ6KXTB-H_'SYJW5]7;>\W0F[_"J'$0'OX3MI''D@#Z<;#K4%M%#,)'=W%+2
MA_>S)@I:'\.O(;;SE9H3C\/I@:ROM/H'4$L#!!0````(``*(9D>"@KP8GP$`
M`+$#```9````>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;(U3RV[;,!#\%8(?
M$.KAI(4A"XA3%,DA0)!#>Z:EE42$Y*HD9:5_7SYDQ3:"MA=Q=S4S.\M'-:-Y
MLP.`(^]*:KNC@W/CEC';#*"XO<$1M/_3H5'<^=3TS(X&>!M)2K(BR^Z8XD+3
MNHJU%U-7.#DI-+P88B>EN/F]!XGSCN;T5'@5_>!"@=456WFM4*"M0$T,=#MZ
MGV_WFX"(@!\"9GL6D^#]@/@6DJ=V1[-@`20T+BAPOQSA`:0,0K[QKT7SHV4@
MGL<G]>]Q6N_^P"T\H/PI6C=XLQDE+71\DNX5YT=81K@-@@U*&[^DF:Q#=:)0
MHOA[6H6.ZYS^E,5"^YQ0+(1B)7S-HO'4*-K\QAVO*X,SL2,/9Y=O/=P$$:],
MO#<;TSA]JA[KO,PK=@Q"%YA]PA0)LR*85_^T17'98E^<T8M_T\LKAV6DEXO#
M_Q#87`ELHL#FKR->8LJK)NQL3Q68/EX=2QJ<M$N;MU;7VWD?#Y%]P.MJY#T\
M<],+;<D!G3_9>*@=H@-O(KNYI63P[V=-)'0NA%]\;-*52HG#\?1`UE=:_P%0
M2P,$%`````@``HAF1T2K#,B@`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H
M965T,3(N>&ULA5/+;MLP$/P5@A\0RI*<%H8L($Y1M(<"00[MF996$A&2JY*4
ME?Y]^9`5VPB2B[B[FIF=Y:.:T;S8`<"15R6UW=/!N7''F&T&4-S>X0C:_^G0
M*.Y\:GIF1P.\C20E69YE]TQQH6E=Q=J3J2N<G!0:G@RQDU+<_#N`Q'E/-_1<
M>!;]X$*!U15;>:U0H*U`30QT>_JPV1W*@(B`WP)F>Q&3X/V(^!*2G^V>9L$"
M2&A<4.!^.<$C2!F$?.._B^9;RT"\C,_JW^.TWOV16WA$^4>T;O!F,TI:Z/@D
MW3/./V`981L$&Y0V?DDS68?J3*%$\=>T"AW7.?TIRH7V/B%?"/E*^)I%XZE1
MM/F-.UY7!F=B1Q[.;K/S<!-$O#+QWFQ,X_2I>JHW15FQ4Q"ZPAP2)D^8%<&\
M^KLM\NL6A_R"GG].+VX<%I%>+`ZWGPN4-P)E%"@_'/$:<W_3A%WLJ0+3QZMC
M28.3=FGSUNIZ.Q_R>"9O\+H:>0^_N.F%MN2(SI]L/-0.T8$WD=UM*1G\^UD3
M"9T+X1<?FW2E4N)P/#^0]976_P%02P,$%`````@``HAF1TCOP2!+`@``@@@`
M`!D```!X;"]W;W)K<VAE971S+W-H965T,3,N>&ULC9;;CILP$(9?!?$`"S:'
M'$20-EM5[46EU5ZTUPYQ`EK`U';"]NUKFX1EO([@)MCFG_\;$P]#UC/^+DI*
MI??1U*W8^:64W38(1%'2AH@GUM%6W3DQWA"IIOP<B(Y3<C1!31W@,$R#AE2M
MGV=F[97G&;O(NFKI*_?$I6D(_[>G->MW/O+O"V_5N91Z(<BS8(P[5@UM1<5:
MC]/3SG]&VSU*M<0H?E>T%Y.QIY,_,/:N)S^/.S_4.=":%E);$'6YTA=:U]I)
MD?_>3#^9.G`ZOKM_-]M5Z1^(H"^L_E,=9:FR#7WO2$_D4LLWUO^@MSTDVK!@
MM3"_7G$1DC7W$-]KR,=PK5IS[8<[27P+<P?@6P`>`]:A27P`F32_$4GRC+/>
M$QW1?Q[:*CG7)LK94[D),S6['U:O.8I667#51D"S'S1XT(R*0+D[$1@B]G@2
MCN?#(RO#R(1'`QU'\P:Q91`;@_BVQ;5SBU"SF8<D%B29&L2A$P(U"YYD:D%2
M8("=$*A9\+A6%F0%#&(G!&J2><C:@JR!0>J$0,UJ'K*Q()N)090X&1O`6,\S
M4&@74`@L-NX*`J(D7,#Y4J@(6"`W!XH65!O"-@<#B\C-@:)X`<<N:Q0!"_??
M8XG2!1R[^A$H[>3!&PZ*EIP#^P6`0'4G#\X!$*5+SH']#D"@P-,'YP"*[',0
M3'I$0_G9M$+A%>S2RJ$9C*MCNWW&IL=\RO.L(V?ZB_!SU0KOP*3J5*9)G1B3
M5&41/JG=ENJ#8)S4]"3U<*7&?&B1PT2R[M[QQ\^._#]02P,$%`````@``HAF
M1Q?YYWNC`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T,30N>&ULA5/+
M;MLP$/P5@A\0RI*<%H8L($Y1M(<"00[MF996$A&2JY*4E?Y]^9`5VS"0B[B[
MFIF=Y:.:T;S9`<"1=R6UW=/!N7''F&T&4-P^X`C:_^G0*.Y\:GIF1P.\C20E
M69YECTQQH6E=Q=J+J2N<G!0:7@RQDU+<_#N`Q'E/-_1<>!7]X$*!U15;>:U0
MH*U`30QT>_JTV1W*@(B`WP)F>Q&3X/V(^!:2G^V>9L$"2&A<4.!^.<$S2!F$
M?.._B^9'RT"\C,_JW^.TWOV16WA&^4>T;O!F,TI:Z/@DW2O./V`981L$&Y0V
M?DDS68?J3*%$\?>T"AW7.?W9E@OM/B%?"/E*^)I%XZE1M/F-.UY7!F=B1Q[.
M;K/S<!-$O#+QWFQ,X_2I>JHWCT7%3D'H"G-(F#QA5@3SZG=;Y-<M#OD%/?^<
M7MPX+"*]2-WSXG.!\D:@C`+E,F)Y=\1KS/:F";O84P6FCU?'D@8G[=+FK=7U
M=C[E\4P^X'4U\AY^<=,+;<D1G3_9>*@=H@-O(GO84C+X][,F$CH7PB\^-NE*
MI<3A>'X@ZRNM_P-02P,$%`````@``HAF1_0[6&N]`0``>P0``!D```!X;"]W
M;W)K<VAE971S+W-H965T,34N>&ULA53-;J,P$'X5BP>HP4E(-R)(3:MJ][!2
MU</NV8$!K-J8VB9TWW[]$VA`2+E@S_#]S,#8V2#5AVX`#/H2O-7'J#&F.V"L
MBP8$U0^R@]:^J:02U-A0U5AW"FCI28)C$L<I%I2U49[YW)O*,]D;SEIX4TCW
M0E#U[P1<#L<HB<;$.ZL;XQ(XS_#$*YF`5C/9(@75,7I*#J?4(3S@#X-!W^R1
MJ_TLY8<+?I7'*'8E`(?".`5JEPL\`^=.R!I_7C6_+1WQ=C^JO_IN;?5GJN%9
M\K^L-(TM-HY0"17MN7F7PT^XMK!S@H7DVC]1T6LCQ4B)D*!?866M7X?P9C_2
MU@GD2B`3X3'VA0<C7^8+-33/E!R0[JC[=\G!PI43L<K(UJ9]Z+L/V4N>I&F&
M+TYHACD%#`F8"8&M^JH%F5N<R`V=W*=O%A5N/'T3W$EZ7V"[$-AZ@>VUQ?UJ
MBW/,XWV3W<)D-Q/XL6HRP^SC^R;IPB2="22K)G/,\GOCF^D0H&I_"#0J9-^:
M,`93=CIG3\1/US<\SSI:PV^J:M9J=);&SJ@?STI*`[:(^,&VVMB;8`HX5,9M
M[6@C%0Y'"(SLQJ,^W3?Y?U!+`P04````"``"B&9'OM*1I*(!``"Q`P``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6R%4]M.XS`0_17+'X`3-X7=*HU$
M08A]6`GQL/OL)I/$PI=@.PW\/;ZDH:TJ\1+/3,XY<\:7<M+FS?8`#GU(H>P6
M]\X-&T)LW8-D]D8/H/R?5AO)G$]-1^Q@@#61)`6A679+).,*5V6LO9BJU*,3
M7,&+07:4DIG/'0@];7&.CX57WO4N%$A5DH77<`G*<JV0@7:+[_/-K@B("/C'
M8;(G,0K>]UJ_A>1/L\59L``":A<4F%\.\`!"!"'?^'W6_&X9B*?Q4?TI3NO=
M[YF%!RW^\\;UWFR&40,M&X5[U=,SS".L@V"MA8U?5(_6:7FD8"391UJYBNN4
M_A3Y3+M.H#.!+H1?632>&D6;C\RQJC1Z0G9@X>SRC8>;(.*5D?=F8QJG3]5#
ME=^M2G((0F>87<+0A%D0Q*M?;4'/6^SH"9W^3%]=.%Q%^BIUI[]_%B@N!(HH
M4,PC%E='/,>L+YJ0DSV58+IX=2RJ]:A<VKRENMS.>QK/Y!M>E0/KX"\S'5<6
M[;7S)QL/M=7:@3>1W:PQZOW[61(!K0OAG8]-NE(I<7HX/I#EE59?4$L#!!0`
M```(``*(9D=PIPZ'HP$``+$#```9````>&PO=V]R:W-H965T<R]S:&5E=#$W
M+GAM;(U3RV[;,!#\%8(?$,J2$P>&+"!.4+2'`D$.[9F65A(1DJN0E)7^??F0
M%=LPT%[$W=7,["P?Y83FW?8`CGPJJ>V.]LX-6\9LW8/B]@X'T/Y/BT9QYU/3
M,3L8X$TD*<GR+'M@B@M-JS+67DU5XNBDT/!JB!V5XN;/'B1..[JBI\*;Z'H7
M"JPJV<)KA`)M!6IBH-W1I]5VOPZ("/@E8+)G,0G>#XCO(?G1[&@6+("$V@4%
M[I<C/(.40<@W_I@UOUH&XGE\4O\6I_7N#]S",\K?HG&]-YM1TD#+1^G></H.
M\PCW0;!&:>.7U*-UJ$X42A3_3*O0<9W2GR*?:;<)^4S(%\)C%HVG1M'F"W>\
M*@U.Q`X\G-UJZ^$FB'AEXKW9F,;I4_58K38/)3L&H0O,/F'RA%D0S*O?;)%?
MMMCG9_3\W_3BRF$1Z47J7OR'P/I*8!T%UO.(FYLC7F(>KYJPLSU58+IX=2RI
M<=0N;=Y276[G4SQ$]@6ORH%W\).;3FA+#NC\R<9#;1$=>!/9W3TEO7\_2R*A
M=2'<^-BD*Y42A\/I@2ROM/H+4$L#!!0````(``*(9D?M]B_Q3`,``(0.```9
M````>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;)57RW+:,!3]%8_WC?6VG`%F
MBDE"%YW)9)&N'1#@B6U1VX3T[^N'()(J0&6!'YQS[]'5Y5Q[<I3U>[,3H@T^
MRZ)JIN&N;??W4=2L=J+,FCNY%U7WRT;69=9VE_4V:O:UR-8#J2PB!`"+RBRO
MPMEDN/=<SR;RT!9Y)9[KH#F495;_F8M"'J<A#$\W7O+MKNUO1+-)=.:M\U)4
M32ZKH!:;:?@=WB_1`!D0K[DX-MIYT(M_D_*]O_BQGH:@UR`*L6K[$%EW^!"I
M*(H^4I?YMPKZE;,GZN>GZ(_#<COY;UDC4EG\RM?MKE,+PF`M-MFA:%_D<2G4
M&F@?<"6+9O@.5H>FE>6)$@9E]CD>\VHX'L=?.%`T-P$I`CH3(+E*P(J`?0E$
M$8@O@2H"]24P16"^A%@18E\"5P1N$:)Q.X;-7&1M-IO4\A@T^ZQO<7C?P>L^
M2!<YZ':P&2Z''AGO?LQ@G$RBCSZ0@9F/&#1B.'!A4AV#7(C%3<2#CF#$!7DT
MI4`7YLE(1%V0I1GF2TW45<Q9-F25#0T!\!@`@=L!L!4`#P&(4H!-E=6XV!$3
MCPL!P^=V(F(E(EHBZLR3$BW/-X00X939A1NA"W_HDP4%B&/L4REJ+8!J"T"Q
M<P$CA*HFQCPA(''*]P4^4$T\3!@".$'.51H1.2,84^@"+HV(@'"0:/^VB\5@
M5C&8T3;$60VF28K-KM%K<05V44YLR8D-.<X^2&,M#\(<Q,R]-YZX)P-'.8RY
M1QVY)9P;PIE3.-=V#(/+A;R&NR@HL00EFB#B]+54AR"G4R^N053Y$DUM3!@D
M[+98".RI`73_X[%'B'\&#S2V@#NW0(&4!<*+6W`-=UF2;>H0&9*<]4L5B&JN
M[)9T!7=9DCTFH#$G$F>J%!J#`OOFLB<%)$8NIXTM(#%\C$/L-*$'"T<3Z--G
MMO=#:DCR&-30=DS(_KM5;9>#ALTESB$Z5Z!QP7U9?#+9M@0-7TJ<I9TKD')N
MZK?9MM_`Q,CDM.ZY`JGIYI$&V4:!P.V>FBO0Z:_"/?+8;H(,-TF<ACY'NDLP
MB.RY$6F/SOML*WYF]3:OFN!-MMU3^/``OI&R%5TL<-=UYJY[)3Q?%&+3]J=Q
M=UZ/+TGC12OWIW>^\XOG["]02P,$%`````@``HAF1YR5?JU2`P``/`X``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,3DN>&ULE5==<Z(P%/TK##]@X09"P%%G
MZD=G]V%G.GW8?:8:E2D0%V+M_OL-(=HD&VWJ@Y!X[KGG?G`ETS/K7OL#I3QX
M;^JVGX4'SH^3*.HW!]J4_3=VI*WX9<>ZIN1BV>VC_MC1<BN-FCI"<9Q%35FU
MX7PJ]YZZ^92=>%VU]*D+^E/3E-W?!:W9>19">-EXKO8'/FQ$\VETM=M6#6W[
MBK5!1W>S\`$FCP@-$(GX5=%SK]T'@_@7QEZ'Q8_M+(P'#;2F&SY0E.+R1I>T
MK@<FX?F/(OWP.1CJ]Q?V1QFND/]2]G3)ZM_5EA^$VC@,MG17GFK^S,[?J8H!
M#X0;5O?R.]B<>LZ:BTD8-.7[>*U:>3V/O^2Q,G,;(&6`K@:(W#5(E$'R80!W
M#5)ED/IZP,H`^QIDRB"S)$5CLF2J5R4OY]..G8/^6`X-"!,![P82P1R(_/9R
M*2LX[K[-H2#3Z&T@,C"+$8,D)DM<D)4.@2LB$@*<*I"I8H%T\R)WN5B:F,(I
MPX-GK6/$8^;"/)H8CX`2*ZV))$@4`?J<(+4(4DF02@)BB6S'I(T0(B$I0FF.
MG'G3F5#A8EKI3`A#@8BSRNL;5#>#PE906+>/$Z>6$8-].RFS7&2:B]S9)(OL
M3D)4SNY!E,Y,SQDJ1-*<*;O!=#,>8L5#-'O(G2E[)+J46'X^=Y1;CG*C-JDS
MYERK#<%>;@K+36&XP4XWA=X"J/#R`[$]V&+#4^;TI$!CZG!"4H^.@_]&*!B>
MB/-A52`5E%DC0Y&!`W0#MS9Q"28$8P_MR-:.#.VY6Q,R-`V5=_:Z2>;1[&"/
M34@,.<XG;Z%`8]'R.ZF\@[LMR1[$8`P]<$:^LD`^763/1C"&(R!WZ%@+"7":
M.)MM:<`0CK,;==5A:9;8P5U:S8#E$/LTFCV7P1B$X)[]"C0V6A;?+.W:`$)<
M^!;7GJY`#%6I!X4]-R'_ZE\]V#,1]*'H_K-?*0RYM*%?P,B>BLB8BN!1262/
M.P1?#1C94P>ASP-6&-5UKG@C[4VWH=U>'DKZ8,-.+1_U77>O!Y\'>>ZQ]A<P
M68)C?P63]?AF_4$_GQ[+/?U9=ONJ[8,7QL7[N7PUWS'&J1`>?Q./RT$<Y:Z+
MFN[X<$O$?3<>;L8%9\?+6>UZ8)S_`U!+`P04````"``"B&9'-0G4S)P"``!-
M"0``&0```'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6R55LMRFS`4_16&?0-Z
M\?!@9N)'IUUT)I-%NU9LV68"R$5RG/Y]]<!84*5V-A82YYQ[[T'657'FW:LX
M,":#]Z9NQ3P\2'F<19'8'%A#Q0,_LE:]V?&NH5)-NWTDCAVC6T-JZ@C&<1(U
MM&K#LC!K3UU9\).LJY8]=8$X-0WM_BQ8S<_S$(27A>=J?Y!Z(2J+:.!MJX:U
MHN)MT+'=/'P$LS5`&F(0/RMV%LYSH)-_X?Q53[YOYV&L<V`UVT@M0=7PQI:L
MKK62BOR[%[W&U$3W^:+^U92KTG^A@BUY_:O:RH/*-@Z#+=O14RV?^?D;ZVL@
M6G##:V%^@\U)2-Y<*&'0T'<[5JT9S_9-%O<T/P'V!#@0ACA^`NH)Z$K`_R7@
MGH#OC4!Z`IE$B&SMQKD5E;0L.GX.Q)'J_01F"MYI$:4<*+N$F9H/8E??2@B2
M(GK30B/,PF*@P23(!UFY$#`@(I6`-PLXSF(!'3KT!5BZB`1[<[@ILOY`Y,,T
MT<0L9/BH-RN]+8`G`M@(X%X@&R?96B\L)C68'*4D]:&6+@IF<0IC'VSEPC!,
M\LP;<^W"`$AA&J/;Q9%)<6147'Y;()D())^U-YT(I'?8:S'$E@ICA+WVNB@"
ML1^U<E$9@23WFNNB$,P30FY7EDTJR]S*G&_]H4`^$<@_ZRV(IR=%?(>[/<CN
MI$SM).2U=P2#,(-9XC6XQ_7>Y02GWFV^'H?%*,;9'17^<Q:"D<MWG&,`3B7@
MIWV>'C(`W?9YU8-LP5\(2C'PGGACL>E_,G)Z1<.ZO>G2(MCP4RMM$</J<!-X
MA+K73-878+8$GO65OCF8WG25+XLCW;,?M-M7K0A>N%0=SC2W'>>2J:3C!^7,
M0=UMADG-=E(_IMHRV^WM1/+CY?(RW*#*OU!+`P04````"``"B&9'P#<%H,T#
M``#H%```&0```'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6R=F-N.FS`417\%
MY0,&VX?K*!.IDZAJ'RJ-YJ%]9A(G00,X!6<R_?N:6XI/,#A]2;CL<U@8]I;Q
M\B+*]^K(N70^\ZRHGA9'*4^/KEMMCSQ/J@=QXH4ZLQ=EGDBU6Q[<ZE3R9-<4
MY9G+"`G</$F+Q6K9''LI5TMQEEE:\)?2J<YYGI1_GGDF+D\+NN@/O*:'HZP/
MN*NE>ZW;I3DOJE043LGW3XLO]'$#<2UI%#]3?JD&VTX-_R;$>[WS??>T(#4#
MS_A6UBT2]??!USS+ZD[JRK^[IO^N61<.M_ON7YO;5?AO2<77(ON5[N11T9*%
ML^/[Y)S)5W'YQKM[\.N&6Y%5S:^S/5=2Y'W)PLF3S_8_+9K_2WLF(EW9>`'K
M"IAM`70%<"V@WF2!UQ5XJ,!M;Z49B$TBD]6R%!>G.B7UZT$?E;RLFZC.CKK[
MJMEMQK<]^K%BC"W=C[J1IEFW&M9JQA0;3>%?):X"&*5@B((U]=!1P'P#0`V@
M:>!U#3P=LFAOH]6$K09\?TRT&8IH&/DDGH?Q$(RGP8Q>9]UJ_$X31G$TBC.4
M!2RF(9G'\1&.K^$$HSC^$`<(\V$49RB+2!B$%J,3()Q`PPGG&X2H0:B]+-%\
M@P@UB#2">.R-?M8T0$8'+1H^'`\(@?&'J.O44R3>/'2,H&,-B(X"Q99`\?\`
M48*C@]SK6GJ3/M3"MYW(GS:NIK)U+L5!1)F%=SO1K'DUG:U[*8XV"A;^[42S
M!M9TM@ZF.."HEG#`+%K@4*+^O2ZF.$AH8.%C760P<B>:-PX2VCH')Q@-+<S<
MB<)Y*%UH"X53D49WVQEG%(VG[-S/)C31Z%/;F#3F"04.)T:FC-RAZ*)Q%)/&
MC()#CM$I`_<HU`+%H#&CW,RSM'@#BV?,<!PQN->X#,<'\RR,JXNP<?M1\RQ&
MS:`Q\^*L8OZ477L4WP+%H#&CX,QCP;TF93A\6&AA4EUDN!N#QHR"(X=%-B:-
M+%`,&C,*CBX6VYC4(KI,&O.G#(XNT!('++(<<.0`O=>D@*,"F(5)=9'!I+IH
M?-1,&C/OS1<@6)A4%QE0#!HS"LXW\.[^G,61`_Z42?L/6M_JBW:HLIT8`PX>
M"*:LV@,-IT<3$V--9SLQ!AQD$$Y9MD<*M3$R3HPUG>W$&*Z!5G1(]8'I$AP\
M$,];Z!F)\`J+.UCSR7EY:!;/*F<KSH5LW\/KT>L"W7.SG(:/0_2X5C=Q>T8A
MJ#/-FI[[[Q*KY2DY\!])>4B+RGD34HJ\6:C:"R&Y(B</ZNT[\F1WW<GX7M:;
MH=HNVX6X=D>*4[^N>%W<7/T%4$L#!!0````(``*(9D<O1!P0H@(``(H)```9
M````>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;)56RW*;,!3]%89]@A`/@0<S
M$S\Z[:(SF2[:M6++-A-`+I+C].^KEXF@<J`;@\0YYYXK74NWN-+NE9T(X=Y[
M4[=LZ9\X/R^"@.U.I,'LD9Y)*[X<:-=@+H;=,6#GCN"](C5U``%(@P97K5\6
M:NZY*PMZX775DN?.8Y>FP=V?%:GI=>F'_FWB1W4\<3D1E$70\_950UI6T=;K
MR&'I/X6+;0@E1"%^5N3*K'=/FG^A]%4.ONV7/I`>2$UV7$I@\7@C:U+74DE$
M_FU$/V)*HOU^4_^BTA7V7S`C:UK_JO;\)-P"W]N3`[[4_`>]?B4FAT0*[FC-
MU*^WNS!.FQO%]QK\KI]5JYY7_24#AN8F0$.`/:&/XR9$AA!]$.)/";$AQ',C
M)(:0C"($.G>U<AO,<5ET].JQ,Y;U%"X$O),B0MD3R\744&V(GGTK8906P9L4
M&F!6&@,5)HU<D(T-"7M$(`PX7<"ABQ6TZ-`58&TCTMCI85)D>T?DKLUHM%B1
MXD=FL="T0#P2B)5`;`2RH<E6IZ$Q2&$R@%*43\=)1G&209S<%6>56'&B)$=Y
MZH*M;=A#DH(X0T[;&I<H7()0#)UR6ULN3F,$HNGLTE%VJ9U=#)S9I98=&`&8
M1$[7G\#NVD$C.VA@9T;U9R.!['_+*A\)Y#/**K<R'965O3\V+$0Q@%$R[2<$
MXU,%3!?@QH!NI76_9@Q0FWJ86S7A/T==.-@HYQ&Q&8+<:V0P-S]BRZ(9_]$0
MCOW`&75L0&BBD-<#7):$*'<7_$R][6=Z.L7`NF@:TAW5%<^\';VT7%=S/]NW
M$4^JBQC-K\+%.G3,;V3;H2ZV#_FR..,C^8Z[8]4R[X5R<3VJF_%`*2?".'@4
MJWT2C5$_J,F!RU<DMT&W"GK`Z?G6^?3M5_D74$L#!!0````(``*(9D<=>S7I
M'`(``)T&```9````>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;)55VXZ;,!#]
M%8L/6.Z01`1IDZAJ'RJM]J%]=I))0&MC:CMA^_?UA1!`;I.^8'LXY_C,8,9%
MQ_B'J``D^J2D$6NODK)=^;XX5$"Q>&$M-.K-B7&*I5KRLR]:#OAH2)3X41!D
M/L5UXY6%B;WQLF`72>H&WC@2%THQ_[T!PKJU%WJWP'M]KJ0.^&7A#[QC3:$1
M-6L0A]/:>PU7NX5&&,"/&CHQFB/M?<_8AUY\.ZZ]0%L``@>I%;`:KK`%0K20
MVOA7KWG?4A/'\YOZ%Y.M<K_'`K:,_*R/LE)F`P\=X80O1+ZS[BOT*:1:\,"(
M,$]TN`C)Z(WB(8H_[5@W9NSLFS3K:6Y"U!.B@3#LXR;$/2%^EI#TA.1.2$QI
M;"JF$#LL<5EPUB'18GTZPI6"<RVBE)'*7IBEJ:^-7LLHB0O_JH4FF(W%1`:3
M.2';,20<$+XRX'0135ULHA$]<F[P$+$;([+DL8=X5HG8\..^$D\()#.!Q`@D
M1F"YF'IL;)X6DAM(G"T7H0NU?8#J\QUO%RT?VTUG=M,Q/TF=?M.1D\#IU8WX
MJXEL9B*;F,@>"^0S@?Q_O]IB)K"8.,B=9;"8U)[N/$^3<.DLQI.XW;]PUK@_
M^HLI\+-IAP(=V*61]I`/T:'COD:Z"\SB6]6);>.\RY1%B\_P'?-SW0BT9U+U
M&-->3HQ)4`:#%_59*W57#`L")ZFGN9ISVS[M0K+V=AD,-U+Y!U!+`P04````
M"``"B&9'6,?#)*`!``"U`P``&0```'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6R%4\MNVS`0_!6"'Q!*E%\Q9`&-BJ(]!`AR:,ZTM;((\Z&2M)7\??F0%=LP
MDHNXNYP9SI+:<M#F8#L`A]ZE4':#.^?Z-2%VUX%D]D'WH/Q.JXUDSJ=F3VQO
M@#61)`6A6;8@DG&%JS+67DQ5ZJ,37,&+0?8H)3,?3R#TL,$Y/A=>^;YSH4"J
MDDR\ADM0EFN%#+0;_"-?UT5`1,!?#H.]B%'POM7Z$)(_S09GP0((V+F@P/QR
M@AJ$"$+^X'^CYN>1@7@9G]5_Q6Z]^RVS4&OQQAO7>;,91@VT["C<JQY^P]C"
M/`CNM+#QBW9'Z[0\4S"2[#VM7,5U2#NK;*3=)]"10"="/ON24(R$XH9`DK/8
MUT_F6%4:/2#;L_#8^=K#31#QRL@W8V,:KRM53Q6=K4IR"D)7F*>$H0ES#U%?
M(>83A'@#=UW0&Q<T\HO(S^GB>X'B1J"(`K.QC<=KDRJUD3#+A"DR.B_NP>I+
MV"I;+I:/-W;(Q0WW;`_/S.RYLFBKG7^L^$ZMU@Z\6/8PQZCS,S0E`EH7PJ6/
M3?JM4N)T?QZ2:5*K_U!+`P04````"``"B&9'OFEP?(0"``!H"@``&0```'AL
M+W=O<FMS:&5E=',O<VAE970R-2YX;6R=5MV2FC`4?A6&!U@X0`(ZZ$S7U6DO
M.K.S%^UUU*C,`K$DZO;MFX3HDC3=Q7HA2?A^SCEP0LH+ZU[Y@5(1O#5URV?A
M08CC-(KXYD`;PA_8D;;RSHYU#1%RVNTC?NPHV6I24T=)'..H(54;SDN]]MS-
M2W82==72YR[@IZ8AW>]'6K/++(3PNO!2[0]"+43S,KKQME5#6UZQ-NCH;A9^
M@>D*)@JB$3\J>N&#<:""7S/VJB;?MK,P5C'0FFZ$DB#R<J8+6M=*23K_,J+O
MGHHX'%_55SI=&?Z:<+I@]<]J*PXRVC@,MG1'3K5X89>OU.2`E."&U5S_!YL3
M%ZRY4L*@(6_]M6KU]=+?P8FA^0F)(20W`F0?$E)#2,<2,D/(W@GX0P(R!#36
M`1L"=@A17RQ=ZB<BR+SLV"7@1Z)>0)A*>*=$I'(@Z\OU5#_!?O4\3U!<1F<E
M9&$>>TQB,.##+&Q,XL,\V9C4AUE:&!]B9:MD-TPDL_6FG#@I)UH@-0+H<X'4
M$4BU0&8$L!UEV]>LQ^0:`Y!"K'X^Y,I!QC;RGT%E3E"9%53N#:K'H-YJDN&1
M5LBQ0I95X;5"@ZP*0".=L..$+:>)]ZVR,'B$2>Z8Y`,!*+SI+/-!.@F,2Z9P
M?`K+9^+U*88^(XLV<7PF5D'@<P&(W4TAOK=%X*]]!:PHO*V\=$#I"!^WF2&Q
M)#)O50WHOK*"V_9@]3T>4Q6W22&[N[!N\P$:4UAT=V'=U@,\IK#X?PKK-B#D
MEA4>(>'V%A1W%]9M&[#[QKN#+@RH3Q@5OHRCP0?X2/;T.^GV5<N#-1/R6ZX_
MXSO&!)5R\8-\3@=Y[+M-:KH3:IC+<=<?A/J)8,?KN>YVN)S_`5!+`P04````
M"``"B&9'6^>O4%0"``"Y!P``&0```'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6R55=N.FS`0_17$!RQ@S"TB2)M+U3Y46NU#^^PD3D`+F-I.V/Y]?2'$02;9
MYB&VAW/.G)D03]X3^L%*C+GSV=0M6[HEY]W"\]B^Q`UB+Z3#K7AR)+1!7!SI
MR6,=Q>B@2$WM`=^/O095K5OD*O9&BYR<>5VU^(TZ[-PTB/Y=X9KT2S=PKX'W
MZE1R&?"*W!MYAZK!+:M(ZU!\7+JOP6(;^!*B$+\JW#-C[TCS.T(^Y.''8>GZ
MT@.N\9Y+"226"U[CNI9*(O.?0?264Q+-_57]FRI7V-\AAM>D_ET=>"G<^JYS
MP$=TKOD[Z;_CH89("NY)S=2WLS\S3IHKQ74:]*G7JE5KKY]$V4"S$\!``"-A
MS&,GA`,AO!'@0P(<"/"K&:*!$$TR>+IVU;D-XJC(*>D=UB'Y/@4+`:=21"@[
MHEU,'=4/HJ.7`L1I[EVDT!UFI3%`8>+0!MF8D&!$>,*`U06X=[$"!AW8$JQ-
M1`RM'IZ*;&=$9FV&DV:%BA_J*D'V7`!.!*`2@$H`^O<>6]T*#4ET%1`F<6:#
M;1[`9MU$$S>1Z2:RNM&02%><0C](K6X>P&;=Q!,WL=%<\)5RDHE`8I23V)N;
M&%V#`,#4_K*92L#>_\2H&$1!!A+K'V,[(S5;5#HI*C7Y0?1<()L(9/_;UL"?
M7A'^T\9N!LS065]^)ID\XUYJ,#VIB<"</3FW7/L;H^/4>07R7IO$5\%B'5CB
M&SFEU#UXDR_R#IWP3T1/5<N<'>'B-E47Z9$0CH5Q_T4478HY.AYJ?.1RF\AN
MZ,FB#YQTUT$Y3NOB'U!+`P04````"``"B&9'"3@[&2D"``!Z!P``&0```'AL
M+W=O<FMS:&5E=',O<VAE970R-RYX;6R55=N2FR`8?A7'!U@$3TG&.+,Y=-J+
MSNSL17M-$A*=17&%Q.W;%Y"D0FF3S84<_`[_1P2*@?5OO")$!!\-;?DRK(3H
M%@#P?44:S)]81UKYYLCZ!@LY[$^`=SW!!TUJ*$!1E($&UVU8%GKNI2\+=A:T
M;LE+'_!ST^#^UXI0-BQ#&%XG7NM3)=0$*`MPXQWJAK2\9FW0D^,R?(:++40*
MHA$_:C+P23]0Q>\8>U.#;X=E&*D:""5[H22P;"YD32A52M+YW8C^\53$:?^J
M_D7'E>7O,"=K1G_6!U'):J,P.)`C/E/QRH:OQ&1(E>">4:Z?P?[,!6NNE#!H
M\,?8UJUNA_%-EAN:GX`,`=T(,/DO(3:$^%%"8@C)HX34$%*'`,;L>N4V6."R
MZ-D0\`ZK[PDN)+Q7(E(YD,O%]5#_(>/LI41Y5("+$K(PJQ&##`;Z,&L+XT-L
M;!4O9FMCXAL&R"3>.,B)@[1`;`22^P*Q(Q!K@<0(I':5[9AUQ*0:`^<(Y3-X
MWRAQC!++*+LOD#H"Z6>C9HY`9E60^Z*NLDE4E.82EMXWRAVCW#*:W1>8.0*S
MST:=.P)SJX*Y+^IF/HF:9)'Z^7#;*2Y.;=P_"X*1N^^B:4DSK]7:@,R7%L6/
MFOVUR:%E!OUF<+H`R:->[@Z$R/+R[O.U`W(W.IB<81T^D>^X/]4M#W9,R.-0
MGX1'Q@214M&3K*.2%^%M0,E1J&ZN"AROAG$@6'>]Z6[7;?D;4$L#!!0````(
M``*(9D>64)Y!O`,``/D2```9````>&PO=V]R:W-H965T<R]S:&5E=#(X+GAM
M;)U8VX[C*!#]%2L?T`8*7XC2D;8OJ]V'D4;S,//L3DABC6VR-NG,_OW8F*1#
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M&I]EXY['L2=GWFS:0'@#034`;P!G`RZO&DAO(#\,TJL&B3=(/@S<T.-Q[*YR
M+X4MEHO6'*-N7PQ\XO,>W@Y.>L]17Z[.?;H)&5O?ER*7B_A]<!1@GD>,\)AD
M"O,28!*8PKP&F#,B[K.<3%6@5(4S!Y]&>ML!(`?@'$CO(`MS;,8<1TSB,%P)
MD>7\=B")`LD@4#Y9L`"3LMM!$A0D"8*HVPY2Y""]MYX9<I!=9I!-UO,YNZAG
MPH:_VW%R%">_C*,(#A1RH.X=*6=8)NP:=T;04P@"-DDP#_(,8RS+<D(^GV3+
M@YKP:;V%((+D.-8<%X$+F![2"%(.!`\J(P3"VN1P6S.O(4A)0APL31[H3B4$
M%UAX/+F;3EAZ/*70*0"I=+KVZ?\0&,=*YAF%3B&(,LM8R3RGT"F_H!-_H"QM
M'"N>*PJ=`I`BZ%#@=4$$DE>$5`66LN#WTDE\VAD%@4X!"-CTZN1!(YT4`Z4H
M^6`Q"R#0*0`!(VRS`HM92`*=/.A$IQ0(@;#D14*@4P`"1CGAX'5!I($+2JI8
MRB*[FTY8I2*GT"FGT"F_H!-D7`K*D+"8A:+0207Y$/8&P&(&1J"3!YTV.\(&
M`ECQP`EL"D#`*''PL@"AXBDGYD]'9KC[T(U%"I+`IA#T'T<G#QK9)-,DITPR
MEC(D!#)!*&7"5@=8RI!2R)2&:Q-A$00L>,@H;,J"`1&V.CBO"HV/,S1<-\'"
M!75M5D]3'PJ7L(5*+%S)KJU%/DX(XH1CDL3"E8$F^21WGA`(;P/QQ>_S6K=;
M=S/212MS:.S([7/K^?;ER=V5X';(YR_]I'SNZ4O:]ZBI'LGF+Y)-]O"^9[R3
M^4AKN=@76_VE:+=ETT5OQEI3NXN(C3%6]Z-E#WVI=KI8GS\JO;'#:S;4<+R9
M&3^LV9\NFLZW7<O?4$L#!!0````(``*(9D<BP3AFXP$``,\%```9````>&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;)64W8Z;,!"%7\7B`=;\!4)$D)I$J_:B
MTFHOVFLG#`&MC5G;"=NWKVT(!826[4WL,>=\,V/'3ELNWF0)H-`'H[7<.Z52
MS0YC>2F!$?G$&ZCUEX(+1I0.Q17+1@#)K8E1[+MNA!FI:B=+[=J+R%)^4[2J
MX44@>6.,B#\'H+S=.Y[S6'BMKJ4R"SA+\>#+*P:UK'B-!!1[YYNW.R5&806_
M*FCE:(Y,[6?.WTSP(]\[KBD!*%R4(1`]W.$(E!J03OS>,_^E-,;Q_$%_MMWJ
MZL]$PI'3WU6N2EVLZZ`<"G*CZI6WWZ%O86.`%TZE_467FU2</2P.8N2C&ZO:
MCFWW9>OVMF6#WQO\P>"%GQJ"WA!\U1#VAG!FP%TK=B-.1)$L%;Q%LB'FW^'M
MM%P8B"8CW;VTH=W?;O6>!5Z0XKL!332'3N-;C;^D.(X5@1<N:4Y3S6;08%WE
M8JG^K%3?`L(>$*T#@AD@L("@!\3K@'`&""<5;*=MUEV;G2:VFJ]TN9GEV$QR
M)(M;.='X[GJ2:)8DF@"\I48.T:B18#U%/$L13U+XZX#M#+#]W]-*9H!D_;2.
MR6>GA4=7J2%7^$G$M:HE.G.E;Z6]D`7G"C3(?=)G4NK7=0@H%,I,8ST7W8/3
M!8HWC^=S>,.SOU!+`P04````"``"B&9'U!_!2`P"``#^!0``&0```'AL+W=O
M<FMS:&5E=',O<VAE970S,"YX;6R55,F.HS`0_16+#PA@EBPB2)V,6CV'D5I]
MF#D[I!)0VYBQG=#S]^.%$$!(25_PPENJ;%=E+1>?L@10Z(O16FZ]4JEFX_NR
M*($1N>`-U/K/B0M&E%Z*LR\;`>1H28SZ.`A2GY&J]O+,[KV+/.,71:L:W@62
M%\:(^+<#RMNM%WJWC8_J7"JSX>>9W_..%8-:5KQ&`DY;[R7<[,/`0"SB=P6M
M',R1"?[`^:=9_#QNO<#$`!0*922('JZP!TJ-DG;^VXG>/0UQ.+^IO]IT=?@'
M(F'/Z9_JJ$H=;>"A(YS(A:H/WKY!ET-B!`M.I?VBXB(59S>*AQCY<F-5V[%U
M?U9!1YLGX(Z`>T+O,T^(.D)T)\0V4Q>9S>L'423/!&^1;(BY[7"CX<*(:&6D
MDY%V:8_+[5[S"$>9?S5"(\S.8;#%A#W"U^JS%GALL<,#.IXSV`\1$8X?6T23
M+"(K$'<"R6.!>"(06X&H$T@?"R03@604P7*<9NW2=)@P<">Q>"+,=.*2CEQ6
M<RX[ATDL)DZ3U1/'N9S8+$<VZUD;AUF[1[%(GW@7JXG+:N`2KO%C@?5$8/W=
M2[-'/WK]P3#3*)B]M@ZTM*#II?F#<F,@SK8-253P2ZU<7?6[?:M[P;9<[_`\
M:\@9?A%QKFJ)#ESIHK?U?N)<@8XA6.BW4^IFW"\HG)29+O5<N/;D%HHWMV[;
MM_S\/U!+`P04````"``"B&9'`1TCJHQ,``#M'0$`%````'AL+W-H87)E9%-T
M<FEN9W,N>&UL[7WI;AOIM>#O\"D*#0]:`DIL+EK=20.R+'>4>(LEIW$17%P4
MR2)5<;&*7564S&!^S#MTY@[F)>8A_"CS)'/6;ZF%I-U.!AE,@K8DLNI;SG>^
MLR^_+<LJ6&?)S^OX*E]GU>^^&8^'WP0?EVE6_NZ;^ZI:/?WNNW)Z'R^CLI^O
MX@R^F>?%,JK@SV+Q7;DJXFA6WL=QM4R_&PT&I]\MHR3[YH??ELD/OZU^>)Y/
MU\LXJX(HFP776954F^`FXQ&2/`N.@O(^*N+RM]]5/_SV.WR'W[L(7N59=5_"
M.[-X5O_V-E[U@_$@#$:#X4G]R]?Y0S\8'+=_N6L]?[F<E%413:M_[WSS;K.*
MZU\.!T=_JG]V"4_/Z(T7:;2H?SN/TK(QC)GC;5PD.2YP%CR/JL9SNO_>;WZS
M=9,ODG(:I<&_Q5$1O(`/&V"N/RGSMC[[IW']D[LBFB79(KC=+"=Y6O_V[<W;
M^D<"\'?Q(D$HP[ROHV5C=V]_?_GNU>7=[Z]?7X?!S>NKCE&N8-T%K/D&,.1C
M\,=X4W_N:ET4=2AT0?3H:#@Z&@\[IGJ1I'$17,%[B[QHS',YG<;P/7P[XR>[
M%IPOEX!BMU4^_1`&MX3WP9MU55:`C`#'QOK?O'Y^_?KV^GD`O]V^>7GS_/(.
M_GAV^?+R]=5U</O[Z^N[6[A![V^?!P=/#AMG&T\!289T#XZ[8!.595R53QM?
M1^4]79$I_A+_O$X>HA2>;R#%LR1-8=O1=(K4HPR*>!K#LY.T#F$D*4_+532-
M?_<-T(PR+A[B;WX(ZN.]SR;[COC#VR)>1<DLB#\"72H!EKC@O+J'HYIZVVO@
M;5X!/FQ_YFT!U*Z`4\-!$0`KO"=AD,55_=$W-&6:9XNC*BZ6,B"].(OG,<P"
M<,S+YAP_YOGL$;;;OK[V=>G!I4D$D$JJ)&Z>WJ7";A5MV@`'WQ?KN!5PSK!=
M;\'A5<5Z6JT+O/LZ1H-$W>=%Q?"8Q9,.F)7VH2T3ZY97\##2Z'P.0Q:`$U7R
M$`=)ALM9MB&G?\Y?O#6X8GBX`:YSU]EOF>1YZYK#((W+TBQ2]MB^DRV#$U&Y
MSU,`3/DMX6NU:=YJ)D`E$Z`G@_Y@,!@"DA0!W.YU_'TP'`S"`?\G?#F(UA4<
M4O*W>/9]<'H<CD_.P_/Q,6',Z3@\'8S#\6"L#R=EB6`D=+)T+8BJ`#A6%2\G
M`"MEV_04T"CY5.A4B&>PBJ<(IK1):6>S!,$#L,";?Y1D1]-HE0!L6DYTO5RG
M1).%).1+H#OW<*)X`FE>MF&!>0<N;C)-&FC+YU"V`'OGB=%^]WES/[)_\#9"
MA+F/JP28VR'@Z)/@NPYA:K\1NT4?'V\,OFQ_K($_>SW.&+37H_EG<\[;._CQ
MZOHU;/;-B^#-V^MWEW<W\$`W#QWO+88V.>QGKF$;^#/Z`J[&0YPUX?YFA<*'
M2[$:-_\=,-RHF-X+4X*[E1,_:W"D.(M1IL+'HMDRR4A.P\O8,F*35#9)'ERY
M:1)UD[2\L?;Z<R_AI@;S(E_JLWG6>(:I<)+!'8^#`QGIL`&%FPQH-*Q;YVKE
MYN_B*$W^%BFG$9*`-`,EUC+E;Z+97]=EU0;"J_LH6R")#^91(C=E?Y;5OI,.
MV.WU[.NX(FH73&)0<V)]OHH^-F%]8[X+5D7^D)0MYZ;C-23!J$RFC%])ND8:
MFNG,*V+U<&GK[_P4)XM[?#1Z@*,%J,G57I?P&4`0*-MTG9JSF'S!%'M=PZLW
MK]Z^NP:%X_;FS]?!RS>W6TC"EP[8?;_?M/`G/57<7!.17\!!)HM,I(;II@,U
M&V?TN;B-RTC7,SZ,K./@KW8RUOU`=GG[^^#%RS<_;8&]I7012@CMLIS=?E#E
MJ#[DV12T,HLK\"G^3JJ-8EK>,G(#[*2R'0$6DD"_Q/O&$-N#_'4_(QK"MGOY
M.D=!!Y:;U"A8XP(O02XJZ.C@?%>M.DR#YD>X_RP`+(1[5:[R$FG+OF\SN2MK
M,+0:T#8]Q>R]@[&]WN>4FC3L`0"T_9FW:^"%$8KV>^\3],%I',^$%2&L`$SQ
M_N\W]I+LL<X7218!\FY]YATHP1L]\395"V<NW(<`VGGZ@*-.`?@):,"+(HZ[
M%KWR-AY_C(MI4M+&'Z,";3AMJK/S!DITL`EZ8^K)<4Q<F/?;4>E+.&EB],2A
M\=-\#JA"2VY3I`UPB6LAO9IL@OD>P+N&8:<5H4'\<<J<&PTY)5X('+'^P@%H
M+$4,J'.(RZ??F%'M:2_I-*R$J"5-XD629;ADQ"NRQ7W>`#%J7EVOWJY7JY3.
M&2XXW/0I4,-UP0>#@\W3_!$V8XRAK5.3Q04>,:2H(0>LRR0#E38,7B:PNEDB
M-^--L8@R83Y?\LX6!OHZK^)@&'SZSV"O@6X31,<1Z+YA\!9(^O(2KG,&TB"(
M/_W@X)O'^)N0;O@WR-JB;//-80#4`DXG!N883`"T0+B`^A(3@.\![`N07NA:
M$Q6U`C8"-XL_5L&")&N:?PF7#@V29*0!SK\$+%J3KK2(4#3$&=)\0<_02=_'
M2_JCN@>$J\I^\)RE[NH^`6Z6+&'ICS$L\8&FSE$P*M<35(ZJ!%Z+YW!>;/&&
M67*@?3$QP9:EXD<KHL8L"<`K%<ZIW\.(]P5(AX`EJ*/+(QD:\V#U;,!(RAQ1
MN!^\R8)7I'1<L,8?@LI6!,_RJ"`D?9X`<ZSR`O:]PGN+FCI\7Z",LLAHQE4:
M9<$!+NK3+^^<S]_"YY_^?A@\)M4]K7F1*\\BRR)=>EC8,OJ8+)._P9\AX2P^
M.H&#F"=,5&`Z5R/G4S<2.YZL3_WP!>1E"SY(FO[VYL?+X"Z>WF=T:'&I>/3I
M%_P*E\GVD`)(3,(4WT$A9I7]X`XAC]N-4UAR1D8(@@OL`/Y(0<9[S(_@Q(M9
MJ6M_S(L/L"U`9M+7`!%F>*YJ7@4DF*,5`R'62:#P!::4,8T)TA(L$:TX5MU"
MQ,O7"QA`*`NA2H+2RCT0'4!"%$>F%4\/V(YD:!)O<D0?V!<*E(CR*G<B7+ZE
M8X<S[0<_Q41,,GH;O4<52B3.XBW6X@Y@"8!A69P&9<X+`.2?`N3*./Z`UHDJ
MH[.<YD>"W?!G`*<?36';!?Z!N(";=<X!(+THHB5/H4#@[<13T#6"=08H0F\M
M`%<+1L2IJN8&$U]'8J"Z@9N<5.N*A8S+-(V+!1.C&[D\ZQ+N0!F3'`+8\OKF
M\N8YH`OCPI62%AAE21RI8MM3C*H2GI9P]-(N$N1O7G\&\J+S$3(HA-C48BTN
MM7ZC<*!HB42)?O.0[TDP"BYI)TU+'M]K0JQ)E-+:'H%</AF>]8^#99*F,"L_
ML]YBW???#0;]LV#<'P16!+I#%26:,D8"K2>S2$[#79,A+7BC0@))Z"+26IF1
M5EC$A`0,.;X09$!DB1H8!E%B@\^(*;S'\V$X/CX+SD[(.CH<P,?GP6DX'%UT
MK1'HWQ_6`+M3!9/#;((2((^``'HR94*@0A@?T,URN<[R/P.@@*$9X@5"2KHF
M/6O-TA)^"&H&//CQ[A60+GX<"$F%;#S$@Y1+`)LUY%N?`_Q(B3RZ2_N63B5?
M3G!7)/]5;(_%UQ,@\HBLQ=M+0E5_F4`)HF":)AFRJR-@0(O8S.5R&N6;:3XE
M0@<(^GO`Q7GT,0Q>YP]1<#O-@77U/8BAIP16EBPGZP(VOU[AY@`OAVRO'HG=
M&FV%267/]XKN,BQ[FI`I_R5?N%%_C(0'Z0;)EG!GD!:OZ6Z5AJX04YWF!;*J
MU-Y&IFN6+L'Q6+($%PU$D*C8X`*_#E'*BQ8Z1`3#D"`XBSFB4U0L8I<UX*@$
MO0KI]RS!S>(9E!\`GL![\-#6::477>X'T>)D*?(B3=<@%^5ZBAN=K]-T0Q+(
M,MH`V8<5TGTF8D[\-_;Y*OY!7--AI?NPR!LT3;`#(-R7IH66-.(YPUT#2#_>
MYWRPQ";Y+)7>XBDL\9=-',&C]!@)?NC>8;X<XFI#.R=<RGBEO.U5T0_>)=-[
M&`,NDN6F));@<3!5(BDH9)P&S$,'$IP:`"]ZB))4X;<`$39VET?,,DJ!\0'B
M9GG%*!L'FWSMHRQ<NG7!)^KC;+<@X*&M*Q(X@@#0["3U^;<C&BN;%Q>0KH5I
M/'PH[PGC@C,D&8L05RP`CISE8W<0P2[)4P;;S'!H)$;39`6ST4!-0S*=2ZQH
MA?1<-I$7"KU)+,8N84D%:J.(S*C?S,T&Z,KY8"3I)ZGX`*OH`Y/H=2GR%QXB
MHJ@'*1HVSOA:.OHXK@?Y&.X2$&\6+2.TJ$2/*"@3/'`89U&S/,#5ZSQX?60"
MI)1,1(PB!`N'Z\TRHSG(4+5C4D,ROE06+5`3+'EO$[S6@/OP9+H1OP!(("5B
M5D3:<SRK74VA!$6$&GUD77;*:9$J@E:1+<QJ[6)6>4F/DQ!4,'V&);03Y\=\
MG:*@Z5`B!#I.3%*`G7H.1T@Z/9PRW%6^7W"AF00#W%.00QWO(MIVRKK%0NG;
M,H)+&2'\$[,:1$\R2I,Q-;=TS-4O^DV-?+G$"X=B%5"M!.@3LESQWQ-?SE,4
M@IO^WKW?W*4WCX`G[C]:#\W\!)FWJ&5D?*>"-R3<17#]*[*-PH7)V$J:E?#F
MC.Z-/660#"H1P<3"S'J"2H4X?$,Q1]Q+*J+>@(I'^6,F>BZH^;#X/LK8)%;I
M\LE"H:)&Y4IF.)2(FRZ)=U0O9B^R=L+'+]^BG6"%=C@V]@J]88D7.0D;".B2
M$8Y:*1GA#[@&XZY2EN816.\S6LAM1<H!B&3O^[?]X,?+R[<LF*GT"\(8<R;@
M2$!7F/(JM`DV./ZO.SQ8MNMV".E5N0!H`$&+$LINZ*_@F^D\^WB?H&.RB'T.
MM&+\(B\:`*6=3'20MQHE8XVJ8V.J=E`,(U[K1DR"Y7#DPXN%*#L`VP$F&)2(
M!#[":R'43)9=JT=8`(%7>"2P_R1C#?K!B%#Z+@V-I"E'GF]4!13+8#D4^H:R
M3#^XB@O2K!T3'P%JGN=5AJ3`L0GRD=&\U@-$P[9M<!M>&[1T[H$]"I1.05Q'
MT*U`K%]'K'RRAW0JO*I8IZ+8%O%"_($T:3DMD@E;>^E*X%2WB&4VXN):S;JD
M%Y3HT233S/4579.?<$5I$C^(+4.<(`*&TAJ4D1OA[@ID:2`VP=Y9POW`M,L%
MJJ`N^B?A%&'6-.9`R4=D>/!T&7_AA</I,>!6Z--?UUE-_KURAWAAAKAUA@"@
M(.$OO:/%ZW6996MX]EV,04C(+%_`CD#3/?JC02I$)#0RQZVA._,$E7&S%H`Q
M`5ABF_`2$XZ3Q1QTDMY[UF&OC8GCCLV/@$O&5M1!=W#W"'!4^VMH)AI,Z1`\
M<U+6FD*2#(@4RY6:N)"+DT`CMPNA@$1X:7A2NULKK-O25>&L.EX(%,\0%'*9
MV[89LOVU8S%&8B:WD\J\,[4,ZTO$/,AH]VM8F!)ZE[U:6*KF6G;Y1W4?1@7T
MJ;D7#@=;1*Y!/O'J'I8/Y/M9/(T<@X?\:A>09/>LU#:(E`,$M.2B0`Q"P)J^
M8?(Y)2&2]6)W?X"NXNK+2P=Q^CUUOE^I\_W.\9W?$>7E6VEB#Z<;8[%U99>Y
M#&1E&-]$]/Z/P4L02$CC!)D+91\TF-A10>1I1S"%<&,"(B#JZZ>;#S?#ER1F
ML$+4?">N$<USCBG^BK.I'=<DE,1!3MA`O"SK*Y"Q'NN1(#5WG.@Z.,-6%+]K
M#X0@%#5@2%1J)X[$BB`09K@#`&G'<P(HD)(;B<,("\;*1U1KV%&.G\Y#9@I.
M\""2MXZ8PQ`-9/`ID#]6_MHB`OO!O@$>#$UT1N=I[`\<[1$!V2KN]%TK9D`N
M*=P[/A_SA'698!:K<42(-CIMO0@6DD?_L,YBL80^QC4XX]K26+5KA;H,UW4I
M6'(D+7VFAC1:U&@P..^#AI(@V\H[CE21"$9T;Z`!^3S%\#81-AYCXKPHVB"2
MEN9N[3JAQH&WG07#"J\S/,V$26]6%Y@<$!$XR6WV-[*\N*9[/F88"RWJHY[Q
M'M,OUX[UI].O3"=.K(`N*_K?562WTR"S+3[`J3.%)U5-6`;'.1B^#=0]WNC3
MK)83__:Y`3I.&.Y&.;!+<*?RG27J/"H];\3V&9*,#$4,)?AF71!T`<5*?_!9
M#B.1S<U8G@(V8M/%R,D@>N_/W.^Y^O05(`6<<\$$VT3IO[,^$.30H.J1,CZU
M3\/VR1QF)8)G2:YNY,O9`\XU"[P@S^>.N?V28W!!5`+)]]GEN^=LN^_VYS@6
MQV_+_;TVA-0)4T7G&3'JT0X\D'[;-A+HLA.X(X'."7O1!1SBQ4//<4-#H^NY
MQ_0T'$&@W]/LB\#\4L0BN9?&KLMHL9)X(3;Y!.C_8SG#B_`DJC=#U_D\H1VI
M^%>6.4:!J6Q,E(KUUY($9.!M2?PH'&V*HS,K)[%AH:N+2#Q'^X#'?EF4,FH>
M6UZ15.(BR9//%D\;IS5-"F`-2%6F]`';;,672_Z`)0:*ILD'<CNCO171GK^W
M`69DXH(-O.M><E+*WEA'(WL#,6]<M$<Q#N!D)0Z"'C6N>0'Y$ET4*U#4C+*7
MK0D%"`(VU4"CSDNEGXZ0@N`YU,`'/*Q)GG_P95+EOS?SYA+9G%S2%_[;(=HG
MY^N"*#LH'>D&;62T>>9)K`89VHTC\&FZ\$1L*4LU"AL8`EUIXCN'<3/7)9[)
M.%'P/<QR?UP&@!H@>G[H]K5(9RV\I^E,>7298-U!W!_"?P/'C(J6]*@YK*4X
M(TD%`2:74B@5RBUNGH]/B.B9F?AQ`DHFV[ZD0?]X3W]@S^K*-U8;(7K<I:=D
ML^_0G@\;F>'<\SABWS'J?Q$="XE'>5G+]\GG5<R&A&D*9P[$@B4*)T"\GC82
M><(''340'DM]A%,UY#"?/K'AP5D+6W]TW49O]I7DOZYG"WJZ']RB0.?&S5C"
MJ+&`O"^T_J'+A+R(D[AK:S..L)"@(R"\4T-'@7!6XGLT"Q2(8W`#W7=TCR`O
M/F+#.QE>)&B]_+Z%/I,"INM,2O<"><K.LS2:?CBZG8)4CGQ])4,GY.%?YK,X
M[0?OK3:Z^W$+6D=[76?Y!)V"Q"F2;`5$C`6(2+F/AM3$Z,BW0L<L>,A1SDPU
MN,T\.4O05@4B%5K!8K+R!&,,E7B!</@SP>$5$UDZ4:`$9$,@$@YB"JT<*)7$
MJL42C\7/$!.U[N-JLU(/"7OHD)H1<-GD4CXE4?%HE:[+HWD<F^<$ZY*/:/(C
MVFZ^05XB1@T,O^QZ72X#+/AO8G+,-&X%#7.IXA2%BJ(<NJ8@8T=OE"@F'!Q?
M5H37$P4RD@)/Q(/!J8%M9$C#\8KM]6@=N="K3F";QG9MO)VGZ-)S/Z#,LTQ0
M!8=,,O54@5"3E!_$OK),`-NJ/-/$,D`!I"3FO5*NGJQHO1+D%BXD!"*.`.',
M4.(_-#.7+IS5=@F?L5+IKJ#0B8C@*RN<60,MR**/WUO]F<BV@:5.J-##*,L%
M$(M,#PH@N&:7'D5;,W]`-T!<D-45`;N,@=8Z-WGGZ8O`&@F9XO`JZ^6%B?Z*
MQD`>AZ@PG[7+FYBQX<#S0A1F.6`>3@?!W>D1&;791FZ\IY@._,P`5?=C+7UZ
M&*SRV0=-'-B!#:AN^18M((@7ASZ#*CHRP[R[7+]S46D6A6CQ%*8^])=?BE'D
M'DWKL^_A`7C"D9+<D\LGJ82!B*8F*:`*2KL9$CEIL.10?>8(<\+4J,PQ\&0C
M,1$P*6[I('DXM$HT,"")AB4YR?4WR5K]&4%)<J9/2I>UN8-B)$.:&F,NK"Q_
MY&AU\:TS/.!,G_8^_7>1LM&W'*/"B7>`-AXG!!PDNRZ`T'J-SBD?&!H2EMWC
M0VX$KQ=I`_P'5DB&$9"Z*(B`[7"^8!8I?DY1GB;3C8O<$I116U4KS$+9(=.)
MDDQ3*;OTHK)RAR`A"I]N+-J#N3E:H3WB8D>`.QMD58\"1"6T@LFF<RO8]+("
MMLB!T786/5;"0HXKEDOJ7`.)L/+6-L.8/?;S,+UUL,+3H^WU81)=$W(;%]:]
M8R2[4Q!:*I&@%-\%$$!?T$9!BF2^-$1N.YW\7L@76DS(?KIK.;172==A3UP;
M-1#91?>L*@\;KSONO.'Z2+5;Y8+@``\$T-*[<RZM*1U>$TU`'3VL<2_A?K"$
M*08M+.*C?'[D\$*&BH1A;W_(/4DQ<LJV#0^GN+V8S$('UJ^OC+-=/$E$?)WI
M"4K$F-4B)?3/G4F"A1W?R*[%SV(,<RT5(*JUJX/,N6O\)/WJ:P0L64_%(N!;
M$]`/S60U07L=4`Y8/,=PLV3N.VZ,3<VW0E3WWIP%NDL!>FQ545\DZ!YH@J>_
MV4P(G[*'`W.L&M945YAU6"F@O@3*Z-[0V"0>(]$F?):I8?*$FZ&&@TFL@UKM
M=!0&B;B73.Z8?5Z1"?^4U<'*Q<V79`]Y,F64L>9`SV)9VQ'=1V+6\Y25`CGH
M6IB#<YL;L[9?;6]6]4.*D<Y;WG[3;S,J@D"$XBK@1<(:84VMC>Q-,Q"U0?DA
M<09SV9Q7190K8G5)S2SM:247S9?E[E*.0R7:O1TV0K[/IC^,,((-TA_->VM=
MFO[:.7".[SNI->BK9<.TD`F:++2GTBZC*P%N%8Q8:U/AJ=_CM-9G)#A?N6[;
MGPR@O!LYJ^G5KMN7@A;+8(%*-B-&#!0HW\3H)Z>T!/D3KH2D_X2:<H$7E71S
M&^+,5@;/EXQ),F+OJ"W#31QL78'-C6@LHJ:R"0VB0=A/;SGK/N:!N_WL`BIV
MU-S>2%QS34<RVGV:S*W:^<C&CYG_B&,8\,TTR$]Y59Z8Q<-H$H\3!>[F\Z#[
MIH9G46D0`[U=&,X9H?_V*,5(_PF'"*J17(']K7`RX`R&N5F_;?,XMV*5BRY?
M\^A$MCDRMFA,JD0E^>=U5,`<Q,;5Z<P!'++/I-BQ/9M7QKLQ<:/_&+CO7(\/
M;BI]E-#<C#.+G78RC'F1V,2I,;!Y`;,J9!":S=AA-NO>$XC?1*<,ZG1O8%<J
M?LU"1,3\OH`;O^1Z+D0)$&CR-\<T=50I8A<3V@ND'H4+"3G-;8>(8Y@80D"J
M]92C/UR*FA?SF)./]MB<BD#>EO;:PM/>W8YW>O0./M_KJAH3/`F&HW`P/H9?
M3D;A\?BXUUTX!A.GSD;C8#0Z#T?GISTIH;1KBT^"BW%X=G*&CH7S`8PPL%FO
M>VZ<C$Q*,Y0OH!JJ1FLI=[4_O#\;8Y[V7F]_93]HGY^$HY,+^&4\N@A/3TZV
M@7M\<1(>GPV"\^-Q.#@^KWE[-/OUX`2@>SP,#H.C_4_D>'0:7IR?X_&'P[-1
M>#88M[F-_"IJQ*1\^<T1"1RSW#[`->X>)1XUAX]FYP&8\*=LDLU<+5!0'1\U
MQJ!BT?/Y%ZQH*Y+A5<$U#<_"$_P9CD_.`+-/T!QVV589+=20%K8AHNIC-KSS
ME!PE<TV1%Y9](NMI.,C.@U%_U)-HK3LL/D(I1BR42Z*_+4SB\%)R;GN19QL>
M'KBEAN9X?@]7YT+?U!JI'=4:DN/@,",WC$VE\"5P7#33J?L!-<U)7#W&<7>\
M'^$=#JYU/LCKVAHOAU8^9(02O$-"/"HK"?G"`"T24%M$NO9LADS+K2J%\\D4
MHBBHHN3RA(F-UK'Y7.:,X3HY,&$%9PVKX=AM*LTDP>\(((S0GHL]\=,O;7[[
M3W^W.K6^B4^7H+#!B!)Z(<P,#Z'"7':*+`%UCJ)@*"H%M612*"IWL:8@#6=F
M9U&J)]>U9K([>A%1%L$4B[MC4[JJ!LJ-<4D#1\"WG6M)!2"J>X%5<I^KH=TK
MCX0(@XNR=B\^6F.TL$;9]G@)``Q&]C$`F[LTF<Z#$?XSQG].>K:.UG,I<H75
M3:@*VEO8,O$JC:[DX#I;_.HI!@Z*C%36`O&,;AA+S1/-,G!<J&BSU-):Z(PA
M^X4976S6*_IZLF%WHT9S.#-)@$8CI--&;#0K^!E=!@,7IFR13E/'5FN2JU3`
MI"&\3!,.G,)DB689&4,+&W*N*<O8=&:+5UUGMDLC4[@N+=UT+*YN0/<5U"WS
M-OV'Z'K:&.&G(.5DHUEI8KIL.7J..-43]0NET6E:>;9,EDD:%6RHYT)KM><G
MCL6BXY2Z08&9X2Z>N;Y_72D38F9Z#5YUVL>D^_Y%#Z/E:KEI19[E:_&!E!AI
M^BK:"%W`\6UHA_/2K400E%*0Y.#3+R\N;Y]AN0ZI8MKZ\/L5J3'P].7M>WSX
M==ZGJ8X&%Z$Q)M%Q7QGS-?EV;/#?P5V^`O">#DX/92!W%`[-\S_#2)'"NG>=
M9#!DT"TF1,[[AUDJP9@H*^=\]P"H2PJ2PP@C8KG&T%RW,EJ_.G$0,>H96[?U
MF)!'0DVP0<SEKIGE&3\T?IBR-F9BNUFN1AM:8S%X]P!I,`.::'8D5(O&,0'<
M,170H2CVJ0]NNQ'$,MU_8QHV/I5K3,>/9Q1HCD'#E$BB<X=!%BT1!ULQXBJ?
M47PGA__+R9X$1T%+<$7?U(2X<$,M$?$"KMLC?F8NAT.'.%<S"@&`KH[$']21
M!,/FLEB2O1RY/&P\J9F]=DSR#MLHPM(I117-$<:&Y^*B89PS28"/B69$,S6F
M(-&B=*[)NI(L98G"QDWD10+#<DVBVFXD($XIV*[Y3YN7)%%<(T<]T?JJR&TU
MX9!K(:`+C\ZL_@0;4%@D*]RTI5B$"*&_#O&C;</']:7DQDNP/;&&XN(O`41I
M'1V4"-F!3XX&8TR%%8'KTW\&-\B+C;BBW]`V:^_!;<J1Q`-<YAO-3S-O8M4X
M6Z=-+,PLO4H+`\DZ12,A$T"U47-88?-]5P^)7+&,GK4:PR1VLN62#E]!)'9:
M>'G&28'6[C\%GDF<42B5"77TYC%R@JFO0M]CXA;)Y\SI70V%RD?96"E+B/"F
MM&W8B%.2%*]B4"<,><YN$).?HG9!VU*S&%$^^P*?A!*FSYFH>N^,ZYM<:\Z`
M?74'J..O[2KDV=ZH;XA0LM0"`XW\^(ZXM3T?VY7Y/@8BW?7J71.UC!))5>O)
MIM$5&\J\T,JCF@O167PC;(VM/VB+@>=CBVHE_KV<CZH>'NI(6XFW_B6&5HH.
M_%,LL6>N9=@$(PK'9ELO%V#0Z@NFO@?B(,H,9!E`:11K!;KL-W)N_@$&WGU,
MI(S"H5Y^D6U0!"R`3J-FB?D-Z-#&@EF:."(&.3.5'9?E%@R5)6'62652BX&,
M@45Y**32I&C'WHWG._J39IEU)7,:,[[K,G`@J(%K9+(\2M&NYWY]GX`,!?+_
MA@<B;@D#:YB(!(92T5`*`Z(YG`%$3K+#:,T=+]BT&6I*]"W)FH^VQ*7V,4;G
M):U\&'SZ'\&?UGFE41HL*#*-8L"R4,J)$%/3QZ)FVW&&'.&0;QH+U`Q0.,R?
M:_/9[#-95&@B9_U'*>N/%9NNXVNL_ON6,>QF]AI0X6!0@_@"S?*]22/4?9J'
M'+!SA1J\6QCUDT]R;BZ#`IY]2-`8T#1RH#E&:+YOB2TV\X"P*]G$$TR&PSCK
M@,*J=40IE[H1G5Q?<Q*91)IKA)=WG#6CJ)P;:)UB%_(<;Y)&324QG=H-HMU*
M:446U@7^;*?Z>:UW$/'7760;(@>70IZ^]1;)R04(/B?RJ_62)K7$6%@B"F/\
M<LXU(VDNXU7=#C>'X/31&DR^QGI:*YFW)'H*A:$8P,=\05)-MEHW=U$H+IS2
M\:X77-.Q<`\H.TZ`X@^=#`09NX@H4U"CA5+%/1!HJ6@])>IZN"J,",D[AO!B
M!F8SI4*N!%%Q*?BU*.)%I$DXEGU_(7$GS9,M@,BID`?#PBCO<B]T\G"I1NN-
M!:C^>@>O,GY.-NEBQ+7=>)93X,.OWC"I3[:0BVA,=U[0:R6AFEXRG<WB:04$
M45ED';L6^!GK>MKKLB+WE)DI!U+:^8Q5CQ[GU?=N3.YJ1^KJP?`P>!*<AL<P
M\F",GK$C^<]\)NZU9-=0NX9Y:8'0V[LCDJN&=1D;[62C<'QRHC][5'3^:TYT
M!/\?C<["\XMS_2G`^2J+!SB-3L;V-SG]AK/@ZQ_^Z"(<#H[]4^///NOPMPSS
M3SC\X=EY>#*XL+_]8Q#@%'=T-M"?7Q$!S@=GX>G9A?VM!P>$GDTC+7;7/M1`
M%;<DUC[UHCIH7RE2,)7<+&UQ-2<)MUU^LE12D;+.C#\[#.%I[UJJZ\^X]6!/
M\%P20]]GIG2`MD4(O"=ZW@TZP'81Y6'PDQZ`'\[PG,*PV1)`01`:W\#_])ZW
M9P+N==#V@`].SL[@;IP&A_[E[]Y:#0;_@*V.S7[YGU^UU6%X=@P[&B,U/C@^
M/:90BT/Z8S0.S\87],?Y"3QW,6Z/(C`($'9FEM9SYLT"O/B%\.SL)#P>7O3^
MA-6Y,*P;!W*;ID83C,U7C.U*-G0^;V\(]V?CJKU3T=[79&Y(0.I96K]'/-^U
MFT;9NVZD2O8NVQ,KI;+.*T?<<#9`X@;01RMQ<%W$.R?VUI3UY\(]V>(H)2L)
M"S9.^XNPHX4(_:5YX&&;P).Y*["RF*F9V\C;\H90CS!+SI+)PA9TTE"/4/D^
MTN@+LF-15CF&+7Q^+)8;EFQSF3,W4QT0KA"O4`=$-&#'V'J?!&.,21H&^Q9^
M;FLMU_G69SV\R]QX#&O8/@`517YIBR+?.*G_V%J9]$`NLL8A%"G6.S%M(^AU
M@=!SH#*/>*Q7H.<0I*XH30SK9))MT[Z=IO&"$C<;A;?"P*LI+(9`*4!>H'<?
MT44*F(=^]B!U7T`)A[R2^"SS+ZF(.RO66)`]FQ%7#8-+]%P\;(I/_S,XN,."
M$@D:3ZO#T"L+&&%("A9*ML72W3`@LNB9^K!HNC0UFZ4JT&ES]V6N(.#W"(IS
M5K"I4]0"2Y&S>H67$;^3`G<F+Y>M3Z:4N[MD-XT@GC77;WI(D"O(*8TP&`[#
M'4=I^VV:.I^:6AJ1]3Z39"+=%H;(3`JT,:!4(V88-X';3<7$"#)T1F`(BT9Y
M@'J=+$OK1B[S@@I,YZM5G(IE&H/-J*1HJ:6,^SP[%RDF"KC2KCNXV%D\Y=0@
M`9?9\.UZA<R#-T[PP<S0/)/\X6F1E^61&94QMV/LOA,6,`ZW3*,P1:)=K"D/
M2(5#J;$<S>=)L53JUWTZWY9?Y00XUZ,H94TZY+8CP+0^HL,&%2;`)QO@;>*3
M]DLCS[X$[0%3V-B#101+Z>;G\RU01/,:8R2YO"_7BS40J'.-UMH3K8'[+H'U
M9+/U,G@C"!Y1-Q]8'KLY>6`2NN13#^:/XD;3X`/>8$R2T'JY0MG<K0UN:F^K
MI-TAG*=H[0'P4]`B/NN0K%HQ[!U;G0,CL_5;W+R=MC4#A(^T'H<?>O<0L:O*
MIO^5S64[R7U15>4%J*'EMZ:$1$'$"(N&4YXX'=R;:963S_#,/3I=);Y)6$U6
M2V9,<NS&)FG;^3JV'9Z.6>#S(II7?'C\P1^TX$A;-5FVD]GBL+K)!B+0\BTY
M'9[J!I@491PQI,DOE6&K(`*":('ZVBJNV!7,,39I$L\E,PE.;X4NU>%0I_=+
M*#Z+L@_%>E5-L>?[S!CFJ$2I]QUB@Z+:+<C00,`R[`E#$6HX]NOX,?BWO/A`
M2.7T.R#+*`)$]E.KO-J8!+UR0+9FT4-B<BU)\NQD^DGE!O"X#7'4$,VP2*JR
MU@6'RVN98O\N%"=V70GZV;FBFY;F1(&TB"<;&M,18*4#22QUE[EI'>5'V=3N
M->/K'Z)LC6=WYDJ=^U":-*[P1%NH#(<>*+E7U.>J@DMLGH>!/J1!8<MXJ@FI
M&%P+FXHLS6%:VA*0/00]TMF']=7ONY$7%%Y#:_=NT_Z$L6V9L+"+X_XI+J\_
M##[]KP#DM/-A_\3%OLA)V)36$`8ANWAM)@Z`A(1_$,/(/`+$C+HCR8H=2E;?
M-OF#XOA#R:U6T$FK'3.Z`2&]*9JK=@4*IWW92,_`V2Q[TD%'H0B+20'$@0=V
M:U7J#"JUH"3!P3YLBCP1P:C"2F(4'D6>N74F&=GXOLQ4Q"O`#YH'1T%)9NB&
M<32G;7W/W:$9QRS&(?CF`N649E(LUH8D^]T_:I-CSQ-O#CZY.CZWGHZ6:@9@
M@'0^C1NZ3$T>O-O1(6(+XG&YOS6YI6K+GT</.0L7-$A+!R*Y)M@=SA17T2X=
MM<`[3[R=VH`)%NA"*ZEYQ6793(C)`?>(`8^U&N727X/[O%@]S-Y?UP<GJC(3
M:ZRM5I8)9?>[749"$]PK0FKYY7>:,I]MJ'#["3D2L;3`J9I]/!#"K%F)Y/T8
MVXJ]&^IJ:LP(&]WH3,-O51OFDB&J75#0<QEO19Z$6K(T<JGW./VV:G=*=_H6
MME+*=+4&67^:;@S#-8D%-O20^T^AN=KIAX>T#O94SB7"#(\0)`1RQ))":W,O
M8!?$VRVHV0]J*I6J*9JR<?JUN^!4A]`.->Z63#$)JBX5.0'^)H/9<F@A&XZ#
M+W-Z#&)H&!^^1D]1BLKDKU('R!W<16^LB%5*@)3LF4P`!PH`-&N:&K(@8J5:
MQ<&LAZLTN%7K#ZF*E8EI?C3^9ZH[''S(\D>X'(M8:FVZSR`FN4"C%G58K8F,
M.N2\IGY9&E,:"UI("7E>&LH_ZN6I5>,_QV+\=#4E:E0"B:W01EJ!5/;62->I
MN0$=XIKE3'9`[,(@'6XY,$NJ8:"[)B\QH0-@ZR@^HDAP(\=[4Y<'[C`JN^M4
M`AZ]%:&1QCUEBGR&"21VLB['FI+/D4T&MRL_4S[V@HM,859.)V43(V,E`K4M
MT3"/9Y1:Z<BJ0.=*7_/!B[:N<K1_3RGM`:[T1@74*OK`&2T;[?;$)C&I5;7;
M0/=LXQB(M*X+V[9$>E%D-0#36H0-@-%3NE1:IDU%3I.Y]CC$QZB&N%95X=0.
M<6KMM!IP''XDKDVCHE(01\X#^1:ZW/9\9D$%:7R:4F@Q&0OKA8);2%%C.J=7
M%K<6"Z7"D8=DI@09MW:EVR^'4@>?7P#Z/F+J[!K4D0V8'*55O4<X&N*GILRT
M']_@1,)BL`>1@A]M(1#-'J$$%Z?3IXN%.XHD.C=68HVI*=QT8[,,.%@EDZHN
M',C,5G@Z.&ZJT6QW*D7!+4QM7Y90:I90/J`1-I+29M_)W7XNW?UTHZ#"XWN7
M"XKE.?CTR_.K2]L]ET[,J9,2J<U<`_]$Z[QTN[CQ?B2(-B]L09:VK7GU:YRM
MV>.U5=V%X=&")RJDR(ILS`W=85:M$*^=<D)T?W%_TE]T0-:)P9GX[+!X_4TF
M]@JFS]JT`S6BPI8E1,L$F1STT*A2HEHL;^&Z_3GZB/K:2?]<1A(!A-N).!5F
MT%A#YI-&_+ZYN%A:T\GDGE/CNNP!="`MW5J;]<KZNYVSTX)+H8EVC4MFC*R@
M4NB4TW28,8+I-;;##":H+%2<?<NWRVT`!`A%Q;=LT\Q$NE,3PK`4[O:TJ_6S
MJX<KM33*(X-02^>F&NNII229%?[HU_N9>!X":E11KMB1YN[+>2OB3H'2^AO'
M1H%5:J01NP.Q@D0\O5P\)&,?DGM[C`H1D5J3C!+.N<LJ%__2WC)<1;Q8\*]6
M7?D"`$HIWPX@OHL74L\`'GW'OJ-+98B4GUZ3<K:^X!H.,0PGEPZ@)O[;23VA
MW"RX@!>(F@]T:U$3549,V`YO(5BR7.NAZ56Q::,_<1U`$\PH&ODC$4J[4H<%
MJ'QW>S3V1%$AKIBYH@9Y[$VH=\UD5Y9KKC2U(IZ`J]1B:Q4GZ[6LVW!@4[?!
MWX=*6[9O%ZBR*=5+-7DI)EM*_!:QW\2;AVW?LLUMX:ZB)#-2*4S4O(BFRO8.
MB%\APR,V4-H.7V+VPN!!!4&]@B@%G/HIA\[8A\[NL/\+]8-$PQCL)M%J<P)S
MO6":0IQP1U04'-^A*6%X?&PZS=7`+?T)Z&->+PC*0.O67%F`G)/#`;]MHC#@
MXE'9O]S:`T?G*N/:DK'&"]EZTK9+RCXK8,%IKL@VDL)<2D2UJRB<$[!H)T)_
MIK4^G!)H$PS.0'AQ$/,A[H/78KIK.C53G4-U6Q!/G&XS^39\<EJZ4G_.N@^V
MXZV#*/CTRZN(^L^3=/(B2E+0A$'P('N#)BFY:P*]GP18='H`V4MK;3Z!'H%8
M>D0=8ITNK\/^`%NPP#57L3H*6B:VLY(F7YN:V\UMF9O",%+'-N',;(.@J<%:
M#2;BHX\LG:6;9&AF**CNZ[LU=^6'.%X)'A9L]9QQ5O+^)$"?Y3@Z@Q0'7+)0
MM7<"@%EK_1:'8A'PUFML9F;_M<63N;5KJ9Z=!%%1:O5B./Z21-0",&F5+!:;
M(_2V?OJ[UN,"N1-N2C]X*=$!#B=[\\_M$!_<O6JT2X>/I".ZJ^JD_!'59.%N
M"VI`'`ZHJ\+=O4G<['*2VN*RW-O!2?W"C'^]]]KZ`:T=%"J+-20.N>-9[>:W
M)(;66UX5R`[\8C]&?J&N37CYRJ=N\%Y/.MENBTWK76X=NO>D-SH^#L].+W8\
M&!Q1)!@'HSWI#<^/P\'PO-'<U^L)=DT]2?9Y9E<$$F:EM[[W$J/3[C`A\"9#
M]S&B#[5X)RUD<%;O".0V+7/2U9%CH!;3-IQ76)+&/L#G/_U";^`'J.MIXB0U
MW;1N>++U2-1#8H;4:HY8\Y]3/FI%/Z3`!ZPOQOX[ELJ%7BUB]+=PH^Q:91`N
MF\25;>SCDSQ;4V5?K:&)N>6P$7X<=P&TQ*CHVG.>!"ZM>]6O-4DQD"/`1-RN
M2?/RW,UOV:Z(HNU[<%9D2UZ*=0942C+CBH*O915%!1V`Q&$*23:.W,E>%CYK
MMA&J^=#4/QGW3P)R(@[Z8_CE.,`^*":XMJ,4%KL0'KFUC3SJUHWQ0U4O1J/P
M['QH1W6_'H4G6+3L[,07L[PJ-)TML414L;9DD9Z13X6\/I>^O#;6ZBNN@W++
MHBR);5S*Q>Z\J];1#4JWP7-D51J_C$WMIO@GB(:,T?AU#RO9G9V=4TJ"."WQ
M')X`S"_.S"?#L]Z)D/V#T6%P,#ZTM0<&Z./MGU\8#R"1O8O!.+RX.*7'13>2
M)T_'5BC%@<=GP_!X-)8GN='?D!9P,C`?G/:.3\.3\V-OG<,1#S@TGXQ&/7.4
M%,1_1Z:TUO!DK]YD,P-,&CKU8%F]6A?1+2UGK*DF%#/>E\S='G;=5GR3YW!C
MLP_*O1JX_`?_KX='^1_V?[U6_)>S;V3/LWX.&.GT?6SFV+<^M8OCG-+BVU^]
M8N<(:L;"AMY@=3=\SKK>V5\\YGXAOM(_M>_S*2.QY?=9P:C)2Y'YV$0!-!L6
M<S0**8_KDE)E4VF9SMD?_K)(OZ26?>85?HSO"CLDAJ&V:J`K\=8\Z\>V&CF5
MS3&T%XEOP.AO-BFC3H&$E@P_:B`C$S]O2@MKM=1B!=%75;2%)$%:@)D2KNL5
MC@_W\024AC<2,CEVJJSYAY!9#N#N\CBXM!^['6\^X[A(.'0/K!58U/?\_R:H
M(AOL!]*K`.Z]7_![KUUSJ[0EV?U"NU#:(>Y+%XS5P"B[@,KY._5VR$\EQ4.=
M4'Y8(,@FU1&,>,01V:":F$7X6A69,8Z!\V!HZ3IE>XYUC3FMU2\Y/FUX,1[[
M"[<.7]X?*>,L<Z3DL7C];[?7P:L_WA&^6*,.M78AAEYPKW2GTD.SKG`AEAUC
M(];'44$NT/AI[/?61")EQK4ABU:*<4[`0ITT\+70>&2]TL'!!%!R&YFR65@&
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M`_IM<U@?@C.E8("W3AFJO1[Z"@WLJ_O8UL[)O=;26%MKVN>B2%29P&G5;AM$
M<[4$-P2%P#?5N%!7PJ%0*.UJ:RU4,0:2F*P4NW:.EO_B+=H)0++EMF8M`=2V
M'0U\@W?.U!*2VZ25!35HV8ML/OCT"_NB+B_?4J'"FTP"%SEN%B`*2G*T<.FI
MFU/[ZPX/=3"OM;93_).48Z*Z-B/.>]9J;EX)7S5BH4">;FI5(;1J;=CNJ;*Y
MQ%BJI#3&_YUIPZU]UVU<!BD.&DWB`&P'F"().+;%Q;2X5\?JA=0K/+A2%<>&
M/SA>(7Z7AB9Q"Z,(C&F&BNPZ=<+ZP95$7B5NAB@RMCROT"6AL4YKFAZ/S%;(
M,HZXU@UNPVN#ELX]L$>!0H3(2:X8Z7*_+F:+"*)=#!UOK",+X1O7ZE^ZLOP-
M+@MH%'1-?JJ%<)*ORX"A5(O7+$!K1\+=84%P^GE-Y;S4[D\G:H%J"^=1,>*D
M3&.6-S1TL8R_\,)QVFBD].FOZ\QC0A2T88>P]55OG2$`**_)]^4>+5ZO2R[T
M6`ML&PXPLDV0BAI9LP>\I=9S4VOC_LHF:))QG&)[\RRNLQ9IW7JM_:5V?:^V
M;G(::/'R=C*%P,+S03F_AI6F%+JEC^9@_?9:&(FZU$+R)*!:KSI7!B+#FV%A
M[8520O>:L>N:,TT["YDI6D:VNVG;-FT/^K;%%-K`U9&62K?*?[VVT:_A>,H7
M7&YL8:F:0V?)?-V'UR"XJ]MS(T_&MG`28,FO=@%)=L^]<ALTS0$"I[Y@_3]*
M_U-JRT8`:1OF[`^#"3BX#(/TS%S-RHDYT)%%)F&DTPV;7M)666O;LRP7R_W'
M$`Y]1L#E24ES&<A*2[Y'Z_T?@Y<<0\ON'<J+GSJC]C7MOHZ;>CB-"8A45;)>
M-4OX,LL,5D@%,=U:2R8>@`B%MIS+9I;KU=%42JX[>*V--/T5R%B-ZN?>C,16
M'B**/=Y^.]RS<.09B6,0,)BD9Q,>[[A"3<]$8K1I\O-:[I07Q`/4@I.7<DQD
M*3A8<+E6J`KJ4[F(^!XCB="J2>7%:TZXTG,PB?TU4!PS^%-U[(N@J<&H=>^>
M65#7:EH%J[YK=PPH69Z*OU')<9JP+GTT&JD[U>VYYCY)OFK6YHX=/IRU]263
M&(6Z#-=U*1S?.HKEXO?GU/7S/MK^V?+1?J2*1#"B>P,-R.<I^B.UT6[L]90O
MS=W:=4*-`V\["X95HP6C.'Q;P>2`2+J\2.D6U/N=XJ9TS*3O#_JC1H$&K?!#
MOUS;"C][/QA<=18)HL#02B\Y:NNJ5-CEF0JE4JJ-*NPRE[)%H,J.*E`D,O@,
M**G6<EY&?;%+<*?R0Y4U`*OD71@E=-L,7H/')..R)Y3SX`=CVS05VY.>C$-R
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M9B5<.5\T79MSY3K)Q2P;F:!#1VY"\!RZC3TFF,[I2=@J$MS,FTM$=,`$"NTH
M8]\.W>[QIO!I8J,%60<T[(3JH;*FZ<`3L:4L-23/P##/6M"?/2FF"XOJ[05?
M2UB--ZYQ)Y#UI7X/_"9LURP_[O50&PM]AZQQP:'@'&KQZ/+R6DKYJ#^$_P:U
MD).63$6G^(P$()C@+!2_ZCW"G7(8,8O6'"E6KJ)IO'U)&$'V9>6:K*WAQJIG
M>SU$;*!+N^-P=-S\#-<[CR-JQ>CW?6:=RWLQGV,,R[ZN?U;O/;F+4,HOUBY=
MA^HB:%O$@%LKD7U'LFYC;?!-"YHIA15Y4);-O2:QC3IT7"".J\$8?V+'UIQ^
M/EL"*\P"!>(8SU1**Y7`:1"49TX,QO<M?(!TSXYV2:Z>MT^SWO=6A]^CH)S7
MTZZ[9KI)3&(NYQ2A"QVYR2LYIZJE7Z`.38U[A((TB4FC^\P>CR`-90\!&H&<
MANG$[;7]'B#M9A67:E;2TD6.+[!\VIV91G$7'V,IL&Z_,;VXRUV);7YO5]NE
M".VEJ8TW\+QICI+-JG6`@^/+>D6,L\QZ97%J[(,62\O<O1YM=N\J8NE:Z,5"
MP':>8KB]^X$XXQEK<$@D.QK?C[G.8L=:)BE&96=:$AV0QK:'PNH]VG6)5T3N
M7IZ'^*.0%`JB-D.1A)K9F=L[BVN2B+N"0B<BMJ),>F;MYEB+^GMK;.!`$H6E
M3JC0PTSR!9"73`^*<MHX8!Y3%ID+<:L@$Y0IX1#F[N\\?9&L(R%LW'7,]N.%
MB?YJT^P<9[W+`=W^;F)=T(`#&DX'P=WI$1D;@VT%;Z-%#%!U/]:BZC:G"9T'
M3:#_@8V\:/F6VL/$F._BL;2BJ^>L>Y<;521+LRA$BZ<P]:&__%(L2/?H\9A]
M#P_`$X[\YIZ<&X1?S]WQ84+",`V6'`:V@7U[D_OO:4L'R<.AM3@\:-@&2W"N
M&U#6ZL^([>CL]-3]T#!#=]#$RV2QQ8"=8!,NJ5X]Q48-+/]38`EJV93R1*VT
M.*.``LH<`%';#VTT:5:CX?X996&[F>)>.+XDX>-I@VQ'R5!LM/3%OTCQ<XJ2
M/MFY:LT+6U;5"K-0=LATHB0['C<57$5EY0Y!8A<^W5BT!W,GYH9+>3S$DE/N
M;I!U4@K5EO`-)IO.K6`[E4WGM;-XO>P.W:+]7GC+#<+)6YL$6I'FEG,!$X,5
MS8JG='VD@Y\O2C<NK'O'2*N@?!J&*(:_Y<4'@`"ZZ#8*4B3S)KAC!YW\7LB7
M)FCL7`[M5;N@9K,.:A!YI?Z-,L:6_HX[;[@^4NU6N2`XT,0[]\ZYM*9T>`WU
M<CZL<2_A?K8XWE$^/W)XH0:^W.U^R#U)L0A'I4?0.4TY)EO8@0VWJ"54-X-]
MV`>L)VB:,IKTK[4?5`@S'?**W9CF'8O7@BU:TM(652!'I'/7^$D.=?-T");%
MM0F8;^?`\``FJPG%LVD_#[)0:,R7'<X8$GW[2'7OS5G$E)&<LKU'7<1:I\)K
M4,+N(&R@T3`]N\*LV^=-D]'-WM`J)IXY3=?W6*8T-V/<Y$M>)4L)05'SHH["
M(!$WGNE99Y]O:=T)*Q=W:I(]Y,F44<;KRVF-9K4=T7TD9DTEY^+NS"ESFQNS
MME]M;U;U]XHUT5O>?M-OLWZ"0(3BJBT\55.$(WO3#$1M=0'.U#"7S7G5MNG3
M*#Y+>UK)1?-EN;M4Y*82>X`=UJ:^4N"7%IMHWEOK.O;73LBBG17=V@R&3$AO
MQJ)UV8V*5:V"$6MM*CPU[?+D+7]&<K2;L[7O<]HE,)/=69':5^!=K[PD*6E%
M'\QOU4RID$P$^J=-7@HUFE?3E03,UISAN?I7@'^MF1=^"E7;"DR:67,1-4U/
M2!<-PF$4EB'O8X>XV\\`H=)*+2K!E-SR#`YI,K?:ZB-;66;^(XX%PK<'(1OF
M5?D]OF@8;6^%,J+8]=P>]^CJJJ%G5!K$H&IAF#>"/O(C+,FER;)J]5=@?RL,
M$!B*X8G6-]X\SJU8Y:++USPZ$8F.W-Y$I%O_O,8Z*P5Q?W7L<WR-[),J-&[;
MGMF9)O)I?Z9_#-QWKL<'=R/=<+'3((<A25[<=C.X/W/0;*9A\9U[`JF=R)M!
MG>X-W'9%`IFQ/,,2\0"WN0%1@L_IO<(./-MDW4!"3G/;(>(8)B*42MUPA(U+
M4?-B#DHC&E3WV)Q*3GOU:_"V\+1WM^.=GG9X.>Z]ZS(I/`F&HW`PQ@9')Z/P
M>'S<^Y&%8S:OS+`;)6?>@WA_/@S/1N-@-#H/1^>GTB6H,Y)+M_@DN!B'9R>8
M^#@Z'\`(@R]H5/$8V]IR&H;G)IE*!N7>\/YLC'G:>[W]E?V@?7X2CDZP6\YX
M=!&>GIQL`_?XXB0\/AL$Y\?C<'!\WO-=41-X<0Z2R,$)0/=X&!P&1_N?R/$(
M&W2<4U.;(>;?#L9M/BT_7YZ8E"_V.2*!8\W;![C&%Z7$H^:-.CNA`QT"F/"G
M;)*M8RU04-,`*IK<[\EKA[+WBK8B&5X57-/P+#S!G^'XY`PP^P2M:!V9TA(V
MQ*9'U)C,AG>>DJ.;KBE*Q;+/O%FC>M`_#T;-V!L)D+N+/C;==NYWE";$8C^W
M_>/O*OK.LEUN[>L&`FYX)<!8-5+*\\6X6AWZR[A2!PRK)U?O2VKE?.YPLS$.
M#M1EW<8B;9&;A*(X.%7*R+=UX$0[XH-I;F0KX27DGP,,XAH\)+][5DDF^U99
MP_ED"E%%5!5SV<?$!D]Q3A9F"!ETP%;$%B:L0MEZL?B59CT@@#`T?RX6RT^_
MM,4L?/J[U=KU32[>6N*($H4B?`\/@?NV8BP%*(P47$0!.I0LA"]6[F*])@>`
MK%&J)]>UYF99$(M@BO#=83H2YM.(.9?+Y5(13GUH.]<RX1+'`JOD/E=3/IZ*
MH6B(,+@H:UGCHS5F$6OV;8\5`<!@H"4#L+E+DC[PN@Y&^,\8_SEI2[2:\J[1
M\PJK>`V3OL0@N[=8-QA)QY>\H_&R'"Z)(AB3H:<8"FJZS?NAE4:!Y=PTFZ'B
M>(;1L#J36=%C1$86,[H8UE=KR8@E+ZH&PS@S27Q+(TC7*3(LZ<%N<0C1G)RF
M]VGJ&)1U@4:<I2&\+"7;$KZN>X:6\C:+>&2S+A^]!`OHS'9I9*_7I:6;CL75
MK?S-BB)=L0$-)R?ZQS9&U"I(%=K(ZR;7L7GT'$.L)TK!G?YI6NE9&C^S-V%"
M.%A[WJD[WG5*W:#`U$H7S]R0!ETITW)FL0W.>-H?8&V3BZ:??1K7<B2+G/N/
M=+CNMS_OM#*2ABPVX,5YZ5;B*LK@68ZJU,&G7UY<WC[#`C52-J_UX?<KTKG@
MZ<O;]_CPZ[Q/4QT-+D)C,"-LN<J]^I8V$O/@+E_!Z9P.3@]E('<4CI/T/\/X
MF<*ZL)T\1"[`US"34M'<>)5(8@P%*\_YZG)?I)A[YQ'3-\;TNB75Q@[XK3K$
M6F>]0K;H`'O=*A1'G`8I$Z>71KW<(-L)&XN1MN@+C'JF#I1"]&@<$]%/]18X
MK:%63M1N!)%4]]^8ABUEY7I%+0<H\P"CR"DI2><.@RQ:(@JW8L256[%;3Q9K
M2;4$D/1-3;,+-^X5$2]XR"MQ']F243ES/X?JT\V3&(LZDF#08A9+GJ'7:*'^
MI-;MLV.2!]S&<**`MT@R<G]QP4/#]:5)Q9F45HV)Y$0SM?S8B@OKBKC32L/R
M<1-YD2PHC;RY&PE'5`*X:_[3YB5)%-<H&(%8127E1*@*%=54(",/5UFO/Z$]
M(B51WV;,235Z)=\.[:1MP\?UI>3&$[(]28L2)4R5(1<=E`C9@4^.!F/,PA:1
M[]-_!C?(RHW`I-]PZR__/;A-.7((@,M\HZF1YLU9/.'.;G33Q(K.\K,I8$5Z
M'5HTF0"J'9Z#.IOONTI3Y`J&]*S562:QDZB9=!:RD[+.,ZUI;'T;4V"YQ%AM
MUTN[)C-/LQ`%?8])@*0AL*#@ZDAX$=T>\H80X4UIV["1Q@BS8Q,EW`E#J3K>
M"6+RQ=0N:%N:'R/*9U]@:8VC2=!Z[XQ[G]R'SH!]]5VH<[/M*B`^[8GZA@@E
M2RTWW72W?$8]A3L*<FC44[B5]@HTAJ/I>UZ9]I#CX.,R?4KQNK_[AI"T>(B_
M^>'_<>O3O[`QLQ'HW!X+NA>J.)F63G?YCH;']8&ZU.<>-X$>2C/HD6D*+6VV
M>SQK[\;D0G6D0F&!N"?!*4!V`&`^=]J\F\\$CLFNH78-X^R^=_4UV]W;R4;A
M^.1$?_9>Y]G1]&M.=`3_'XW.PO.+<_TIP/DJBY=FV[;+^F5[PM#7/WP@'</!
ML7]J_-EG'?Z68?X)AS\\.P]/!A?VMW\,`ISBCH"(RL^OB`#G@[/P].S"_D8U
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M/QAP#=J&^^H56@('%^U?`J_JJW0ZKG]IJ%R)6=S&S-'0=%K2\P_:TNCK+[H$
M382]QMBV<*S>9CKR2U/F\D?LI1O<<J58K!?3%E':7E[625UH4%SW!"AY7XZJ
M"=V/R1+[0!O+DW:&:AU7*GMIHPMI6U=_ZJW7)<^!P8MU*\E3DFQ<P:LHF36A
MG1'&7U%S\.`OKXCDM?"-2>4%EJS:U_BB7@FT`4+'+RC."NH92:)28W%PF"FG
MY0F-2-'L4/P:8]!K/%^D`8?V#K7>'*7Z<KO8V;7MR>-M][#V3/MHWJ7L&FW'
M!O]")WJ#R4K-TN*V+`%7,\2B!/&B[2!W16F%',QM<A.4';*Q<-_1."*[*/&4
MZVY4-TJOL1'J8B=OUL)7VU;;*FDTHI?_:]!^+.]:HS6WO/#^*P41A8$T?-D"
MBJ\U5S,2IA[2V7ZT(S$JC]0P".+#+-IT13(Y819-*N@ZD9T61M2:A\H+((YP
MF((-;VO&,G0=R[4&HM\:SM5%[UY$4_9"7$G8;=>#GT-Z/L?@?+@/AW<VQ`&[
M7:.&6'PWMTFX[^SAON6TWBOR5&PC'OM97UON3KLAN`N@6\S!7:^TF[V[C[;#
M]OO%1MZ]SJK;M/+#U[2?-;M)?%V363M6?+7AWID:Q%W'QR?3I"[;[9GUY_\R
M[,#O78;1W0L&\J/VW&Z$[7QI]"4OC3M?^F<;&[LOUY=9(?>Z6G:4T!C=;LE#
M#&K`>@6["=MJ[6(U>Q8`MI&]9\99^JQ=2'5,@6+6:Y!I%G<[WJ\?(9RJT1:[
MCK73YOA3Q[WJ/)<V<7@?2/O#;`/@"T^SEI)'4>LM;@&%8^KT+%T=@&G5LUVS
MP!=Q@U]GF]P+LG:?3?:PW3JX>^P_1%G?^/8;]'156%VG\>8Z54/`H!&>1\,.
MSMK?W+[H;?AR:71FDZ[*HBF#?!8MHT432/8M$F?;C!8%Q7=0&U94*3M0A[O'
MZEQ5X[K2KD?G8>\WOVG;]PT&B0"540M`2Z?2X(W)XN_$X[<F'YVV9.P:5F6.
M7#"9UK54.;P^V+`_&/R7!L"VCFD+#30@"7-M`&%(R)?VHW/96$(6&[C>7=OB
M3NJ=K%U*6?-3$J_XF;>!JY_M=>5\L1$%8!KP'3NWMN)HNZ6Z@Y:V*R.*1[L,
M<(.&F=S]\FS;RDQWRRT[^<G&)5.PD$LW;:>G;11T)[.R5@<_;EC;-*^M"7Y/
M*=$TRPS:>F]VK>/*M0Z+"[/=4N$T:IQKB^P6SJW/&OLB/DRV@8;52P/#.048
M%MVXHP/6H_?#-)<Y*?Q]I'L2?->!>&\PCW[881;N5B!ELY?:8U/K:K``PALD
M^)=AW3GRCB)Z]S-,[?3.M%!VU_/21=4=D>+6=)@/KA^VJ:+DJVF*9=W"MG$/
MM1KVALPSFG=6QG7@1DF^VP89-@8A7U&[X&2+.>Z6+/\R^O?P+^,F:5XY<S<\
M%HQ272R1?%-?966MXDGGJECLZ8(7^<%^_:K^L'8F:71]\KX];0',\'/PRT.`
M1AJA^^VH\>VO]M@U]:)_3>?=__YOOW0)ZH&4/W++$7#6`F6AQ23YU#L-F.PF
M25P`K=99#HTGW3Z2%BU[9_\.)RHV]YL0E5*_0LOKBP'NL'%2+==YFSNR@^T;
M=@T?J$M:N4B@A:8F,7O]13OM^PV#N2[V/J?:YE9JZ81ZT-T*M54"!*X(A_`*
M2PRU=&I]%6WZIF=GZ^W2]J4-'E1KP]JIMM>?VV9NQ?1%42(,:GL'0F+)UW!K
M.JV7\D<QU[D-1.'DJ2P7G=BJ0S-9D,=UY?DHJ98'#N4F!FZ7)L>MN@KK);;N
M6MVENZ-;Z+;-FX:KFHBRI;UNITFY`SVW=U'L0M'O3&)=1AU9@&SNP%NKP3?H
M/BZA1(\R06NK>]=A>]L0DYZU5MZPGF?Q.1J&BPEA6^/&-*?NE0+!;I5]F]RD
M+NXIN[CGXMH)S?6:Y$4AA2>C%7SK!FA]5Y;5#_\'4$L!`A0#%`````@``HAF
M1_51(J*G`0``9Q0``!,``````````````(`!`````%M#;VYT96YT7U1Y<&5S
M72YX;6Q02P$"%`,4````"``"B&9'2'4%[L4````K`@``"P``````````````
M@`'8`0``7W)E;',O+G)E;'-02P$"%`,4````"``"B&9'KY;B"&X!```W$P``
M&@``````````````@`'&`@``>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-0
M2P$"%`,4````"``"B&9'%J/<N(8"``!6"0``$```````````````@`%L!```
M9&]C4')O<',O87!P+GAM;%!+`0(4`Q0````(``*(9D=-5VRM/@$``&D#```1
M``````````````"``2`'``!D;V-0<F]P<R]C;W)E+GAM;%!+`0(4`Q0````(
M``*(9D>97)PC$`8``)PG```3``````````````"``8T(``!X;"]T:&5M92]T
M:&5M93$N>&UL4$L!`A0#%`````@``HAF1U"\U2=5`@``U@H```T`````````
M`````(`!S@X``'AL+W-T>6QE<RYX;6Q02P$"%`,4````"``"B&9'\MW-U4X#
M```0"P``#P``````````````@`%.$0``>&PO=V]R:V)O;VLN>&UL4$L!`A0#
M%`````@``HAF1\#D4A9.`@``]`<``!@``````````````(`!R10``'AL+W=O
M<FMS:&5E=',O<VAE970Q+GAM;%!+`0(4`Q0````(``*(9D<SZJ#S(@0``$<2
M```8``````````````"``4T7``!X;"]W;W)K<VAE971S+W-H965T,BYX;6Q0
M2P$"%`,4````"``"B&9'98LAZ>`!``!J!0``&```````````````@`&E&P``
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!`A0#%`````@``HAF1[E7<>"L
M!```$10``!@``````````````(`!NQT``'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+`0(4`Q0````(``*(9D>J4B/,>@(``$,(```8``````````````"`
M`9TB``!X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"%`,4````"``"B&9'
MO2_?.\\$```6%@``&```````````````@`%-)0``>&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L!`A0#%`````@``HAF1W*(.GJ@`0``L0,``!@`````````
M`````(`!4BH``'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+`0(4`Q0````(
M``*(9D=6W\X5GP$``+$#```8``````````````"``2@L``!X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"%`,4````"``"B&9'#=FO`)\!``"Q`P``&```
M````````````@`']+0``>&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L!`A0#
M%`````@``HAF1R`,EP:A`0``L0,``!D``````````````(`!TB\``'AL+W=O
M<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"%`,4````"``"B&9'@H*\&)\!``"Q
M`P``&0``````````````@`&J,0``>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM
M;%!+`0(4`Q0````(``*(9D=$JPS(H`$``+$#```9``````````````"``8`S
M``!X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L!`A0#%`````@``HAF1TCO
MP2!+`@``@@@``!D``````````````(`!5S4``'AL+W=O<FMS:&5E=',O<VAE
M970Q,RYX;6Q02P$"%`,4````"``"B&9'%_GG>Z,!``"Q`P``&0``````````
M````@`'9-P``>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+`0(4`Q0````(
M``*(9D?T.UAKO0$``'L$```9``````````````"``;,Y``!X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L!`A0#%`````@``HAF1[[2D:2B`0``L0,``!D`
M`````````````(`!ISL``'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M%`,4````"``"B&9'<*<.AZ,!``"Q`P``&0``````````````@`&`/0``>&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+`0(4`Q0````(``*(9D?M]B_Q3`,`
M`(0.```9``````````````"``5H_``!X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L!`A0#%`````@``HAF1YR5?JU2`P``/`X``!D``````````````(`!
MW4(``'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"%`,4````"``"B&9'
M-0G4S)P"``!-"0``&0``````````````@`%F1@``>&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+`0(4`Q0````(``*(9D?`-P6@S0,``.@4```9````````
M``````"``3E)``!X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L!`A0#%```
M``@``HAF1R]$'!"B`@``B@D``!D``````````````(`!/4T``'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"%`,4````"``"B&9''7LUZ1P"``"=!@``
M&0``````````````@`$64```>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M`0(4`Q0````(``*(9D=8Q\,DH`$``+4#```9``````````````"``6E2``!X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L!`A0#%`````@``HAF1[YI<'R$
M`@``:`H``!D``````````````(`!0%0``'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"%`,4````"``"B&9'6^>O4%0"``"Y!P``&0``````````````
M@`'[5@``>&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+`0(4`Q0````(``*(
M9D<).#L9*0(``'H'```9``````````````"``899``!X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L!`A0#%`````@``HAF1Y90GD&\`P``^1(``!D`````
M`````````(`!YEL``'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"%`,4
M````"``"B&9'(L$X9N,!``#/!0``&0``````````````@`'97P``>&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+`0(4`Q0````(``*(9D?4'\%(#`(``/X%
M```9``````````````"``?-A``!X;"]W;W)K<VAE971S+W-H965T,S`N>&UL
M4$L!`A0#%`````@``HAF1P$=(ZJ,3```[1T!`!0``````````````(`!-F0`
K`'AL+W-H87)E9%-T<FEN9W,N>&UL4$L%!@`````G`"<`@PH``/2P````````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950362505904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 15, 2015</div></th>
<th class="th"><div>Apr. 30, 2015</div></th>
<th class="th"><div>Jul. 31, 2009</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jan. 07, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Amount of contract expectation damages</a></td>
<td class="nump">$ 113,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Amount of award</a></td>
<td class="nump">194,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Expert witness fees</a></td>
<td class="nump">$ 81,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_WarrantExpirationDate', window );">Warrant expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 28,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_MaximumAmountOfReimbursement', window );">Maximum amount of reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_AnnualLicensePayment', window );">Annual License Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=pip_GroupThreeMember', window );">Initial Maximum Maintenance Failure Obligation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_PercentageOfAggregatePrincipalAmountRedemption', window );">Percentage of aggregate principal amount of convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_NotesPayableAggregatePrincipalRepaymentAmount', window );">Aggregate principal amount of obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=pip_GroupFourMember', window );">Every 30 days until failure is cured [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_PercentageOfAggregatePrincipalAmountRedemption', window );">Percentage of aggregate principal amount of convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_NotesPayableAggregatePrincipalRepaymentAmount', window );">Aggregate principal amount of obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember', window );">BARDA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_RevenueRecognizedFromContractAudit', window );">Audited BARDA revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_AnnualLicensePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual payment due under the licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_AnnualLicensePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_MaximumAmountOfReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of reimbursement to be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_MaximumAmountOfReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_NotesPayableAggregatePrincipalRepaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial maximum maintenance failure obligation and additional maximum obligation every 30th daily after initial maintenance failure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_NotesPayableAggregatePrincipalRepaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_PercentageOfAggregatePrincipalAmountRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of aggregate principal amount of convertible notes relating to the affected shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_PercentageOfAggregatePrincipalAmountRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_RevenueRecognizedFromContractAudit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue recognized during the period based on auditing of a contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_RevenueRecognizedFromContractAudit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_WarrantExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant, Expiration Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_WarrantExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14557-108349<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14557-108349<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=pip_GroupThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=pip_GroupThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=pip_GroupFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=pip_GroupFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pip_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950498153280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><b>Note 3 - Fair Value Measurements</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">The carrying amounts of our short term financial instruments, which primarily include cash and cash equivalents, accounts receivable (billed and unbilled), and accounts payable approximate their fair values due to their short term maturities. We define fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. We report assets and liabilities that are measured at fair value using a three-level fair value hierarchy that prioritizes the inputs used to measure fair value. This hierarchy maximizes the use of observable inputs and minimizes the use of unobservable inputs.<font style="mso-spacerun: yes;">&#160; </font>The three levels of inputs used to measure fair value are as follows:</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<div class="CursorPointer">
<table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 2%; font-family: 'times new roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="width: 2%; font-family: 'times new roman';">&#149;</td>
<td style="width: 96%; font-family: 'times new roman';"><font style="font-size: 10pt;">Level 1 &#151; Quoted prices in active markets for identical assets or liabilities.</font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5pt;"><font style="font-size: 10pt;">&#160;</font></p>
<div class="CursorPointer">
<table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 2%; font-family: 'times new roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="width: 2%; font-family: 'times new roman';">&#149;</td>
<td style="width: 96%; font-family: 'times new roman';"><font style="font-size: 10pt;">Level 2 &#151; Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data.</font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5pt;"><font style="font-size: 10pt;">&#160;</font></p>
<div class="CursorPointer">
<table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 2%; font-family: 'times new roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="width: 2%; font-family: 'times new roman';">&#149;</td>
<td style="width: 96%; font-family: 'times new roman';"><font style="font-size: 10pt;">Level 3 &#151; Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&#160;&#160;This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs.</font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">An asset's or liability's level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&#160;&#160;At each reporting period, we perform a detailed analysis of our assets and liabilities that are measured at fair value.&#160;All assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments which trade infrequently and therefore have little or no price transparency are classified as Level 3.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">We have segregated our financial assets and liabilities that are measured at fair value into the most appropriate level within the fair value hierarchy based on the inputs used to determine the fair value at the measurement date in the table below.&#160;We have no non-financial assets and liabilities that are measured at fair value on a recurring basis.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"></font><br/></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:</font></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><br/></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;">

<tr style="vertical-align: bottom;">
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="14" nowrap="nowrap"><font style="font-size: 10pt;">As of September 30, 2015</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Level 1</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Level 2</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Level 3</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Balance</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt;"><b>Assets</b></font></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"><font style="font-size: 10pt;">Investment in money market funds<sup>(1)</sup></font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 6,430,038 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 6,430,038 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"><font style="font-size: 10pt;">Total investment in money market funds</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 6,430,038 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 6,430,038 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'Times New Roman';" width="100%"><font style="font-size: 10pt;"><b>Liabilities</b></font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"><font style="font-size: 10pt;">Current portion of derivative instruments related to stock purchase warrants</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 2,355 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 2,355 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"><font style="font-size: 10pt;">Non-current portion of derivative instruments related to stock purchase warrants</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 227,898 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 227,898 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"><font style="font-size: 10pt;">Total derivative instruments related to stock purchase warrants</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 230,253 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 230,253 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt;"><font style="font-size: 10pt;">&#160;</font></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;">

<tr style="vertical-align: bottom;">
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="14" nowrap="nowrap"><font style="font-size: 10pt;">As of December 31, 2014</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Level 1</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Level 2</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Level 3</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Balance</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt;"><b>Assets</b></font></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"><font style="font-size: 10pt;">Investment in money market funds<sup>(1)</sup></font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>6,429,104</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>6,429,104</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"><font style="font-size: 10pt;">Total investment in money market funds</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>6,429,104</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>6,429,104</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'Times New Roman';" width="100%"><font style="font-size: 10pt;"><b>Liabilities</b></font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"><font style="font-size: 10pt;">Current portion of derivative instruments related to stock purchase warrants</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>178,509</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>178,509</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"><font style="font-size: 10pt;">Non-current portion of derivative instruments related to stock purchase warrants</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>629,170</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>629,170</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"><font style="font-size: 10pt;">Total derivative instruments related to stock purchase warrants</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>807,679</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>807,679</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<div class="CursorPointer">
<table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 3%; font-family: 'times new roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="width: 3%; font-family: 'times new roman';"><font style="font-size: 10pt;"><sup>(1)</sup></font></td>
<td style="width: 94%; font-family: 'times new roman';">
<div>Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets.</div>
</td>
</tr>

</table>
</div>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-size: 10pt;"></font><br/></p>
<p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'Times New Roman', Times, serif; margin: 0px; text-align: left;"><font style="font-size: 10pt;">The following table sets forth a summary of changes in the fair value of the Company's Level 3 liabilities for the nine months ended September 30, 2015 and 2014:</font></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap">&#160;</td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap">&#160;</td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman'; width: 20px; text-align: center;" nowrap="nowrap"><font style="font-size: 10pt;">Exercised Stock</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Balance as of</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Unrealized</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman'; width: 20px; text-align: center;" nowrap="nowrap"><font style="font-size: 10pt;">Purchase</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><br/></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Balance&#160;as&#160;of</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">December 31,</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">(Gains)</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman'; width: 20px; text-align: center;" nowrap="nowrap"><font style="font-size: 10pt;">Warrants&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">September 30,</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">Description</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">2014</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">2015</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 20px; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important; text-align: center;" nowrap="nowrap"><font style="font-size: 10pt;">2015&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">2015</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"><font style="font-size: 10pt;">Derivative liabilities related to stock purchase warrants</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>807,679</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>(577,426</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">)</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20px; text-align: right;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>230,253</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>

</table>
</div>
<p style="margin: 0; font-family: 'times new roman';"><font style="font-size: 10pt;">&#160;</font></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Balance as of</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Unrealized</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman'; width: 20px; padding: 0px; text-align: center;" nowrap="nowrap"><font style="font-size: 10pt;">Exercised Stock Purchase</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><br/></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Balance&#160;as&#160;of</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">December 31,</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">(Gains)</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman'; width: 20px; padding: 0px; text-align: center;" nowrap="nowrap"><font style="font-size: 10pt;">Warrants</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">September 30,</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">Description</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">2013</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">2014</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 20px; text-align: center; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;" nowrap="nowrap"><font style="font-size: 10pt;">2014</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">2014</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"><font style="font-size: 10pt;">Derivative liabilities related to stock purchase warrants</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>1,740,235</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>(464,703</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">)</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20px; text-align: right;"><font style="font-size: 10pt;"><font>(423,739</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">)</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>851,793</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>

</table>
</div>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><br/></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">At September 30, 2015 and 2014, derivative liabilities are comprised of warrants to purchase <font>1,775,419</font>&#160;shares of common stock. The warrants are considered to be derivative liabilities due to the presence of net settlement features and/or non-standard anti-dilution provisions, and as a result, are recorded at fair value at each balance sheet date, with changes in fair value recorded in the accompanying unaudited condensed consolidated statements of operations. The fair value of our warrants is determined based on the Black-Scholes option pricing model. Use of the Black-Scholes option pricing model requires the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. Changes in any of the assumptions related to the unobservable inputs identified above may change the stock purchase warrants' fair value; increases in expected term, anticipated volatility and expected dividends generally result in increases in fair value, while decreases in the unobservable inputs generally result in decreases in fair value. Unrealized gains and losses on the fair value adjustments for these derivative instruments are classified in other income (expense) as the change in fair value of derivative instruments in the accompanying unaudited condensed consolidated statements of operations.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<div>
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;" width="100%">

<tr style="vertical-align: bottom;">
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="7" nowrap="nowrap"><font style="font-size: 10pt;">Quantitative Information about Level 3 Fair Value Measurements</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center; font-family: 'times new roman'; padding: 0px; width: 20px;" nowrap="nowrap" colspan="7"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Fair Value at September 30, 2015</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">Valuation Technique</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">Unobservable Inputs</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>230,253</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;Black-Scholes option pricing model</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">Expected term</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">Expected dividends</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">Anticipated volatility</font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Assets Measured at Fair Value on a Nonrecurring Basis</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">The Company measures its long-lived assets, including, property and equipment and goodwill, at fair value on a nonrecurring basis. These assets are recognized at fair value when they are deemed to be other-than-temporarily impaired. During the three months ended September 30, 2015, the Company recorded an impairment charge for property and equipment in the amount of $<font>36,981</font>. These assets were written down to their fair value of $<font>0</font> in conjunction with the sublease of the Company's leased office space (see Note 4 - <em>Commitments and Contingencies - Leases</em>). As of September 30, 2015, the Company had no other assets or liabilities that were measured at fair value on a nonrecurring basis.</font></p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 30<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14172-108612<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6957238&amp;loc=d3e14064-108612<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 21<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13504-108611<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950364043760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financing Transactions (Controlled Equity Offering) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>May. 23, 2014</div></th>
<th class="th"><div>Mar. 25, 2013</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_EquityOfferingAxis=pip_EquityOfferingMember', window );">Equity Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_EquityOfferingLineItems', window );"><strong>Equity Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_MaximumValueOfStockIssuableUnderStockOffering', window );">The maximum value of common stock issuable under the controlled equity offering arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares', window );">Commission owed to sales agent, expressed as percentage of aggregate gross proceeds from each sale of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_RemainingValueOfStockIssuableUnderStockOffering', window );">Amount remaining available under controlled equity offering sale arrangement</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_EquityOfferingAxis=pip_AmendmentToControlledEquityOfferingMember', window );">Amendment to the Controlled Equity Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_EquityOfferingLineItems', window );"><strong>Equity Offering [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_MaximumValueOfStockIssuableUnderStockOffering', window );">The maximum value of common stock issuable under the controlled equity offering arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission owed to sales agent, expressed as percentage of aggregate gross proceeds from each sale of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_CommissionOwedToSalesAgentExpressedAsPercentageOfAggregateGrossProceedsFromEachSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_EquityOfferingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Offering [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_EquityOfferingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_MaximumValueOfStockIssuableUnderStockOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum value of common stock issuable under the controlled equity offering arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_MaximumValueOfStockIssuableUnderStockOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_RemainingValueOfStockIssuableUnderStockOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The remaining value of common stock issuable under the controlled equity offering arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_RemainingValueOfStockIssuableUnderStockOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_EquityOfferingAxis=pip_EquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_EquityOfferingAxis=pip_EquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_EquityOfferingAxis=pip_AmendmentToControlledEquityOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_EquityOfferingAxis=pip_AmendmentToControlledEquityOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950362185664">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Schedule of Warrants) (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 13, 2015</div></th>
<th class="th"><div>Jul. 31, 2009</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Common Shares Underlying Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,922,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_WarrantExpirationDate', window );">Expiration Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 28,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Subsequent Event [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired', window );">Number of common shares expired underlying stock purchase warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pip_ShareBasedCompensationWarrantsPriceRangeOneMember', window );">3.97 [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Common Shares Underlying Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_ClassOfWarrantOrRightIssuanceDate', window );">Issue Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_WarrantExpirationDate', window );">Expiration Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pip_ShareBasedCompensationWarrantsPriceRangeFourMember', window );">1.89 [Member] | Derivative Instrument Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Common Shares Underlying Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2],[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_ClassOfWarrantOrRightIssuanceDate', window );">Issue Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  01,  2010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_WarrantExpirationDate', window );">Expiration Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct.  01,  2015<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pip_ShareBasedCompensationWarrantsPriceRangeFiveMember', window );">1.63 [Member] | Derivative Instrument Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Common Shares Underlying Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">903,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_ClassOfWarrantOrRightIssuanceDate', window );">Issue Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul.  01,  2010<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_WarrantExpirationDate', window );">Expiration Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pip_ShareBasedCompensationWarrantsPriceRangeSixMember', window );">3.50 [Member] | Derivative Instrument Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Common Shares Underlying Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">371,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_ClassOfWarrantOrRightIssuanceDate', window );">Issue Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun.  01,  2011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_WarrantExpirationDate', window );">Expiration Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun.  01,  2016<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pip_ShareBasedCompensationWarrantsPriceRangeSevenMember', window );">1.61 [Member] | Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Common Shares Underlying Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_ClassOfWarrantOrRightIssuanceDate', window );">Issue Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2012<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant, Exercise price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.61<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_WarrantExpirationDate', window );">Expiration Date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar.  01,  2022<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">These warrants to purchase common stock are classified as equity.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Because of the presence of net settlement provisions, these warrants to purchase common stock are classified as derivative liabilities. The fair value of these liabilities (see Note 3 &#8211; Fair Value Measurements ) is remeasured at the end of every reporting period and the change in fair value is reported in the accompanying unaudited condensed consolidated statements of operations as other income (expense).</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Warrants to purchase 500,000 shares of common stock expired on October 13, 2015 without being exercised. The warrants were classified as derivative liabilities.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_ClassOfWarrantOrRightIssuanceDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Issuance Date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_ClassOfWarrantOrRightIssuanceDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of common shares expired underlying stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_WarrantExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant, Expiration Date</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_WarrantExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pip_ShareBasedCompensationWarrantsPriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pip_ShareBasedCompensationWarrantsPriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pip_ShareBasedCompensationWarrantsPriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pip_ShareBasedCompensationWarrantsPriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeByNatureAxis=pip_DerivativeInstrumentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeByNatureAxis=pip_DerivativeInstrumentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pip_ShareBasedCompensationWarrantsPriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pip_ShareBasedCompensationWarrantsPriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pip_ShareBasedCompensationWarrantsPriceRangeSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pip_ShareBasedCompensationWarrantsPriceRangeSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pip_ShareBasedCompensationWarrantsPriceRangeSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=pip_ShareBasedCompensationWarrantsPriceRangeSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950367992976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Transactions (Loan Agreement with GE Capital) (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Mar. 30, 2012</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Debt instrument, carrying amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement', window );">Warrants issued to purchase common stock, in connection with loan agreement</a></td>
<td class="nump">46,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 1.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Issued To Purchase Common Stock In Connection With Loan Agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_WarrantsIssuedToPurchaseCommonStockInConnectionToLoanAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt before deduction of unamortized discount or premium. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, with initial maturities beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 16<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(b),22(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950552323504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><b>Note 2 - Summary of Significant Accounting Policies</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Basis of Presentation</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Our unaudited condensed consolidated financial statements include the accounts of PharmAthene, Inc. and its wholly-owned subsidiary. All significant intercompany transactions and balances have been eliminated in consolidation. Our unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#147;U.S. GAAP&#148;). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The condensed consolidated balance sheet at December 31, 2014 has been derived from audited consolidated financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission (&#147;SEC&#148;). We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included in our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC. We currently operate in <font>one</font> business segment.</font></p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Use of Estimates</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period.&#160;Our unaudited condensed consolidated financial statements include significant estimates for our share-based compensation and the value of our financial instruments, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.</font></p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;&#160;</font></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Foreign Currency Translation</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">The functional currency of our wholly-owned foreign subsidiary, PharmAthene UK Limited, is its local currency. Assets and liabilities of our foreign subsidiary are translated into United States dollars based on the exchange rate at the end of the reporting period. Income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. Translation adjustments for subsidiaries that have not been sold, substantially liquidated or otherwise disposed of, are accumulated in other comprehensive loss, a component of stockholders' equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive loss at December 31, 2014. Transaction gains or losses are included in the determination of net income (loss).<br/><br/></font><font style="font-size: 10pt;">In June 2015, we substantially completed the liquidation of PharmAthene UK Limited, which we had acquired in 2008. Prior to substantially liquidating the UK subsidiary, currency fluctuations were recorded as foreign currency translation adjustments, a component of other comprehensive income. As a result of the substantially completed liquidation, we realized an approximate loss of $<font>0.2</font> million in our condensed consolidated statements of operations, which represents the amount of previously recorded foreign currency translation adjustments related to our UK subsidiary.</font></p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Cash and Cash Equivalents</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">Cash and cash equivalents are stated at cost which approximates market value and include investments in money market funds with financial institutions which are stated at market value. The Company maintains cash balances with financial institutions in excess of insured limits. The Company does not anticipate any losses on such cash balances.</p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 9pt;"><font style="font-size: 10pt;"></font>&#160;</p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Significant Customers and Accounts Receivable</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Our primary customers are NIAID, and the Biomedical Advanced Research and Development Authority (&#147;BARDA&#148;). As of September 30, 2015, the Company's unbilled accounts receivable balance was comprised of receivables from NIAID. The Company's receivable balances (both billed and unbilled) as of December 31, 2014 were comprised of receivables from NIAID and BARDA.</font></p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<div>
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Goodwill</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;"><i>&#160;</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Goodwill represents the excess of purchase price over the fair value of net identifiable assets associated with acquisitions. We review the recoverability of goodwill annually at the end of our fiscal year and whenever events or changes in circumstances indicate that it is more likely than not that impairment exists. Recoverability of goodwill is reviewed by comparing our market value (as measured by our stock price multiplied by the number of outstanding shares as of the end of the year) to the net book value of our equity. If our market value exceeds our net book value, no further analysis is required. We completed our annual impairment assessment of goodwill on December 31, 2014 and determined that there was no impairment as of that date.<br/><br/> Changes in our business strategy or adverse changes in market conditions could impact the impairment analyses and require the recognition of an impairment charge equal to the excess of the carrying value over its estimated fair value.</font></p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>&#160;</i></font></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Restructuring Expense</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">As a result of the Realignment Plan, we recorded approximately $<font>2.1</font> million of restructuring expense during the nine months ended September 30, 2015, including approximately $<font>2.0</font> million of related severance expense, and the remainder being&#160;legal and other employee related expenses. <font style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">Additionally, as a result of the September 2, 2015 sublease of a portion of the Company's leased office space, we recorded approximately $<font>0.4</font> million of additional restructuring expense (see Note 4 - <i>Commitments and Contingencies - Leases</i>).</font> </font></p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Financial Instruments</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Our financial instruments, and/or embedded features contained in those instruments, often are classified as derivative liabilities and are recorded at their fair values. The determination of fair value of these instruments and features requires estimates and judgments. Some of our stock purchase warrants are considered to be derivative liabilities due to the presence of net settlement features and/or non-standard anti-dilution provisions; the fair value of our warrants is determined based on the Black-Scholes option pricing model.&#160;&#160;Use of the Black-Scholes option pricing model requires the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. See Note 3 &#150;&#160;<i>Fair Value Measurements</i> for further details.</font></p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Revenue Recognition</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;"><i>&#160;</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">We generate our revenue from different types of contractual arrangements: cost-plus-fee contracts and fixed price contracts.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.5pt;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Revenues on cost-plus-fee contracts are recognized in an amount equal to the costs incurred during the period plus an estimate of the applicable fee earned. The estimate of the applicable fee earned is determined by reference to the contract: if the contract defines the fee in terms of risk-based milestones and specifies the fees to be earned upon the completion of each milestone, then the fee is recognized when the related milestones are earned, as further described below; otherwise, we estimate the fee earned in a given period by using a proportional performance method based on costs incurred during the period as compared to total estimated project costs and application of the resulting fraction to the total project fee specified in the contract.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Under the milestone method of revenue recognition, milestone payments (including milestone payments for fees) contained in research and development arrangements are recognized as revenue when: (i) the milestones are achieved; (ii) no further performance obligations with respect to the milestone exist; (iii) collection is reasonably assured; and (iv) substantive effort was necessary to achieve the milestone.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">A milestone is considered substantive if all of the following conditions are met:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.5pt;"><font style="font-size: 10pt;">&#160;</font></p>
<div class="CursorPointer">
<table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 3%; font-family: 'times new roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="width: 6%; font-family: 'times new roman';">&#149;</td>
<td style="width: 91%; font-family: 'times new roman';"><font style="font-size: 10pt;">it is commensurate with either our performance to meet the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from our performance to achieve the milestone,</font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -16.5pt;"><font style="font-size: 10pt;">&#160;</font></p>
<div class="CursorPointer">
<table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 3%; font-family: 'times new roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="width: 6%; font-family: 'times new roman';">&#149;</td>
<td style="width: 91%; font-family: 'times new roman';"><font style="font-size: 10pt;">it relates solely to past performance, and</font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -16.5pt;"><font style="font-size: 10pt;">&#160;</font></p>
<div class="CursorPointer">
<table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 3%; font-family: 'times new roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="width: 6%; font-family: 'times new roman';">&#149;</td>
<td style="width: 91%; font-family: 'times new roman';"><font style="font-size: 10pt;">the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement.</font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.5pt;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">If a milestone is deemed not to be substantive, the Company recognizes the portion of the milestone payment as revenue that correlates to work already performed using the proportional performance method; the remaining portion of the milestone payment is deferred and recognized as revenue as the Company completes its performance obligations.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.5pt;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Revenue on fixed price contracts (without substantive milestones as described above) is recognized on the percentage-of-completion method. The percentage-of-completion method recognizes income as the contract progresses (generally related to the costs incurred in providing the services required under the contract). The use of the percentage-of-completion method depends on the ability to make reasonable dependable estimates and the fact that circumstances may necessitate frequent revision of estimates does not indicate that the estimates are unreliable for the purpose for which they are used.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.5pt;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">As a result of our revenue recognition policies and the billing provisions contained in our contracts, the timing of customer billings may differ from the timing of recognizing revenue. Amounts invoiced to customers in excess of revenue recognized are reflected on the balance sheet as deferred revenue. Amounts recognized as revenue in excess of amounts billed to customers are reflected on the balance sheet as unbilled accounts receivable.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Upon notice of termination of a contract from the government, all related termination costs are expensed. Revenue is recognized on the termination costs to the extent those costs are allowable and billable under the contract. Because the government may require an audit of incurred costs, revenue is recognized when the Company is reasonably assured of collection.</font></p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.5pt;"><font style="font-size: 10pt;">&#160;</font></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Share-Based Compensation</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">We expense the estimated fair value of share-based awards granted to employees, non-employee directors, and consultants under our stock compensation plans. The fair value of stock options granted to employees and non-employee directors is determined at the grant date using the Black-Scholes option pricing model. The Black-Scholes option pricing model considers, among other factors, the expected life of the award and the expected volatility of our stock price. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the employee's requisite service period.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">The fair value of share-based awards granted to consultants is determined at the grant date using the Black-Scholes option pricing model and re-measured at each quarterly reporting date over their requisite service period. The value of awards that are ultimately expected to vest is recognized as expense on a straight-line basis over their requisite service period.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">The fair value of restricted stock grants is determined based on the closing price of our common stock on the award date and is recognized as expense ratably over the requisite service period.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Share-based compensation expense recognized in the three months and nine months ended September 30, 2015 and 2014 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"></font><br/></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Share-based compensation expense for the three months ended September 30, 2015 and 2014 was:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<div class="CursorPointer"><br/></div>
<div class="CursorPointer"><br/></div>
<div>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
<td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt;"><b>Three months ended September 30,</b></font></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
<td colspan="2" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt;"><b>2015</b></font></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
<td colspan="6" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt;"><b>2014</b></font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td colspan="2" style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td colspan="2" style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"><font style="font-size: 10pt;">Research and development</font></td>
<td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;"><font> 12,034 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"><br/></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;"><font> 52,434 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">General and administrative</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"><font style="font-size: 10pt;"><font> 81,723 </font></font></td>
<td>&#160;</td>
<td></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"><font style="font-size: 10pt;"><font> 228,286 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"><font style="font-size: 10pt;">Total share-based compensation expense</font></td>
<td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"><font style="font-size: 10pt;"><font> 93,757 </font></font></td>
<td>&#160;</td>
<td></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"><font style="font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', serif;"><font> 280,720 </font></font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"><br/></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in;"><br/></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in;">&#160;<br/></p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman', serif;"></font><br/></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify;"><br/></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman', serif;">During the three months ended September 30, 2015, we granted options to purchase&#160;<font>100,000</font>&#160;shares of common stock to non-employee directors and made&#160;no grants of options or shares of restricted stock to employees and consultants.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify;">&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', serif;"></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Share-based compensation expense for the nine months ended September 30, 2015 and 2014 was:</font></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="6" nowrap="nowrap"><font style="font-size: 10pt;"><b>Nine months ended September 30,</b></font></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman'; text-align: center; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;" colspan="2"><font style="font-size: 10pt;">&#160;<strong>2015</strong></font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; font-family: 'Times New Roman'; text-align: center; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;" colspan="2"><font style="font-size: 10pt;">&#160;<strong>2014</strong></font></td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"><font style="font-size: 10pt;">&#160;</font></td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"><font style="font-size: 10pt;">Research and development</font></td>
<td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;"><font> 85,259 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;"><font> 329,655 </font></font></td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">General and administrative</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 395,470 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 843,048 </font></font></td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"><font style="font-size: 13.3333330154419px;">Restructuring benefit</font></td>
<td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"><font style="font-size: 13.3333330154419px;"><font> (53,741 </font></font></td>
<td>)&#160;</td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"><font style="font-size: 13.3333330154419px;"><font>-</font></font></td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">Total share-based compensation expense</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 426,988 </font></font></td>
<td>&#160;</td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font><font style="font-size: 10pt; font-family: 'Times New Roman', serif;">1,172,703</font> </font></font></td>
<td>&#160;</td>
</tr>

</table>
</div>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify;">As a result of the restructuring and termination of employees, during the nine months ended September 30, 2015, we recognized approximately $<font>75,000</font> of share-based compensation expense resulting from our agreement to extend the exercise period of the vested stock options for several of the executives who were terminated. In addition, approximately $<font>129,000</font> of previously recognized share-based compensation expense was reversed for unvested stock options forfeited as a result of the restructuring and termination of employees. The $<font>53,741</font>&#160;net reversal of share-based compensation expense is reflected&#160;<font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">in restructuring benefit in the above table.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">During the nine months ended September 30, 2015, we granted options to purchase <font>112,000</font>&#160;shares of common stock to employees and non-employee directors and granted&#160;<font>117,500</font> shares of restricted stock to employees. During the nine months ended September 30, 2014, we granted options to purchase <font>1,357,755</font>&#160;shares of common stock to employees, non-employee&#160;directors and consultants and made <font>no</font> restricted stock grants. </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"></font><br/></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">At September 30, 2015, we had total unrecognized share-based compensation expense related to unvested awards of approximately $<font>0.8</font>&#160;million net of estimated forfeitures, which we expect to recognize as expense over a weighted-average period of <font>2.2</font>&#160;years.</font></p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><br/></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Income Taxes</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0;"><font style="font-size: 10pt;">We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is &#147;more likely than not&#148; that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense. As of September 30, 2015 and December 31, 2014, we had recognized a full valuation allowance since the likelihood of realization of our tax deferred assets does not meet the more likely than not threshold.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Our income tax expense was $<font>0.02</font>&#160;million and $<font>0.03</font>&#160;million during the three months ended September 30, 2015 and 2014, respectively, and $<font>0.05</font>&#160;million during the nine months ended September 30, 2015 and 2014, relating exclusively to the generation of a deferred tax liability associated with the tax amortization of goodwill, which is included as a component of other long-term liabilities on our condensed consolidated balance sheets. The income tax expense results from the difference between the treatment of goodwill for income tax purposes and for U.S. GAAP.</font></p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Basic and Diluted Net Loss Per Share</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Income (loss) per share:</i> &#160;Basic income (loss) per share is computed by dividing consolidated net income (loss) by the weighted average number of common shares outstanding during the period, excluding unvested restricted stock.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">For periods of net income when the effects are not anti-dilutive, diluted earnings per share is computed by dividing our net income by the weighted average number of shares outstanding and the impact of all potential dilutive common shares, consisting&#160;&#160;primarily of stock options, unvested restricted stock and stock purchase warrants.&#160;The dilutive impact of our potentially dilutive common shares resulting from stock options and stock purchase warrants is determined by applying the treasury stock method.&#160;&#160; For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potentially dilutive common shares is anti-dilutive due to the net losses.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">A total of approximately <font>6.0</font>&#160;million and <font>10.9</font>&#160;million potentially dilutive securities have been excluded in the calculation of diluted net loss per share in the&#160;nine months ended September 30, 2015 and 2014, respectively, because their inclusion would be anti-dilutive.</font></p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><br/></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Recent Accounting Pronouncements</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><br/></p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">In May 2014, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (&#147;ASU No. 2014-09&#148;). ASU No. 2014-09 clarifies the principles for recognizing revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance affects entities that enter into contracts with customers to transfer goods or services, and supersedes prior GAAP guidance, namely Accounting Standards Codification Topic 605 - Revenue Recognition. On July 9, 2015, the FASB voted and approved to defer the effective date of ASU No. 2014-09 by one year. As a result, ASU No. 2014-09 will be effective for fiscal years beginning after December 15, 2017, with early adoption permitted but not prior to the original effective date of annual periods beginning after December 15, 2016. ASU No. 2014-09 is to be applied retrospectively, or on a modified retrospective basis. We are currently evaluating the impact of adopting ASU No. 2014-09 on our consolidated financial statements.</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">In April 2015, the FASB issued ASU No. 2015-03, Interest &#150; Imputation of Interest, or ASU No. 2015-03. To simplify presentation of debt issuance costs, the amendments in this update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this update. The amendments in this update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. We expect that the impact of adoption on our consolidated financial statements will be immaterial.</p>
</div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18861-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18854-107790<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950293503680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 17,389,409<span></span>
</td>
<td class="nump">$ 18,643,351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BilledContractReceivables', window );">Billed accounts receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">110,656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledContractsReceivable', window );">Unbilled accounts receivable</a></td>
<td class="nump">$ 659,663<span></span>
</td>
<td class="nump">297,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">196,478<span></span>
</td>
<td class="nump">199,194<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">18,245,550<span></span>
</td>
<td class="nump">19,250,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">248,270<span></span>
</td>
<td class="nump">325,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets and deferred costs</a></td>
<td class="nump">53,384<span></span>
</td>
<td class="nump">53,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">2,348,453<span></span>
</td>
<td class="nump">2,348,453<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">20,895,657<span></span>
</td>
<td class="nump">21,978,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">306,172<span></span>
</td>
<td class="nump">391,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_AccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">1,453,123<span></span>
</td>
<td class="nump">$ 1,195,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Accrued restructuring expenses</a></td>
<td class="nump">$ 619,119<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Short-term debt</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 746,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other short-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilities', window );">Current portion of derivative instruments</a></td>
<td class="nump">$ 2,355<span></span>
</td>
<td class="nump">178,509<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,380,769<span></span>
</td>
<td class="nump">$ 2,581,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveNoncurrent', window );">Accrued restructuring expenses - long term</a></td>
<td class="nump">184,018<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">431,015<span></span>
</td>
<td class="nump">$ 493,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative instruments, less current portion</a></td>
<td class="nump">227,898<span></span>
</td>
<td class="nump">629,170<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">3,223,700<span></span>
</td>
<td class="nump">3,704,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 100,000,000 shares authorized; 64,358,834 and 63,603,303 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively</a></td>
<td class="nump">6,436<span></span>
</td>
<td class="nump">6,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">$ 240,151,146<span></span>
</td>
<td class="nump">238,780,633<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(229,528)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (222,485,625)<span></span>
</td>
<td class="num">(220,283,320)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">17,671,957<span></span>
</td>
<td class="nump">18,274,145<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 20,895,657<span></span>
</td>
<td class="nump">$ 21,978,241<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_AccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). Also includes the aggregate carrying amount, as of the balance sheet date, of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed in the balance sheet. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_AccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10A<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32022-110900<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BilledContractReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3(c))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BilledContractReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum as of the balance sheet date of the (a) fair values of all liabilities resulting from contracts that meet the criteria of being accounted for as derivative instruments, and (b) the carrying amounts of the liabilities arising from financial instruments or contracts used to mitigate a specified risk (hedge), and which are expected to be extinguished or otherwise disposed of within a year or the normal operating cycle, if longer, net of the effects of master netting arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgesLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13495-108611<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent obligations not separately disclosed in the balance sheet. Noncurrent liabilities are expected to be paid after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section P<br><br><br><br> -Subsection 4<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid after one year or beyond the next operating cycle, if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section P<br><br><br><br> -Paragraph Question 4<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledContractsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3(c)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 912<br><br><br><br> -SubTopic 310<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51666815&amp;loc=d3e55302-109406<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledContractsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950293650192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (2,202,305)<span></span>
</td>
<td class="num">$ (7,325,995)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation', window );">Realization of cumulative translation adjustment</a></td>
<td class="nump">229,192<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">426,988<span></span>
</td>
<td class="nump">$ 1,172,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative instruments</a></td>
<td class="num">(577,426)<span></span>
</td>
<td class="num">(464,703)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">108,798<span></span>
</td>
<td class="nump">113,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">46,310<span></span>
</td>
<td class="nump">48,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Non-cash interest expense</a></td>
<td class="num">(51,820)<span></span>
</td>
<td class="nump">$ 68,130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of property and equipment</a></td>
<td class="nump">36,981<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on the disposal of property and equipment</a></td>
<td class="num">(7,600)<span></span>
</td>
<td class="num">$ (5,393)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Billed accounts receivable</a></td>
<td class="nump">110,656<span></span>
</td>
<td class="nump">1,427,113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInUnbilledReceivables', window );">Unbilled accounts receivable</a></td>
<td class="num">(362,232)<span></span>
</td>
<td class="nump">1,895,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(9,602)<span></span>
</td>
<td class="nump">23,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(85,175)<span></span>
</td>
<td class="num">$ (846,090)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReservePeriodIncreaseDecrease', window );">Accrued restructuring expenses</a></td>
<td class="nump">800,769<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">$ 149,438<span></span>
</td>
<td class="num">$ (773,517)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(284,937)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">$ (1,387,028)<span></span>
</td>
<td class="num">(4,951,585)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(68,277)<span></span>
</td>
<td class="num">(92,269)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from the sale of property and equipment</a></td>
<td class="nump">7,600<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash used in investing activities</a></td>
<td class="num">(60,677)<span></span>
</td>
<td class="num">(84,269)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt', window );">Repayment of debt</a></td>
<td class="num">$ (750,007)<span></span>
</td>
<td class="num">(749,997)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit', window );">Net repayment of revolving credit agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,091,740)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds from exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">683,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, including exercise of stock options, net of offering costs</a></td>
<td class="nump">$ 943,601<span></span>
</td>
<td class="nump">15,341,264<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">193,594<span></span>
</td>
<td class="nump">14,182,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Effects of exchange rates on cash</a></td>
<td class="nump">169<span></span>
</td>
<td class="num">(7,585)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">(Decrease) increase in cash and cash equivalents</a></td>
<td class="num">(1,253,942)<span></span>
</td>
<td class="nump">9,139,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, at beginning of period</a></td>
<td class="nump">18,643,351<span></span>
</td>
<td class="nump">10,480,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, at end of period</a></td>
<td class="nump">17,389,409<span></span>
</td>
<td class="nump">19,620,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
<td class="nump">$ 108,134<span></span>
</td>
<td class="nump">$ 105,916<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income statement impact of the reclassification adjustment for translation gain (loss) realized upon the sale or complete or substantially complete liquidation of an investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Deferred Tax Expense (or Benefit)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510177<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 6.I.7)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 6<br><br><br><br> -Section I<br><br><br><br> -Subsection 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 958<br><br><br><br> -SubTopic 225<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51659069&amp;loc=d3e92212-112881<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Impairment<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51719941&amp;loc=d3e2921-110230<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51824106&amp;loc=d3e2420-110228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of accrued expenses and other operating obligations not separately disclosed in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInUnbilledReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of the amount of revenue for work performed for which billing has not occurred, net of uncollectible accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInUnbilledReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or cash outflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with either short term or long term maturity that is collateralized (backed by pledge, mortgage or other lien in the entity's assets).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph c<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3098-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from other long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 12<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReservePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net total Increase or Decrease in the accrual for restructuring costs during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 5.P.4(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section P<br><br><br><br> -Subsection 3, 4<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReservePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950358818864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Summary of Changes in Fair Value of Level 3 Liabilities) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 807,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Unrealized (Gains)</a></td>
<td class="nump">$ 359,796<span></span>
</td>
<td class="num">$ (560,487)<span></span>
</td>
<td class="nump">577,426<span></span>
</td>
<td class="nump">$ 464,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Ending Balance</a></td>
<td class="nump">230,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230,253<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">807,679<span></span>
</td>
<td class="nump">1,740,235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Unrealized (Gains)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (577,426)<span></span>
</td>
<td class="num">(464,703)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales', window );">Exercised Stock Purchase Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(423,739)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Ending Balance</a></td>
<td class="nump">$ 230,253<span></span>
</td>
<td class="nump">$ 851,793<span></span>
</td>
<td class="nump">$ 230,253<span></span>
</td>
<td class="nump">$ 851,793<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226008-175313<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13495-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950364236608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Schedule of Quantitative Information about Level 3 Fair Value Measurements) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivatives</a></td>
<td class="nump">$ 230,253<span></span>
</td>
<td class="nump">$ 807,679<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226008-175313<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13495-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950503120960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Liquidity and Organization<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Business, Liquidity and Organization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business, Liquidity and Organization</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p><b style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px;">Note 1 &#150; Business, Liquidity and Organization</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">Since&#160;<font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">2001, PharmAthene, Inc. ("we", the "Company") has been a biodefense company engaged in the development of next generation medical counter measures against biological and chemical threats. During this time, we have devoted substantial effort and resources to the development of the prevention and treatment of anthrax infection and nerve agent poisoning.&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">On March 9, 2015, our Board of Directors approved our realignment plan (the &#147;Realignment Plan&#148;) with the goal of preserving and maximizing, for the benefit of our stockholders, the value of any proceeds from our litigation with SIGA Technologies, Inc. (&#147;SIGA&#148;) and our existing biodefense assets. The plan eliminated approximately two-thirds of our workforce and aimed to preserve sufficient cash and cash equivalents to finance our continued operations through a period of time that is expected to extend beyond the adjudication of SIGA's appeal. We intend to maintain sufficient resources and personnel so that we can seek partners, co-developers or acquirers for our biodefense programs and continue to execute under our government contract with the National Institutes of Allergy and Infectious Diseases (&#147;NIAID&#148;). The Company estimates total severance payments to executives and non-executives in connection with the Realignment Plan to amount to approximately $<font>2</font>&#160;million (all of which was expensed&#160;as of September 30, 2015), with substantially all such severance expenses expected to be paid in 2015. Historically, the Company has performed under government contracts and grants and raised funds from investors (including additional debt and equity issued in 2015 and 2014) to sustain our operations. The Company has spent substantial funds in the research, development, clinical and preclinical testing in excess of revenues, to support the Company's product candidates and to market and sell its products. We have incurred losses in each year since inception, and have an accumulated deficit of $222.5&#160;million. If we continue to incur losses and are not able to raise adequate funds to cover those losses, we may be required to cease operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">As of September 30, 2015, our cash balance was $17.4&#160;million, our unbilled accounts receivable balance&#160;was $<font>0.7</font>&#160;million, and our current liabilities were $2.4&#160;million. As of September 30, 2015, we had approximately $<font>3.0</font> million of remaining availability under our controlled equity offering arrangement, although we did not sell any shares of common stock under such facility during the three and nine months ended September 30, 2015 (see Note 6 &#150; <i>Financing Transactions &#150; Controlled Equity Offering</i>). We believe, b<font>ased on the operating cash requirements and capital expenditures expected for 2015,&#160;</font>the Company's cash on hand at September 30, 2015 is adequate to fund operations through at least the end of 2016.&#160;On September 3, 2015, following a payment of $<font>81,347</font>, representing a $<font>75,000</font> final payment fee pursuant to the March 30, 2012 Loan Agreement, $<font>10</font> outstanding principal balance, $<font>208</font> accrued interest, and $<font>6,129</font> legal fees of the lender, we satisfied in full our remaining obligation under our March 2012 Loan Agreement with General Electric Capital Corporation (&#147;GE Capital&#148;), as discussed further in Note 6- <em>Financing Transactions</em>.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">On July 6, 2015, PharmAthene signed a license agreement with ImmunoVaccine for the exclusive use of the DepoVaxTM vaccine platform, to develop an anthrax vaccine utilizing PharmAthene's recombinant protective antigen (&#147;rPA&#148;). ImmunoVaccine is a clinical-stage vaccine development company located in Halifax, Nova Scotia. PharmAthene will reimburse up to $<font>210,000</font> to ImmunoVaccine for their efforts in developing this vaccine. In addition, ImmunoVaccine will receive annual payments of $<font>200,000</font>, and additional payments for the achievement of certain milestones relating to contracting with the U.S. Government as well as achieving certain clinical/regulatory and commercial milestones, and achievement of sales targets. Additionally, ImmunoVaccine will receive a royalty on sales related to the use of DepoVaxTM.<br/> <br/>On September 2, 2015, the Company entered into a sublease agreement with a third party with respect to a portion of its leased office space in Annapolis, Maryland. See Note 4 -&#160;<em>Commitments and Contingencies - Leases</em>.<br/> <br/>On September 10, 2015, NIAID exercised the first option under our September 2014 contract for the development of a next generation lyophilized anthrax vaccine. The option provides additional funding of approximately $<font>2.3</font> million and an extension of the period of performance through September 30, 2016.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">We can offer no assurances that we have correctly estimated the resources or personnel necessary to seek partners, co-developers or acquirers for our biodefense programs or execute under our NIAID contract. If a larger workforce or one with a different skillset is ultimately required to implement our Realignment Plan successfully, we may be unable to maximize the value of the SIGA litigation and our existing biodefense assets.&#160;In addition, in connection with the Realignment Plan, executive officers who have served the Company for many&#160;years have been terminated, and, with the exception of Mr. Richman's continued service on the Board, will no longer be available to guide the Company. We also cannot assure you that we have accurately estimated the cash and cash equivalents necessary to finance our operations until SIGA's appeal has been adjudicated and we have received SIGA's payment, if any. If revenues from our NIAID contract are less than we anticipate, if operating expenses exceed our expectations or cannot be adjusted accordingly, or if we have underestimated the time it will take for us to prevail in SIGA's appeal, or enforce payment of or collect any damages award from SIGA, or if we do not prevail on appeal, then our business, results of operations, financial condition and cash flows will be materially and adversely affected.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">In addition, we may raise additional capital to strengthen our financial position. There can be no assurances that we would be successful in raising additional funds on acceptable terms or at all. Additional sales of common stock may be made at prices that are dilutive to existing stockholders.</p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 272<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950368161680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">64,358,834<span></span>
</td>
<td class="nump">63,603,303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">64,358,834<span></span>
</td>
<td class="nump">63,603,303<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950551769856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrants Outstanding</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;">

<tr style="vertical-align: bottom;">
<td style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Number of Common Shares</font><br/><font style="font-size: 10pt;"> Underlying Warrants As of</font><br/><font style="font-size: 10pt;"> September 30, 2015</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">Issue&#160;Date</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Exercise&#160;Price</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">Expiration&#160;Date</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 100,778 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 8pt;"><sup>(1)</sup></font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;"> March 2007 </font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 3.97 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;"> March 2017 </font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 500,000 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 8pt;"><sup>(2) (3)</sup></font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;"> April 2010 </font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 1.89 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;"> October 2015 </font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 903,996 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 8pt;"><sup>(2)</sup></font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;"> July 2010 </font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 1.63 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;"> January 2017 </font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 371,423 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 8pt;"><sup>(2)</sup></font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;"> June 2011 </font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 3.50 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;"> June 2016 </font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 46,584 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 8pt;"><sup>(1)</sup></font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;"> March 2012 </font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 1.61 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;"> March 2022 </font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 1,922,781 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font>&#160;</td>
</tr>

</table>
</div>
<p><br/></p>
<div class="CursorPointer">
<table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 3%; font-family: 'times new roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="width: 5%; font-family: 'times new roman';"><font style="font-size: 10pt;"><sup>(1)</sup></font></td>
<td style="width: 92%; font-family: 'times new roman';">
<div><font style="font-size: 10pt;">These warrants to purchase common stock are classified as equity.</font></div>
</td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<div class="CursorPointer">
<table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 1722px;">

<tr style="vertical-align: top;">
<td style="width: 3%; font-family: 'times new roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="width: 5%; font-family: 'times new roman';"><font style="font-size: 10pt;"><sup>(2)</sup></font></td>
<td style="width: 92%; font-family: 'times new roman';">
<div><font style="font-size: 10pt;">Because of the presence of net settlement provisions, these warrants to purchase common stock are classified as derivative liabilities. The fair value of these liabilities (see Note 3 &#150; <i>Fair Value Measurements</i> ) is remeasured at the end of every reporting period and the change in fair value is reported in the accompanying unaudited condensed consolidated statements of operations as other income (expense).</font></div>
</td>
</tr>

</table>
<p>&#160;<br/></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="width: 100.0%; mso-cellspacing: 0in; mso-yfti-tbllook: 1184; mso-padding-alt: 0in 0in 0in 0in;">

<tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes; mso-yfti-lastrow: yes;">
<td width="24" valign="top" style="width: .25in; padding: 0in 0in 0in 0in;">
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10pt; color: #ffffff;">&#160; _______</font></p>
</td>
<td width="24" valign="top" style="width: .25in; padding: 0in 0in 0in 0in;">
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><sup><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';">(3)<font style="color: #ffffff;">___________</font></font></sup><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"></font></p>
</td>
<td valign="top" style="padding: 0in 0in 0in 0in;">
<p style="text-align: justify; margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"></font><br/></p>
<div><font style="font-size: 10pt;">Warrants to purchase <font>500,000</font> shares of common stock expired on October 13, 2015 without being exercised. The warrants were classified as derivative liabilities.</font></div>

<p><br/></p>
</td>
</tr>

</table>
</div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 50<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 50<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 28<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950294097200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Nov. 04, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PIP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PHARMATHENE, INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001326190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,451,334<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950293246752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business, Liquidity and Organization (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 03, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Mar. 09, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Business, Liquidity and Organization [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected severance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (222,485,625)<span></span>
</td>
<td class="num">$ (222,485,625)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (220,283,320)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,389,409<span></span>
</td>
<td class="nump">17,389,409<span></span>
</td>
<td class="nump">$ 19,620,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,643,351<span></span>
</td>
<td class="nump">$ 10,480,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_BilledAndUnbilledAccountsReceivableNet', window );">Accounts receivable (billed and unbilled)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Liabilities current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,380,769<span></span>
</td>
<td class="nump">2,380,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,581,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_AdditionalCommonStockAggregateGrossSales', window );">Additional Common Stock Aggregate Gross Sales available under the controlled equity offering arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Short-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 746,146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization and Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_MaximumAmountOfReimbursement', window );">Maximum amount of reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="nump">$ 210,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_AnnualLicensePayment', window );">Annual License Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_ProceedsFromAdditionalFunding', window );">Proceeds from Additional Funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Accrued interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,134<span></span>
</td>
<td class="nump">$ 105,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization and Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Debt termination payment</a></td>
<td class="nump">$ 81,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoanProcessingFee', window );">Final payment fee</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Outstanding principal balance</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Accrued interest paid</a></td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalFees', window );">Legal fees of the lender</a></td>
<td class="nump">$ 6,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_AdditionalCommonStockAggregateGrossSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Common Stock Aggregate Gross Sales available under the controlled equity offering arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_AdditionalCommonStockAggregateGrossSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_AnnualLicensePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual payment due under the licensing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_AnnualLicensePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_BilledAndUnbilledAccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts receivable, billed and unbilled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_BilledAndUnbilledAccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_MaximumAmountOfReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of reimbursement to be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_MaximumAmountOfReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_ProceedsFromAdditionalFunding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of cash inflow from additional funding as per the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_ProceedsFromAdditionalFunding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoanProcessingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses paid for obtaining loans which includes expenses such as application and origination fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoanProcessingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt, after unamortized discount or premium, scheduled to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB Topic 5.P.4(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section P<br><br><br><br> -Subsection 3, 4<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.(a),16(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph 2, 3<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950293565152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Contract revenue</a></td>
<td class="nump">$ 1,155,839<span></span>
</td>
<td class="nump">$ 962,451<span></span>
</td>
<td class="nump">$ 9,374,155<span></span>
</td>
<td class="nump">$ 8,363,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,125,865<span></span>
</td>
<td class="nump">1,728,929<span></span>
</td>
<td class="nump">3,962,019<span></span>
</td>
<td class="nump">7,528,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,231,035<span></span>
</td>
<td class="nump">$ 3,192,427<span></span>
</td>
<td class="nump">5,246,396<span></span>
</td>
<td class="nump">$ 8,289,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expense</a></td>
<td class="nump">422,482<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,519,273<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">35,005<span></span>
</td>
<td class="nump">$ 37,125<span></span>
</td>
<td class="nump">108,798<span></span>
</td>
<td class="nump">$ 113,272<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,814,387<span></span>
</td>
<td class="nump">4,958,481<span></span>
</td>
<td class="nump">11,836,486<span></span>
</td>
<td class="nump">15,931,676<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(1,658,548)<span></span>
</td>
<td class="num">(3,996,030)<span></span>
</td>
<td class="num">(2,462,331)<span></span>
</td>
<td class="num">(7,567,767)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net</a></td>
<td class="num">$ (9,888)<span></span>
</td>
<td class="num">$ (46,930)<span></span>
</td>
<td class="num">(48,492)<span></span>
</td>
<td class="num">$ (173,356)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation', window );">Realization of cumulative translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(229,192)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative instruments</a></td>
<td class="nump">$ 359,796<span></span>
</td>
<td class="num">$ (560,487)<span></span>
</td>
<td class="nump">577,426<span></span>
</td>
<td class="nump">$ 464,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="num">(691)<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="nump">6,594<span></span>
</td>
<td class="num">(1,470)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">349,217<span></span>
</td>
<td class="num">(607,337)<span></span>
</td>
<td class="nump">306,336<span></span>
</td>
<td class="nump">289,877<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Net loss before income taxes</a></td>
<td class="num">(1,309,331)<span></span>
</td>
<td class="num">(4,603,367)<span></span>
</td>
<td class="num">(2,155,995)<span></span>
</td>
<td class="num">(7,277,890)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="num">(15,437)<span></span>
</td>
<td class="num">(25,068)<span></span>
</td>
<td class="num">(46,310)<span></span>
</td>
<td class="num">(48,105)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,324,768)<span></span>
</td>
<td class="num">$ (4,628,435)<span></span>
</td>
<td class="num">$ (2,202,305)<span></span>
</td>
<td class="num">$ (7,325,995)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares used in calculation of basic and diluted net loss per share</a></td>
<td class="nump">64,187,618<span></span>
</td>
<td class="nump">58,952,731<span></span>
</td>
<td class="nump">63,858,500<span></span>
</td>
<td class="nump">55,577,550<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income statement impact of the reclassification adjustment for translation gain (loss) realized upon the sale or complete or substantially complete liquidation of an investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_OtherIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentRealizedUponSaleOrLiquidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period arising from products sold or services provided under the terms of a contract, not elsewhere specified in the taxonomy. May include government contracts, construction contracts, and any other contract related to a particular project or product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Income Tax Expense (or Benefit)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-04.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 5.P.3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 5.P.4(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section P<br><br><br><br> -Subsection 3, 4<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950551695216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financing Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Financing Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Financing Transactions</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><b>Note 6 &#150; Financing Transactions</b><br/></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Controlled Equity Offering</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">On March 25, 2013, we entered into a controlled equity offering sales agreement with a sales agent, and filed with the SEC a prospectus supplement, dated March 25, 2013 to our prospectus dated July 27, 2011, or the 2011 Prospectus, pursuant to which we could offer and sell, from time to time, through the agent, shares of our common stock having an aggregate offering price of up to $<font>15.0</font>&#160;million.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">On May 23, 2014, we entered into an amendment, or the 2014 Amendment, to the controlled equity offering sales agreement with the sales agent, pursuant to which we may offer and sell, from time to time, through the agent, shares of our common stock having an aggregate offering price of up to an additional $<font>15.0</font> million. On that day, we filed a prospectus supplement to the 2011 Prospectus for use in any sales of these additional shares of common stock through July 26, 2014, the date the underlying registration statement (File No. 333-175394) expired. As a result of this expiration, the 2011 Prospectus, as supplemented on March 25, 2013 and May 23, 2014, may no longer be used for the sale of shares of common stock under the controlled equity offering sales agreement, as amended. On May 23, 2014, we also filed a new universal shelf registration statement (File No. 333-196265) containing, among other things, a prospectus, or the 2014 Prospectus, for use in sales of the common stock under the 2014 Amendment. This registration statement was declared effective on May 30, 2014. Since the expiration of the 2011 Prospectus, all sales under the controlled equity offering sales agreement, as amended, are being effected under the 2014 Prospectus.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Under the controlled equity offering sales agreement, as amended, the agent may sell shares by any method permitted by law and deemed to be an &#147;at-the-market&#148; offering as defined in Rule 415 promulgated under the Securities Act of 1933, as amended, including sales made directly on NYSE MKT, or any other existing trading market for our common stock or to or through a market maker. Subject to the terms and conditions of that agreement, the agent will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of NYSE MKT, to sell shares from time to time based upon our instructions. We are not obligated to sell any shares under the arrangement. We are obligated to pay the agent a commission of <font>3.0</font>% of the aggregate gross proceeds from each sale of shares under the arrangement.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">As of September 30, 2015, shares having an aggregate offering price of $<font>3.0</font> million remained available under the controlled equity offering sales agreement, as amended. During the three and nine months ended September 30, 2015, we did not sell any shares of our common stock under this arrangement.&#160;The expiration date of the existing universal shelf registration statement is May 29, 2017, three years after it became effective. The controlled equity offering sales agreement, as amended, will expire on the same date, unless amended.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Termination of Loan Agreement with GE Capital</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">On&#160;</font>September 3, 2015, we satisfied in full our remaining obligations under our March 2012 Loan Agreement with GE Capital. The Loan Agreement was scheduled to terminate on September 29, 2015. The Loan Agreement provided for a senior secured debt facility including a $<font>2.5</font>&#160;million term loan and a revolving line of credit of up to $<font>5.0</font>&#160;million based on our outstanding qualified accounts receivable.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">The final payment fee was accrued and expensed over the term of the Loan Agreement, using the effective interest method. Financing costs incurred in connection with this agreement were also amortized over the term of the agreement using the effective interest method.<br/> <br/>The termination of the Loan Agreement released from us our obligations under the Loan Agreement, which were collateralized by a security interest in substantially all of our assets.<br/> <br/>In connection with the Loan Agreement, we issued to GE Capital a warrant to purchase <font>46,584</font> shares of the Company's common stock at an exercise price of $<font>1.61</font>&#160;per share. The warrant, which expires in March 2022, was not affected by the termination. The warrant was exercisable immediately and subject to customary and standard anti-dilution adjustments. The warrant is classified in equity and, as a result, the fair value of the warrant was charged to additional paid-in-capital resulting in a debt discount at the date of issuance. The debt discount was amortized over the term of the Loan Agreement using the effective interest method.</p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950498139696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><b>Note 5 - Stockholders' Equity</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;"><b>&#160;</b></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Long-Term Incentive Plan</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">In 2007, the Company's stockholders approved the 2007 Long-Term Incentive Compensation Plan (the &#147;2007 Plan&#148;) which provides for the granting of incentive and non-qualified stock options, stock appreciation rights, performance units, restricted stock awards and performance bonuses (collectively &#147;awards&#148;) to Company officers and employees. Additionally, the 2007 Plan authorizes the granting of non-qualified stock options and restricted stock awards to Company directors and to independent consultants.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">In 2008, our stockholders approved amendments to the 2007 Plan, increasing from <font>3.5</font>&#160;million shares to <font>4.6</font> million shares the maximum number of shares authorized for issuance under the plan and adding an evergreen provision pursuant to which the number of shares authorized for issuance under the plan would increase automatically in each year, beginning in 2009, in accordance with certain limits set forth in the 2007 Plan. Under the terms of the evergreen provision, the annual increases were to continue through 2015, subject, however, to an aggregate limitation on the number of shares that could be authorized for issuance pursuant to such increases. This aggregate limitation was reached on January 1, 2014, so that the number of shares authorized for issuance under the plan did not automatically increase on January 1, 2015. At September 30, 2015, there are approximately <font>10.3</font>&#160;million shares approved for issuance under the 2007 Plan, of which approximately <font>4.4</font>&#160;million shares are available for grant. The Board of Directors in conjunction with management determines who receives awards, the vesting conditions and the exercise price. Options may have a maximum term of <font>ten</font> years.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Warrants</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;"><i>&#160;</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">At September 30, 2015, there were warrants outstanding to purchase <font>1,922,781</font>&#160;shares of our common stock.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Warrants to purchase <font>2,572,775</font> shares of common stock expired on January 28, 2015 without being exercised. The warrants were classified as equity.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">The warrants outstanding as of September 30, 2015, all of which are exercisable, were as follows:</font></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;">

<tr style="vertical-align: bottom;">
<td style="text-align: center; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Number of Common Shares</font><br/><font style="font-size: 10pt;"> Underlying Warrants As of</font><br/><font style="font-size: 10pt;"> September 30, 2015</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">Issue&#160;Date</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Exercise&#160;Price</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">Expiration&#160;Date</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 100,778 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 8pt;"><sup>(1)</sup></font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;"> March 2007 </font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 3.97 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;"> March 2017 </font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 500,000 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 8pt;"><sup>(2) (3)</sup></font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;"> April 2010 </font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 1.89 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;"> October 2015 </font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 903,996 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 8pt;"><sup>(2)</sup></font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;"> July 2010 </font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 1.63 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;"> January 2017 </font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 371,423 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 8pt;"><sup>(2)</sup></font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;"> June 2011 </font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 3.50 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;"> June 2016 </font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 46,584 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 8pt;"><sup>(1)</sup></font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;"> March 2012 </font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 1.61 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; text-indent: 10pt; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;"> March 2022 </font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 1,922,781 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font>&#160;</td>
</tr>

</table>
</div>
<p><br/></p>
<div class="CursorPointer">
<table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 3%; font-family: 'times new roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="width: 5%; font-family: 'times new roman';"><font style="font-size: 10pt;"><sup>(1)</sup></font></td>
<td style="width: 92%; font-family: 'times new roman';">
<div><font style="font-size: 10pt;">These warrants to purchase common stock are classified as equity.</font></div>
</td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<div class="CursorPointer">
<table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 1722px;">

<tr style="vertical-align: top;">
<td style="width: 3%; font-family: 'times new roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="width: 5%; font-family: 'times new roman';"><font style="font-size: 10pt;"><sup>(2)</sup></font></td>
<td style="width: 92%; font-family: 'times new roman';">
<div><font style="font-size: 10pt;">Because of the presence of net settlement provisions, these warrants to purchase common stock are classified as derivative liabilities. The fair value of these liabilities (see Note 3 &#150; <i>Fair Value Measurements</i> ) is remeasured at the end of every reporting period and the change in fair value is reported in the accompanying unaudited condensed consolidated statements of operations as other income (expense).</font></div>
</td>
</tr>

</table>
<p>&#160;<br/></p>
<table border="0" cellspacing="0" cellpadding="0" width="100%" style="width: 100.0%; mso-cellspacing: 0in; mso-yfti-tbllook: 1184; mso-padding-alt: 0in 0in 0in 0in;">

<tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes; mso-yfti-lastrow: yes;">
<td width="24" valign="top" style="width: .25in; padding: 0in 0in 0in 0in;">
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10pt; color: #ffffff;">&#160; _______</font></p>
</td>
<td width="24" valign="top" style="width: .25in; padding: 0in 0in 0in 0in;">
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><sup><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';">(3)<font style="color: #ffffff;">___________</font></font></sup><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"></font></p>
</td>
<td valign="top" style="padding: 0in 0in 0in 0in;">
<p style="text-align: justify; margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"></font><br/></p>
<div><font style="font-size: 10pt;">Warrants to purchase <font>500,000</font> shares of common stock expired on October 13, 2015 without being exercised. The warrants were classified as derivative liabilities.</font></div>

<p><br/></p>
</td>
</tr>

</table>
</div>
</div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (SAB TOPIC 4.C)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Preferred Stock<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section C<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950361886912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_FairValueMeasurementsLineItems', window );"><strong>Fair Value Measurements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of property and equipment</a></td>
<td class="nump">$ 36,981<span></span>
</td>
<td class="nump">$ 36,981<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet', window );">Fair value of leased assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Derivative Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_FairValueMeasurementsLineItems', window );"><strong>Fair Value Measurements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants to purchase common stock</a></td>
<td class="nump">1,775,419<span></span>
</td>
<td class="nump">1,775,419<span></span>
</td>
<td class="nump">1,775,419<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_FairValueMeasurementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurements [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_FairValueMeasurementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 958<br><br><br><br> -SubTopic 225<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51659069&amp;loc=d3e92212-112881<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Impairment<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515133<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51719941&amp;loc=d3e2921-110230<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51824106&amp;loc=d3e2420-110228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, by major property class, net of accumulated depreciation, subject to or available for lease as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 840<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6454179&amp;loc=d3e41551-112718<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=pip_DerivativeLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=pip_DerivativeLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950293172928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2014 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 09, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expense</a></td>
<td class="nump">$ 422,482<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,519,273<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax', window );">Realization of cumulative translation adjustment included in net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 229,192<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected severance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_ShareBasedCompensationExtensionOfExercisePeriod', window );">Share-based compensation expense, extension of exercise period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_ShareBasedCompensationReversalFromStockOptionForfeitures', window );">Share-based compensation, reversal from stock option forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_ShareBasedCompensationReversalNet', window );">Net reversal of share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options granted | shares</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,000<span></span>
</td>
<td class="nump">1,357,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod', window );">Restricted stock granted | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,500<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized share-based compensation expense related to unvested awards, net of forfeitures</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized share-based compensation expense related to unvested awards expected to be recognized in the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 15,437<span></span>
</td>
<td class="nump">$ 25,068<span></span>
</td>
<td class="nump">$ 46,310<span></span>
</td>
<td class="nump">$ 48,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities excluded from computation of earnings per share | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="nump">10,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember', window );">Facility Closing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Granted in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsGrantedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_ShareBasedCompensationExtensionOfExercisePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of share based compensation expense incurred during the period due to the extension of the exercise period of vested stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_ShareBasedCompensationExtensionOfExercisePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_ShareBasedCompensationReversalFromStockOptionForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reversal of share based compensation expense due to unvested stock options forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_ShareBasedCompensationReversalFromStockOptionForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_ShareBasedCompensationReversalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net reversal amount of share based compensation due to adjustments during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_ShareBasedCompensationReversalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Antidilution<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Diluted Earnings Per Share<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Contingent Stock Agreement<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Income Tax Expense (or Benefit)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e689-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 20<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32211-110900<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e709-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB Topic 5.P.4(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section P<br><br><br><br> -Subsection 3, 4<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 5.P.3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 5.P.4(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section P<br><br><br><br> -Subsection 3, 4<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950494395120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Assets and Liabilities Measured at Fair Value</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><br/></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;">

<tr style="vertical-align: bottom;">
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="14" nowrap="nowrap"><font style="font-size: 10pt;">As of September 30, 2015</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Level 1</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Level 2</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Level 3</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Balance</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt;"><b>Assets</b></font></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"><font style="font-size: 10pt;">Investment in money market funds<sup>(1)</sup></font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 6,430,038 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 6,430,038 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"><font style="font-size: 10pt;">Total investment in money market funds</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 6,430,038 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 6,430,038 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'Times New Roman';" width="100%"><font style="font-size: 10pt;"><b>Liabilities</b></font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"><font style="font-size: 10pt;">Current portion of derivative instruments related to stock purchase warrants</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 2,355 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 2,355 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"><font style="font-size: 10pt;">Non-current portion of derivative instruments related to stock purchase warrants</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 227,898 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 227,898 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"><font style="font-size: 10pt;">Total derivative instruments related to stock purchase warrants</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 230,253 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 230,253 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt;"><font style="font-size: 10pt;">&#160;</font></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;">

<tr style="vertical-align: bottom;">
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="14" nowrap="nowrap"><font style="font-size: 10pt;">As of December 31, 2014</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Level 1</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Level 2</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Level 3</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Balance</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top;" colspan="2"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt;"><b>Assets</b></font></td>
<td style="font-family: 'Times New Roman';"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"><font style="font-size: 10pt;">Investment in money market funds<sup>(1)</sup></font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>6,429,104</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>6,429,104</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"><font style="font-size: 10pt;">Total investment in money market funds</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>6,429,104</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>6,429,104</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: top; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="font-family: 'Times New Roman';" width="100%"><font style="font-size: 10pt;"><b>Liabilities</b></font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"><font style="font-size: 10pt;">Current portion of derivative instruments related to stock purchase warrants</font></td>
<td style="font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>178,509</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>178,509</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"><font style="font-size: 10pt;">Non-current portion of derivative instruments related to stock purchase warrants</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>629,170</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>629,170</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 1pt solid !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"><font style="font-size: 10pt;">Total derivative instruments related to stock purchase warrants</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>807,679</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>807,679</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; border-bottom: #000000 2.80pt double !important; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<div class="CursorPointer">
<table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 3%; font-family: 'times new roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="width: 3%; font-family: 'times new roman';"><font style="font-size: 10pt;"><sup>(1)</sup></font></td>
<td style="width: 94%; font-family: 'times new roman';">
<div>Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets.</div>
</td>
</tr>

</table>
</div>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Changes in Fair Value of Level 3 Liabilities</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap">&#160;</td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap">&#160;</td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap">&#160;</td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman'; width: 20px; text-align: center;" nowrap="nowrap"><font style="font-size: 10pt;">Exercised Stock</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap" colspan="2"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Balance as of</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Unrealized</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman'; width: 20px; text-align: center;" nowrap="nowrap"><font style="font-size: 10pt;">Purchase</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><br/></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Balance&#160;as&#160;of</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">December 31,</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">(Gains)</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman'; width: 20px; text-align: center;" nowrap="nowrap"><font style="font-size: 10pt;">Warrants&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">September 30,</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">Description</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">2014</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">2015</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 20px; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important; text-align: center;" nowrap="nowrap"><font style="font-size: 10pt;">2015&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">2015</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"><font style="font-size: 10pt;">Derivative liabilities related to stock purchase warrants</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>807,679</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>(577,426</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">)</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20px; text-align: right;"><font style="font-size: 10pt;"><font>-</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>230,253</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>

</table>
</div>
<p style="margin: 0; font-family: 'times new roman';"><font style="font-size: 10pt;">&#160;</font></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Balance as of</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Unrealized</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman'; width: 20px; padding: 0px; text-align: center;" nowrap="nowrap"><font style="font-size: 10pt;">Exercised Stock Purchase</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><br/></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Balance&#160;as&#160;of</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: right; font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">December 31,</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">(Gains)</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman'; width: 20px; padding: 0px; text-align: center;" nowrap="nowrap"><font style="font-size: 10pt;">Warrants</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">September 30,</font></td>
<td style="font-family: 'Times New Roman';" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">Description</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">2013</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">2014</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px; width: 20px; text-align: center; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;" nowrap="nowrap"><font style="font-size: 10pt;">2014</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">2014</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;" width="100%"><font style="font-size: 10pt;">Derivative liabilities related to stock purchase warrants</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>1,740,235</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>(464,703</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">)</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; width: 20px; text-align: right;"><font style="font-size: 10pt;"><font>(423,739</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">)</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>851,793</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>

</table>
</div>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock', window );">Schedule of Quantitative Information about Level 3 Fair Value Measurements</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;" width="100%">

<tr style="vertical-align: bottom;">
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="7" nowrap="nowrap"><font style="font-size: 10pt;">Quantitative Information about Level 3 Fair Value Measurements</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center; font-family: 'times new roman'; padding: 0px; width: 20px;" nowrap="nowrap" colspan="7"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="2" nowrap="nowrap"><font style="font-size: 10pt;">Fair Value at September 30, 2015</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">Valuation Technique</font></td>
<td style="font-family: 'times new roman'; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" nowrap="nowrap"><font style="font-size: 10pt;">Unobservable Inputs</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font>230,253</font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;Black-Scholes option pricing model</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">Expected term</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: white;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">Expected dividends</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="white-space: nowrap; padding-right: 5px; padding-left: 5px; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">Anticipated volatility</font></td>
</tr>

</table>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quantitative information about the inputs used in the fair value measurement of liabilities. This disclosure may include, but is not limited to, the fair value of the liability, valuation technique used to measure fair value, the inputs used to measure fair value, the ranges of the inputs, and the weighted averages of the inputs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (bbb)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsLiabilitiesQuantitativeInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19279-110258<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19190-110258<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950364237904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policy)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Basis of Presentation</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Our unaudited condensed consolidated financial statements include the accounts of PharmAthene, Inc. and its wholly-owned subsidiary. All significant intercompany transactions and balances have been eliminated in consolidation. Our unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#147;U.S. GAAP&#148;). In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, which are necessary to present fairly our financial position, results of operations and cash flows. The condensed consolidated balance sheet at December 31, 2014 has been derived from audited consolidated financial statements at that date. The interim results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosure normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to instructions, rules and regulations prescribed by the U.S. Securities and Exchange Commission (&#147;SEC&#148;). We believe that the disclosures provided herein are adequate to make the information presented not misleading when these unaudited condensed consolidated financial statements are read in conjunction with the Consolidated Financial Statements and Notes included in our Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC. We currently operate in <font>one</font> business segment.</font></p>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Use of Estimates</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period.&#160;Our unaudited condensed consolidated financial statements include significant estimates for our share-based compensation and the value of our financial instruments, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.</font></p>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Foreign Currency Translation</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">The functional currency of our wholly-owned foreign subsidiary, PharmAthene UK Limited, is its local currency. Assets and liabilities of our foreign subsidiary are translated into United States dollars based on the exchange rate at the end of the reporting period. Income and expense items are translated at the weighted average exchange rates prevailing during the reporting period. Translation adjustments for subsidiaries that have not been sold, substantially liquidated or otherwise disposed of, are accumulated in other comprehensive loss, a component of stockholders' equity. Foreign currency translation adjustments are the sole component of accumulated other comprehensive loss at December 31, 2014. Transaction gains or losses are included in the determination of net income (loss).<br/><br/></font><font style="font-size: 10pt;">In June 2015, we substantially completed the liquidation of PharmAthene UK Limited, which we had acquired in 2008. Prior to substantially liquidating the UK subsidiary, currency fluctuations were recorded as foreign currency translation adjustments, a component of other comprehensive income. As a result of the substantially completed liquidation, we realized an approximate loss of $<font>0.2</font> million in our condensed consolidated statements of operations, which represents the amount of previously recorded foreign currency translation adjustments related to our UK subsidiary.</font></p>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Cash and Cash Equivalents</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">Cash and cash equivalents are stated at cost which approximates market value and include investments in money market funds with financial institutions which are stated at market value. The Company maintains cash balances with financial institutions in excess of insured limits. The Company does not anticipate any losses on such cash balances.</p>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersPolicyPolicyTextBlock', window );">Significant Customers and Accounts Receivable</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Significant Customers and Accounts Receivable</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Our primary customers are NIAID, and the Biomedical Advanced Research and Development Authority (&#147;BARDA&#148;). As of September 30, 2015, the Company's unbilled accounts receivable balance was comprised of receivables from NIAID. The Company's receivable balances (both billed and unbilled) as of December 31, 2014 were comprised of receivables from NIAID and BARDA.</font></p>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Goodwill</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;"><i>&#160;</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Goodwill represents the excess of purchase price over the fair value of net identifiable assets associated with acquisitions. We review the recoverability of goodwill annually at the end of our fiscal year and whenever events or changes in circumstances indicate that it is more likely than not that impairment exists. Recoverability of goodwill is reviewed by comparing our market value (as measured by our stock price multiplied by the number of outstanding shares as of the end of the year) to the net book value of our equity. If our market value exceeds our net book value, no further analysis is required. We completed our annual impairment assessment of goodwill on December 31, 2014 and determined that there was no impairment as of that date.<br/><br/> Changes in our business strategy or adverse changes in market conditions could impact the impairment analyses and require the recognition of an impairment charge equal to the excess of the carrying value over its estimated fair value.</font></p>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock', window );">Restructuring Expense</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Restructuring Expense</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">As a result of the Realignment Plan, we recorded approximately $<font>2.1</font> million of restructuring expense during the nine months ended September 30, 2015, including approximately $<font>2.0</font> million of related severance expense, and the remainder being&#160;legal and other employee related expenses. <font style="font-size: 10.0pt; font-family: 'Times New Roman',serif; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">Additionally, as a result of the September 2, 2015 sublease of a portion of the Company's leased office space, we recorded approximately $<font>0.4</font> million of additional restructuring expense (see Note 4 - <i>Commitments and Contingencies - Leases</i>).</font> </font></p>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial Instruments</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Financial Instruments</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Our financial instruments, and/or embedded features contained in those instruments, often are classified as derivative liabilities and are recorded at their fair values. The determination of fair value of these instruments and features requires estimates and judgments. Some of our stock purchase warrants are considered to be derivative liabilities due to the presence of net settlement features and/or non-standard anti-dilution provisions; the fair value of our warrants is determined based on the Black-Scholes option pricing model.&#160;&#160;Use of the Black-Scholes option pricing model requires the use of unobservable inputs such as the expected term, anticipated volatility and expected dividends. See Note 3 &#150;&#160;<i>Fair Value Measurements</i> for further details.</font></p>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Revenue Recognition</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;"><i>&#160;</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">We generate our revenue from different types of contractual arrangements: cost-plus-fee contracts and fixed price contracts.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.5pt;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Revenues on cost-plus-fee contracts are recognized in an amount equal to the costs incurred during the period plus an estimate of the applicable fee earned. The estimate of the applicable fee earned is determined by reference to the contract: if the contract defines the fee in terms of risk-based milestones and specifies the fees to be earned upon the completion of each milestone, then the fee is recognized when the related milestones are earned, as further described below; otherwise, we estimate the fee earned in a given period by using a proportional performance method based on costs incurred during the period as compared to total estimated project costs and application of the resulting fraction to the total project fee specified in the contract.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Under the milestone method of revenue recognition, milestone payments (including milestone payments for fees) contained in research and development arrangements are recognized as revenue when: (i) the milestones are achieved; (ii) no further performance obligations with respect to the milestone exist; (iii) collection is reasonably assured; and (iv) substantive effort was necessary to achieve the milestone.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">A milestone is considered substantive if all of the following conditions are met:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.5pt;"><font style="font-size: 10pt;">&#160;</font></p>
<div class="CursorPointer">
<table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 3%; font-family: 'times new roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="width: 6%; font-family: 'times new roman';">&#149;</td>
<td style="width: 91%; font-family: 'times new roman';"><font style="font-size: 10pt;">it is commensurate with either our performance to meet the milestone or the enhancement of the value of the delivered item or items as a result of a specific outcome resulting from our performance to achieve the milestone,</font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -16.5pt;"><font style="font-size: 10pt;">&#160;</font></p>
<div class="CursorPointer">
<table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 3%; font-family: 'times new roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="width: 6%; font-family: 'times new roman';">&#149;</td>
<td style="width: 91%; font-family: 'times new roman';"><font style="font-size: 10pt;">it relates solely to past performance, and</font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 33pt; text-indent: -16.5pt;"><font style="font-size: 10pt;">&#160;</font></p>
<div class="CursorPointer">
<table cellspacing="0" cellpadding="0" style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; border-collapse: collapse; width: 100%;">

<tr style="vertical-align: top;">
<td style="width: 3%; font-family: 'times new roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="width: 6%; font-family: 'times new roman';">&#149;</td>
<td style="width: 91%; font-family: 'times new roman';"><font style="font-size: 10pt;">the value of the milestone is reasonable relative to all the deliverables and payment terms (including other potential milestone consideration) within the arrangement.</font></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.5pt;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">If a milestone is deemed not to be substantive, the Company recognizes the portion of the milestone payment as revenue that correlates to work already performed using the proportional performance method; the remaining portion of the milestone payment is deferred and recognized as revenue as the Company completes its performance obligations.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.5pt;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Revenue on fixed price contracts (without substantive milestones as described above) is recognized on the percentage-of-completion method. The percentage-of-completion method recognizes income as the contract progresses (generally related to the costs incurred in providing the services required under the contract). The use of the percentage-of-completion method depends on the ability to make reasonable dependable estimates and the fact that circumstances may necessitate frequent revision of estimates does not indicate that the estimates are unreliable for the purpose for which they are used.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 16.5pt;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">As a result of our revenue recognition policies and the billing provisions contained in our contracts, the timing of customer billings may differ from the timing of recognizing revenue. Amounts invoiced to customers in excess of revenue recognized are reflected on the balance sheet as deferred revenue. Amounts recognized as revenue in excess of amounts billed to customers are reflected on the balance sheet as unbilled accounts receivable.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Upon notice of termination of a contract from the government, all related termination costs are expensed. Revenue is recognized on the termination costs to the extent those costs are allowable and billable under the contract. Because the government may require an audit of incurred costs, revenue is recognized when the Company is reasonably assured of collection.</font></p>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Share-Based Compensation</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">We expense the estimated fair value of share-based awards granted to employees, non-employee directors, and consultants under our stock compensation plans. The fair value of stock options granted to employees and non-employee directors is determined at the grant date using the Black-Scholes option pricing model. The Black-Scholes option pricing model considers, among other factors, the expected life of the award and the expected volatility of our stock price. The value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the employee's requisite service period.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">The fair value of share-based awards granted to consultants is determined at the grant date using the Black-Scholes option pricing model and re-measured at each quarterly reporting date over their requisite service period. The value of awards that are ultimately expected to vest is recognized as expense on a straight-line basis over their requisite service period.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">The fair value of restricted stock grants is determined based on the closing price of our common stock on the award date and is recognized as expense ratably over the requisite service period.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Share-based compensation expense recognized in the three months and nine months ended September 30, 2015 and 2014 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"></font><br/></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Share-based compensation expense for the three months ended September 30, 2015 and 2014 was:</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<div class="CursorPointer"><br/></div>
<div class="CursorPointer"><br/></div>
<div>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
<td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt;"><b>Three months ended September 30,</b></font></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
<td colspan="2" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt;"><b>2015</b></font></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
<td colspan="6" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt;"><b>2014</b></font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td colspan="2" style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td colspan="2" style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"><font style="font-size: 10pt;">Research and development</font></td>
<td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;"><font> 12,034 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"><br/></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;"><font> 52,434 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">General and administrative</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"><font style="font-size: 10pt;"><font> 81,723 </font></font></td>
<td>&#160;</td>
<td></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"><font style="font-size: 10pt;"><font> 228,286 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"><font style="font-size: 10pt;">Total share-based compensation expense</font></td>
<td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"><font style="font-size: 10pt;"><font> 93,757 </font></font></td>
<td>&#160;</td>
<td></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"><font style="font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', serif;"><font> 280,720 </font></font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"><br/></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in;"><br/></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in;">&#160;<br/></p>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman', serif;"></font><br/></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify;"><br/></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify;"><font style="font-size: 10pt; font-family: 'Times New Roman', serif;">During the three months ended September 30, 2015, we granted options to purchase&#160;<font>100,000</font>&#160;shares of common stock to non-employee directors and made&#160;no grants of options or shares of restricted stock to employees and consultants.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify;">&#160;<font style="font-size: 10pt; font-family: 'Times New Roman', serif;"></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Share-based compensation expense for the nine months ended September 30, 2015 and 2014 was:</font></p>
<div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="6" nowrap="nowrap"><font style="font-size: 10pt;"><b>Nine months ended September 30,</b></font></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman'; text-align: center; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;" colspan="2"><font style="font-size: 10pt;">&#160;<strong>2015</strong></font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; font-family: 'Times New Roman'; text-align: center; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;" colspan="2"><font style="font-size: 10pt;">&#160;<strong>2014</strong></font></td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"><font style="font-size: 10pt;">&#160;</font></td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"><font style="font-size: 10pt;">Research and development</font></td>
<td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;"><font> 85,259 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;"><font> 329,655 </font></font></td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">General and administrative</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 395,470 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 843,048 </font></font></td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"><font style="font-size: 13.3333330154419px;">Restructuring benefit</font></td>
<td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"><font style="font-size: 13.3333330154419px;"><font> (53,741 </font></font></td>
<td>)&#160;</td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"><font style="font-size: 13.3333330154419px;"><font>-</font></font></td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">Total share-based compensation expense</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 426,988 </font></font></td>
<td>&#160;</td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font><font style="font-size: 10pt; font-family: 'Times New Roman', serif;">1,172,703</font> </font></font></td>
<td>&#160;</td>
</tr>

</table>
</div>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify;">As a result of the restructuring and termination of employees, during the nine months ended September 30, 2015, we recognized approximately $<font>75,000</font> of share-based compensation expense resulting from our agreement to extend the exercise period of the vested stock options for several of the executives who were terminated. In addition, approximately $<font>129,000</font> of previously recognized share-based compensation expense was reversed for unvested stock options forfeited as a result of the restructuring and termination of employees. The $<font>53,741</font>&#160;net reversal of share-based compensation expense is reflected&#160;<font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: justify; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">in restructuring benefit in the above table.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">During the nine months ended September 30, 2015, we granted options to purchase <font>112,000</font>&#160;shares of common stock to employees and non-employee directors and granted&#160;<font>117,500</font> shares of restricted stock to employees. During the nine months ended September 30, 2014, we granted options to purchase <font>1,357,755</font>&#160;shares of common stock to employees, non-employee&#160;directors and consultants and made <font>no</font> restricted stock grants. </font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"></font><br/></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">At September 30, 2015, we had total unrecognized share-based compensation expense related to unvested awards of approximately $<font>0.8</font>&#160;million net of estimated forfeitures, which we expect to recognize as expense over a weighted-average period of <font>2.2</font>&#160;years.</font></p>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Income Taxes</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0;"><font style="font-size: 10pt;">We account for income taxes using the asset and liability approach, which requires the recognition of future tax benefits or liabilities on the temporary differences between the financial reporting and tax bases of our assets and liabilities. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized. We also recognize a tax benefit from uncertain tax positions only if it is &#147;more likely than not&#148; that the position is sustainable based on its technical merits. Our policy is to recognize interest and penalties on uncertain tax positions as a component of income tax expense. As of September 30, 2015 and December 31, 2014, we had recognized a full valuation allowance since the likelihood of realization of our tax deferred assets does not meet the more likely than not threshold.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">Our income tax expense was $<font>0.02</font>&#160;million and $<font>0.03</font>&#160;million during the three months ended September 30, 2015 and 2014, respectively, and $<font>0.05</font>&#160;million during the nine months ended September 30, 2015 and 2014, relating exclusively to the generation of a deferred tax liability associated with the tax amortization of goodwill, which is included as a component of other long-term liabilities on our condensed consolidated balance sheets. The income tax expense results from the difference between the treatment of goodwill for income tax purposes and for U.S. GAAP.</font></p>
</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Basic and Diluted Net Loss Per Share</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Income (loss) per share:</i> &#160;Basic income (loss) per share is computed by dividing consolidated net income (loss) by the weighted average number of common shares outstanding during the period, excluding unvested restricted stock.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">For periods of net income when the effects are not anti-dilutive, diluted earnings per share is computed by dividing our net income by the weighted average number of shares outstanding and the impact of all potential dilutive common shares, consisting&#160;&#160;primarily of stock options, unvested restricted stock and stock purchase warrants.&#160;The dilutive impact of our potentially dilutive common shares resulting from stock options and stock purchase warrants is determined by applying the treasury stock method.&#160;&#160; For periods of net loss, diluted loss per share is calculated similarly to basic loss per share because the impact of all potentially dilutive common shares is anti-dilutive due to the net losses.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">A total of approximately <font>6.0</font>&#160;million and <font>10.9</font>&#160;million potentially dilutive securities have been excluded in the calculation of diluted net loss per share in the&#160;nine months ended September 30, 2015 and 2014, respectively, because their inclusion would be anti-dilutive.</font></p>
</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;"><i>Recent Accounting Pronouncements</i></font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><br/></p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">In May 2014, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;) No. 2014-09, Revenue from Contracts with Customers (Topic 606) (&#147;ASU No. 2014-09&#148;). ASU No. 2014-09 clarifies the principles for recognizing revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This guidance affects entities that enter into contracts with customers to transfer goods or services, and supersedes prior GAAP guidance, namely Accounting Standards Codification Topic 605 - Revenue Recognition. On July 9, 2015, the FASB voted and approved to defer the effective date of ASU No. 2014-09 by one year. As a result, ASU No. 2014-09 will be effective for fiscal years beginning after December 15, 2017, with early adoption permitted but not prior to the original effective date of annual periods beginning after December 15, 2016. ASU No. 2014-09 is to be applied retrospectively, or on a modified retrospective basis. We are currently evaluating the impact of adopting ASU No. 2014-09 on our consolidated financial statements.</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">&#160;</p>
<p style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0pt 0px; text-align: justify;">In April 2015, the FASB issued ASU No. 2015-03, Interest &#150; Imputation of Interest, or ASU No. 2015-03. To simplify presentation of debt issuance costs, the amendments in this update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this update. The amendments in this update are effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. We expect that the impact of adoption on our consolidated financial statements will be immaterial.</p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 305<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Financial Reporting Release (FRR)<br><br><br><br> -Number 203<br><br><br><br> -Paragraph 02-03<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 5.P.3,4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section P<br><br><br><br> -Subsection 3, 4<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13279-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 60<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 19<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 954<br><br><br><br> -SubTopic 740<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 17<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for major customers. Major customers are those that the loss of such customers would have a material adverse effect on the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6404-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 18<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6351-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 280<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 42<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e9054-108599<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6327-108592<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18823-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section B<br><br><br><br> -Paragraph Question 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b),(f)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6061-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6143-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6132-108592<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950368193824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-based Compensation Expense</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><font style="font-size: 10pt;">&#160;</font></p>
<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
<td style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;" colspan="6" nowrap="nowrap"><font style="font-size: 10pt;"><b>Nine months ended September 30,</b></font></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';">&#160;</td>
<td style="vertical-align: top; font-family: 'Times New Roman'; text-align: center; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;" colspan="2"><font style="font-size: 10pt;">&#160;<strong>2015</strong></font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; font-family: 'Times New Roman'; text-align: center; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;" colspan="2"><font style="font-size: 10pt;">&#160;<strong>2014</strong></font></td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';" colspan="2"><font style="font-size: 10pt;">&#160;</font></td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"><font style="font-size: 10pt;">Research and development</font></td>
<td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;"><font> 85,259 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;"><font> 329,655 </font></font></td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">General and administrative</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 395,470 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 843,048 </font></font></td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"><font style="font-size: 13.3333330154419px;">Restructuring benefit</font></td>
<td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"><font style="font-size: 13.3333330154419px;"><font> (53,741 </font></font></td>
<td>)&#160;</td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 1pt !important; border-bottom-style: solid !important; background-color: #cceeff;"><font style="font-size: 13.3333330154419px;"><font>-</font></font></td>
<td>&#160;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">Total share-based compensation expense</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font> 426,988 </font></font></td>
<td>&#160;</td>
<td style="font-family: 'times new roman'; padding: 0px; white-space: nowrap; padding-right: 5px; padding-left: 5px;"></td>
<td style="text-align: left; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; padding-right: 10px; white-space: nowrap;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; border-bottom: #000000 2.80pt double !important; padding: 0px; vertical-align: bottom; white-space: nowrap;"><font style="font-size: 10pt;"><font><font style="font-size: 10pt; font-family: 'Times New Roman', serif;">1,172,703</font> </font></font></td>
<td>&#160;</td>
</tr>

</table>
</div>

<div class="CursorPointer">
<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; width: 100%;">

<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
<td colspan="6" nowrap="nowrap" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt;"><b>Three months ended September 30,</b></font></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="font-family: 'Times New Roman';"></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
<td colspan="2" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt;"><b>2015</b></font></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
<td style="font-family: 'times new roman'; padding: 0px;"></td>
<td colspan="6" style="text-align: center; font-family: 'times new roman'; border-bottom: #000000 1pt solid !important; padding: 0px;"><font style="font-size: 10pt;"><b>2014</b></font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td colspan="2" style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"></td>
<td colspan="2" style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
<td style="vertical-align: top; text-align: left; font-family: 'Times New Roman';"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"><font style="font-size: 10pt;">Research and development</font></td>
<td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;"><font> 12,034 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"><br/></td>
<td style="font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;"><font> 52,434 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; background-color: #cceeff;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">General and administrative</font></td>
<td style="font-family: 'times new roman'; padding: 0px;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"><font style="font-size: 10pt;"><font> 81,723 </font></font></td>
<td>&#160;</td>
<td></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"><font style="font-size: 10pt;"><font> 228,286 </font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-width: 1pt !important; border-bottom-style: solid !important; border-bottom-color: #000000 !important;"><font style="font-size: 10pt;">&#160;</font></td>
</tr>
<tr style="vertical-align: bottom; background-color: #cceeff;">
<td style="text-align: left; font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"><font style="font-size: 10pt;">Total share-based compensation expense</font></td>
<td style="font-family: 'times new roman'; padding: 0px; background-color: #cceeff;"><font style="font-size: 10pt;">&#160;</font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"><font style="font-size: 10pt;"><font> 93,757 </font></font></td>
<td>&#160;</td>
<td></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 10px 0px 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"><font style="font-size: 10pt;">$</font></td>
<td style="text-align: right; font-family: 'times new roman'; padding: 0px; vertical-align: bottom; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"><font style="font-size: 10pt;"><font style="font-size: 10pt; font-family: 'Times New Roman', serif;"><font> 280,720 </font></font></font></td>
<td style="text-align: left; font-family: 'times new roman'; padding: 0px 5px; white-space: nowrap; border-bottom-color: #000000 !important; border-bottom-width: 2.8pt !important; border-bottom-style: double !important; background-color: #cceeff;"><br/></td>
</tr>

</table>
</div>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in;"><br/></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in;">&#160;<br/></p>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950551769856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesTableTextBlock', window );">Other Liabilities [Table Text Block]</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<div style="display: block;">
<table border="0" cellspacing="0" cellpadding="0" width="69%" style="width: 69%; border-collapse: collapse; margin-left: 0.1px; margin-right: 0.1px;">

<tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes;">
<td valign="bottom" style="border-style: none none solid; border-bottom-color: black; border-bottom-width: 1pt; padding: 0in;">
<p align="center" style="text-align: center; margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"> Description </font></p>
</td>
<td valign="bottom" style="padding: 0in 0in 1.0pt 0in;">
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"> &#160; </font></p>
</td>
<td colspan="2" valign="bottom" style="border-style: none none solid; border-bottom-color: black; border-bottom-width: 1pt; padding: 0in;">
<p align="center" style="text-align: center; margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"> Present Value at September 30, 2015 </font></p>
</td>
<td valign="bottom" style="padding: 0in 0in 1.0pt 0in;">
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"> &#160; </font></p>
</td>
</tr>
<tr style="mso-yfti-irow: 1;">
<td width="35%" valign="bottom" style="width: 35.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';">Accrued restructuring expenses</font></p>
</td>
<td width="2%" valign="bottom" style="width: 2.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"> &#160; </font></p>
</td>
<td width="1%" valign="bottom" style="width: 1.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"> $ </font></p>
</td>
<td width="30%" valign="bottom" style="width: 30.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<p align="right" style="text-align: right; margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"> <font>244,769</font> </font></p>
</td>
<td width="1%" valign="bottom" style="width: 1.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"> &#160; </font></p>
</td>
</tr>
<tr style="mso-yfti-irow: 2; mso-yfti-lastrow: yes;">
<td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;">
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';">Accrued restructuring expenses - long term</font></p>
</td>
<td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;">
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"> &#160; </font></p>
</td>
<td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;">
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10pt;">$</font></p>
</td>
<td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;">
<p align="right" style="text-align: right; margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"> <font>184,018</font></font></p>
</td>
<td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;">
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"> &#160; </font></p>
</td>
</tr>

</table>
</div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>39
<FILENAME>0001144204-15-063377-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001144204-15-063377-xbrl.zip
M4$L#!!0````(`.*#9D=Y<#;XMK@```E,"``0`!P`<&EP+3(P,34P.3,P+GAM
M;%54"0`#%QP]5A<</59U>`L``00E#@``!#D!``#L7>MSHSJR_[Y5^S^PWJIS
M=JO&$X1X9AY;><R<3>U,DDHRNWOOERD"LJT]&+R`D_C^]5?"&`0&&V21V`GS
MX9R8A_K7K5:KNR4U'__V-/6D!Q1&./`_#<![>2`AWPE<[(\_#>;1T(X<C`=2
M%-N^:WN!CSX-%B@:_.WS'__P\4_#X5F([!BYTOU"NIL@Z9_8C^TQDGX+@_GL
MG70=/*)P>??BYN)6.K/#^\`?#NG+3_>AAX_I?R4"P8^.<12H"C`^#29Q/#L^
M.GI\?'Q/;[\/PO&1(LOP*'UBD+[@8?_W#4_3V_=VA%:/S^.P]FGKB-Q=/4AO
MN#A[EGU./UK>9!_%FQ#[5'!.AN%I#?,C3)X&EF4=)7>S1R-<]2!I%AS]^_NW
M6V>"IO:P3,!%)>`1<MZ/@X<C<H.\"]2A#(809#*)AF/;GF6OC.SH/B&3WJ"O
M:,579GA6P#6;V.'4CB?(1^^=8)J\(5M0'I!.EJ2/E*7C*`%[@T92PN)QO)@1
M/8KP=.91Y,FU28A&GP:D]>&JA?=/D3N0CI;M+-7%"?P8/<42=C\-+I;8K.&*
M5O84\F,<+])KV57LTNLCC$(IP8,*;*SD=';QC\%GF0@9*CJPY(]'Y9=7I(XJ
M:*649BC$@;M&/^FJ^',..VL\O5-LF6EE=2EE?Y-$U"%0:&\=F$12V*(E<K[2
M7QG\O`M^'IC&$!F$\3FQKY]S-E:MY/=*+R'?95YAU6QU1X10U8)0U4,5JMI>
MJ&HW0J5C%Q[FV(7=C-V+`U.L@C7KS+Z3,0U)ZX<FD11V1Q*APO[YU<;A/VUO
MCB[\V3R.OJ$'Y('O:'J/POS>=V1'\Y"(PH^C&^3,PY`XNLN'7D"DN5%"8PHI
MNYS><`F,IYF''1PO,4HN)L\M??7413O.>#M=9'_^G="P0V>R2*1P\H2CP>>U
MY]?E]/&HDNJNL!BA?PW1?^<DP%C48-K0/]O`94:\(,M]]=,V::W2:VTCK55Z
MK=TCK86]UC;26MAK[4MK[>O6S%X%:M,BO9/8.XFBM;:CU-4VK>V=Q-Y)/#RM
M[9W$WDD\$*U]W9K9JP"?X?J7'8:$WJO1@[VR4-BW?0?;W@7IU'!.V2OB*`C_
M]>A>[2IEKXF])K*"WL_UX*:)P5YAWYK"/D]N!_;3=J][+[!!H78?3*^)O2;6
M3=O[M>.H5]A>85]P)]-6W3LG+3_8,7Y`W[!]CST<8Q3UFMAM=G`EZL699T?1
M$LT,SXXW=,;K<BB;6,5>,WO-?!&;2;P'XP!W?U+8G>7-`),W([^T@Y#/>C8'
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MER<4.CA"N708:]16GB(3WB>/=NC>+69H#W3_>0_HY7G\W`"LA)[J;=.>.?RD
M2RZ,5;:E:L&C3E`B%?+%A]GSIY(.5^])([W>OQ:]SSJSU_LMHKK%3[W:OQ*U
MS_KR=6I]8S'D86_OKHM1K.:)A-YAWY"#(.W*1I:T6OXZD+IU;#"_8J-%,+_B
M]?F6D/O0O@_MWV2*<VTD]-F!WEW<C^S`FQXZ?8+A%0V=9T\PO.6AT^<H7L_(
M>?8<Q<$-G#[-T:<YWMIH8--\WP+2H=?VPK[W#MQA^A;XXQB%TW-T'Z_W_SJ?
MKRK756/=^MY]PT-<H5\SZ)7@>8=X*O0N5F:R_L0^/=(2(A<?N`^RI3_7^'Q=
M_0EITXKV\\M_YP37U6B$#K=V(W7\BGSD#F$5?R_0DZFXN^A)=2AK0P7^/"%8
M78KW+J`GSL+`\Y#[VKNW,=,OT.=IQW2Y3O[:NW=/>O+97>?J,WY?GFA$>^!N
MU(7O!%-T&Q-'D[;Q+7"2$+TX^S;@_XW[V/65U7K=V4_=V9^R9AL.XR,?A;9'
M1'?B3K&/HSA,\M5O1WL:2:"W/36VI]>?_=6?0[`_Q';'X=R)Y]3=.YO8X?C0
M*X8UG;)JV.XM3;V7TVO*BVO*WMD48\VF'-R6VQ4;^S/\C+7A=WA"5=L+];DU
MM8_<]C1R.X`!V>O.GNK.(=B=/FK;WZCM$&Q/KS_[JS_[8W^6ZU:`Q`OJ0;B/
MA?6?!'9G*WDR[/=5//MZGBQ\9?8\:UIA9]B^=U]@TJ2=T'K2S%5"K-,%Y"'(
M58+^@L5]W#]OY_=1\HG1^,L#.O3=W2)V0;>A5Q+>.N5*Z;Z09B:ZT$XS$X5Y
MOB3\E^G,"Q8HV2,?TI+#AZV-Q91I$,7$2Z/18OA0TI(:OOL4?.V75YWT2R-!
M=+"[CUIK2277;U!'YCY>*LB/V_-2IT^77\/^C*-`58!Q3)Y8-;2ZQ39.6ZIK
M^1J%R9&>$@47/Q`U*#-*7[R<3\G@C8.UF:0Q+%84U2TRY,Z1'Y"`;S/!M'^2
MTTU-**XWNKK+\+U5>LO35#5=LPW2UM:OYVN=4FQ[1OYLUG)6\39$,QN[:<Q,
MQM]5/$'A212A.#J;AR$9)@GI.WL,!E*JDC=H5-@2.9!HP\E5JIB2BQP\M;WH
MTT`>?`:6KAKFQZ,6%+DA*NL0TV]C;X%H`4O=`6(E&,@I+U-1-4V3<SAM":N\
M4E`T68=*(\+784!,5KR@QP.IV::;1I/L[R7*<&A\`E!44S%DMC?J2;4'I?,)
M!RJ:82@\H!C=N0Q\I]A5!I^(-`A-1E\K2;1`8?+)I#V*WX+`?<2>MR)L<6H(
M5$U5@SGI5;N;J0&9C\^&Y):L9\0XS:4BFY:F:T9Y%&ZDQ6GW%&`9Q-J`+;0<
M)YC3@[S+@U;E68'3S$%9!^R`JJ;2"@FGW8,6@);>#$ER_,%QPCE:S0[1:GI(
MGV.^])<!XS2$@"@=H&<96E'=!2BG<03`TE0:8',`K8P%TB"@W,&<UI($,@1A
MWL$;2+7'U-QV/D7XV,?>IP%I$PVDHR(MFN.[2W-\91K-S20W#873-AJJ#E1F
M\%20J)B(&"THXZ@PFXUPR"1@+<U%ZU2*4*I*@U!]_3MRQRBJ&!]*A9UM-E]I
M6HZM,=E=T598YD:CV3`UV=H9[X8^KC#4S<1HRH;.(-O6P1L@5)CD1C.F9A+Q
MM(!05L1UYTNI,+I-I*%"(`.M7N4W>H*;$578V2;"42T(H-$>4>5G<BM@59C:
M1FJCD!XSJ_19(+8*$]U$9+IB`3;6:87MS([HUAOZ/QI^/-A>,C+C,SL,%V3&
M2KY.G$6C%0:^D1-B0--267O0B&SM0,SP</K'4%&@(<N5(W`[44Y'F5`D(M`;
M$#T+IM/`3^KG7-OA59CL87`3D:S2:AF8IIYSEH]C0%U<?AU\EM_33"W3,]N)
MUZ(MUP'*4#8RUFG>JPP0R.F_2HQEDENP7431G,'5R*FNP:6K4#--J&Z`M:36
M#E(C][D.$M1E"&7(#ZDXW'E]917JE1`J1G4M;<Y\`A5!4]HGKHOIEB#;N[:Q
M>^&?V3,<VQ[S4H:&-\F@DN=`P;G=3I07I,J=FC`-4]8AY`?9:A91.=US8!+%
M@AK8:18AD>5\.O>H35N&E,%T%J()756BOBG=,D:_"/PU"!$>^TMWS%G<A;8?
M><O]8^Y_YE&<9NFN1G?V4\97<\]^<XC5)49.?WZH*):FF(4$AVB,Y;@YMK&/
MW"]VZ).NC!B"YVA$E^HRGCA#`<*3HIJ:KFAL6+^-*C=*SFB!H)05$T)%YD>9
MC-A)X+DHC):5&3)4G($#,'0#6&R&<9U&8PR<H0(P%4,%JM8<`^-Q$;.Q`1%O
ME+"6=]U&D1,?9Z2PGJMMA^\4TRHM2;T6VR%$'$1L[KV7^\9:\P!ALPG<3HEW
M$@&RKC'3<2VA(IX?_GWAP2A_,D/$F=C1-4O7F;EW`ZGVF#C-O6(9*@0<F-;\
MS:MY3/=HNL1,9:`:Y=CY75R&)`>XCD."YN#6PRAME]A`4!BU+2#5FAKS[@+2
MU:RXNGMJ1]BAQXNP-X\9:9:,?.U^J>VX%3)-$]B,4F[!P`?86@=<><:Z*6#`
M"_A?Q*>;D*LG=+_=&%W.Z9ZIJU'R(J/@-7SH<GO!KRMU$NN9FJFQ&LT'3"AS
MH'TG53*G:9IA%+9PB&".,>`/R,]C,EWA&@PES!8D#AF[3%$FUQ`,Y%+T$A@3
MZM`JY!PW@MEX#C%#IHH0$[1T\F1Q,;&>-@],380`#1+PZ4#G@KGE7%4&5!<A
M3TU1]<+J^Q;J?%`-(4JIF,0%-SFA5A61R/#Q36=K:U/`4@Q8Z/,UDBU`\4U9
MVZ*#<S0+">HDCY#M@N*852K"`]DTBNL\.:4&&#B,?U6(`A5V5TL]AJL9W>!*
MQ+[:*)$!$6+.`2`V5#79)?$RP:9XA%ATH%D0Z`8'GCPAE2$28LF'Q/(HD(V4
M*D@VQR3$;`\-33<,W6B!Z8+0)!Y(>1HQA%AGU50M1IM+M)H!$6)[@0$A&_IO
M1/+##Y'MT5#H-QO[5&17?KZPFG>9$*M+/#V5W7FRA3@?4EY37.Q,735DR(DT
M211?!GY0U,=29YM"#+FN6>5MI;64N5`*,?5#H+(K]VU@;D<H9`Z`=&&(44UA
MZ(3,",2;,@VC-3IF?2(,IC0NP/Z<O)(:RL"/3M$H"--UC#O["47?L1^$.%ZL
MC`9QV(JM+/.EWU$\"<@=HOO)VD8V_$Q!\PT)KRQ+8XW8L['R\C(4-#\JAF%:
M\M[(D#28:NDI"09&^9*1*6;^U2%88W:-9CM@0N9CU03RFB9O`7:)XG6_R10R
M"2<+;9!%5"#6!(>0*79H0*4XQC?@J$NA6-63:$65O<T!@*:9L'$*I19,]5Q9
M49UN8W))5]3"XO_NZ1RK>HIL+25%,W6MNW2.53U7MI0?,,ALJ?!EG1KF2*SJ
M2:ZM/!5BL*#6;3K'JIY+6LH4`DM1%:.#=(Y5;?M;BE*E.QR4-MF<JK2&56'N
MVV.!FBQKO)D5J\+$<W27`91&$&H3&5:%B6\O"L4$*C2K(O26>14@5]CY]G)1
M+<TDL[&(O`J0*XQ]>PD-@:Z9FFJ*2:P`N<+0MQ?3$%J6+D-Y]\P*L6\BI&29
M;"J9)[,"Y`J3S:%`N@5EL9D5XAN*L3J6876<6@%RA;'F4"]-EU76*G207`&R
M$%L^U"W0978%R$+LO=E5;@7(0N8!J%H*:)^^V`ZO?$J94R%UV8#P(-(KH'Q4
MFG?:@;)5R.>_I?P**)\!YU0;E6[18A<@]C7!`LH'SSD#%DV%:]SNEF$!Y8/H
M?%U!BW&8(E(LH'S^G'M\*:K!0FJ;8P'E\^7<.JJ8*FR69&FX/PN4SY8WE-&&
M'65,Z-;%CC)0/GG>4)@;$)N<B'?;=07*Q]N;B+YZ3YD*3$,'#!LOOZ<,E`_6
M-^FFZDUEIJ4I!CN_B>!N4QX#E`_C-QZOU5M`:'6(Q)7;?,;$=I(S)K[+G#BY
M08YG1Q$>8:=T`N4F=;-_S`+_UO;05?@-D^G%+:0@0/GD?F,3N'^<\"84]X\3
M(<MJBF(!*RT]\KR,O+P`>=?4-N_0:GLFK(JU^E-LH%SO@'-M&Y:K?0A'_+Q2
M$;(L-S2`KCRO7"J:7V=.S"(?L.CRK\$N(]72Y@`I:@60Q*`:#\B.-:Q<`&+'
M*?"Y4`M9?QQJ)ELW9E_&1;D<A:C`3.BX*)>IX`[:H`IE]87&1?U42_,1)U=G
M%QNGW'6A\*Z6=C^8A+/*N]IZ@*P*<4V&*Y=T#UD]@#[@=80VJ]LJBT'/P4YI
M`JWH2I=+EG!NUU)TBUW5JR;:#I@0KP0`XCFQ>W^;(#M'(T0ZW]V6[BS7+A&R
MU6T+<4ZD0C;^EO:^M4*Z+,GR#TPSXLOD>`Y.R)[?H09,MMS$.L'F@(1L\]5-
M`%O@R5=+$U,Q*M19SHHLYQB%Y!`,G3V(V@S";K"%[(;5H`5W@TUT-D3$"IRC
MY?\O_%7QV_5Z!*!<;X0WBBM5<6B"81?48@)K,CP-P!ZZ%@%[59JAHD8&*-<Q
MX4R3Z(H"E4VH*S#L!%M,%`U,2S,U4S#PM*[_RF)7UO?/."G70^$\5JW+&\7?
M!))8ML0<?E%@(:+NAK%2)>Z<!S%3I:D!0VLRHE/ZW'"%3*1#4]7ETM&'-GBK
MBEE?)U^=*3>4`Q<RNYIRL6IO<R"[,]!-AKQ2\K3H>;$D4Z+IV3;#RL+P0J94
M8G15N-%6MH/7%;."4MP&U(#Q?-RN+%CI8`3@K$'37K=J`8B9:A53M>!&>98`
MK.WTH#4<B;=)OY+DGBY^1#06RB1]XL3X85D?NV+O4,8,3V&9RE2H:<A*<8_*
M#O"Z857,#*Q:&M%!K1M6R0R2;,FZ"TX<$CJ$J/9[-SE;0B9EW538%9[F.';'
M+V26MA2%G>NX\8>!@Y";[):K".>J&>@@%FZ!0P`#0J)B4Q;"0,UH6FY7;#'8
MQ03-NJP7SDKO!*X;1L7,[J9:&#\B&655X88$)\N1>35:?J:`^6Y)SI.8=6M#
M(RII5.OD1B`[XQ>TI*U:EM4=?OK]ZFCU`>L,.W=-H,WN54L0@BI%R!8PU!JK
M5(NB'C@M!$^_E4N>7"\E#L04$"(AA<Z6<MQ*GQNNH/I"4`6*KG(#KK$T7[%/
M7FQN!L74)@(6+-1`V0U<-XP*F:R!"DS%U)1N6/TR&B$GOAI]>7(FMC]&-W:,
MKOSJRO,Y8V)B<G86:X-#!`>"`NU"=,'/0_4S6S(W8HHS#8&B04MEU*L-&!%L
M")F!Z0<*57;Q0307-5][`.5Z3K0B,&Q2J5M63=DR=OMH4$NHE47%FYA:79&A
MM55%-D)=K672U<T<D9A"?K()V*K4+*DF(,3,KK)F@8KR:^L@3CPO<&B1Y^H=
M!N7#CHU+*_W<4IUA^>WW+:5;M4+%KF90=V.OZ20I@#V3;J\SGY<],46.2KMF
MG@.XF**$Y5TU/,BK'ST)0SK)TK#@=)$_DJ:33A[MT+V:)1[/;^3!.+KPE\8_
MYY!C_JRK/@^40DI%+.+\%`5WN\G"$':HW*E?_X/PLR1"'<>R7*H/F_')Q4@*
MF'>-_5GTI:KH5/O:YTNYP*3Z>;<*D[FETYD7+!"Z1>$#=E`UJ<L@R1<A-VDU
MN@N6W\/*[I\%47P9Q/^#"%].,/;9#S>`<@6L1M\&&6K+1"0[;CJ#6MK4&8YM
M<CE]VH\"+]UJ2>:6:])?1+C)SZM1&E/97O)9AB0%<8XCQPNB>8CN"+^G'ANH
MUU3<JA@ZGW_QX@\N?J"O_OK%'=OA[<D)4*"JT>)]Y-^O4A0O//1I,"+M#4?V
M%'L+Z5CZ]0Y/421=HD?I)IC:_J\?!K^,XP]__`-M;T;_I'_<KUYV`B\(CZ4_
M+[^-\4%B&JMHZYV47'DG142-1NG3$9'?L03@>YC\(RRH*K!F3ZO;E-"QY`<A
MZ=;TVH,=8J*/^54/Q<0;&D8SF\:GS'7LH^$D.:.97PS"&0F?HF/)GL?!!XD*
M<VA[>.P?$Z[L,$XO8=]%E(9,H2178KKE=D1:H6WYZ(/T.,$Q2J@R"!^Q&SR2
MU@'Y,PC='%32T/`1W?^.25NT06)W@M_1D+P13Y;W$V$3Y4(2D'ZQI[,/?P8:
M$>OI/*)I*2*YY;Y=^C$CVW<E5M%HOQS=KWKH:,9T&]O5!)@\BZ52UV0]<[OL
MF:D=CC$1B+Q$=(M]!Z5X=#DA0-O:,RU(KCZ6>OO5J(;DXFCFV42BV*?@I3_A
MZ2P(8R("PKH7V'%*.^DQXB^`=](U,7#3DWA"/-MW$HE*WTM_&3RBP3N)7)(&
MU*C9_F+P5VEB1](]0KYD2_?$OJ-1XJHYR_L2\L?VF)IC/WG/S:O=2<%(\@E<
M:9SXSLFVZ2ERL6-[4K(/!H7DMTV-62398QO[44PI>,$X>8;JL#-!T^1'/"'!
M<AR]E\Z3[27D-XZDF*C*.^D1$8@/">F`GNR.YO?T:'5,#*>$1D3N<=(4H1+,
M0X?0BH,JJ/32+*1+Z`E2^DI,::[NDQ8G(=T([]-$R^H1G^YR(>CI0[,`1P$]
MEO^^.!J.J.YU,_9*A(2V?>5+WVD-0\EZ)]')XYU$Y">=!F3>H_(XQR&10Q"2
MOIO-PN"!2)[>3\HJC?U$:D0C?>DO5+`I3M7X<,/<ITM\JSOF_[?WI\UM(TNB
M,/S]1MS_@$=S.MJ.H-A<1<D^[@A9MGLTTVW[6O9TS/NE`P2+%(Y!@(U%LLZO
M?W.I`@H@P$VD"%+59VF1!*JRLG*OK,S7+X$%XEO:ATD`>P=SS$)*(\(-1V1/
M[1_NU/TW?&P`/X?TZ%#FD,/3.'VDM5EC2KZC,`1MX`,,R$%G:QP&4WH!DTPF
M3)PT_<WU;Y?65^'<^D2(B![FC6P)^(@.-H*&0XD?+AUZZ6QB4R)=T_J*U(7H
M$!XLP4<GA/$&*X(/H%[C^^`4J!J,"K46$`/?89F.H!ELV*L1TJY$B@!"'V-#
M0L2D8T>WS##XA]""CO#"F.P(06,Z')3%S<IBQD#803*!`:P96YW(#C`=_&#'
M%C":`,\(;6`<#3A:P$1#\1`@B\"Z[-&_DI&\7H*O(GY^)K*`O6Y:?X)?Y],[
M\/84V!P;+.K`9YR)*P`0@(M\X5E1P```@SN`N4B([]8,!*U/>^L$IY*#X2,(
M9\OF$WSX@+2!B]7V`3`]">TI3Z&0P,L13@(J-0&QS6]-@)9#)E!\$.N@9I3Y
MT>;>K4`4L-<QO$G;!9ZE"">L=Z^E@$@BX)$(0WR13CT?KR^OWVGDP[1QI<0I
MC(H$@1L'IB4L&HM'X.ZI4Z@,:*J31D(H\$^UKP"[#F+0R:@:02]R'@YD3U$0
MTU\Y8OR'TN*D+O)"+!4YH,(]G.&%[1&W@EH#:7%O,[T`UD?9LS:AZ4;,8HJ4
M6-T6"Y67#090$]HP/0X8)3!8MGRARC/JM#A$M+BD?'"PIO6?P(%!B!K#>V#V
M5XA%+0:4@FH8WN7=+MEI1NB$/!I6&S;LX<@:PQM2:KCD`:#@>P&6CY=0BSL[
M[>H+>F7(&D?(QI*R"37#2+^@N_82%Q`E$7$#TEW&D'F20,BC&0*I:S8&2&K=
M4):;;>A*#5@$3(%4E6(]3O4YYM-Y?%W\`,:CS0DY?0S%)@(V0_M!1R&P-)#(
M*'%0W/@C]%HD_1%?A]\%+SL2L'O@)JNG(Q(!I*(!7WA?;62!#Q,QI0H;MOD!
MH+<BM"/Q$4%N98,&H]>`5NVL#2NLD;N_`LS_Z'0ZS?X<23:MZS&)#8W1:6XU
M,0G44`#G`,R8"PP/T$[#1L*VP302P?"]@U0"B`C@5WZ=;(ZI_8#T%PJ2.H0$
MA\X6M'T\+(5_6<&CK/A)LPQMC[@1F?P?[4&S-X=Z?CB1R?^X;Y3R#'A*KW[(
M0;)7:31=XK2:@\4RIY$J72(HX`U/RVB]%["U_^B40->TJA=)=F11*^?`ZC9;
M.;`L)0&)>U"UD2BXLUV/@7G0U`I)F("0(@5#,!X+,F;M+-0""_.`U%`;`SS`
M9$2BQ%(H"R(*Z>!\#AV4L[TC9R&).0:O@68>*4-9D/',1H2/O@&\%]^"((67
M1B68L%Z`IK7(SSS3_4Q<NHO+3L]Z+>W6::0_>I6M57;7_2372OBC45Z26!B"
M/01RIV$-=41CU,4*6+:E51&9`B6_L2IDBX?ZI[."`"%,[D2J)-`4H.VM,,GS
M\HUF@'EO23[$9<@!:R@5$6A;)7ZY*044"=*`!2C:/K!E\/Z9YAJ`?:V-KZAP
M#&@+[HDJE,HG0:>CY[S=Z/;R'-(`Q,PX>L3OYEX8]!O@>^=I%ZU"+YUB#%L^
M2T),PXB5@\36OUQYQ_H]`#E\.0%28D+-S=`NC!YH[5]GL/&..X/9).<7WNVT
MSO,OVYP@3F8C'F,QM^?>.6NT.Q?YMSPQ0;THF#]P`1Z2>$B<C=&Y:.RR'AXG
M:+"0LZ*8-AAZR@W(6)814+)XMEGDF9#UW@-:`Z/#NI*D>!6$H#QY-,WR^^V]
M>D(S_V!M$7KO3A*QG1%BEA9"R1QX2GPGIM6,1UC@!PY,X0`'_%<"0O9,$;\6
MD@!S8.*C`@')[K`KE<?^]72:^,'_`*V@3%/N()@S7H(WY:TD$HH.WHD9//CC
MZQ_@#/+CX(K%:`J2K2-M)C(SI).OG@.+VB.'4P?M9])FP72(VQ&CF1.CK4V&
M"CB3(K?IX>?+G+&?!QNE26JFG0+'3$0ZMQZ?4-$6>7Z%Y/&?8,V/[1\-H),[
MV[IQ`C`+FSD,WH-V`DC=Z1`8&]8RP\7F.:_=FA<,\%`I;MU0AE/(;I/0I;$8
M"34LT$^-X49A(`D0&@*(*S_)!%`T)^0ZK7G86!!HMG;ZMMI_L"91GRBQZ8B0
M[&M0U&BS^P*WSF-U0J8=6_WX,?63OC5OFM9OF6M@HT&!^C>2HY,ND@.KO?LE
M%!,T3X/P0;J8TZD(,7BOS2W!SX,8V7@_,\;*?F@J7Z:+0P]F$?ZL,'@`8^$!
M%18/0DMC4Q07(CD@I7Z2#L/P%]IE[>^<(NHH7M2=)T&"F`0R>(KHAWADZA98
MTK8H@$%.^@-_!>(;-3%YF!9Z%-)<0O^`QD#-".8\\#N&0Y&R+GW?G@6>"^@"
M`?P`&F/4!`"E2=*S3O,BB24?Y@VZ<685</(9\**#!N&I]3OYX451N0P9[=0X
M)*\=_6[84P0:L3-V0U#PP:R@-31<@IN7Q1`4B1;BCO9<D-1["&:W+M7D*`HD
M]@SEE#/.P8MTAD![A/39>*%'W^R6&[)$GS['>"*Y51083>-"TH<F+T`9.W-F
MTMEV%5$AL-[LN_[NE=.?''4B(QV,<(SD)12*B-*H%#FG3A!B(-3+8C<CY9/+
MJ!;L>Q;4\@7ZVT#7Y&5O):05A"51+"9817SD$(,J12FC!Q9Q5!(LQ+TC%Q=+
MD8;O0!"1H.!?XL6*B'1GUYW./"G$8+JYX!(X([A0-+4>='\Y\96_+:.Y(A^E
MQ0\4@]4"LRL$6#-*R.F?%4-AC2RB)L41H/S^-N`=IFCK*"<0<3N`A!ZR:3&$
M$?'S=%@"`E/&>4GJ-[+),>(R4W+PC[!I?7&=6SS[BK3H;,2'T,H)HJA[@Q4`
MT*(7^+B/@$[I;#)&)PF(`QU.<K%L+PJ0E"G6@40LK(<@R1,QAE="WN,\%5<'
MEG.$K(>8-6\(/'_7R\>#M>,D%38F,3=*89$*;J3>DSH>-I-B^$3**E:5Q?'S
M]$[!'0\#6[!,'X=&TPR=D%C00)E7J046\6A`$AHJ+;F((%38&W*L.XIE8"-$
M48OD#8^XXW0!Q(1Y-%(TW8UY`V/[.QM5223C^;B)2*LY3-&PPF=&U5Q!A`=]
M:UPED.+(GMI8%-C&A`3&!PZC`34**(B@YD&&DA.@G<AB)3U#!L"!X?D,(MW(
MAMQ@EX[N?.:NC"S&X+%&O+8A,CK0OHSCDK4&EE2$E&53BK(8'9B7DA,H4I"I
M6&&J=U44`H5Z#")TDJ(VP]PLB.AQ4N(AJY>AJ-`M]T'BX2F+)DB10G#B0KR9
M`Y4!Q4A!L+`P`.G#&B3&8+IN5DI;L1A"DN)Y:H,$L9%8W!0:Y*41%J=&\4BG
M#U(,ZX=M<YOZR\B]PT]:G;4M9[YDJ6EO*=@(PZBB(_.U7CZ*[-I0L>G;RBE#
M`YDRM/J<&8S9#FAW7"XG8$&#EA._A4$4W=AZJ99BQ[>5H>RV-#!7G79!+0=8
MXQ?V+#"[Z;T,K>'?[0S8?BFPW5/LYE()[-G)KYU6(0UKU:D+MV9D<?7T-O6-
MF.0;<%1T?5N86?@YR1?BY_PY[3),U:R%G$#G5HP2O-RZ4HZ93%,E3LBRR#B[
M#I<>E>1^E;='>++<K\<+\$+6D)[W`Z.52OFJM`I<'14]?'-RE8#='7X.*)*H
M`<Q2T@&W?H:2U)]@PC!]EFDW]%G",@1%+\)35+KV+`*(U%^/SC^2KX<B=FZ+
MWV9K+T]'RN=1Q81M'[`=RCRJ.)=')7.%VJW63VKC)"9"M4Q0TS&%H612TS"(
MXV"J;W,\*J&-2M*@;8E'RU\OPO[:DINBI;TM&$Q/Q'(H4K$,.:\MN:6\Q#0Y
MS6H#W9):RN5/Y:'!W0<B\=^<@$#Q@_O0GKTYX7^O0<D8<*!TOL4',H6\O1S%
M[PRUO\2A-O)&]%%\-@YF^8PY3XSC9;F`I4Q?ONI:S+=D=*N,4'.$J#+ZD`QU
M`LP_),7-/)WF'\OG7>H/:B3<V53X8@JB/^$X;;M/F,J^6I56M[EKC]4?1P7A
MLZ7$WIJ4N(3A:R8)GXQ.=SM+V:8?P[KVA[TMRI6M<H0UM)WODQ#<XE$J!1Q'
MB/&XG%F686.).;-LNI50I5JW4_!*.ZO9B0&V"L0KF+WKXPH7_,.2_WMM5>U?
MX:8"&KG;P?(_5D6GOLP0/:!U:>+)EZ8?M%GG_4:G?V'-KW;-I6^PPWU<_>Y6
MN;:E\G3`&XXY8([I=BX:9_W^>BRS>SOND:II=62HK#(^.]%K#>PV!+`#CM^5
M`'LJF'?./9NRR$6_T1NTZJ55ZJ(Z*N24?.0TY"@J+4-]AVC@KW:L0@Q%5YE)
MO6ZCU3O?H]`_(%=E_AZT<ERR@S-U+W)O7LL!J9.5PU7;C9'M'8=/8!P>&&(K
M."LGJE[TNXU!K[V^J'JYTLG"H7M)ALL,ESV>RTZ?J_?WE6]]8U[(Z9#2XQV]
M[:!,5GP&GF#%"7VG>8[)):,`KR!4G])7,E#!#6A7.@SU",SL"`M;M-Q[G;/&
MQ?EV+?>C</P,`1\$`2][86F]*DZPHG';C?:@TQBT"I=K=J++U$=,9--^EDFW
MZG>3"O<\4N$6Y*3M*4UN+6:D#+>O5*7@^'+AZD4@G<,AB#2S[*DW?9?<>4#(
M[ST5\K?F<)A\K4IN/XIU'0OV=N!AUQ7"HSV%,0EC)OUE!^DO[4ZCU>W5ZVA_
ME57*\AE;HO,ZGFP8!G@2!NAW&KU#9(`Z&;$F6:VVV05/=+'FB1#UU(>;M<.>
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M+.YX5JR7N!5`=[KVDKZTZ[<NQK6W6Q>[7SP0F!M]&NL%28%O;T!XNV.PIOQ8
MUOF$<3X''K:PFZ_'V&EUGT4]1D]V!"*<84E9'6NDI]QR(VGWE>$?Z_QOMSSQ
M*M!\HKY9=C)R8PJCX*(XH*)*Y6)_F+2:<)26QK6X#9V0#3!DPRW<C;D.KWA.
M@ZT7[F\#SWLX#>Y]V3`5N,@.'YK8R)`ZKTA:YQ8\JOM(K+=[PJ%D/Q^][KG6
MWY*+KV=E?IO6YDO,)IB%8F9S,PI9A)L[DF%Y=6ZB0)6GJ19RUH!,ZT/DB;1O
M'K9SQS33F%K9:5U;N`?(Y>5G]17W;E$=J5Q?EF^'K;=5XRZ%?<(5SO>XS<0>
MB%QMG+YOT*NR\#)VUJ7<9RR6GH3<1$Q_EELQ4H<[O4R[[!!EC6TW!"25EZ>N
MJ`%>*/?-G2@J%J;:Q$6W`IL"QM8[@(+S>-L-;HN1EH$';X.JO5/E<@UA2]!D
MQUR<&A]A6(A4W6D5]++;G\('2E&0&]2V]"[M/*#>I:&Q)':`A?'3UAW4.&KL
M1MA#$0O^-ZTKV0?&]:DK1EH7?1P$L8_]2D9IW6JY930OZR=%AJ4+7$3G*7EJ
M?)%M!39UF+HQHDYOZ87]E?%^.!=T#Q/D`VZ,3)UK"$M(($[H#G$/'[)N.)EJ
MI3=`O]YBPSJ+NJY$4:'/U<W[JQS;9&W>&*_4!"5%2Z3ZF(PLK(J.JPU%KL?:
M%.OEQ[3#&9(E*0MND`=0>,*FSB?W6'@=GH[$A@R(TX<PF)1?_TK\0O>(*WV(
MM%2Y=:,-`4C";C51;JN1W2ZYZ]$70=TU850P0J>@!$[_.R4R:H;)^>]S;(.%
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M-^?3^'?8FM_1Y+LD"O]/X6$DYEL66>NT-FC54!(U.[LXUWHUK`3"HZ`NZ<&P
M$HY_1.XKW_7>G`#]BA/KEZQGB([@K)''!]GC+9VX/,@Z6`-=&%WI=+6V(0MG
MSF,)T""`XJ_(`G$>]-:D8!#01VE>DAWP4!(M*8FD'K&FEPBS%,8L#4=/H?4/
M6<./I36.+9<4^J0JR,4TQA+'66PCWUWVVW];O[M3E]JSN1&WHPP<;53L%%ZJ
M@)7BF9N`'(=8;J5JEIF/,(SPMG0(CJ_>X%HH;XK,=CO7,KI4%V,H)Y@*77G#
M`L0T*D(@Q^*KUOCY#ER#26'&2#4&PQD6F0`ZF>K1!M+<*1I<U36*/%/NF@8.
M&9@&@&E\"H\/N3N8YX*QQ?8"ZGY4UO?85@M,HEG`G4$;[`R"$SY-%%:E6D?;
M(!2WV*<2)@(3"K4R?0NNCFRMJO6G^EEV76]:BOU2^HDKUD78!$P`["(_L`Y0
M%32E88^FWKG9FM@N]Y?#YP5/6(P-C(3J)"B-6A\;63$!O,#W7NJ=3(M'ACK'
M+N6O:VS'#+S!'4^Q:79NNW")GE`=[=3F2:BJ>(L#4=09;Z3:6=+:.JW6>=/Z
M#)054M.T4LI0M`@CZHR<[MS8PWIW,G9Q+\AQQT@)TGJ4LNBRC9ZCF[(M992C
M5,#.NV3V*0:M0I.&(D)GB%TGN:FKWIR5J:78_KC5[.3]==6B5082*@QOS=PN
M=/#CG4B[Q$<<K^2C&NSK"D+`#9*(NGQ*'*Z*0+WQ,,*6VZYU;=V-S8F\57)E
M1WC>BO]ZGW6MK+)`VJL?4QZ#!7*ENGK2'QI^3-`AQ>A59>=3%-/$9Z1AG2"*
M5;P]8VJ,((3?052SMTKG+M+]=>F\.@U&@*<J'M33W,N1@A)YS]:-$RGETLA^
M!H(^%<?"59_:*6B8F+0,K2(]KUDT@^M3*U262?!+$I(L`X$>Y0<?!9BRA%UE
MT]ZJ%C>I)VT64!/@V_S,*[2)7(ES\\S^A_VO(+P"<00B.I2/5K+ZRD?Q1\'J
M6D#62C%$]*CZ55I9PTK#_NL?V<Y"8'BP_IT,N<"<U(XX"\*]=>$G/&SRK,O1
M'7+"R,K=&]?R@JS+)+X-0HQ.:H<J;R^_O+O,':M<$H/.]5[O-_0.T#]C$V;N
M3YH=#8?IAJ<G=?=VQ`:/RX:W]HQLLDPKR@F`G\M&BJP70["?+#4GK$T!\!*-
M,AAZ_C"03+<5IJ?A"!/K6A4K2(B\2/DM"$;8T1@DT36(4'_B`BSL$JJ?^/U,
ML)3DN>Q/L&`W8M?9&>4K'-163BCY5Q`8M0FM*`06+?),]<X2$`YV)+@7LQ7<
M"7D(;;MA%@0G=Q!Q!$*>^%"=&T11`+H]5H>%Y'OQ`7]$)X9H[\."V-5W<'2.
M<5`\9:*@L^F\$A,J<G$)#KVGY^#<OQV=/P02#Q=B[IM.808^<W%#\)G13W+H
M"^[\SJ$"-\88S#3`GNWN=VP53EW;T;3@W],X+/>>A@5\J0;9C>3:^!";$C(H
MJH%`YZRR%R"/IL)F"V?(^1#<#9M1#BY^[,X\-SL-]ZGA+V,@QL50():.+"(I
MW0K1&T3/2W2,Z'68>A@$W_-G&"HP<3V>!Y&;TD?T0_[M!C8.'R<A^:JV;WL/
MF(-%BV<OF\^%4V\41^#=U/&)U!)%JK5\BD.PW>:E--<WX7`$10&8)D+6'@!-
M;EQ&@,K0*(]16%<9@>AMZ"VZ12XF#]3"G!O(Z\0D492VHE<',`B`/(/382'D
MI-D.A)V4[F7V)T5U?/TMF"[$6-G?";=USS,G?G+L,*1$'[F;2/L82%3'/".-
M5=?55RNKGX+7BZG;ERGK_PF<__Z'&W\*WU%,S?8NP9.^HT#FIS#7,*#:-7Y>
MJ8SY+@KOM?N+M5$=];*!2P)B7P1==B`V^NS9*OJE(G.9EPS;GPMZ=9KM\J`7
M683ZQJBXMQ:P]A>W4I:V,7OAE#"W"([6`C@XUA6AKB/;6<*B'[FCWSV">8<"
M9LKVRQ,362R#0XQ")KBG@ZJS^*:U$/?-56XUR7*GTRB`AT)0<_#PPC?RSP*`
M4W'*M`,"/PC5+_R8[4?N*>SM)+$G`-/[CZ??;O(#E/XX=$?Z:Y=?3F\N)1VE
MIXS>0P/U1Y&JLMWL\&9BD-$3-I_CVQ8=5_`>Y1T@>@85\AB5.MV?6IDB6\U>
M)278*<05Q/DB@JW%/#"K9YU:6?0-L^;B+%/L2B5]8(X4//@[PJN%XE[FE4?)
M;;3%\92MZ83"N2\HM_]!W?9IG";!76=)&$7OZ'EE<V5I@1I*3'AE_?!*58*/
M/_HE0`$Z%",ZJA!V3,FD2&,VV:=T@(9I-[D7@W$L.,64ZF*#U\2'192&S+G`
MN70K3/7*G2N1>0EF76;;R;#HW$E=WE'CE%0-%LX35G"GF6?Y-+-_)2/*SH0Y
M;O#(3[H,TDM1'N(])]]PZ(GRQ&$Y?!XS%%5+&R5"V;7L@3JI0PEF9NQQ]EL*
MH,2X'_BGY/C8X8@"OZ=\_X92<H,[%Y.!H]<ECBH=T2LXW4CW)'+'X6\]V_E^
M>N/<!AC["69R:!=+D8-Z'PE/2T;+_OJ6978M'R'#MI8)EOC!$'0F1[-<?P8.
M'@>P;>69SX1#IUP`=T,+>H^LNP"/I,@358?R]"1(,?3-1[A[2A5T+0ETOU5@
M-Q8<B#02J]8?[)H61`<=MRN_#Y!HN][:^60KB>Z\M/_"*8/:A;E*AZ$DU^R(
M);U$C*5AY@#D?-W#8W\*>9D'TUQ!<LB,58X%<YXEY>8^S#@E!PDNE$F9)&0X
M>3=Z1>=SIS,/Z'@L1/J<E+[N#[PD0<&>])?%S+3%36N?-?NKEC"HH7;^HI*(
M`[\:R6$:9?FWO,KBJZ2#7&0%!Z`,83SV'^EN'6<?63@XOJS4HQ+V8+N#&"*9
MC5,+._0Q](4*>:5'BZH(TQ^(N!R1P<;+>66YX]P7\.(8XU6L[03=N<"1.,?:
MC;[+-&806P!+X$N='H%V0+LC?2^2BEI"E,RD*I3!.VE."!MT43H4G?+XV<R1
MCF=U!R;U*W4(0C41>5F9)DDO_@@ON'^=Y6.1KY3B4DVHL`?;:4W`M/#51@$&
M,8HW08\L#*13AM?+1$BW=Q"Q4P&6F:;WE^Z^/)VRI5$34]6I+,X&$_T+D^]Y
M'++9>*]UAY"]21QX',H$++G!/)P:!%>GMBA-PU);OD/A<*ARX!M%.A!)*96I
M#<ZN&NBQUH;VX,Q^8&/X11:8*?F5;!Y@E)=Y^SZL*+V=4P%%(61'*5#()Z]@
MZI=Y\".9=7B+=]9&K^$!>$*+MNND'`P]=Z(RT/"@!6":T460H(`3.KJ@P=R7
MU#=',!$2Z]H1,,D0SUDB.HYX34MZX=Z]S-++P'X7XS'>&Z-XNWZQ4\*:G]'0
MZGRP4ML/-])=)1W+(.;Q]JVZ7@-;%=PC86KG#4@@0.2O#MU66*M!E-X0JM@P
M*@<+5PVJ=1>H!9VL-F@0A=T62FLTRK&Z/RTM^+3+FH42BK-5H9!I)A<KC'G1
MWN;2^"085#U(;I"#:'"04!4N"5[T!'3ABU?S\(9Y7M#*>[3"O\6'U-EF[NH8
M9U9[P.R4CAR+*;XED^CSH6=;&0,.GOE2WK5N28`[4@)5J3QN+-ZN)RN+1?_I
M=I&1<C+FU`@9(V2>AY!AORBBJQT>E\:PHUCG8@HQ&X8U#&L8=N\,.Z>Z<T9\
MZCS)<`=:\*B"P8+7U#RGDJ)3)9U*&:G1_$X^DY\%L:"[/-HLRD\@/^\EF20R
M+J`YFB7NUCZK7AY)E/$:+;#<?H\$H)O+OG#83'/=<KG/F=//D;9"@L!<F$&/
M#%#FFA.$2E'`3/=!^!VH"DO#/"A-@=&Z*(U5+0YWO=9R0^A:Y3)P:*UC02$Q
M3ETKBV'(TRFU9I7PQW=:*R(5)L2]5H@;0Y2E1P76"Q0%X!;DP@=Z'"G2`JOV
M,+@3+PNA6AGJA8W"-J#V1)P&XU,M\,NTPP'M)0_I]"YOB$KB2`/60*(3\%XP
M&?)%5BQ-N[Y7$HMWY<GN2-%YQ.4XLTQ3*TE#@&JFEPRQ5F]C&?`C,<.34H40
ME=FKJJ]H4IZ?I#_SA^5\Z.S(K.%\QC$6\^*0F8OWIL!S`^"1RS!7.%(A]G2X
M]&Y3/E,YOLW-&6*-*<`>9UZK`DZS),3[R_29KVO!MWP]'/`Q,LRW46*A?@JH
M)^[.9'&IE`+PLHFLU2+3$?)!8WE[ECF8%4:,-0NIK)ZZQ:-&8<*1A5UD*1?]
M><5R^%%"U[0N9:4=U[\+7(<9*[L>E+M?5U@1R78*5X\]3B&0[%"HJ*=IAKE9
MR]5$;E95"DA>TLF!M]KTBRX5F;CS_!D)'NF!.'$YQZ:0*&1G`CHEL0FFD_M<
M6=*F:R)21FNORN.N,$U!'>'%"+G?95IF_N4TL3TFDYCRI;)A;8Q\\ZT2K/8)
M.TX?YL5]5ETI#SMQCTJYQZ-?+!O%]TJE=J')&AF9EI]C*NNF]*R$S__5><JZ
MN3!+$UOR>3#E1:@_S63]NVL?E1Q8`9CW/)<#N7)=HZ/(C"%4G1*N+!U93Y%I
M<DQID'^F_)VS/T:%!#N]<)I-M="M"6;;L8!7J>91@U+XTLSS$7"F$P>AK!B'
MGBXH7$K28S;/T@USU=AF2-]LY!7`H&<#61JO#`*:J!R(0C:&M+AH$"YYEWE;
M*^0)$G0K9`,J][Y0.`Y-24),+OO/<\=91LD]9T&.\H]HZ8#Y?$WT'ABJ7#B#
MA^&K;H!V+U:IZ%G*86!AT8"">`0]K`@#"W+0K2F,?IUB)`RS*[`HM[HVJ)#]
ML[3;P0Y.3?FTRE\-J+U>O%="WPO93.>?;=*R#`"<IM<583A*"/H[L4.8@[PX
M5;")BT/*C7?#ZOW.DZ)<#5>S1&=E)X2X"!ZC#S:C2;I^XCI<``@ES61IFC46
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M=X;;]7H>'P"!=`Z'(%#T[V73=\F=!X3\WE,A?VO9(%O@UK*LEUS+R[)^IVLS
M]8YG*>'VHUC7L6!O!^E/=85P/99<UHBWN.K'-2+>3K_F+Q77=G8B,U>!N'X-
MSH^XT?@6&W[CWU:[TVAU>\MZ=#]U6^[-VV-O1N>/@\4PP`$S0+_3Z!TB`]3)
MB'VD6EQ]3;]QUAU?4AY-7=^E6H?NG5AUR_;L,3P%[>ANVZF*/H'3IKMK^8=D
M&&W>J\L_IDA1.H+:@T^%J">0+_7&GBZYSMN-0:>[GN0JV8*2!PS5&JK=%=5V
M.N>-SOE9W11NO1%HG%]U>D_%1BJ[7`JMXNP^7.'ZV0F/\2)6I.-RYNDTSU=A
MGU&`94CSSQVQ]W+`*,U)\8MN8]`?')3M83C!<,)V.:'JH66UI65F0(EM=-X"
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MQ6WO@.>\W^CT+^IV2K^7$]BG`]YPS`%S3+=ST3CK][=Z)FIR,X\J-_-H$LXV
M99&+?J,W6'J^>3R;LMX.E,HI^<AIR%%46H;Z#M'`7^U8A1B*KC*3>MU&JW>^
M1Z%_0*Y*M]FE?UKM?J_7OE!DFV\:/P0U,G;WY[4<D#IY9#+&IC&RO>.P[ME)
M3X_8"L[*B:H7_6YCT&NO+ZI>KG2R<.A>DN$RPV6/Y[+3Y^K][3$QOUZJN^*$
MOM,\Q^22DLS&U1BHX`:T*QV&>@1F=H2%+5KNO<Y9X^)\NY;[43A^AH`/@H"7
MO;!./F"[T1YT&H-6-X?0W3BUJR1A[S4E^U%:9/<9H87&'K(WM^9`4T'M?(L$
MK7RYUAU\E<1*2NW52];.9F'P0U4R_8=.D(/^7#IOL>)S1276N7Z@]B04W'H4
M$W*QNX*J$2Y"QXW2QN:J,2FL/TWA58F^F#X:B3L*2<OGX'4GP8!T!'P8P,K"
MK*D#=G^X]BUD8NZRO6"E[<Y%Z5)GV`TG2"+O04?94@3<RT8C823+OB9^U8JP
M!BP7#MZ<!KAN=6Y![!GFJ3E+HQ:Q!(\QN70]5.18MD"ISE_.F_O+Q=777%KH
M8K/\L>FMGH@!>Z<RI5;[OBR?-0AGM[8?O;+L)`Y6DC<((7T3A_`BMAC#T7PQ
MIQYX`O!W@GL8O_T:NZB-,K!H(`!^^-V%L7!`3"#Z+I2'1+^/W&CFV8!3UZ=Z
MXKK.&GN!'<NY2;AP5_CY:)RJD4Q-N*QXQWUJ-K_E\&3R>75HWFT@<!?<I;!R
M@@BK-VUPA6*E9A+XDP2DX@)'>]#H%\7@BI<KFM9Z>.FMAY=&MS]H#/K]S3&3
M;_21O9K'C]ZP0%U`R4'B!WGT5-2:;Y;86L^^J/=E7,4?MS863\>``S:06UW3
M:JWZ4ATKZ[-C!X=JC=]JGE>0TA0[G6%[*A'K/?!R%=L;LI'=O>IR@@"D<.?Z
M/V#Y?]MB?21&IS;:+Q/=WM&AZC0[%5`]"#M<<F%IOI?3!LV9\MV=KJEMXE?[
M1Z$'5-;":?"L6C@Q/BQ`B(@(Y<^^;5,!PC6@^U.H9GED(LL.G3&B5FL%8T>1
MX'X*V%62FP@16]O.K>)"V5`MDF9SU@L1N&N<(,/BL,KRH1N#:C!LE)@V@T,S
MR@Y5>T-!?3*'(KX7LNO:&(QOW\%6R%EO&;++<7`[8OU#W@X"'>6@=E%#7E*+
M$I9@W$L.FPB"=0U"!BPP-[I53=ZX-2<"0X(%&TAD+0YQ/CF%[%>G&ACJC2B&
MU"340SG:M!#97I2343I.V%%+`)H0&T/23[,@<N4-2Q\XT1U;+O6YD535&[R>
M!H!9S_U.+>/!8L:.?NK7\]=9AU`U$KX=@?$',]"EM[2C!FY*+)Q;'P,LUA1H
M#!7HIR3D;I;4YRXG8.D2G6JT`8+-]M1.5JV!'"Q4(6`9^ZKEGB0X):QA@V@+
M*VXCOH,]X6_;F@6#FDMWIX'B/*]TGX&F'6Y91CAS;P-6`+Q+J5N'!(1`9;V.
M>:O3%JQ3[#E)+9)+\$_W>Z/;P#-]95:#!JELGA3(A2\8#*TJW:PL!B22XCO=
M)>^,UKR9G=Z+Q1Z1$7([Z&_OH5$Z>96U7#+Y6G=R&[*S/+PK?C@>2.L[HD$6
M1MQ(.6OFF9-;FA2/H@"$*4HK[!K-*$#)-D71FO'#!-CD'@!6TMZE7LQ>,E)A
MDQQ7<ZLZ+_`GIQ@N*0IZV>QV1-U!R=C'XT39WT?KZ2IC*B6$P4&:*.M,FFF+
MG+*(@:WCJ81*K:&@Z51K9%85^-NWYDW3^NWR\O.ZIEZ5I<;VW,R=O;KT_<3V
M?G<=7,9GU5-=V7'G>3ON6K/<0*:Z_.VWFW<GL)T.&,1>A/>2?^U0K.>?OU1-
MD#<GW]LAMGJ//HN03--*J_+B65F58*&[#JL8UTN0%C^"A/\]B"(+,&41JHRU
M^3B3_84'Z'R);A<[E:\RA%H9Y+P3;ODK*'E0UM`.#=%,E$W@<V($W<;\`,,'
M$@C*!;24"^@G)%VUF(4,8B0Q=FFGH34)S1YC@R4N_9AZO,481#T:BM6*'CZ`
M<&4,DHFG[5+:5%F`''=DIV>TI&SPC4]'R)&@WAK62/*FD$)L!<)`;:/-M)P0
M2BA`=5-UIS-LB(T:%?3(+,`&U>B**`#S1-3@)JX1ZFAM(]*_9B'(\!!E8;%%
M;:.:K`@6V;I5!>GN[9#C7=G87TDI2J@RL`,RYR78WD,%X,7#H_R!R0(`BLT=
MR4WT'E+C*J1.H0_R]:F(;['U8@EJK!)204;.*``_%78_:Q,8N:!B[)#-H2')
MD\+S0ZTU>,6N5J/'C?)T"1)"*,-+0?H$'07SO+V'2**,%LX%^70+^*Q9%4C7
M+?9<F+G5O%CR2ND>1<(!04U&YBUP-?=]9$&=M:-41"+M6D5-:M=TBJ(7M`.[
M=8USW3'0R,T-V72.$(3[(/%&&"7(T=.Z=N<2DRYO_P$)7'+(!U[Y'`9^@.XZ
MVHDR^EAE$'9:S\H@_"(P,&MEN++RR'H*8S`K#K/DR&![Q[Y9DLL>#WKW<Z8K
M5UTHOY3N!FQ<!D_9,>JU;_UA/TC^1V'S(8U5:E1T@T8%'8Z\#;"+\8LLEO?A
M\N9M%KM["7HF2D#.E+[\;4;MC[6W+V^^Z2]_#)H$"O!DP_HB[H0/2HK4^16L
M,[31RB*?_PK6`)91&%DOO@8S4)5GK;.7A8'UT;1)FE;A-RRT!23ERC@P6#BP
M_ADV$$?'6H7H<"6AA`C4YDC`K+&T$'";V0X#C3)U,4*`CCN7F..>S12'=%*H
M750A,OK*\4Z9)\$PD`TV4L$0>),C&&1L`E)CU3DXDO%:^M)CC0':`VASHJJF
M!2#!YX#!(`48!),$?`^,/]C2@J5Q&!'8%QV#I1@RI7;L.OJSA:`%H=8_-PT'
MEZ)D1@DM,"S@%G[&,$4Z=\/R[2DJX%**N0I&L#,.XT'M=-\Z38GC2Q:U;UJ?
M?.N_$ACJ0AT0$D$#@5IW`=G-ODQ;NN-(-P68-!.>S"+J^3Z>(Q*P"X&'+3Q.
MHW"ORKIIS#U)\9JA/B;NQ-B-,$9-QW'P*["G3U;Z&'&<1H@1:!AGT&`\"[('
M[9'J9(]&:DS.0A*3J\$(E69<$+HP+$PROQJ;0BRI=;IL_K-Y)G$5K:%U[)*1
M#])(MQ<`$&I:/Z4]*S[!W>OY0`$L%3![0J`O[($M0][2WM8,6UHV?%T$)0O'
M9=YS=L0"#E#,VJYI5$^=5<\*OH#9IQKL$Y@(ER!GO*),59H^XTZPI;L-ZUJ=
ML<D-[L/&76.0(_5@U!,D,PKO@VH*T!<&(3-^P#S*"%"6^3YB&-/$I+:<((JC
MACS(!/^&N)Z=(!!7"5L;\I"755K)^WHJB*V?R-&SV;'#4"AH,L\L%_KG0P7.
M"H*71XE#4*?Q?L<.0PHK2+5/Z9H*IG2>-`"#ACPI`?I]!.J#CFKY?$$_K*9L
M(PI2<*)LJM51[90M.(U3D9K@F,="'/*<U2C&`8O:;EX<*X)96QOVV8Z@LUMW
MFBHQ1`X!@B:./B`I&95>H\Z2BWH%Z6E%/9)J='>*P0(0%=Z<:IEW<-?U6?,>
M[PWP(5D^?JR-@F^`>5;BY[:?BY]+E40_@CEG=<`,O$E@2T(*1FH8RSG`$F>T
M2<,C.`?92]5B_<2)@IN?-<%LCIC6SQQ(?#L9409_Q:ERN03E\VN6UDSCO!NW
M=CB]A&]]@?K7:;+`C.EV@^<]G`;W&-N.DB&XE2XP#-CW(-(BC65(NN)AA.T_
ML$MG.UGL7"JZ7)32<^5U"50'&>SLB6V\Q&P"T+8S.^3A<;$A:S72B9PJ@*%4
M^`5#FB.%#^1YS867BOJ;3X#<X#R1'B=(S\US$8)K?@O\35\:'K#U]H1`;*38
M)USQ>=IC-A,#^/8(32[Z7C^!H6,$,MA0XX/+1$I2?Y8#`Z31]<PO::E88]M%
M#Q+57`:#2FYJI#D)5!5?AAMD.K,=W>*E@'MI<*R2^V"!JIW+=8(-C7@_1\`Q
MZ'B30:0A;`F:;*G$,T-$&0(5T$OK1N$#U1?(#0HBW`GMD@R]2T-/;4"1XR"2
M9*5YRL72;(JF=26SPUP?S74[M;S&01#[J([00O,"M,+DEM&\^4A^Z0(7T7E*
MGAI?9%N!'K<,",R2$&T\RB=V?;ZWP:=R8>+)/)%03.0Q`DT:.:$[S*P_FNHF
M.X_`-]ZK6-)5,)V"^8:+UICGYOU5CFW^1`@]5]R)S.[*T(*3!G<NHN,6S']<
M+>#*'H%]CD8D`#ZUO\O3+0W)F=%-.6QNY`F;#CC5^2M8?YLQ($X?PF!2?OT+
M[#.:,<TJNM*'R`*C-]H0@"0T1J+<5B.[<5*+]842/M'4_``K`B5P^M\ID2%A
MR6.9DA3!L>OI&4Z`:T)P%CAAFJ=#'_TH"MS(_$6#(2;%`BN`6SQ!J%<[J:GC
MD?]>39]O$0F/]S*MWZ1QKXG(KQ1;1U&7>O,5:A&9$?D?O>Z"%$PSMC-]G`H.
M=>&"N=(&9W.J+@>A,&)O5PI_9$JT&::I"56>>MW0Q3HEW)"%@=.6OV`IL2<#
MKU52OY'F9Y0!(P\:>'290!CI.3U9'CE[PUI"PN.M2]TLS)"*4@L%6^75&K4@
MC.<*E;B13<1:22U^&J!U0SF7Z,5/P,QX*\^;)=;DGQD`KH]JPX_GE:F&C3!`
MK0\3.'%"O[":=^C,FC,N]?6!&)7Q&0PBI',]F8C<&H,?@``%!2@`\]85:3#G
MP?J*7H;W9"[D(0O.L;1-@*0=A3[)83D/;RQQG'EZ#=TYM+[]M_4[N&T@`AJ4
M#PVLX06.-BJ>;97*-<7/<Q.0&17+K23[!P1RWM\:8;,A#/2I>QM\!5_:EF3$
M2+&)U_M3"[T@XBR9D:G)1%B`F$9%".18<^ERN1G)!+ZS87GY;,GY:34RU7TO
M+BN@T)`>FI*=CI8JV>H@<0'3^!3>#.7D'\_].Y%B&$4JRL![K&2`U[,#0M"X
MP:8QN"331&%52DL4N:&`S<3<>9E?5DAEITPUO,DAPNAG"S5F#/NJV"^EG[AB
M781-P`3`+O(#ZP!505/J!$HD<D3!FH`?Q9>I*.?,XLREO*>D,O)26V$N/;99
MR#'1TTUTCEW*7]=X:@R\D=XIS6\7+M$3=$!`-W!X\R145;R5WO+$6SZV0T8+
MK:W3:ITWK<_JV+:<,A0MPH@Z(Z<[-_;P5K[TY*AV!9X'A/)BPWC%C9ZCF[(M
M993G3KP5@U:A24.1K!G"E\DHXR'+N6-J@;$*ET_REV4LE3[G+KR#H5DQN6A`
M=M-/NI&1=NVMI%`'X7!5!.HG1PA;;KL.SX2HK>%PA;$HE/KTQWN@+C`QGRJ=
M[4!<L!1'%+@3&8Y(NA)[D&+$$T`5-,QX$?VI\#M(6+;=^;2-G0&7DKI3UPSL
M=O&@G@:K1)[#%>Q\-TZD<$K#DQD(^E0<T+N28><I*(:8E`.M(@TZ+YJ!,YX$
MBQ+X)0E)!$U==52J!D^O0:+(<MP961WPO51"F"F=`*RYF2N/^;9.6!>K=I0N
M*<]0F4>Q5Z[5S^.R=#TDK4MU<H'IJD"G6/[+</+:1TA\%>-!2\9#/OMX?7G]
M+HLNO'7AIQ%=C[X<W2%1CZQ<>Z!W67L@ZS(!/SC$L(L6Y'U[^>7=93Y_LN*R
M<T,&38G??HZLQ`?OP<N.9E!AJ@U/3P[POBR9'"Z;OMHS\JXDK2C'RS^7C119
M+X9@P5AJ3EB;`N`EFD4P]/SA!!E/*TQ/PQ$FCC-ZZL9@HSD[@_`W>8VUMLRM
MA%8!E;6)2"@$%@W93/6E]YJ`E!U9/H:B9+8;9B$Y\J(01R"9B7E4%+-PIYI<
M%ED"@8X=T$R&!:E"&>A1R[PH_98RIYGBJ6S.G>=`8'J81LR$IS=82L["4"?7
MUF#OG"/`;@BN)KH7#GU!QW?R5(FK2534,,#?04:X(0DT\<.-T`[X4@TRE:C#
MM?%)&)WJANH.7LXJ>@%"1.99T:,4#.4[983R*5X_X]Q8>:26W<_3+^;)"UDL
MD@I!#T3/2_U:UC`(ON<CJLJ?OQ[/@XCD(#`'6]X?S-[&(E9@KX7DXMF^[3U@
M(@<MGIU3/EQ*G3BJ1L)'6!H^D5JB:.YR.MA.\Z*5>\^E]^K4@6#((A^@R8V;
M9</A,6^Y:V]=902"\&4'6]A=2$P>D(CL$95/U(E)H@A=1UG4@\/!,B5,98<I
M6`@YZ9&I2AZ<*Q`#)*>]!=.%&&+Z&S$F]R]CSESZG]Q-I'V,OVEUHE)6K:.2
MV5A$[A7:?$>1]UKM\=K(]GI9EB6!GB^"TH*)SK'B5UH)EB-.U;72.LU\)=$T
MF*-J`J8;H^*Y:]>D93>5TF(6P=%:`(>\?DL%8M$BE;#H)W3HF(Y@WJ'(78OV
MQ$1V.>/065HZ40VJCNZ:UD+<-U>ITBR3VJ=1``_AI61X>.$;^6<!P*DX9=H!
MB1R$ZA=^S/8C]Q3V=I+8$X#I_<?3;S?Y`4I_'+HC_;7++Z<WEY*.9/E<-`<:
M965JL]WLR(NH$5;2MOG8S[8H#,][E'<KZ!G4F&/4NI0JOS)%MIJ]2DJP4X@K
MB/-%!%M+J:<]Z]3*PE.8&Q-G^2!7ZHP8TT[AP=\17BU6]3(OW1?7>SQ4AV+W
MIXEI..@Z.U@V883UPPA5)_3^Z)<`1=I0C"@H+FRJ8$DI$#:9=&GR?>[%8!P+
M3NUR/+`7^2J8'7'Z'^?@Y?(E,%<C=X(1RQOGF3DD(WES9T)YWX93P318.#]/
MP9VFCN3S1/Z5C"9\6\RZP<,E:657%8N@=<G;F6FYO(JE:146V&ES4A\,G*[8
MX_25%$")<2PV&\D+D/H5>TJ%"^Y<3,*+7I?X=G087%'40C]X?>O9SO?3&^<V
MP!B'NEH(+@S*NFDP$EYI>8MO66K&\A'RI15E*D?B!T.\&DJ.I^O/P"?BF*NM
MG%E5A!#@;FAQVI%U%^#Q"Y?_DL>_]"153`'K`'=/">>N=O$HSVXL.!!I_T-(
M^R.[-:.)#KZ@(ETE0*+M>D^7$')<0KKDENX!B.BZ!X/^3$OE"6+Z4+\HKZK*
M@11]F*G*UGQY&UU3D@^<.!>]HM.@TYF71*=C(;1+WB0XW1^85TRAC?27)ZL-
MV3YK]M<[$JF58OVB$O@"OQK)8:Z?1JXD0"Z.P+?VP--)J!KB7&DO"P?'EY5F
M4W*:KFH[)&YQ:BQ`A8$>U*4K/3I?&BD4JF1A"ALOYQ76>=6_P,OU&)UA126X
M-@V,Q/F-;O1=IA""`0ZP!+Y4QWA=/*O%,!8B+7'`$"4SJ<5DJ$JUM+!!C:1#
MT4&$G\T<Z7A.RW8I)TV'(%03D<N2*8$T5UYXP?WK+&F''(\4EVI"A3V\#3\!
MJ\!7&P48Y`K%-NIRZ>'PO7Q*>$?$<H6I3&4OW7UY@&)+>X3K&V51)9CH7YCX
M*N]^<@D$3]54R%V'X.)9,DM';C`/IP;!U:DMRNH3R2TWU>/FH/E&80-$4DIE
M:H.S-%\]LMC0'IQQ*<S(>I%%.4I^)7,%&.5EWC0/]5.^D7;*IZN`HA"2_6<0
M*.235S#URSSXD4Q-N\5K'J/7\``\H<66=5(.AIX[46E*>*P@"TPIVLH60X%Z
M&LS%97A8"D46?L;H0X!UGZGR*P;?7].27KAW+[,<I#NZ@8Q7+2BZK-^%DK#F
M9S2T6E(:+=L/*DR8>CDZEEVN.*=2VP.L4BUK6:KH.A(($/FK0[<5\)8T^;!O
M3JZ2,`K"SP%=/=,N/E/_&\L1GB=K,F!Q6_HLF\#1YQPL&Y>?D*\7ZC@4%UA>
MC2(?*8P)SUF/.]"7N<(9LN,=\J$]B\0K2_U%I2BHXVJK]9.Z`+ZL*6D<S/2[
MXEDO/CE6]Z=E\&UI:\L[`DHHSE:%0F9"7*PPYD5[FTOC<T^LZB@PS0D-#BX2
MY)+@I3*9FO#%:S%IP?>4L>75,^'?VK(:0=HZ38NC@+[P@-DI9S464WQ+9EKG
MX[BV,@8</.&DY-R2'FX%J$KE<6/Q=JW5,_`QHH7^T^TB(^5DS*D1,D;(/`\A
MPWY11/G_7(UV9D>QSL44'38,:QC6,.S>&79.=>>,^-1YDN$.M.!1!8,%KZEY
MSG:DECBRO0-':C2_DP^XL^KAV2RY6I4OLZI,0G<T2]RMO4B+XXHR7J,%EMOO
M$3;+Y4H)'#;37+=<>F[F],NJI_G3]KDP@QX9H#PM)PB5HL#ZI$'X':@*JRD\
M*$V!T;JT'=>2<-=K+=&"[MXM`X?6JOH<^:.*&(8\6%)K5NEM?/&Q(E)A0MQK
MA;@Q1%EZ5&"]0%$`;D$N?*#'D2(ML$KM9%\60K4RU`L;A66M[8DX#<:G6N!7
M%N.G@/:2AW1ZE]<([2@7O402G8#W@JE_+[+Z0MH=KY)8O"L/94>*SM-RORJO
MTDK2$*":Z25#K-UU7P;\2,SPD%,A1.6QJLH'FI3G)^G/_#DWGQ>KBGCY_%JL
M?\,A,Q=OZ8#G!L`CEV%F;*1"[.EPZ4V:?%YN?)N;,Q34DM/C/&-5\T0V+J+/
M:5%COD,,^'BZWF,'SGR%+#W]%%!/4YW)XG<I!>!]"%DG0682Y(/&\HHE<S`K
MC!C+?%$E*G711(W"A".+*J1E+K/G2TIG-ZU+6>7"]>\"UV'&RM7%SK)F"RLB
MV4[A:ME17+'#7!7.5#/,S5JN)G*SJC(<\AY)#KS5IE]T[\7$G>?/2/!(#\2)
MR^DQA1P?.Q/0*8E-,'G:YV)L-EV*D#):>S4K=2K3]T;-M&AXJ9:9?SE-XZ9:
MK)SJE`W+_1GI#@46R(,=IP_SXCZK;)*'G;A')9CCT2^6;)$-)EF[R/JV82G8
MZ3FFLFY*STKX_%^=I^SI4O(.7?&GYQU/W6^D.CC4)-G2NR03D/5.<*D5^_^9
M<FC.@A@5LMOTLD.R4;?J`5_=K#WK8=^8:]+.C)KE^N5J&<VPL36;:04P<FVE
MRB"@B<J!*.132)N)!N&"49F_M$*2'D&W0BJ><M`+99?0&"3$Y%+O/'><Y83<
M<PKB*/^(EHN73Y9$^Y^AR@4D>!B^F@5H]V*5F:TW'<9+Y@4!IS=#QTP*O.6#
M\:M3C&5Q.X'LFIM"]L_2\@9+-C7&TQI9-:#V>O%>"7TO9#.=?[9)R]*%/TVO
MUV'W$4SI^3NQ0YB#_#!5EX=+J\F-=\/J_<Z3HEP-UX)#=V,GA+@('J,/-J/)
MN7:"DZ4YSEBR3U8"=M+D:-40CT6XKPDGKF+OCZHW/K1C,JM2@6-V^5&[?%-5
M13!KEZQG1I*!KK>Y)B6[3G<[+C20M5M,R47*A47B`,=(RQB'V-F!JP3IQDH0
MCH5+B?SUT#-%&)9U8]OS=JOXT'J]S'%3=YAF]+1GA\5=RGDWCWISP\-+_;"R
M>)@ID;'@3/!@SC4W.+P<!G$<3,O/+_.3SUW*S+BS_)!PR<&@)3>%>_M4#@;;
M`+OEOSDY.P&LW(?V[,T)_SO=.KW?CT.MWI:>2JHC8%Y^VI?):@-342TVZ_]S
MIVBFP?960;J2Y!JR(;!8%-"ZA^6.]LYPFYY4'@N!=`Z'(%#T[V73=\F=!X3\
MWE,A?VOY'%O@UK*\E5RO-$^,EU[>7TI7.YZEA-N/8EW'@KT=)##5%<+U6!+<
M-.?[)`P2?W2JFD$ZCA#C<3FW+EO@$@FT;+J5,/&EXN+-3F3F*A!7S/,X7.&"
M?UCR?Z^MJOTK]+-$"W0[6/['JNC4EQFBG[`N33SYTM1#^+?5[C1:W5Y)D9`U
ME[[!#O=Q]9NN4O=''T_GCX/%,,`!,T"_T^@=(@/4R8A]I%I<?4V_<=X<7S,>
M35W?I=I\[IU8=<OV[#$\!>WH;IOJU(Q.F^ZNY1^28;1YKR[_6+Y=MO[@4R'J
M">1+O;&G2Z[S=F/0Z:XGN4JVH.0!0[6&:G=%M9W.>:-S?E8WA5MO!!KG5YW>
M4[F0RAYQ0BO`N@]7N'YVPF.\B!7IN)QY.LWS5=AG%&!5SOQS1^R]'#!*<U+\
MHML8]`<'97L83C"<L%U.J'IH6:EEF1E08AN=M\"D;RUCJ_H82K7:MZJ0X%/?
M_I5HQSYN[OAA<5K=+M*FUH0B)Y$KX-DUCG;"5CO/3UN\E*>?<5O(>Y?5`%PI
M7XZJ%*HT;G5W`>MZR/+&>1)3N])NM1H@-/([E3XINYC0]2(MK19&K;C[@"'!
MJ3W2)O,#E<E+/1L9K""TLJ'G,G_G+EIH&>D[S[PMW=8YU.V$.^J<LKEV&N[B
MC,UZUU(VV9//('MR/SE9BY(VUS)]*4/KXV*NI&4?8/+D-M-:%KFZM9IOR>A6
M&:'N)6"JITIM*'Q!:`7^!+]/TSVSKU:EU;HF/QT\A,^6$GMK4N(2AJ^9)'PR
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M8&9'6-BBY=[KG#4NSK=KN1^%XV<(^"`(>-D+Z^0#MAOM0:<Q:'5S"-V-4[M*
M$O9>4[(?I45VGQ%::,TANVMK#C05U,XW.=#*EVO]O5=)K*347KUD[6P6!C]4
M)=-_Z`0YZ,^E\Q8K/E=48IWKZ&E/0L'-0S$A%_LCJ!KA(G3<*&U-KEJ+POK3
M%%Z5Z(OIHY&XHY"T?`Y>=Q(,2$?`AP&L+,S:,F#_AFO?0B;F/MD+5MKN7)0N
M=8;];((D\AYTE"U%P+UL%1)&LNQKXE>M"&O`<N'@S6F`ZU;G%L2>89Z:LS1J
M$4OP&)-+UT-%CF43D^K\Y;RYOUQ<?<VEA2XVRQ^;WNJ)&+!W*E-JM>_+\EF#
M<'9K^]$KRT[B8"5Y@Q#2-W$(+V*3,!S-%W/J@2<`?R>XA_';K[$/VB@#BP8"
MX(??71@+!\0$HN]">4CT^\B-9IX-.'5]JB>NZZRQ%]BQG)N$"_=UGX_&J1K)
MU$;+BG?<:6;S6PY/)I]7A^;=!@)WP5T**R>(L'K3!E<H5FHF@3])0"HN<+0'
MC7Y1#*YXN:)IK8>7WGIX:73[@\:@W]\<,_E&']FK>?SH#0O4!90<)'Z01T]%
MK?EFB:WU[(MZ7\95_'%K8_%T##A@"[C5-:W6;"_5L;(^.W9PJ-;XK>9Y!2E-
ML5<9-I@2L=[%+E>QO2%;T=VK+B<(0`IWKO\#EO^W+=9'8G1JH_TRT>T=':I.
MLU,!U8.PPR47EK9H8R^[\K;7/DK7W(WQJ_U#1`38L^^=5(!P#>C^%*KG'-FI
MLM%EC*C5^K'8422XJ0$V9^1./L1;MG.K6$'V)8ND[9JU%`02'R?(-3BL,C_H
MVIX:#/L-ICW5T):Q0]4E4%"[R:&([X5L7C8&"]AWL*-PUN"%C&,<W(Y8"9#+
M@4!'.:A=5%.7U">$Q0BW9,->?&#B`J>#&>1&MZI7&G>X1&"(N[&+0]8I$.>3
M4\BV;ZH/H-X-8DB]-CT49DT+D>U%.4&AXX2]I02@";&_(OTT"R)77G/T082Y
M8\NE9C.2JGJ#U],`,.NYWZGS.IBMV!A/_7K^.FNTJ4;"MR.PP&`&NGF6MK7`
M38F%<^MCE,.:`HVA%ON4A-P4DMK%Y:0<W613W2Y`VMF>VLFJ-9"7@W(<S%-?
M=:Z3!*<D)FP0;6'%E<!WL"?\;5LS(U!]Z#XM4)SGE>XST+3#?<,(9^YMP%*8
M=RGUK9"`$*BL93!O==K)=(JM&ZG3<`G^Z9)M=!MXIKG+:M`@E<V3`OG1!:W=
MJE*02FTCD13?Z2YY9[3F]>CT<BJV6HR0V]T[V/]&Z>15)FO)Y&M=C&W(!NWP
MKOCA>""M[X@&61AQ/^*L)V9.;FE2/(H"$*8HK;#Y,J,`)=L416O&#Q-@DWL`
M6$E[EUH:>\E(Q2YR7,W]XKS`GYQBS*(HZ&7/V!$UV22+&\_T9),=K36J#&R4
M$`9'2J*LP6>F+7+*(@:VCJ<2*K6&@J93'8995>!OWYHW3>NWR\O/>^I^N2->
MWJO1]M:.7(<EN.LEN-4?08#^'D21]1EHA>Z.&V/N<1;Q"P_0^1)="W:<7F4(
MM3+(>2?<\E>0L9&5:8>&:(7)5N4Y+D77*#_`\('X3;DYEG)S_(2$E^:72T<]
MB;&7.`VM"4#VBAHLT.C'U*LK^MGU:)I5*WKX`+*+,4@6E+9+:>M?`6+2D?V(
MT5"Q_=@]'2%'@O9H6"/)F^!L^M2O>SEAH##79EI.""44H#J&NM,9MFU&A05B
M>A9@&V6T]!6`>2)J<*/2"%6@MA'I7[,0'/?0]1[FVK`VJLF*8)'M254@ZMX.
M.::3C?V5=(Z$*@,[(&M9@NT]5`!>/"#)'PHL`*#8P)"\,.\AM5U"ZH;Y(%^?
MBO@6VPN6H,8J(15DY(P"\%-A][-6>)$+QHL=LK4Q)'E2>'ZH-;"NV-5J]+A1
MGBY!0@AEURA(GZ!K7IZW]Q`MDQ&QN4"6;F">-:N"Q;I!G`NEMIH72UXIW:-(
M.""HR8:[!:[FWH8LJ+.6BXI(I-FHJ$GMFDY1]()V*+6N[:O;W1JYN2%;IA&"
M<!\DW@B=\!P]U<.LJV-H[8O`._C6)8>$4*Y\#@,_0'\>K>@G";<M0U`Z^/;.
M&[/LBCV>,.[G,%&NNE#W)]T-V+@,GK+SNVO?^L-^D$R)$N!#&I_3J.@&-3U%
MY=\&V#[W11:_^G!Y\S:+5[T$X1\EP/RE+W^;4=]=[>W+FV_ZRQ^#)H%RVKIH
M6%_$G?!!<Y".O8)UAC::/N3G7L$:P%P)(^O%UV`&^NNL=?:R,+`^FC9)TRK\
MAA6>@*1<&?L$LP/6/\/.U>A,JK`4KB24$($N&PF8-99J&[>9C2,0\U,7O6)T
M5KFV&3<+IMB;DT+MHER7$4>.\<D#>H9!=7!G00QOLM=.%B`@-58M:R,9HZ0O
M/1;C(-*!-B>J7!=XQO/`H&,.6GJ2@$.`/K<MS4H:AQ&!#;DQ0(AA0NH#KJ,_
M6PBJ=;7^N6DXH!(E,\JD@&$!M_`SNN;IW`W+MZ>H%4LIYBH8P<XXC`>UTWWK
M-"6.+UFDNFE]\JW_2F"H"W4R100-!&K=!63,^C)?YHZCNQ14T>QJLE6HV?AX
MCDC`6`,>MO`<AT*<*MVC,?<DQ2B&^IBX$V,WPK@LG0/!K\">/IG.8\1Q&A5%
MH&&<08/Q+,A(LT>JA3I:CC%9\$E,]C\C5-I60>C"L##)_&ILWT_@!V4R+IO_
M;)Y)7$5K:+*Z9'F#--*5.`!"W=*GM&?%)[AM.@?1P7P`6R0$^L+FRS+,*XU@
MS=JD9</715"R$%3FTF;'"N"5Q*SMFD;UU%GUK&"@FWVJP3Z!B7`)<L8KRE2E
MZ3/N[)^VN@WK6ITKR0WNP\9=8^0A=2O4$R0S"N^#:@K0004A,W[`!+X(4)8Y
M)&(8T\2DMIP@BJ.&/+P#IX.XGCT3$%<)6QOR8)-56LG[>@Z"K9]"T;-9J'TH
M%#29NY0+=W,@G=-1X.51XA#4:8S;L<.0?'VI]BE/4,&4SI-&1="0)R5`OX]`
M?=#Q),?4]0-:2G.AR`%G:*9:'=5.V8+3X!&I"0Y$+,0ASUF-8ARPJ.WFQ;$B
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M@+[?'?3:JP`/4S.4BN`N/2`H).FJ#92IP0K<_HK@_I6[''X%@T]$]`?QZ\*5
MG,JEK`??X]9T-K^F7FY-O;77]"-R7_FN]^8$GA<GUB^/`W!0BO1!*=*IE-BE
M/WJ7%1*3XZV`_7:GU>T]+?+/5UV;+%,#2[O,%:E9?77G[4&G^[2KNUAQ=0OA
MON@.^H,GA1L!*F&)02E+/(KB^IW>$U-<M[WJVAY/<4#>G?.SIUU>B68O7=YB
MP,];@T[K<8"7/WJ)9UP3LIC>/F2/?+8?\*M+3.IEQ1K]1H=AUW[!=.F6Z_N%
M/$7S1/H:KS]^`'%'_J)F?6T5XF7FP`KC?DF/+<GB^`;KX4G$:!XO)99$J1HK
MP<MB=75-IZADXWZPW?!_;"\1[\"0]@)T)C(`"K;!M2:\T_>N??#PHM]15+29
M@;+?_LB\D^@+'D.AFEV!R\YZW5:K>Y[MXV*`-UO<V7J+ZSQB<=O9C<%Z`'?W
M#O#Y"@#OA43>`:/=D>2_Y/30%.2+NE!\$<05%]!KU86JJT%LUX6.JT'L/"7E
MKKK5OV?9F%<<1<\`[CX=W:Z*TT7@]NI'I8O`75,//H9B\T9;M]\OHY-Y6#=9
MU2H*L!:0?PQ\IPC\FLKPB0F^#.)5M.'^:+X,XC65X?;(OC,XOR@5D*4`;[:Z
M_BJ:LCXKR.!>4WT^,>5G<*ZB0_='[QF<:ZK.+0KW%DR^A$;66LDJ6O4)H5W1
M3>B7:-?>:;MSVFWOVN;N7+1;O9UZF?T2);MH<7OW,OLEBG41P'OW,OLE>G4.
MX+V02*5[T2]1K/NA^`V]S+,2W;D?JJX&L41-[H>.JT$LT9"[H]PM>)EG):IR
M5W2[!;?MK$0?[IM*%X&[IA[<FB'2'ISW6Q<[\S//5E&!-8&]Q$\X6U,A[M_3
M/%M%(];*TSQ;4R%NC?3/0$@.6COV-`>K:,OZK""#>TT5NB]/<["*'JV!ISE8
M4WUNC<K/6X.SP3(AN=9*5M&L]8%V0\7Z)]_>W`W(WWQ57^8WV_7Q/OTG/WM-
M`[XDEZD\/VL[2SGM#P:]CI;AL`30M39BPQ/,U:'?>DQE4*)+NUNEG?:@U^IT
MEP7+-R2>DFRE\D2X+1%/[ZPW:'5W0CSGI5ITF]"?]]N#B_6(Y\JS84EC.<>G
M\`O>!?BDW9!/H=_PT+,4AKFU5&7##`;]7EN32\O`76L_JN.[VV;1&^=6C!)/
M?!JGJ&(?]M(?Y=!""F?TR4_5#=;,B+YBO:PTU3I;P,IIQK_*^[WXZL_O1Q,[
MO+F\;'>ZO?[@').,6S^7%)NW*AO\/DV=/[S=&`'*P?F)@O!S0%GT>F<*JB+F
M",^3]=)Q=^BSO&5"GR6,L@:[$WB>/8O$*TO]]>B[->675.9N\)1>M<G?"BI6
MCF]8<>Y6D&I6TFK]I/9A6_T\-FG0<B*+SK\YX7\O:Q^PT\'+NKDOF["B+C\V
M@YGO]5*`+FU`W>Y5@KJ\SD)%O;GY*^Y/AM$M]XDQ=+4I774V)RO2OU9[CU1D
M-F?)YG2>=G,>54[JP``[7*+H'CSN:PO8(1+%6[ZB>Z"XWW_#N;G&27&@-4BJ
MP&+9.]8R0,J]I!7)<6LKTXFN%JL\,ESN0"QM&4,&PLTA-#O^W"!\YCN^V];P
MVUL.Q@@Y6((!4X)\6%X'<!6[Z*G5RSK#;Q0LV2_X>Y0"3]:.^.E;7S]3M!EB
M,L1DB,D04UW0]F@+B4KB[22V<<*'@6].\#!P]95GR?]8"&T:^.(!SV2_B]@:
M`]QD744)'<.^:+\D',B/NXE"U8J:-H_W'7FC\L=@8'M-RJVS1J_;:K2ZY^LU
M$]]6G&@MY)0MNT@-?1Q5?8<0\5>UB<_7=1&&LX^,LT\-/QM^-OQL^-GPL^%G
MP\^UXV=C>=?SC&4_,82OU!K,72&2\#SC!9WF.6;"CX($T].?J^1Z+!:.7GI5
M(ZA6$LS8)H;+#X'+:^5S&-XVO&UXV_!V+=C"\+;A[?KRMK'.]QI?6)"A4->\
MU4."<!=W$^I%@6:MQ[[6%;GL$=`;#C54:]9J.-3LI%GK<:[5<.BQ[*19ZS&M
M=;]W(#<[?\>'AOB'5CB.UC)<)VYRP.*B5A2TO:LUA["N(]JN9ZIK:[H;AGD.
M:EF&>>JT&X9Y#FI9AGGJM!N&>0Y@6<=W$UOU&,)S93?PL0[P**TC;KE^%(<)
M-9ZP0N'9L1B!]PP#8OGO61(ZMW8DK'NN@KYAKO5!"8\C2<=X'IE3M1(=SU[O
M&M8QK&-8Q[#.$^;T=1K=?G\_^7R&@0P#&08Z%@8ZQONS'P/_U-F[]W<,-VU7
MN1U?*W(^WA(!M;JB<P"%`<SU',/2AJ4-2Q\&.1N6/@Z6MCJ=0>/\HEY7[0QK
M&]8VK&U8^T`C#+4[6>;Z7":<8$H#[`4+1^J`'$A!`&.I&-XVO&UXV_"VX>W]
MN2+=5J/3[];*%3$\;GC<\+CA\1JP1QIR4!]M`%?[>>3>99]F^I0\FU5(`6KP
M%PWK!GS^\6LLPSUQ`;,M^,]Y<?,V7L$L@PD`M!S/CJ(W)U=)&`7AY\#U8Q'J
M01!<D^4(SY,8?7/2.J'/N`GJLX1%;J<3>)X]BP`B]9>D"WH,]RV<VI[\[LX.
M71LQDOOV7O!>YKZ,XE#$SFWQVVSMEN?ZXO2V[-U*DFQ8,2,]8J13J`;':_VD
M@D$KQI26AHXVZM,GJ?S-"?_[9)O:9MW!]<4X`BEEE\%6K:]SNU<)ZE)>N(PP
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MQ\W.WO&A(?[QNVL/7<^-7;'#VY`U)*M:4=#VKM0<PKJ.:+N>J:ZMZ6X8YCFH
M91GFJ=-N&.8YJ&49YJG3;ACF.8!E'=\-[*N]-^4^*.%Q),D8SR-OJE:BX]GK
M7<,ZAG4,ZQC6>3K6:0_.&_W6A6$@PT"&@0P#U?9\;C^>W\?`/W7V[OT=PRU;
MTQ&^-L4!:G5!YP"*`IC+.8:E#4L;ECX,<C8L?1PL?887[08MP]B&L0UC&\9^
M[HQ]?*?*7)?+A!),48"]8.%(G8\#*09@[!3#VX:W#6\;WC:\O2_>/F\-&F>#
M_9Q<&@ZOT2(,AQL.-QQ>'FY0'VT`5_MYY-YEGV;ZE#R;54C]:?`7#>L&_/WQ
M:RR]/7$!LRU96L#U1P+?;37[KK^E]<PR"`%<R_'L*'IS<I6$41!^#EP_%J$>
M#L$56H[PL+^N`_A]<](ZH<\2W_0Y!PO^C5L53FU/DL>=';HV+B3W[;W@[<M]
M&<6AB)W;XK?9`BW/]<7I;=F[E538L&+&<\1XEE3H!)YGSR(86?WUFH,V.%7K
M)Q466A9=2IO1SZ6,\5C=GY9RR4X3UW8!A??8[G(2JHO>BF"E%(L?KGW'2T9B
MA$7K'3NZM6Q_Q'^(OQ/WSO8H6A;X5GPK+-MQ@NG,]A^`6F&CD:4B>!7^HN`F
M!=2&MF?[CK"B6R'BJ#G/S)N+`?7IG[\DT>G$MF>O;IQ;,4H\\6G\P7;#_[&]
M1'!'Y$M_I%4$^$/841**T2?_B\!L(P#_K1VYT5><[2N(A[=>X'S_]?_^'\OZ
MIQHZ'7"%<;[YP1#XX0Z'N_9G20P_![X#;]F8T93.8+FC-R=?[4GGO(>-MGV4
M3%_$^,W)NTZKW3]MM>&_?WT-_N)/%Z?=ULFO2KK`JS^_'TWL\.;RLMWI]OJ#
M\PL4^#^76$I696KD%N3I?F6G+BN+LE3"LD`D'8Q8W4!V2NNF5'SF)R\IOL'F
MP)L3_G?9[FUVBVKC@77KR!%(#FL?&A2F?J+.]O5"]>[]F>/?G.<.BA)&'7([
M2O9^<UC?_Q"AXZ(-<8.'<,>'.\.5AX##]<Z^MZ=AMX^2W9&&1@H;[\=;Z1O8
MX%&,=TT==26VVNW*-S\4`,6_Q>A@&/800=FA&OTL<U=VC;1A^,OA;$=-N$O*
MO`Q^.\K^WKT4K)..?.QE0Z-$\:%WPA'3H0BM;KMA=&A--N7%;[;K1R\/AIL/
M$90=*M`_5<[G$:/O&7+EC9C%4E:V=BXKZZ1IE^%Z\_S]Q^BMR`G=&1Z(;+85
M6[8.-J'1Q^!M&P3=:;5+.H/M`7G;&;PFDJ<&N]I_VEW=N?8Y5,#R-D:.,$[5
MF1R0A4X0^8?DX>(\W>0?4Q4Y)*GI#V[5L"'2>J9[:<3.T8J=8RR%\RZ[J.9E
M*2=[OZAFBF'5J1C6/A-.:Y4_^NPSQ`T[;8&=7O0'@T:O<[87?GK"/5LY,'E`
M:UJ9#G='=-412:;WS8AR/U<"GW#GC(RO^PX=DXSO=%N-3K]K3*;-KMQH%VF6
MK'T[$)O$\-HGAJ\JIX_EQ-VDK=5Q5YYEVMHV3L[S*FJ7^=R624RK+_^8Q#23
MF&82TXZ=RY]?8EK-5>2?6^Y39SC$)(F9)#&3))8[UR^)=IDDL8/?U2=._=MW
M''^GY+8TF7POR5^'1!Z'1GN&Z4V*EDG1,N>-.^]7V!CT6HU.MR2W<LT%'OR)
MHSG`-PRUA22MWEFO,6CMYP3?)&F9)*URHNQT&X/N?C)QZTB41L+7E+,.0,*?
M]\%HNC`I6NNE:,V70]U%S=**JJCOW,CQ`APY*BEOVG\6Y4WAH2'^\3&(A=6U
M3BW$CD7HL23:J=D4;=:PG*AG6P+[2:I</QZQ7V^%Y8!33!6$[2GX^UA=>&P%
M26A%MT$8PSK"J35V?1MHT?;TGET-Y%7GUIJ%+HR*=.!R\>+JPL4-*EF<<,,O
M1[A$[=8+X`T/_'5\(_'YP\L&?4P?G]D/]*P]FX7!#Y@0MCB^%;"_8]SD.]SD
MR!K!3H/7SS]H\,/C24CLU[3^%-9(P(*$]B:FDF%!9?'#N;7]B<`U.3B!'5OW
M0>*-K*&0$`.<XR`$X."=2,06_#VS70HVQ*'M1V,!/Z;AB`?K!3PI?K@Q#_D2
MZSKC3/`)$#H#C,(`TR"*+7MT9_NQ/1%!$N$V?8?!<28J]*RFRL:%<6!DBH<!
MYFEJVZ%^[4,1WPOAJS%F-JH+F`K1".O!\:89-UA8)IJP$@H,G?%<$6%?#ZH0
M+NPP?7>$8VD83"(B(7@N%`*$\IWP])]O71':H7/[P`/!\@/<D'\+1KR+$B^"
M03AL(^?0!FA:7V_=2!MF:@,5I._#BT2VJ0A5(^(RIJX__VCBSSW<+/+F-`I8
M$X4)L,R#B(K<:>78$YF)EF_1\HF1EBZ,<`KD-PX\+[B/7AV>%#*U]I^DUGZG
M%K7V5X:")^A=K##FQ=DVE_8[B9ZV)2'HMU];_R\),!Y,$C@BR>E0T)@E9$1B
MUD4>P?U0`E"3MJ@WMF@H;I&EV\U^T8`W+&U8^BA9NJ.S]*<Y31^`<D=K":RB
MOPO\GK74D,(!]CL!RQ74;OY1%`01V`J>'5;907/2XW7)&)DP66E`)8=2&\L/
M8CG+:QR!ER;7F3ZDV2_PC&.CY0?T&H8!4#'W_GC0'Y+V(-A[MI%F1IH9:;97
M:=;5I=FW>6<DX_,HF:%CQOP,0B-FAO<#Q=$D*=`G1-&2O0:;YHYA`P$<]HEU
MKP-<D]2QG+=U,N2G?Y'[)45I!)P1QC9(+I1YZ/=-@Q$X/`UKY$;DL`OI^X_!
MIP&G)[X-1H$73%#>(9!*),;"N?7=OQ/E7Z)OIL-=Y:353W35-L*S$C27,IKQ
M<XX4'N`C._+W;GPK`Q>E/CV0QM!&%U<VIH)=%U$L7P92L_T'WC[>9GA\,75J
M\8E28KR,+6&#`N>0!1+@#!8?C!K6O<`_00=/+=L:"2!2CBS9WD/DIJ&MS6(<
M&BB7GE<U".I_#HQ5+RJ'L"4$CSNB1=W4V*$]PB?&H0#V\6-/<;\(!4``FV-3
M5HPF+61,"R-%,UBD[SS06DDSPORXVD@:2-T2+CNHF,03\<V?$L^1F(1B0C87
MDE<6+MTPF`;F"?,$1P8QY@F[AS'/U?@QQXR%$!0PA0BG&/\LO%X1&U012S:1
MA@)X6V,$A0&@+S_P3Q^]<H#9QD@KGXS@0MPRD?_T6ST'@W['\>G!P5@CAPP1
M3;PW(`U#$9&0P`V[XMZ`(,1+:83\%`Q^+-NR-7;JU3([?-MXJM@$4ZE@YY4*
M]GM'\UBNE;1[FV?^7I(YD[LN93U]#<GCNOM[+'3UB!QW&2+;(Q69S5D6"7W:
MS=E!L*:V@!TN43SQ'4-#%/4F"E5.Y#!QOV5#8ANYHVGX>P$6R]ZQE@%2GCJW
M(CEN;65EO47WNLHCP^4.Q-*6,60@W!Q"L^//#<)GON.[O4Z\O>5X,B?\DF*;
M!'E%YO=FA65VJU[6&7ZC8,E^P=^C%-C6RG8,VJ,V]7FAS1"3(29#3(:8ZH*V
M1UM(=!-R)[&-#<NM7/MW(HHY?\6WIH$O'M*+2@`W65=10L>P+]I\45E^W$T4
MJE;4M'F\[UAN*>\``]N[TFR=-7K=5J/5/;?F4;![\;(><FIU!_K9EQ0PG%UK
MSMY/>R;#SS59A.%GP\^&GPT_&WZN*3\;R[N>9RS[B2%\#6*J(K,\DO`\XP6=
MYCEFPH^"!-/3GZOD>BP6CEYZ52.H5A+,V":&RP^!RVOE<QC>-KQM>-OP=BW8
MPO"VX>WZ\K:QSO<:7UB0H5#7O-5#@G`7=Q/J18%FK<>^UA6Y[!'0&PXU5&O6
M:CC4[*19ZW&NU7#HL>RD6>LQK76_=R`W.W_'AX;XA]:2B-8R7"=N<L#BHE84
MM,6N8`>PKB/:KF>J:VNZ&X9Y#FI9AGGJM!N&>0YJ689YZK0;AGD.8%G'=Q/[
M*@E#3)ZF[@>!CW6`1R)T[VQJ3*1W"PB%1V7IXP`&Q)ZPLR1T;NU(6/=V&-JJ
M&^IQ^WQ'DH[Q/#*G:B4ZGKW>-:QC6,>PCF&=)\SIZS2Z_?Y^\OD,`QD&,@QT
M+`QTC/=G/P;^J;-W[^\8;MJN<CN^5N1\O"4":G5%YP`*`YCK.8:E#4L;ECX,
M<C8L?1PL;74Z@\;Y1;VNVAG6-JQM6-NP]H%&&&IWLLSUN4PXP90&V`L6CM0!
M.9""`,92,;QM>-OPMN%MP]O[<T6ZK4:GWZV5*V)XW/"XX7'#XS5@CS3DH#[:
M`*[V\\B]RS[-]"EY-JN0`M3@+QK6#?C\X]=8AGOB`F9;\)_SXN9MO()9!A,`
M:#F>'45O3JZ2,`K"SX'KQR+4@R"X)LL1GB<Q^N:D=4*?<1/49PF+W$XG\#Q[
M%@%$ZB])%_08[ELXM3WYW9T=NC9B)/?MO>"]S'T9Q:&(G=OBM]G:+<_UQ>EM
MV;N5)-FP8D9ZQ$BG4`V.U_I)!8-6C"DM#1UMU*=/4OF;$_[WR3:US;J#ZXMQ
M!%+*+H.M6E_G=J\2U*6\<!EA5LX[X8CI4(16M]VP.JUV;S?AL940NEZHTI#5
MSLBJLSE5_2[NA&>U]TA%9G.6;$[G:3=GWZ[#4P)VN$31/7C<UQ:P0R2*M[9G
M^XXX4-QOV9#85FFH92IER^5^G[#H58[H:K'*(\/E#L12_8M+/QL(S8X_-PB?
M^8[OMRSA6@'A(<=*(A'OL`CA;M3+.L-O%"S9+_A[E`+;6MF.07O4ICXOM!EB
M,L1DB,D04UW0=GQIV]<K-%2.$CJ%?=%^23B0'W<3A:H5-9D&\;6^?'+6Z'4N
M&NU6R>GH[H7+`5\^,=E>AJ_KS->URM(V_&SXV?"SX6?#SX:?#3\;N[NVYRO[
MO/;MKA!%>)ZQ`G.#I%XW2&HINP[D!HFQ2PR/'P*/U\K?,+QM>-OPMN'M6K"%
MX6W#V_7E;6.;US,SH:[YJH<$X?$W-3=K/?:UKLAEINE,[7?2K/4XUVHX]%AV
MTJSU.-=J./18=M*L]9C6NM^[CYN=O>-#0_SC=]<>NIX;NV*'MR%K2%:UHJ#M
M7:DYA'4=T78]4UU;T]TPS'-0RS+,4Z?=,,QS4,LRS%.GW3#,<P#+.KX;V%=[
M;\I]4,+C2)(QGD?>5*U$Q[/7NX9U#.L8UC&L\W2LTQZ<-_JM"\-`AH$,`QD&
MJNWYW'X\OX^!?^KLW?L[AENVIB-\;8H#U.J"S@$4!3"7<PQ+&Y8V+'T8Y&Q8
M^CA8^@POV@U:AK$-8QO&-HS]W!G[^$Z5N2Z7"268H@![P<*1.A\'4@S`V"F&
MMPUO&]XVO&UX>U^\?=X:-,X&^SFY-!Q>HT48#C<<;CB\/-R@/MH`KO;SR+W+
M/LWT*7DVJY#ZT^`O&M8-^/OCUUAZ>^("9ENRM(#KCP2^VVKV77]+ZYEE$`*X
MEN/94?3FY"H)HR#\'+A^+$(]'((KM!SA87]=!_#[YJ1U0I\EONES#A;\&[<J
MG-J>)(\[.W1M7$CNVWO!VY?[,HI#$3NWQ6^S!5J>ZXO3V[)W*ZFP8<6,YXCQ
M+*G0"3S/GD4PLOKK-0=M<*K63RHLM"RZE#:CGTL9X[&Z/RWEDITFKNT""N^Q
MW>4D5!>]%<%**18_7/N.EXS$"(O6.W9T:]G^B/\0?R?NG>U1M"SPK?A66+;C
M!-.9[3\`M<)&(TM%\"K\1<%-"J@-;<_V'6%%MT+$47.>F3<7`UL7"I+J'(&L
MNN:>Y79F&/Y2)A5FM6/G8L)DBJ&H@"'4`W,::HW8*U#+&"1!<(^DPJ(/.U7#
MEV$,1&9%R13F>L!D+^?6]B<`E<M$-K;=T`+"2P3^B-]<,=']'%F_BSOA65U8
M:5KM`4>DIWQ8/?9=B&\C2_A(TC=B%HOI4(16M]6P.JUVGZ@;_NB]6B;-MT1G
M^U4TNF(I*AX)RP+Y71NB7::#-E`TTA0LU36+.>;UB;2=WISPO\MV;[,K9QL/
M7"+,UCUA*4R-9`#4XK\YZ3R==[=O5._>^3O^S7GNH"AAU)G3H,K*V!C6]S]$
MZ+AH<-W@B>7QX<YPY2'@<+U$@>UIV.VC9'>DH9'"QOOQ5CI2-KA?XUU31UV)
MK7:[\LT/!4#Q;S$Z&(8]1%!VJ$8_RT2?72--CPG4?CMJPEU2YF7PVU'V]^ZE
M8)UTY&-O9AHEB@^]$XZ,`+4;1H?69%->_&:[?O3R8+CY$$'9H0+]4R7('C'Z
MGB%7YJ+E!X/&K7NCV[SL\!B]%3FA.\/[\)MMQ9:M@TUH]#%XVP9!XSE/+9"W
MG<%K(GEJL*O]I]W5G6N?0P4L;V/D".-4G<D!6>@$D7]('B[.TTW^,56^1)*:
M_N!6#1LBK6>ZET;L'*W8.<:Z0>^R6WUZ+LB^;_69RF%UJARVS^S<6B7;/OMT
M>L-.6V"G%_W!H-'KG.V%GYYPSU8.3![0FE:FP]T1775$DNE],Z+<S_W))]PY
M(^/KOD/').,[W5:CT^\:DVFS^TG:!8,E:]\.Q"8QO/:)X:O*Z6,Y<3=I:W7<
ME6>9MK:-D_.\BMIE/K=E$M/JRS\F,<TDIIG$M&/G\N>7F%9S%?GGEIOZ&0XQ
M26(F2<PDB>7.]4NB729)[.!W]8E3__8=Q]\IN2U-)M]+\M<AD<>AT9YA>I.B
M95*TS'GCSIL[-@:]5J/3+<FM7'.!!W_B:`[P#4-M(4FK=]9K#%K[.<$W25HF
M2:N<*#O=QJ"[GTS<.A*ED?`UY:P#D/#G?3":+DR*UGHI6ENL'5MZD%Y5]75W
M!4,OXT4%3AMZXRO=_[)#86$5WY`R#X)QZG:A1Y;Z8@4;?=!O]-H%\9WN4G0+
M8T94R3683@.?_;JFA35@T\%Y6C]R`2SV_H:B"L11(O`!+.HZ@Y$%IA/!Z+Z(
ML89L[`ELX66-A1TG.#$L^9<@!'+T3Z,8/MCA"+Z+W=.1ZR7447P6!G=N!'\!
MQA%!-KP$CFB4>'&#(`N%@\$+^"76Z\_")V$[M_F:QA;6.6Z`HHQO]=*UVFOI
M:&Y)V>3$MY.1&W/9Y+("RK"&6'"3,EAT,!.AC8N(&*'YZKA!$F8H=@%S(A;A
MU/6I#C/M+T/PUK.=[Z<WSFW@X4[-)%9<3/JSIL%(>$WK6Y06W%W^.*SQ[\1%
M[./S";^:^,$P$N$=I1FZ_BP!H*($\&?S8^+'3#CD^P.0#=HCQYW1HN\"#U8)
M^_]`&Y0^"5P+%../8/57&:X!E0I4.XJ2*0&8"RT05"7@X&"Q.W9QJX<!T-W4
M?I"[2.]4A"1^UO#^&L9R0@$_$RR/690U$3YLK^<]2&K$`7.C9],V4/AZR#/:
MSU7++!LW]V(V+FQ\FAMF3?#\FX#U@@@?#>9J,MNC?R51S/0I2R]'HJK+'G$]
M)J4RRF'B`)X/<8W!5%@O$"7``2\5A<B=R+,3['3%\-OEKWEM\_1"??5D7TV]
M/^NTWKG@Y.-R?/<6^!YL'F7^?PE*G9CYX]H?(U))9(.(2^*T:/H'9*G_(9;Z
M`P0!Z$[B@FU&IK>&TNKCIP5U5P?[#LS7BZ(><92BD8I=9F8>T>%930[`-MTI
MW"1F]J_"N?7=OY,-\X?W?@9V>+C_IEM>UV1Y'?(QW[.,II@+;R8X^2AFR$!;
M[C6;'=C%#KS7/?`="^`=-KE_HJW82`X?)XG5=5F/`&M)NR\#]M&`_?3B-0U;
M/@LCUTA9(V7KR/<&[*.4LI>EYT8K2MJU:I1L<H#QR':IJQUJ/-41"SSD$LHC
MZD@J8^%T]JO%/3%\;GT,_%`X21BB"_?6CES6?6YYE&!;:WF2CM5/A.VO6?]6
M:\J8CBP7T.X%R.3N'2*>-J*!IX)>@LS3P!/[&1@,\N#T[\2=T9D_?IH$P>C>
M];Q&X;">-LS7-VR(&T;'YI&0DZ2G_1.?#CSS0]S?"CI1?*#'1D),TU0%.K<\
MC6]M_S06&$FT0Y``E@LK<X%XFM:[A.;$\\CX-A1+6]$V]-:V6@*"+\>D]3JW
M@')!YZP5&%%'H%.PH&(\T/R''MWJGC4NSMLY.BC@XU[`2N]#-XYAZ:/@WI>G
MYX"3_!%L;MQ6;DCJ'1WX_TI\AV(>E!I!I^G8@]Z.2AKYTM>8?C)V,:\"U8+U
M(@*L?0QB8?6L4\I`$5,<'MZ:NO+$&1=_!=,"JH7O8++(J?4[G6H31/S"RZ9U
M28>[R[!^:X^`8N29M$0(H%K/18$=CQE)4TU.K$!V"YE/B>9__I)$IQ/;GKU"
MR4."YYT;.5Y`?/(5Q,!;+W"^__I__X]E_7/N40XY_YY!JQ\$:N>`7U$OI(-9
M[NC-R5=[TCD_P\,B'X7-%S%^<_(.$73::L-___H:_,6?+DZ[K9-?$68L,`6O
M_OQ^-+'#F\O+=J?;ZP_.+S#._G-)Y,JJU-7FV-H<6T_,L;4YMC;'UN;8VAQ;
MFV-K<VR]JN.JH#?'UN;0U!Q;'_0.F&-K<Z!R5`+X0$/\!NRC/%`QQ]9&RAHI
M6QN^-V`?I93=X;%UR=G(9@<>^=.3*[JC3!77K^P9O.O=T/WE+P)C(F+T(0@_
M)'BQ^#J*$KKUFYZ7#/+G)=>=5FMPVNZ<=MM_T7C7/H9]`)3/GNU_O8>_'_Y_
M(@QNQ)WP_Z!(Y(F5^"Z_S;.>X+5,=VI[T9N3T_[)K]T^!8"RM:\-[M96>SZ_
MVO,MK[9WMMW5TL-O\6013_B$'Q$U7.(=W@F=&KQ]R![Y;#_@5Y?W=CCZF""\
MG\8\VV42WP8AG0^GV+B8PX8Z'=L:-MJM;@$=6U_/;M!U9[L><ASLSF]X73K%
MVD5K]UCK]7:$M.*J&'<S%V9`T#_QI7,\C`YM)TYL[ROX\=G2VRL>KJZ,B%\_
MMUO_^\]?E@!08'^\>_UI+,MH?PJ_H,9*UXDGUB1&KVS/$Z.W#ZK<MGPPRE;3
MJ=S(A1MT_?$#T/5%IS,X;VM<_CBHYB6<S`ZX]$>YW(#L*'W^\/NBN]?#[RT5
M(,$_THR)A7D2I%F'J3[>?:I2WF;9>N(1I6#=7/]V:?T.Q#*QTR+8[M;7N//U
M7/M6V@X"M.Q9P[H7UMCU,->$:K5XMHO)3U2=(;9HU3+OYYWP['M,5KH*DI#R
M?[!,AB/"!RX7HKT-S#01HP:F"OD3F?,2WP*!1`V5Y6+=VG="ENIPO"3"@WDR
M<C$IR',=K*:`A67NA!=D"5FPFN\"*8V?Y;(0".3/D34*DXGEP%,N5TVY!`$1
MWSV$$IW][FOKQ5?A!'=N""(C?MG`VANHVFE*VYJ*<(*Y.9-0<-67H8CO!6=I
M@<T::CDZ6$*"BI^0,0KX053.8R$*%"KX/<+FV"9LPY2^F`2Q"T/@")AJAK_)
M="8<GO**N*B)PD@.9/6<!&,.?LJ-PCF;!T>CV7DZ2,=V8PG]62Z8:)S0%LQ<
M'P\5),TZF!$V!IG!^7)J#S`9:QABO1VLV"'"V.:T,J7=K&#H24:G6D5)9"6S
MV\"C8;`0C@-;S/LS`Z\&I@\`"B"W8#83GBS\@WJ>JH0`:=I3>R*B)L]NPT,V
M<5R$<:-(I:RA+L/*06IOTP7?)#/,1.&%-RW`#Y#V+"`.`4YRPB"*3M-158I9
MZ=CT]A_V`^*UVU@PC<(IYD^&B4<+E_E_-!$L<CQVD?@F2W8'6',;.]"`1=^)
M,)(PJ2$7;0&LQJ:4R)04,)0VA]YY>H(G,$N22TC1PXB8T4.VL4A@'HDKB>!R
M+/X<*8H\,![\Y%N7R20!%7#>D$6^5N1!"VS(`(RH43*U/DEN1+1]PNR#!N8\
MRH%Q5/5MCD"`I'$*-%)C*2IA-P25[DJFL#88F0L<<5J'Y"Y5(BC+(RWD@08P
M*=#*V)5Z0U,&Q!88EL`!ERYUC+%8AE5/\72C4IB!'$[_E8PF,H<6)#90*:'D
MS@ZICM!,A&B2TR+FP,9"2H%/"11V'`>A+QZBG],B3R&)>5]$L"2!$@8V[I,3
M!R@ZVP-]ZQ24^":Q()4;8]4O:312=;Y0O`!Z$7K8&5BU"QS)T[&]]RZTQS%O
M'G_Q7W*!7#/+P0QC<O'3_%RNI>3$:AK\;HX0#H]),D75/E/89B'O^T`ECE+]
M;IQ:67>!E\!F`QW-P)0A"D9J#(7G"BQLAB('2`W&A4';"E???"HT=8,5I2+K
MK>U_#Y-9[#S`OHZ$4G??FC?-_&](NHHO;H($50-8@"[LA>L04>-:_S<(OQ,'
M@,CS!2=6XY,"=T^NAZ%/MW-N$M"]J!!&]IV+5#YR'3NF]/I*&Q">8RXF`>^0
M!\'5^(#.,+XF<8'LJC0#`_#V\LN[RZ:R^W)8'&9P`4F3=84X![9WD$?N<57#
M!QI3R]*'GV,^P1F#+@&%*D`2!*%^3P`TT.%1YW_9?H*$-M`STE>1X9Z(D?Q*
MY/?(#9%"I-970@4K["=#<`GAW2_BCNH]?@Z#68!_*-G`VQZ*L4>;;F?2G%4J
M0`*V11C\0(DLP+'-W0-H%YKG6.#[>M+42\FC1"V`F0_N1844)D('H.2=!MI]
MM.7Q7D603)C6T9U(37%*HF-UL:*4<Q#->1G,N&+2')$HK48:,T$DT";*=O2"
M=W07).GML-JH1I-(CNL1Y0=011[384[GK&X^E)%<GL@N>LVS_)%"RJ&2WLB$
M09"_!C&`DP&1JW3ZHOVRU$:9F[#=;;873_@8NZ;!7NAW'V_;@-=Z\_6TTZ,%
M1LE,FVW0X\V6WUHO4/Z*D(HZCD4HRZC"`/+YWN!UZE[/#0:>MCZ8>N7\M33*
MLP%!$JL(`_D9`LT@Z^;]%:H;5!7Y*;6%98.^E`S^HO-R72;?C0T&!(V4@8/F
MMOJ\W>POWFFLCZD<CFIB_WQKA]-+>,87:'+2!NO$#O(CSK`0N=,9%>MD9#3U
MUW].#586ST&&,T(2>3MC5`12U6K:E3>(:IH.!88RZ&!,7E,C50J;RV5U0?6*
M$>UFDBZO8,`<FAS33"*\D16[7#:87>-,'52YUCZ>^(,R<>G:G><)JC:+EXB"
M)'5M-3HLBD3<F$B([V0Y@14#;`*>ZA*ZP4]:L"^#6H\?D`/QAQT"<!TEG[7%
M\FV]8"9\NGT6@L7*`^M$J69000IDP$L0C9[5EEJ+AXR#X#O!#"Y[$,88VR=+
M`M^7,X5B!B1%\^`H&+AH*[#*IRU]3U]A.D[[8%6H<O!2LP[\;0^4WB2K52L9
M5BZY@"KX(8\1IK.B9BZE)24J8.MF'EZE+$:'"\&JKVAQ8UB6Q$1`191#).,H
M<Z`KV`1OWF+LB>;(@S^V[X)0:F(81"<#?DLI?#"V9GSN%K%,HW@HWMG,JG+G
M8F]@K7DCA%5%FQI9&`FF(S_F'K2\K!\\.C"GX$\J[`QB8(CN)D7@V61"04XA
M>3L+PV=F4^1.?'<,/IV?JE&6Y3:JF\A%S:A,'+*L&C"!8V.Q;AGNBS87ETAZ
M:K2XBIRTV")1`,R"CX#-CH[?./%4,6\.J,L8ICJ'P*<?1*S?C7Y0"\42\2GI
MX"A4^SN-TX(*QM#B0DIWQT@[ZLIWZ@:L0*IZ_?B43Z5(;V:XI4+3(VN6##W7
M\1Y2!WL48.X-+`XO#,,KGMQD@/@6,(%7HEVI^O'L.AJSSJ8M!"<G3@T,#&5P
MD!960;Y\AFH:D=!*PTJ!,*;DB0-CC[R4X=R?!PY/>.BUYO`/0F-&I=63&=_,
MIF-EW*4Q6$"%\($4R%DX#:DZK0@.GR6E-I1I@/7LA_^B.8/<X#HO@K_QG0-P
MZ0;1,=4+M5O8=('&0[8*DMBC@OV9@E!V=LJ#8'R#16V39<%O*A[QW"F%H-"9
M`$Z>"+8H<L\@V>M(`[<\`#:;\KFI0"X`5@0J%'=T*T](&A[Q\3F#AJ[`%=,K
M^,5H&J#._H`1H?/3_Y9RA`V*CO2#LX@2&;`X#)_I!2-"E6+7BEA29J%D`P9I
M=7QEQG)?!]BJ41"!I$/<:AZ)=`=BX8^D1L&*$Z!.(SSC`"W&YX,YB/`@4=]E
MC'X`8I3I7`RR*=K`UR:8I\!=%R3D`V5<?8!'@4.G02@JQ;`L\Q#+:%]FF(_%
M",OYZZ8^".4H'[]`J9#$`6;`.53Z'^3/@XJ>Q?9W)'A\3F">G,,F@\TSK7"8
M_/9!.\24,D^>OTHK5A%KBC#53&(.8?24`I7`)"0,\5S7<\>Q1`55D`@\.E_%
M^`MI)\\+[I<?;^'&$=41N8%G:*6^%\(:!SQ0_A097OD!#J<;*4,7%9*'+27D
MP3832^:!EHBBN>E2I=%`A0/OL>F";18T(ALS=>3\,KDI1?0UT]XL2K#F.^0N
MRSM-A:VL2J"G=7:;7?H'*+;7:U^D2:R;5U?@F.6IK.B@?5]63B$(9[!_T2LB
MCGS-(2"2,"YFFZ0MRD!T^!%&1W`L7\SE;O/P]^XHN(?1V_`G&!094#00@#[\
M[L)8.&`$(O*[4'V,Z7>0AF!;`T9='X'/7<P=>X$=R[GGJMX@::.VGTN*W<T>
M4K4*LVM:(K->[@?M.1"PH)!!0$ENDY8=-S*Q99Q8JKS,--#:A@##8OAYAPU#
M]IM6]5L`.M(G\:6R"P'C.\JNVLM2/RN;7J8=*%XE7S.*3S%X>3H6(K5+TB,I
M96^P+K`=L.%M1^8@H.(#M0^D07%':H@5H7%#59Q([=!AH(;?_/B:1@C%)&&/
M!M0K-K2A*3*_SHU(@Y&7)2V3=V),Z4AJSZQ+>N\2,P`?K!=9R/;=U>6E%JME
MJY?TSR2#S%8%EE0')WG`=TDG+$`/WD-#K@_4H,>>./Y%$=FRI281J'PZF\XO
M-6/(K+>0--]I`4/E'TJ(#LQ]^5.:X60^\<D'FA193S(VG7!3R.SA#$"\6R";
MN;7.Z6B+S['9-%8MCC`HB4=_<B/PQ)J.HA7%`>J2M(G3#5@Z_V/_6'[0D!KC
MR@I[$#9L&T*2GL%AJE(N9),VY$+0T,F2$4OXFN-A]X+K:"GZ8+>>0CH^MK?"
MQ;K^78!Q"%IEMBF+BYSUF^>+#B'5X;DR4#%,A-C"8Q@O\\70?I=6''L\TH+?
M431RAP3')"(C$&',.7C,2C*5A)([F&0*/=/(&`9.5"F,ZJ@+\`C;Y*I6?!N1
M4]-*`UVCH!``R2)?0M*3C+235X.@9U$-7,V(XH"6&(^1^H-<"(?S[S#7(V8N
M&XFY"*<:$)_)0B4P,H^8L_39.6$9QX=EJ3TAB1>83/DDNDO*O&AC6[ZQ<O'Y
M\#F/$*)MSK#C5U@,(+LS;<KC>?U!WCWPAA,ZMR-&;_!2R(^Z!2.-O$?;+X>K
MD8L/I!$[0*5P95Z(SG$J#PM>'R<87Y'AR312-B<)8'LD$+RHH#@D7D+#C<!A
MP#]-A<*=4%WE:*9FQBM?\R"IP"$#E&]_6("'`U],2A%BB[7983&VU@%14]2S
MP,.`(>94A&[`5R<XIL/G[QZF:T>IX+;9'.!0PR2TI]803Q`PS#I221+2H"`-
M#M8$**Z(A@3_V$DH`RVU#C@TC[DA8/A@U$&R)O[%S)D_M<T,:FS/QSE"E&B5
M\KS>\3(7-<ELI3364+0QY,FGEH`-8T=)-.,JG/JZM+<H3O1`]"C[>F)@&/Z-
M9>@H4M.T;BB4JA0C#\G:&^DZDY8*(UG?Q<0/A3L=)F%$FD^V/*3W6$U'^3.,
M#1`H.Z"6(_&P:#QU0KZ("6;$L0J2UY$N502J6(;WH)V1/T4Q0KIP[7IBTQWF
M5H>80A>PZE9W<:6F^:_$PZSRU@7*ACLR._%\4`7Q2*O#6TB7H`E%)/4;FP2J
M^2FH*;+7(_%WPMI:GNK>DYN20:IWUI2QX9O3;BZ,+5T;>"?-X09')K4I9"MA
MS"XB9B$O@*&D@\`T>ZL,[C1Z)Y\JKD-ITTQ)CH3CV8AWUOH@V&BM%);G5'>V
MC#!>1Y%['K9\R>D8P/$Q6(YIEAH=,9&BDLM[0=XBNIND:*/TQIM*JP)>3E%`
MV).YOP@+_H9=9V6KU#$)N'3LE]KJHL"CH2CQ"E9#Z.*L5L*YDG"86X*9IR2]
M..C\!0]XV[V>NCY31#<9\O)KAA?X!I1-XD:WZO)-NU5H`0V2#TLEZQESG?/=
MG??OD&.SC*#T2E`I6:9G`RNABR/$8\49'9\;URJ5.T0C$Q7Q")3<"Y6["^;=
MB"M/HUE,(0&<?HA%O7!S00^XP>@E(IUAP:V/9"@]9;N,`F5?9U7VFL_*LD;2
MY<2OK.TAVH2C^0M1%6^]L+4\LC^0QX1/1N@'V_7`7,OED]W++`+*`LA@G-D<
M[,>\>5":E/]$39SQ9A#%_P-?G)*I*0]R<=&Y;+]FOIKU3ZDG.P&1.V%?'?``
MDM73K==2QN!C:/0%>.6LPK'KL&R2[DO)[9*;A5N)6V&5K+YI?0)7C=+6`*L_
MW&DRU2[@I*=#;I39]N553[732^D2#8E&\)8.HP2>4!D6"Y)]6\U.J9]]8,S[
M(5!G2*5HSRB-SM@+Y#:5?DHEO5'5=T_+&M@SM0DZ[NRV0(D@L67B9142I#`.
M+94N:@%EA+8ZG8MN@Q#'8@&CSKN5XAOS`$AS3D+U\=<FYEV3+:V"%D=[-@\\
MR6,,FF"0%_,&U%H.B]Y5_#$28"'28:8NC>65W?1L5SI7J6G9D'N33RDH7`3\
M+L1,DFC("8;D>:YC*:EG<8<U=?0B'SVA[4IA+1H[#4F$.7C3'*IT_07@*;.Q
M"M1<WHP6'+$!JBG%S4--A\W<R>3A%.\S:OG5U`Z`@N.@L_=#.^D;L!SZ7[/5
M:K6S@T(^.>S,YNH$S1\\\HECWE4K'F;FCB.;::V@W^5UZ8(7ESM`6^S2U6,=
M&L(7%&;:="7Z^2F>AKCCA\<O;X55X2T0]!;/E-&@YV]B>A/?09)[6+C0?CV=
M)G[P/[;CX-&X.C;(B@@DF5?V3LR"?-CXZQ^6'B^^DZ.`IQKCZ7"#SENYY@`9
MN2"L0_N'I9Y+L.;4OU'>Y!/%,)0X'6*T)$ZS:BAZ'+L3$!C:>5CX63\.:Q96
M@Q%HRP%%3V4`([R-D,ZMET)P9+38"QSE@O\G[./8_M&P/@9WMG7C8&6!9EEB
M+,>'T-_%Q>;45P<<`Z"-O`J#ATI1[H8H7(.0)9>$CD/3;J2@+MRKS0]42'_T
M,=:LVS)YV%KSL,F+]EFX.,N?5!%@YQ9C_6D00F;%`2VCRO$+=HV*N>''RKB?
MC2XIFFR1'!V?3F^PR[W[19ZI!C)9'S9LBA$#-$G2N27X>1#99XHQ6(?AD,MT
M<7@&N@A_5A@\V%Y,!\L\2.&\13)&&5/H/+%BJD']I,JZS:CJ(>&UCD*'K)T.
M7B?IAW#4,8I;A\FN42K9/>=>Y871*9Y<JV`XG8785)^#C$/B?[H-KM]B:0WH
MNHU6[*2L<U0A8)LVNBKH11L%;SBBV.S#7"@/\_3#6,8UJ2=:25<L/(GV?1M/
M>4`X_6&'#QY)*+[=S0ZBAV&A]*AOKLL6/U6X8'&/1B_LZ;]9KP?1O'AO-7MY
M&IJ[!4F)]WR[EH-0\G2#Z[$$&$='`#",A=TL2/+I46+]H"+5#S[*T27=TVHH
M$!]CAN^3P6:P@TBP%3=9.5LU99ZT.=J#]<(7:6PB90`\S[?Q7@=PEWA)3G,Q
MACBT/0HR1+>";LG)(E>@?>6YKN.$"1VNEU!6E.$9\Z8IEA.]JA\U;%4]8O4Y
M@N[-"3>6.<G]EG]0SICFJPZQ[EVN*C5'B.G2?&G/M6)/-MFJ[.SBI[0?F\RQ
MA*_2'C9EO=D8X[(H;JO9QI1-^9TLGLM?2NB*Q;>G47#Z,([=4S<,[NE\+OUF
M[(:8[@G?/HBH4'/[3N**:W47>\BE:;&^X/\CT51HQ:.*>E,<O?B;:N0VR_7D
M44>%BNCR&U96F5<U"=J=X;"8!`F;8QOO4\"@"T?F(<%.C9S0Y18A"RFV6)>X
M8DMT[-'_V@C8/"YW;F%M&U$98Z^')[T+FB'C7>W.9ZGR%K2*,^2]=?*NZ+!0
M$/+M@C"7RJ?;_ZF2(R0A=_O-UD]Z9X97UG]<7;U__^%#GK[U_QWV/EPNMI36
MH6")YLY2+'>>&Y(WEN6JP^M2E+:?'4K_L1$FNZWE,J#U6%S*X<D\+55WLD?*
MX2`[%['M]1J#LXM\--E0=>VU8D=S?3Q[;<]'VP1N!7>D6[!8(5JGEH=U#\L;
M[JUOWCT;M&ZL`H\'<0N:R#[A^H];.;7/>XU6^WP>P\^/W/:B@1;W8UK^J3Q,
MB;_HA;=*!\BW`%J]GT>^%\CO011E;SR\CV+*"/LT_BSOS>(#60N07FE3D_9I
M:Z`U-?EV\R[7<N;LY-=VFQOU:$UG5IIY(;#ON%(3=:(1(XY,I)#V*YJ5M+5F
M)?"IOP!N;#!T,==P:3D0C\+P606&ET+:[K:W@.&T,\B-B&5!Q??R@"H%<;`5
MU)ZWBXV[%DR>=1+ZG!:X_#2^5`F@GU7^YR6=VWT1(S'ED&L*]/FJS85^`[$W
M^WH;"C'73NDS\)&^C.[)KR!VVBUN,;0>9-F*L!M-]-E^0!DR_]X7(;-!>(!L
M01=;6%#)MG3DIJP-V6.W"`3$6BOZ$"1AG7>HVUJYGU7U>G:S05_X#NZ7]%;N
MAS"8JAH(7`(A742G=!&]W")ZN(BW;C`56"_=NQS=X6GE"%O0X85V4$KOLJPO
MV5HM?EAEL?US;;7+P<Z66-HPZU,21[%-F;;YSF7OY3V;=-55K:XZ.1'7.?]+
M3K!"YS5J[-7I#SJ#09_7LQ&,.^E6UFV5*W;NME;:'4X-!=3FB"]XL>J3+P7,
MND@!O348G.^JV5G98._EO3<"/OTQ':&=X:7_%'@!P@?11./IR.F<_-IM7@R6
M(&;96G9$,.5V"B'FG:";D]1@%(,*R/5J((F)57%7*A0KR&BN#VB-R&B^#^J3
M8:N:N-K-\XMZ$M=\(]6=H`L&696X+EK=BXNS>A+7@D:KN\;6(N(ZZ]:2N-H+
M.JQN$5TW[H]5::L[:/<ZRY"U']IJM_>&K$5*L;],S.^)M*I[OJZ.BJQ_[;IV
M5.^L?]ZK)QEUGP8Q"\71LG:ZJ]%,I>&N^FN_HTZ8:N&]57W`W9@!O^(M>7;7
M%O@<.NC9*N4SY'?03/F55078=KJR3`?AR@8\'Z^L%-R55W,VMQH`OC5(5\.?
MNFV:5SI_*\V[!JU4Q=5VB=%,\N+"8*ZS=4DE;2(NZT.#;,DN=T?O_T[`U<<X
M19&?YAI,=]NKQNCJW&!ZZ7'8&@G,#N[`FY.K)(R"\'/@%O*8.2NYF'I<3$W.
MYT"6I1PSF!N7OI6OAR)V;HO?:@5V2ROAYH]H8L*V#]@.Y>%/G"O:J](D6JV?
MJO*?Z;H_WCJ4IWM\KE4X\U^0D9G+]TRK"V/&)V>+YHH89T=BF)"=RT3U@_O0
MGKTYX7^O3AT?T_KX>*H3^!;K^CE2T8Z'EH[)[9@\Z@^EN!!OM@3CQPT[GP(Z
M3]&%X\9YKBS9]CG$5B!SIX,_BH_+`2NCMV7`/H8>-UT9RGB1+0]%_=-N[!'@
M?ANR0!FDV6I);Q_\7M06L$-AT,S67(=+*]+F*C2FEH:HKD3\A^,(,1XO5Z9X
M>6DYYO+(>*)ME=D^:\%F5:&H4'T?-W&=A6AY/&C3-`:#\Y(<E#47N`'N*]<G
MGU(7S]KT\":+/M?7+"_HOVB_I"6I2LB[$!ZEP!:7U<<'U7=\[Z[_]!29*Z.I
MM:38/@.IOHA8+OW98KV6;+(P9_)P91L>8NY'L-64$(]B$?608>UE,NS15@^G
MOQJ;9_MRH<^UD)Z3S=-Y:;WH;F3W/$(*+$FQ/F(ID38D*2.RH\5S+=GA2&T;
MS*$QMLUQ\<_3RRG5";VBC(*)XAR(-+AH=1L7%V?/RZ(QULP320G9FL08,WOG
MA*,U9LZZQI@Y+O[9@YA2G6I,<.:`94%WT&[T.GL2!\:4.789D?@"!43;F#+&
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M/=/OW`@[LU+KVPTERBBM[I-V#G5%U+2P\^C8=L-<V]$H]Y#U(A+"PFH[5E=5
MMN_+RO;4R?@#OL^5TO\0-M:%I[+QA%]ZP'J)_4?Q:_J5NN928WH?F^Q:`FCV
M`7ZF+KS^Q)H!K,&(&H#C4[`^?T(->#5`:3Q\@3N\<S]SV?H=QTA\&VOW<M/;
MM=K?`K("&"Z4O5.M%[)MR<MMBN/9/+=4F$B;=@E%^V&N%5"+VS)A/P-M&.XV
MF#6VB8>>%P3?X?GV>8^_5S:F[<65O1J*DFCEKJ$KM=11C=%Z6;\C$&W%%38[
MJ(TT2[J>;25P+'5(.Z9_BO+3^HO_6:@DJYK''1*.-,E<B:[-NG#(.W'ZJ&4X
M_RO[9TF,<'>@KK7+95N[UF:6=ED^F.8J<[BJ]BU7UL9_EFE4/9`L;Y7FYK8B
MJJ*%ZB.G?(6L^PY?J"LX[:[L9HJMYX,DMH;"I8987(MGQ'HXU>OW8E7]O4`E
MK>:!/[X#358`<^-B?86:?Z4OES2=R6K\K=JVXK!K_.$NXA]DBO6M4TO'U,\6
MXXJV9KA4J.S3`U3K*'@+.P9Z/0#);OT]`)/GJPBGUK6/I9N0^SY[MI]9MK7%
M\6I>]A,A]-JGPC#DOV`)0C32?XY87$KRM>P9.CJ"37XJ(U.&?;WN*&V%]0*?
ME\OM#5[3F[1'\JOSUR\QE.K<LB,U@K6-@Y!FF:`T0CD,$MQ-IT"WPP_\T[\3
M4)$D?EFL!]2_!1UU=K$`7N&X#`F%8^$G\"+&Z/6C)X?U@^$K:H'H.G$ZCHU-
MG2*:1G]\&/@)]D9\@?Z^<!`4D#S9PO@U?56@JR0N80%CUR$LPJAB.O."!X'>
MW258!0B@[7D/C0RSA#B;6Z;\&^8L(F/!\FF&JC5I$(U`!8+RDR#!#TC)L'5(
MSN2()1X>"9=IL#TP?`VYY;QA!4E8P2,V.*XC=EX!M;E];2`IHS6%>SD.@VG.
MCNDV"^4TTY6#HO.0E*51`\/J[_6:9WG;I_@X@#"U?[C39&KY:;51^6-*:2-B
M/5=6^P4.@55Q^(,($@B%S5CXDX("DU`(/PN`H&F&K\8('?,TOKSI?/=!XHT4
MM@2^!3M(L3-@/+"`A0T3/`@[;("Y!KOH(V0N;<X%8ID"#N&(AD:[#CSQ,+;A
M>\^=`NMC#`?GAQ]D@"+=HR873Z4OL0EJI,)`)8MFMK5]'_@Q!5::B(`&-'M<
M/X&_;\,@F5!67Q]D5#+\%_!?P[H-[G'0!CZ+.%;]G!A(EEZ!7X['^-9&7D4L
M#44E5O5-B1+G-@,2K5HW*I_SWL8`CHT6(\ZOKG>UR4[NP0("GOXQ&SQR49+'
M<SLK-WQNVCX(S+BD`"UM`:`;HVK$@C^HY1V*9XU%P)_IKL9;*1M7`*_Q,JR9
M";UZWEZSM^*T"/Z=[7H44<*Y2>:S[_$V``F.T[U+!3=0+5#7OQ+?X1U#$@<1
M9T\X+CD22+JNC\1X&\!F.@)T5B1U`9,M?":=@C$X-],?1.K2]P%*!]75M#Y)
M_3*U'ZQ;&_5P*E!P'@1-7W4L_+Q`0D8UVF2!,:N\KP,P7A7(!4SN&.C5`5PH
M)4@RIZY\D'5>JPPNI$EJ%7R<Q1G0(M!C#8;>UP_E=!K]`6![D#>$5@CFI%>0
MSQ\;S*D\WGWNFY=#G,XZ-NU,&=.!3M>T9)@J%E1R#4:^C2Z?YP7WT:N%B]S>
M$?E^C\/UTR#3N,$T;C"-&QX]^*/X^+#KPIO&#:9Q0VVR8H^92$SCAKK><WKZ
M:TNF<</1I=2O19&F<4/M;\J8R^";R3;3N.'8N<DT;C`VS_IRP31N6&.]IO"6
M:=QPR.QPI+:-:=QP?/QC&C<8BV8S:6`:-Q@IL3LI81HWU(43CM:8,8T;CHU_
M3.,&8\IL%+0UC1N,C#"-&XPI<Z#BRS1N.#K^,8T;3.,&T[C!-&YXEN?<IG&#
ML9M,XP:3JW/`,LPT;JB=(64:-YC&#6811[*((]7`IG'#02W++,(T;GAFY=E-
MXX9E5IYIW&`:-SQ'R6`:-YC&#:9Q@VG<8!HWU+PIP2(I8!HWY`3U0G29Q@WZ
M+IO&#:9Q0XT:-^0_:6T<5NV_P&T;9N[LE=R&K!(-UI])VS-T6BNV9_CK78JL
M:Q\42H)J7FWQ'U1<["^J@/86MGFDUX)7#U%)I"]H=MRX/_B-DU\Q9>>T!?]M
M__.72FA77DQ[U<6L"NDG7\BUR=\TN`>GK>ZJ<%\AW7T:RZ=DDXUK65XXOX;.
M'C;D`PRBK:QUVAJD*UL*^LJ[T]W'RH(DU%;6/\7%;876>MNFM1LPV?TJ:NMT
M=D-M_2==13NWBC4H:XT5G3VA#&@--ES/'UP^F_P[V9*''@350"4@Z9M/XS$P
M`A:V5VL;Y-=V#:OI(@2=_E^L#=0K$D1J=$&/?KMY=P+ZSG&GMA>].3GMG_P*
M_B;]P\"O!=&C%W(^OY#>::M_VNG^=:GZ)WP-KN"1$%MNC/:T.JSLZ488)_AT
M+T9?@QO;$]'E1!#K@9D"M',9?09[`[ZQ@5+&EZJ>_F]A$`$-!8X0H^A#&$S?
MV\XMO@ZSLX63XN)BXTW]#!I?7W?WY%>P_[IRS3L$/L/0%S&U7>R^L"8%=%OS
MJU:,N?YF=_6]7A.D?(.K=V(89TKG"E@9(Q^7TR`!:S<%OCT//$DV`/[WP/:C
MS_8#3K8*Z)V^!'T5"/*P_N[ZL+PK,(O=^(/MH/GZ(`G];1""RP_O7=D8CH@?
M,M@["V#7!EP%]I3%-H%H3M%&5,T4"/6S=!:XKBYOGP^RP!?4[>!K@#B^Q%X<
M%,M+5[:R?;%PCYC"]:5>?_QP\FOOK'_>RVG?#>'-[V&ISE#E1$D'I3^FO=G:
MV9)[U5RTC!"!\VFI^DH[(#>;9^UL0S<"+[]"#&02)VIAS#_!8_OF!T-P:N\0
MOFM_EL31%P%K0:(A10R?DA`9%%2T&_TN_;,'DF(9`E:V7U(P>*[?P4SQNJ5Z
MO4#R/R+WE>]ZX.&'"2#KEZ=<78DMT\NMKO?8U65[WP(:[W0'W8ML]W>QN!7(
M_Y-67#Y%18GIL\KB,U?B]\S#7Y7GVX-!O]>^6,(.&KCYQ5V.5(>O#ZX/-J!K
M>]<^-14CDWU!T\3N^1$T31SB'W3"<::?<$A<P-Y^!21&-LE(/M<8+HFKU/^$
M]:D;QV06LFPQ:2FS)CLHVAW`QX323[[*?NY36+&+#2HL*BU-IV'8HXMX4J*;
MLPFPNQ\;MA%);CNU2J@EDYU^#5\UZ/!M[.+;]"N>K]V\OX*G9F!PS\!:2"(K
M2F8S/J1L6'RHE@<+HZG8:D9[A1_CFB,#>JK=L`+5KZK=MCZGSS9*^K3="]E(
MC-9"0$;"\QK<H0[/9JF1'?R[D78RHZ-!7E1U!QSL%>5RQ[BLSUB*,.HMA:\E
M,QS_'WIDN-UOYL/"&:W(QEFF04LY!0,)=%6?MCGZ];/FA#J!]*S+[&O9LW!=
M2L=W<K1>2F?80&RO5(8/I5IY"<VI/HI-ZY//#>]&]@-AE7FX@FVSKH\YSJ.F
M;IB<@,T)_0>)K#0U0(.JX@1$(87Y_$QM,DZ%`H#^2++V(8`(%YQ([NB7GLM;
M+SX`[-;'H&F!OW3:'O2[%[V7ZG2EB;U&;&PAFG@QP^9&_".-TR@7*;:^?#ZC
M*<@LW.T\;2(E^('E!?X$J&$H$#6CM/LK(D?K*5A$1=:.;W4R)3")_'&=9;P"
M=E^0;BTFHX!Y>"?"B+9$>.,547IQUCGKOR3(.`P!,P/H$YD``2CU)X@TC7KR
MS*BC5B,:G6"JT)%G9MGCL0+L>SH`<SP;Y8,`K%%?6]Z\!]4GIM>T;K#]KFP+
MJ`A!@3%/"IXG`7WL'C4HWT8>Z1%T\'YAI=G,1AW,0?/MT1N0BE_B5I36BB&'
M#R3#IB*^#:A5\M2-<7_@>\^^)W8?X8C471C[D_IZM^3X%$8^A35]%['Z^OQU
M!A01YMCU.0OI2P+<U6OWD5^FB3>Q\X1P@[XFIU1=.B2TVA?=;GXA0,%>,LK6
M.[5'0G9!!ED*Y/SQ?V_>6W_\]U=B1&K:3+PJ?KC<(Q.XAUYGF(DKY]00LG#`
MC,R"VE:/3^WO(@1&XKZO2C]P<UE$E=:!D_@*-(VV(]DNW(,^(FF`\V((AGJF
MXB$_Z`U,:`(^"4)L;(U)60!ZJIVQY2UG3J9+(05,V)B%Z(,Y@H&Q09"[#@U'
MLH*-5@'HAI=A<QM6F'A"]9J>))[*\)*)9?PKK"/#*3:?U8AG3N%;0SR$`0V-
M@B7!'#&,?K)?V+3^Y.:NV"PV&'HN[[\:DC0I#YN1!'GGW`DU?3WWZ@S(.4.K
M3?CD2'FQE6FW8!/\I"1?9FI,,%B.Q$G1<EX=M2<N*+%R^.H@*>HEMRXKVPE*
M1*YF[_UCT3:F+;)#.BM`C9\VWWV\<?$NH6>(R6_A"6Y;#]-8("WBV\BBYTJ7
M>"_2SLA%^BXS?16LV,E9)ZIT0[_FU?:(<26UN11N*YHY,`>93!<$ZZ`AUT:]
M?2U['&-R)^;@.("'S)[@))Q--1!)/#9.52?L"(?'=30`<'@UPWL=B+=>K)2&
MB;Y2-^C4=,.C`>LR[\#]]MZZLF=N;'M/$3DZ5(Q^\BO@T9A9XV5,*8@HVPP3
MK1-LAPHL'*H#2J652($R+^/O6B61Q3O%S%5\!MTQ[-V>>*SM8KGYQ$(9G)*1
M^Z6#4'[\2'ID-L@BWX4_(K2U!-IV0S""Y/F>9EW9>:G;:1;:3,YU/Z?NX1Y.
M3:8'8.8N\$BZXZ4/\OOH++$B3+0T2B0M"VE7Z$UK_TYL3^8!.@X>K4:R2SKJ
M@.8.J"M/-EL=FZX;N!@Z`,.&MF\L!-$!K"U,!&?]RXQ[P,:=U&^J=WL\M_\@
M6R.EPC+7D.X*B2B6=G]3"^4[011C5WH\]V%J=]+S3Q4@<G-!(VK^BQXW.,=A
M#&Q6`5CVRBH@:8<'EO;W5SFH)@/G%PT$X`FB%[+ADHB)9HY%R]"E(ER88HI7
MBV(TEVE1Z"HQXS"O2'C1H4^&2(XQF_&R5S).:4>1B*.JM5R7X;8$(KS.@>?3
MR#69R`!@9$9L95HNU\JJRLK%N:[X2LC/4>&"3(Q&F<J_K3#%\'RY@FG!C^2)
M<IF["KEL!B"1:65*&D3F:"[9*D8P?$AI2&YW;CAZ0>M#;;G@2XU<V#'<!'2*
M,C?-26!A4ZR02S^@[+!#Y*;8/1VY7D([8(\PW9LNO>0G`GK7THT!;&GZP"AL
MY<A`&[MX<_>%<@##+H43WDLM4CBSW=&IZY\Z<F]Y/#HV!;A83(_<B.2;NAZD
M3$!7YJ4QS/E'270L9LL"ZZS*F[DLZ;GLYK4/3/F\=23<5VG0ZX-G:Z?&%RN?
MHXY!&(E__C(W5C;%%<HV^!+`L+W_!;/WO3_*I1[V5LVE/OGU]+3=.>VV>;ZJ
M@;.IWP4.90-]IDM<<_.NFO8L4V#I;YZZ=.!LWJ\<++AYF`X#+YMOU13EDU\_
M7W_FB7(C91.\!U:*'S"`&E[!S),@S#*5>JOF\YS\>NDX(+M#\N]I,)ZT9/3B
MU%^DL^/'']&Q2.=>-;L7EOB?EU_^N/SZG^\_OF]8UQ^O]*GSHQ?GO@+$ATCB
M(_'COX6V\%636DY^Q>LDW<Y9^Z*E3UL8>&[>+$^)$Q_*$BYZ9V6I16T`HK<\
M<>*LU^NWN]U>#J@%L\Y3>L8,'^";+"6F-UB+UO-47ABT:E9FAL*\JV=D_+]N
MV:S:H//S?GV8:;2WNM!JMT[_7WXR'"F?A:+G<:9YXZRBL^7U5Q9=:V5'?<(P
MJI9X\Q4U[GRZ2W]U`;:+=!<<3[X%*G#FV0^OK"$"F+LMN>&5T;.+N1NC\-7"
M*^ELWLO2(ZUF&^N1R.]DB1+^\K%71/-W0=4-."X8EL(LX4QO^?N"_X\N_1:J
ME:GB;D//!N05?E/796=Q_IID/O%(`L$]O5,@RMI]'\S=.NN=B)S0G9&UN-&E
MQ,*6S-U+;"-@=;J*NR&BM)NZ:^$)R`XXT<?\54/&.]N=SU1.(99%"<"=F`]@
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M4U2"\#'@4WX=BNYF4`#I`N660I'-D@?DBZZCKNA45(MBKUR315U.O_*":,4:
M`[W"7?<R2(JU!$KNGL[M8'_#'80W]:(!U5,M0"!\$.&=*-O2TN.?];=T\72;
M@59Z%9C.4U<[G:BLU:*=2'U,D")4O8OWLOI8"D+I:5"[!5"DA(:?NOG+UW_=
M),-(_)U@"8X[47(EN^(XK:]5M]@(\+EZ+5Q.XM/XBW"GPR2,\I44^B4E25:B
MR?9<Q972B?+;?CV=V6Z(WW\:_PZ6YN]`Q:-+RH'Y3^&-/@3AMR@['3LK/ZD:
M+#VIRD':/;LXU\H<K`3"W+':3(3Q@\SJ_QI\"B]5#C$\_XEKG\)0F%+T463(
M/2LI'K(*R)KH67?N125.^%S2=3YSZAAFBD9O;:Q5ZJNO@K?BL^UFU']6I71:
MW;5*B,"BSMO=WJ"J]LGJH!7JH@2V3Z>>$<KV#T(CGO*4`H"\HQ//^NL8]/-U
M4(H0Y`&\N0U"6DY:%"7386=5)3W6!ZJM050R98$+9;9.?J?+,Q$>CZ].2],1
M^M2%G103VP/T:>@I+^_U>(C.VAW-'DHG7L/Z.%LU->&O]].9%SP(JI468A+6
M2H6"VKLQ0,Y*:W&5JM,\=0W.^ZV+34R0TB<S>$J4SRKPG+<&9X-E\#`@GNM_
M?S4.@M@/8OC5_V[]H*_BAQFX%#`Q72@XD=^&`3H:MW$\>_7++_?W]\T?P]!K
M!N'DETZKU?T%?_X%'SRAP=7P8,;G1H7/=AR$:E"0U0+L$DKX:ZLO;T-<VG\`
M%CI8V.:7K0YXMNT!!]L>\'S+`_:WC</^MG'8WS8.^X_!86=^P"YF>VT\8+=L
MP,?@$%.CMCMB*8B/06+9@.W6EG>EW2D.J*19;E10JD$2.N#Y_)AZ,"AF)@G_
M]-M-81[U<GL=D:=>.OGUFBZ`R+1_.[KE2ZWX!V8\PR*X(4!)0X&*-@)#VT.M
MB/?1,!'^G[_DEEBZ[LLPCU`[=-1B,)N_R#)Q4+)J>&?)PN43OXQM!V-+$@&6
M3`IK[V13.IMMRJ/[Y&P/ZYTRK'>VA?7=L$)W,ZP?;`>2__B!A3I>6Q5M1XZD
MV<CV:+I;1M/=;=%T=R<TG6G/]8BZM)"_+-Y?AWK]V]O5#$/ZMF;?/G9?<209
MA,S#C$X(?/_/7W`T]Q7^/WS\_P-02P,$%`````@`XH-F1Q1N1^T_#@``$LX`
M`!0`'`!P:7`M,C`Q-3`Y,S!?8V%L+GAM;%54"0`#%QP]5A<</59U>`L``00E
M#@``!#D!``#M7=USXC@2?[^J^Q^X[.L1DIF;W9VIG=LBA$RH)2$%9';O:4NQ
M1="MD5C9D.3^^I,-QE_ZM#$6S+[D`[I;W:V?6BVI+?_T\^O":ZTA]1'!G\\N
MSR_.6A`[Q$7X^?/9RF\#WT'HK.4'`+O`(QA^/GN#_MG/__[[WW[Z1[O=HQ`$
MT&T]O;6F<]CZBG``GF'K"R6KY3];#^0%TLVW@_%@TNH!^D1PNQTR>PC_\2G\
M\01\V&):8#_Z]_/9/`B6GSJ=EY>7\]<GZIT3^MQY=W'QOA-3GVW)PV_=8,>0
M)O[0V7R9)D42T0B'%CJ):$]"_-N0*9)0YI5^>1^17G[\^+$3?;LC]5T>(9-Y
MV?GM;CAQYG`!$F*D)FZG]/;1)S_Z<$@<$$3=J?1D2T@1_M>.R=KA1^W+=^WW
ME^?,B#/6?ZW6I@<I\>`8SEKA[\?Q(-/F<@[H`@1SB.&Y0Q:=D*8S"1A@%A`'
M[=[H_KI_/^E?LS\FH^'@NCOM7T^F[.==_WXZ&=WT1G</X_XMHQE\[0]'DPFS
M,FHT>%LR'/IHL?1@_-F<PMGGLR5:,F4O/UQ\?'\1JOI=M>8Z52P-=9D%RR4)
M/+>$YEGVZIJL%S[Q%F"V+JU,6D(E?0PZ9?30'W>G`_9MO9V?;N=0MO6ZD]N;
MX>C7NG&=-%.G95?=8?>^UY_<]OO3&BS*B4];X@#/67E1S`LC<Z9I^!I`[,(=
MYD-+:@Y2D6:Q;AYQ,OIX87`F-.N+]`0V`_Y3%(;9Y/L,P+(3.JD#O<"//XG<
MUKZXW$;C[[8?_]XCBR6%S!`?K>&`3>(+>`^#T6P*7N/F//`$O6A>U^4(4!`Z
M3(NCTY3E(]9]E*/:D/C^#:$0/>/>BE*6V+Q-*<`^<$*L=+$;_;=!3M?][\H/
MPCY7.*W>QG+^KJNQ;%>E!E"79GL-4"=6C?U9&#W9I&%+T?%7BT4DK8W8,(KY
M9Y0LS+!'#NSU7N*'UJ>6AJ:M@+3JUI!0%U*6FI^U7IB,>1#]V=A08WHE9@E&
M")<F!^P<S='A469C)1CE!,>]_\Z.[M\'R,?0\8#OHQER<J"_83W2'?4&8P@\
M]#_H/BX)G@`/CN@0_;E";D1^@/"\9PUKB.E[T_#H!IY5WK-K]MB;6=N@DXHY
M;19T5CXSDBQ#4N#M,O`.+P6O-3G/+(S-`R%O;?O[D.#G*:2+:_@4]%\=;Q5N
M@%TCWR$K'.0BC3;]%A<:](W%\[1>=R!8410@Z(_A$KR%N/%'LP>*L(.6P!O#
M!4"LM^AH=L,4!]Y_(*""(+POL;G(65UL<^%.'S6D-C]F(Y12HW1\JJZ)77FL
M@3T#'!HP?2'5P5X051[@*5&G"VJ1OPX#Y%3KQ1GQLND9,+4;V]0@NH84K9EA
M:]CU?1B(UH,BLASXBV2-18<!7L--YN3?`$2_`F\%0S!YQ%]1*#!3CREGM(JI
M^?Q<V'NDI.G\/#G?3'K,JL3;-;4DE@P1>$)>%&"40X-#*QP?&5J[[-PL4O(I
MLPF+CM4[%IN&!Z\'22G;52,D)2`]3.0M',$@N2?8,<=/D4L'0FFN8T>1T`/[
M!%*Z$;O2H7+'O">]@W[07&FW3\4@W2,X0'C%DN_1$M*HE_TK."-TNY\U!:_0
MOT.8L+S[;8`#2-G,WL5N5DK_SQ7[^@X&<^*F)G]AXG5P#0I9W`$U:#Y:\>%)
M;.@1?L3+*)S-+`^HJ%TS,(OG9&,E?MX8T']=0NR+EC=*^GQ\$M,WC^`F`$K,
M?<E'\P&5SYQ,BI6V"]DI(Z_1&KDP-G84JR^<2'09"_%?S=@\Z-6H(Q5\(8B\
MHC:S45C=EIT0DX=,`94`/!:%QU)(,0EA1K#(AYGWV7/)QD#PB.GV//4+0#B,
MI".<+)U$V:HF5PXD2JXC`XV9%RJ`2-E0'%C>VQ%9HD(`T]Q,CXE7AV)UEF:$
M*",?5`"4JIUX;Z0RGKB%"E'K^RP-D9:$<"H?FE$@54IQ:`6.9!@TWC<EAE03
M.L<YA"U)Q"CK'<FFH(0R']EYE,WCN.%%M]I_5BVWN>I*-MX;>>($!Y2-3G\,
MUQ"O1-F)B*SP;$F>K'G(RC!#M"WDXXHC.]W_19EV+8%WZF\#NC)LY>E$02NA
M.YK^5]E8"@`<H?S"W,8@,(8^9-Z<A_LV#*0>68913+Y4T>+)04/!8Q%,"OU/
MREFN`$S<3!HN"O%V!8]KN*300;Q%AHRD<+"?)CD2&$CL*M'K66EVI0=?(&::
M>PR077>!,/(#&FVZR`.$)E<."DJN(T&'F?4E`*-LH+C)VO`4$]"5$];IXN?>
M'-!G8:(A(RU.*!S2(X&(AIWEI@^.5,LV1W=+K*T%5PS,,R2J%E-0<VLX.-3-
MPT*SWD)E::G:"(Y0619J=_E7<A5&8TMFX(<96O@KW`-8`R]<]S]`BL*-`(="
MX,-KN/DM6DZ7$)%?:AN):&RX]V<SZ`2C6?_5F0/\#,>LHT>8K[S`665$Y)QE
M)J+Y:%$*'V0O+A,\`FN@4#H`F2EBUP*'1=50PP=*PGH&]^KMT8?,V!N$`7;8
M#-MU6-*U*=#F;"B*RT+W(+181UI)Z/$#?J]NW>\0J*J:70M"9H8#H1OM@*>?
MN(O.@-(/Y@GP;\R?@[H!?_.HWA,J277W"?/&"OJE06Z@EUU!/JWXP/=7X4V,
MHUF/+!8$3P+B_*&!8RF?!+\"OE/'K8Z[#HE7@3['$7?9`@RR7ST*7>$BVHA7
M,][F>$\=L[IN:RK.YG2R:P,PK?2O@%(0GFE`ZB#QB:,.BP2I1993!ZC"28?$
M95&5+1S_90D<=Z-F9VB/^,+M!Q5Y'H9"\I.$H)YS:H>?4(TM]#Y8<MPN,'E3
M/[3G/05#H7I["MI"FT=[37L*Y=QZD#T%;=4L"\BIR2,J]YRQ3YBVP=N#QR82
MYJ#0.5$MA$:ZH"E!DCTH)32/[3UA4Y!,F+G0*+AK:BC*+92:6;:[L)V7IJ3K
M,!TI-`:VL0!!.J(CX"1A7=:!M:/:0#'+:@8%3MC5)NPSB3$4JI?$:`MM?D34
ME,24<^M!DAAMU8JI?<-U+1E+![CK.'0%W=3].\Q+T8;XSD3U[6+[$ENLE*DH
MMOFAL2=HD]J<;32%:*J=J^ZIJ*Y=V=(UG$%*H6M6(J;)5:@[5G"=(K[-7%4W
M?)7:V'4"<YKU[G6`S+`X?I^(XE326W((4@S6,?[E3]YI\REG^`+?*:+/U%V'
MGZ,+^MBU&<=-*L(;N'VV8@5/GCY.!7PZF6B6[]O`J=Q=C>2267UL7V\]4+@$
MR(W'US:;B!-@Z?7FU80I$:TG[-N`>0G''A[[>DIN!\3WEFS+%<UXQ&RIYX53
MC0/1.AS%^@-`PJO$.Y?WVX"WVFV'1S-7IRUX?[`6O/'\DVAMG'D46;63CS3K
MMX%<I=.:2T'2*FUQ^Z,EN'U@T\0`_X+"VV$V%\4(3_)$A(43NR+A*2)0Z9"Z
M\<938(NNCW;DN),YH/"*#04W?*T@2T%DFT]RXAS(1,2G"#0MQ]0--I$2\0[\
MA1V(2R[8Y%1:J(H5S)CSMS]H,I\B0DLYKF[$ZBH5(_C2DAGYKRM]:T;K7N[]
MW1M,M2\'MJAZIOZ7QYP&TLS?T+X_7`E>XF[):5+FJI?PVC"ZAD8W4)@+D-V_
MHQ!PBM@L[<"Z@6NB6(SJRF=/?UUT_==%UWL>:(UW8%T#M<$KLR]M.;Q;+`&B
MH=ZC67@[P)"E:N[F6.46>BYSQZ/XC2PFO/G]7CW>4QI&5=Q6^XZOGDXQ>+_G
M@->^R\JNNL/N?:\_N>WWI\U=4B8][I8>7S?^YNZ-`O*W$'-IN(98])YA\<NW
M9>;P!V'Q#=LY&?&@.;_@#1MKKLWKLEA"Z1L+$=$KP07=;<2K=5%>@=<6>.1!
M0*IY08:>;5.9&^OUFDC`94GI^%5TP!W?MZ^N=U#2YT`DH3\"X.A::P@6B=@$
M()94;\<U$*E7,BC*"C0X"KO!$HXC@(F^Q89`D0I.H&+)WMJV^(M;]"7/2@PX
M"X^?:W`>`83,/6`():T&$DA94E0M?+:7K:6$6%*S%.\PD+#8@AX^;+2-U4V'
MY2(3A/Q@!T)2,+XGV)&&&2DM[PV115J;P:!CGBX*!+*2[O_1CN[_0HC[PN9(
M465%[NM\[<3N:YO[56"$;E<F[$GO65*GE7W>-KH_<DX\IJ2_>4F<H%=UV7*]
MK6:SP1%JF]7FV8!G[4XB.D;RP:YJ(ST,N,]OGU]:$L=2VLE393&A&`X6)<*\
M'N8#P"3K3;$)NKR0XMK1[;PS9WG_:W!H%!S8B0C)^DC?;"5".(LCJ72[$).4
M:`UPJ'1T%Q(+?K?0?8:^>AXQYB\\AZ_-?RS8*NN2,D@S:,NN6QQR3[4J3IFD
MQ/GC)@'QL<!'R]@R6!$)WM?]#-S:H^U-./%KTN*-HFWCXOA2BC=5\6/`:SLP
MJKC"!">&[=AU74+ZW1:*C%=,F4]Y>92VHT7?S#(QA"O5K@L)-J\ZT5W_**AY
MNWC6KX0DJ-`SMPPRA))E54,6P$-OEU?*H`")7?N]BA6SMK5&*V>95+OR4M[2
M30D1/2:-=?110<7(:B.XJ"3;=:-8>DY40D5.+$E`C@H:6E::[;T))-J5A2;+
M<9,91I-+N'-RK'.-F=U&<%&*MBMGU3ZJTCZ<4A]''<LACM+DZF<YO"9V1SKO
M+)EF4B_%DY;H"LCRU;@%LN;1H8<'A8%\-,C[OR@R.="SY&B[Z[HHM`EXF^M2
M>F")`N"I7Y"ISYC?1]5@/!;,&#NA#(IT&DFBBB6P<IS5(C04;C?ZR&))X1QB
M/SI2D#T7Y^6>?+N'P6@V!:_B/?RZ6BH>`.R_I:-!>NUN+C4TZM`J&4N6G*6.
M80`0AFX?4,P6KG[*ZFLX0X[PZGQ]QL(>@IKQ6)!K[(0R0-1I),$5+T@+'W3<
M?A'^>`(^9)_\'U!+`P04````"`#B@V9'/&HY6?$H``!GE@(`%``<`'!I<"TR
M,#$U,#DS,%]D968N>&UL550)``,7'#U6%QP]5G5X"P`!!"4.```$.0$``.U=
M6W/DN'5^3U7^@S)^C4:C&:^=W<HFU;JM5:695B3-VLF+"R+1+=ALHI<@6]/[
MZP.P;R1Q!T$2[-'+>JP&S@T?#@\.@(/__.]OB^1D!3."</KSN_/W']Z=P#3"
M,4KG/[\KR"D@$4+O3D@.TA@D.(4_OUM#\NZ__^M?_^4__^WT]#*#((?QR?/Z
MY.D%GOR*TAS,X<DO&2Z6_WYRCU]AMOGU]N'V\>029,\X/3UEG1.4_O,G]I]G
M0.`)E2(EY?_]^=U+GB]_.CM[?7U]_^TY2][C;'[V\<.'3V>[UN^VS=FO<;[O
M4&W\P]GFQVI3I""-4J9A=""=*!K_[8X*<FC9%/KU4]GT_,<??SPK?]TW);&H
M(:5Y?O:WSW>/T0M<@$-CI&]\6I&;H)](^<<['(&\'$ZM)4^D+=C_.]TU.V5_
M.CW_>/KI_#U5XAT=OY.3S0B"+,IP`A_@[&3[SZ\/M_R04%R<Q6AQMFW#_@U3
MAKG3&,Y`D;"!*NGEZR6%&$&+90)W?WO)X$RJS&ZDF8P_,.G^(*!]YD%BO``H
M/5W`Q3/,?$I;I^M#TH/^)>UN3+LE[4'>%RI7%A7/\'1/WJ/(0NH>I`9)XE'*
MDEI5JIU(37D8J>4+R!8@?X$I?!_AQ5DISQ(M3PDF8$G_$\%8+QOK\/'#^0\?
M?OSTH92!H]!>'I@Z"U)V;2W!+(\@=I5AU[F]%*L%P<D"S%;.HE0I^)$G0K,5
M3I)6$AUH>,`*P:_N:-ET;B7%%2)1@DF1P=-+O%B@G+J+G-"XYQ*G.8V':%R$
M(+F".4`)<1#4DKZ/47:>?MN^ONQY41"40D+NT&\%BE&^IEI/LSE(T>]EJ.+%
MJ,9,>D#)':1A4^=8:7#Q\_UP=]F[WAZ\=@)>YY&[W]YUKTI"@T&4(@8$%K[7
M*,-O.?W<'#Z:3!#[+V[):\<MP5&-1<*"<IP)PX,R-)@!\ES&!W31-0=@><;4
M.H-)3G9_*14]_7"^C<+_L/WSWV_I>FT!'W.Z$&,HV87_DV]HC[P$/,.D7,^9
M]LA1SFQ@U.,L,,VO:F&OF>[U/F;:7]5B8!YGDVQGB6W0V&)=-,OPPFX`L9O.
M5WOQ3WXZ,>!WDF-=LRO!,H0J_.X$9S',?GYW3G\JX^&?F,^#=)$\`PE;Y@\&
MK`=(()7P99+&5W`%$[QD^EQ_6]+!@9]K2\`&O"QZ-D!FU-,GU$0+6B.8-<83
MM]'>!FX;OE7`V?`;`>RNZ0<.KR%\A-D*1?"1?G7@!?W$TZ_^@JFTF71)LK7'
M=/8`(SRG\0V,[V&&,&U'<AK_I/"66D[F_3OBTH"S=RZ#C<I62!B+==BB36)L
MN\X-&YIV[M<K=(4?W-)J0E?B6=BJ\[$4DO<_[S_\,3@7Y#VD^OMY2$%538WN
M8BI.Z0&BJH_!8>L7NGS*0$(_UI-X0<U!\HQJLH(F<955WP;2#/L&'ENY6*!=
M=&7'<00`9)MF<9'`Z<S/9^$)/">R#W^GO!H`[XB7QPFAV..I3XMNS:;WWX(<
MB'`2=2*G@=>OR<=-N1]^,)MSK<:RLO/5>V#8QZSJ.X[L5B<^[/SP@0-)GA7P
M\$><YO!;?IV4P/OY'8%S]H]ATS%4PB@O,I3.+ZE5YI#HLC":#GSR1=HA\+C`
M6-?6J18=FP/4"D+_A9>,$D@.R/NXS\B?"5+RG>?JV9;R4!"^02E((P22VY39
MD=E:D:#7M&Z`5]IZL`G[E(&4S&!&:.RX<684--.90%#R1&4AXI^4B\XN6#3L
MZI=%[PM:'8AP+\84>AV):%5_TXE((\@!7R:`4&7^"C)J@'R:/:#YB\I5:-LW
M0*UH'Y;.RMEOT,-$[\'FIG[4L(NRPLDFY56=;B8\1C![[A.0?@$+J)@PHB8-
MK-2;#*Z,<B:(&TD4&@SO0J-C0RV$J*Y2K`)90JE3[(I.H?S],<?1/VEX33]#
M:`696$^O]-_K_X,9?H0KF`I7,`X]MU:RZMGOFD8R)KB-NDI0')8O+@P&PLH+
M3B@W<OU;@?(UEP5IXD/=NHD)6>OA/OEXL<!I*=LE6*(<)&6V@[`=_6P%XQN<
MW11TL0EO"2FV-QR$@8`KG69X8$^GGSED.N#8GTUJ4TO#OQ9#./,-8<:)DOD&
M+94S;8!$NHG(NMA2EP17\-#&E.H$=G@1Y59Z9;I1V*;A8!IM^OT`=[*8QF8&
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M]3?J7Q#A`GL/E"I)*&=*P:'4GUULD>F#,W]L/S0T+E'F!8LU.BV0N*5S%#@4
MV:0/%-;Y<AC\4R\[KM/R3#AA56PR$.4%2)Y@MI#MNJI;-W=>9:V#1(VY?B[8
M,*'.(>#/XP@%=_[T/D,1W/^X_^:?VP2`IK1,PCX]K>"`Z-,V7D,\8]X<B/^C
M:S?V*TB*@TCL)`N,G_`=NY.2W:9TLJ4P8E;X*\I?[C!H9OC;D*@X/'L2P8'/
M@R5<7*,S2PYJ/_:0>>#N6KI\9K2'EYP_,0K*@GN'G+ULKAT.<F5L6P'4D^O8
MF&DZFT%VAXX;LXJ'T+2L.`)I2U_^KLY`=DA.T4HJK/_#<<+9HK,E-M6`FR42
MRKL9HJ)H</"MLSNY!L,LN#ZA;B0=9.<K%`92"K?0=<VDDO:_B:XQJ1"8^@L2
M8JIB4([O@L]C\4S@;P6K\K:B_V&'`Q5W?32MF]M)LM8A::L\-Z)MK]=XL"M"
MNK'"]FJ**W>(^=1VL;3TQS=3E`>8E6W5F!GF1*-^A.1P,3_:*.6B`,O@=XGJ
M'EYZ9%753/J-['>PM=\KX1=2/[PRNN)OI*<![7X#6A5O"BUELN<L("HV4W_W
M.GQ'AMRIQ+YC0\%'T3TT5)^Q]!D<^CSM)!S3S^`;6A2+;<9F<XN3W1RC&/S*
MTC6;+/=66L%@._6O8,"R_U!.4;JD;:._[6+7C5>X1PTUSM1N@6'J54VI]C\5
M-_<VR]%]A#E52K0[+&]4F52B1L'-'*TFMM-#0;#3(UGBTP#L11'"<#]]9<GO
M1Y!`,IEO*J=GD%">$W)/YP@L7_.;SB;S>0;G((>_9)B0^PQ'$,;DAEKU&D0O
MK/MNFUET9J![;M63!5UR"PZG_=G6%O!]2-;_J:[[#*X0+FKB[2ZS3V>5^^\/
M,()H)?22SC0J*'>@$1QVV]K!%I'N_'B<O?=Y8LM[08URFK`8(LK0,XPOBOQK
MBLJ-SNT?-P=#-GHJ2AC[("DOL^%`,B@,=V`E&TA[93^"LT#[)06,K\H:I)N*
MMYM/PA?X6OXDW0>PZMQ,>!IV#A*=3IJ[X-"24?\'=QX@LRD5S#F?X$BA\MVV
MIA`4IMK;P/:;[<K-]:R..[HF"YC&;$O^"9<'+C&[D6"8BK?N6T&41=^PDO:N
M2EME\NV9\)EK3>IZF'-)E>>`!ZMH#5!63LL)7<SEK)#/'0+/*"EOY'R&@#U>
M&D_3!W9+ITPTI_$7G&:[_WL!"-(^5=8)CV;U;+\\!@N0?.BA>M#$._T.QJ&'
M(V7=0A-W;V]Q06Z?VM0NI'K78LBC<YYGZL5Z:P$FT$U6IORCM>I=`/.>LMFE
MZCF\142R*4\\6?246435L_^*.C9#+/(6QG90^P$Y=^'L-N`Z@B-3%>WW__P+
M@AF5^F5]QQZ8-9N;!IWETU/9>7C35$::\*):SU4M#8-9JZ`QZ/PU@8%F"IN:
M1S>9%:+HYK->A#'-[*IB^Z!#>3;2IJL)6+FN_9Z<M''9.G"JK:#&I)R]%I`R
MMF/"X6VZ+')23L)S,_C)>\A0)^HQ/-CT_D0$.ZWVQFB3\A?B3L%W!'"KK+7V
M&ETAPL2CUI@\D_)FN`1Y=IT;(#3M/)AIKF"&5N5SMA51+ZE?@=+J9B9=&F90
M=^EW,EJ.)W927#@-S3A7YY\1QQ%,P$W6PW[N&?=KX,V@WX!/RZ\@R>LN^""@
MQ!!FG;BGY=6=^IUWYF.)'?463CHMV_IKPT;LPKS\T%VN412)&*?>.DNT\E7_
M+&0;@=/L-!LH+:8]8#Y0]8AG9^E`LV+<?28$PRN?VWO6RPJ=O>>]S'#:9=K+
M&K3])K[ZN+YBL^SN:F_2-CSM=\_17+HQN:!*)N*C=<;HHW7&Z.,198S$VG>?
M,6KR'0'<A`MO.NTB^\P(W\LD.5+M->K\B%3]+E,D`J:C`MW&=6M15F\FA=6N
MV0C6^QK=VJ_PI0S"O(/;]YK>?,M^D&6]B7@CF.BBC^0GZV#FDW4P\^F(@AFQ
M]MT',TV^(WA*0OB)M`EA;`*7D8<K/08IK2$T^O6ST]9JOXMH2Q%MAW*X:Q,1
MFJUPD@1P<>(").SR\>,+A'GY1"H=D/T#/H\YR$N'?0DVUS8Y0$G/'[8C*SV9
MZ$IV^&CC8BT2WNBR@T%7^5%.1==>KRBT180X9#8UC"9%ZR:;)$[6RW14UP?>
M3BF_G5(.>+<FZ+V:`/>]U8_W-7%J](B@MO5@VCYE("4SF+&8]1%F*Q117SV=
M"00EK``:$?^DG,I=L&C8U2^+_AV!!D2X%V.*'8-8M*HGZ$2D,3B*MS3:\:;1
MSM]_""]QNWTN1XDQ89L&JAIM^L51)^X"FQE`""R?`E5Q)Q9$A+2WG.TPGLSC
MBMPYF^MS"6Z9YPUSB]$D?=#M[J%"@N/>&/R:9A`DZ'<8_T+GT!TF9)H>,"6;
M_X:]&IY`VVO\/L'.,)U[!U-Q!MD/ZMY/&"W4_3@&#:L1[-F*@FWV%N/7%#\3
M&B,QE3?A]`.,,%4V08!9[:&QI;7Y"JW+NL,6F3Y?K`P2@NU9C=]1]3`$_6T_
M=*%#_S6N;YFQ0'+PSWO]&M/(K'&E5J&J\7BA;&6&SL!H*`4')TTAZT&VZ0DD
M^'6X_?FR9"V=DS"^Q(LEC0C*V;HI9#LI\A><L4BF4GVT'(Y[.G2D]F[U`TCG
MD(-,LS)QI\R:E8P[8C9<4>CH!<;%_FD`-]4NUKQRJK,!_3!M#EW'3/LXC]`Q
MUO%`0R1^.K`376L%M_O1<?SG)3R;1_7<;'><_'ER.:<A%M4]H1CW.4ABA]"I
MHC7'T*&"(F\PQHG-JZE^5[D[3EV&:,.]Y=PA!/U,9<-A\?UMEVGG:?YJM?(T
M?X6)`['<V[U(<A!IFD+I4PC.-"II!@<:/3]>W>$`8S]V[#ZFK3_4X"YO"(A^
M>L6M$<W1<$!TA<9WBVB9'4-%-"^O:+NV=T13&NV]M("*"ZJK5+Y?7$MM&2RR
M!1*+MC/ZQO8-+K+6T.:).""[2N2[!;;4DJ'B6B"P:%NE=UBC57N/S1-Q@76%
MR/<+:YDE@X4U+S`'ZS_U#^M']*TUJCD:#J"NT/AN,2VS8ZB0YN45/73;.Z+A
M"J;M,<U3<4%UE<KWBVNI+8-%MD!BT9.Z;[EY%T[2*JPCRLZKWB@:;WK>K/[K
M,27HW9(_ON_B7*R_@)S5?9%O?JL;2V_CU!M_'UO01J8:>!=9(V.@./T"%NJO
MA:JI%*/5IOU[:\U("'$E54Z(*C$',1H$E(,Z%-`2"])/?Y]H4.RLMP.#V>?3
M-QP\[E\<&!]NN.RB8^F2RKQ3905ETJG?!9/2Z-A150T`#IQV*Q0+#D%](R:O
M((O9+6I%""-LTWQAJ=[F^PA85(89.$X1BR:ZZ!;86GC"YLQ\4TSB8GUH<P_6
MY;T]IM=!N31F)M%^TKID9;06;LNJ__!*#"#M,M:K3<7EO:N"Z=>?G@0**I@;
M^<RQS".%.7<4P>@@4\<LA@UD\@P9\1Q%S9Y.AZM-[9XN!'.IX3.D=RZ>2?FT
M6WZ]HO_1!->:UDT/*6O]?03<9L8:^J*)1DA/A[TZ`ZLZ'M"UUP-VN.L7FH%1
M`\WB(H28CP8C00><=7&5WTYE6S4Z!OJ6:L="#@R+#Z.,BP(6VJ_<AW`PX>XY
MY,N!OGV'<G/8@_,PW*;MQ'UXS#9?)H"0Z6P;BDVS!S1_R6\)*5B5CBN0BRJB
M&/>IY)H-^H00=3ON<-_)JJ;8FJKGB_9V(@:U]!.*_:5@`T[#0E9WJ"S0>`F2
M!,87ZUW^?MM0%L%[HMIP?JVI'MO4Z,;<`U6I\*5$4`E]D5(D9^[@AF+EKR\H
M>FDJLC67HJR,'Z(&D\N&Z/<TMYR-'=#4<M`AJ%6ZT%W4[+'_<:_4N<WGRI26
MR4=*3^M[FCZVI@UHUIB+[NFB5T^[8[(,]/5O!<K7E1+RT_P%9D\O(-W8DSTC
MO8(DA_'F2^VZ9>:;O^TNFC_^QSJ1AQK"H6JF]:YNEU?HMF[J^ML29:4BDI2$
MLETE#2%I=VS8-S7)`.D&M5A=7EX3?A:G14YRD,8HG>^7;*6FI8"'TJZZ])<I
M'5U*3$_G&+'JPZ2AI,Z,Q99?9NN])/'AU>-3:J<%RLL/`%7B$J<Y502F$8+D
M"N8`)<2A:K%X/AXX31J<.*!4IY]%M^IL,^KFS=?LN369B<KN6O00:B3IT67!
M6^N1P"YJUN:T*<O][#1D=03E7W=UTR\*0JU`R.-&)*(ZJV+2I[D:4??I\]R*
MS0!C-ZT5X!/RJT7A1GR"VE#92JC>]Q6U:8*DWF:`W5TCVV,SK<11A8I##09"
MRF$=![$==OD6?Q\#KSH2U&K<#??S/8^\QYW\>Q;83<K`3GI-3-JF$E8(VO2\
MY!":#IMI(!ZU*L5=>""GQ,_/]Q]^''"*LM?$:I^;W9W%Z>SPY[7B6V]/H#&U
M;0B,(`IPMD>;D,"!:5`[PG7YM[(K/QL&/90X:_3H/Y)P&#(IRE3J"YV6.7,Y
MRL1,@XH_O,)*&IL,`"Q%I-(9KLR"F!Z1Y3&^*5\+4Q?ME36I1#=\DWZ#&Q,K
M8B-M#(:V1GX7]TC)"L*><]_CIRQ,*VG1'+WA2LK:#IY=W5?3L3,ISDJ'+K33
M8[DB0-6V-SFK,IKPTU3;-M&FGD?XAZ*448!!#Q/0#!=<ZD=(!QGS6%+*2PN9
MD$-'KZ"1AHX#P$81.OI"C5FDV!UN?`<6JA=WQ`V:8<5@;^68V`\;:&(^@H*@
MPN35F??G0\YVK@YG8V[S=3KK\[CR^PAB!)DV;6("GF909SU+\937404M1(/<
MQ30V^Z;S%FX.J?G,W=/BAC#D@@E6@RC]YO8PC(IOK.DHFGU#W<=QR-W@S^`;
M6A0+Y4@*VS1&LM&FWR^KR,K83'[Y4&Z:5P=33$?T_1QR8D("J30O]"MQ!5<P
MP<ORFW$X%\R^'1F(\B=\#[,9SA8W."N/`).+M:;NB5?:35?@A_88/OD=6+%5
MN.!5'C[4^-/[0:,-=^VTY1&\TO8W'P8MV.(737ZFC5TI&"\:>)I@W169$2ZQ
MOR[I8*;Y]KJ(=*&M:E99;HN;]1P:>+4]-M;?-[+JM6>T0G0)DL\H@23'*=RR
MEE>KUK2L0$7:\@C08F:%[@&CDZ/+W-UC7L0T]IAF3QF[6B!_,DK5KOHHE+C=
M$:#%Q`+=8T4MA:?S2D*D7""<X#F*[E!$HPTX62X3%&WN-BZ7&5Z!1`H>VZX5
M/)EW/0*(.=JI>]19"Q;4WF;P*PUY&B[DM88R#QOT8L,P;SBRY4;[;"6!T?LY
M7IW%$+'9]4?V#S:I_EB95/1/?[^#<Y!<I]1XHD//BA9;<PM;!)P@TFODDN91
M4>6O]+O=Z7<9W8TX0J\G^[DRKO6?>\MRJ(R)M8+7AD]`:C=<0A*^*HG*HJX%
MC.G'-IG$*U80,)9XD<U=ZGRM"L+:4*K'9&Z4^@G1I`.%?1J"@TR5925N:L6J
MBR*U';@![GO:ER,0A2"6GD`="[3V!1\#JRI\7,7S72\AVU>^M[U^;%NV_L_M
MO^\!5)\VQ\I;W7JWNO4!N9.WPO5*[=X*UUNYCK?"]7WX#\=P1'S?G7Z;*5LP
MA]/9%YC?9WB&-I7LA%6[3)I7;\$KF_?C&UQK[%BHVJK`CA&?+G>/+C((HI?-
MK466N"I`4@F2F"!41(1%<+#M6EU_&G<-&R:.)F@%&6N>76XI[3'[`'/*GFK$
MJDH_@@22"SC#&;Q"),_0<U'^A+.F\`)8^2)9@5M[DF'#T+/)6L'3FRR>-J`D
MM>6*;.=F;R`4U\@3-ZE5CVLV"1LF&I5:5HJ3T/9T/^+X2]NZCJIUD5K;H;4L
M-^NQ='$U.IK,YQF<4\[W&:)R+D$R6>`BI6XFAHNRY*@F8C4G((EA30B$#956
MYO`6YUIPYI-LX919N28Y6E`MIK-[^@-Z3B!K(%DT6_55%UZ1]0T7>FV,X(PZ
M-Z8<X/XC',!=@06=/V3[D?T5)(7LD2#SCFJH"3N.#F=Z]7V#3,610YA;63SQ
M:@SGD-R#-=O+X+WL`UQNWRHHW:UHZ>72O[K.LNL?+I+:&J/="LJ)<5A)Y3NJ
M_'Q3*![F^:;,,PT@V=%#F<_2]V@Z*U6/<+%EKW![]V3`BL?/H"7M-L=4+S&1
MOC,I:L(AI-ID#)"0JN0!`P+:_*#[O)A0/"<;IC<0;A<`@H^.JEGU6H*P6;AC
M:JA:JR^%DCX_MD.6,_M,;9O#E)V@4DUJ63/N2GRS6;A`,%2M]027TN>!X#&3
M*OJTW%(Y,DCRPZ)?,.WM.E8<@6G'<!'AK'XK9V')D4>-Q\3M`US!M(`/,,+S
ME#T?Q/8(=CL`DR)&H@^%>:<*6DPZA8T4:[5;H<2"&X\0CZG?29H6(-D&+=M;
ME0),J)I54"!N%O:X&ZC6:J25]/FQ]?B*W+;8RV8!.YT]0+1X+C(")6-LTKQZ
MWUG9/.PQMU"UU=@;\>$Q,-SK:@Q'L]4BC7V]G'8#4%8FYCY#P!YM*^W&C4L%
MA68=*CC4=?`UFX1\9$^DZ1OK-.CI831#<V-+M;A9H^:SFR\&]$5E(<;U!-I>
MR8OU_I]_03!CEUW6=^RJB^+J@5WGQG+.M'/?%Q,,AAVW-($9(+G;"9:\@JJ+
M)]20UT)Y"-F)A@QU9C3Z/ZIL.<@B*#J81WB6V4P4(4*M1`BJ$&?O0)6>H`\"
MJHHK.3TAU>S<_6!8#<*IWJ;+@D8P3,U/ROL]!CUD*!3UZ/>NC]N(B7"GU5Z-
M,1/^0J@I^`K*GGX8\G+A#6)99022VY30&+;<?%9$@NK634S)6@<>ZQDIZ1K<
M:8A[.M#O!QQ/&4C)#&8LZ?`(LQ6*4#J?S@0ZE"50B/@GY3>T"Q8-&/IE,4"H
MJ($,[L6:8E<I%JT*^$Y$"BJ4'-DLD0:B8Y@GJCAUF&EB&+>&,E&&C&.WEPV4
MD:NP30.HC3;]1J>=#!,V,X`06CX%JN)1+(@H?AVR3GEE07B'P#-*4+XN'_4Q
MRV?*^\C3F*(^@4>T%@JW3UHJ6`15>'(O\DY@!,E6QWB:/L"HR#(ZE2X`0>1K
MBI\)G5Q,[7)UQS;1Z1Q*4'GJHJFT6=JH:[XR"'?'=]`\J@)WHKG0D_5U:2Q>
M:N&TZES:H$+JHYV:^BSPV":G6>8XD+EIG60.=G9Z/,M]!3.THD*LZFI("E4:
MM*X<,U"V'BBMW/E@85M+J5'8E;R[`Q`F<HK"_N`>1)X6.<E!&E.K2/R[:3>3
M-VYKW?H[>F9^>,91:8=C--:<NG1G.B&^%,RPT]GC"\@@N?Y&%UN("&MBM:14
MK2;B2BE$7/DSC>.)K;;,@]ICN<\P7>_GZ\?B^1^0%9>?9I,50`ESY:S`//T1
ML-.>=]0B\`ML'J)M2Z;AZ>S)A(A03T9IX0F=.0>5(;E=+*G&3,OI[`Y3:6F,
M$$\(@3GY"TQBJLA7Z9U?J[X-%!KV#1EZ+NJWP)L=.WG=IMX/?U\APH[04N5.
M+PI"52-4P=\*%--8E7KS:38'*?I]4YH(YNQ1)5^GQ*ND+W%*<(+BS:,Y:7Q/
MOQOLSA3[OY5\^2/]B_XTN5_"E2C"%V%?D58K>0X#+SO/W@5Y7];DR'=]9MXS
MJ'#G)N:<F1\-=C%@)Y*/_YS_9_`/G%T6),<+MB,HWP.3-^2N8_,-^][MZF2P
ML84Q_(*Y(5']HK=4DJ`2]%_``DYG-6F5B75M^P;J%.U[3V,KQ@3;:RC,]?$L
MJJ#0D_:$#7'AJ1+(F\,"*"]8>;5)DL!LOJ98OTUG='F#<,%`S=8R\L1Q*SK5
M0E1N=/I--NN'#/NSBA!24@GVI:A:<>X2<6^O:G6/NPZ>V3)&GO=WMX8\U.;M
M2RC=&N[]6Z@Z;]'R8VBV`>O]<S@D0![8^Z&*2)S[O?G*[.'W8XN[9:KW%F[S
M`H0''>5Q64$+$7RZ^!@9Q<Z\@9O#;_%F]HX6-X+=Q":^5N1E.0[E*`K;<.OP
M6IN>WU,76!F;R2\?RDWS^NI71">HX63)]1QFBROXK'NQ4=64J\TL:GIL[M[`
M(+UY?J4LODIG=@,Y97BI;JR!W6`I%N5H*!!DGF$1<5#A(>BG'EDV?#J[S.@B
M2GV;1MZ0JZ;+-^SW$Z,9`&RAE!$`^`LO"KJ!#7][AR!=;/;K$E0KS78^P6RA
MZ=LK>'W`,<,1A#%A11IOF>0@N2E$AQO-&E<?OE$T[N],13<[FL:&Z'A_TD".
M+@]!EJ=&V',\&9257I0UJ0"%;S)V>&B4[A@44NZ>3B2*]V^VIR&GY?-+R@.O
MNJ;571AIT[%#Q-`('4-%*X6G@X+B`KV[ETFV+FM32Y0\X0M6/!BRLV5?ESC=
M"36=7;-G'F4/M7F@5BWWVX;:V+'ISY0=P]>'H/)3BF\EJ'L!FT.1:L\HLBIC
M[?-QRDKT-HECM-DI-PN_I>TE$;B@_=B18V..'N-PN2@<EMXJH@<!I#8UT_WB
MR*VJ^J`O3-+O;R)X`%OZ>S,3=/A]S##2J=LA;N2L.:"X/13IZ9;/[J$8@)J+
M0E63YIV=6I-C0(Q"Z1Y`(^0>6AX:I.7WE1#Z,:4`EZ:@)>VXW#/7[AAPI%._
M#P\D%8%'U)"[ZRS/?BA*=@\SA&,4;2/_)Y@MR`5($HS3W9_H>E+AMMJ2:^#3
MG=PQP-B3,7M`>VM)P]K_?WS!62GV!<XR_$HGL"RD4[1L0%G8\AA0JC=!#P!4
M"<%C:Y^X'?+R;>6%*=!\8:H\_^]^^];364C()G24%ZSH#7L$DXX..S:>L;(U
MXLNX+EV;IR>-N@YW0+0F'AWBN72YIVJJ5'K7M.<3AS9CAJW4%)](-.!7.W>J
MXA/4B<7'Z`7&10)9TJ(B<ZE?0MU87+XH*[J$W8)"\W-C0Z'+J]1MX>5N"B^H
M<V$O.F8PKDO-"BNI[E68]3)W^/T?RFTS[%*?J+.$$*@6$LB]I)QS4`Z3'?1J
MZ*DNSJ]KWZRS+V_?__T,PP'"]NK:.CRN'KZ63U"HN0'1ML`B9CD6S?-,BK9<
M85AAVYZ+WFO'`MMI)ZYD+^-2K[FJHAX4)+PY$OF3'7V[$M6!79^^Q.SX;K?>
MY.-@ZW*VCTPP`4M_;R(_HGF*9B@":3Z)(K:)22UPCQ,D?+.ZLA]MU[&R,VW:
MT=<^NY*?K,:4>2=3S7JJ!V4Y+-A172Y99L9WMVMNP6_\M9>.^6J@Q4"VO/"G
MY]3B&E]`Z'B[Q1?"+;ZW2WS?\R6^<;N#MSM\W=SA&[K@QSAKQ;A%",858.S"
M@K>Z+F]U7=[JNKS5=>EH2DJ_O#U,2F4&SG!6&F;7G.?ED+[U$A!61I#]S_5O
M!5J!A)UI47Q3]1V:KP$I.HSCJVNL<LO/L`$?3S>?/6XTHXAM9PHE%_]5[34\
MD!1M43N3[#U4,`!!<Z_:C[V$3DTN#;=OW58*3]\W8;)[_T;&A+V!--^<1926
MP35H74EO*UL/<`JL[3A@6R/(]YH<1=FEPTU$""LJ"LLARN.N`%VB*E#KSR>:
MA7I#>L4A@\7C?"[#+2BT?P3#+ABT>=IBR$?/WIZV:"(CL*<M/-98^P6O8):R
MSS"[\9"!2+P38]*T$D#)FP;Z&("A;F[5_K7$P[K4^E;/W\8##%7/?TB$?+?'
MT5ML\[B?0'?8_'$]=.Y67RJPLZ(2(+T=.C_&0^?7BV6"UQ`^0OJ-92_I*)?>
MFM8-Q$A;!WSTW$Q#]\/G.OI!@>/M1H*-=KW=2!@RW_%V(^$X;B2T7_DVDW2`
M29"O-\4R!,M?H_:5-;"F?7^E)MP.RMNHV_*,O!FKH-S(\94=<$.*A9(M0&+$
MQ=,^NM!7/-!H)RU8X5Y,9?X=QJR8YBZ9,REB)*IC:=ZIXC5,.H4,""?%6_H/
M"W[R//L@5]QF>0)>YY'+';<NRHUQ(ZJL)L:/OZI8V%T`Q6+J$JD*?BA:*K7L
ML8"';C"DA<N,:W-(.,@+C;W=9QO'?3:3T6MQB4U!_NWFVMO-M;>;:R(@O-U<
M&]'--9"2>[!F#DT]^M*&@KJ_S8;!CKY.*=?1E],-:NE?_ZI=@BQ;[Y]W,8HF
MQ5V4866S2[_8<(XTE9KZ"3DE+`)&S"TA!=LXN0(Y/#<"C+"'$B^-'B.!BTI/
M/V@1<PCJ!D;U([C;5]G>'MO7TKT$2_I+OC8(.DQ)*,(1/8E@\=7"$JZ`<V(9
MU/%/D0:71991C=L@4$?"`(%R$J-"H*$E?")0RS*HHT"-\O65LO5&WTM1!_5#
M!K4.P6+)6$L_'TLA`PXG'M^<J[/?[P.RC_5GG.;L9L7_0B`ZFFS9L[+?8MPS
M.%2XZVT+#Q=.'$X&?0A,X!$Y5W@%290AT1.N;<D8?-G49(+#GB>+^/S"&;'E
M4.GVZICD0JJ!4/<PBR![/N]_"I"@&8+Q!4H2&&]W.<GF:5A)J<:..-0NOGKF
M$!QRN[>CBW?M2J).KPXY"OTU?1:+[0_Q6A;M(:]@<4R8-[5DCZ#7B\2C/IP7
MW7:/&C[0P*E\0RG>:@CF9F<13`BH<X-*`L&!M[45/&4.31CRP/-X7G42_Z,@
M.7/O=<D>X(Q*ED:P*N)-@G$F198O<M4'X%N1"PYUGBWDXAZ]L.<1.61NNZ[(
M!2"(/"XS".)I^BO($-/UP7A71-]=Z095W8.#8TL+^'&!!NQXN+DEL@W20W;>
MSKJO-$4T/C_FJGO[-)&;APHG\UR5_WHV@U&.5K!%O*:@81RR"6D$ASL?MO`?
MN*EX\CATRVQW@<-JMM4(=*(.2H35.XP$3@HM_6!'R(`'RI\]YE1P.G_:'I.Z
MS^!RLP5#_[5`Q6*_%K[/4!JA)1"F3-PH5#,BMA2"@TM[.SCE,QPY\H!RVROQ
M`:C-G;NG5]P>61PI=XA52!T#UF26Z0%T/&L>?1[W1/X*6)G'G+!S5S!^PO=%
M%KT``ME;VSA]S''TSUOVXGC*/LLX?<+L$.ADGD&XN?G!8=`/P0H2VQ(,$H]>
MK>2"2D\"^*IZ),0F>\H^V9YQN(%P.F/3B,EQ`1)V1G`[>00@M.Q909MQSR!A
MY::W"WYL.?%`&3+C?YD`0J:S[2289@]H_I)??Z,R(P*I*X[@_D>R_97(<EZM
M:#7+MKO1"@Z+/FWCNE!HQYO'J\>-@HU[+3WOKR`IJ---5S#+T7,"O^`<DDD:
METUV3GDGIL#3M255?3+2F51P^/-H&1?GV)HUC[XA-P4JZER5A1TV,6I%-79Y
M<3JKJ/D(([8N1]*:&UYH-KQG2YK!H;@+6[EZ4S\R\+@>\AB]1*?'%Y!!XAG8
MED3-D&U,=&S0=K.69VS;"L&#.YQ]DHKD!X7*(,AL*]>@O_IZI*I_L.ATM8&G
MBY,&_'C,#;DG<IO&101CR91AVEU_6\*4R+9(K/LW,&?1/UC,N=K`%7/V_'C,
MN6VO>%K*'X3=95K+&'M[3UVV:#?KU5R>ZWH%BRH[?9V7W(9<>`0->?>DKMC7
M%"PPU>%W&@P@$AG7#%#T4WX9A?V"Q9&MSGZ^A"H^/);<=D=\?0$W9QFV/I.I
M(?W625MR7S5!RV`1HM?+_4LEI\P7"-CO0\C*!F[_SO[S#`BD?_E_4$L#!!0`
M```(`.*#9D>W*BEQ9Y\``'M:"@`4`!P`<&EP+3(P,34P.3,P7VQA8BYX;6Q5
M5`D``Q<</587'#U6=7@+``$$)0X```0Y`0``[;UM<^0XDB;X_<SN/^!Z[VRJ
MS)1=E<J:V>W>W5A32LINW:HRM"E5]\VEG8U1#(3$;@:I)AG*5/_Z`T`R@B]X
M<9`.$A&2V4Q7*@AW1P2>YW$'"(+_[7]\W\3DF69YE";__7?O?__S[PA-PG05
M)0___7?;_%V0AU'T.Y(70;(*XC2A__UW+S3_W?]8_.__VW_[/]Z].\]H4-`5
MN7\A=X^4_"5*BN"!DC]EZ?;IA-RDWVA67KWZ<G5+SH/L/DW>O>/&<93\_8_\
M?^Z#G!+6BR07?_[WWST6Q=,??_KIV[=OO_]^G\6_3[.'GTY__OG#3W7KWU7-
M^=5(TSY*>+?#??N>_V\?1.OW?_C#'WX25W=-\TC6D+E]_]/_\^OU;?A(-\&[
M1H`\^F,N/KQ.PZ`0/Z;Q>Q!E"_[7N[K9._[1N_>G[SZ\__WW?/4[]NL14OY^
M61K3+W1-^']_^W*EC/F'GWB+GQ+ZP$?K.KBG,>NS<%&\/+$QS:/-4TSKSQXS
MNI;[BK.LY8KW[0^\;^__C??M/[4C_#2ZJW<,F=1]?YMAFIV.^4?7[%^MX/1[
M09,57=7A>0#-<(OX`ES"\\YW&K:\QAPX:=;^3D_1$^OR^W_]^0\??A8=9A_\
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M9AO^,[!?E?T*[#<-7\*8_5QKPG+B`\U^_#TYB_.T[FXNC(*'ATSH"PGKT0TV
MZ39AO=>-[\GQ#[#PQ+YE<Q1XDYP^!>P'IO$+645Y&*=\0*LA:/U0\X[U?_MI
M+UI]H3O+VL(>9&&M->R?!IVJ6OS$QB:D3\6[N)G[UEFZ&2KCZ2AUK412I$CR
M1V+E@X_2H-#3)9'_>&^5RUOUR.#T(8(B)1#F:U$U)G5KPIH3T9Y4!J1A\7HP
MO!_<&5#,@T^(XU,;'!?]XGHXF$\1P7RZ!S.MP2PRA@!S_"I!?#HGB$][(!X^
M>5FM(IZ<@_@\W6S2Y+9(P[^?U972G[(TSV^#6#YWL31M3EW`IN/):ME+Q(D+
M/+*!J5!'BWU+4C8EHBW9-2:B-1'-2?`<1#&O7LF6UX%ES<:+T#2..=?_L8V*
M%U:UK6DFBN4L8WVD_(M[0'1;\*5C0"$C.=!%A^/^`1^UV+*)B0-Z46K9P/ZU
M8%=?9SE%+TZ5!0V&7F39!$8"\>F;=J/C7UNBN<4_:H'VMVU>\)&^H/?%59(7
MF:@]OE`VM)3]SE?5&MP7UH5/<9IF-Y312MSXD19MX]VU"KDQ[A`T8ORWP2SX
M1O7&)"4CG"_VUKLU6\)7]OAZ76DN_CPA_`[7BFR?R(=W#.#%([E.DQ73(N']
M/DC^3I9<4U@;'H?\<'WU<?GEQQ.Q8$<"LN:!^4+?^]__Z__EP\(<!MQ3;,A)
M!6FXVZY('2PE<4O1D?UP1\>R9-T1DCL@>P]DYX+4/DJN"2]D[^:-72KT>,LO
MI,)X1`?PB^61G7%(LU-UWCOI);XR<SWM!YUGL#>*J>#C+\4P:V\6=,4#WZ7G
MN[G5I9A:+:N9U:]T<T\S6:%M:]NLJN&VX]7$MI^(];)%:(-,@#TM=DTYY/BL
M>6]`2@M2FY"OI='_YT,A:PVG=-0HR_@-]=$ALX]@1JTTK8(B`5G4D`.@_'J0
MK"\''6-94N@-SD(?(Q[E+%G]EMR7_PQ#OFTI_R*V]?`T^9D6DA1D9]C(/U##
MT7RUZR%>Y@''U;,5Z&91?UQMQ"HWC)46Y9ZYRGQ^<EI")AT^F!)2PART&>D9
M5#'SBD5$#)CRC%*V%#N5ZK9D!]Y]:\*:OP:L:E.(.[2BK!(`0V&O!UB$10'M
MJ51=R0\2=?WQ54!6-T-W"%G$6??'C`;AXW)]OM\/S6^W107/ZV??@FS%9OM1
MNI)5/):FS9H';#J>FI:]1*Q[X)$-[(0Z6I0M^2VAYO[V<->8!+PU7WACS<D[
MDFQ%V<W:\[W@.5FS&CO]QJ<P41(5465+LY#_,P]B\?S%&5\,>G[)[G[U8*IN
M#<)T##AD-`>ZZ!#=/P*@5E,V,7'`+RJJ$O[+-6FT)OOF1+0GI<%KP:Z^KG**
M7IS:"AH,O;JR"8P$8E9AW5[]Z8S<2X5\_Z!26\B-LOUJL*XMR-QB';$H.P_R
M1[[0]<R&CA5_O_)GV*+B15F)@=HWRB]#^]&4!?4'K]`RA=-S4V^]X)=)X_H)
MJ5MXDT=@PY]:CY"$0UJ[-G%F!1EF,6,.-`)@O&SI0NSX$::M2;`PAE)]Z"-@
MEQSF:&.@=EI!+8Y8DQ7'UZ8&VM.Q`DU7$*`!#3/UQT&>+]=_%7O(BV7V)7IX
M+*[R?,N?_[X("MDV8[!-LP0PVXSG#K1?B*4`(*2!0D8/"]&$SS*K1F29$='L
MA-0-"6_IP?(('!KIH)&3L<IDVV&6#T!$+1=`P4:"4)0-*ABV47B\(-17$<@P
MQ*DFC%'0*PI0Q+%H9)4%__OH`:>M)K`!AUE5\!6+G)]SM_Q&5W>I>'#J[(&E
MT\OO3PRU.5V=Y?MMG<MU^SFKFRP-*5WEG]@O?!F$C]Q\N;Y]##+IL^H31&M6
M,BZCC6>\^]\"L7IRVEF#R#B,O=@[)^FW\NRDO'RRDP<XX2=ME"'XX52-;>GI
MNG&0U8-X(O2I"D2XW!"Q2EO?&,M%-!^JO@D(F$Z,<IGBNHO:T>K7*C&H=;'C
M;LXF+Z(6WPL,]T_NTNK1<1&"[&*0L[SQ4!DOWKM/G->1"`]%>"SAB3<MP[W)
MBQN$'ZG`X,Q;'/8/?<;CN*_SZ<SIM(5,>?=9'(Z1\[,7WH3'#>Z/57BPYZ_E
M'?=DQ>_$1PGK8QC1_([OB53-0<T6W7FDS@)'1<U]0I[/:0,"Q$QCOVANK4I6
MI-6$?!6-/'@("HJ%/O7!`.J15VTI(>"<J$,O\0VA1B%N5VJ_2LR9:U4DU.'5
MC)H83NH^0[QQX#M]U>`SUBM8X'-2-^3=6-=10J\*NE$N8`/-I!6$S@R16.;>
MN:@EM%&A#-,X:9"L//JXPS+>DHBF7E$-`!4%W\`@DU-.;:[BW>SP=%-T&.*-
MAV:[_,AE*>`5@1-8CF#"$[DPT01R5YT8@B*@]/1-0F4C.1U*AU4PU>\H?L.<
MAK]_2)]_6M&(_9;O?^'_X.7-+^]^?E^]"^T_L8_V9V1\BH.'#N*5UZL?0G)]
M%+>4\<9IO,RMFB3]UHV36_C?\^)=/2:I\6?LX+?7;@]4YR-KE[\-\BCW;C'$
M[>-Y#G.0E<G49I@Q#\(Y9W`HGV^BJT]4L<]'WJ0U)>HV04C?\JB84YU>!%-6
M[A@LQ"?E0WIT1=;4DVTABO%*(;^O-'VVFW93I?.QQYU'2'S;C7LY/^`C7WU(
M^*>'.O"&^MYFZ)'J]HY3_!I=$L`2`?R(E&KLW__T@60TR--$K($%!1/>A+[\
M2R[T0)3E_`U/#"W?HB*A>?GY"7F*M_GN`-6#E0U#W6V%'L05P?89IW;'^5O;
M-A*AA>UHHECW$R]UVH36,PON:<'?OMUY[67GI:/EI@;6Y!USLR'W:9:)Y^5S
MDFX+\7YOT5;[8M+RQ9^!>&_8GI^$OW2T/-T_W][_3;R-,R7A(W\!2+FS0KP]
ME)\9R?Y[0A[3;_299MZ>X6^/\704]"3B`/;15@TO&899H-@%16(7+VFZ9^;[
M?E+^5!C6%DBN48Q24L&C8==:=I&QP,RJL[\$620[HE[H<4N-7Q&0=;6:<R`[
MJ^YVCVGSQZE^Y2_8.4M6_TX#V0GREI;*RDYCB<Q68Q]=576ZP#9$5?OI9IS&
MB1CB03K16$R@>'/?>&H&CX:E4.2I&:KTH..G![!U5RKI0Z)`5E(FR4%[]JI`
M:U$AX<+6076DCN6V-M+'Q4$OJXON^,0X3H-$Z&K,;Q#S_?\9747%R?Z@F)47
M#WA/@EUX482,7=2"*(N>67)_IOO`U2/GN?)M.G"C5AED-D)@)+1GF,4/(*:)
MAD87BWV;YE2[;N71*T4LT)$.&SLIWTS&7:IY@4;<F@84;2P2RTKFU6/14+E@
MHQ'SSOT^VG44W$=Q5$04(O;*UE*5E[1&))2R+RYT718,2J.^;9,]C:M>LD8]
MY`JZF#`B9TG/2D6/B4'E1I[E808#JB/(QP\IH/0.!Q72Y%#M'W]"J(\U'%NG
MKPU;^DD=`K8P)V]5'F/SPLN$]??E*EFGV4:DM;/[7!Q'+LOH%F;-U`XR&\\;
MB]XA)GM85`.1($X6=2NQCE*V(XV&Y&O=U`=JV4`E'3J,,JH!S#N<\P>>J&4#
M--YX:(I"X@V<O4&<#)Z8D[SV>U#/OD>R#=KJ1@W=ES4:32-U9#Q-E\;0TT1B
MLNB]O)=_[`'\-8.7PGYJ";#[C=LPG@@,F`JJ\&X+!*Z.QP<%K<K9@\&=@EVD
MFR!*C!K6;J94L;H9,G3;T5TIV2Z*#80KHSZ$RPO>@;@SD!H82X=<#>.RN0[(
M3L'A3MD:_NV!(56W(X&&A<9!P>%.YZXUQXX86BK5[AKQ]`9#'UQIWC7X"!&5
M71_>USX]Y&X:6PW*54!0P_Q:_NSZY*AQ)X;7%B=[J"U?`68LQ-$.->XD4GFK
M4M=,*8YH]Y%TT5W)(O!VI-2H#VYO5O2U`ZE!M?&6HZRY#LU.P>%._<"W%15F
M1PL-"[6#@L.=SJF.KM6T4JH<UF&AFMBN-`YV%*W,I@]C7PY@U`VA!L2FDV4E
MK74`=@@*=]H&/2E6;G6<D+"0-1@H,$7M4Q!E?PGB+?V5!ODVHV)OLVZ:"S-H
M2)W)8#3`83W"$T!C/#WT#>8+?IV(!J39PK/9#1`&J?U`24BB-VSS96:X84HK
M(-(8J''!?:U@TVHR'MQ0]JH90F!O5P.$&X6ZTU>,.MW^-434(>YBDT92S7W,
MC4UU`5;1:^Z)XWH`-B_2F*I)XDM-#!AM,S=,DR:U$8`1[M'D/-U#)U1:X]>$
M)?O,;H4F=QG=S7LU#*$&@TJ7Q8\05-:)VPY4F`D[2H+X)GCAWC]1NESS1\.O
MTR#Y6)Z*5AW=(LO>=I;-5`ZU',\<NSXB)GEP8`.E@'X6HB%Y*EORLR7YOP6H
MTH04N\?]J[/N3NK7!7IP")TMCM(1`RRC(\Q#AYN^(1BUL+`(B8)>47((_%9M
M^4FZ_!VXXI@*WIY4!O7)<Z\#M?K:Q"%N<:H68"ST$L8B+@Y\3P?+[RO!L;8<
M<HECS$)I6[`B3!1DM[1@7V,EJXF4C9KECZ31>+8I(R,6-;(8!@KU31;E9]54
MH/K4`R*HARZ%_=`R</<:=W`\#110JP.Y=UL8B)Q_9$#0YVMK*.!DX;Y;](0K
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M-_T#DO^^>57UL0]\2^_]0>IG=]5`]E+[KJ$DL[L;;/02O^W99J#W!?ZA#[6Y
MN@<--EYMOW?II+1ON[<:<U[8?W^*LO(D+"Z6!SG@QL(=-N#8JTIWK($AT4B:
M=%--JPD.("51D=--.P(`DTV#Q542%1$KE#;!]VBSW1!^/D5!$W'ONYYTIO=Q
M]%#BEA_L%JQ6$?^C8=5H0:O9:_'(YJ]1_$*"-5]9C79Q>OX]V!*B!$B?"FH8
M]:C0:"HA@UNPH:>[KF\[H.U3GOC0MZ1G/?3FQ`<>?+SDUW3J)/UU`UABX'0O
M-[]6PO%K0PX^57*SW(O)P</$F"[A,$%/F=]20\+L-NBERWT#)`!W(V*GRH9_
M"'9WS6OM^I9Z!\G>($D`J1C(/ACKAC(H.AML_%35\FPST(TT=>!##4A0D,%&
M3$X[EVY24\N]U9CW9F;_^;!'WIQS0"./F&^NHX0NU^?B;6^?@I`?:?_RL7Y+
M^GGPQ#XJ7JHM=,OU_]H&<;2.Z.IC%,=T=1:&_"7K^1<:TNA9\62?HPB-C(<>
M832M''UGO)R+WT$]K['C+;A#OBV\=$EJGV3GE-1>ZWWBO/7.,2D]D]HUV?OV
M8,[KBC+I!!B5*!MRI+8T'CWY,6LP%UV;E/B\"G1'_3?FCP/H@7,?I:+&[A-V
M2>ZB?]-*P&DE`;NW%)-U+0'W.PD(*[\GY!\[XM^7Q`]JXF<[GQX]A'.0"J";
MUQR4`LP_L_HMN9=W#F]J90PQ?FZE"3&7PAJ_]>RS*UT/G4BL.N#H(JMV?5PS
M+#-S,&06RD\$E56&0I'90U(!#Z99^KY-JP`8$RV-!KPIP%B4'KP&S#G;4G?*
MD^F6OH,32\'@"=<V.>8IU]Q2X&#2-9<4H$Z[_K&-6+]>SK*,<:0\*DNYFP+0
MNC49TK1&T#)C7S"G*+I@)H%1VRYV%TGSJD>W;2%#GEJ.BY2!2JLNF68"%6[%
MJP\S&%!E'?J*(&6H\,:#"O,YHNLT>>#'[5S0^^+R>QAO5_Q->E$N]%TFMY#V
M3<'5MQ_/#DA_$$77$,[`$JWU@E\N3TGC#<BN!:F;>,`3T/"GUB,D8XK.KL.5
M.4&&*L+&0",`)H3X]4%,+\=((,.9"FLCV,UKTR*(#?-:8[0Q6&,SSCO>AR/$
MDW;6AH4GS/E4(]!-1JMC#=F_-M%VLYOCW611$D9/@?0NU3`/BC(`Y`&53!9]
M=E,JP#H`YQO$WV+?B#R5K4Y(M";?*/^372'%(VV<9LF?/N-_18EXH)U=R^AS
M&C_S[!"W%X^>LB@5Y2IOE8>/=+7E:T2;H-AFO,A?,0\^W"(:"%NE%MAC7Z4-
M`$]JM?"20*[*(&AH5/)(2J4&FRJSYBV3G>7K1#VXQG*->_0Z#!(3_8[#@/BX
M\#^=.WOX=&]A#CY!:TSG?)JO#F6?1.GJ[ELZOB#MN1I>F39<3:TSO6\Q6ZW:
M[`FJ\.P=J_3G*8A6U:D'7#[649:S>=6WE+S0(,NYRK1TR:=78XP&[1A%45%@
MA+#L7(Y2&!\(-6/MVNZ#&S(-KV9)Z8,_L/O&GRY6O&/0',7O/OC,57"[(XZ(
MI*Z+A^:E-UIUX>,?K1!KX.IH%G$(_')]6Z3AWZ_R?,NW4_V6K&@F/JG?]RXI
M?`?9-ZI=2_O1:C*HOWAUK6UXO6S8>5O<,<+79W@]B[=B\#EPNMFD"<EY4Q)5
MUF3+S85",+(6[`OR"3']QY9/A]/*(0GV&P$\J&:'(3$=#0Z)/%CY:6N"UWS`
M+$OM`R-R@1>@]:%4Y?MA6)$I6I#:B`BKZL/:[O6A7%M=3H5SE#K2+B)V\6@?
M'1/NIT[%_Q6R0E<<3L8*Q#+P,V5U9[J.BB^T8"/*2IA/[,>]#6*:?Z3K-*,7
M45YDT?U67$JSCQD-PL?E^IP#)`AE&_.P7#:*Q?$N1ZL(UK?"*RD1>J27FM$!
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MQ0;Z2\[440:`A!=EQPL3[4O-A@(%\S'$SVE!\YO@A2^]G#T\9/2!!=C=BOM2
MWZP[VR@>2QQDWUSJL+,?7ZT-Z2_B(H9E>$,99N7M[:TX(Q";C@:1K-:R\=,I
MK'SF#>JZ@G5@1,Z(%0-N0"H+LC-I[-7:&9'2ZO5A7#_GGPCE.+-YJXCH4W?K
MZ)A@9Y/R/;R?=O`.RH%A$^N]]+]"B&LGS5-!'/%66+7Q*GB@RW4_<!GO"UW1
MS5.SHFF4?L,<-&H_6P>CR3VLQWC5GW5\/;LMW2WV[3F9`RW5&?M8<5=$/.<E
M(@-F-&;?KKR3R^^9!^LU#0NZ(OECP'YY#RJ[@8!,QT-$(@EVCMJ:X#DQ,,N[
M`9$Q2<$+O`8MEFMI@5?I]M[L-6)=6^--AW:4*L\R)':9-R`\*NA/A^<"4:Z\
M2OCKZK\)X>^H`MS=J#G[%F0KNC+4>ZKFBNJNWQR5PJK>N*G<)-'@[.P9=YC8
MO"$:E$WX7B+QQ+;8H,#:W-Z]._WEW\3ZG"C*6!-FLMJ&A6]5F!(F2B(:@*4B
M7==,3;&)H>BJ5I+&&0[#?AW4V"A3M3DV:($+FN'@0B]6>@%<EB;28",P5F_Z
MZ._4V+)ZHWGGH338/:O7U\:CPR*TNAB!1<S*@4WY-V<L*254>3ZTLDVS1NBW
M&4\755S$:D`2PL"+GL6B\9%'Y_&J1RT%_<@R^';;=C`[!090T[#4N>7XBX3+
M/R1'`P%]/K4$`4[F['E%3Y?2"+98.&VIP0$C0)O%;!&`F:\R^AREVYPEQ)#2
M5<XW(8H'CMC/P#<;\J?#Q#-'Y7L5Y-/?H3Z:^<[>QW@2#.TW8KX<T`4#AZP]
M+FH34MN4V_YKJW)KOWA,L'P6MK;T@(Z#D9>B`$%&9EM?';(?`@]0:X9!P9$Y
M(&J.-Q8,AH$'/,`IBZRCHI=-@WJ`30=QJ%#%`HZS\LEPSH+.(^,G8NF!?;AK
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MBC4+*703GTE)@;A,?LMW<G\,<KIBLZLGFN2BQFF\!_/CR[[)3?5@`B];/P51
M)KI[QOI9;E3+SY)D&\2?TFQ-HV*;T2_]Q^DGC=FH1R>(.5JG)OM=\&K>*;JL
MET+W/5@(>W+/'9!FD.8+=LG]"VFVNZD?#^2A3@@/5M4=C7`GI`Q(]A')E]D?
M@I^6HNDL#)`HN//8;<U_$R3K<RKTDXQI.CNS&/&)3"DS'_5R]+&6HX]].5*H
MT9L832Q&VEG6L<D1RDS.?2^QYW[3]'AN53JM5.E=6?R$356BW_F_Z0D_L:VR
MR4GV)BR3H/@U",MTY\5=)NSW?+E(^6R]HU&JRXW3X=J71Q_\)8LV_BRXCE?]
MZ5ZMQHOR+_*U_'OFFWK*\4A-OZ'DU*YFL_9A7=HQG7Y1Y@OE1ROR1_3%@M%O
M253D?V)6[(.KI#Q0#',]QB(<QE(,*-Q\-8;%K^'!`@RLMXX*"TAPV#SG7C?/
MV8>I[NJ(0*2*Q$^<+6,=<"5B0T&<(L2>]"C5!R`L4N%Q^#+CQ;(*M)_S20S.
M8HI!9*[>1,8UR(]69N9=,X%TT)OE$FAG9U2;4[X'9:<5Y7:LA[+-FS:XPN7Q
M:H/S30!_%3L^BOR&]81^X5W^%#VK'_X>[L0X-]0[<:20D)Z[GL<9^C!$S+0N
MU>50;4:$'1&&A%N2TM2#[:$C``@0)@L@F\5&YPPB(=X1POV,PQ@=FPS:V8&:
M#OX\U#\?'P:4YBX9X;",UH:=IC@V=@&=&*R0??_[?_OP!G73^0<S0'V.JI`1
M9WQ5V',RI"IL.)F.\+V>SU`5-ON`Q/>]2]LTR"P/L"KL`W"8-*B`/$@8=LX&
M"L.\A)BE*FQ'QR;#@*J0T^$`4R4Z'W"J0C1&3%L5[L/.5A6VNX!.#%$5_I<_
MO$$=K2K$@_H,5>%2<T[D8!\#:L(EXAF#@_L]?46X!)]3:>_1,@$RP\,K!_O0
M&R0)*@0/T8.E_!2]@R#"')7@TN*PSB$^!]#@\'(C-@]0BD`L)DQ:`BZ=G4@Z
MK`?8A&#UWX??_^$_OV$<I_I#P_@,M=\M?:;)Z.I/XF5`_=?R,AG9)7V?O@9L
M=P*'[TV?E@E0F!Y>)2B#X2!]4.-YB#XTO`U3B-F),4=-V`V/3@K[NK"DQ>%E
M31>\0*D.,9DQ:878C#M7C=CM`SY!RKO'[]\0CU<KHB)^CGHQ^CZ^6NSZ&%(K
M[GU,1_INOV>H$QM=0.+[SJ-M,HR^'V"%V(/>,%50('B0(M2^!NK!G$28I2YL
M!4<FP8":D-'@`/,C,@]PJD$D)DQ;">ZBSE8'MGJ`30BQ5OBO/[]A'*G^P\+X
M#+7?'?,Q_DZQQ,N`^J_E93*R2_H^?0W8[@0.WYL^+1.@,#V\2E`&PT'ZH,;S
M$'UH>!NF$+,38XZ:L!L>G13V=6%)B\/+FBYX@5(=8C)CT@JQ&7>N&K';!WR"
ML#KQ]##K1">(QZ@541$_1[WX+1U?+79]#*D5]SZF(WVWWS/4B8TN(/%]Y]$V
M&7Y+#[!"[$%OF"HH$#Q($6I?`_5@3B+,4A>V@B.38$!-R&AP@/D1F0<XU2`2
M$Z:M!'=19ZL#6SW`)H18*_SY(&M`;(RCU']8&,>L_:*')%I'(0MU%H;\/451
M\G"3QE$8T?PZ2NA503?=-VS:&S:K/*#A>!9;]1"QGH/&-=`5YF;1:$?V#4G=
MDGSE;8EH[`.![6"3#A]0&5%!#CKL]`NNJ%47/"(&5$5]]096Q7!."E=)E>0F
M@]SQUZC99H^6$31S5$9N:=CJV409HXXY@H*E"S/Y1#O?>==&!YQS,E2!V2:,
M+9@V'1HG2PC[:&.1"$H$QX_%X=H_"(VHFL^/QGQ,XQ6;R5Z*-Y9JIPKFUDV5
MU[4>3RAS7Q!U71O,0".-[:)YD917?2N=`&.>6@Z,C"9JJPX_YD(5JCX;P@Q&
ME%#D5X4IO?@BH`IG(5+C'WW)T1!K.+A.7QVXM*N%&.#"7`'LA5%.VO0MM3D<
MK2#6]\%E[@9.Q!1V+0K\RXX#WI2YAK$U0-\XN9);F`#O&#5N<S-XPJ2TE,OF
M,4'&,@W#0>,H_9:^W:?>?9QAV#E]#7ICF68MP(.=7J_8;\%FY,_TAHWEW3?V
M[Y?_EV:IX;`..\MN^H58XC`$WD?D]`P*#"`0P$]))[)K27A3PGKMU:D[EHCI
MD\P:;CW*F3U(*.@35M&+`F!(%)SNBH8N4LO6A#?W[]B+"6!K+C0<`1>O$`'$
M<E*8`./BX)=O.^>B>ITF#^2.9ILND%\9;(TECBO8HI=`>;ZE*_%6\?,T>:99
M$;%*ZW-:T/PL*=^U=<,X\!CDM-[ZI*R)AKOJ%4E#7"'1>?BWP"ZC!O4$PO<!
MCNOT)4R)L"4-8R*L"3.O7OE9.]CMT/5A1_I8E$JD8C3F^\IA[U(F)0?%(/SB
M;F`?W+"G4?X-YL\;?;I0\8Y`B#7E@.!NBLR!'7'$HWK]C$0EC](U"1LD2@2)
M@J1^E^Q33:)OE8.3DGEO7.IBQC\N81>ZRR=><>4L?I$%8;$-8CZ-4=6R^M;=
M<E75&D<,]'U!+CJ5P0",5MA6E*VNDL9E,9/TA(R&$>_S#021'J'D5A+.S($I
M]#),$V8PGO;%U.M`E+G@&8DIO+)%X=])9:*)-1Q:K+ZH016PFF%%BN.#DS'G
MCX438N86)<-R714%91EQEU[39$6SJX0%3F@HGLJ+BL?K-$@DZ7RHBT:.MW<Q
MFDY#>XU7#0SH@9YWU@X7Y2R9U?AU^5Z7_1R*PHY$"9\`5);D&S,E,;.=G[*#
M89=BP$!";5M7;;X?``4PBY=!L7'AS\N<D@#+=;T(5"\?W:6D-"17"=F;$FY+
MKE\Q_K6UTK0,0*FJK(-BEUJ#.H!,A-.W3#`&"?,S`;$@K()>?G^*,E&_7`2%
M;$^TMEVCM%.T&TU<;7R\(DT51L]`N=6B^OB$["\0?F5^"NE',P7_\!(J2-NW
M\3XI1C"K&'6``?C@]4A=AAP=0+1UPU"(H%0`<L_8:5X=90A26,(^/H3H\NE@
MA/0S(Q9"/M@@Y)EF]^DPC'P8B)$/>S6A>ZRLC@,K'UQ@Y0-Z%977M5M]\^T\
MW6S2I-J*MB_D6'''RKBSAXQ27I*HRZV1#OMUV6"'6*P:^8W0*[WA_0&1=*C[
MFLMY8X5BMX.E]$'J_<_2!0NR\^7!/C$D-,N$`H<A$CT9Z%@J/(?*.@>U\YB>
MN&1<HQJWY1Q?/&PQ[HUP.BAY33G,*<;0+CB:BXSICE/FG3:8MU^%W&TU"TOF
MB0UH)ZI521*\D0\"*;_)A[BN^5E4?T%\E>3L.V\+NER?Q3'-'E[.DM55LA8=
MV.8744Y9_W+EPZFC_#3J[X%^1FO1J/[C5=M#NZ$7GF%>%U_H$_O=J-";9)UF
MFW*N_$2S(H@2?CP;`W7MF^R<\]LEE7NQ)78?@-01R`^_^WQU=G7QNQ\]J+K'
M03=%0Y%$<P;Y:TO-01$*LY`>W@$'9.)E\S"F^/-\X]P\T9;&<S$%I1`>%AF[
M_AW>"Q>$8=6N2!%ON-=6I;/A'K$&_1BE&[J*PB`^6ST';"Q67UC9P4;GD77@
M@C[3.'WBI=/9MGA,LZAX45:A(STUZM#!GD:+P<CO@%>+#N^(7@^&^H75HWOO
MI'9/:O\BR38BD%T(#\K0L=A-$4$D$9J!'MM2<W"LPBQ(QW3!":-X43J,+AY5
MI3[01EN9SDD<E.IT:&SL^G1,/]SPA]6H'\^^7)R]T4$Q\K[1`;%HO<G2D-)5
M_HG]]%=)5$1!_&F;K%@5(JE+S8T;I:>N\6@RFWN"5T!J8^D9J3%MEH'%(R7!
MAK_=0#R1'^2/O#*,TV^$,X+]6UB2=6E*@IP7BZ651[?]`>A([<90PCNU49M:
M,Z$/L]`R1!F*/%XNU5=+?%772=7@F)"D+6G&8PFE,-&XQZX]#*$&0XI5$&>E
M?F4TI-$SJ[YURK53K1/R[3$*N=J%\7;%SQXA89IS+]'F?LN^CJC7PW3SE";\
M7[R2#\@Z^LX#4-JX\A2\B'-PM^QO$H2/$<N>PI@+:CFS)ILHIGG!VA-^()P/
M1P(A`EU7K"``'?^A9-U^2%63_D/%F+NG5%'1'PJ&[ROL&73+AN?ZR2[?J@'E
M$,H>RX)LU.LVE3Y4Y1(.#AZ0M=GP)C'9/]?GT6:T80,/>?(4./283XZZVZ8E
M#6")`)9V[]*"Y5>Y"IRP?)MO-R+QQC%9-9;`=JF0I=R,D@VM<BMK%E;'49"T
M/LF#-:#?:19&.5T=++X`SW-"\86Y;VG+)_3+=744R&7],\NV)AF:-G<?*9N.
MO\=KZ`7B'B)U),.-6I5A-W<FHB&G30WUXC%@Y6:0D/L&Y#U(IL:Q3VW&2';_
M56'2N<4Z/:Y0M]+H8@S#E-@0LX-1??;1I3]JB8,<_9Z54=C!V7FB<HZ^N407
M:""$3IL0JI6(QC0LRM_PWJOTBP0H[6:0<8!"3,]G#RSI/P0%K:;!Y2)'?I=^
MI%^JA8[?GM*DCKU<7P;A8]DA209'\-9(\J.\C68<PG?!*Q7&=49/VS&^>VO\
MM:_]@ECIK:+Y;O%,K&)QBYKX7!HH<USI@P<E"0:84V1$2;1DA->VW!PLW3`K
MJ+'=<$8U7H?MS.L;&>2LQ:[:!^%.=C4:9Q;W4Q5O;\228\=3:J%4CV/B8Q>8
M8_OBCF&G38:-S%]O+).#R%>6(9;4R^PA2*)_BH+NG-7M:1RMQ!]GR>JF+);$
MG\OUIR@)DC`*XEOVB5AYXYNWPSC-MQE5O<S9A?M&T8WK?K1RN?BV>&4Y<N_T
MTH8:;+'_@"M7<YMV<)]N"Y(VHIWP)?-]/+&0?A_D4<Y-GQJA^=_K.CC)=]')
M:A?-@\+>"8-2UZB5*"=FF+:4'K$*8,X6T/LUG0+P^433'SGO4?RFP^R=4[+W
M2AHZXLT[J@^+X-HIR&%07#))F:=\NHX2>L7^+7L%):YCK)*IX7A>F>Q]PYGE
ML=D?A[*X#X,BAU^Y/R(<'KH0]B&/)X$J.J%)WRX`HNCY1U6[6@:P.(/8K2DX
MVRMB.$\_;G-V/?=@\ZO_]'-7>S@E(&:]<1X'>;X[K'Z9?8D>'HOEMF"S5[&*
M5-^%O7T,6/]T^Y=&>FI4%(,]C=:ED=\!;VEE>$?TPC/4KWIK57V>FS#8;V0@
M6_ZZ@_B%+R(K7C;JP5K(6,RFB."12-!`CVW-.3@V82Y1C.F"$R;QG"U,.7?J
M$[[3C`ASTK`G^SU#I0N?=IWYP!MM\IZ3.2CW+(?&QKY?.:8?;@C4VDXW//N\
MD<BX3V]6$B'>DK3MPE.4H52X+3\CZMO*S^2:TNK_?+5MW0U<.2F]PNM:T?XX
MJ]HV3D?)B@SR8R2E_-5'"<JL[)FSEMUWP`%S1M6QPL,;3U`K6"RFS%*]EI'G
MKEWWO7!!&&W="LTN;Z1!K5C12#.L6JW&0HQ#3L/?/Z3//ZUHQ,;C_2_\'[R4
M_>7=S^_??7@OBEGVT7_<90'OQNW+YCZ-.P147J]^*LGU4517QAN7[&1NU8SL
MMUY4?Y+R[WDYHQZ3U/@S=A#>:[='KO.11;W7)O=N,<2\^CCT059F?YMAQKP5
M5)T(<T&SZ)G-X)[IIR#*Q,/QDKFPN7%CPJMK/+K6,/<$;^JJC:4O&C2FB_J`
MKI`E'9']=^<]K';-293D1;8M]UE4[]59;3-QQL\CWYK_E&8%_^N)F:0^/-0.
M@$AJ-Y"2C*\V:J?UF2"(.?\S1!D*/ZZE-0#WEPF_3D2#8T*2=LHU'DLHDR>-
M>^P9DB'48$CQN0[]1JZCX#Z*62OJP<0%$42Z*0@"B'#?61"G#U%X'84TR>G9
MTU,<A>6.DZ>G+&5Y1O>2`BO3]EL)@*88ISY;]1+UO0/0R,9CG6&.%G5+4C4E
MC;:D;DS*UAX4`-8(ZI[J/`1_32Y"7?1.;?8-O<CG^\-CXB"W.L$?@%VO3BB?
M`+RF(_D=PA=SZOAK?=S<3?`B9BC*K&)HV4@BRI:C66?H`UZ*4`?2\TIEM]A=
M(/45?]3>-+*IQ1!(R*"P:&-_<LQ@"K,NQ""\<-F5(,8?C<6`C%9!QX`&4Q]O
MB^V*38*6V5T61+%:';7M&MJH:#<:Y=KX>+JH"J-'N=QJ47U,EADI+_@CB?KA
M3,&_O`39TO9M7$\*$DPA5`<8`!`N@GV(^*.!8S&BU;^A*$'5ONU]7):BGRB]
MH0Q9TB/A=<V:RB=M-A[3FNB(NB>/8D"US&BQ_Y2PCTGUN0^:IQO'%/J;R[`L
M:=Z!\G380)4[E7][7`BQDR+CT(&AE[E!T,`4N=^>V!=-BJJ"5-9WNF8-D9,W
M&PUD770\D5-$T8-9:K2H/JVG+OX4=MIQ3*&_N03)LN9M)$^(#4R14_JWQP47
MN2XR_*GGQD%#*W/#P(%R3U+J&/MNI#+(`(R<'C%&=+<?!V($\9;C=51$#R)%
MW-*"]8]'N4K8\-.\J#)O\"#;4F1GV$B74,/1++#K(5Y*!<?5$P7H9G'W2/DN
M(E%%B=/QRB;5(:!/0;02+WH+,G$Y(/'.+\EWCCW(TI:`2H</M82(,`=M:GH&
M9,S\;Q$1`\2\1MBW)/NFI&Y+]HU?`U*UA84[K*(4'\!0V.6(15@4R+*2Y2;-
MBW=_VZX>!%3S:/,4T[W^9D'Q.K"J*W`<8A6Q"!)/AWP,<KHZ3S=/-,E%],OO
M!?NG.-^G?M#Y1NS6E:V'#O/07"JU]3!^I6Q8GQ$76*T[8%ACL_17OR67E47B
MT2Y^3C!=B=?8UL;\82^Q.!<EX3;+VKNXR[W;[!,!X/*`]2I6_?:_W8GK55OV
M\3.#,?-3/C)6O6#(@_)K*()3!$C)%@GM/'76#WWG$NJ"](#0J#P2R]B"/\*&
M-(W(SHHLU_NW?)2&KQ/T^K7Q"6&/4NW9QL0N^X;$QT7_:87^=^KL<=).#)VD
M\$IIH"L;)Z6!\T+R"WUF0`YB_B+W6Y[VR_=X?$JS-8V*+>,8N**$NS*6EA!7
MCN0!_BU<%YN@G@S1"X#C1=T&5(!65>8VD=6/9%WZE=6GWM:6%E@&"(TU,\QZ
M8W8)$1ZO>>:^$`7VP0W'=*7I"=GQCSL@PD/UWCG2\/%&GRY4O".0PTH6$'R:
MDA;8$4<\TA2Y)R2K><0AVTI,=5YZXY$,+_[Q:+)2^#.5[BJ%VH"+6V'C6!H:
M_9JJ7"U#CN$Z]R!N'2>TV!,X,"^(5G5HL/K;-B^J%Z8=7,G9A)(%J?L(A'.7
MV=J0="+@3E?_U<%&@A96T9T0UO1X03BB%+.'X03%%8\R;1551QR+1G%T1D-`
M:^74+`8>,2R'5S8#8(E8J_PI96X3GLS.TZ3(@E"])]S4M%&9J)N.II.I%WAU
MB":2GCM*P\7^"JDO[79[>E`Y&$<XM1D)"1-4)FT"S(`>S&)`&V,8<GCJUV'G
M6*"CS>[CP(.2RY7.L5.X-M!`#)W*,71V?"C2)>.1*)KN_-S+A/7^Y5,4T^P\
M*.A#FKUT<&EHU3A+5]IJ]+FKFMCCS]65.]<?O2JS690?$O$IJ3^>_Q16W<"E
MP%]9<AZKI'7[5-;)H(!^$*\JAC4F>#8]0E1HS^D=@@O,YT[Y]"79TB\T3!^2
MZ)]TQ9=B:VT]VZXBV:(HW*@Q]X`8C2X$X#W#FX^`8NIK`X"+1=6&3>SK1I*-
MG^4<G[_)E1OQB^(!F[!RY<%<Q@([Z;"1E1079N-VF>$)5C%G/\!H8W'*-;Q&
MZKY9>3M[7]KREL<,1>U\"1^,*',H0!CLV10PY&A,LAF6^`<#XL>S+Q=G8G$T
M\>%@:H<0U$VV'$"P/P%S`L$/-A!D<\7[%`&$'S!`^.$U@O##M"#\@%<8+UE5
ME5TE8;JAUVF>?THS&CTDY_R)FR1\N<N")&=A(_'F=?%77-T."/G[?Z)U?63J
M[J;T%QK$O->_/:7);1#3978=_6-;O;Y=4F3/TX%&P3YU!T;+QSR_&-Y$8O+^
MZS5MXNXLRE`D9[]2^:1UM'GBU6+UW%K6\=O8[\'W=)%BWP7R$$0)^2%FO?Z1
MV951R9:%%9YR%IN_:I#?"HUI(?Z=;^_Y"[KXB?KQR_Y*O.^@F$DE)!*[G<O^
ML3[PT/QG(53,TSV88,VD&^G\3)3DF&D[TLY7;_JI[3#FY':&GONDG7S2+2*2
M2D-Y3%(%)754T@A+6%S2"$RZD<D^-*EC$QZ<\.C\(-1&_#?1FY,^KUKV4)8^
M)NXR]C+*#-WW2OU.^9(C;["KTUBUO>4^GVFK+-Q7C&^*-2?N7[=B8:R43=QE
MV*K;'TK%2N@#F\&MO-(L\PK>Y!UZTZQ#T"S=`N8KTJQA"ZO#MU=]H0]1SFE0
M?`XV71DT->MML.HV0]I6(X^.M<6JYQVRGZ9C5&^GV7],^.>^[*=1#)]D0XUV
MH/O[:=K-91MJ)H&$HZU6DB#VV&ALMCHR=`#V6]GB`W/'U5F2;(.X>KE>=8BR
MY/:/KEGC)HV\V>CZ4A<=[X:'(HJ^4),:+<I/R5-U5#=_)'2;K/CVX4>^BL\;
M\]U0P4-&?3E=6#O"*70T)'6)K'F[>I@0-9C+O$K_]HCA\E=AIGZ?:'7ET(&A
M71@<!HV!\C>\_#NG_*Y^?,48_/U_4O7^>D6[7@'8:X>4[A7QL4K`OGM(GN]:
MU6F^^IR("X1=\271JT91DNGU`]Y/])WVLDP_$38<U8*R*`-`TJ@&CQ`F@(K0
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M%[6,AC1ZIAZ<=(Z.,MTV"S24(1YU]&N:%(_QRQ>65LJWGTB*`V6;1D$@:3.:
M",JX>(E?%D*/][[%HOJ(P9KE]2J][]>_4Y:_`_$T<$R#G'J0O-7CF8)^?@FT
M>VW;<)X$'9@)6.[<$AD\T=;8X)^2\N/#!8`VA]I"`"57]KUBYT=Y!%LDG$I5
MXH"1H,MSUDA`S&>?(I8G(4E-W["1V50-1V-7WP.\'*>,HP>QPDR:[>Y?RK>;
M):OZ@3'_LIYAP%/XT$@@+S=HXWYB(&&F0TV$(2#BB5%<(5ZFQ_%(T2;*X5A!
M29D*U]AY4Q-F$&1.:\AL?,RC")#19=01D)GZ;+[S=,-&2+Q/0)S9FR^W!7^X
M5[+P;&?4WU>@-<*ZD0SH&=J.`WTLT)UEG8O=36;1J'K!3=F,--IY<\L9`@K9
M_6<XF&J.P8RE]Z7G!J&KK0VFD&/1V-STT,#CR2L#)&1W!"(D4?=-[!^`8#_4
MLB[XKWF]?T[S7'6VBI5=<V\%S&[\C76;_B'NOP"&-=R`!WFIC_NH3ND0-X$Z
M,S82UJT]F+O9028=/)JR._D0^\Z]?9^`BKHG!!P0`:1BWT@%TVL!4W&.X:XU
M$<W)KOWQHU2_X\013E'FG+!(V%-0>%0,N/*3Y#-^]`?75(.DO@*LZJ:SSK"*
M\70W+!+^0]GPN!AH_?"[Q?4.IZ\/G;HGBYVA$_&`Q,N\B#8"4SQ$]:2("'Z[
MO8]91-H%N*55H^X&68VFG47?\&IN6%`]WR`^%KM&%=>J1^4J_N5U0P]*;1N,
MI`,'4$(Z@'6;<MZ@$K/`AH8;C4BQ^K+#9%E)UPVKUU_738\;DMJ:V@4H4>II
M2!SL:AH:<SPV3]5Z>>1@U!7-3L"(N//B\OL3#5DTX;PX#_+'LBJ2U2&&ILWB
M0]ET/(D,O4`L,]21#&Q1&2[J*V7M4-3/$O"+/A01I@%.;09"1@:%28<!TX,'
MM1K0Q1@&')'W:^B4%PF_6IU=>BS(T6?U4=C!R=\JY^A)6Q=H((1.M>IS-!#2
MYN)Q$$+,NC?EHV5_">(M7:[%`N1^,4*2>D'M6P_Z:=LC/.P"Z`_F@W[Z<*9G
M7736B^HR>>;7^4;(![$>'#7OM7F0G&$02*U'2?K$B\:N^\3+C$##?7;/%&@$
MR,IG]TJ8_:6&67G;H76O[/A09GA^#P=G2,_OZ2+@/[]GBC8&;J=*5>-J=H0H
MTS^_AX0RC-M4^@CXMZ?,\<;@[,-KPYGN!A0:SOHWG+!Q]LL`G-V-%;5?1H+M
ME^K>9Y00UJ[(MF%1OLN5LH*='T97O[7H"''WRQ2X^P7Q^>3@>[39;LK-[,OU
M%QIM[K<,/XJ#.R'-FT\M:YN/?SH1T!O$9YGUT0R/+.J,%]75QMDE6;,!Q\8]
M7Z2/5A[,;T`82&W'2?:<H\:L\\CC?#A#?2K:%&<XQL2STA7*JJ=;EFO2:G)L
MR-(_38V"+9QGK'4!T!^W-@4;`;%3HY`='<2TCVGC0&RZ!\PNJC3X*<K#(/YW
M&F2?V"?=54Y`R\:C9,J6HQ_=,?1A_$-CZ@#Z9W-4=HOZ`BFO$'Z)B&OS/X%C
M&M'4XJ>7/&FCL&@_7C,Y5M"?[=+%&00:GK:/'3;:1[3&`&?"D[W;/;BA692N
M8.(I::N4SU9;9%)(^H$MH>T0-GQH6O;X4%[TDQ&RT=5P0@T&-2<:-CI63(0=
MQY+:C3001#)9/4X868BK/9`F%-AK^A#$E^+YV[/OD4Q6%2T:8MIK,9H&BICC
MA;/O6(_T;ON%^("4GY"O_+.9CX/6#5$*^$TE\.VT;(/6--BN*X$[YE:3_)N7
M)?F^O(PFT\UH>%F]\@K38-%X+[K\S_D!*1T-J;!*QDNFI+R97#P=C*BS7+MS
M#A_:5D8]Q,$%)4K]\"*DPW60WXLONLW?/03!$Y>:?_V)QD5>?R)NX30TI_KX
M/\["D*\>1<G#31I'843SLWO^CK>P>QL';E#]$!"#4;B&]VB<=H'BJ"$/,%_<
M;C>;('OA"Y^WT4,B7D7*3U[;F9#:AB7ERFKFQ&R!A]1^Q#ID,AONZ34`=Y/3
M+;\)7H+[F);OIC503=%83K->8TR**7J"2J]^##"UNJ:+^G-272#5%:^8HQI>
M%6OT<%`PIF.D9,N4\$&M0P"AAN)(O!:Q1M)3>>F8$*0L87`P-'=YDVWIBA^\
M:-1:1<.^SO8:8I%$T0,T?>W[!W&B:[:H/A/'PYYX)ZJJ<93103_F$B)T#*0D
MF`H?K@14%F8(4"KA%%"1[NB;><$4!S,0^1R`&E]D\S/[_:#*V6^K%L]F6VQ^
M]/N!+J&M$%;D:%AVA'1_Q3M>2$961PTE$#3<V-MHZ3$-;EQ+:R?20`"9!9:\
M(W'*SR.EV>9X0&4CN=:PFEMXMYMMS/?C+XM'FIVGFZ>,/K*QC)YIXSBK-*/1
M0U*FBO#E+@N2/!;;D,]6?]OF!5]:_$R+Y?HN^*Z6;5>1^J*/'PF+^JY^`[2$
MXZ"#(+5!C[MH."7"*VFYK9^4%$\U5)Y)[9HT?).]<\*\\PW)S+\WZN:,53)M
M=$QAB:YB1Y2J\NO1"U>%AI-^SB(<59&SDXY42$?8DH[YGT8\%@&`E%8'*0'S
MEG6[=X7>!-'J*CD/GJ(BB,_WKP1056E@PV[1!3#$T41P#Y%*(D@\@%"9W31?
MD<L;L0*%5,U:[\;P1'C@2.GKB"W*>J)@="#AN#\(=9.$86$QH"I2Y!ZL_('/
M=U'R+BP;O@9\FM.6$X1ZDE3X.\:2,`KBJV2=9AN1`2^B/&1ET3:C=_1[\3&&
MY!A+/\J4`_:#S&_+_F,G)'AX&])#O3858&=#&D9D;T6^<CLB#'W91S08A1JY
M&`9HM78`_>FDQ'-N.$Z%-KUP0)+Z#:>L:?)0KBD%(6_KR^QQ1A)8I-#I:#!S
M@JTGD?E=^H7R\8MBRB:4^QGH7<K/C[S)TN=H15<?7W[+*2L4=F^:.&/@>F;?
MV+RKUF&H7IIV$0I)K=S]"EC)WDD/(5+G(/"BX97<I63G5ZRK-]?CV45Q'G'M
MG7Q\(=P_GQ/O7_VU#^'?-F67!).(KW,Z]]49/Z1,P%^5>#BJAAQU=!X5*1<?
M]CK",)/M="1A.A)7QY0E]8G46RX<4=)X#UNP\_K'-[G`AN[1"<:\16$LG-.5
M>(GOQX!UEM^=H$GY-K'+<N.-JLRS,NX6;D!C'#6UZBE2<06-"1`ZF*O%KEWY
M?FLB6I)F4U*U]427[`#45YHA`.PI!\B)1`O\`[";!`\/C85DGH3O4GYG*N?-
MWMT+'(=-'-/7AV-S#G2*Y'GS5%)$JRC>LN1);VFXS40*O?P>QEN69?GKIGB/
MM^7AI<OU99`E+-GF-S03WZD\5$Z5QC!]=[,<CF\<#<'\GD@Y$JE+`.%!B;1H
MNB%[/Z1V5+[6L.&*[^>KG?'3=:K,7/KS1+U0\=\7-P?TZBD?1@R),!X;>]T4
M"&@]FXC&8H[/'+W;,3G?,YG63!8OS0T;3$[7A-9,9M.YLC9YH[`]]@Z0Q/,6
M/WE.B_Q3$&7B*/S]C273;1BH7;=H,=OA2!JT?TC%!B`<0(&,7A9EDQ/"&U4O
M4&IN5O#M7@(8)7U=L`18C_$F>PF;?<&FFU0*BHH`4I$"1:/C!Z$Y\3B`H0<)
M`Y0=0*G`";=<BOP`1>_*MZ<Z#>6#E0*;<.YT_!T*Z2#5;$GD[>WEW>TACS]0
M_*`(\$#6M'*FE3%4^+J0+0N4^IB^39@$(5&%0-3!L]0<?BL"JCE66K._T1$<
MW&@"E44UGAXHB>$,+5D;J:X@GXPDBXNI,E;G9;4LZM+(KS.RI..D`"WP9*QF
M6Q6`'8ZZ0WFR/`6K8U.)57T$B7^B90<#H(3!@."/H($F?HJV.H%S,@U0],.!
MX`V8%'8M.P+HZ1Q1-;1Z,EC-&#LV!FI,`1R'TTA9I($(XAIZWE)/7[:((B#'
M3DXML3.KO'X,\BA?KJL7$I=G,B2KQN'F_>.Y3<^I8KCLB/4XERC4Q/A6.-(_
MLB=F?H\*L!#6?'-(TYXP!^8C\[U[V!4%RCV)021(5X?&N.[+U8'3SDGB'-TA
MM_SC:;AD8-IFX!NA3"#QGE+S%@I1'//=LXFH6;[0D$;/_/1XU:JUL7TWQ:O;
MXPB)J3](R5D3!L!\I?6BO$3J:Z1QT1-J&P>\SUL@1GJ45-E)^#87K.R2SU.:
M1WP;%R#_:`..@!C/',MMD1=!LN)EV7T)N*!^HT:V:WI\>#,G`03$2>0;&W.G
M+@H>;;0Q@#O=J=KK`-GI%"`[=0ZR#S8@>Z;9?3H.9A]&PNS##F9[=)'[@/D+
MCQ%E'Z9`V8<9*U'^%#*KF?E_+O^Q93V*^5/+HEI^,:U-6=EV*E2@+0K[K/J)
M4[E"0YJI"/.T$`>5\'4A\8]&RW)%Z,7#]2`[^/1(.P1]7?J"?/2I[!UXG2S.
MP",CH5C<]>#P#20X?CV8-=;/+E$[Z[*(O(>2=]C##4!I!^$-]_`>N4PP59RA
M?!3F:@J2K[R!U]FC-?1`^DG@`F,<-X323`JQV9E5G`=9]A(E#^+Q!#N2R6UA
M?.O:NJ2>O)].6=@+.9B0'4^:,N^L('7;\F$RKVFJ``^4L5KL`<G;]@'F\7S0
MM5P$I5F4KBZ3U=!"3Q8="<>M0D^<CD;W;4](4!#*+J1K4GZ)UX/D@:4?#I;1
MEE1AT:R65TL@W!9!5F#A&;;@"O5EP/,]?8@2_L#XJT2U::W6*:JQUG!AT:S6
M<T=-Q&61L?#\08/G5X1;T^JO4]QZN"HL=.LJ"3,:Y/2"EO^U6QS6NH"M$2M<
MN%QMT_;:Z8JQ*O+@)3>Y0]WZL;`@M0FI;7S6`0/,H.MR$+`"%^>DKL!K=+Y`
MWLD31]8=P,4^GXS\4/_Q(XEJG$=)F?H.+0>ZQ/[0I6D'Z)]WH3H.\GRY_BM+
MV$%2++,OT<-C<?F=9F&4TYLL"NGN8EY=S=^K$N487]V,.<P7CHZ,^1Y(.71@
M%P"",LCS0ICQ*5]UC:09$1=/2&U,A'6C3;YKY(O,C`)H7V\0\-Z3G2$^)?IS
M:/1Q<]]W<$\<\8AGZ.K#!F^>>.LWAO2AX"%'\)86!T6W6FH$;[(;WA=7/#G=
M\830-YH8L.`C3?IKE3/7M!?I)H@2F\JU;0&I3VL+=P+1[I/#6G,7:"##*WMU
MW4B^EDU\V80!0`",MU+8@+A96@(9.!76IBO,&O%&@>X_=-.5(X?=L-II`/"\
M6[3(BXN@H/QTZ[\^1N%C-R-5"8MO4[?(`?9.`6G"QJDS=MM_,W?)QJHOPZ3!
M(H1NJ8,[*<_)_\;=2!8Z2,.5OQ(S`-<@%1K,%XA,P9W#E.S`>#A9(K;LDFM"
M\G3>'%MN]\8L"$X.@EO>%1*%;I>^J3UDEHBY1]_4'X<S1/@.?:6UKDSW:8.^
M<=1A)3ID>[[*#EB<3X&MZ6:$NV@C0&:8#1XIS(;-`RV!YI]T?]YN[FFV7.]?
M>W0>\&>5/[YT,Y"-P-M[A:0!&Z_N"&W_W1RF%*O.#-0$BQB5;BSWNK&L=:/T
MPB\UWHE8.B(?7_;SPN4!W``?`&^8$`WF#4BLX-Z!DG9HA)PN#UOVR3DS>4ZO
M&,B2^GFZV:0)$2^OR\EOR8IFL7AXK#9[XQX,1@?"/K>WX"WZ,>'->,M>N6?@
M_@9]3J(\W[*\Q\;YB?WFCWQ#9%Z2D;$S+-F9%VGX]S<BPO!T*$3T[B9_XZ`Z
MFP)?8@:IX%MF[A1)TCN'-7@[VD`A:3K15-&-9AY+@PP=,.ZK<06B=O/811AW
MIT?D=$5H-^AX:#9V8^:M['4@.0L%F,/*OU'0G'?=B(UM5&S$<XJ).,2.]8@F
M_$3E_4M-C>?%#7+2S2F63G#X/*CG2/G&-C:`XG8N%XWVY3."38O62ZO].V1N
M&.;Z@C`&NSUQL'(FD0K_.>`FP]EW`9L,XL9(@PY!EPZO&?;FK#@I\/W/F(97
ML`WR,21?(K]Y:U"_)\R65J]XL_.H%P?OW@0W#&'#9`+XYC@K7P,E0HGW:?4A
M36[Y9$E[^)ZBF83E[69H1)9%Q^-JQSN,CBVC17TG@W_DU=%WJJ&3TD<SR#*&
M-)O+23`!')P5>;T@]KBH"[5Z1>*$_)\___[GGW]^3YZ"C#SS)O^5O/_YYY.?
MR_^O%]^#;?&89M$_Z>J_DG_[Y>3#O_Z7D__RX1<AY?_VX>3??OYP\N'G#W7C
M:@V?7TP;<_N@(+<,'%3<:_OP\PGA&B!:7="P^O2]^/27$\+\/-&0OZ\D?CET
MX((*0#OHSE[$59TI;Y1>B0$W:[6LM5JRVZVQJ2KK"[J`=X)8\;5EVY;SZO9T
M><T[=DA'64<2#2PT3&E::0DS'8[LE!]^%U<3;3"D^IF@I=['A2H;!1Z$*Z_T
M^'9[GX=9=$]7'[?%;TDYH-6'3_QU@/G^/2M`T1[BTJ#L=BZ=T';(MW*3(RQ[
M8L]ZJP"M;'-2IANR]T#NMP6I?9R0EI?&2P/]E)!!2#;JS`A^F*3(QK59KPZ,
M=:[G4L,ZY)9^W<Q,WGGWSCK_2&6=X>>CE5>U0GZVF]E#YV]]"],<KFGAIO[N
M]\G17*X5:$#QW;"7SNGVU_UDNFSTS56X$C+&.GQO":C%I\39))FI&V\4X)0S
MON#(,6<_^QN(.E^4_2;(EMEM$11T)58+;V@FNFI6>).E6NG5EMA,-/417?DU
M`:T(J?33S@2L&=_66C8L;]WPX\;+#.$=0XV(T3$5"#<-7U4>M+R='ZNNLX<V
M+@IH^]ED=P?I=6#4)JN@HM27+%-F/\!C$@`3TPS"P69T0*\<S2&L'XO0.9#.
M(OQ[&`*"`7--9_$0A,844---B[=IYA(#'GK0NY#/)M+CQY[]A&(P^GP1^_/@
M*2J"N.S?%YK3[)FN/J79IVVQS2B_"18D/0:,]J-."U`_V-RUZS]Z`@&'MR(W
MT&L[U51&=<JIS0BS(Z4AJ2V]TP%+%.K$81"@-7H!\Z<5$;^YX3K96?3"`4EZ
M-V^RJN4;!VRRYF0LF#N_/F7TD29Y]$RODC#=T)LTCL*7\G\!3PY:F?>S*=`<
M2RBL>HN6.Z%106H`<[9HM21ETQ-2-B-?J__Z^%B@':!DHC`$DA(E`+F1"H"/
MH':5].#!\=!=I;@&OJ_3O'RLYRP,MYMM+!:NE\4CS8B,"*\-[)#$YQCNOJ6Y
MS[18KN^"[_#,UK4P)[.]A2NJ=_OD+&4U`@WB\<Y>FIC(#YS`/YX0UHP?L\0:
MGI"SHLBB^VU1[W^Y86544GA+W1X\(&Q58`I`S]H2Q,CI@.CF3;2&>*,0V4\F
M,</B<<)L2!X8!+29U3X13Y&R.=<S332/<,J;]72]VPR)0_+H6`K>\PXA2<=H
ML?N$5!_Y0@O%R$FXH!WC/OS;S668GP0-=C+ZE.81?U`1HJ22./;(*#6S_(QD
MU6^5T3#-5M5CEU'RG$8A^T.\7X85XN0A?:99LO$HA0\%$4!%;6&$=PIHU['5
ML9[@:9\DR``4G?91=/#8,!Y[:8^-_L&42-CX8(,-BX<%)6$&H./#[Q9'DG7V
M/S0>*#[,6V`Q-!01FYA=I\G#'<TVG]."YC?!B_:)/I!5O_S26V%1`](WM.+,
M$`S$%JV/1:,!$5=(=8E-LAG6MYE/DVD8,&0\LT"4A'0Z:RD'YX>BHW5<<\S1
MF*R*QATJ$W:-/-6@#(/\D?T5>7.;T@TF(;4C*BIGGHGG17Z6YVD8\17YOT;%
MX^7WJ%AF%U'.)BU!?,8/6!''<B^S+S0OLFU8;+,H><BA-R"Q`_32#UX`)'G`
M_L9820VQ7Q"M00NW$+[(WAGYQKP1[HZ_6JMV2/8>Q1NW6CX/X<XJ.E,DVN>(
MC7V1Q`HDT].C9;RCV@&U>U-2GU<DK0:,]$\TR;V9<!X290&5S2&0=M9ZZ8+>
M%U<)[QU?)[V.$GI5T(WJ]7Z&UIU*1MD:1:0,?<&I,=1!S*JALEWP"V1_A7SE
MUXBXZ$GJ-HUSC]0P8'3YJ;#JDPV*I+EX<T.S*%U%(9L!\3_YC"C_&,1QFB;U
M1^E'>L/FFB!BV;O3,L_&G0-JVG\;%]RUZH4MN2V<=]E_0FIC4C4EPOR$5`YV
M'S-6W%-RX\V"Q6C,&E1D,`OT,@-W:]*A@^&5DRI\5&?<$8Q7V()B[&MLHB3@
M!Q'Q-3]_;@/[PQMC`3T_<V8OCL&O:-`WEB1H9R]=T/<$+[D.?(V"PG3QB;$U
M"?F<^"X+DIQ])@Y7].U%"89QEI+3^M4'<B,YK;QZF4&;YW>:F[.:EMIJ]@[Q
MSI>F#RYJT#OPS5:9W>(V?*2K;4SY?F5^X^4=3W&D4T\RPHCF'K%%-<J&/":#
MA#Y!W<GO5T'P,Q=#ZF?R+H*"O@<Q16JA94S'P@%SI'URP:!N(%LFM>W[<['=
M4Y:\@8\,DH^^@4DZR.@9U;(T,4N/L[D8]C'(H_SV*:/!:IG\)<@BSO\O8+J9
MS;7<TYD[(**YMRY8J8UJ2U&-LSY?16-2MB9LHE>W)U\\Y2\`3@8R@P&I9[;:
MC8GFWD#:T:LGK,+CH9LO7%RG0;+?H!0EK,"C>4$R=IWDPNBU8=IRB<(%JF=?
M@MAW\CS(LA<V0S[;I-M$MQ!A,M'FK*Z)`U++>^4B-_4BV3*VXZ!W]ZZ^3LH&
M/A)4@0$#*;7(T=.P;6JBWN1XFV`]7!)P'/!VZ]I1H_P):^P%1XT]RR0P!GT^
MB?U^FVWYSSQ*DYLL"H$S%X"]/@WH[%UPU-Q?)PE"&]::M!IO_>E+HW7]!V]/
MA(&7;`9@RD1M,"P-+%?[,5+>'V1/D8H,T1$AODM2X>[""7GBE\@3S<K34E\?
MK&W3EQ-@>Y38?DM8N<)Z^4^ZXO>NP%,9C9TVD4GM'-!<TS\7B4L>SI;-,B_]
M1-5H1>IF/A)9!Q$#@<WHTM-68F^BZXS`G"#OJ*(B('279U:O!HN6200'C1XE
MC5\#OGN^>.$WET#90F:@31-M`P<TE/7(16+HQ+'E6\N\GPKJR][>(I4.O(%P
M&K#H>=8T-!%L4H!-(/"]<&.05CX956W4)*LCQ9:EB@]%%]KA/IH05L?\#+SY
MU@LX"F&GDA743:UF1XLXT_%`2(CK'QDTVY:JZK8IOWEWN5Y3_AP>?Y%4R*X%
M#[#B`>A#O^W*Y,/%1BQ8OYULS3*&MMZL9?`HV;Y5WS'G)B=D9T3V5CYR'(HV
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MZ:J]`?XU`GK$1`43TK/G-]C1G)J6DHSEYN@\31_P<M"0XRME=F56J<^1].X`
M2=UX2DEE=Z2CQ$).DLF0XDS)AQU[*+<4$XCZ8)5TS=_3DL;/?+WIFA]CQCXY
MS^@J*L1+.<1D@S_5=!R(`NGQ$$S-K+!KFK$Q*U^H=!=\K\ZD_$@3NH[4>_-`
M5CWE-5@A<0O4-RQ%-@6#4$WO8U$WJ%]?QU^/5;4A52-?*`:#A81N-GCJ$T]K
M+2.A!T!T)/CFF*,16>[`JS`9E9@L@N_4FV4D-R@$)`!<''J1&+ZP:4"9U`VY
MH-]0(?_-AJA$Z_<`5^1;_N$L:ICM:<,_K(HEOU@C&48E491#KF+&WD!-A@G@
MX51Z.V&&X*0EL/S-.22.@OLHCHJ78P`+6$CMX#*S7#YEE!\'SF9&2J'L-^E)
M9+,)$OK[4;%DL>49`O2&P:+YER^HE@R0!,_*8>SC>-]4AF"G@^U(Y#H![$:]
M%+;&CT)]>@."_?@#E`R*`,1MNPVGKC;J=D)8HN#T.-@/V%X+'OUYM]!FT7/`
M=R:=Y3DMU-M_Y,UZ.:S;#`G6\NA8N:SG'8+ICM%B_PD1'_F";,7`2="M'>(^
MOMO-91B?!`R6N2XM@ABB<I(@]J@0R^8\(G]+-<T+L>LF2L@F3>@+V039WVE!
MUMMDY<WRR5"T`+*A+5YFKNGKSEQ7TZ^(YN?ENTR-&JDV4>JES`29+NI>8>NH
M-)(->R0.FOI:7WXY(><^O5X6A``-E8RX49.J;ZHCV"QH<S0I,00<!SOQ)MGJ
M]WSB#TF7]SY7>RSN'RKS3L.Q0&BA[6-AB#@3T@1Q-3,RA!P)Q5,+*)*,QF)C
M(/OU\X+?C7YB/]ECD%/R+<BRX)C1:IZ9H:'5CYG;QY?/_(E,>O8],L_?9(V5
M54F[,3(Q93W!KD0Z,6P8V#)M5!\GY/Z%E)?(5W[1FUU3VB'6<$@#"35WFD8Z
MUF@A-',];U/(VU3P+G/8!#7[\%0EK])]XX=L5&$I9DAF`:84EYBQJ[R?Q$NZ
M+I/5P))G3-G-ZVT6F>\J_!C$_*42QP.>864T$#YN"V>[BKD$T&T19,50"(TH
MEWF=_)$^1$ERG"@:5-Y"4=0O:#%1]&&J!0`1:2A^/C2SF,_3)%OD?'")G`].
MD?.+TS7^;J2AR/FE7NT_QDFY+=I^<8FV7WR;2GQFOZK]W8&^%61ZT;1RQ[E^
MWQQ..5K!!M*OX4,V#>'HVC?QF&@24,`HIT03B'I[:R`)IX;A=/</.C%'X['<
M^B1+"2<DIGE.PO:Z[G&#<]@\:`0\W<Z-&G$FO*_0B3H>HFS6Q/YZ%[Z..PP8
M,!XT$1L#8S_N-GP.-O0BW021>J^SNJFRO&DV1>9JOQ?8A4PK@@T5&X:M.PS\
M<_*UO.+=[07)J&JXH\2`FBY[$QU'-(B9@Q;[$Q7RLV3U9[IZH+G-K0:@O9)`
M1GMD5@'[BTTU<U@;_IF\-:NV1EOQB'O9^J0YO_"-J5!,:>AK!TLUIPU^=$3W
M#-F.IR&0Z(@0/^@-3N[Q;3%7<8?P>3?"1OE3F@?QG[)T^W25A/&6WYT3+PI)
MBBC9TM7RB69!(5XXE;)_%B\W#)P%^R*7_]A&3QO-DABBZVY>1'&-(RR(WQ(I
MF^+T"*!"&($6M1<BW/`3\"I'I.F)[%R=D-H9^Q=W)]+USJ$G(H:)_;Z^X3.K
M)WP((22:>%R\=5,K8'5L&@+S"J-ZY.//-%Z]6Z?9.^:2S7*9DSS*"\YD5G+$
MG*7\_^^W4<S#^%)N>,]4<Y'B+5=G+6TN@XSO$<EO:';+WU`*.VT0:-4I2(Q6
M*)H%[!M.&6$.9A88DX]%W8"?<$M$$W_/+80BHR<"=I#JLMM@W2>N%UATDAHA
M,4>#DB>TCT$>A2);743QEM\&^4P+<IWF#:`>-RB-20<;EEZE"C'^+)%5HP],
M%0HK0ZKH63FAIZ)O;E)%/Y@]*[L^9*FBI.G9GJ9^<E*%"R,G]8`R,;)C;6;D
M+$B<)%'(8HZ&9#M1K*I?.6&)(N:)@E7$)/<W46"!TCI1C(6E?XG")CW8)`67
M!)P@`0SGF$SL3TJU]YA,EA0:0AL@65P"9SJ]'J/2>VWF>EP=9/L#U^4?#T*8
M+;$T3(2!:/)*<.TJ<KM*W&W=,TGE/:;BUE3:)WX7V-8US+""&ERQ3`*D281X
M7,'<*)0O&N7Q0<GQ4&Q92[(MNN:59?'"T^7Z\GOXR#!!^>N%ELEYD#^R0IW_
MA]\">`YBON=!I=4#7'0%W,H%#AD']!I)ZNTB`]AJXW!1MB;+-:G;BU?4D65"
M>%NQ"B/^T;#RA-%#@-:G^7"X]IAOX4HB!WZ#WDU:LNT`+OK%L06B?<YO9=.:
M`/S]=>R3A(2L_6L%NSG130;W>5/BYBE.7RB]I=ES%-)Z_D17Y^F&GX0M[I2?
MQ:('[%_+]1<:I@])]$_Q2KXH9>WR(K^.$GI54.6+NAU%Z296["@X,N3FNR.E
M9_3.`30,.>:B=D@JC_O[+*PP;3HE>Z^\)-C[):5C(CR3K]PW$<Y]N8GOB#]]
M"75*U)[&XD:3R/!K4`0WM8N#/DXN#:("DHK#N_N>.)PTU2%]4P?WZF"NP0Y,
M'_ROY#ZGXLAWNCK[%F2K7!P,T[S.O\_GM/AW6G2_Z:<TJS[B[=Z/*?30.S&D
M#D3LQ'1)`?V7F["*Q.P[4B;!ZY)%#;H+2LJHI#R=J=6&!V8-"\)"2Q(1BTX:
MX<G[`\I#^.0?EJ9<B="@'(;6F8$I[G6+X7P%-.Y7\$T5>?G]6Y+MY2MOE-YA
M4^^JMZXUCV_9UBH9E"K)FX35M7O><N>5G\CP2/D=.=:%-R7T@4=O6EC]',<W
M&YBZ\)^ZQO<]@QU(Y3YO.IJH'C_R9#-#7IDK@4R8*WP7F,.JAN<N?#%KW!.Q
MSRQ=DW6:K6G$7U#BRV:4(Y*8^:K4"47&D]KSF6;\10>_TLT]S8R5H[2ULN[K
MM$8656E?L&NN;A`;'6O;-NN=Z@KY6E[S[B:5?)@U`J##A9J\+2L=]?1`FHXV
MGX)0O)GH/$[S*'G0DD;;MD,915L4PFC[@4,750@S6>26B_IC4GWN&5'T0]NC
M"00)79)(;?H4@0%G2H)$V5^">$L_ONQ>XW4>!WFN><<@R*9'&*T-$G$`_<(B
MD#X4A$@Z#PM^F8CKY./+_@UK1#3QZG6$,#1(.`8'49]K&EL9YV;&GI/IGSGB
M2!#R:=AK`YYQ(H,)O5DG%+N>_4J#G,V*^2%=?XV*Q]^2]#YG4Z?@/J97R=.V
MR/D,*.%92\R,V%_;+&.IBS\1NCN\].4VB)5G7[L,I4HSJ*%P%<+!KX"<U'![
M:"%#F($;*?2$-!R3;\PS:;HFI6_2=GY"=N[%@0.-$\!?3HB(X9D.NJ"76C[=
MD5FIN8@A-5+].J3#;4V"W=%Y-$3L=?Y.LS#B*\^WXN4W-_7+;_[JU<MO#E\$
MX*77P<D`VGNIG'0.]C*K/Y1"D-`'?J=E)BF`O0'+4>@W*9A,"DQOW#I@*9CS
MW5Z[+U3V6IS@O$T*_B"M:>JFME#-P&06N"*H[A/R?$@:R$*')/;-!;[R\@FI
M&XCC%#S3$LWXJR7!"!HEK_N6&GK.@32WY;,BWBC(E6?O5`C+CA9A\#)R),;\
M6+TK7[APEJP:KQ&JTM5JN<]$K,'GE&^I:22F.YZ_3+J/Y5^5)<;[QV4ZUO=%
MSD`(W;(0C]'1FMFM43SES34U?E1NTYQ\%;:^W5Q`(X!:Q)`YIA2\L7$T\HA.
MX\.2TFO#62U.8CB0U&OD4QF<?&]_I/7:ZHP6W(BMVQO5:Y>XI#;?1%@[Y0=3
M:817>/;P#`8WK'&BPRIRNM#B:_79"VXU8-Z;T_FNUX9=?'!3P,WCOJFSA5Q5
M+]W=W)5$'+:ZVG.DNOG:J@!]VR-H`1S0,J@!=I!%S:X+V"+EC*"=[+:B-#`.
M>OE*R>M%Z:#[<#@X]6-)A2_RQ"GO8WYVGQ=9$*K>:PPQ4>48J0DN336]0LXI
M\D@6;)0Y4"TBD*]U$]\XJ8.!FHMF\"@9*#'5,`\"N5EVGC=&]U-&_[&E2?@"
MVW]NLE3O0E=;8N\'-O41?4>Z)J#5EF"EGT5S.]WNDJ^;@XT8T6T1!@),R5"U
M!^UF83`Z9^'K[I]_CFC&!N7QY9H^L[$%419@K&:MUAB;N(">HG-7'].*OCI7
MK?G9[KJO#(9`1D=B..0T/-8XT5+9%\BZ?@C%%!H+NWQV]H;>[IC.@E\_YFOE
MK?G&0N?_V@8)^SV"(GIF%]=IMA';LL2-)M-+WY&\ZC=%V7MUL9UEZ'=SLKEJ
M0&>L=\-8QY!MTFHX.2%--Z3AI[J73;Q[<ST6O$T[<D;RQK!GQ]:[<5_/81)R
MBCUH@_KDG)F\!K@-'^EJRTB6KM4\#.[3;4%$PB(?B&)!Z8V:,)0="#G]J$KT
M-U[%G=;>/O+V-O+N(\,7Z2:($E/=XCJNJK)Q%Q=7:EW_/LC5D</N6JBTLUXT
M*RSISI5ETGT,5_+H;N?)7>F)&65`W\HPYVQ59X.)A$*9+5S%U^23UZY1;@M&
MI[WV0*S:"T_D_DUDYA,9>%%Z1#+C1V';N(L,7DS3V0`V2#B;=^OZY6Z+Q,!%
M+*F'IB(U&I"O_BX]:<$`VB9AO6PDLX5ME)@4>F[SLS+B2`QV\J+'*RN(R(,G
M(`3L^2'\R_6G*`E8D@KBJR0OLJT8XILTCL(74P*`V*H2@=X6EY60?B(G!D-(
M"W)J/34IFJ[)KB5I-#TA96/RM?JOOTD$!"@UI2WPJ"2VSH>&X+[`V6VR,49&
MPK5(/C(LOQZ\PE.1`\3ZD9J:-4=_OP)LX=S&!^3!(;4/=P]CF/KM\%$B3>B!
M3V4H/6H>+FHDN<:^(#^79:P`!WN4`XA;I4!`?`$?[?`)_M,]E*3M`3(/NAOA
MWIA@!04/N.!=\MSM-;=.F0I+0*+L63K3!T4?W27%?L!A$M#UHSS:N/$LAO=,
M5R$&Q&\]W""<[GB`,=F$U5F>QO@8Q/Q=.[>/E!9_RM+M4Y0\@,YV`IBJG\30
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M1PKZ>[.@OS\`KG4Q`.*:'#@0IKVW8=ID:)M,T-^/%O3W74$_=I`-$O0A,/-.
MT$^M!?W46M!/G5/L="I!/QTIZ*=F03\]`*YU,0#BFAPX$*:=VC!M,K1-)NBG
MHP7]M"OHQPZR08(^!&9^"/KX9R/!#QTZ".7N\`MGSYDY^!6\.^)BX`.5F(%;
M:=+\#I;JA?+FHRR\/TC,!<M</D]N_>PH8DBGSXP?@H+X?@#%X.=B<4,O;K>;
M39"]\`?USA]9%YB.1$ES2S>[4"]@-D*_20,V3(].'.:M`ON/D>G.#->W[M9B
MJM8X8JCO"U)%I`P"4"*%K?3A2+].2C8,<Y_Q(%ST*"NWDK!N#B"Y28R:6(,1
MI7K@]B@Q94X$(U$UKQRG&8T>DG.61O@S#7=9D.1!*#9JG"4K\6<LLD?UK*]Q
MYCW67U?2A_O#X>K8[X.4%D9T`T#SP=X7E2FI;4G3F#!KTC3?G2WAWUQV-&[[
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MOB`,:7AL@4$UG75.=+SV!L/`M/.'$L4)?0@*NK))/,;@6'#NIJ*5D,X@YNGH
MJ<9TD*P(?8V(MDA1+C`];]*B"<V"F,VPSE:;*(GXNZSY*X$NOS_1)%>=>P*T
MZJ8IDQ4.MV%]0TI,QF``"AM\+*H&8AFPW814;3QA*Q`5?9I:P:G'3KVUA)8^
MX-#-G`80<S0@13*I(,ES1M!J=-Q0-*<*9##ZG!RT3Q%8V=HE"M2]WE;]G"1I
M6#QM`/,$2"">[0RW`X\MB4&/)(!\6--Y>NC.D6>L'EV`^M+DG%>(WK&):!1^
MYTU*:;KZ%L6Q*N]T+G=3R^XR#@4[T9`2Q-XK@#]UXT7]+T]8T!V(/M#E0]5#
M<M5,`E8W@^E&,IO.X:,JA.]`Q]6L4<:1]4)IF!A>)04;K^@^IN6-AOJ2]I4]
MUO8*K0+8H^(?W%]<M8.$A1/'[&W'*U%1[!M7=X=/2'W=_W?YV"--25I;L*HX
M;?2C)KUW>'>:$&#1$8'O;TJ9`K[@I.02P+.FM:O-4Q!E_,[#<MWMYE6RHFM6
M]A<T9D7_ZO)[&&]74?)@*+HQ7':2WSB7*/J`\:UP4N3(GIC%8U2`Q=Z:WU"4
M9-*]BW?"!_EAYV6797_T0XM0H-R3)T2"=/5JC.N^A!TX[9QDZM$=<LL_GL\;
M#`P?@^S!EP=8_6.3,?_[PR=OJH3K-'FXYETL^_UG&J\^I=EORNT!5K::O*^Q
M15<:8S_Q,[DNI)UDJ#UU<C-O^$ZTK'(SX6W?K=/LW=:7;01VZ-&*`Q1\.@U0
M^M"3W0OL.D^'^LA((.XD.,_WK$T!7ZLDA@W@>=-2$J8;NCL-_9I'BM)$<_8!
MP**;@G06..0U]PDIW6@#`?BIL5^4%QNO'*@O>_4`.V3\^RP$@Z;'/+6EA&]S
M(LU-<C#$&P4YD0A>)>C,@H\$.Y_$_>R>[SX(58_,&%KK17W?V@7-NGUQ(N:-
M(-:LVMDNSI>?+RX_WUY>$/:OV^7UU<79'?OC]H[]Y]?+SW>W9/F)+&\NOYS=
M7;$&C&65J9],ZZ'`Q#(%;`S\JJV,W%+B;&I6\><0/K%?[CQ-BBC91LG#DI70
MY0/5'RF;`-*RW5WPG>:_1DF:1<7+5<)DG^:%N*'1],(?7BA>?J7%8\JN/+,F
M_,OJ2[!)>R!E_T0]0%2427\S3)6:JN-0Y9NF/W5U(IX;Y`W)/A[9!R1E1%*U
M%C%)'9344<5VW9[#,C0I8Y-&<)_D>%JJ*R1^#KV1IXU)>J)*16^B)^VQY>PG
M+8(8.ON9KO]>J1^?G7VF!8FY5MV7"A>5\E5POV\"-2_.7[E$^32SK6?<%^DF
MB!*[A<NV#6SILK9QN:34[I?3Y<M=J,&K294'W6I2V<3/6:X""]`5)2F$@"M*
MI2UX36DZY$VYG-F(.!*"AB7-HP?AT(7-03#T(`6P%%8]2O61)G0=Z1<WE:VE
MLB]IC4@[95\PI5X6!,JPOFW-+'9E]Z#K#]5%7[8;&L99P283,.0LZEFI^#,Q
MDAQ*MSS68$@UY)K-:0CUZ?@-+"@!)7DXF"0RC`NG4Q"<;,]MTD4;#JC3%J">
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M-8;"%%)']$S=R9*BEP[K@7[$@:K2=:3,ZZ(AV;?T6#E4H(&I@QYR(/YW7``Y
M/A]@'9WX#@Z-@UV>]3Y&<<R27E#C-7MU>!V6L5`0ZVGFN0E>!J6=CATXY^SL
M'/.WTS_7V68?;@Q=:R^&/%,U\YVT78A8,%:.+CA9*WL;IDX,S.EF8+VH"`BM
MYE`E')]>"QQ'9(_A@/0L;US0-<TRNOI"GVFRA><-A9TQ;_3L'-%3T3]7>:,?
M;@@KNU[V>>.'NM&/)$I(W8Y4#7VEJ@HD`*KJ\64F:L<>0M29H#E1YI!%1<`H
MSQP[.&:O!8X#,L=X0'J6.7;+<>?!4U0$L?E);DL'QERB=N"(N:8>N\HNFKA#
M**QT)Y^G[.]D5>U]?#[<%EL`S@/Q:::^RA%$`[S!^$1I2AL>$^P\<9T_,F\T
MYR55N@-Y]>I>?@>I<>_HCZ\1Z0/2G`NL>Y;X?DONQ<+K?BT0OI-$8VM,=U);
M1RJ@Z:>K)"</.83R,D_RU%:W;-SJ\?8NL0XZ`(Z;D6<FM\0'A-<S`W>R&SZJ
MV$@8YAEK!]@#NNF##]P!>0D/NIYEHYN,/@71JIXK5EOFZST3Y;F.X/1DX\R8
MKV#.'.F`S3=QE=&`?1@B#R#7\IQ7F>X7$>NGYO9[%TM[7_7$"J0`@1D`>K/>
M0)Q"!,A[$DV67<&=<<4GGG]K\D@V&H9;9ID4U?SQC3PRB'A)GYD3^FH;TM5Y
MFCS3C#\4N%R7_R[X.P0NZ'W1>9UU+X=;VO?2-M@>260L^XN5G.%A(?H!];:H
MFI)]6WZV>:,UX<WK'.R+:MAB2B(4PV#95P:@'YD8>(IL1RNI-M$1(<ZSXF60
MQ2]MB#.]]>W)^>E`#4AX[F$]<UHK#^XR)2]IJUZ*ZK1"HJLT-E:ZZ3J',*YM
ML]B=$>I9<I"/F80MNL'M,Z+56H;["5#@;#+3CV(-B/)IY0H2E;2>D(3Z\DJ4
M@;@`:*4=,KS0/3;#N(B>HQ6M#R[<W=LR2*'94*&..D-4JIA[B*NAVGAP%FG<
M[&G%9_-UJ^I8YI/]_@>_B`9`BI)[8)2IR*AVH.:G!PAU5'J#PF)`M94#(G'M
M-8`2G"-P8>E%)BG[5.6VSU2]O4[?7)$U^LU1F:CJ#6Z&D$2!DZUGO"=8>8F_
MQUA<_/&$?/:MVE(.MY)E!H"HF-4U4_-I8D@YE71IL.'8DLAW^79#;ZOY\?@"
M:_=PA'FATU5W^`(,;+6CV5*_XE&V=#'?;?;!R<I'%<!ZLBOL>BL@)V*QW"^&
MR$;3-.>5#+UAUBMN$IAFOFYQXE1HNW$&`4:V0D(R&O-%&O[CA8V[+DE:^+/5
M;QR2;%=0P%CR0E=O@FAE$-1F$X62EDU0J=&,BJN=E6<X!X3!'OK\3[^@W1HA
M):8EXZB",F^JQK"CT7:J@+L`=L,N'F,(\D<BMJ6LTXS5E>750T4`6,[,&$`\
MA+KA%';R=(4"EG#N4VL<0(^;;IGL3D&K$2`P<;`P,!\G#8;!O`='[]Y.]"F(
MLK\$\99>1'D8I_DV4]\8A1CU<IW>"(D)D)YAY4-#+`A%M"X6C>LGA+<@H@G9
MM_&%/R!`2!AE`:0^PW3&,L[-#D!'*=H8<BP2RZE+W8(_D+A)$_I"-D'V=UJ0
M]399>3-;<8%$0-+'Q.*L,YOK-'E@R-OP*=8="]9\87PG#^B:=M1?WA2%<KI>
MX"B](H*955+#!?_T'?]8K!>=$'Z%?.77/'E@73NN/>H`4-"EB\RD3Q(09N8C
MAO;-B?K&!G*@OK%.WQ,W!+%X.Z+"5$$2KUY&9QAC(U%`[T"4&YG)HL#0A'3A
MCSC`7D>C:]JEBK0I#E$TO4"BB3P"@"0RPX7X]&3WVIGJO]Z]?48[NGV2F+'0
MHXC$1$*0:9'CI-17!AH&(5[6B\\]*=['(\58J`_'RKQ%.7T(XD]4>91'[WI/
M-G?7D1#?B8<ED'NW$$C7K1?BGX3_VQ<D=\=#`E_YD/416[63P=31J#H2KZ9W
MB^$M98H/\)K_#.F:%(^4Q#19T>SPAAL@4>8!GU>,]N=.G9=/%:M42=FP*T^2
MACB(5O8`2;!D_@'0[ILMFB\BJ3[T!-SJ4>RCW#3B/;#W#"2HGPX=EL*7%D$,
M$#YYF"$PX5)XQZ/NGN?W[@5"X^!B5L=!@$&[U2IQ[>:&JR+0(-"<MM4E/!YU
M,=Z&'0B7.6_)]KMC.+O6;&!,M\CG=II[Y"K]6IT]JS&7I6/O#I8%##R`0\"#
M8]6&$$9-!C`W4Q=]N#%($SND^KG<DP-=<1$V(+D/P9@ODR.S7)OU&9\OSA38
ME@@MC?4.[B!\P^&LQ2_^(+N>Q]C+WG[FXO.,!33J-C*F'7=?A.HL6=T6:?CW
MQS1>L81X^8]M5+S`BTZ0N5KB#.;8U`#U%ET<35&MN*1WUBI=^:F9S;:D;.QS
M*0N#DXZ@-H#4<%?K1DMLGR#MNB`V!\?#MK@3<'7V\>KZZN[J\I:<?;X@MW?+
M\__YY^7UQ>67VW\AE__KMZN[?W]MF+;)2(Y0[4LNDVRGA&<R@+$ZCVF-L2D/
MZ"EZ#M/'M&*YSE4S?REVO?N<OB`8TA$=CD$-R35.M!3W!<.NDY8I-!:81<+R
M>+[C$*PV.<D!7'W)1]*D.7!.-7`N-5'!.>W<":6N!,V5O".M'AO61>3(TM&^
M9)P(CZ[7P-1!QP-3NEHF#N/)&VW_A=!7@=#1TQM[C,Z</D)^R,5YFBM?CB-K
MTDL+S29(E.M'Q9+[EF<(@QH&B^HO(O[TA0Z2$9)`7SF.?9#OF\H`[72T'17D
MG0!VPUX6U^7`AX<\\`!]@P[]S+J5T.7Z/*.KJ/@4A%Q?7WX-OD>;[>9CFF7I
MM_+EF>R*I@2V=]'3/1L72$RQ[S66;EI%AA#,PN&"MR;+-2G;D]J`5!9D9T)J
M&U\X.@!F$@X/!FN?X7!7,@7P&O*.DH=E!W"Q7R8?AOYT3<(2_>O*Y(1L*OC?
M[^`?OG+X`U+<5`3P)D7^2C?W-`,DPG9#3;JK&Z(SO-T#_-2U\V]'TLIL1\0J
M#7TM/_?FWH!R)+64DHZZCC:E@9X<"H3,6R/V*'I!\S"+GHHH59ZO,-`-H%;4
MNW&6/"&]=U<S&J(/RYU:IUW2?MIESW[1R$_6W5GZQVHK`(+2J`64(8E4YPZ6
M3#TDQ615I;$3^.R05)?]6I*LWDC1!X,WM/"FSJP[6VV3'[,48W(!2*]J%\Y4
MQ-1K=VE5$WF8:"@=JM-I_73)(:W%&'$&$@P@6B%2H7(%DPF/,#]9UM1V`!?\
MS6>H#FG)Q2W*!Z5$-SA'?/S:(JBK![,MNX",]=,WK.O&>GZLS_OL>!$]!+SZ
MO*4%^R'X";/ZEQP#+'I%G<8"B>7&/F&5;+I`$.*J[1?[BV1_]<2OUR5#1E]"
M3"AD^BQ46LI(-R/.')5)^GBC`"?>=,_^F17D6U0D-,_%<5G'B3-`;8.#M)F/
MX@Z2FRP-V5BR!/.)*C5<U:YWSG"O'=(1PXKX6*<+]]U##A;N6BWX1V3_&3\O
MT!-Z*`=0<HBP?JQ[1.BVEQT=/!$LW(BJ-,H`?'`!_10E04R>@A?QGH/U,>##
M+)4#$#*[+.8WP4MP'U/]/71E0XDP=ANB44#>`SQI[/F'8;]C)L0Q)]6'OMU"
M5P^DE`#:09?AOVT@)X`!(-.^B."N.NK]UZ#89F(;^Q=:R5:^7-]D41)&3T'\
MA?)3X%<T6ZX_17D8Q/].`S5;<-Q*7FXPSBW::Q`POAT6;T?W!O9JA5%!>B]A
MV'LY(7L__*[#SA._4/GBGY?>"'?GBY0@H5SZ>@=$_O1E:IQ[^2LCCH"9CJI*
MA$ZYIRBO67F6>.,6%",'PZ[97P)6=]YPQK>ZI:800#['6=T'_'1M=<ZWQ$XD
M57)7)U7/SOK6C*:6E,#3OOL6>N(XQXGSY&%YXK?4<G'[F&9%68BMV)7CP(J5
M)MN@Q1OE-,C^5<)U_NY;.GY"UG,U?!+6<#5U>=?[%I-/MIH]0*W>]HZ[^K\W
M;$ZIEHTI%;E*Q`2*,'/_J&^-S#'%G0KG(\JYG<M1)9P/K)E[(M3NB!OZ5!.>
M?WOC07?,O6."-VGX,QM(\!RFWUB32IN-T6G?[PE^.FS%L&-LP[2;TO:7_*.I
M9'RU1%3B04>TO9&>2A/AQWEBZ(0:"B3QU,MNR7DEEIQCOI&E_C&?V#3(GX==
M4%!E)>#VN)I9A//\/$V**'F@2?AR$6R"!YJ??0NR%5V)<_N4@@PU[(FSV1")
M:-`>8HDV(!Z$=T8W"]Z&-!J=D*H9J=J=E.>Q^L)",%0DC+2$69^;)@<RGGH#
M44=Y`106`ZL\7YQMTBV3PW1-`G[E-8`2D#)<P-*G5'*9%]$F*"B;=[`+T7U,
M>0-8-M';ZA.*RM8%8?7]=))6E"&MV:KP)$DN=4NQBZ!J2W@S+ZEL`(^)S2#L
M&>@L]V%D]/S0G2+=:"(C8;B==!B"RF.JZ?<G&A;EXQZK4CQ?#X!M,Q(JA#W*
M2Q'-/[Y\YNMC_'&Q?<?/OD>PY`1QH,U0>@<.N`[IL8M<98AK2W:MNU[6(F5+
M\I5?]F:/K#60#&2W`*.>[SI')M)[!>@),I@Q/":RRP6W-VRK1GE6='N4UZHN
M7J1\GQILEB6ST,^MVA8NRE)9GYS,HSJ!K"O/EKUDSE13M&SA)4GE`#"5EQK4
M&$K*IJ6QD)P6:E/,>WKQ1F%.EA=>">ILIS*#<3>KO/_*.E#0)&`_K^XM$ZIF
M'2'O-T.AE"HZCF1+O)LYTS-:-#[QZ>T3RI'K<<$PQEWX=YOW,6]$PY0P_UN:
MG6_S(MTP5;U)XRA\*?_WCGXO/K+(?U<B'VS9(P/`$HD?X#YB4082$,(BLY^%
M:$1VK4Y(V8)\K?[+FQ+1UI-,9`,9"0MM\=8GIM&#C*L>@=5)G02-BX):L5<_
M>DBB=10&2;%'KWAUUUD8\F5COL\WI-$S?Y;X=2#76%.YPN[,-5:S?YHE8'5#
M;6I!7`%3]\!%X@`OT4K,%O6?7JU/:4;0P!?`6FK?P,0%*3*F!+YX\8;V:`YI
MFQ[<6VV0D"Z)BP7RMFL(OIL6B_JE27Z=O2$?*0FLU0/:1W2CK0S,CL?=4:'1
MC6`)`%X\5!\<[L@#4CU\[-&.C6U[=7,N;#^&[?B?'I,$&$]DM0+"G&>J?@XV
M=+EN95CMC1!C^TZ:T[1'`;^Q/SCI3Q?&S`2U=:/B\VKAV3S,/8)`D=&EBM*N
M3QLXF"8D$"W.@_SQ)DN?HQ5=?7SY+:>KJX2?M9>$4?)P%A;1<_DJYOM<[*92
M,6NPHR[E!CC"X>+@;X!$TB'Q`>RU=[M@-H0;D=J*?'PAW(X_[KRS)'M3-N.K
MC'U1@.%P[$O#6&CW-,/:H41,#H<F3DKZ@=UPP9?Z<-*2%,'N^AL30O,C=/-P
M8=;%1];=JR1DZ9_?@3Y[#J*8+S??I>?I9I,FMT4:_OTQC5>,!Q=1O"WH2IUR
MA_GI9UQ;/UA*,JS_:/G6.CQ(/BR]BFQ;VI`?N-6/9&?'L5Y:DJ;I":F,O9&8
M@4"4*<PH3$ODQ<Z?5%T.@QZN\NR`7CC@"<^RG"E1Q918,"4HBBRZWQ8U6<*2
M+'G#_HTCD"0\.4O0%A#M(ULM,A9I$<0N>`);AASB=_%YNZ$9+U_(FOW_JAJS
MBCE/-"/Y8Y!Y<H-[5F*8%D)G(<:L"ZKR4OHJ>:9YT2JERZV36_;9\HF#+4H3
MU4UT'*>P=2*P4Y>38<MOYG3]"-Z7P7-C:`C)NM+]"_E!+"Q%R8]DYZ>QLG1"
M]J[(WI<WVH4!;.@\>QAA@#-NH'/P[/N0B&A9.8,K@K%=<LW(NJ8..2>W)0W9
M_]4L/)"EK)GI-G2):R;"S;WT)>MZU3O<\L+2*:R\`#MUJ6J6W\QI>0'ORV`Q
M@X8PE1<[/P=>7M@"&ZIWPP@#5#N@<[#:'1(1IRPO;+KDFI'2\B+=L?!`RHN9
MZ3:TO)B)<'.7%_NU%LA=,\@=,1?+E`[O9-FO*K;N0/ESNI=\H/2+?C;+>8:E
M.A?#;I<(GM*<T>S9]B;-D!LP[9LKASO^=G<Z#`AP<X?"\N[#@+MT0^XLB+L&
M#`#Q0=/?;CW?-/S]=7B,X?_@^N:3B&`[_!^.8O@_8`[_!R?#_XO-\(,?<.C'
ML`7`+Y*[ZP>,A%\PD?"+?RMFDL6^81NT`8X&WWB;9N<IX!M,?8,-8X.VSJU^
M@[;L-MJA;-"&P''$^OVX#=H:AV-6Z6>GR90;M$W=<,$7/KNY.H*[6BZ8@'CW
M"I,+<R\C`5?`AN5<@*/!=Z.F$1/`-YCZKA-&SM6YU>=<V;VE0\FY$#B.6-0>
MEW,U#L<L7<].DRESKJD;+OC"<^[R"&[UN&`"XBT=3"[XF',ESW"-WQEBZ73P
M`\K3WY"V_&93/[B,O3,$&L*T,T3V2/,A[@RQ!?:(!SSQ=H8`G8]Y[--;(DZY
M,\2F2ZX9V=H9\M3@Y/H(GJ.>DG*(SU=/0;J92XQOU3&?K$_L"R3LGR$5[\BV
M.7YXJ)M>&6'K!DFOAO4>JU2PC@Z1(DNG3'J^D;T):=OX?YKQ8`1*Q&<4EOMB
M8^=.)B\'P0I'L_<!G<"G!\_-_!3DI%!SY+7S`)!VIV;"O*F5=:]>6"AOG%]^
M?Z))KGJ)N+%]-UFJV^/PW]0?I/2G"0,@LM)ZT;Q4[^2L+GI"5>.`]SD)Q$B/
M>BH["<?F@I6;>9\VV@A\\8QPQ_M`TN*19KM-0K2\[,L^(42(F?4=`61^*K;I
MEB;4#JK@V'=BH/USK.AVMR.-7G0*[]]]1C!&X(R$WD4TV5OP<VIDNIE4@*(B
M0%3<\).FAS\>/RJ'YXL1N)PW?VSYX=_+]>Y^XBU]$),35=XPM>_F"W5['#::
M^H.4'S1A`*136B_*2V2Y;FP]J:]ZPC?CB/=Y!@1)CUTJ.PFKYL*5&W771AL!
M,'&#IH18NFX\LYN7UX\/868%1\#8K(J]ZTV51DR;%XWM.XJM:8_"+&-_<!1;
M%\9,*+5U8S=4?<V[PMT\Y#U"05'2I9/2KD^GV8#E1++UT48@K+WCKBJ^<T^*
M;TQD&:4:`UM^2354HJ'2[(HYCJ5X&$%DTNLI*RS88,L!`/9=H<+):K<\R@!X
M-%:W>^IY^#"Q%TL`4/P01^-1+YJ6*H%$/_]#TP=DD;0\`D9FUQ!*[XZ#T0VF
MF@;@HV$D%AHB3`$3MZII?5Z,W'(A?B@^4K5Z>K-'>BQ@X,II"9EYU3-[")+H
MGV*@SME8I7&T$G^<):L;!E6:%.+/Y;K:TAG$M^R3<N/)192'<9IO,VK:).DJ
M3%>WT</@L-G1MT?*&/B]`\@'=M!%TR-IN23,)VDZY<OD.[=D[Y?L'9.OWFWS
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MTHPT>GA"^#/OZ9JP7GJ2+ST:-G76];"3BMSM3T\E%8`_G3L^]7>S$N/9]SNH
M-%`^QLP;EIK-9#?<;K8\!DL'14/>@[V:1TD8;U?EBVH2K\Y#]^B7/0BE-B]+
M^=-7K[4:[2T8/GTGV#LX_E"J=4(?V$1X=5AZ#7L'B%\]?M/K5ZS7IE>W>-17
MO_5ZSM?'B]_A.@KNHUB<`78GWG5OVBL",I*M96F,\%*6L6>(*SZZ6$`U5[NH
MUD4:#<A7T<2_$ZZ`D)`+&A1*4H51&BM(#X?@8:V5[]5G@F5O=3`'*]BR8-X4
MN.I?PI]U96D?IZDU):%UJ[UB2Z9VJ?>LL]3;6-GE:[7+(UNKU1#-27%H)+:+
M*J\?U$W!=F!"XNT2I:*K<RD*7SBL-2.L-4,^_SRBN>;\RC#)BMU\VC#OIC+^
ME<[RG!;Y9X8GT7OE)C%=6UD]UF^+IX*J?B!60Y(00.GI65:U2/DYV5_P2":4
M`RMGN0$'4HIV;10,FQ(V[G*?--)`_.R/T(K3Y.$=Z\:&!"66^):$%5U3UFY%
MPC3W*O6,Q!1,^`>B:G[95622.B_<T"Q*5^SSC`8YO:#E?TT;>=$<6TRPH8Z=
MU\!VW]#]Q!G<GW$E+3`,9/O3?A^2?UMX\:!M5;@.HHU-B0H+8%>.'A@E)Y^"
M6G1K"F[N$WS88F=]8J9XZ[HO)_9XS<-1D\7YF#A_-=*X7W%NG@:J6QMNQYWC
MU_3JOKBY`7=N.QV4V/9ON9U4Z]`^S0DUHVR\PR:'A>G6VKFVAI\:1^[2DB+6
M8$#M$TC^F&9%.46,]\V."U0PD1\!*Z_D&+8PIS4PB+*;M19MC]Q(\Y#%.KFY
M9$^$E\MV^F$W$LIN`4]J:";5A/":1+&'+>JI'/16]KR7[7%`LQ;O85";7\)M
MWWT%,Y))N>O7%<%ZABCIX]Z'97!1$<[[5V,!\2"GWM"79.F-%02<%W_N-'_L
MB[.,3A0O1CEF_,'D'PV!LZ:!FR!:727_,TK8_S+<T5Q5P:L;=N1>UA"%8NH>
MX,BZU+^901*S!?^,"3;AGY+Z8S\HHQG''DV,8]XE1M^@3X8)\>%$=A5AA@!%
MO*DD3=Z)5\E']2]&?<KPX^!B5-)A@)E9,5_$_KF[]"S\QS;*Z$W&=;UXN6'C
M7YPEJTOVZ=-&O19B[Z"GL'`'2,RR[3&6(EO$A1`0[&Y1MR5W*:E:D[HY$>W%
M_NN=A2]LM8:6A,4#X=GG-M21C//>0AR85&P?P+7L`";:>1JZ8;_08\"/T$_7
MY*D&.M^Z15\SQ`$);`J0>Y'P=L>K)0_G?!>?(;VIFBN26;\Y*J]5O<%-5)(H
M<*+VC/=):'\&=/)`SOW90FD<:R7U#.A0T:QKIB;5Q'ARG!6DX89#BRO^1;TE
M=[U#ED>;<_&0!9;PX=B:5YX9!CX'&WKV/5)*LJ1)5X9;37"H(HF*)+=MSP`>
M-`T6_"_"_R1?^0>>;!Z5#E(?Y>JA[.&ZT52"9;<#[F;II1O`;N1%G7LD8V]6
M-?#H>Z%>%^DFB!*#?K4;*12L;H0*Z79D7!7;^8:CN3)IHKG\R#,\=P9,B6CI
MP*H073968]HA`)RJ6B.$+1(ZRG8$6`#K&PP-\VI<1I^":%7=[F/S^L;37OJ-
MS!:6736$6.(P!-Y')-T$!010".!G436JMUV(1=_6D[)>;8FVP4N?@-9@ZW'2
M[$%"5)^0ZD;@@7%1("M2007:^E6P8ATW+1_>J8:A?#;W=:#6G$L<X7;FK).&
ME*YR?@+?7X,L"Y+B\CO-PDC]3FZ(22_/Z$R0:&ON%59FT4:"\%/C8%%?+0_>
MKZZ370-?R`C`@(2%8.3TR:<VE;%N5KPYR@^&@..`)W:9T(+?U6O`CU:7^?V^
M;Z7%T2(0D`"P,.B-Y']AV:E>K2ZWH*?)PQW--A?T7CW=L+37)`.#/3I30?W%
M3Q.FL';4U7OK))`?]JT9B7^LIB77NX<TN(U_C(;A2DMO&VCJF*[UHZ>]5^AV
MGI3,T1%A7K[\HFK`L]/J5>+8*F>Y0K*7V>R:O]MQN3[/Z"JRS6126V`6Z]@Z
MY;BTGVZS5S?D<$JW/>VS%F]'&DEKN2:B*?]'V=AOFLO!`Z:X#GM0<K=\P(D]
M&W0G34W]R$@8KF=063,M9?0YC9_%MIER-(*'C%*/-DI.@.+!20H#Q]XDIZL\
MWP9L/%C'TLTF36X+]0LCP'::I*2P0V>UMG_XR4@5SH[$<B^=J5/=B/.X;$9$
M._^8J\>(EK40>.GX*K77<W569#K/->JH"!`M[]LT01HU0!J6(,UYRY/JU5$\
M]317\<1%DC[Q,YSS$_%.*?9INE[3S+?-G0X!;I62L"#N32H2KU9:6S^19N]!
MDYZ,'M#E`-AG_)1E#FRG#"9_G;F4>$\SFSP=P(-I`Q"FY;X=3'4:8/"D5P/O
ML.X\"4+BHX*^GQB+1TIR\8IRSQ]5FQCT5JG/)>SG3H?R7K$9O#K_&4WZ"4]C
M@L5Z8Z_04IHN$HC.:@<+77KBQWE[PU8S"&3TA$)'PD:EJ91^<P+.55[1!QR'
MO"IS2/*#F!T=*^P@:0`)>%X(_>WV_F\T+.[297;V'$0Q?Y7EIS1;UH<M7?-3
MK,WB;^M&D1#@;E`Y:]M[W,1A$1U.:;#3/<DK$P[B-",[*[)F?^WLB#`\\2_S
M6"-0*0L#L:P2"J@[M7AXS@JGV<VJ$_CT$.\$#**,/`?Q5LR98GYEY=D6\+DH
M`,Z6TY%@UJSZA:&/_DHW]S13)$Q)BTXN;+5`(;0D)DX&:SLVLZ_9?B'^\.QQ
M.]GH]$BB'L(N^ALM^\!V.LY.-+GKWVK`Q<ZT(QARH^1!!WU^H=(<>M&[+A,I
MQ-,/>O$0!0I\T,6^=8U4CTXYZ(^('*6`LRUV[13X=#&N[@3)XCR+9OL#'V*8
M#!D&>5X)HCEE/\[C6;*ZH,\T3L6ZB/X(?9!-5ZKT-C@PA_0+2=(,H0`LT'I8
MU)?%4G.C@5^'Y\.0T.>/!8!ZC-+92E@V-^[<2*XQXD@`ED\P5!`LWWZ\:W*\
MT#/+.2+X/)3],_X@X(/8`'R>)N*5B7?I#<W6:;;ALWS^;$7^\>6.]4Y7M6+Z
M!J41:]\.:3_P>[I,2_9=&JH>MI':&M-,<PU/)Z3VQ1E6>2O7PX6_$\+]^55#
MHE(`*&+C&`:3.LL84$D\8`)/F-^']&PB)O?JA3<N3\GE@86+'VP^U$*(]U][
MYB.J;[Q"J.E[;AWM?\_9"Z%6EYS*9R,2JGCZM;*/2@),^51R#%$\]S%0Q=-/
M"OM6"G5Z-A&7L4NA-S8/AN$!\MG#8JA:K])OJ(!;VMP8P+TQ#^_C!#<);#9L
M`/P8;QB0KV5+KX5$#AB[15S8GA"S!\OEW*FA.OU]!;L])R!/RGL,KPRMXVX\
MC,#KW.FFR**PH*OS(.>]Y/_A>_.?@YAU-)=_:LI#HUWV$]0(EUAR,/I;H:6T
M,3T!Z<;P``O^L9`2\8]&`__*Z/$PE0D-%O@E^C/8M528\"@UL5YMPV++#Z,X
M?PRR!^4QU+JF,GWI-<73#44O$/6@'P'(\Z[AHO4IJ3[VB+*J$95343_^4HIU
M3!34F0XMKJI,>:!AL*GJR`9PO'K]^'C@0*K#@="9O_ZK.\2+U>R9?F8_J/9]
M,C`CG<9*C/#YH^R9`]V5Q;*D4M]%AU)5@Q.R;^(AO=1XT!/-A",MX7K&!NK-
M@S_W2BX/.1:(7-W/PC#;TA7)9"J?DW<D3MG?_,3P8\:D71H8C4I_4D.5J\P3
M?ZT!H.S&G[1K>^2N!+>=<,O-Y>6X?TMSIH$'%5GP:;#4$%9N302PR:IVVR5A
MM8,.UNYI0M>1A\O`B%@;5-;;H\T?':]2C/Y]D0`+0'&/^]8]0)_<E?4V[X/4
MV:L*>J_>_@@9?5#9!'O;H\825BY-AK/)RG>[MSGJ/1@*]^.$W*`R?0CH_!'V
MLV3UA<8!7\]/<W&#,:S^_1ZB\@!SG>1KS?%Y">BM@V2@CVI)5)VS3IK@-].J
MMH0W."%U<_&GAQ2&H$G/9S@>M=36N#'PW!]$NT\[IN!XT.8):0?>G#[33!Q-
M'[Y"&-OE*"=`EF0OQU`^M8$R0\=]B@KF4UPPGS;`W"ZO7B6@3^<']*DOY5A5
M)M[0+$I75TF8\4/9+FCY7XMIM]X!8!:N<N!LLJ3OL;LYNC+NL!F4PIUJ!E\V
M)W5[\D-M\:.',@##%FC"!<(G9/8E=P2;C'F"\<G6!S3A,<%^R*L'[K`]:&T!
M']UN:C=]2%CU]H<2WPE]X#D:%>$#ZC>3P\5N,**$!&]H5X[YO&CWIK#C=::H
M0$5O]4?P0*RTM\0E5@YN6RK[YN+FN"R8[7W+OH].6>;C`18@,!AN79I0I+][
MV;,VW<(TP\\+$EY'";TJZ&8`$WNF<#HV3%USLM=+Y\1L1AS%SKVC[DX6UJQ:
MV18-R5?>E(BV_I.VCQL;YJI09T'?G0LK#JLQ.R61BX!U8W499`GK8,YF&-O-
M5JSG7-!U%$;J70E0PQZ)S89(%(;V$(O`@'@0^AK=+.HVI&Y$&JU(U<P7VH)Q
M(B&M)<;ZE#4YD!'6&WPZ6L(`A<4`:K5DL0/FZO4`$[`NX0*:B.L0QE"N[AZ!
M`J/`\_3UPM.\D.`$GO,N'#S39$N_T#!]2"+^0O6;-(["ESOZO?@8-UY0WJMT
M@':]0L=HAT158/^PRAQS.`@[35X651/2:$/*1N0K;T9$.V]F)U"02-AJAZ\^
M50WV,J9Z`DU'%0XD*@)&RUWZ/90>/R(!U0T^)F?=W7D;/M+5EK\@F[]V[R_\
MK7MGXE5[;#I_'07W4<RZS!\P"/)M1E?+A'V/;<;G_!^#/,KO^&OA3(G&28Q.
M4D*.@:(23KXW3K+#[II9='`C+FIW_!61XH61PN,)*7V*);^&5U*[)2S7[AP3
MX9DE7?':5>]2KQO:]$31)3N[\HD:JR^U1R\"3LH*_!Y.K`:\7&GJ@4D#@J(A
M&6]<'P_&(V"[)T78!;TO+&LJM8FR1)*9((N=NE?8!8PTDHT"21RTY(1?/X`B
M08,#C0X8T:,F==]4Q]%9,.<X7RH"C@,?SV9W--N0ZS1(3@A_27<-PHLH#].M
M+T_PXD//(J.,!9\G>O]KP&^@\S2U7%^GR0,?^`$YP,Z-,B]`W2#SUJ[WV/D#
M'-V&UD"GK3RSM^%_<:MW_*"C0\D_EAC4",,@-*NE`N9.)Q]>\\)QCK/H!#Y!
M>"Z\815[&#T%,;D)7C;BB-\T(<4C)T.5)5\[%2SRYE1D\"2_UK=L;VAV^QAD
ME,_\0GY*>A1O"[JR3+.#O"FSK:4W9'$9]%VP<Z]M)VP4QLYW*Q/O=I\Q6R*,
M3\1:<5B^Y:=T<``I>1A>-7(TA@!J3;+RJI.F`V*4XZQMWQ=GU.JNSO:)U*?;
M&Y$&IO=YJ.1+LM\\Q>D+I;<T>XY"6O>;/[6_X<_6!?SF^UDL^L+^M5Q7]^3_
M25?E\V!\&WNY+FPN!?!CJ0L%S%C8HH?_.Z`7&:A=M-))Q,A[#5VR`J5R3"K/
MI6H2X9LTG9.]=VZW]U\?)2`B5*6,?_6+`Y+I1-D9IS6"C1=3*^>O0T)<5U7(
M/9U)2[H5F5Q-WMWWU.2D*2?IFYQ,)B<V%>#!"<IQ58_PQ20W\5Q7D>ZFSVY^
M#T^KR:&+6LC1'5>5'B^-.6*?^WQ@O[R&&W>"K'`H&G,8Y>;P93[T^*VR4U5E
MUN^Q?I,,=W@]8M'PI)S4'"8*7&($>U"6?``/R`(+[C-V608);*-]9G\M+6N?
M.M,]2MW;&3$<8AJ1LL6I6G2,GG0R8@_V.61!KF[BT_QL6SRF&=>UWY(5S6X+
MIF;+)_'$(,-M_O'E\CO-PBBG-QG3R2\,RA2F)"Z#*L7'35!DO7+YRV!+G*.^
MVJBBDRZ`BL*3\DI.]F'(EL<A(A`I(Q$1ZH3<OY`Z&A'AB(CGJPP[Y:=&N2?0
M!;78NPBNRP^3Z-$L*87W]C&-6<?SRW]LH^+E<UK0OP99%B1%OLR^1`^/-@N3
M`_VI$X&M/VR-'_9]T.7;NAM6RFSIO2VZ#>-_(:4YX?8GI/9`THR4/@Y@W]M0
M!.ND<A0I-"IHYU<K<(?%,\>+9T-ZXY!P8O%KN]D$V0MGW(Y6RVV1%VR^R.8L
M;RQ20\1C'LV[WD0?^",1%^DFB!)59I>UZ6;K=AL<99#%1<JJ'=<`XK8L%M6?
MY&OY@2\93#I2?3YI!K3'D&9;">I=C[L;E>]%L`2`4..C@8!9)BU`,*^<R=?^
MN?(^4-['CR_[)M7C8&??@FQ5ZO15PI<`Q3-BR^*19G>/05).X_+/:?),\X*N
M/F^;;_'N2N74\;LR/%U\'*I/_7LAI8\)NPU0ILEZLU#><FU$XXMGS7951")"
MGM2SPT94(L*2@L6MEN'R$[(+S?XI@GLBKY,3O"_=,VE,+RE,U0])PGF3.7E_
MW51+D_;>([WC5=Y^_6H_T3XA25H06B[I\K6L-VV:#^BO6)T\++6MZF*K(M:I
M%$]1'H[0MJKPDNRD]5EY;&5B$*.A]',*GPG3[J@<*98M&J5YV/PAJ5>[)E$0
M-3!+0#'EH?X"LDR52_XDRIJKI-P"B;V>H0V"M6BA"#)OR:[]YC,O/ZCZYK#F
MEH?$6$C8+164OOF+<4OONS,//Z79FD;%-O/EI;B.Z(17AD-HBU9I2X,AEM.'
M(P]^3=O579Q:)T2](K;GI>5E\L"OT]4;G3'`=A2$/LPBK)S`5YL*\[/G((KY
M0A++6.+;89=CP'!8A9DQW+P:#/PU9B[6S+UT*,>FX,H%B58!]_&E]0APJX"K
M;NOPYW_KG=EU%%ZXE57=@>L\E'9XBF]'=#3E-X1%S`&'+2U^%7J0SLZG,;O%
MJIP$.V58,V5X>%,&E\@\6FTXBDIQ]Z")XQ*Q%\=1;=B(XY5R][Z_7]5@LWO3
M2?0^JI/Z;^?^N,2]3R5GJJYBK2LQWS]+Z4S%O1<(KVNZ=B]G4(IF%??TE*7/
M#"N\B(OR?!LP"KY1'0]_1T1V#VNU<O7Q+%E=,3@E1?1,Q;.]Y<N8K:HQD"=0
MO67PY%`P0=_!9<UDZL!0K=/[5=<]U0$"S)#L+,OC!$AIZ[/2P1`)U#(;>,.T
M2NL1JD:><F7"\L'<#R>DV>\ZZM/FC11M#'A&"P_3<+=2`!^X<?8]RJW2-$HD
M4!H?&<FA=*'\!B[+@+$='*IXX^(NY*<+\6N^/$?JD!)`R<3D'TQ01T6$"BXN
MV>>6X\8<+U=-\L3_W+'^L2S#O]WG8$/U)PXX#&6[CCTHU#0K52-^A8E6LX?U
M$&&9:DC@1;DNS2_Z]E"_2S[8KU"-9Y_U$M6`D`-6J3"X/K<@@])+/[E<1PF]
M*NC&08D,"(97)6N#S5TH`WZ)V6ME?1^=ELNZT,HG!NP.]I37W3P,$7&\%GPT
MMF$6X'!V(];@FJ"H9;B-FARH\`\HQ%$BN93\"<IPE-_`0[$?782/B^M4Y@^@
MIL>AEEM]'U'1CXKH6-D]J.?3K+BCV>9CFF7I-_[V9*4L*UOV9%72$DD6E7W`
MDC59`(@L]>T6XD/"/R7[CWT1`O5@2HAL&OD^$7L6,B)-"!-'=SSE<0;AI;QC
MR3Y^5W#$K.B]-_O-QV$%<*-Q&%HD-PKQ\')J@Y=GFMVG0Q%S.A@QI[];-(YB
M)D]9E(314Q"3^R#V:9_;2/R<NL+/Z9R)-WI(HG44!DEQ%H;I-BE8E\0-\(B:
MWWM@9=Q-ST!C'&I9]10IB4-C`E@'<[5HM"/[AJ1NZ>-;1>T@U"?J$`CVF`MR
M(B&S?Q!V4V#`0V-AN7/FOP'8KPG+YCK&*9KGW195!(6X6[5<GP?YXZ<X_9:?
MW>=%%H3*<P,`)MW,I#7!(3.@5TA92!\)P%>=@\7Y\O/%Y>?;RPO"_G6[O+ZZ
M.+MC?]S>L?_\>OGY[I8L/Y'SL]L_DT_7R[_>DJ^UJ2_Y!P*//E/AH.JQ4V,J
MX:0-%&?AX542IAM^;Y@O0V7TD29Y]$RK3\'4M/&B9BO,"S:!;?J.SFE@<"N:
M@WP"F;_\]>;+Y9]9NZN_7)+KY:W7"F"%0ITH#("S1B<@WK32,8@7,ZC)QVT>
M)33/JY=JY+IMRQ`;E5+(;7!U0=<O9!50A++@O-3#HOZ4U!_[M4L7A``U2P'`
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M^,;-GVZ!/^L645T7D9=X+)W:U'`SSS(MO]D$-9_391YH"%"->/`+/;:PME,I
M1TL]0.>6FG88-)R^:G6\W`,/`E[O(3]$254(__C&/OS5GYGX-__ZSR.;5;$N
MEJ\$_YP6]"+*PSC-MQDU/I%B:R^K(&#V>"IETU_$N@`8%B@Y(&^+9E-2MB6\
M,=FW]O$A%6M4R25D`#"E6@'QHY`%'['M+MF"HR."?/?BSJKQOU0X?WU0AB4^
MQV#V+)T9-SB9#(P)"WTSDZE'KE*2Y<8EI;DTZ?BW.<DX\``B@C<BJ0PA1)L,
M8!/EA5:X,4CK*W^Y8OK'8X38`'$?`C+/Y)LG&6L)EQF!YAW.F2;KF<L9QDA)
M;[F0%ED'H.M2-`"+K,'ZWC2&%E.^;"YM=0Q,.C#1G)'+-:$&DDA:#_E*%AN"
M6),"0@1GZ+`L;M(BB(<4-X.+&E[,W/&HY:WB3DES#'@94,%`$#-OQ;*]S]D(
MT:2X?&;_(X[MUCQ$J6_=E4Y5:QR&Z/N")*+*(`"**&P7^PM$7*E.T??I>37#
M./?)`@)&CR]R*PEI@$B:C3>_4KY7!L::=EL]9^JV+AC3[H<3ONQ"6+.ELNQS
MY6MYQ4^B=(;61!,I$@PD*6V,%'$/'#>++<I(`Q%4'@O5QM#Q0,=<D8P`CT]U
MB?ED05-[O<[B'[YFZH\3O;4])5!IW>.,ET<!&L?<Q"+X@7\J.R.7ID/6%()L
M?WB?QKX/LN/#E:U"#T*65TIM6NTV-#?H-/8*MZ$W;E3:;E5;92S3:-\6LTV#
M;202=`%;868FD0^+UOW9K?Y%,Z;VYG48W)>^F/KC;"W&Y@4L2FO5>HQ?;T`Q
MCCED30;V-A*5'6A=9OXW@VR?GF)Q_DD0UT=@7B7K--L$D`.#[*Q[3`-:(_'.
MJJ]8+(0&A7`2YFO1;$AX2\*;DD9;#U.?'9`D]!V"Q#Z905YDU/80RHZF./#8
M:)@NIS\-5*_V^YG3-0DYQM<<X]'>]G4!&S!S<@OM66=5=UF0Y&L&X+-D=4NS
MYRB,DH?&@5Y7">OD5IS/Q[-N+K^D+2-=A.CD0]P0*$KCXEOC9%;DGIFE"C7@
M0C3AVK5K1!JM/"NGG6"_IW0.&=850\Q0?<4\<AX[*2O0.S@MH<5VGC=*3P.[
M@R?UO+42"[!<?Z&\3V$A'F#5%SZF]MTJ1MT>1\I,_4&J+S1A`-JBM!8RP56B
M==$W=3".>9_J0)CT6*NRDU`0C*SIV/1;<A_QTWO.^3D^;!J4?Z$AC9Z#^[B+
M8@N+#J.T%BB<`O0)AU7Z0&9>Z>P7]46RNTKVE_T@%F3P>]2"(Z9++HUEGUZS
MPLQ)46F*-PIOO.3;(2XHW^B6D^S(`6>LPK`@-VN-]%N2T2#F;WC_$TLOUVF>
M+Y,+FK&>%=&S\M`MH%5/W0U62-0#]0U+Y4W!(,S3^UCL&Q#>@OS`V_Q(TH0T
MFOE"0A@P)$2T052?BEIK&1T]@**C3&"..1J3XG2G1^:"$H;'=1!EY)F?"<VK
M_=6N&;NVFPX>-SP!N0(7H&@'F)KBN#FY%!)U/$A/6]+Y`V_DRP%CSH!H.EX4
M'8C]`T7=`/$#"(A_*(&8T(>@H*OQ0/R``L0/;VHI'\NI0/IA(I#^,@"D=SAY
M_1<4I/XBDTS"VQU[A;D?NZE`^<N<T[Z<+M>7>1%M&`25LSQIH^ZDKM,(AV?2
MR$A3MJYO`&O:)@OV-UFNR>X33Y@A'ZX^$73#VD-]J[$$Y.Z'W\TTJ1_"%@=B
M62P76?PHD&">Q%AA8=9EK;\&6188'K^6MNFH6Z<-"KJE<7&TK>O:#.FVQ:+Z
MT[.GJ>4CU8.S;D"[6&ZU[4/9^;@[$;5^!$L`<$FK/LB/``-&1;-!P;QZ1J.'
M1S99.'NF6?!`RU>P+-?E2=S+;9$70;**DH>/01Z%*KT;XJ.KAW8^<'@SI-](
M>FH9&D`W*X^+NCFIVI/]RW=*$]*P.2'"RA.^#D);G\\C0-MCNXTOB1KXCGTW
M.<6Z!\@D$#FIID%0T:!Z;=HV9Y]%"0F#.-S&Y0,_C!KW8@`36I"8S;KYJZA*
M@]?+#',FG)`;:#<O[**ZN95AWP=L?IS^;G%!DW03);SZ(&OV_R4!HB1,-W0/
M?]*C4;KW15C;35J_A^45,\5T!V52ILSYNC9=3[L=/4M6%U&\9:T'%)]F9Q95
MJ,Z9<]$Q?Q/W=:FV#^.T1^-:6:DNJTJU6:B6=2IAYJ2R]U]O`""U$AXPZ&WT
M1^W43H@\)='D!:ZA*Z[8-+CD9=[(JAKP0RQ_IR/9J(+8/<U\7&RJNM:K5.PR
MOLD++-6KO;B4)U/?G29W3?#!.J3T:;OP=`AIW(@\J+0`(0Q4%)4WL)3XQ84I
M<[2V#^BD&)"5F[FXFHW_$(O-VX>1E)U39F@:=D8:UVM3RKA6JU/`MS@,Z0,^
M;23K4S4ONBM4KYP,`Y>>W)$!:W.O;5S89E^DI5IM+_#I\.&-#K8H\(4.NVW$
MS8&Y9O]B']8?L?]A<W'*/OG_`5!+`P04````"`#B@V9'(;M#RIU(``!YQ00`
M%``<`'!I<"TR,#$U,#DS,%]P<F4N>&UL550)``,7'#U6%QP]5G5X"P`!!"4.
M```$.0$``.U]6W/C.);F^T;L?\C->=V\54U/=W9,[88LRUF.45H>2]DULR\=
M-`G)Z*8(%4$J[?KU"U"D1(*X$Q0)I5^R7/;!N?$[N!X<_/O_?=[&;_8@Q1`E
MO[S]]/[CVS<@"5$$D\TO;W/\+L`AA&_?X"Q(HB!&"?CE[0O`;__O__F?_^/?
M_]>[=],4!!F(WCR^O%D]@3=_@TD6;,";+RG*=__[S3WZ#M+#7V\?;I=OID'Z
MB))W[VCC&";__"O]YS'`X`W1(L'%__[R]BG+=G_]\.'[]^_OGQ_3^#U*-Q]^
M^OCQYP\5]=N2G/XURHX-ZL1_^G#X8YT42EC#A%H8GEC'$N+_FA-%3I2LTM]_
M+D@_??[\^4/QUR,ICGB$A.>G#__U=;X,G\`V.!%#-?&[FMX8_A47OYRC,,B*
MSZGTY!LA!?V_=Q79._JK=Y]^>O?SI_?$B+?D^[UY<_B"*8K!`UB_H?_]]G#;
MD+E["M)MD#V!!+P/T?8#I?EP#7$8(YRGX-T4;;<PVX(DPP1=4Y1D!'4$?1#@
M:Y`%,,;$K$)*]K(CP,-PNXM!];NG%*Q_>;N#.Z+=IS]]_/SS1ZK;OQCR_]#%
M%BH\"@"T4//4M+,&ZRP$*++4H6K<78O]-K%6XM"VLPX88/3=5HFJ<7<M$`YV
MUKXXMG;@#7LE0&<-:G%XE6.8`(SG\/<<1C![(=&X2#=!`O\H.BHGP:XMQ,WW
MW77YO#M76F1=M,A<:4'^"4$GO%<<W.C319...BPS,AVB(\Z[Z>+N>G:WG%V3
M'Y:+^>WU9#6[7J[(OU]G=ZOEXF8Z6?YZ,U_\MK10UTZ,BSX>HW@;K/<=>OH3
MASX]?3693^ZFL^6OL]FJ!P\S[%WUE)(9RQR0B5CO\R)&2F?$A$%HB92BY1G\
MN@H>8]"?0ROV#F9Y<?!]$]K/\ZKF#C39[5`6VVM2-7>@B;4.3J3;BW<BG_:E
MO\,@)C]TZH]//%SH9.V4HJD+#>P5</550KC>H]@^1)H\SC4C6=S/'B:K6_+7
M?J<D=3GG6F/TN[@XXZQQ\?7^8?8KH;G]VVR^6/8]>VR+.]NL[3Y(">$3R&`8
MQ#U/X1A9#M;>UDLSX&1=!JS%.Y'^R5K\)WWY]1W+SP?I"=C0_>AY\`@T(,/C
M%:=I@Q7=^_Q,]SX__5NA95-"7=5="C`!4=$AT!WBAGCPG($D.JV2J0C7FZ6%
M+I4V,0H;"L1T5QBEZF_P]Y.D"6\R6W&(J0<*%KHM,IA1H[5:?'!N#&8ED6\$
M;DD/@:46J9MQS9(U:]I6A\TD;=H9I,?E$_FQA9GFEGU)\6%7]&7OPB=XFH"L
M4[0U^U;(VA'W-8/>_/6-AM`W&7JC+PRE$4A_>?OIIX]OWQ#GK4&:EO$H<4[A
MF0RD&#0BUPA@]7,F#,+W&[3_$`%(!'SZ5_H#1=^_OOOXJ3PF^1?RJ[_/27<1
MSX@AV<OD&;)0DU"4SN12^`(@M7EV6.'RK6#QR105L1-`K`/\6##.\;M-$.PH
M*O[T`<09KGY3=$XU>)2__OLT#C!>K'\+TC1(LD7Z`#=/&0<LVO2E;S7H?0&2
MJ>EVL-*04H+L3__V_D\#=C[V6)LCC!O&7[W<!1F97RS6IU_S>BI[!@P:31CX
M!D]KYW3#JXG8JI?\V4OX/@3$%@DZ6W]GP%?[NV_8$IG6#3HUKA4R/@XYK>H`
M#>(&XOPG8O(UV(,8[0H'T"Y\4^P"4$>D09BMT#U(URC=WJ!T0=9;*0F7%=%.
M!BN7O%E(NN'M'9Q[<&G'4'"CT7$:ZF<8'3?-JBW/)=@<%F3B\-!JP\!>T<8W
M.)NXH!M,%9*.O;B?Z,L?,?@])^;,]N0?1;>LH&81)Z+V#FM:9G=$F4C&<?/E
M?*ML[K[>50J"\.DPP:6=<A[$-?.^!VE$.FEX2HNL[>V9-JWM[^DW'0FH-#;M
M4">O2&$FEE[M^.E+K8!W[G6W8%<Y3P_J@>@&`+:#DI$T=HM9$N]0H["R(SK:
MW$L4?!X#".Y`=I^B-<P>0$;,(2;>$%\N@Y@LP`&9'X)KB+,4/N;%GU#*8IT#
M&E<L:R#KSM([4#KV8D<0=]>F!/U?1@%ZE`%\'[S0"<-DLTF+T]#[%!+;=T'\
M`';!2]%U;U&><!%NT[X.9[/V_F&W@W^Z`M5,M/5Y2Q^P)+.$$!1WSQ;KMNX'
ME1]`!+:[>C)0#9=V#&K`-&7@'3([>:@C-$UE#[4*5F+S.!B4LQH%$D7D`MRU
MR;U&F<)ZAYAJ2RH1].<Q`*@\B)P][V!ZN,M$T,]!CI2N!AD!G7=8T;&W(T@$
M(DIT_)LI.O8@?43.\;','V-(L(P!6225L.;`0T960P>?S#MP:%C;$1M\"6/9
M()O##&X*TY8@(^92FVX3TCT!G)VZ/@Y,S!K6@*/;T#LH67FD([AT958)*6,8
MIQ[`'B0Y>``AVB3P#Q#1A6ZUC)WD$>3U2OJ-:E#3:>0=S(P]T1%B.O*JWNQ?
MQX"O29+D03P_]+GWA]4H!U$RLAJ&^&3>H4;#VHXXX4NHD&$\0W8\SGT-GN$V
MWQ[6@(OU`X#;QYQ@3P`.'?(:2.3DWH'%P/J.H)%+JL!C/($>Q2EU&0I3A#-A
MFB2'A$V$;)!X!24-*SO`A\^]@HRGB&G/YLB:DIHG!)"R10M/DA:>PDO7!T[0
M)A%6@N_<LZ`^<KY?KH,M63G@<J?K;T&<"S&HW5":X\UOZ"<B33WB`I@:,DM\
M^IG4S1@XPQG<!AE8K._)'^!C#"B!'D3E;>4H%;6]!*!J^<4]5D5B2[@:;Y&-
M`JY?`YAD(*%5%V4S0!$9`\(VF9=X4UCK`%IM"=976=Q<^-.]`3HK[BA>HRTQ
M@,&*Z,^UNY_-/SO+GH1H"R):ZV`2[:E+(T'V>YX]H90H\!5L'T'*J.^`4SVW
MTI;38`$C_'S(I6^8V&&%'C,I;87U<%9^YF\@NF*,E!'&\2W#K+INW&1B[;-1
MWC7F]DT&+73N&[ONP8H*TXL$"#LF/D&MOV$)!H.PB:>1AG$,J#785WT(R[:"
M^7N725YC\2S;59@#WL3155^B)<7KO2[)Q.Y4SF;RB'DYT)UXL-V0&8_A06IE
M<ZM,BTX%'A%P331HUVP12/8:S,R"]G"M7CI>:K20[T,T6PP.2XN:!N)]"(DW
M!)C4%R_9AVB*'0B0XFG,#<I3^3RF3<%.9.H4(\,,_ZLC'?.T0-'@WYC*U/F>
MYC+GWB45?_@5(5#,8#DD[*=OD'CW[<4&=OSX#<:GK^_GIF-1IX.+%`D%K_@)
M'R=GW3XM$@.DMG!I6ANG#9K!<<_S/](S20#T&L?F1FB#TPG97B_1VN5MV-HW
MQJYC)P4-+E[/2CN4*J$W^:7S5Z>\W=6ZJ?,>'JQ.B]>XJ8HC=+XH1%S8X*A^
M3EWW,<W.KR"*T0:&92;29+>+X>%M-?)CBO9!+#L7,6K:/`C1;.IS('#PBCJY
MSCW.3RK6#EDT5;/-&'*='0MC@#.45'F[6`A8!64])U9$>9EPU'/,.=`GU,0V
MG\(QV)99'D&`%^DJI?7(A5"3TM5OHO'I+A-F.DXY!\@$>MAFF#F&V+<=^11)
M5@:`$&$RLAK`^&27B2\-EYP#7GPUO%Z-E07XI*LJ+@U;H*Y)XZS\`'U88E(\
M+"&,%R%-O=!`FV;P2.&[%>D9)8![@^>Q6$";UW'CY:/#:E1#^%"K="72P[+(
MIS(9C;J#3=Y^]POM&HKR/D)%KRYH.9H=$E6-2GDY2R-H\24IBEEZG\C%V"3=
M3I?2RD$UGIY>B1(QI(QZ?Y$<":`Z9U(VP/3O'UH^GI-?]/O0U*YZCM[1I.,:
MA7F9$S(K,B=O$SHQ/""&G_MCVJPV-=%K=J9\[PG1)*+:W,3!AK%1^/=:QC?S
M]T&O`QA]#Z2VCW,/0$=$E83+L![!K3Q=4$SSE/KY!N(PB/^;+*=F9#'5KN*D
M0UJ#BIC4.]1H6MT10&(I0U4SM`%39?&A-+(825*Z&HP$=-YA2,?>C@`2B!BH
M"H\->%9I$,%DLWS9/J*8`QKNWVM@8?[N'4AD]G4$!\-ZH+*]]G?4;F`,TBD!
M]`:E+QQH2*A:-]88*N]@HK:U(UBX`JR+QPV&F0>PH>6K@R2["[:\04A&UD(-
M2^8I;*36.L$-*V&@NOCVN)D">F80WY*EZO-_`'%O(Z!K(:=%YRETY/8ZP4Y+
MQ!C>##)$#]IN4;+,4/C/Y1/Y$GB19S@+$CK\BJ&DT:B-*VDC7T&F[PDWB)/*
M&\.3E*9+K],*\H;\AO>LLX*2L_QJ47J'+CV;'2W!6D)LBS(/#J/#8E(/2!Q:
M(90:M)Z#26RW4S@UQ`Q4`[X+H.AYA01#]3]S8'/XL[=(X5CG"!P'SNZJ;`UV
MQK/.0H`B5Z<\L]]SXK_%FOB"C.2<EQKE1+43'!Z1JP28)F_N$;R*3*CIX`?N
M"@\C;=LXD=+F6Z7#\/G99FLXSA$\GA*M4)&9AN(81$V-A8E0QFUKR#!H.R*X
M\'.G;/V@1%$SK<I`C/4!C6-T:0))$S.>PL,]$N0??53??,X6PA-^]A:E\,O7
M*-V]4;K=0HR)^Q??0;1"Q8N#DPTHRMJ2CX-!-,'<A[6^I`CC^Q2%`$28/@HP
M"\(GVGRQ/BS?.8:?05K->;U*&U'TM0&$SNUN91S/V=+OO>HV4.E0;H3=Y+3T
M0%&"]U`SFO><FYBHAF<>D0\P5!IGCAX>RV.J]2B>N2DOX!<J$F#27<U;C'-:
M[>@;696EQ6\J^SB(L&I?OW]GUMX'''5QB3G$#*6-Z48R,78/4=[H)`O=D["H
MB'3<9W\`(8![_@.3MCSJET',>?B`PZZN,<>BA<0J[7$<O>$#H--X8IIU?VC)
MH89&8PX^8+&;6\R1:"QO!-OCW:I4UH\D:4I_F,)'$%WEV;>$S%]S$)6_+!X5
MQH<`K%=3Y!2M[,J24\/2GN784=Z#X\Q@[T:!$21_=KA'5$4YB*YSZJ##"=AA
MN74'OA=_$KUQ8-:8O6FDV=@7%%LYPPZONJ(&.A'7V$-;<?I1!95P[VPUNMZN
MJ3=WSY1S#J;$0L&6OV%Z8.=TNW3L'A1MKG9Q8XWG^6NJ]';KF',PJWM/5WGC
MF'=4.R[DF)FJCQXE7_M=JZ$Q=`T>,^U:[7)B!D$BXL'O%RNLX/9`!J75^>SY
MG5#'NNE#@^>U[($_90\\Q]9KU8,153WP.2MNOTV<)<7=!#`MMM"^@H!V]D6=
MF]9DM7Y"J-6@?EJH:.`L@X#W1DTM=?\NIPBHSF9GSR`-(>8>.73D5#_YM^4T
MZ!15\Q,CE][BS&3E:AS/[VW%>UVM266U:--7LQF[L:MLY@E>+?U@!4Y]65X_
M,'N[W1%74/,7ZSFBFQ)[FC&#089_!7%T@])OPF?CC=HRF-1LZQDP;3S2"9V:
M`KU^LOL^13N09B]D2O@/0`M_+M+)/H`Q7;G2XI_DCP%]H&5.G`7N@&CKP)8-
M`UQS-IYAN*.?.L'97/9`99GT)^.BPP<UL6H2/H:C"`TKD,7"0Q=$C=UUE83C
MS?,AKY[;=X-'\ZY>YC!XA#&]ZTPG)Y(==ZTV3`>G:.,!W&RL-T:<II`QW#=W
M@KGCC[]"T@FGX=/+G-;GU@.?1F,Q"J6-_82COC]<X%(J;0RUZ#H`%"9!$D):
M8`1GZ>&JK021<FH6@B)JGS"G9;$]R$3LQU!;RD&W5_7H$.#2#]$B>0!AGM*S
MLZL`0_PM08\8I$5ZUFVRRS/R9T1\$L/"G>RH(#V=.IM<46?;G]S!3S?T)@.\
M[OI,'T-P6B+5F]OA]Z>OUWNN1_^<CL:Q(MM`IXDHE+A-QA,%,HMD*S:#-`29
M+.F:[1+><N<:UIZ(Z0T')CQ$>-3C,1Z`ZDV2>?VUA;?4?:]$&6XGK*?$F&Y[
M78,4[HD']LT!1%!R0(.Z7C-?1CT>S/4^TB-3YZF`V9?&5?\LU?3T*-&05?$=
M]-&%6W`1T#]+TWPT6HCZ7UZ+\2#?J,_D=;I*AZB0K*,!MZ?E23XA<\@"??;(
M7*5!@HG2>))$2Q*[,"31O%ASEMO%JW>8_R?IY*(/$0SVW8H8/E@4>RGH+,X5
MQ1%?N7K$N%7*Z]EYF<TA[>NY-`S"&9K!(=H+[I">3P3`=*E2'<V,*J<>W\'5
MR,%R0S'`Z+M-<JB;L)A\#])(<8F'2\.$!4,S7`8W31HDDV`03=%V!Q)<QN+Q
M,5E\]7*B*9^)+90_69!$]W&0T,+W\HL%/8IB\\=[$35XW\4'%CJKBP5]6$.U
M1I9Z+RKY>F'BM%B\>KD+:&4E23\B)V[=Y.(3C\!49<\@(Q6:.:K(5'PJ9&2K
M\,X:3T8]UOB\1U*T\:3<:=)2SE!T]M!4C;A;:>)&(T(,!P>M33!-ZY7(.<EJ
M;U^)97A[]SI\`E%^+%?8&H4.-R8F>?:$4O@'B&I5=8JR(G34(<-3=:7B/H4A
M>*#C%B]C\;Q"V0E/ST('#Y<S>17IS>)%U_9Z5;+>TS/*V2:O#UUH8KBOJS6W
M&OPSB[3TMD-VZR]9(8W^)&FM-3M*^@$CLO\O-G@X]V*BKTOA#LYHNV(NN,]]
M'F'N>@2IL-=.H9_OYG._(+72MA+BX%W##U4S:\#HLBG!-4!X*"IZ&:?6#(YO
ME_%N<>;B1%*?@]YH]G7[G)3V-<P9E:UR;U]O`YOO9S^7FE'1ZZ%CM\R*/E33
MR+`8^*2%6X^E>L3@.LAX=^VUVZAJ/S7;C!2<SA80L@I1$N^Y[XTERDKK2#65
M'--K3J6>L^<=3`L_")`KI:NA54#W@R!4QTN#H%*@V)A*I9L68".6.*FZU^#3
MH>9>R><'0;H++X^G?U8K[O>S+SR;&[XZ_A&7?\6?!'/G3KQTZ@&J>?T`(>;2
MVV</LX[*#U1)J[]0PQD=;>D;9[\]P?")-;GTB.R-)2=,-8+/A.D/'H76_A]5
M.)I8X77M1FY?=!SKZ3W5XD;I-*!OL5^]L(XP&0S-N>H,BR9<?_#0M/\"HXI-
M(S.\O@6GW$`4[1\>GA"I7<]:9$\@73T%R>$3X#N4[`'.0'3PI>V=&=?R32_2
MN)/_`W4-0WW5P3J1,QH\T.N/W(TCOME5%WGRV0W<`^$5"'LFM2TC&R:7%9#\
M&Q:=G7N.D&I>V+!1>4R[J=KZHSSM'A0M)C9!46/R&A0:SAUQ4-14]G&D6"3=
M!XH6#XN0J/%XC0BU:\<;$#6-QU1I35?])=B#I'-$<+A8Q$2#RVM4Z+AWO''1
MT+F,C+]X%1GPN7M<L#QLHN+$XS4FU*X=<42<-![HR+E3/*P(C^YS)PX7BYAH
M<'F-"AWWCC<N&CJ/Z:TE;0.^H^YQP?*PB8H3C]>84+MVQ!%QTMCKAQ\+_SRA
MF)B`#QO1=RAKO47/GMAH-6*/612-AH\'/:OJ9QSG+(,BB@6IUHT#BIZU]?7.
MBO+!<_5=3/FM,3']\)A7W(Z47Z0TNH7%EZ2X`\G>AS)^LV]DX))>C)+2RD$U
MGDF%$B5B2!E-`41R)(!B-P&[@6FXZK`(![O$ICPL?PH--PE<PY#,;R9AB/*$
MOJQZCV(80M!^F;,^;S9J6)\L:S9T=K<AP$]T:-P',3U>_TJ+#)%Q\AZD$''O
M,.C0U^\JR.D'?2?.\",A<P]P7HW3$WJ\$R`7-E#B(Q=)#W3'-`?TZ0QB(9DC
MT=S-*4J*N=8DCR`[8S9K5,.43B,/@67LB\[HTI'H=<[[`Z")0R$-FF0S)8/&
M!H@29F6DS/R"3^H9X@SL[H0SN9Q1G3G*;!*]4:[?2'>0'[KBIJ%5J,.$QQ18
MC;?,=27:YCX-O3JB0_\DB9@9@*0.DKH!F\TO:>`1_(SMMX:=CB2GI5C/"+<Y
M2C:D5]U>@T=5P2T9*0,Q/JF'X-*PN3.L^#)\W3K\&OP#I=,<9VA+G[81PTE,
MR(")1^@AE)3V=@823X*OM=(>%(5^6W]G)^LC**IKCQ61=9TA4F/L:S'IYHH"
MX8P,R>1W(-U+\:+72KKDX[3R$5M&GNB..)4X7ZN5MFU7'!&K&["/A4D:])LM
MHG%%Z_C*Z`3C?'NXE35)DCR(;U"Z!I!6K7_@EVXZFTQE-HI3F8,?-&D`3)J$
MTM\7$+T>)E18GGOB5-'Q9_EJF%OTLC#,0%1D)WQ+8(:_T/P<$-TFPE.=<XAS
M$8-:XGZ$\#/W^_DC3TO':G7K\`AKW%_<=+_8_KMI2!I)P5(^Q&8T"P"3'Q;K
M8UZ560>FY*#LDR0<?`)=)^\X[CDD8DLX?A[O"$Q/3%-,Y@[D2]32_TY3"6XR
M2$=62I3JL/(>KL;^<HQ;'?G6V5/G1_`=X.5C:+?1QF31YF+`U_9`3R@K!%5P
M\K-VTH28'\$XI\_7G0I%S9[#.(^J5)/M+C^XC@P&09H0=V$R&!2NF6RI`T5;
M*"YYL[LM;GA[@OD^/6H5&XX5JG:W_8PA>A1XJGY4I?]Q*J'K-V@]J"UNX!F$
MM6WOA$N9E*K#/G>A'4=@@WB'R-CS)47Y[C:A@49\07X;(NJ5'$2+'3@4:;]/
M$?DQ>Z'W7NA&/DV#V%%_B&#ID#4+8">L?8.Z>W]V"PHG^E3A<^X%H)OPF6UW
M,7H!9+!*]S`$_/G=L5Y=L46&5R@+XOK?Z<'8'<K^&V2GK-S#\I@L-,I?43I1
M$?1AE&!"\MQ*>!:\@WZC3F%^;LVK#N'<9S(C[Q#.'?OG#O/7B!9X?IS!>XI3
M/V^)?`E@,D<8+Y+#-`8>5I03C(&POKI6&R9>%&T\P[R)!SKA5B&HPMZYZSBZ
MP=[M=A?`E$Y_%^M;XJ%D`Q]C<+#M-HG`&I+!$,1P#Z+#U@=QUA>$HN\PC@70
M=,&206XWEIX!VZ'_.N&^FQY56/CY+A190J(M6`7/LV<Z](`KD!![1;L+"FH6
MS")JWW"J974W"(I$5+NJYS[H<H.NZOF*<D\BV2S!IJ@N+\"7DIY!F(3>,XSI
M6MX)91(A7M>/*MXJH)/G%#S1E(<].,03G<R0I2Z`FV2:$Y.2\&65!F2"'18X
M2*+B_^+R/#"D#[`4B3S%7Z-_Y#BCWJ$G()/%]/8!!'%1DFB'DF40@T4ZA[_G
M,#I,YP$9/$C\"H`]0@V94!J5AIX%[ZA\YZZ[&)59QM<]/Q\ZJ`1L@JRD'<L=
MFN)"1DS5HJM\.N2'Y<^BW6;3YK);-=+FGD6>I5\ZA86^3*]?C+5.1RX?#"HR
MD+$@%[Y?(:[>UA((\2Q&>O5QITARK5FU%/=S%GM*X^>7/>#_5EK,SP5+WE!B
MS7+PT-&H7<$.+V[\)P@4L3ZM(<=:#U\+&[!E&J0%4>7$BFH9HRF%*JU^(:F2
M85($E2=#5AV#+7_J'8Q@`A;K*5$7RDN?B@E9^'`(1P<=<<53I9V:P&G7.N5Q
M]A4V=\&6V-*H\"'M@)3T[-ZEF'YP+$DJIR!SBP5P:@MI[%6*F0]0AYE[[^,+
MVH,TH9/2JI2C\'D'%6GMEH>8='!8J#\X,C)7``RAF.I&AYC]4/>"');@D4_H
MVQ2\,CQ\Q)RU)M4SW.9;J2U<FE8EJ@;-X!'`\S_2,TD`]AK'9F6I!B>G@^A0
M?A.NLH2@EOFLM4:J<QG)?>O#3C;,7FI[&OP5NR9U;9R04@__P5VLG)&I7T1X
MZ:!,->9(E?!UCDMG\8MU8T-;.L=5TC/=MX1^'`C5J,J%S,V7P5`LL=Z9223Y
MBK535BR9O`5)*)_H**B%"=(,]>`H4T.&F]TL,UJ`+J$D?FHR(\%75-T$(8Q)
MKSR-$2862S$EI640):#U"T\Z!G=!DX"_DSJ7P[UL`QP^:]-Z%VTN>\M&35VO
M!B&C=E;:XE1_`U=K[3R(5R#=B@R04[,&B*B'+?.I\2&0J<F\NIYB.<?B%3+^
M8WH$M2C]MUB7CU3>8IR#:(7F-`C3VX2HGH`B/>@WF#W-4<#.,+NPJ&'*G(4O
M0.OH'#OTF0L=4V6I*<T\.VJ_2!_@YBE;Y!G.@H3F\%?IL(<W)ZL:6=S'N+IQ
MJC_39<O)%YRZ<94=7*UEVSY=,@;4[F#J!+,-/AT06_*Y5+SRW'0>M):2O4XJ
MY-K<>,SW^$=<_A6+<F([\6)?Z+'CY0/(7;K+'.@=I=N6BMZ#]!&-%.['N#[6
MVIH&<0RBJQ?6`2;`-^>J$P(F7+T/!FL7.@X+$SULWW(82X"@[18EA;.FP0YF
M07P8[<IM<5JHY":G-3_IVH/N5XI"PI8/&P3F?+R"?4<W=0"ZN>2!GJP<^/9$
M<]8WV0<PIB7$B7^*;'<!_OL6Y^I&A5*<3]%T)J?;!UU_"@[T'O:X8C//GE`J
M*1/5FYR>HK$FYT<,0Y&;AX^_FF8#W=/7/-T2/MXLIY2>:HWBF6:%_LCT`$\+
M4\U7F&6\O7X[GKL&DCV_K*+76=B.X3%!-:A,33:#E09WK^?@-S`A*PD8Q*<J
MTA)8*:C9_!`1M2^0TC/7#E!"WEY/&VD=97HU08(A'@D#G":)+VB1&&8'D29#
MKZL/<;M/:1JM1@N=,8R?2MOA/A.M*;Y(^(F98H+ZW26&8/!T.1U/(PWC1+>W
MQ>R/=Y48MM6(^O[<8ZKXDZ^^(_DG;Q&PG[Q&X-TG%QG7\9/7V%:]VWN7[PN-
MQ;.B7'G]/L[$T6R>O%2*UY/7HH;6FEZ,3:)#(6F8;!9KSM0*TUQ=S/^3_#9'
M#R+8"R!.10P>`:I),SJ+<P4!(U"N<:W$J5)>QU<U`95&")](,*,?#4JYDW7.
M9-X$7'6>O'G\P)@0[T_>)B$Q!^X!U73UG?S\\O]`BN@%F$0XZS%LR>Y?ZK0<
M#4KX4R,[#RC`TYPF:8OPNI]IKX7O4`;8>FWLR9%6(_882-%H<,1I6B7<3#=X
MM5LN2KRGWO&Y[E$@KIP,2Z_"<6D8/#$T@\.GEQD5TO.)Z):<0Y7JHRJCRG'/
MX*.#G=-!+M;1!^IBA/,4O+O*,4P`QL<+]4$2+=)-D,`_"HG7(`M@C%U=P:NS
MGJ($H[@L+4P^6?VKUC[-DOSF<+__I+;H9+,/]K7IA%OVKB96G;2:2VY`NF7L
MRH]ST;W*,^_7]X(UU*/G.4<#+FVHAG%7NE?=K)_'4[+2D8I:F9+C*C[I18:!
M@7?.`&RY-KZ6:Q`7%FP5!Q-6(&0KA+4)+QJ>2L^<$9P\79Q4?QBJ^)X$D>T2
M9IS">S\`_D1^."/L:BK89I0X+O1VGZ(0@`C31TUNZ:NZ07R3%[<X.;-<-7%M
MYBHC]A=G[1DC,O2-:[C-V>NY,DW&M,M=UFB8;%(`ZJ_-MPMKM$C:A3-J)!<(
M+H4?>H=46_Z8TKE/K\-1BZ3U,%2D-6")22\08)I^Z1UH8CT&RL#D`FZR(8%`
M7^<J^]7)EKX9@U?H"CR`$-#W5NFC8)7VB_4L")\.)G$PZ8!;#;:=N%T@LMUY
MMW?P=U)U3"6U)DF2!_$<AO1%V/)Z$`_X$K(ZHKEDEPA5M3_ZQR!7!]LR0STN
M5B915#SSKKM>$=(+EBP<^@N$G(F'SKIPX2AC6S_(,0C+`O>'SIE6&H7;QYST
MH8).3H>\!D$Y^04BT,`_O0-0KHMMQ9)1'++07?C3R?WAW4$8EAT\+<J)KX(X
M1BBI?D4F'?<!%-T0[\J.V8*T9W=A$>'8O[U&3'==;8MDC2*B;A.B!L"9)$IX
M)`SRFR07BF:)'\Z"T*9\Z\=61U)Z:D[6B/$-`,)#<O;O[,GXZ>\7BC>1!\X"
MMIIPW_,R@J28DF-:(Y]8)$S*$-"U,C):=)>*/X5'SH/#MA(#U;AV5?P(I<5T
MX@JE*?I.;!)U@!+*5@$B#N6%@E+ME;/`DJM&U5$:GTN.94A^??!YC`\^G_&=
MU=<7GR_HQ6?O<//ZY//8GWP>>-/Z+CALIM-]&ICE&4WFB&.0;E[(0'Z;K(O7
M4'*:N@8"#,0O?7;B4T^NL.,S.-BT'Y)VX2@!%I6O3%O*'E-NV!4D9D4P#.))
MM*=5E8OW)LEWHL^=7H,]B-&NJ!-PJ#"9O0@1VY%3#;/6G/Q!K1MGV>+66KK7
M5;@Z+;$4U[&=\F;F!(YX.\LY.1X8URJV'S-JOJ0(XV40MS9-;9K6<U.TFP[>
M";C%`NKD.D$/X43%8R:+MFK5P'?N<RC!R$=?S"`&?TL>#S^&89$&=D@!HS<*
M[@`OT<"L86-<TVMXF0BV<MLY\*NKF/O$OTOYM#U><3\'`-RJ7^5/&W=R0^]M
M3`-,YW_T/[34R9[TV=19V31(TQ>8;(J["8+YCU%;MG*I7MO+"YTNSNL[+@QU
M\[IL\QP&C_25<OJ,5IZF[?1"-6%K,[A->+GX5;KE7&#E*>+Y\V=T?WU5[J\K
MP"FFY!QUM2@O&)Y*QYP-GSQ-JCT5/Y/S'@#-1PRS/*7W:)+H`<3$`]$4X6SV
MO`-A^;/HA5;3YNR->NWFEPMO2Q>>"_/ZZGE=4N^!UB1+0#0+TH2F6I`U9+[-
M"U.OP1J&4-1MZS=L85_=\))1;^BV\^%=K9CM-OI(YB1%<0UIU@2'@E<+A7]N
M<]9B0\4]%*DM7)I6B:$&S>!AQ_,_TC-)$"<UCLWR/@U.MEVX#-A#N4^4X"#&
MMLQU;"9#@XN3W(5!JG;2G76,<+#;653C=!/#Y6XMZ6OO2><=DK6?XJQ.W8")
M;EF#P;JNJP!#O%C7,4=+S,)-`LDH$R196^L5^<971*5_"ASC@B7CNFXL!^\(
M-*"">O&?H"L1ZU/O6[KIX?4TG+]=65CYHH*_45NM/>Q66\\`;>.13LC5%.CU
M!6'ZT&\*R#"*X1[<)F0H!0<#-5%JV)P%JG9SW[!JYY=N<-66Z??SNPB3M2[&
MB*Q^R3+V-Y@]S9YAMDBO(=Z1R5\\"3.X+[;=%VECOT>WYW4NH(5Z=P*\BXN>
M?-LQ<MQI97V98!3!1<\"]*)$0LFI\N`[;M76=@(@E[UM]:51`*G:<+P'Z9(L
MU8$>J#1;,0!3MO(,;&9>Z`0\I:BJ._-S=GL3P+0L8LI[R.9@K0"+1FW9U];U
MVGJ&2QN/=$*GID#K:\3CP"A*`=PDAQ-X$GOTB::`7M5)Z"M-Q?_&A?LTIZ^=
M^;%8MN?G&[X=>:X;YNV5\#KM[0M"T7<8Q\5=M2Q(-O`Q!F1.#C)<_4G:71NW
M9V!NT-XS6-MZIA.,#81Z79[DL,^R"I[U.F<5>:M,F(C<,PQJVMT)<F(9U03!
MSPVO.;VNJP<O&6FK'!B/U#-8:=C;"5)\_K85:4>!IF9)`Y.]?H.6TC>O+F.'
MW]P;G9"H)<[KPIIWX'O-%2E*R(\AJ"WT]%!JRX8M?6+,QC/\=O13)S";RZY&
M<#\W0Q_HZ_`Y?<T!;9+B=K(>EK7;M9)QE>T\0ZNI)SK!4T.8=3'94>"QV.J]
M(E.;B)X9@P0?DHIW96X.F4@3W\$]N(^#1+Y)VH%3JR:C!2?/4-S=6YUP;27>
M[V*VWXKW<G`&MT$FK)S,)V+PR1)Y!CVIC9U0Q7)V5Y5GV!SB[#6'^,RC4O@$
MHCPN'KAJGDK2%-*0%H."<9Z!J"AMH)H[=>3&CDZVW#SK)MQXK=LH9:M"CHEH
M5(QF04Q['UA4"_OE[4??CPAK+MGN8O0"P!*D>Q@"_H@^B0M=BGMBY23V#Q`=
M7N@H4IT,8J<?>>+H<BW/W_CKU?.N(M2UDN[2_8>=/)!_0M+X=0;A=S]9+P'5
M=Q_)*3?5LZP?O6_4+_`U4+_8*.'EY]3%C2?F[`L7;-YH/U+8/%/74@;[*J62
M(.+;0$MA)%C4\YDU9L<-S<:#]TU]00IU=*2@AW*L;KU;TU6SZJ?>?_0SS^*0
M/W*LIS$O756_><_-YI&VX";T"%J,S7+I6Q):;?2L'\V;$CK?LY74I.<"0=A*
M)+93FX22O)XA?"$KJ#2@B8*3:`L32.=5]!2B[%>DU5",VK()GWIMQPI*\>,Y
M-DXQ@V?[61U-F5Y7[.>_2J`#4X.6[9)RZI;^0=3<(5T!JB71ZWZT<2]U2J9J
M&\&#/OH-9/4-F09>8E#/?`?0$PK2.;-PV%L.\%WZW;5!Y]H#$("@%^L:%S1=
M6W6\G^[P@OHEPTI_C3<41*0:5L5I'-S?'?9$Y?4LY<QG*5UJMW6JTG:A]=C.
M7WGM_#76!NDBCCW?N^GB[GIVMYQ=DQ^6B_GM]60UNUZNR+]?9W>KY>)F.EG^
M>C-?_+8<KC>)_I'CK$AU7R':OR<A+%[T.?3B<X3)[VG%L?L4[2'QQ=7+-S)"
MW":+':!+ZF1SJD6CZH=Z%,7V8+V(<O6VUH(`)CUI(KYAW;Q@3>R(`XR+""K^
M>C3R`00Q'96_[5!"'Q-;I'/X>UZ6:F:^QG`*U-[Z.K<"PW?-?6(?C>"KB@:&
M'NP^/DQU9GN]WHVY+C4^7DHNMYJNR-"U%I;?UVS5*K"E:'7QX6CGOS/'D+:2
M7A<4O09$:5I'KST4RDA:D*Z3_$#X%7IF,+#6-?*Z<.B7`";4'XO#8+,F'B$^
MR%[H=:>,%O@MC@1$)XU&C=FC1LW&/PS.K;PY4`3HZFI\^?[S(3:2XF'B:.CH
MN-WN`IA24Q9K^C+8'.Y!="C8\RN((S+;^R;,"#-JR^:$Z+7]84+#QI<#18:F
MJEZ72R&N2FD1F&MP^&_-.=-@![,@5NS"F#-H)TUI,_AQHL36JT.%BH&^7M=#
MNP\@\<I_P*+L&R#.%L6%F)#!/X_PA\&YTDL#X9FGE]?UJOF'L:+C+2FQ5F&+
M'PC#6MX:",<BW;Q.5/R6I.7.ZFGM<@U2N"]2,H55,/1:L64Q5*U^&)B;^6\@
MO"N5-*XA/+)5;&N>-0G#-">*G1YCGR11<91Q=%GM;]J3>#NVRJF]*=O!H\MB
M(BZ=QG?RJSA34U-'^93=5+?J`.M25KYE$@DF_1(@/8;X;K1)4YV0:#6]1-C+
M_=,_M%ORS?.//1@+"BOO@Q<K]#+MM*%[;'>QN.5[YDR@/0KW^[&:MH'527%9
MD%(;KX)V2KRVVET<7N6>Z1FO+>$57OTLV-PV\%M")C\Q-;`:1?0GU)*V2MQR
MVUX<=M4>ZAF_7`7,ZX..?99`O+@+8%1%:YF=4TWU#^=;VK`V8:;$N1ZSBP.^
MA0][C@0]C<R?'1E7:#0N+M(+M.D>'"XBL1X1A(,Y`]F-4P4#SV%O[2NG4#?1
MPN^:_'<@X^VCEN\,&ERSL&?4>G+"G)$'[ILB>N\H)[\K`8@2T?#IAJFU6_E,
M!^]7.@`,]>1;09]CKFGS59!N&EJ?/R/2&0[='=T'+\6IS_&E4])-T]N^PNP)
M.7DKAT)$?B'HUO1'+[@5RS;.?!O7_(_X(P0@PC?D@_T6I"G-=WT&:0BQ<%VO
MTX3%IK3)I>!3WR_]8%0JW^N'8^NF/9!E616,Q5*,IJ6N0+J]!H_"1#33]A+\
M*MI?()A-/-8[LA7*>'VA4&3G'":`_&=*C!%>*S1JJPEOINV%0UOFJ;/"FE'$
MZSRUNHVW&.?$+X"8AK9;E"PS<741[782*`O:72",=3S4.X0%2GA]GU#@G=MD
M#[!1H0Y[1GI;'5)&'KBO^PZ2(5-KM_JU@Z0#,/4.DIUOS7H<B:8:.TC:&EIW
M1V/:05JA2?A[#E/0N*@Z22+5%6=S!H)=)AT&%Q(3UC[K!?\FVA@OAL:[-\6Y
MEZT#=W,.DOFDDL.E`-[::_T@WD0=KQ=+`C^9EX6S9Z0W+3(HZ3:>*#"\ZW.&
MTGIFX:)Y_:<?O7^0N.J^##%D:AUO?BU##&//J6][B;*N&GJ]#&ET)N+P:-.T
MT5ZGN1SP"BWO"XMU@5X?@1P+_2[6U",W,?JNFNSH-&'OZTN;#&8\U85,9^E_
MZ)1V3R:[9!2?$&RDZ0N!P=^"6'A#Q*@MXP[-MH/'I]:71MU\(JKP+Q%=CT5-
MD=5IO''_ORL2-6?)X(OSWK'Z]T^O:-7PRGGQ:IP^<L`KT2;-QHE8HV1W&Q9:
MZ!UMPKL;$'=)<N^&9$5B^\_F"]HQ3,!GZS4(B4-FS^%3D&S``W'1(N%[0`!E
M&Q;L6\E&++R#<@</=82RF>0*R@XG_!Y\G<Y7,CI^(QOYU2::PUP(?[^4?NI#
M/U]**K_Z4IX_H.;F2W7>T.[XI70VIOW,:U[FNUU<>":(*\_<)FM$'T"B,%%L
M?)BU9O=`=%M[!V,[OW3$KK;0"K"^%C`YE`*EQ4$%L.21M*Z]UTF&!Y@A8)"6
ML2)`Z0EK7DZO"ZD`Y.!.[F#//:[W6XSB;;#>1\,]TU9<X;\)8%IL<EQ#',8(
MYRE0O;FFVXY]0$W=;L`77:KZD-+:%R*RULLN+-G@(:[_T9"VN:+ZGBI1S;=7
M6!'6)^UCV)@X3*J+Y`..`X0#ADZCUA`B;^0GXHQ<X0)_*H%>'R8>+3JX9)+4
MZWI^!0$U,5K0U^ORE!;#(`1W*$FK_[T*,&P^&LT`USE_!N,.^7O]#>;L@^T]
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MSX6E3.Y(`8?;TU9CZ"EY:(!0PF-,<-19A2@0J>LM-38ERJC@*5%B3$"]379Y
MA@NK?OX*MH\@5<%2W$($0EZ+\4#."#@\Y"D=HL*9C@9<N/$D>YT\Q;/LDS$L
M/QG#\M-EPY+OD'/`\A,#2S_7^SS+?C*&Y4_&L/SILF')=\@Y8/D3`TO/%]YU
MEQR79GKXU&BJ,[=L-1TE8D5+%=5\4NX8`\`R"BCGD"W!7G>CI\2HVJ;"E!@(
MA-6>=)H(,]5X30;'I>&^)3=U3>D+`23U9/-SV7@R;=&X!^DC&BD>38!H@L#+
M@]Y9,==A83.&)$JN37<H"<U[OW8K'?C56UT:$(4>Z1>2=;&V\TA>3SA(!O_Q
M3LR[Z>+N>G:WG%V3'Y:+^>WU9#6[OIK,)W?3V?+7V6RU'#B]7RN77RMQ?P19
M^M+<?&E&_LCR\*5U]XQ3[;E5\)K9].:7K<8P$!R,*&=06D@6T'+1T*+U!AQR
M*RVQTF+J]?+I"T+1=QC'`K2P?V8`<OJS!Y@0V&(,@Q,?KY\LJ#U/JYPS2FD9
M3`AH/0"(CI7&:!$P]?I$15A7^0Y(*FPKF[1+:DN:>(`G`YN-827G[?4.=&.8
MU9G%Z,Q>1@,8T9Q$-'DQ`0K#6SAW\?Q]U"LR^(*(ULNE5CZ`$)!U]&,LW&93
MTC/`D=#[`R)=HVT!)>'O=>_S6EO5$0`=%E55@M&L.J6?*S7BFUT`H]GS#B08
M$&MK,TOY8&G0LC4%TVCI#R3-'6$+2"U)7B\?OR6/C1$`GX8``0PU6C#PD[;P
M!W;ZAMO"32K!ZZ5F^X18_R:4WB:GK(&%V;1J$;7EX^>?/Q:6D%_\?1*&:0ZJ
M[@!7_4$I3WQ0;-6VM,^P[>#AI/'A4#>/J$_N."%F*-#KN2^Q$^6T&'+P0KL.
MQ1)<2LRNQ07$GJ#.R&8KF*DD>#UU/9UTWR;$Y+Q(0R-1]"N(-@";Y,EHMA<F
M+RC;>P9(6\]TPJB!T`JV?LYQM3,*M?,(QYX]J`$Y!WF"$FS),@+]/)R?HV2S
M`NGV&CQF"A2)*5D8\2A]PY'2VFY`XK&O9F?O_^QG5=UBVJG=*RFH>>>V%]`_
MZ5G="5M"$55/Y>=:^P'0T3S,<GHY@/P/2/>*-8!&"P9ETA:>(4W?^DYHDXHY
M]FA^=F@U#Y`)Y#)#X3^?4$Q,PG0?/WO1W^S1:BZ>C2F:CV#I])KC;?&]>\SR
MEBI@D^?M,((]^S3:>[8.OXI,IM>;+>KM%/6&R6BW1+I`ZRQ8\CRU1F6]Y3AL
M.?Y>#O9TO-(/(`622Y3^Q4^4UM;VRKF0G%BRL7(Q,Q\M#[A$GT">U_D.[)I?
M+V?>9/HM:^`U_K0]X1"#,IE>)T3P=@.46-1KI+%5<S&8-/*(0URJY'J=/V"\
M?V.\8Z._1^,9'K4]X1"+,IDE#O_L*0Z/;S&6[^P&\3W"4.>M3(.F+6SJ-!T<
MI486MFZE6#^**935OJ72YT:,1PZWW-QV]"GTI7L]9$W",-_F,?%-F=.'ML2*
M)Y#@(KTE1%LP1QC?H!3`37+8*0Q?5FF0X/@`HN@?^>%AM#M`?+L*GL7Y<GU)
M:B?;N9<T@C`R&4_[][8PSG2&WE[4J]8U[S_ZN<2>1%'1'9&.*8#1;3(-=I`^
M?HNV6Y04?A6%EG9#-E(T&OH&?%-?=,.QAK3C$?5'/U?<-6.DE_\$9.P]OQ:9
M9P!3V-D)3FW>U0SP_4<_YQ</(`M@`J)9D"9DQ8]K'?\U6,,0BK=L=!NVMFW4
M#3V#G+$O.H%01YK76]G:QWK:!WFC/+KKN@'C$E.2(S@'6<V#%/<[%3=\1[MM
M>'@<.DB*2X@D;LB$E:P=YR#``%_3D(KQ8#7^:@I.&`6UGUBSXL$9_`UXN+I^
M^)4(>HI?'FB2RY9>+V),E-+4KA-R:`:/<KO/@O2,%L2\D<SJ$B%'UD!Y1ER,
MT$VA6`<H<L(:6D2$?D-&RWR7N!$)'&C;C0N>VHX%\?1B!]*`FE9T_E.`<>$(
M#I:,VM6@I=G.;Z39.,<E\#3E&Y^F?S[@,`$;.J5VC,09SN"VX$O5O`]>#D]Z
M$`.6.:U.A`&[?C=L54.A5BN_,6CN&)<(U)(^T%*,C[[G'0B)OH5Z&2U'=`@B
M'N04I'6<"4D]!Y>>"YPB2BC2?1*^/8Q*BXLML,7Z2TJZX%-GS,&2%GT-4`IZ
MOU%EX@R7T%+(-4ZH<#5,.CLGI250Z`14619$0-@^I6P1^HL\;?-=04XFL%I7
M?O1R>[)FD3*Q44HK!MRHTAA=8LXTA=$%[#CIBY_\O#IU76I<!!/YK_!P1DS8
MNE+9)O0?<$KS7:.-)["$VF<OD<:\'TFMI[LZ#V2H%T!.HX7\\<]F"_]!J.\0
MUVB42K:^_C<&6"[#)Q#E,9F_-O+4B7L>0'$`.D4XPRM)D4\+#NQ9H@D'_V%L
M[S#7L#;2I!KHC;>?X\$3,FJV48L*^XI[&)-G*+HRK=E*=H.&UVHP+ZR(`.8[
M-Y^O9>Q7TC.62^@'#UG=;XG,S1>$I$)B/0@EDFQ/"T<<<7.8@-L,;"W"KM54
M/_9J34?BE*<@W0C+-<A(I497I&..N/9G%%W2XUMN'G%'B<)K>4=)EW']Q&*"
M(?P&JI%/E"2EKX/XJW!D.^T2+^K;B+K'LWV@F@*VF0I##UPW04AO0+U,R9R9
MV/<5;!]!*NBDI;2MA3F7=G`TJF<YR,Q@`=B$<IJ+;"Y_)Q$_2+XD/>D+@_`U
M![+W',@S^FM%L'`5BV\FV3&Q\5B-R>`=2>=-D4YN<[TO8JJ,NUGCB/.Z5X>W
MWD8=G*^=F;!Z4?'Y5)V77B-%%2.VD?^=DY%;7'=&*N&GSF?@J<XZBX/OFS`:
MK(N@U<=.[U.H=IH4U*UC70&ULP>CBNO=]-LV13W0`87@!-PF9+@@,VAZZ'03
M(Y3>@S2DGW'#2S9TP:[^K%0G=H/W`*IOC9P[3=`+"!0Y/CO528&A:M%S\=PT
MP`R\QFUK2#5HZPLL;=UAAT$#:=9'@OT##G\-Z#Y#]G)-%"_NTI!1][]!P.[F
M6+04@DW2TD^HZ;K"!=`DL@:J3":^-%?>2[@!8+&F94_G*$BN@C@@'709'AR4
M&;9DK]7IM/0%97:NL$.9MJQJS_K<*;1<F%$S%NM#XENU+WJ%TA1]I]ONP8[\
M*GLI55^L_S,/8KB&(#H\T5Z]*"A\G[='"378.I?@"[S[=:U=&#C7R;J<^'BB
MI7I#N66>NW!1BN@>+Q(1%QXPNLX]:\1(E!HH?YD?,K6*[??TZ?IB@"0_;6&^
M/5IUG\(DA+N`&Q%V'.J`-^7@#9X[N<82KJ8RJ\7;.'IP,^W);R"*5M]1=URV
M6-D#M,;J0I$J<M99(%L37F%W%%UI4>GI%N,<1,4=@2E*]B#-()DFW:'L5$SW
M/D_#IP"#WX(T#<C(P,%N5U8U[-JS\@6[CIQEAUU[X=4Z<Q3;&95:!TM6J%*W
M5I;Q-B&V)2"D_EDANG*>;%)0%);F(-@-PQJ.NS+T!<U.'6>'Z:XJ5,CV\V'2
M:1Q@O%B73EBD#W#SE,V>R3`$,2"#4`B.?\3E7_$G4:)!%UYLPH$=+Q]P[])=
MYI#O*+U"N_&]/S)./*(1X/TT8E43L6+DN@]>)+?]-%NUDF84K;Q"JY$+.N!2
M):>JP^5GG63FG)&,.70[GI[^B'I5C1;2K`VFA4^8TS?='F]2&;Y>16L:=15@
MB)?$@B!:)'\+4D@#Z4$;<NKF4OS)FOL+1FVGN$*F3&`%4^/:<",9E)N63LFL
MXX5>RN%59C5I(H4EV\1?*$J-=P4_5HC7CR$QIIUF'(<?,?%5,0/6ZQ\UVLN1
M*&OO,2RUW>(,HS*)U;31SUIA34._)<$6$4/_`%%5E$4+J9)V4H1RV_F+3+4;
M7"&2*ZD:K?U\<[)I8#U]30N"O`92[#4;^`LZB>&NT-844<',UYT:<4;N;+VF
M>[%[T,X!EJ^=]7C(5],J'OXBU,P]SE;<*JD5CHWWUT>)XS(GDVYKZ5W1X360
M(K39P%\X2@QWA;VF"-O*V*/$63VLBB=QHPZ=I8B!=D_99N`O+@T<TT<?V1;I
M=RW:VR3*0UIWI5JP+=:U=1SU`ZUEGV`1:HW;,Z`U:.\39FW=8@]9`XG56MQ7
MQ!ZBL32'6B;$II"RA4(.I5]X4YG:!5D<WA6&_'QK=\Y)L_X:/,-MOFUE6PO`
M9<."09T9"Y_@V,$Y]C@U$VK\GM38\=NR\1K@,(4[SIMH7=EHX%C.QG<L&SC)
M+9[E@KTN"LXSMWQJI$N?K&*A@64Q"]]QK.D<MQ@6"[5^4&8D>P"U_.SKHM[@
MX?9`+5>[-3%?@I!N&D-A65XG/'GO:-OS]`GU+MUG'P8=M:A.^\]]:ZK7J%@^
MD>^,'8>%(5.]N-!F>@&!8>=`YY&AK485&GZ^ST,=I%U(4$[,V0P>56G`)A9D
M;[M(**4[WF-YJT7QG80[VP:/K_!%B'>PF==4?*UC+O.7T*WM7M"@SVJ5(A?R
MMMU/&#I7F6;Y9^5]6%HQ6_(ZC8R4749Q27T!D(:A=NCA,_8US9VU1OJTCYQ8
M`9_1/.HC188$02;/^/!DR$#D^\,]]3T"Z>,'8D+))LYHGCU00$*P4V/RX`%?
M@F@[AGGJP+MG,^@]X.I:FAPV0L)6K],F]`DV*COM8</A[/<+&>MLMT-9/&S9
MZ-&O_)15<V;/89Q']&$5?AZ\-KV@_@V'?O"`5"_O3*TV7N1I"+`^"D)9$`^]
M+5*WK<RJA@`_5,5Z<*T^SP.@G16Q=;&^(<8',:?<KFNVG,EJ-[8>8+HG'UKO
M;W37HQK`WOM9.<3``;<)M;A=N,P%*_M8J+&Z3/R+?'4.S-=DN[LJ.N!L[76>
MUK^IDXBL"LF'"V):OIK@B,)HC>@G(;_5?XS,F@_C(`L^'G4D7;UDW8M8"+Z(
M+N2U#SG'6?_Q@==B-T'G^2^=)NPYO;2)1YV`@>W6\2Z7X74AB9-II^G08EV?
M)ADBT(R-$)6Z;+Q$JI6/'*!75Z[G[V(6@]5^B]'O9&`F/PRW17D3P+3(4#M]
M(:P8O'2:M%ZIEC49,%TEA?N`7H:NO8(H'+(EM*T1FTL[>$^@]>60F<V"H)>)
M:J9:<$5<1GP/-QO]H</ZJ-9MLLLS7`/6?^9!0FPH\%9;#VE-(!QQ%;G0EJMW
MG8I;/W;L?CHKX_4-LZ/U-;N_@H!Z*UHD#S0#EV;K%F41OR7H$8.T>*.I<!;Y
M,TKH98^#7W2CIP=1HI!R*LK?..O/XZZ"SZF&%[+8/3IG@C$H7O;6\)+A2MBA
M#.$RV8D,[X*O3Q]WC#K'JKD\81URKOXZ51^+\=I3"5D;#?-][E],?.!JE.:+
MNHR5.D8A7.]1/&"RX&L_0-6Z>BE?3UX^`9!]25&^(R./[":925.1,Z1-_>T<
M]#WBJH^02G3750R+T../OT*0DL_X]#('>Q!++E69-1:C5-IX>->4<\8B3ZFM
MJO3FD!4/D:/T>(PGKO50P8MP"V^I0EVJ##?H]92XC.@O]PFI/WZ67DC1:*'8
M"FZT&`]8C2`GV?<5.T2%4!T-9)N\#<G']>M'ASM&PW8FZD&?/UG0'YK4?8A0
M!\&T02K;NF30N/H.GD^.Z7E%S=G#*S!%H2\\9Z^T"^<4W=@*9QNV;"\@%)QX
MU'F0V&IU#!]/X^>4P5K=N9=-M>74+-I%U/Z"6,M^5]@4"1NJ7C;W,N-M`C.B
MXRG5Y&@F@R$]XMHU1AGQB!#4L3M#AIY1@LM.G^I2I$R/$G=_^>AI7_?#9J0Y
MP*C+K+4.$-7+;#-^1G)7E$R;)9'W$/V[^,F^'QRD+<\,#E/C\?L`4R(ZS88&
M*F^_X#>8/;5227`SEZ1YWEUYY649Q$*<]RE*8Y.SNZB+C+$S?)4S!&@_5ACG
M+7X^Q'<"-O1MG*%C^UN2@B"F;SY^"6`R1Q@ODE-/)@I3S59,Q"E;763PF/GJ
M#'&@5,@V\6\D=<57:9!@HC;-PUJ2N(8A\1&M9M%:8F-:P`GS_R0]9.M#!!,L
M;D4,'UF*W11T%N>*HHNO7#UHW"KE]1'>;T%*G"$O/LBE81#.T`P.T5YPA_1\
M(@"F2Y7J:&94.1W=.;A^,4CVV7'D>S==W%W/[I:S:_+#<C&_O9ZL9M?+%?GW
MZ^QNM5S<+.YG#Y/5+?GK8!EJMPE1'!QU5B2G*:A;C[,)J`?K+Z8H*50@T^H]
M2%I[Q2HRQKXVV>`=A^H#(6TC!=V`0$`]HMN,O1YC9D&:D*X.WX.T>-R`+KU"
MT@E>PSC/3IT#`R'-5@RBE*U\`IB9"^SQII3C=ZH!USP3U)E@[0(0UB^N?'\V
MF#7*K!<SZ[TNHM?JN[=J]5)^7G(\6$YW<&Z(Y^D4`"8Y72'L0%IX"5^!-4K!
M@6X5/`/\%28HA=E+]4PMZ;*;7&:_Y_0E4)`](?*7/2$IUA#2N>E9->#.=\^D
M@4\Q-=RGL8_3L^I<QK[Y=<LQ%'T^>J!\9_J*+(?74+Z$%%)S0XI#[1_\529W
MA2J'?PFK/WMZ('0'LE/\3/8!C(M[RFB*MEN4%`_0/:&8F(CELQAK/@P8+?CX
M!-.N;K('L(7D$MI^OA[8L%<'M#J`]!AL_0#IE#GHY;!ZAQ)TF&LDFX-19?>N
MV*/5;L>"2=W.*X`9NJ$#Z-22;!,$1]%;+2KC2K-4-]B5]`SP)/0^`4[7;'N@
M221X72!IT8P>R:`HH12!RM<!4FVJ`R!Q!DOS8]<Q#):_`;AY(A/#R9Y8M@%W
M.3U-7JP/KU$O\@QG01*5>7.BS7,K'FPB@1D/GP#9Q3WV4#646FVB^EF[468L
M:ZOR!+(;,P-<RYA="L"U'=8/TF7B*\C[^1J6P.K2NE:8FV%=Q44/Y&(N%X!N
M31<YA[58;H7G<R^6N-=,%]D32&N;^"@EYB33G"B5A"]%3ARQEW[P)"K^+Z[R
M].,`8[B&X0$.T3_RPV;_0YGO_&V'$IJVOTCG\/<<1@49@^[A%*A=ASVW`H/'
ME/[&`1K!)Q($IM*(ZN+MN97W_(Y*=;17>E-XQL6E:IUM,51^05_/V"[X%$HP
MWNT8)XB*6=P>1J`Z)SZNRQ6X4C<40$W6T&_T:;O$)2!E0KW.>:T,;'CB#HC/
M].7D`C2VR?W&H,)\E\AKBZKP9OYP^!@`)W2"Z2&7Z>&6KYC3=8`+T$EDV6\^
MC&'7N)C\FD)/KQ%['*%HY"<(C5SA`HDJ@4/M';Q>@!\)(IW<<#>"I.X5=D^/
M)*X!43J$O.TI&4FK"E"=9'!HJ8_JD99Y`OP(V3=K]-39VB:(C*3.P1>0$)-C
MLAZ:1%N80&HNA;]\)-5LQ6!)V<HO>)DYH0OBE)(N(XFD<H%N=I)N5I)OP%(9
MV@5*'-[V4Z\QK`0>B"_(=WBB.SJT1C7:T;UL>?>EU89!E:*-7P@S<4`7M"GD
M>+W31FS+TCRD+Z0GF^E3D&Z$/9>,M`TS#JEWZ%*9VQ%4'/;5\92W+]^='O5Y
M=Y5CF`",#^=O,'L)DFB1;H($_G&8=0XV5->4F*($H[@\'B0!7O^DM1(RQQ0#
M9?*Q2][LE,`-[^&F2%WT/P%+]99?7V)<?@VNF.'[1Z?@16?[)*)^V(4YC6FG
M<S,\?^G0H-;4=/'U_F'V*Z&Y_=MLOE@.5W*JV,2=HBWQ![$&%V^Q5_DG=R!;
MK%?!\WU1<IC\/@4!!M?@\%]5W^^,,6_WOB/C80\Y!,IW3_>AU]HGB^FM-.VG
M\I'%=QM(0P,`G%W#X8<I=W'&'B:-Q<=:PUMG-[2.ML9B?HZ)V:@HW!O$=&R$
M16&+7]Y^M#GR'5?VE0M'GQQ[AJY-+*R'7HHG[+7#L?\VWO0=/$NLR]*,86?M
M.#=>K`_>(/9R?*284UIR82+3F,N`%5);6BFZ.(T6K;JIDA:#=S:V7QS9N$30
M/1CJT*R^*I'M=9VI2ZV:X@!P%M54.D",7V7%87Z+GQ_!^?:#^R_G0D5WM4S&
MN&5V-9E/[J:SY:^SV6IY7\#F"61D/14/ME]6^][';<U[A&$1'=JS%V53\91%
MTG3(>4I5&NQPA_06XUQX%UY!W9Z?\*G'U$NIOR<RM5_=WPB%,C,0OC#;V<=(
MDMQ:=DWR[`FE=#M%%W;M%BKHU5M<#OR$?N@+@G6!7A?CJEE&1J=%6G@F*M[C
MJBI*J\&H:BD&I;CE)8!3TR_N02H6['YR/62/J:[DH=-$U6>.JT:'LT[3N#I'
MYUZ35Y?#P?W"0>;]M+P'!MF`L_A3%=M#'?`[E*EW'W4:M6;N\D;#[<B&3R#*
M8[!8\U4LGP+#B_2!UHS!JD2CSOQ8Q]GS&T$OHX44Y-Y[PLY'IE"]V^F@B.?I
M.X<^Z;5+&O*0B*>8?JZC<7LMQXPS.]&BB['T3O<N15_P170AGX;K0_)'#'[/
MZ7V,O49ZMHJ<#0\A^7`]!J.2LH=0T2M,'E4/H/IZR-QN4:P+1#6B7"SB'%%=
M_H7^\QA@0'[S_P%02P,$%`````@`XH-F1UQYP*_+#P``@)X``!``'`!P:7`M
M,C`Q-3`Y,S`N>'-D550)``,7'#U6%QP]5G5X"P`!!"4.```$.0$``.U=W7/;
M-A)_OYG['WA^N7:FBNPX22>>N!U9EE/-R*8K*6WO7CH0"4JXDH`"@+)]?_TM
M0%($*7Y)=A)JCB\>"M@%L/O#+A:?_O#S8^!;&\P%8?3RY.S5Z8F%J<-<0I>7
M)Z'H(>$0<F()B:B+?$;QY<D3%B<___3WOWWX1Z\WY!A)[%J+)VN^PM9OA$JT
MQ-9'SL+U#]8]>\`\RAU/QS-KB/B"T5Y/,3\*]T(X*QP@"YI`Q<6C3^A?ER<K
M*=<7_?[#P\.KA_-7C"_[9^_?O^_KW).$5+A%A*]/3\_Z?]Q.9KK8E)C4$_<(
M52(Z..'::<SC@OL)XWE?92^0V)*K7%=N&4SBM_TH,R'EV"LM^%T?<A-"RB@-
M@V):5_*^?%KC/A#U@`ISXFSYZIER#'BI0"QMU?L^9SYP162FR*1"17F-/OH5
MQ'],#'C79)TA7:\0#Y!<88I?.2P`CK.WI^_/3Q-Z%Y.LY@5V7BW9I@\9BOA-
M[_2L=WZ6D$.O7B*45N$AL=`MB3-T^0D+DI*312CQ#>/!-?90Z`/,(?T<(I]X
M1*D#^SC`5&8(C&R)^!++.Q1@L48.;B896(AE:1M!E#*)))BG3DM2UVM"/18G
M0:+JD!=)KYQBS](&<Z'@OCP1)%C["@B=MM(]$)3<2ZK[<\WQ*U!.0J'@K@!+
M]P9@$2"U;MDDK3<I`G%GIY0=>X9"V!IS2;`P+*K_4E(YR-]7*F!Q0K_-0KG8
MVU<H8"&4M%@F'RWVE0E8L/]EQ5'ES$$`2WU\FHXK+3>R"1#*11C&2^)&(NI?
MVW*3DE-`?H)1R.I9U\P)E0\Q/V'`M494$@F#)YBZJ@T8/O3S)>0+#P5V;?J3
M_LX;:<P=DU1QY@RA.6.VLQ7SQ:F)@I^M]QE(J'UP;VC?78_N9J-K^)C9D_'U
M8#ZZOAI,!G?#T>R7T6@^B[#9BZ,:O]<`VK8X^-X6:)DE6G&15E1F!^,S8;Q'
M'`A76!(0<7],L^S5`)\?`K#U7::*[SO`]P=\-H>_MZ.[^<R^L>]'T\%\#+F-
MP"YAK0;Z33.@T[(M^\9*2^\@?A[$0_OV?CKZ!6C&OXTF]FQ_I'=+J`;\[2&`
M9RJQ5"T=\,\$?C#[Y69B_WX`X%O.:J#?'00T%&[ITCN`"P"^)L+QF0@Y[EV%
M@E`LQ(1\#HD+$2O$KC9?(DK^JX6)<-V'H0K.LRADWI8&/Y+R?K"V)>KXV2RS
M`[%DQB*80.MTRA+]K`;@=1Z`61@$B#]9S+-F9$F)!T$/6-K`<5@(<QBZM.Z9
M3QR8<'4PE,#@;8(4!/6C&H+S/`0WB'#K-^2'V+K%2"4J9]?INTS?#G)2?:L?
MU?I^D]?WD`4!D5K'VM<,F>[HF':]O,K98,/3X!J=O]UQ,Y(Y?ZV8[V(N_FF-
MP-7+IT[590Y%&OY$UJCZW8X[(11!5P;//>>("N0HPJY?E_?K,[-CG]6H^\?=
M`70A\.=0A:>C3>>WZ\*5?+Q2';"\?D[`8GVGOYZZ)9Q*1&0.D6J'<_X\1.9H
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M9(#0O^N@V%T\*(3"-*G?%2R=<32<33F8F2XO^EV-RKM=`RF;5:FM$JC,AT`A
MALKV/,R!L$.G"3H^>E@Z&7SBE#J$=NRF#*$)0]0:+#F.3DP\$+FR/HZL(5K#
MJ.1W*#5!:;UFTL^@%*?4H;0;SY6@=`\FXY`U\JU[]!2%$1`C0&.L.>:!I4#L
MH&H8Z/D!\C;Y,"].K`OR=AU?DR!O(`2.]XXG!"V(3]2!](3!M9`TRNEP;(BC
M0[P-#"UY)+?)=5CNNLA2+--Y\G"%Z!*P(]0DAXPD4C<`[I!LO*QH'+$`*\D<
ML"A;46S`4MT#WNQ:<^5)CP[-%T`S6F;?!\R8HWJ9?[\S.]UJ__.!G("'/,@X
MLXQU)KKCI&N`C4K___"\'_KY"Z)Q2O8BJ;Y&2H(UX]*BA9=3RVX\1[>V)\S1
MA56PJ%^]A*^GDGIGKWOG9Z^@ZN2Z774SBN]1-VQ`PJ!J?MN\SI([V0TKU=2J
MQG>]T]>]US\>6&_Q_>XF;3`Y[R)&U9SW2O5G[Y[=G,.:\E+M*+B,WJ0A/N<9
MKA=IB'G#?3^32/@.,HG2N_/-V^`?;HME-^M+*B_D41^]E+EY"RHOZE>UH)"Q
MCWTIDI1>6M1.>^+[_;I!ER<#Q^$A=N,]+3&@K@TC)1^&7%WW,^+\[03DSSU8
MH@O3^FF%BX!1&*WXTUCB0/EWD#%<"$EDJ"343VPDI`1(3BQ*?%]%,)<G$NH[
ML1!0<^3(RQ,/^?JM"DV\0+[J?9<G#LPRB4R2UV"BS)WK!D0]5%:IP77UZ(1\
M-?0RJA=@!\LEUQ8&C1-BAOR,%AIS')$2_A,"#=1VC1=R#/1<W]V>8@\#M`X>
M4PD?0DY!PAN?,7Z/N8/U&RFF8IY32J0L\+"J[2KUI35EJL0->7RAIUPG\.VJ
MWW.6+O-&J[S)(N\M#A:8&PIHSA)+JU]&N7!9@`A]`7FCWP>)>T548\&D/]%%
M]!EMDXLI=C#9J/KNC!-A?S:E_ZHVX.+%H29PQ3%R5K:G@8,JPLB\HUA\\("X
M>Z_+,S30F,/400+%-^[=0R16JF=NP%,!:+=(AARZ:5[&&K(V"N8C(6POWB6S
M^90L5W(L1*AZR#4X'D.X>M*,@)#RK853_4NH)Z[L!^S.F1YG!C`[E#`F@V>%
M:=5`I$[5]K+#TCUG#L:NN.$L&$'?5>RVIX^[&./;%ZWDJWKY>JLW#+9H72:G
ME"I"LZ=`PR"[5C)77JR>E!K"A>Y87\BS&TL*^;9#P*UKSJ-?2WV`M%]T]!JR
MD$<^%[LW.-N;\SDMB<H:2)4-HQK%8'NPM,P4LRW?#C7*#]]"+UQ!;_P71KQ,
MU`H&$_"E2M+9W]B57P/Y1A^O265(CG;DX\HFM*T+*--&&Q/#<LD*B-HG4ORD
M%?2LZ$$KXT3;(*[`D*T1==L\:7:Z,G@DAB\MRCMLW',)5"GB:/&K2'*M^T^9
M+$ENZ[I<MID%XW4I0;L[5MX1',DL.=O,7(Q8F-G>N%!M\.O]??,T0$$/JZ-K
M6T<K;&\.JBJ:%B-&*/+C$U(0R]J>.AVE#D==1>%F'-T98C9E:-OBVTT(P1S6
M",VPE+YQ)^3/HKSCB>EU_3<P*<E[P)V,UCD_78]-<6'+C?1V-GR^XKBXZ9F<
MEC;^@14W/4UO7</5$&%[0VTL-\A1P?W3%>.</8!+':(U).F51.5N;._7Y*'I
MJY+5Y%3R%R^X;=[O0`%+5^*?K;J*DMNGN_B:[$#-CY?1R)ZWG4JB]AD2@V@2
MJT?9%W+TZ/BA^J<&ZM20PL(0JIJL)4-D_4*0*<<]Q^LH?(&O@(3!MF]NCXP7
M*Z`18^OZ[GX"1+LP,`0<K`*CA+;IXA8]DB`,=)AG>WJ/76_-0$6?J(NY3DGF
M6JD"]F0[&J.XPX`B\XB<8@FIT""UOZ*W9JZPQS@&0X_^P8/*8CR_.9EJZ/DE
MM41I#3K1'9-8P/Q'5;C=I=KV_FEB'X,@ZTGW9&O'%G<#=11NVFWEBL298A<'
MZZB@1!_[\K7-EYCMWW;_>$^H6,I=JM;)I,XV#_39YGQT4Y#5NI@&AJ0-86%F
MMSC9>E>^9GNP*@HU,SCMSWHT%CK%"AH8FO8=]_9F;(D3KQ_Y],F!*_48A_D6
MAQ&X7SVE)/%:E[;:[1K?`-00N28Q``-`/HQJ'B9J%6F:.1#R%:IJFQLY6.0I
M5E&"([&K.]8G2J3XJ'8DL3NF^6-$7[:6S(*M/F?22J4F.[8P<#K0&T#R&_!.
M>>=]"&_KO'MC(0K600_A/5H%%*RF'L!ZM.+/\`;30Q6083Y>%9#'@Q60LAZM
M^(6K\@<Q'Z\*=M?V#V!MG_CIDVOIBVO)@VL%V\Q-Z=NVW5S9[MRV<Q/:]FX_
MFV\316<=BF"L(FH==CN-S0-61M!RE,94S2T@1+R'&=C\`;Z?_HTY*QYOFS*T
MS\4DDUSLZMG7D-&-^F^8ZNZ)6L(;T&C:<!]R9P7>-'&@>=D/*:$E\^>F6K*C
M2:EQ5T5M$^04449DRMJ2:Q[Q,D>,1X3@G$VP6ND84Y"`8OVXT.]$KM2!EU32
M_3F/9O4HEFGTN"81;?:^2TEV!MUO?\<E,;$$F<3TC(4]$R:`#D#:OO"U(^W!
MY;1N5>%.$R!?G0%7=:O%>-_'?/D$7FI,/2U'**Z)T(]$Y-W\@>RM<_I7A`7@
M#1WD#]R-LAFU2(01@`MR7*MGBMA:KQ^%<L74A8"\(@XNH'6JR*R`JT<VD'\3
M4C>S,%Q%<S2.+?;9!5:^F],.H1KLZ(:J5]E>/.B.'B$R!-LS5DW+*4P9"95X
M"4/7MW5.VVW!N'-%FX)BSJYPL@WS:<UH(H/MJ:N!=FZ?\5F%'`ONYLO],/P(
MF/VYT7(X=>^-]WEL+WXM$?G;__@ITK>"<A.5ERVUO;.;9\E9,%U]J?+:-K,M
MO-MLAU+U3F5:B6^)[N46.)^#"VA=W+2O)!`=/T<1,7OKU!`/_NF-N^VF92IK
M%<WQ3'@AP//9DC@3XJAW:@;KM4^BUW3@D[,-\@M"PH8<K8L!;XF/A00\DI=S
M\[*5$K1.E)D,78*%S>=<O6VWNTY5F-T^,<*%'_6C&[Q[):<XMVW'`CZM/<ZH
MC+M,'HGBW-8!,0%GMM1$T3TA\T9\T=WYIO1?%:Q##\B,'F5TPQ:BY'AP;G8J
MHX*Q'2'VP5MO4YC;<P'S7W7>-5WO3(_HB#K=-"GA>,;):ADSKSTU(#T>N3\R
M:#95"<E*]\[=JE**UCDYA0$-U?R8+6$B@UW5-Y-6#T*MI?208#WM\<"HWQX<
M4X<%>,*$`"/$9$FCQPB=)^,?#,!43O_RXT[KJ(A>;\/J7/UJG2IWBI&OM*+6
M&/2K13RZ)X2RJQ1?N]ZC\;K1B<<XAHZ#`V-QIS"W)=VM?I0=!T%(82;@.&3W
MS%9A9NM<A;D4G#YB6;EB7$!V--U1O_+C/TT++G@49!U-1]1W^BMD*\L_&@$-
MUPH]T`9FI([)Z*?/AUB(G#MN2-X2\9N\,0(M"=3KSEJ$9-:N0\Y0/>LOL#%G
M:43<#I.M1UX]+*S/>JNF2_7V9`2N(6XI14OPK1<R7E6.-Z[TDXEI%\[<<JDB
M.QIQXPN9D1>RO2DFP2+D(K>-5TW51F&C_T40/=8-/_\'4$L!`AX#%`````@`
MXH-F1WEP-OBVN```"4P(`!``&````````0```*2!`````'!I<"TR,#$U,#DS
M,"YX;6Q55`4``Q<</59U>`L``00E#@``!#D!``!02P$"'@,4````"`#B@V9'
M%&Y'[3\.```2S@``%``8```````!````I($`N0``<&EP+3(P,34P.3,P7V-A
M;"YX;6Q55`4``Q<</59U>`L``00E#@``!#D!``!02P$"'@,4````"`#B@V9'
M/&HY6?$H``!GE@(`%``8```````!````I(&-QP``<&EP+3(P,34P.3,P7V1E
M9BYX;6Q55`4``Q<</59U>`L``00E#@``!#D!``!02P$"'@,4````"`#B@V9'
MMRHI<6>?``![6@H`%``8```````!````I(',\```<&EP+3(P,34P.3,P7VQA
M8BYX;6Q55`4``Q<</59U>`L``00E#@``!#D!``!02P$"'@,4````"`#B@V9'
M(;M#RIU(``!YQ00`%``8```````!````I(&!D`$`<&EP+3(P,34P.3,P7W!R
M92YX;6Q55`4``Q<</59U>`L``00E#@``!#D!``!02P$"'@,4````"`#B@V9'
M7'G`K\L/``"`G@``$``8```````!````I(%LV0$`<&EP+3(P,34P.3,P+GAS
M9%54!0`#%QP]5G5X"P`!!"4.```$.0$``%!+!08`````!@`&`!0"``"!Z0$`
"````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950293174096">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Schedule of Assets and Liabilities Measured at Fair Value) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current portion of derivative instruments related to stock purchase warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,355<span></span>
</td>
<td class="nump">$ 178,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Non-current portion of derivative instruments related to stock purchase warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">227,898<span></span>
</td>
<td class="nump">629,170<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total derivative instruments related to stock purchase warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">230,253<span></span>
</td>
<td class="nump">807,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,430,038<span></span>
</td>
<td class="nump">6,429,104<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Total investment in money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,430,038<span></span>
</td>
<td class="nump">6,429,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current portion of derivative instruments related to stock purchase warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,355<span></span>
</td>
<td class="nump">178,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Non-current portion of derivative instruments related to stock purchase warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">227,898<span></span>
</td>
<td class="nump">629,170<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total derivative instruments related to stock purchase warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">230,253<span></span>
</td>
<td class="nump">807,679<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Level 1 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">6,430,038<span></span>
</td>
<td class="nump">6,429,104<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Total investment in money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6,430,038<span></span>
</td>
<td class="nump">$ 6,429,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current portion of derivative instruments related to stock purchase warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Non-current portion of derivative instruments related to stock purchase warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total derivative instruments related to stock purchase warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Level 2 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Total investment in money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current portion of derivative instruments related to stock purchase warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Non-current portion of derivative instruments related to stock purchase warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total derivative instruments related to stock purchase warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member] | Level 3 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Investment in money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Total investment in money market funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current portion of derivative instruments related to stock purchase warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,355<span></span>
</td>
<td class="nump">$ 178,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Non-current portion of derivative instruments related to stock purchase warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">227,898<span></span>
</td>
<td class="nump">629,170<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total derivative instruments related to stock purchase warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 230,253<span></span>
</td>
<td class="nump">$ 807,679<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Included in cash and cash equivalents on the accompanying condensed consolidated balance sheets.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13495-108611<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226008-175313<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51825145&amp;loc=SL20226008-175313<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13495-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13495-108611<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13433-108611<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13495-108611<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Trading Securities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6526789<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27723805&amp;loc=d3e24584-111560<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 320<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51813488&amp;loc=d3e22054-111558<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Available-for-Sale Securities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505594<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph a, f, g<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950294028256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Leases) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRentCurrent', window );">Accrued restructuring expenses</a></td>
<td class="nump">$ 244,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 244,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRentNoncurrent', window );">Accrued restructuring expenses - long term</a></td>
<td class="nump">184,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expense</a></td>
<td class="nump">$ 422,482<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,519,273<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember', window );">Facility Closing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and due after one year (or beyond the operating cycle if longer) for contractual rent under lease arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 5.P.3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 420<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 5.P.4(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 5<br><br><br><br> -Section P<br><br><br><br> -Subsection 3, 4<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_FacilityClosingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950358786560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,324,768)<span></span>
</td>
<td class="num">$ (4,628,435)<span></span>
</td>
<td class="num">$ (2,202,305)<span></span>
</td>
<td class="num">$ (7,325,995)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="text"> <span></span>
</td>
<td class="num">$ (5,869)<span></span>
</td>
<td class="nump">336<span></span>
</td>
<td class="num">$ (7,162)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax', window );">Realization of cumulative translation adjustment included in net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">229,192<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (1,324,768)<span></span>
</td>
<td class="num">$ (4,634,304)<span></span>
</td>
<td class="num">$ (1,972,777)<span></span>
</td>
<td class="num">$ (7,333,157)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e557-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 20<br><br><br><br> -Subparagraph (b,c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32211-110900<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10A<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669646-108580<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e689-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 20<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6915805&amp;loc=d3e32211-110900<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e709-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950364063280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div id='EdgarSAA123457890000' style="font-family : 'Times New Roman';">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><b>Note 4 - Commitments and Contingencies</b></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><i>SIGA Litigation</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">In December 2006, we filed a complaint against SIGA in the Delaware Court of Chancery. The complaint alleged, among other things, that we have the exclusive right to license, development and marketing rights for SIGA's drug candidate, Arestvyr&#153; (Tecovirimat), pursuant to a merger agreement between the parties that was terminated in 2006. The complaint also alleged that SIGA failed to negotiate in good faith the terms of such a license pursuant to the terminated merger agreement with SIGA.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">In September 2011, the Delaware Court of Chancery issued an opinion in the case finding that SIGA had breached certain contractual obligations to us upholding our claims of promissory estoppel, and awarding us damages. SIGA appealed aspects of the decision to the Delaware Supreme Court. In response, we cross-appealed other aspects of the decision. In May 2013, the Delaware Supreme Court issued its ruling on the appeal, affirming the Delaware Court of Chancery's finding that SIGA had breached certain contractual obligations to us, reversed its finding of promissory estoppel, and remanded the case back to the Delaware Court of Chancery to reconsider the remedy and award in light of the Delaware Supreme Court's opinion.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">On August 8, 2014, the Delaware Court of Chancery issued a Memorandum Opinion and Order, or August 2014 Order, finding that we are entitled to receive lump sum expectation damages for the value of the Company's lost profits for Tecovirimat. In addition, the Delaware Court of Chancery found that the Company is entitled to receive pre-judgment interest and varying percentages of the Company's reasonable attorneys' and expert witness fees. On October 17, 2014, the Company and SIGA each filed opinions of our respective financial experts and Draft Orders and Judgments in accordance with the instructions of the August 2014 Order.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">On September 16, 2014, SIGA announced that it filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in the U.S. Bankruptcy Court for the Southern District of New York. In connection therewith, SIGA filed with the Bankruptcy Court an affidavit indicating, among other things, that it expects to continue to perform under its contract with BARDA. SIGA's petition for bankruptcy initiated a process whereby its assets are protected from creditors, including us.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">On January 7, 2015, the Delaware Court of Chancery issued a letter Opinion and Order, directing the Company to submit a Revised Proposed Judgment that reflects a lump sum award of approximately $<font>113</font> million in contract expectation damages, plus pre-judgment interest on that amount from 2006 through the date of such order. In accordance with the instructions of the court, the Company submitted a draft Revised Proposed Judgment under seal on January 9, 2015.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><br/></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">On January 15, 2015, the Delaware Court of Chancery issued a Final Order and Judgment, finding that we are entitled to receive a lump sum award of $<font>194.6</font>&#160;million, or the Total Judgment, comprised of (1) expectation damages of $<font>113.1</font>&#160;million for the value of the Company's lost profits for Tecovirimat, also known as ST-246<sup>&#174;</sup> (formerly referred to as &#147;Arestvyr<sup>&#153;</sup>&#148; and referred to by SIGA in its recent SEC filings as &#147;Tecovirimat&#148;), plus (2) pre-judgment interest on that amount from 2006 and varying percentages of the Company's reasonable attorneys' and expert witness fees, totaling $<font>81.5</font>&#160;million. Under the Final Order and Judgment, PharmAthene is also entitled to post-judgment simple interest. PharmAthene's entitlement to interest from and after SIGA's bankruptcy filing may be negatively impacted by the proceedings under the Bankruptcy Code.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><br/></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">SIGA filed a notice of appeal with the Delaware Supreme Court in which it challenges various findings of the Court of Chancery and seeks to set aside the Final Order and Judgment, and we filed a notice of cross-appeal. On March 2, 2015, SIGA filed their opening brief, and PharmAthene filed a response on April 1, 2015. SIGA took the opportunity to file their reply brief on May 1, 2015, and PharmAthene filed their reply brief on cross-appeal on May 11, 2015.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><br/></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">On October 7, 2015, oral arguments in SIGA's appeal and PharmAthene's cross-appeal of the January 15, 2015 Final Order and Judgement took place in the Delaware Supreme Court. There can be no assurances that the Delaware Supreme Court will rule in PharmAthene's favor, or that PharmAthene will receive any payments from SIGA. As a result, the decision could be reversed, remanded or otherwise changed.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">While we believe that we may have a right to receive a significant amount under a possible damages award, because SIGA has filed a notice of appeal with the Delaware Supreme Court and because there can be no assurance that SIGA will not be successful in any such appeal, we have not yet recorded any amount due from SIGA in relation to this case. There can be no assurances if or when the Company will receive any payments from SIGA as a result of the Judgment. SIGA has stated publicly that it does not currently have cash sufficient to satisfy the award. It is also uncertain whether SIGA will have such cash in the future.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">PharmAthene's ability to collect the Judgment depends upon a number of factors, including SIGA's financial and operational success, which is subject to a number of significant risks and uncertainties (certain of which are outlined in SIGA's filings with the SEC), as to which we have limited knowledge and which we have no ability to control, mitigate or fully evaluate. SIGA disclosed in its Current Report on Form 8-K filed April 29, 2015 that it entered into a modification to its contract with BARDA on April 29, 2015 to increase the provisional dosage of Tecovirimat and extend the delivery schedule. The modification was subject to approval by the Bankruptcy Court, which was granted on April 27, 2015. Furthermore, because SIGA has filed for protection under the federal bankruptcy laws, the Company is automatically stayed from taking any enforcement action in the Delaware Court of Chancery. By agreement of the parties, and with the approval of the Bankruptcy Court, the automatic stay has been lifted for the sole purpose of allowing the Delaware Court of Chancery to enter a money judgment and to allow the parties to exercise their appellate rights. The Company's ability to collect a money judgment from SIGA, if any, remains subject to further proceedings in the Bankruptcy Court. <font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 13.3333330154419px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; display: inline !important; float: none;">The Company has not </font><font style="color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px;">recognized any potential proceeds from these actions in its financial statements to date.</font></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><i>Government Contracting</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">Payments to the Company on cost-plus-fee contracts are provisional. The accuracy and appropriateness of costs charged to U.S. Government contracts are subject to regulation, audit and possible disallowance by the Defense Contract Audit Agency (&#147;DCAA&#148;) and other government agencies such as BARDA. Accordingly, costs billed or billable to U.S. Government customers are subject to potential adjustment upon audit by such agencies.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">We have agreed to rate provisions with DCAA for 2006, 2007 and 2008. In 2014, BARDA audited indirect costs or rates charged by us on the SparVax<sup>&#174;</sup> contract for the years 2008 through 2013. As a result of the audit, in March of 2015, we were able to record revenue, and invoice BARDA&#160;in the amount of $<font>5.8</font> million in connection with these costs, all of which was collected in April 2015.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">BARDA has started an audit of our 2014 costs related to the partial termination for convenience of the SparVax<sup>&#174;</sup> contract. While we do not currently believe the results of this audit will have an adverse effect on the Company, we cannot provide assurances that it will not have such an effect. The Company has billed and recognized revenue using the provisional rates as defined in the contract. While the actual rates for 2014, which reflect the actual costs incurred by us, have been higher than the provisional rates, we have no assurance on either the amount of additional funds we may receive as a result of these higher rates or the amount of time it may take to recover these funds.&#160;The amount of any such funds is determined as a result of future audits by BARDA.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">Changes in government policies, priorities or funding levels through agency or program budget reductions by the U.S. Congress or executive agencies could materially adversely affect the Company's financial condition or results of operations. Furthermore, contracts with the U.S. Government may be terminated or suspended by the U.S. Government at any time, with or without cause. Such contract suspensions or terminations could result in unreimbursable expenses or charges or otherwise adversely affect the Company's financial condition and/or results of operations.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;"><i>Registration Rights Agreements</i></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">We entered into a Registration Rights Agreement with the investors who participated in the July 2009 private placement of convertible notes and related warrants. We subsequently filed two registration statements on Form S-3 with the SEC to register the resale of the shares issuable upon conversion of the convertible notes and exercise of the related warrants, which have been declared effective. We are obligated to maintain the registration statements effective until the date when such shares (and any other securities issued or issuable with respect to or in exchange for such shares) have been sold or are eligible for resale without restrictions under Rule 144. The convertible notes were converted or extinguished in 2010. The warrants expired on January 28, 2015.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">Under the terms of the convertible notes, which were converted or extinguished in 2010, if after the 2nd consecutive business day (other than during an allowable blackout period) on which sales of all of the securities required to be included on the registration statement cannot be made pursuant to the registration statement (a &#147;Maintenance Failure&#148;), we will be required to pay to each selling stockholder a one-time payment of <font>1.0</font>% of the aggregate principal amount of the convertible notes relating to the affected shares on the initial day of a Maintenance Failure. Our total maximum obligation under this provision at September 30, 2015, which is not probable of payment, would be approximately $<font>0.2</font> million.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">Following a Maintenance Failure, we will also be required to make to each selling stockholder monthly payments of <font>1.0</font>% of the aggregate principal amount of the convertible notes relating to the affected shares on every 30th day after the initial day of a Maintenance Failure, in each case prorated for shorter periods and until the failure is cured. Our total maximum obligation under this provision, which is not probable of payment, would be approximately $<font>0.2</font> million for each month until the failure, if it occurs, is cured.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">&#160;</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">We have separate registration rights agreements with investors, under which we have obligations to keep the corresponding registration statements effective until the registrable securities (as defined in each agreement) have been sold, and under which we may have separate obligations to file registration statements in the future on either a demand or &#147;piggy-back&#148; basis or both.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0;">&#160;</p>
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><i><font style="font-size: 10.0pt;">License Agreements</font></i></p>
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><i><font style="font-size: 10.0pt;">&#160;&#160;</font></i></p>
<p style="margin: 0in 0in 0.0001pt; text-align: justify; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt;">On July 6, 2015, PharmAthene signed a license agreement with ImmunoVaccine for the exclusive use of the DepoVax<sup>TM </sup>vaccine platform, to develop an anthrax vaccine utilizing PharmAthene's recombinant protective antigen (&#147;rPA&#148;). ImmunoVaccine is a clinical-stage vaccine development company located in Halifax, Nova Scotia. PharmAthene will reimburse up to $<font>210,000</font> to ImmunoVaccine for their efforts in developing this vaccine. In addition, ImmunoVaccine will receive annual payments of $<font>200,000</font>, and additional payments for the achievement of certain milestones relating to contracting with the U.S. Government as well as achieving certain clinical/regulatory and commercial milestones, and achievement of sales targets. Additionally, ImmunoVaccine will receive a royalty on sales related to the use of DepoVax<sup>TM</sup>.</font></p>
<p style="margin: 0in 0in 0.0001pt; text-align: justify; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt;">&#160;</font></p>
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><i><font style="font-size: 10.0pt;">Leases</font></i></p>
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><i><font style="font-size: 10.0pt;">&#160;</font></i></p>
<p style="margin: 0in 0in 0.0001pt; text-align: justify; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt;">The Company leases its office under a <font>10</font>-year operating lease, which commenced on May 1, 2007. On September 2, 2015, the Company entered into a sublease agreement with a third party with respect to a portion of its leased office space in Annapolis, Maryland at an amount less than the Company's leased amount. As a result, we realized a loss of $<font>0.4</font>&#160;million in restructuring expense our condensed consolidated statements of operations for the nine months ended September 30, 2015.</font></p>
<p style="margin: 0in 0in 0.0001pt; text-align: justify; font-size: 12pt; font-family: 'Times New Roman', serif;">&#160;</p>
<p style="margin: 0in 0in 0.0001pt; text-align: justify; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt;">The present value of the Company's remaining lease liability (net of the sublease rental income), is included on the balance sheet as a component of accrued restructuring expenses&#160;as follows:</font></p>
<p style="margin: 0in 0in 0.0001pt; text-align: justify; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt;">&#160;</font></p>
<div align="center">
<div>
<div style="display: block;">
<table border="0" cellspacing="0" cellpadding="0" width="69%" style="width: 69%; border-collapse: collapse; margin-left: 0.1px; margin-right: 0.1px;">

<tr style="mso-yfti-irow: 0; mso-yfti-firstrow: yes;">
<td valign="bottom" style="border-style: none none solid; border-bottom-color: black; border-bottom-width: 1pt; padding: 0in;">
<p align="center" style="text-align: center; margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"> Description </font></p>
</td>
<td valign="bottom" style="padding: 0in 0in 1.0pt 0in;">
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"> &#160; </font></p>
</td>
<td colspan="2" valign="bottom" style="border-style: none none solid; border-bottom-color: black; border-bottom-width: 1pt; padding: 0in;">
<p align="center" style="text-align: center; margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"> Present Value at September 30, 2015 </font></p>
</td>
<td valign="bottom" style="padding: 0in 0in 1.0pt 0in;">
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"> &#160; </font></p>
</td>
</tr>
<tr style="mso-yfti-irow: 1;">
<td width="35%" valign="bottom" style="width: 35.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';">Accrued restructuring expenses</font></p>
</td>
<td width="2%" valign="bottom" style="width: 2.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"> &#160; </font></p>
</td>
<td width="1%" valign="bottom" style="width: 1.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"> $ </font></p>
</td>
<td width="30%" valign="bottom" style="width: 30.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<p align="right" style="text-align: right; margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"> <font>244,769</font> </font></p>
</td>
<td width="1%" valign="bottom" style="width: 1.0%; background: #CCEEFF; padding: 0in 0in 0in 0in;">
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"> &#160; </font></p>
</td>
</tr>
<tr style="mso-yfti-irow: 2; mso-yfti-lastrow: yes;">
<td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;">
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';">Accrued restructuring expenses - long term</font></p>
</td>
<td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;">
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"> &#160; </font></p>
</td>
<td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;">
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10pt;">$</font></p>
</td>
<td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;">
<p align="right" style="text-align: right; margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"> <font>184,018</font></font></p>
</td>
<td valign="bottom" style="background: white; padding: 0in 0in 0in 0in;">
<p style="margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: 'Times New Roman', serif;"><font style="font-size: 10.0pt; mso-fareast-font-family: 'Times New Roman';"> &#160; </font></p>
</td>
</tr>

</table>
</div>
</div>
</div>
<div align="center"><br/></div>
</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 460<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 440<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950362426192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Narrative) (Details) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 28, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2008</div></th>
<th class="th"><div>Dec. 31, 2007</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants issued to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,922,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired', window );">Number of common shares expired underlying stock purchase warrants</a></td>
<td class="nump">2,572,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pip_StockIncentivePlanTwentyZeroSevenMember', window );">2007 Long Term Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_StockholdersEquityLineItems', window );"><strong>Stockholders Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares approved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pip_StockOptionsContractualTerm', window );">Options award term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of common shares expired underlying stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_ClassOfWarrantOrRightOutstandingNumberOfSharesExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_StockOptionsContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Options Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_StockOptionsContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pip_StockholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders Equity [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pip_StockholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pip_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pip_StockIncentivePlanTwentyZeroSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pip_StockIncentivePlanTwentyZeroSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.3.0.814</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>70</ContextCount>
  <ElementCount>160</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>27</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/pip-daei</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/Statement-CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>101 - Disclosure - Business, Liquidity and Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/Disclosure-BusinessLiquidityandOrganization</Role>
      <ShortName>Business, Liquidity and Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/pip-sosap</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>103 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/pip-fvm</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>104 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/pip-cac</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>105 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/pip-se</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>106 - Disclosure - Financing Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/pip-ft</Role>
      <ShortName>Financing Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>202 - Disclosure - Summary of Significant Accounting Policies (Policy)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/pip-sosapp</Role>
      <ShortName>Summary of Significant Accounting Policies (Policy)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.pharmathene.com/role/pip-sosap</ParentRole>
      <Position>13</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/pip-sosapt</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pharmathene.com/role/pip-sosap</ParentRole>
      <Position>14</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/pip-fvmt</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pharmathene.com/role/pip-fvm</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>304 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/Disclosure-CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pharmathene.com/role/pip-cac</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>305 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/pip-set</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pharmathene.com/role/pip-se</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Business, Liquidity and Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/Disclosure-BusinessLiquidityandOrganizationDetails</Role>
      <ShortName>Business, Liquidity and Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pharmathene.com/role/Disclosure-BusinessLiquidityandOrganization</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/pip-sosapnd</Role>
      <ShortName>Summary of Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pharmathene.com/role/pip-sosapt</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>40203 - Disclosure - Summary of Significant Accounting Policies (Schedule of Share-based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/pip-sosapsosced</Role>
      <ShortName>Summary of Significant Accounting Policies (Schedule of Share-based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pharmathene.com/role/pip-sosapt</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Fair Value Measurements (Schedule of Assets and Liabilities Measured at Fair Value) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/pip-fvmsolmafvd</Role>
      <ShortName>Fair Value Measurements (Schedule of Assets and Liabilities Measured at Fair Value) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pharmathene.com/role/pip-fvmt</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Fair Value Measurements (Summary of Changes in Fair Value of Level 3 Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/pip-fvmsocifvolld</Role>
      <ShortName>Fair Value Measurements (Summary of Changes in Fair Value of Level 3 Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pharmathene.com/role/pip-fvmt</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>40303 - Disclosure - Fair Value Measurements (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/pip-fvmnd</Role>
      <ShortName>Fair Value Measurements (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pharmathene.com/role/pip-fvmt</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40304 - Disclosure - Fair Value Measurements (Schedule of Quantitative Information about Level 3 Fair Value Measurements) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/pip-fvmsoqialfvmd</Role>
      <ShortName>Fair Value Measurements (Schedule of Quantitative Information about Level 3 Fair Value Measurements) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pharmathene.com/role/pip-fvmt</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/Disclosure-CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pharmathene.com/role/Disclosure-CommitmentsandContingenciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Commitments and Contingencies (Leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/Disclosure-CommitmentsandContingenciesLeasesDetails</Role>
      <ShortName>Commitments and Contingencies (Leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pharmathene.com/role/Disclosure-CommitmentsandContingenciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Stockholders' Equity (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/pip-send</Role>
      <ShortName>Stockholders' Equity (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pharmathene.com/role/pip-set</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Stockholders' Equity (Schedule of Warrants) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/pip-sesowd</Role>
      <ShortName>Stockholders' Equity (Schedule of Warrants) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pharmathene.com/role/pip-set</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Financing Transactions (Controlled Equity Offering) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/pip-ftceod</Role>
      <ShortName>Financing Transactions (Controlled Equity Offering) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pharmathene.com/role/pip-ft</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pip-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Financing Transactions (Loan Agreement with GE Capital) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pharmathene.com/role/pip-ftlawgcd</Role>
      <ShortName>Financing Transactions (Loan Agreement with GE Capital) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pharmathene.com/role/pip-ft</ParentRole>
      <Position>30</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">In ''CONDENSED CONSOLIDATED BALANCE SHEETS'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression.</Log>
    <Log type="Info">In ''CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression.</Log>
  </Logs>
  <InputFiles>
    <File>pip-20150930.xml</File>
    <File>pip-20150930_cal.xml</File>
    <File>pip-20150930_def.xml</File>
    <File>pip-20150930_lab.xml</File>
    <File>pip-20150930_pre.xml</File>
    <File>pip-20150930.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm139950358820224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Schedule of Share-based Compensation Expense) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 93,757<span></span>
</td>
<td class="nump">$ 280,720<span></span>
</td>
<td class="nump">$ 426,988<span></span>
</td>
<td class="nump">$ 1,172,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">12,034<span></span>
</td>
<td class="nump">52,434<span></span>
</td>
<td class="nump">85,259<span></span>
</td>
<td class="nump">329,655<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 81,723<span></span>
</td>
<td class="nump">$ 228,286<span></span>
</td>
<td class="nump">395,470<span></span>
</td>
<td class="nump">$ 843,048<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring benefit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (53,741)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 14.F)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (h)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 14<br><br><br><br> -Section F<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
